

Introduction

Adverse Event Reporting System (AERS) Report

The Adverse Event Reporting System (AERS) is a computerized database maintained by the U.S. Food and Drug Administration (FDA) to support post-marketing safety surveillance of pharmaceutical and therapeutic biological products. It plays a critical role in identifying new adverse events and medication errors that may not have been detected during clinical trials.

This report presents comprehensive Graphical summaries, summary tables and patient-level listings derived from the AERS database to support ongoing pharmacovigilance activities. The analyses include adverse event frequencies, drug-event relationships, outcomes, and demographic trends. Data used in this report were sourced from AERS 2006Q1 updates, which are released by the FDA approximately 4 to 6 weeks after the end of each calendar quarter.

The AERS database includes the following core datasets:

- DEMO: Patient demographic and administrative information
- DRUG: Reported drug data (suspect, concomitant, interacting)
- REAC: Coded adverse event terms using MedDRA
- OUTC: Patient outcomes such as death, hospitalization, or disability
- RPSR: Sources of the report (healthcare professional, consumer, etc.)
- THER: Therapy dates (start/end) for reported drugs
- INDI: Indications for drug administration

Patient-Level Listings

The Patient-Level Listings section provides detailed, case-level adverse event data as reported to the AERS system. Each listing includes information on patient demographics, suspect and concomitant drugs, therapy dates, adverse event terms, outcomes, indications, and source of report.

These listings allow for case traceability and support in-depth clinical and regulatory review of individual adverse event reports.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4793437	Initial	20040101	20041203	20051011	Periodic	62	YEAR	62
4799889	Initial	-	20051007	20051013	Expdited	-		-
4802758	Followup	20040330	20051003	20051013	Expdited	85	YEAR	85
4806822	Initial	-	-	20051020	Direct	-		-
4807735	Initial	20050214	20051003	20051019	Expdited	62	YEAR	62
4807884	Initial	20050904	20051018	20051021	Expdited	59	YEAR	59
4810789	Initial	-	20051010	20051024	Expdited	-		-
4811786	Initial	20050628	-	20051027	Direct	61	YEAR	61
4813034	Followup	20050101	20051013	20051026	Expdited	74	YEAR	74
4815387	Followup	-	20051021	20051027	Expdited	56	YEAR	56
4817144	Initial	20050502	20050509	20051018	Periodic	77	YEAR	77
4817145	Initial	-	20050516	20051018	Periodic	62	YEAR	62
4817146	Initial	20010801	20050517	20051018	Periodic	73	YEAR	73
4817148	Initial	-	20050523	20051018	Periodic	-		-
4817149	Initial	20050318	20050523	20051018	Periodic	58	YEAR	58
4817159	Initial	-	20050620	20051018	Periodic	62	YEAR	62
4817167	Initial	-	20050606	20051018	Periodic	-		-
4819355	Initial	20050725	20050728	20051031	Periodic	64	YEAR	64
4820164	Initial	20051005	-	20051101	Direct	-		-
4821833	Followup	20050101	20050208	20051107	Expdited	74	YEAR	74
4826267	Initial	20051004	-	20051109	Direct	-		-
4826274	Initial	20051012	-	20051109	Direct	-		-
4826360	Followup	20050207	20051024	20051109	Expdited	68	YEAR	68
4828303	Followup	20050809	20050811	20051115	Expdited	12893	DAY	35
4832882	Followup	20050529	20050530	20051121	Expdited	71	YEAR	71
4833762	Initial	20050220	-	20051118	Direct	39	YEAR	39

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4833775	Initial	20051110	-	20051118	Direct	-		-
4834797	Initial	-	20051103	20051114	Expdited	68	YEAR	68
4838069	Initial	20051103	20051104	20051123	Expdited	-		-
4840105	Initial	20051114	20051114	20051125	Expdited	40	YEAR	40
4843170	Initial	20020806	20050520	20051027	Periodic	61	YEAR	61
4846119	Followup	20051024	20051117	20051130	Expdited	15	YEAR	15
4846435	Initial	20010101	20051121	20051202	Expdited	-		-
4847003	Initial	-	20051122	20051202	Expdited	-		-
4847053	Initial	-	20051128	20051207	Expdited	-		-
4847638	Followup	20050302	20051125	20051205	Expdited	20	YEAR	20
4847706	Initial	20041009	20041122	20051205	Expdited	17	YEAR	17
4852120	Initial	-	20050906	20051123	Periodic	-		-
4852895	Initial	20040101	20051108	20051212	Expdited	66	YEAR	66
4854233	Followup	20051008	20051104	20051117	Expdited	86	YEAR	86
4865588	Followup	20050717	20051205	20051220	Expdited	34	YEAR	34
4867362	Initial	-	20051214	20051222	Expdited	-		-
4867364	Initial	-	20051214	20051222	Expdited	-		-
4867367	Initial	-	20051214	20051222	Expdited	-		-
4867370	Initial	-	20051214	20051222	Expdited	-		-
4867373	Initial	-	20051214	20051222	Expdited	-		-
4867375	Initial	-	20051214	20051222	Expdited	-		-
4867377	Initial	-	20051214	20051222	Expdited	-		-
4867384	Initial	-	20051214	20051222	Expdited	-		-
4867390	Initial	-	20051214	20051222	Expdited	-		-
4867392	Initial	-	20051214	20051222	Expdited	-		-
4867604	Initial	-	20051214	20051222	Expdited	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4867630	Initial	-	20051214	20051222	Expdited	-		-
4869006	Initial	20051024	20051205	20051223	Expdited	71	YEAR	71
4870242	Initial	20051205	20051228	20060102	Expdited	19595	DAY	53
4870243	Followup	20051121	20051124	20060102	Expdited	27492	DAY	75
4870244	Followup	20040906	20051114	20060102	Expdited	18	YEAR	18
4870245	Followup	20051203	20051212	20060102	Expdited	50	YEAR	50
4870246	Initial	20051022	20051219	20060102	Expdited	69	YEAR	69
4870247	Initial	20040503	20051219	20060102	Expdited	79	YEAR	79
4870248	Initial	20051117	20051229	20060102	Expdited	25582	DAY	70
4870249	Followup	-	20051216	20060102	Expdited	-		-
4870250	Followup	20051216	20051219	20060102	Expdited	12286	DAY	33
4870251	Initial	-	20051227	20060102	Expdited	35	YEAR	35
4870252	Followup	20051019	20051114	20060102	Expdited	12188	DAY	33
4870253	Initial	-	20051223	20060102	Expdited	59	YEAR	59
4870254	Initial	-	20051221	20060102	Expdited	-		-
4870255	Followup	20051201	20051212	20060102	Expdited	-		-
4870256	Initial	20051202	20051221	20060102	Expdited	69	YEAR	69
4870257	Initial	20050928	20051221	20060102	Expdited	-		-
4870258	Initial	20020101	20051221	20060102	Expdited	53	YEAR	53
4870272	Initial	20051228	20051230	20060103	Expdited	-		-
4870302	Initial	20050101	20051221	20060103	Expdited	18	YEAR	18
4870303	Initial	-	20051222	20060103	Expdited	46	YEAR	46
4870304	Initial	20050928	20051222	20060103	Expdited	-		-
4870305	Initial	-	20051221	20060103	Expdited	51	YEAR	51
4870313	Followup	-	20051208	20051228	Expdited	-		-
4870319	Initial	-	20051222	20060103	Expdited	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4870320	Initial	-	20051222	20060103	Expdited	-		-
4870321	Initial	-	20051222	20060103	Expdited	-		-
4870322	Initial	20041117	20051222	20060103	Expdited	-		-
4870323	Initial	20041121	20051222	20060103	Expdited	-		-
4870324	Initial	20051111	20051222	20060103	Expdited	-		-
4870325	Initial	20050701	20051222	20060103	Expdited	35	YEAR	35
4870326	Initial	-	20051222	20060103	Expdited	-		-
4870327	Initial	-	20051222	20060103	Expdited	6	DECADE	72
4870328	Initial	20051221	20051222	20060103	Expdited	-		-
4870329	Initial	20050721	20051222	20060103	Expdited	-		-
4870330	Initial	20051101	20051222	20060103	Expdited	66	YEAR	66
4870331	Initial	20050501	20051222	20060103	Expdited	-		-
4870332	Initial	20050101	20051222	20060103	Expdited	-		-
4870333	Initial	20050101	20051222	20060103	Expdited	-		-
4870334	Initial	20050901	20051222	20060103	Expdited	-		-
4870335	Initial	20050523	20051222	20060103	Expdited	-		-
4870336	Initial	20051013	20051222	20060103	Expdited	-		-
4870343	Followup	20051007	20051007	20060103	Expdited	-		-
4870344	Followup	20040501	20050715	20060103	Expdited	-		-
4870345	Initial	-	20051227	20060103	Expdited	-		-
4870346	Followup	20051107	20051128	20060103	Expdited	-		-
4870347	Followup	20050310	20051116	20060103	Expdited	82	YEAR	82
4870348	Followup	20030530	20030603	20060103	Expdited	-		-
4870349	Followup	20030401	20030408	20060103	Expdited	-		-
4870350	Followup	20051127	20051213	20060103	Expdited	-		-
4870351	Followup	20031226	20050512	20060103	Expdited	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4870352	Followup	20050718	20051214	20060103	Expdited	-		-
4870353	Initial	20051117	20051226	20060103	Expdited	-		-
4870354	Initial	20051222	20051227	20060103	Expdited	-		-
4870355	Followup	20051001	20051020	20060103	Expdited	-		-
4870356	Initial	20021205	20051222	20060103	Expdited	-		-
4870357	Initial	20030110	20051223	20060103	Expdited	-		-
4870358	Followup	20010214	20051213	20060103	Expdited	20	YEAR	20
4870359	Followup	20051104	20051114	20060103	Expdited	-		-
4870360	Followup	20031118	20051124	20060103	Expdited	-		-
4870362	Initial	20050401	20051222	20060103	Expdited	-		-
4870363	Initial	20051201	20051222	20060103	Expdited	-		-
4870364	Initial	-	20051222	20060103	Expdited	-		-
4870365	Initial	20050401	20051222	20060103	Expdited	-		-
4870366	Initial	-	20051222	20060103	Expdited	-		-
4870367	Initial	20050613	20051222	20060103	Expdited	-		-
4870370	Followup	20050817	20050819	20060103	Expdited	25635	DAY	70
4870372	Followup	20050628	20051216	20060103	Expdited	29609	DAY	81
4870379	Followup	20051112	20051207	20060103	Expdited	60	YEAR	60
4870385	Initial	20050103	20051222	20060103	Expdited	-		-
4870386	Initial	20050801	20051222	20060103	Expdited	-		-
4870387	Initial	20050801	20051222	20060103	Expdited	-		-
4870388	Initial	20050101	20051222	20060103	Expdited	-		-
4870389	Initial	20050314	20051222	20060103	Expdited	-		-
4870390	Initial	20050601	20051222	20060103	Expdited	-		-
4870391	Initial	20050704	20051222	20060103	Expdited	-		-
4870392	Initial	20051116	20051222	20060103	Expdited	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4870393	Initial	20051101	20051222	20060103	Expdited	-		-
4870414	Followup	20040801	20040921	20060103	Periodic	66	YEAR	66
4870415	Initial	20041001	20041203	20060103	Periodic	62	YEAR	62
4870416	Initial	19990101	20041203	20060103	Periodic	90	YEAR	90
4870417	Initial	-	20041203	20060103	Periodic	-		-
4870418	Initial	20041201	20041206	20060103	Periodic	-		-
4870419	Initial	-	20050103	20060103	Periodic	38	YEAR	38
4870420	Initial	-	20050105	20060103	Periodic	23	YEAR	23
4870421	Initial	20041201	20050114	20060103	Periodic	41	YEAR	41
4870422	Initial	20041001	20050126	20060103	Periodic	52	YEAR	52
4870423	Initial	-	20050201	20060103	Periodic	5	DECADE	60
4870424	Initial	-	20050202	20060103	Periodic	-		-
4870425	Initial	20040101	20050214	20060103	Periodic	36	YEAR	36
4870426	Initial	-	20050217	20060103	Periodic	-		-
4870427	Initial	-	20050311	20060103	Periodic	-		-
4870428	Initial	-	20050316	20060103	Periodic	-		-
4870429	Initial	-	20050317	20060103	Periodic	-		-
4870430	Initial	19980101	20050318	20060103	Periodic	38	YEAR	38
4870431	Initial	-	20050318	20060103	Periodic	-		-
4870432	Initial	-	20050322	20060103	Periodic	48	YEAR	48
4870433	Initial	20040624	20050323	20060103	Periodic	57	YEAR	57
4870434	Initial	20050301	20050330	20060103	Periodic	42	YEAR	42
4870435	Initial	-	20050407	20060103	Periodic	-		-
4870436	Initial	-	20050408	20060103	Periodic	-		-
4870437	Initial	-	20050407	20060103	Periodic	-		-
4870438	Initial	20040701	20050414	20060103	Periodic	6	DECADE	72

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4870439	Initial	-	20050510	20060103	Periodic	84	YEAR	84
4870440	Initial	20050313	20050510	20060103	Periodic	42	YEAR	42
4870441	Initial	-	20050511	20060103	Periodic	25	WEEK	0
4870442	Initial	-	20050518	20060103	Periodic	88	YEAR	88
4870443	Initial	-	20050526	20060103	Periodic	-		-
4870444	Initial	-	20050617	20060103	Periodic	-		-
4870445	Initial	20050621	20050621	20060103	Periodic	-		-
4870446	Initial	-	20050627	20060103	Periodic	-		-
4870447	Initial	-	20050701	20060103	Periodic	-		-
4870448	Initial	-	20050706	20060103	Periodic	52	YEAR	52
4870449	Initial	-	20050713	20060103	Periodic	55	YEAR	55
4870450	Initial	20050725	20050725	20060103	Periodic	-		-
4870451	Initial	20050729	20050729	20060103	Periodic	-		-
4870452	Initial	-	20050815	20060103	Periodic	13	YEAR	13
4870453	Initial	20050824	20050830	20060103	Periodic	45	YEAR	45
4870454	Initial	-	20050901	20060103	Periodic	-		-
4870455	Initial	-	20050922	20060103	Periodic	57	YEAR	57
4870456	Initial	-	20051019	20060103	Periodic	57	YEAR	57
4870457	Initial	20050901	20051123	20060103	Periodic	68	YEAR	68
4870458	Followup	20051006	20051220	20060103	Expdited	-		-
4870459	Followup	20051118	20051205	20060103	Expdited	28	YEAR	28
4870460	Followup	20051114	20051206	20060103	Expdited	-		-
4870461	Followup	20040926	20041018	20060103	Expdited	-		-
4870462	Initial	-	20041207	20060103	Periodic	-		-
4870463	Followup	20050421	20051115	20060103	Expdited	-		-
4870464	Initial	20040101	20051220	20060103	Expdited	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4870465	Initial	20051201	20051220	20060103	Expdited	-		-
4870466	Initial	-	20051221	20060103	Expdited	-		-
4870467	Initial	-	20051219	20060103	Expdited	47	YEAR	47
4870468	Followup	20021127	20030128	20060103	Expdited	-		-
4870469	Followup	20051116	20051123	20060103	Expdited	-		-
4870478	Initial	-	20051220	20060103	Expdited	-		-
4870480	Initial	20051120	20051221	20060103	Expdited	84	YEAR	84
4870481	Followup	-	20051007	20060103	Expdited	-		-
4870482	Initial	20051219	20051222	20060103	Expdited	61	YEAR	61
4870483	Initial	-	20051221	20060103	Expdited	66	YEAR	66
4870484	Initial	20051008	20051222	20060103	Expdited	57	YEAR	57
4870486	Initial	20050727	20051223	20060103	Expdited	-		-
4870512	Followup	20040906	20051114	20060103	Expdited	18	YEAR	18
4870529	Followup	20051118	20051206	20060103	Expdited	63	YEAR	63
4870534	Initial	20051118	20051227	20060103	Expdited	-		-
4870535	Followup	20050912	20051209	20060103	Expdited	21199	DAY	58
4870550	Initial	-	20051230	20060103	Expdited	71	YEAR	71
4870552	Initial	20051105	20051223	20060103	Expdited	38	YEAR	38
4870553	Followup	20051203	20051205	20060103	Expdited	49	YEAR	49
4870566	Initial	20050101	20051225	20060103	Expdited	80	YEAR	80
4870567	Initial	20040902	20051220	20060103	Expdited	35	YEAR	35
4870568	Initial	20051119	20051222	20060103	Expdited	93	YEAR	93
4870569	Initial	20051107	20051222	20060103	Expdited	78	YEAR	78
4870570	Followup	20051201	20051220	20060103	Expdited	-		-
4870571	Initial	20050911	20051228	20060103	Expdited	39	YEAR	39
4870572	Followup	20031225	20050316	20060103	Expdited	56	YEAR	56

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4870573	Initial	20051221	20051222	20060103	Expdited	88	YEAR	88
4870574	Initial	20051001	20051222	20060103	Expdited	75	YEAR	75
4870575	Initial	-	20051228	20060103	Expdited	31	YEAR	31
4870576	Followup	20051126	20051129	20060103	Expdited	50	YEAR	50
4870577	Followup	20051104	20051123	20060103	Expdited	60	YEAR	60
4870578	Followup	20041027	20051209	20060103	Expdited	18	YEAR	18
4870579	Initial	20050422	20051228	20060103	Expdited	47	YEAR	47
4870580	Initial	20051003	20051222	20060103	Expdited	84	YEAR	84
4870581	Followup	20051121	20051208	20060103	Expdited	67	YEAR	67
4870582	Followup	20050919	20051208	20060103	Expdited	47	YEAR	47
4870583	Followup	20050831	20051209	20060103	Expdited	77	YEAR	77
4870584	Followup	20050919	20051209	20060103	Expdited	77	YEAR	77
4870585	Followup	-	20050816	20060103	Expdited	56	YEAR	56
4870586	Followup	20040301	20051207	20060103	Expdited	55	YEAR	55
4870587	Followup	-	20051220	20060103	Expdited	3	DECADE	36
4870588	Followup	20051101	20051206	20060103	Expdited	81	YEAR	81
4870589	Initial	-	20051227	20060103	Expdited	66	YEAR	66
4870591	Initial	-	20051221	20060103	Expdited	36	YEAR	36
4870592	Followup	20051130	20051213	20060103	Expdited	-		-
4870593	Initial	-	20051223	20060103	Expdited	81	YEAR	81
4870594	Followup	20050101	20051209	20060103	Expdited	17	YEAR	17
4870604	Followup	20050901	20051209	20060103	Expdited	80	YEAR	80
4870618	Initial	20051001	20051222	20060103	Expdited	63	YEAR	63
4870623	Initial	-	20051222	20060103	Expdited	20	YEAR	20
4870624	Initial	-	20051222	20060103	Expdited	-		-
4870651	Followup	-	20051222	20060103	Expdited	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4870659	Initial	20040101	20051220	20060103	Expdited	-		-
4870660	Initial	-	20051222	20060103	Expdited	53	YEAR	53
4870661	Initial	20051223	20051223	20060103	Expdited	21	YEAR	21
4870662	Initial	20050201	20051222	20060103	Expdited	-		-
4870663	Initial	20010101	20051221	20060103	Expdited	-		-
4870667	Followup	20051208	20051219	20060103	Expdited	-		-
4870668	Followup	20051218	20051221	20060103	Expdited	-		-
4870669	Initial	20040525	20051220	20060103	Periodic	-		-
4870670	Initial	-	20051223	20060103	Expdited	51	YEAR	51
4870671	Initial	-	20051223	20060103	Expdited	77	YEAR	77
4870672	Initial	-	20051221	20060103	Expdited	35	YEAR	35
4870673	Initial	-	20051226	20060103	Expdited	34	YEAR	34
4870674	Initial	20051227	20051228	20060103	Expdited	73	YEAR	73
4870684	Initial	20030101	20051227	20060103	Expdited	67	YEAR	67
4870685	Initial	20050901	20051230	20060103	Expdited	59	YEAR	59
4870686	Initial	20051201	20051230	20060103	Expdited	44	YEAR	44
4870687	Followup	20040701	20040723	20060103	Expdited	23	YEAR	23
4870688	Followup	20040108	20050223	20060103	Expdited	-		-
4870689	Followup	20020801	20050324	20060103	Expdited	-		-
4870690	Followup	-	20050413	20060103	Expdited	18	YEAR	18
4870691	Followup	20050826	20050905	20060103	Expdited	35	YEAR	35
4870692	Followup	20050904	20050909	20060103	Expdited	85	YEAR	85
4870693	Followup	20020906	20051028	20060103	Expdited	49	YEAR	49
4870694	Followup	20050606	20051110	20060103	Expdited	2	YEAR	2
4870695	Followup	20031008	20051111	20060103	Expdited	34	YEAR	34
4870696	Followup	20050929	20051128	20060103	Expdited	50	YEAR	50

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4870697	Followup	20051101	20051205	20060103	Expdited	44	YEAR	44
4870698	Followup	20051128	20051206	20060103	Expdited	31	YEAR	31
4870699	Followup	-	20051214	20060103	Expdited	64	YEAR	64
4870700	Initial	20051017	20051219	20060103	Expdited	74	YEAR	74
4870701	Followup	20051209	20051221	20060103	Expdited	1	YEAR	1
4870702	Followup	20051116	20051220	20060103	Expdited	75	YEAR	75
4870703	Followup	-	20051221	20060103	Expdited	-		-
4870704	Followup	-	20051213	20060103	Expdited	-		-
4870705	Followup	20050803	20051222	20060103	Expdited	77	YEAR	77
4870706	Followup	20040907	20051222	20060103	Expdited	54	YEAR	54
4870707	Followup	20051119	20051226	20060103	Expdited	74	YEAR	74
4870708	Initial	20050101	20051223	20060103	Expdited	34	YEAR	34
4870709	Initial	20050101	20051228	20060103	Expdited	16	YEAR	16
4870710	Followup	20041007	20051226	20060103	Expdited	39	YEAR	39
4870711	Initial	-	20051221	20060103	Expdited	-		-
4870712	Followup	20051216	20051222	20060103	Expdited	-		-
4870714	Initial	-	20051220	20060103	Expdited	7	YEAR	7
4870715	Initial	-	20051220	20060103	Expdited	29	YEAR	29
4870716	Initial	-	20051220	20060103	Expdited	45	YEAR	45
4870717	Initial	20051214	20060102	20060103	Expdited	75	YEAR	75
4870718	Followup	-	20051228	20060103	Expdited	34	YEAR	34
4870719	Followup	20050212	20050617	20060103	Expdited	28	YEAR	28
4870720	Followup	20051126	20051220	20060103	Expdited	32	YEAR	32
4870721	Initial	20041211	20051230	20060103	Expdited	26	YEAR	26
4870722	Initial	20041211	20051230	20060103	Expdited	-		-
4870723	Initial	20050630	20051222	20060103	Expdited	69	YEAR	69

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4870724	Initial	20051126	20051222	20060103	Expdited	65	YEAR	65
4870725	Followup	20050826	20050926	20060103	Expdited	26	YEAR	26
4870728	Initial	20051129	20051228	20060103	Expdited	92	YEAR	92
4870732	Followup	20051208	20051209	20060103	Expdited	-		-
4870733	Followup	-	20051220	20060103	Expdited	54	YEAR	54
4870734	Initial	20051119	20051220	20060103	Expdited	-		-
4870735	Initial	-	20051222	20060103	Expdited	-		-
4870736	Initial	20051215	20051220	20060103	Expdited	-		-
4870737	Initial	-	20051227	20060103	Expdited	62	YEAR	62
4870738	Initial	20050401	20051220	20060103	Expdited	-		-
4870739	Initial	-	20051222	20060103	Expdited	-		-
4870741	Initial	20051117	20051221	20060103	Expdited	42	YEAR	42
4870753	Initial	-	20051216	20060103	Expdited	-		-
4870754	Initial	-	20051223	20060103	Expdited	-		-
4870755	Followup	20041113	20041116	20060103	Expdited	53	YEAR	53
4870756	Followup	20050908	20051024	20060103	Expdited	53	YEAR	53
4870757	Initial	-	20051223	20060103	Expdited	53	YEAR	53
4870758	Followup	20010401	20010402	20060103	Expdited	27	YEAR	27
4870763	Followup	20000420	20051005	20060103	Expdited	65	YEAR	65
4870764	Followup	20040901	20050331	20060103	Expdited	67	YEAR	67
4870765	Followup	19960101	20050511	20060103	Expdited	61	YEAR	61
4870766	Followup	20020601	20050418	20060103	Expdited	80	YEAR	80
4870767	Followup	20030101	20050831	20060103	Expdited	56	YEAR	56
4870768	Followup	20040418	20051005	20060103	Expdited	67	YEAR	67
4870769	Followup	19991101	20050928	20060103	Expdited	57	YEAR	57
4870770	Followup	20030724	20050927	20060103	Expdited	72	YEAR	72

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4870771	Followup	19990929	20050920	20060103	Expdited	75	YEAR	75
4870772	Followup	19990101	20051005	20060103	Expdited	74	YEAR	74
4870773	Followup	20030127	20051005	20060103	Expdited	-		-
4870774	Followup	20030601	20050617	20060103	Expdited	57	YEAR	57
4870775	Followup	20020214	20051003	20060103	Expdited	70	YEAR	70
4870776	Followup	20020101	20051005	20060103	Expdited	63	YEAR	63
4870777	Followup	20040115	20050920	20060103	Expdited	88	YEAR	88
4870778	Followup	20041101	20051114	20060103	Expdited	62	YEAR	62
4870779	Followup	20010303	20050926	20060103	Expdited	69	YEAR	69
4870780	Followup	19990411	20050929	20060103	Expdited	75	YEAR	75
4870781	Followup	20010101	20051004	20060103	Expdited	80	YEAR	80
4870782	Followup	20041028	20050928	20060103	Expdited	52	YEAR	52
4870783	Followup	20010101	20050118	20060103	Expdited	50	YEAR	50
4870784	Followup	20030101	20050914	20060103	Expdited	52	YEAR	52
4870785	Followup	20020801	20050831	20060103	Expdited	66	YEAR	66
4870786	Followup	20011129	20050907	20060103	Expdited	72	YEAR	72
4870787	Followup	20020101	20051005	20060103	Expdited	60	YEAR	60
4870788	Followup	20000501	20050715	20060103	Expdited	72	YEAR	72
4870789	Followup	20010906	20050930	20060103	Expdited	48	YEAR	48
4870790	Followup	20040901	20051004	20060103	Expdited	45	YEAR	45
4870791	Followup	20010101	20050901	20060103	Expdited	76	YEAR	76
4870792	Followup	20010101	20050401	20060103	Expdited	46	YEAR	46
4870793	Followup	20000918	20051005	20060103	Expdited	63	YEAR	63
4870794	Followup	20000409	20040720	20060103	Expdited	47	YEAR	47
4870795	Followup	20000301	20050930	20060103	Expdited	62	YEAR	62
4870796	Followup	20020101	20050516	20060103	Expdited	66	YEAR	66

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4870797	Initial	20051119	20051222	20060103	Expdited	23	YEAR	23
4870798	Followup	20020504	20041022	20060103	Expdited	35	YEAR	35
4870799	Followup	20020101	20050401	20060103	Expdited	53	YEAR	53
4870800	Initial	20040101	20051208	20060103	Expdited	50	YEAR	50
4870801	Followup	20030601	20050119	20060103	Expdited	68	YEAR	68
4870802	Followup	20050919	20050922	20060103	Expdited	64	YEAR	64
4870803	Initial	20051220	20051222	20060103	Expdited	-		-
4870804	Initial	20051213	20051222	20060103	Expdited	49	YEAR	49
4870805	Initial	20051118	20051221	20060103	Expdited	17	YEAR	17
4870806	Initial	-	20051215	20060103	Expdited	16	YEAR	16
4870807	Initial	20050501	20051222	20060103	Expdited	63	YEAR	63
4870808	Initial	20050314	20051219	20060103	Expdited	38	YEAR	38
4870809	Followup	20050628	20041115	20060103	Expdited	-		-
4870810	Followup	20050806	20050811	20060103	Expdited	53	YEAR	53
4870811	Initial	-	20051222	20060103	Expdited	50	YEAR	50
4870812	Initial	-	20051220	20060103	Expdited	50	YEAR	50
4870813	Followup	20000719	20050919	20060103	Expdited	44	YEAR	44
4870814	Followup	20050920	20050923	20060103	Expdited	45	YEAR	45
4870816	Initial	20031215	20051220	20060103	Expdited	71	YEAR	71
4870817	Initial	20010513	20051221	20060103	Expdited	68	YEAR	68
4870818	Followup	20000601	20051005	20060103	Expdited	56	YEAR	56
4870819	Followup	20010801	20051005	20060103	Expdited	74	YEAR	74
4870821	Followup	20031101	20051208	20060103	Expdited	48	YEAR	48
4870822	Initial	-	20051220	20060103	Expdited	-		-
4870823	Followup	20040929	20051005	20060103	Expdited	47	YEAR	47
4870824	Followup	20031001	20051129	20060103	Expdited	68	YEAR	68

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4870825	Followup	20021201	20051005	20060103	Expdited	46	YEAR	46
4870826	Initial	20020101	20051223	20060103	Expdited	69	YEAR	69
4870827	Initial	20050101	20051222	20060103	Expdited	11	YEAR	11
4870828	Followup	20030519	20050505	20060103	Expdited	61	YEAR	61
4870829	Followup	20000616	20050831	20060103	Expdited	57	YEAR	57
4870830	Followup	20010429	20051004	20060103	Expdited	64	YEAR	64
4870831	Followup	20010101	20051005	20060103	Expdited	59	YEAR	59
4870832	Followup	20030903	20050914	20060103	Expdited	98	YEAR	98
4870833	Initial	20030101	20051223	20060103	Expdited	36	YEAR	36
4870834	Followup	20000701	20050802	20060103	Expdited	34	YEAR	34
4870835	Followup	20020101	20051129	20060103	Expdited	63	YEAR	63
4870836	Initial	20040101	20051220	20060103	Expdited	51	YEAR	51
4870837	Followup	20020401	20051005	20060103	Expdited	50	YEAR	50
4870838	Initial	20030717	20051220	20060103	Expdited	47	YEAR	47
4870839	Followup	20011101	20051017	20060103	Expdited	71	YEAR	71
4870840	Followup	20020513	20051005	20060103	Expdited	53	YEAR	53
4870841	Initial	-	20051219	20060103	Expdited	60	YEAR	60
4870842	Followup	20040530	20051005	20060103	Expdited	81	YEAR	81
4870843	Initial	20030101	20051221	20060103	Expdited	-		-
4870844	Initial	20040101	20051206	20060103	Expdited	-		-
4870845	Initial	20030214	20051223	20060103	Expdited	-		-
4870846	Followup	20020317	20051005	20060103	Expdited	92	YEAR	92
4870847	Initial	-	20051222	20060103	Expdited	76	YEAR	76
4870848	Initial	20030101	20051223	20060103	Expdited	74	YEAR	74
4870849	Followup	20010101	20051005	20060103	Expdited	53	YEAR	53
4870850	Initial	20030101	20051223	20060103	Expdited	71	YEAR	71

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4870851	Initial	20030101	20051220	20060103	Expdited	-		-
4870852	Initial	20020101	20051223	20060103	Expdited	58	YEAR	58
4870853	Initial	20030728	20051220	20060103	Expdited	63	YEAR	63
4870855	Initial	20010605	20051220	20060103	Expdited	39	YEAR	39
4870856	Initial	20040101	20051223	20060103	Expdited	69	YEAR	69
4870857	Initial	20020101	20051223	20060103	Expdited	49	YEAR	49
4870858	Followup	20020101	20051005	20060103	Expdited	34	YEAR	34
4870859	Followup	20040101	20051004	20060103	Expdited	-		-
4870860	Initial	20030101	20051220	20060103	Expdited	-		-
4870861	Initial	20040101	20051223	20060103	Expdited	35	YEAR	35
4870862	Followup	20000101	20051208	20060103	Expdited	71	YEAR	71
4870863	Initial	-	20051223	20060103	Expdited	58	YEAR	58
4870864	Initial	-	20051223	20060103	Expdited	-		-
4870865	Initial	20001001	20051222	20060103	Expdited	57	YEAR	57
4870866	Initial	-	20051223	20060103	Expdited	75	YEAR	75
4870867	Followup	20020616	20051208	20060103	Expdited	67	YEAR	67
4870868	Followup	20030114	20050829	20060103	Expdited	33	YEAR	33
4870869	Followup	20041006	20051005	20060103	Expdited	70	YEAR	70
4870870	Followup	20020101	20051005	20060103	Expdited	51	YEAR	51
4870871	Initial	-	20051220	20060103	Expdited	60	YEAR	60
4870872	Followup	20030101	20051005	20060103	Expdited	75	YEAR	75
4870873	Followup	20020328	20050914	20060103	Expdited	64	YEAR	64
4870874	Initial	19991219	20051221	20060103	Expdited	40	YEAR	40
4870875	Followup	20040101	20051005	20060103	Expdited	39	YEAR	39
4870876	Initial	20031201	20051220	20060103	Expdited	-		-
4870877	Initial	20030101	20051223	20060103	Expdited	69	YEAR	69

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4870878	Followup	20050305	20051017	20060103	Expdited	60	YEAR	60
4870879	Initial	20051105	20051220	20060103	Expdited	-		-
4870880	Initial	20000101	20051223	20060103	Expdited	70	YEAR	70
4870886	Followup	20050530	20050615	20060103	Expdited	-		-
4870888	Initial	20050101	20051223	20060103	Expdited	77	YEAR	77
4870890	Initial	-	20051220	20060103	Expdited	68	YEAR	68
4870891	Followup	-	20051017	20060103	Expdited	53	YEAR	53
4870892	Followup	20050223	20050228	20060103	Expdited	-		-
4870894	Followup	20050101	20051206	20060103	Expdited	-		-
4870898	Initial	20051201	20051223	20060103	Expdited	50	YEAR	50
4870900	Initial	20051030	20051223	20060103	Expdited	-		-
4870901	Followup	20051101	20051202	20060103	Expdited	-		-
4870902	Initial	20051222	20051222	20060103	Expdited	78	YEAR	78
4870903	Initial	20051228	20051229	20060103	Expdited	55	YEAR	55
4870904	Followup	20051019	20051021	20060103	Expdited	66	YEAR	66
4870917	Initial	20051017	20051223	20060103	Expdited	48	YEAR	48
4870921	Followup	-	20051129	20060103	Expdited	-		-
4870922	Initial	20030806	20051130	20060103	Expdited	73	YEAR	73
4870923	Followup	20051122	20051122	20060103	Expdited	1	YEAR	1
4870976	Followup	20051021	20051215	20060103	Expdited	58	YEAR	58
4870977	Initial	-	20051228	20060103	Expdited	35	YEAR	35
4870978	Initial	-	20051222	20060103	Expdited	-		-
4870979	Initial	20051201	20051229	20060103	Expdited	52	YEAR	52
4870993	Initial	-	20051221	20060103	Expdited	-		-
4870994	Followup	20051029	20051115	20060103	Expdited	71	YEAR	71
4871004	Initial	-	20051223	20060103	Expdited	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871005	Initial	20051201	20051227	20060103	Expdited	-		-
4871006	Initial	20050801	20051229	20060103	Expdited	46	YEAR	46
4871016	Initial	20051221	20051226	20060103	Expdited	13	YEAR	13
4871017	Initial	20050101	20051228	20060103	Periodic	-		-
4871018	Initial	20050903	20051228	20060103	Expdited	-		-
4871019	Initial	20050101	20051228	20060103	Expdited	-		-
4871040	Followup	20030820	20051005	20060103	Expdited	-		-
4871057	Followup	20040430	20040519	20060103	Expdited	75	YEAR	75
4871073	Followup	20051117	20051208	20060103	Expdited	77	YEAR	77
4871074	Initial	20050901	20051228	20060103	Expdited	-		-
4871086	Followup	20000515	20000911	20060103	Expdited	-		-
4871087	Followup	20000427	20000927	20060103	Expdited	-		-
4871088	Followup	20000403	20000927	20060103	Expdited	-		-
4871089	Followup	20000522	20000824	20060103	Expdited	-		-
4871101	Followup	20000525	20001102	20060103	Expdited	-		-
4871102	Followup	20000209	20000804	20060103	Expdited	-		-
4871103	Followup	19991126	20000419	20060103	Expdited	-		-
4871105	Followup	20000124	20000821	20060103	Expdited	-		-
4871106	Followup	20051220	20051221	20060103	Expdited	54	YEAR	54
4871127	Initial	20051218	20051219	20060103	Expdited	-		-
4871134	Followup	20051201	20051214	20060103	Expdited	75	YEAR	75
4871141	Initial	20051108	20051221	20060103	Expdited	14	YEAR	14
4871146	Initial	-	20051221	20060103	Expdited	63	YEAR	63
4871160	Initial	-	20051221	20060103	Expdited	60	YEAR	60
4871180	Followup	20050329	20051122	20060103	Expdited	42	YEAR	42
4871210	Followup	20000813	20001219	20060103	Expdited	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871211	Followup	19991225	20000410	20060103	Expdited	-		-
4871212	Followup	19990614	20000210	20060103	Expdited	-		-
4871213	Followup	20000723	20001102	20060103	Expdited	-		-
4871214	Initial	20051022	20051226	20060103	Expdited	-		-
4871220	Followup	20051001	20051102	20060103	Expdited	-		-
4871221	Followup	20001017	20010112	20060103	Expdited	-		-
4871222	Followup	20010525	20011012	20060103	Expdited	-		-
4871223	Followup	19991223	20000410	20060103	Expdited	-		-
4871224	Followup	20000512	20010130	20060103	Expdited	-		-
4871225	Followup	20010608	20011029	20060103	Expdited	-		-
4871226	Followup	20001108	20010801	20060103	Expdited	-		-
4871227	Followup	20001231	20010619	20060103	Expdited	-		-
4871229	Followup	20001205	20010713	20060103	Expdited	-		-
4871230	Followup	20010102	20010619	20060103	Expdited	-		-
4871231	Followup	20000927	20010301	20060103	Expdited	-		-
4871232	Followup	20001025	20010525	20060103	Expdited	-		-
4871233	Followup	20001226	20010502	20060103	Expdited	-		-
4871235	Followup	20001206	20010301	20060103	Expdited	-		-
4871236	Followup	20051214	20051220	20060103	Expdited	46	YEAR	46
4871237	Followup	20000702	20010327	20060103	Expdited	-		-
4871238	Followup	20051105	20051122	20060103	Expdited	-		-
4871239	Followup	20000925	20011211	20060103	Expdited	-		-
4871240	Followup	20010312	20011012	20060103	Expdited	-		-
4871241	Followup	20010120	20010525	20060103	Expdited	-		-
4871242	Followup	20011005	20011205	20060103	Expdited	-		-
4871243	Followup	20000908	20010130	20060103	Expdited	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871244	Followup	20001001	20010112	20060103	Expdited	-		-
4871249	Followup	20010218	20011127	20060103	Expdited	-		-
4871250	Followup	20000810	20010301	20060103	Expdited	-		-
4871338	Followup	20050701	20051108	20060103	Expdited	81	YEAR	81
4871339	Followup	20000101	20051006	20060103	Expdited	57	YEAR	57
4871340	Followup	20000911	20051005	20060103	Expdited	73	YEAR	73
4871341	Followup	20030702	20051005	20060103	Expdited	71	YEAR	71
4871342	Followup	20040903	20050930	20060103	Expdited	52	YEAR	52
4871344	Initial	20020323	20051222	20060103	Expdited	-		-
4871345	Followup	20030901	20051017	20060103	Expdited	65	YEAR	65
4871346	Initial	20020529	20051222	20060103	Expdited	57	YEAR	57
4871353	Initial	20010101	20051223	20060103	Expdited	54	YEAR	54
4871354	Followup	19991201	20051006	20060103	Expdited	51	YEAR	51
4871355	Initial	20040101	20051223	20060103	Expdited	63	YEAR	63
4871356	Followup	20000101	20051006	20060103	Expdited	66	YEAR	66
4871357	Followup	20040421	20051005	20060103	Expdited	52	YEAR	52
4871359	Initial	20031201	20051223	20060103	Expdited	75	YEAR	75
4871360	Followup	20031208	20051215	20060103	Expdited	53	YEAR	53
4871361	Initial	20011214	20051220	20060103	Expdited	55	YEAR	55
4871362	Followup	20040214	20051005	20060103	Expdited	-		-
4871363	Initial	20030804	20051223	20060103	Expdited	-		-
4871364	Followup	20000713	20051005	20060103	Expdited	-		-
4871365	Followup	19990721	20051004	20060103	Expdited	57	YEAR	57
4871367	Followup	20051203	20051213	20060103	Expdited	58	YEAR	58
4871368	Followup	20020901	20050920	20060103	Expdited	75	YEAR	75
4871369	Followup	20040501	20051005	20060103	Expdited	44	YEAR	44

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871370	Followup	20040301	20051005	20060103	Expdited	77	YEAR	77
4871371	Initial	20050801	20051228	20060103	Expdited	72	YEAR	72
4871373	Initial	20040701	20051227	20060103	Expdited	77	YEAR	77
4871374	Followup	20040629	20051005	20060103	Expdited	-		-
4871375	Followup	20020105	20051005	20060103	Expdited	40	YEAR	40
4871376	Followup	20010101	20050831	20060103	Expdited	63	YEAR	63
4871377	Followup	20051101	20051129	20060103	Expdited	69	YEAR	69
4871378	Followup	20040101	20050920	20060103	Expdited	71	YEAR	71
4871379	Followup	19990101	20051005	20060103	Expdited	57	YEAR	57
4871380	Followup	20020101	20041014	20060103	Expdited	60	YEAR	60
4871382	Followup	20041005	20051005	20060103	Expdited	62	YEAR	62
4871383	Followup	20010101	20051005	20060103	Expdited	66	YEAR	66
4871384	Followup	20040619	20051005	20060103	Expdited	60	YEAR	60
4871385	Followup	20040401	20051005	20060103	Expdited	50	YEAR	50
4871386	Followup	20000101	20050831	20060103	Expdited	47	YEAR	47
4871387	Followup	20020214	20051004	20060103	Expdited	63	YEAR	63
4871405	Initial	20040101	20051223	20060103	Expdited	42	YEAR	42
4871406	Followup	19990101	20051005	20060103	Expdited	50	YEAR	50
4871407	Initial	20051108	20051227	20060103	Expdited	7	YEAR	7
4871408	Followup	20000901	20051004	20060103	Expdited	45	YEAR	45
4871409	Initial	-	20051227	20060103	Expdited	43	YEAR	43
4871411	Followup	20051201	20051209	20060103	Expdited	56	YEAR	56
4871412	Followup	20041001	20050211	20060103	Expdited	56	YEAR	56
4871413	Followup	20030206	20050914	20060103	Expdited	-		-
4871415	Followup	20050701	20050805	20060103	Expdited	60	YEAR	60
4871416	Initial	20051224	20051226	20060103	Expdited	59	YEAR	59

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871417	Followup	20041218	20051005	20060103	Expdited	55	YEAR	55
4871419	Followup	20030101	20051005	20060103	Expdited	62	YEAR	62
4871432	Followup	20040213	20051005	20060103	Expdited	53	YEAR	53
4871448	Followup	20051023	20051028	20060103	Expdited	72	YEAR	72
4871560	Followup	20030601	20040520	20060104	Expdited	-		-
4871561	Initial	20011201	20051223	20060104	Expdited	-		-
4871562	Initial	20040628	20051223	20060104	Expdited	-		-
4871573	Initial	-	20051223	20060104	Expdited	38	YEAR	38
4871574	Initial	-	20051227	20060104	Expdited	-		-
4871582	Initial	20050815	20051223	20060104	Expdited	-		-
4871583	Initial	20051207	20051223	20060104	Expdited	-		-
4871584	Initial	20050101	20051227	20060104	Expdited	-		-
4871585	Initial	20051201	20051227	20060104	Expdited	-		-
4871587	Initial	20040301	20051223	20060104	Expdited	-		-
4871592	Initial	20010925	20051223	20060104	Expdited	-		-
4871598	Initial	20050215	20051228	20060104	Expdited	55	YEAR	55
4871599	Initial	20051221	20051230	20060104	Expdited	72	YEAR	72
4871600	Followup	20051123	20051125	20060104	Expdited	55	YEAR	55
4871601	Initial	20051205	20051228	20060104	Expdited	53	YEAR	53
4871602	Initial	-	20050926	20060104	Expdited	-		-
4871614	Initial	20051218	20051223	20060104	Expdited	76	YEAR	76
4871615	Initial	20050701	20051229	20060104	Expdited	-		-
4871616	Initial	20050301	20051229	20060104	Expdited	-		-
4871617	Initial	20051111	20051226	20060104	Periodic	75	YEAR	75
4871622	Initial	20050624	20051228	20060104	Expdited	79	YEAR	79
4871623	Initial	-	20051222	20060104	Expdited	78	YEAR	78

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871624	Initial	20051001	20051227	20060104	Expdited	-		-
4871625	Followup	20050501	20050620	20060104	Expdited	56	YEAR	56
4871626	Initial	20051114	20051114	20060104	Expdited	-		-
4871627	Initial	20051211	20051220	20060104	Expdited	64	YEAR	64
4871628	Followup	20050101	20051024	20060104	Expdited	-		-
4871629	Initial	20050101	20051221	20060104	Expdited	-		-
4871630	Initial	20051101	20051221	20060104	Expdited	-		-
4871631	Followup	20010201	20050624	20060104	Expdited	40	YEAR	40
4871632	Initial	20050301	20051229	20060104	Expdited	-		-
4871633	Initial	20051205	20051221	20060104	Expdited	-		-
4871634	Followup	20050703	20050704	20060104	Expdited	44	YEAR	44
4871635	Followup	-	20051222	20060104	Expdited	-		-
4871636	Followup	20050401	20041104	20060104	Expdited	39	YEAR	39
4871637	Initial	-	20051228	20060104	Expdited	-		-
4871638	Followup	-	20051220	20060104	Expdited	-		-
4871639	Initial	-	20051228	20060104	Expdited	38	YEAR	38
4871640	Initial	20051226	20051229	20060104	Expdited	67	YEAR	67
4871641	Followup	20041212	20050902	20060104	Expdited	77	YEAR	77
4871642	Initial	20050529	20051223	20060104	Expdited	68	YEAR	68
4871643	Initial	20051001	20051223	20060104	Expdited	76	YEAR	76
4871644	Followup	20051208	20051209	20060104	Expdited	-		-
4871645	Initial	20051001	20051227	20060104	Expdited	83	YEAR	83
4871646	Initial	20050830	20051222	20060104	Expdited	41	YEAR	41
4871648	Initial	20050825	20051226	20060104	Expdited	0	DAY	0
4871649	Followup	20051212	20051214	20060104	Expdited	30236	DAY	82
4871651	Followup	20051031	20051201	20060104	Expdited	77	YEAR	77

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871654	Initial	20050825	20051223	20060104	Expdited	-		-
4871655	Initial	-	20051229	20060104	Expdited	-		-
4871656	Followup	20050917	20051027	20060104	Expdited	33727	DAY	92
4871659	Initial	20050901	20051223	20060104	Expdited	46	YEAR	46
4871660	Followup	20040101	20050426	20060104	Expdited	55	YEAR	55
4871661	Initial	-	20051222	20060104	Expdited	-		-
4871662	Followup	20030101	20031003	20060104	Expdited	41	YEAR	41
4871663	Initial	20051001	20051228	20060104	Expdited	71	YEAR	71
4871664	Followup	20051222	20051222	20060104	Expdited	76	YEAR	76
4871665	Initial	-	20051227	20060104	Expdited	-		-
4871666	Initial	-	20051228	20060104	Expdited	-		-
4871667	Initial	20051028	20051228	20060104	Expdited	-		-
4871668	Followup	20050101	20051007	20060104	Expdited	-		-
4871669	Initial	20051219	20051227	20060104	Expdited	71	YEAR	71
4871670	Followup	20040920	20040924	20060104	Expdited	57	YEAR	57
4871671	Followup	20050101	20050927	20060104	Expdited	-		-
4871672	Followup	20051208	20051215	20060104	Expdited	-		-
4871673	Followup	20051201	20051201	20060104	Expdited	24	YEAR	24
4871674	Followup	20051205	20051208	20060104	Expdited	45	YEAR	45
4871675	Followup	-	20051213	20060104	Expdited	-		-
4871676	Followup	20051126	20051128	20060104	Expdited	40	YEAR	40
4871677	Followup	-	20051216	20060104	Expdited	68	YEAR	68
4871678	Followup	20051115	20051212	20060104	Expdited	75	YEAR	75
4871681	Followup	20010301	20010504	20060104	Expdited	-		-
4871682	Followup	20041121	20041125	20060104	Expdited	62	YEAR	62
4871685	Followup	20050611	20050614	20060104	Expdited	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871686	Initial	20051013	20051220	20060104	Expdited	-		-
4871687	Followup	20050502	20051121	20060104	Expdited	-		-
4871689	Followup	20031008	20051116	20060104	Expdited	-		-
4871692	Initial	-	20051220	20060104	Expdited	62	YEAR	62
4871693	Followup	20051001	20051026	20060104	Expdited	-		-
4871694	Initial	20050611	20051220	20060104	Expdited	55	YEAR	55
4871695	Followup	20051107	20051202	20060104	Expdited	-		-
4871706	Initial	-	20051201	20060104	Expdited	85	YEAR	85
4871707	Followup	-	20051018	20060104	Expdited	78	YEAR	78
4871708	Followup	20050225	20050225	20060104	Expdited	26806	DAY	73
4871709	Followup	20031210	20051116	20060104	Expdited	21262	DAY	58
4871712	Initial	20051206	20051227	20060104	Expdited	57	YEAR	57
4871713	Followup	20050729	20050812	20060104	Expdited	10260	DAY	28
4871714	Followup	20051019	20051215	20060104	Expdited	34	YEAR	34
4871720	Followup	20040801	20040921	20060104	Periodic	66	YEAR	66
4871721	Initial	20041001	20041203	20060104	Periodic	62	YEAR	62
4871722	Initial	19990101	20041203	20060104	Periodic	90	YEAR	90
4871723	Initial	-	20041203	20060104	Periodic	-		-
4871724	Initial	20041201	20041206	20060104	Periodic	-		-
4871725	Initial	-	20050103	20060104	Periodic	38	YEAR	38
4871726	Initial	-	20050105	20060104	Periodic	23	YEAR	23
4871727	Initial	20041201	20050114	20060104	Periodic	41	YEAR	41
4871728	Initial	20041001	20050126	20060104	Periodic	52	YEAR	52
4871729	Initial	-	20050201	20060104	Periodic	5	DECADE	60
4871730	Initial	-	20050202	20060104	Periodic	-		-
4871731	Initial	20040101	20050214	20060104	Periodic	36	YEAR	36

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871733	Initial	-	20050217	20060104	Periodic	-		-
4871734	Initial	-	20050311	20060104	Periodic	-		-
4871735	Initial	-	20050316	20060104	Periodic	-		-
4871736	Initial	-	20050317	20060104	Periodic	-		-
4871737	Initial	19980101	20050318	20060104	Periodic	38	YEAR	38
4871738	Initial	-	20050318	20060104	Periodic	-		-
4871739	Initial	-	20050322	20060104	Periodic	48	YEAR	48
4871740	Initial	20040624	20050323	20060104	Periodic	57	YEAR	57
4871741	Initial	20050301	20050330	20060104	Periodic	42	YEAR	42
4871742	Initial	-	20050407	20060104	Periodic	-		-
4871743	Initial	-	20050408	20060104	Periodic	-		-
4871744	Initial	-	20050407	20060104	Periodic	-		-
4871745	Initial	20040701	20050414	20060104	Periodic	6	DECADE	72
4871746	Initial	-	20050510	20060104	Periodic	84	YEAR	84
4871747	Initial	20050313	20050510	20060104	Periodic	42	YEAR	42
4871748	Initial	-	20050511	20060104	Periodic	25	WEEK	0
4871749	Initial	-	20050518	20060104	Periodic	88	YEAR	88
4871750	Initial	-	20050526	20060104	Periodic	-		-
4871751	Initial	-	20050617	20060104	Periodic	-		-
4871752	Initial	20050621	20050621	20060104	Periodic	-		-
4871753	Initial	-	20050627	20060104	Periodic	-		-
4871754	Initial	-	20050701	20060104	Periodic	-		-
4871755	Initial	-	20050706	20060104	Periodic	52	YEAR	52
4871756	Initial	-	20050713	20060104	Periodic	55	YEAR	55
4871757	Initial	20050725	20050725	20060104	Periodic	-		-
4871758	Initial	20050729	20050729	20060104	Periodic	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871759	Initial	-	20050815	20060104	Periodic	13	YEAR	13
4871760	Initial	20050824	20050830	20060104	Periodic	45	YEAR	45
4871761	Initial	-	20050901	20060104	Periodic	-		-
4871762	Initial	-	20050922	20060104	Periodic	57	YEAR	57
4871763	Initial	-	20051019	20060104	Periodic	57	YEAR	57
4871764	Initial	20050901	20051123	20060104	Periodic	68	YEAR	68
4871766	Initial	-	20051109	20060104	Periodic	54	YEAR	54
4871773	Followup	20051129	20051208	20060104	Expdited	49	YEAR	49
4871774	Followup	20050726	20050826	20060104	Expdited	-		-
4871775	Followup	20051101	20051221	20060104	Expdited	43	YEAR	43
4871776	Followup	20050301	20050607	20060104	Expdited	71	YEAR	71
4871777	Followup	20051125	20051209	20060104	Expdited	82	YEAR	82
4871778	Initial	-	20051229	20060104	Expdited	-		-
4871779	Initial	20051213	20051229	20060104	Expdited	26	YEAR	26
4871780	Initial	20050101	20051229	20060104	Expdited	28	YEAR	28
4871781	Followup	20051227	20051228	20060104	Expdited	-		-
4871782	Followup	-	20051230	20060104	Expdited	50	YEAR	50
4871783	Initial	20050101	20051227	20060104	Expdited	-		-
4871784	Followup	-	20050808	20060104	Expdited	87	YEAR	87
4871785	Followup	-	20050926	20060104	Expdited	-		-
4871786	Followup	20051130	20051202	20060104	Expdited	17	YEAR	17
4871787	Followup	20030101	20051228	20060104	Expdited	51	YEAR	51
4871788	Followup	20051101	20051228	20060104	Expdited	42	YEAR	42
4871789	Followup	-	20051228	20060104	Expdited	14	YEAR	14
4871790	Initial	-	20051230	20060104	Expdited	-		-
4871791	Initial	-	20051228	20060104	Expdited	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871792	Followup	-	20051229	20060104	Expdited	-		-
4871793	Initial	-	20051229	20060104	Expdited	-		-
4871794	Followup	20050208	20050225	20060104	Expdited	64	YEAR	64
4871795	Followup	20050324	20050407	20060104	Expdited	46	YEAR	46
4871796	Followup	20050706	20050719	20060104	Expdited	45	YEAR	45
4871797	Followup	20050313	20051013	20060104	Expdited	-		-
4871798	Followup	20051003	20051027	20060104	Expdited	59	YEAR	59
4871799	Followup	-	20051123	20060104	Expdited	-		-
4871800	Followup	20050826	20051122	20060104	Expdited	82	YEAR	82
4871801	Followup	20050511	20051206	20060104	Expdited	63	YEAR	63
4871802	Followup	20020701	20051213	20060104	Expdited	28	YEAR	28
4871803	Followup	20051214	20051215	20060104	Expdited	71	YEAR	71
4871804	Followup	-	20051227	20060104	Expdited	-		-
4871805	Initial	20051103	20051228	20060104	Expdited	83	YEAR	83
4871806	Initial	20051108	20051228	20060104	Expdited	64	YEAR	64
4871807	Initial	20051016	20051223	20060104	Expdited	31	YEAR	31
4871808	Initial	20020101	20051228	20060104	Expdited	49	YEAR	49
4871809	Followup	20051130	20051223	20060104	Expdited	69	YEAR	69
4871810	Followup	20051212	20051223	20060104	Expdited	29	YEAR	29
4871811	Followup	20051101	20051223	20060104	Expdited	75	YEAR	75
4871812	Initial	20051119	20051229	20060104	Expdited	63	YEAR	63
4871813	Followup	20050901	20050927	20060104	Expdited	55	YEAR	55
4871814	Initial	20050620	20051222	20060104	Expdited	-		-
4871815	Initial	20051001	20051223	20060104	Expdited	81	YEAR	81
4871816	Initial	20051208	20051222	20060104	Expdited	-		-
4871817	Initial	20050922	20051228	20060104	Expdited	48	YEAR	48

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871818	Initial	20030119	20051228	20060104	Expdited	62	YEAR	62
4871819	Initial	20020501	20051223	20060104	Expdited	54	YEAR	54
4871820	Followup	20010101	20051005	20060104	Expdited	73	YEAR	73
4871821	Followup	20000101	20051005	20060104	Expdited	48	YEAR	48
4871822	Followup	20020101	20050801	20060104	Expdited	-		-
4871823	Followup	20030828	20050921	20060104	Expdited	73	YEAR	73
4871824	Followup	20011001	20051005	20060104	Expdited	41	YEAR	41
4871825	Followup	20051219	20051219	20060104	Expdited	79	YEAR	79
4871826	Followup	20041028	20050217	20060104	Expdited	82	YEAR	82
4871827	Followup	20050801	20051124	20060104	Expdited	79	YEAR	79
4871828	Followup	20051026	20051205	20060104	Expdited	40	YEAR	40
4871829	Followup	20040401	20051005	20060104	Expdited	60	YEAR	60
4871830	Followup	20000101	20050302	20060104	Expdited	52	YEAR	52
4871831	Followup	20010611	20051005	20060104	Expdited	56	YEAR	56
4871833	Followup	20020101	20051005	20060104	Expdited	69	YEAR	69
4871834	Followup	20031201	20050218	20060104	Expdited	79	YEAR	79
4871835	Followup	20000101	20051005	20060104	Expdited	27	YEAR	27
4871836	Followup	19990101	20050401	20060104	Expdited	-		-
4871837	Followup	20000324	20051005	20060104	Expdited	55	YEAR	55
4871838	Followup	20010101	20050920	20060104	Expdited	61	YEAR	61
4871839	Followup	20040901	20051005	20060104	Expdited	65	YEAR	65
4871840	Followup	-	20051005	20060104	Expdited	-		-
4871841	Followup	20010101	20051005	20060104	Expdited	53	YEAR	53
4871842	Followup	20000926	20051005	20060104	Expdited	70	YEAR	70
4871843	Followup	20000101	20051005	20060104	Expdited	75	YEAR	75
4871844	Followup	20040501	20051005	20060104	Expdited	64	YEAR	64

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871845	Initial	20050726	20051230	20060104	Expdited	58	YEAR	58
4871846	Followup	20030122	20050415	20060104	Expdited	63	YEAR	63
4871847	Followup	19990101	20050914	20060104	Expdited	44	YEAR	44
4871848	Followup	20041001	20051010	20060104	Expdited	72	YEAR	72
4871849	Followup	20040810	20050524	20060104	Expdited	50	YEAR	50
4871850	Followup	19990101	20050914	20060104	Expdited	50	YEAR	50
4871851	Followup	20020101	20050916	20060104	Expdited	73	YEAR	73
4871852	Followup	19990101	20051005	20060104	Expdited	38	YEAR	38
4871853	Followup	20000101	20051005	20060104	Expdited	82	YEAR	82
4871854	Followup	20030923	20051005	20060104	Expdited	49	YEAR	49
4871856	Followup	20030101	20050505	20060104	Expdited	66	YEAR	66
4871857	Followup	20051207	20051208	20060104	Expdited	68	YEAR	68
4871858	Followup	19991109	20050912	20060104	Expdited	64	YEAR	64
4871859	Followup	20000101	20051006	20060104	Expdited	49	YEAR	49
4871860	Followup	20020101	20051005	20060104	Expdited	58	YEAR	58
4871861	Initial	20040101	20051220	20060104	Expdited	-		-
4871862	Followup	20000901	20051006	20060104	Expdited	89	YEAR	89
4871863	Initial	-	20051223	20060104	Expdited	-		-
4871864	Initial	20040104	20051227	20060104	Expdited	70	YEAR	70
4871865	Followup	20010201	20050916	20060104	Expdited	65	YEAR	65
4871866	Followup	20040101	20051006	20060104	Expdited	60	YEAR	60
4871867	Followup	20010701	20051006	20060104	Expdited	44	YEAR	44
4871870	Followup	20030501	20051005	20060104	Expdited	67	YEAR	67
4871871	Followup	20000101	20051104	20060104	Expdited	57	YEAR	57
4871873	Initial	20030101	20051220	20060104	Expdited	-		-
4871874	Followup	20001227	20050907	20060104	Expdited	61	YEAR	61

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871875	Followup	20050303	20050909	20060104	Expdited	62	YEAR	62
4871876	Followup	20000210	20051005	20060104	Expdited	72	YEAR	72
4871877	Followup	20020402	20051129	20060104	Expdited	63	YEAR	63
4871878	Followup	20000901	20051006	20060104	Expdited	63	YEAR	63
4871879	Followup	20010603	20051129	20060104	Expdited	83	YEAR	83
4871880	Initial	20030101	20051223	20060104	Expdited	-		-
4871881	Followup	20000227	20051130	20060104	Expdited	53	YEAR	53
4871882	Followup	20021101	20051005	20060104	Expdited	61	YEAR	61
4871883	Initial	19990101	20051223	20060104	Expdited	54	YEAR	54
4871884	Followup	19991108	20030102	20060104	Expdited	66	YEAR	66
4871885	Followup	20000101	20051006	20060104	Expdited	58	YEAR	58
4871886	Initial	20041001	20051223	20060104	Expdited	-		-
4871887	Followup	20020301	20051005	20060104	Expdited	80	YEAR	80
4871888	Initial	20030101	20051223	20060104	Expdited	73	YEAR	73
4871889	Followup	20010717	20051006	20060104	Expdited	77	YEAR	77
4871890	Followup	20031229	20051005	20060104	Expdited	-		-
4871891	Followup	20020114	20051005	20060104	Expdited	66	YEAR	66
4871892	Followup	19990919	20051114	20060104	Expdited	69	YEAR	69
4871893	Followup	20000516	20051129	20060104	Expdited	52	YEAR	52
4871894	Followup	20021201	20051005	20060104	Expdited	-		-
4871895	Followup	20010705	20051006	20060104	Expdited	62	YEAR	62
4871897	Followup	20041001	20051215	20060104	Expdited	28	YEAR	28
4871899	Initial	20051101	20051230	20060104	Expdited	66	YEAR	66
4871900	Initial	20051226	20051229	20060104	Expdited	67	YEAR	67
4871901	Followup	20000101	20051005	20060104	Expdited	57	YEAR	57
4871902	Initial	20051219	20051227	20060104	Expdited	51	YEAR	51

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871903	Followup	-	20051020	20060104	Expdited	21	YEAR	21
4871904	Initial	20051113	20051227	20060104	Expdited	22640	DAY	62
4871905	Followup	20040712	20051025	20060104	Expdited	77	YEAR	77
4871906	Initial	20050401	20051228	20060104	Expdited	22	YEAR	22
4871907	Followup	20010101	20051005	20060104	Expdited	36	YEAR	36
4871908	Initial	-	20051222	20060104	Expdited	-		-
4871909	Initial	20051101	20051222	20060104	Expdited	59	YEAR	59
4871912	Initial	-	20051226	20060104	Expdited	-		-
4871917	Initial	-	20051228	20060104	Expdited	-		-
4871918	Initial	-	20051227	20060104	Expdited	36	YEAR	36
4871919	Initial	-	20051227	20060104	Expdited	35	YEAR	35
4871920	Followup	20051207	20051207	20060104	Expdited	56	YEAR	56
4871921	Initial	-	20051227	20060104	Expdited	36	YEAR	36
4871922	Initial	20051203	20051227	20060104	Expdited	74	YEAR	74
4871923	Followup	20051101	20051201	20060104	Expdited	-		-
4871924	Followup	20051008	20051222	20060104	Expdited	57	YEAR	57
4871927	Followup	20000427	20051219	20051230	Expdited	78	YEAR	78
4871928	Followup	20051208	20051215	20060104	Expdited	-		-
4871929	Initial	20050613	20051220	20060104	Expdited	61	YEAR	61
4871930	Followup	20051126	20051128	20060104	Expdited	40	YEAR	40
4871934	Followup	19880906	20040804	20060104	Expdited	30	YEAR	30
4871935	Followup	19940101	20050829	20060104	Expdited	17	YEAR	17
4871937	Followup	20050725	20051018	20060104	Expdited	60	YEAR	60
4871938	Followup	19980201	20050629	20060104	Expdited	20	YEAR	20
4871939	Initial	20051212	20051223	20060104	Expdited	21	YEAR	21
4871940	Followup	20020301	20050623	20060104	Expdited	33	YEAR	33

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4871941	Followup	19980601	20050331	20060104	Expdited	15	YEAR	15
4871942	Followup	20030406	20030409	20060104	Expdited	52	YEAR	52
4871943	Followup	20050312	20050314	20060104	Expdited	35	YEAR	35
4871949	Followup	20001030	20050928	20060104	Expdited	38	YEAR	38
4871950	Followup	20051026	20051026	20060104	Expdited	22	YEAR	22
4871957	Followup	20051201	20051208	20060104	Expdited	27817	DAY	76
4871969	Followup	20051016	20051026	20060104	Expdited	50	YEAR	50
4871971	Initial	-	20051130	20060104	Expdited	-		-
4871972	Followup	20050227	20050421	20060104	Expdited	73	YEAR	73
4871973	Initial	20050622	20051220	20060104	Expdited	47	YEAR	47
4871974	Initial	20050812	20051222	20060104	Expdited	67	YEAR	67
4871976	Initial	20051204	20051221	20060104	Expdited	58	YEAR	58
4871977	Initial	-	20051224	20060104	Expdited	56	YEAR	56
4871978	Initial	-	20051223	20060104	Expdited	47	YEAR	47
4871979	Initial	20051209	20051222	20060104	Expdited	28	YEAR	28
4871980	Followup	20050623	20051101	20060104	Expdited	59	YEAR	59
4871988	Followup	20050801	20051128	20060104	Expdited	64	YEAR	64
4872010	Initial	-	20051220	20051230	Expdited	35	YEAR	35
4872016	Initial	20051001	20051228	20060104	Expdited	-		-
4872017	Followup	-	20051122	20060104	Expdited	36	YEAR	36
4872018	Initial	20050710	20051227	20060104	Expdited	-		-
4872021	Initial	-	20051227	20060104	Expdited	-		-
4872030	Followup	20030717	20031208	20060104	Expdited	73	YEAR	73
4872033	Followup	20050613	20051031	20060104	Expdited	17149	DAY	46
4872034	Followup	20051116	20051118	20060104	Expdited	29885	DAY	81
4872043	Initial	20051225	20051229	20060104	Expdited	31	YEAR	31

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4872044	Followup	-	20050929	20060104	Expdited	72	YEAR	72
4872072	Followup	20050401	20050715	20060104	Expdited	68	YEAR	68
4872074	Initial	20050901	20051229	20060104	Expdited	64	YEAR	64
4872075	Initial	20050101	20051230	20060104	Expdited	-		-
4872076	Followup	20040106	20050818	20060104	Expdited	70	YEAR	70
4872077	Initial	20051020	20051230	20060104	Expdited	79	YEAR	79
4872086	Initial	20051201	20051228	20060104	Expdited	-		-
4872087	Initial	-	20051227	20060104	Expdited	20	MONTH	1
4872123	Followup	20050702	20050705	20060104	Expdited	-		-
4872134	Initial	20050901	20051222	20060104	Expdited	53	YEAR	53
4872153	Initial	-	20051117	20060103	Expdited	-		-
4872155	Initial	20051201	20051219	20060103	Expdited	62	YEAR	62
4872156	Initial	20001101	20051222	20060104	Expdited	63	YEAR	63
4872157	Initial	20051214	20051219	20060103	Expdited	89	YEAR	89
4872159	Initial	20030101	20051219	20060103	Expdited	23	YEAR	23
4872161	Initial	20050101	20051219	20060103	Expdited	-		-
4872163	Initial	-	20051219	20060103	Expdited	43	YEAR	43
4872165	Initial	20051101	20051219	20060103	Expdited	67	YEAR	67
4872166	Initial	-	20051222	20060103	Expdited	65	YEAR	65
4872168	Followup	19961113	20050406	20060104	Expdited	15	YEAR	15
4872169	Followup	19980824	20050812	20060104	Expdited	17	YEAR	17
4872170	Followup	20050418	20051216	20060103	Expdited	69	YEAR	69
4872171	Initial	20051201	20051217	20060103	Expdited	-		-
4872172	Initial	20051012	20051219	20060103	Expdited	23	YEAR	23
4872173	Initial	20051217	20051217	20060103	Expdited	-		-
4872174	Initial	20051201	20051217	20060103	Expdited	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4872175	Followup	20051220	20051223	20060103	Expdited	28	YEAR	28
4872176	Followup	20050101	20051220	20060103	Expdited	32	YEAR	32
4872178	Initial	-	20051220	20060103	Expdited	9	YEAR	9
4872179	Initial	-	20051221	20060103	Expdited	74	YEAR	74
4872180	Initial	-	20051221	20060103	Expdited	68	YEAR	68
4872181	Followup	20051031	20051010	20060104	Expdited	-		-
4872182	Followup	20051218	20051031	20060104	Expdited	-		-
4872183	Initial	20051208	20051216	20060103	Expdited	-		-
4872184	Initial	-	20051219	20060103	Expdited	53	YEAR	53
4872186	Followup	-	20051216	20060103	Expdited	55	YEAR	55
4872187	Followup	-	20051216	20060103	Expdited	60	YEAR	60
4872188	Initial	-	20051219	20060103	Expdited	59	YEAR	59
4872190	Initial	20030930	20051221	20060103	Expdited	79	YEAR	79
4872191	Initial	20051130	20051226	20060103	Expdited	68	YEAR	68
4872193	Initial	20050228	20051220	20060103	Expdited	78	YEAR	78
4872194	Followup	20030704	20051220	20060104	Expdited	-		-
4872195	Followup	20050509	20050621	20060104	Expdited	71	YEAR	71
4872196	Initial	-	20051228	20060104	Expdited	-		-
4872197	Followup	20050502	20050523	20060104	Expdited	70	YEAR	70
4872198	Initial	20050101	20051228	20060104	Expdited	49	YEAR	49
4872203	Followup	20050705	20050708	20060104	Expdited	13	YEAR	13
4872220	Followup	20051014	20051214	20060104	Expdited	75	YEAR	75
4872266	Followup	20040201	20051214	20060104	Expdited	72	YEAR	72
4872267	Initial	20050101	20051220	20060104	Expdited	70	YEAR	70
4872268	Followup	20050101	20051212	20060104	Expdited	70	YEAR	70
4872319	Followup	20051116	20051117	20060104	Expdited	59	YEAR	59

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4872382	Initial	-	20051227	20060104	Expdited	-		-
4872383	Initial	20030201	20051228	20060104	Expdited	48	YEAR	48
4872384	Followup	20020701	20051005	20060104	Expdited	81	YEAR	81
4872385	Initial	20051126	20051229	20060104	Expdited	-		-
4872386	Followup	20020101	20050103	20060104	Expdited	61	YEAR	61
4872388	Initial	20040626	20051227	20060104	Expdited	-		-
4872389	Initial	20040101	20051227	20060104	Expdited	57	YEAR	57
4872390	Initial	20031201	20051228	20060104	Expdited	-		-
4872398	Initial	20020918	20051222	20060104	Expdited	28	YEAR	28
4872399	Followup	20010901	20051006	20060104	Expdited	59	YEAR	59
4872400	Initial	20050401	20051228	20060104	Expdited	-		-
4872401	Initial	20030101	20051228	20060104	Expdited	-		-
4872402	Followup	20020401	20051005	20060104	Expdited	70	YEAR	70
4872403	Followup	20030101	20051005	20060104	Expdited	49	YEAR	49
4872404	Followup	20030101	20051005	20060104	Expdited	58	YEAR	58
4872405	Initial	-	20051227	20060104	Expdited	-		-
4872406	Followup	20040101	20050920	20060104	Expdited	71	YEAR	71
4872407	Initial	20051001	20051222	20060104	Expdited	81	YEAR	81
4872408	Followup	19840705	20051130	20060104	Expdited	18	YEAR	18
4872409	Followup	20010508	20051005	20060104	Expdited	51	YEAR	51
4872410	Initial	20030801	20051227	20060104	Expdited	73	YEAR	73
4872411	Followup	20010121	20051005	20060104	Expdited	70	YEAR	70
4872412	Followup	20040801	20051005	20060104	Expdited	79	YEAR	79
4872414	Followup	20000331	20050112	20060104	Expdited	56	YEAR	56
4872415	Followup	20041004	20051005	20060104	Expdited	71	YEAR	71
4872416	Followup	20010201	20050705	20060104	Expdited	60	YEAR	60

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4872417	Followup	20050601	20050725	20060104	Expdited	55	YEAR	55
4872418	Followup	20031206	20051005	20060104	Expdited	74	YEAR	74
4872419	Followup	20050201	20051101	20060104	Expdited	51	YEAR	51
4872420	Followup	20020601	20051005	20060104	Expdited	34	YEAR	34
4872421	Followup	20040420	20050510	20060104	Expdited	49	YEAR	49
4872430	Initial	-	20051227	20060104	Expdited	-		-
4872431	Followup	20040704	20050214	20060104	Expdited	71	YEAR	71
4872437	Initial	20040527	20051222	20060104	Expdited	0	DAY	0
4872439	Initial	-	20051229	20060104	Expdited	-		-
4872440	Followup	20030913	20051005	20060104	Expdited	48	YEAR	48
4872441	Followup	20010101	20051005	20060104	Expdited	66	YEAR	66
4872442	Initial	20031201	20051229	20060104	Expdited	-		-
4872443	Initial	20040901	20051229	20060104	Expdited	-		-
4872444	Initial	20040401	20051229	20060104	Expdited	-		-
4872445	Followup	20020501	20051003	20060104	Expdited	70	YEAR	70
4872446	Initial	20040829	20051227	20060104	Expdited	-		-
4872447	Followup	20041101	20051005	20060104	Expdited	85	YEAR	85
4872448	Initial	20020801	20051228	20060104	Expdited	-		-
4872449	Initial	19990501	20051228	20060104	Expdited	59	YEAR	59
4872450	Initial	20020701	20051229	20060104	Expdited	78	YEAR	78
4872452	Followup	20050313	20050519	20060104	Expdited	64	YEAR	64
4872453	Followup	20020101	20050105	20060104	Expdited	63	YEAR	63
4872454	Initial	20040801	20051229	20060104	Expdited	54	YEAR	54
4872455	Followup	20040101	20050110	20060104	Expdited	56	YEAR	56
4872456	Initial	20050501	20051229	20060104	Expdited	62	YEAR	62
4872457	Followup	20020101	20050408	20060104	Expdited	50	YEAR	50

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4872462	Followup	20020101	20051005	20060104	Expdited	67	YEAR	67
4872463	Initial	20020101	20051229	20060104	Expdited	-		-
4872464	Initial	20050801	20051227	20060104	Expdited	-		-
4872465	Initial	20031201	20051222	20060104	Expdited	-		-
4872466	Followup	20010101	20050118	20060104	Expdited	50	YEAR	50
4872467	Followup	20050501	20050609	20060104	Expdited	74	YEAR	74
4872468	Initial	20051119	20051222	20060104	Expdited	23	YEAR	23
4872469	Followup	20030801	20050427	20060104	Expdited	66	YEAR	66
4872470	Followup	20041101	20050103	20060104	Expdited	31	YEAR	31
4872481	Followup	20051030	20051101	20060104	Expdited	-		-
4872482	Initial	-	20050531	20060104	Expdited	-		-
4872483	Followup	20051024	20051026	20060104	Expdited	-		-
4872484	Initial	20051118	20051226	20060104	Expdited	-		-
4872485	Followup	20050725	20051006	20060104	Expdited	-		-
4872486	Followup	-	20051210	20060104	Expdited	-		-
4872487	Initial	-	20051223	20060104	Expdited	59	YEAR	59
4872488	Followup	20051027	20051108	20060104	Expdited	-		-
4872489	Followup	20021001	20050420	20060104	Expdited	67	YEAR	67
4872490	Followup	20051124	20051216	20060104	Expdited	-		-
4872491	Followup	20050619	20050708	20060104	Expdited	-		-
4872492	Initial	20050525	20051230	20060104	Expdited	69	YEAR	69
4872493	Followup	20030108	20030630	20060104	Expdited	-		-
4872494	Followup	20020714	20030220	20060104	Expdited	-		-
4872495	Followup	20010713	20020121	20060104	Expdited	-		-
4872496	Followup	19990908	19991110	20060104	Expdited	-		-
4872497	Followup	20021113	20030825	20060104	Expdited	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Code for initial or followup status</i>	<i>Date adverse event occurred or began</i>	<i>Date manufacturer first received initial (or follow-up) information</i>	<i>Date FDA received report</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age</i>
4872498	Followup	20030915	20040322	20060104	Expdited	-		-
4872499	Followup	20040606	20041025	20060104	Expdited	-		-
4872500	Followup	20040615	20050111	20060104	Expdited	-		-
4872501	Followup	19990108	19990707	20060104	Expdited	-		-
4872502	Followup	19981216	19990521	20060104	Expdited	-		-
4872535	Initial	20051023	20051223	20060103	Expdited	68	YEAR	68
4872536	Initial	20041201	20051221	20060103	Expdited	-		-
4872537	Initial	20050901	20051221	20060103	Expdited	36	YEAR	36
4872538	Initial	20000205	20051220	20060103	Expdited	27	YEAR	27
4872539	Initial	20051101	20051221	20060103	Expdited	25	YEAR	25
4872540	Initial	20050101	20051219	20060103	Expdited	75	YEAR	75
4872541	Initial	20051107	20051228	20060105	Expdited	56	YEAR	56

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4793437	GROUP 3	Male	-		-	20051011	Consumer	-	UNITED STATES
4799889		Female	-		-	20051012		-	AUSTRALIA
4802758	GROUP 4	Female	64.3	Kilograms	64	20051012		20040427	UNITED STATES
4806822		Missing	-		-	-		-	UNITED STATES
4807735	GROUP 3	Female	-		-	20051018	Physician	-	FRANCE
4807884	GROUP 3	Female	49.1	Kilograms	49	20051020	Physician	-	UNITED STATES
4810789		Female	115	Pounds	52	20051021	Consumer	-	UNITED STATES
4811786	GROUP 3	Male	81.2	Kilograms	81	20051021	Pharmacist	-	UNITED STATES
4813034	GROUP 3	Male	186	Pounds	84	20051025	Other health professional	-	CANADA
4815387	GROUP 3	Male	-		-	20051027	Physician	-	UNITED STATES
4817144	GROUP 4	Female	47.2	Kilograms	47	20050829	Physician	-	UNITED STATES
4817145	GROUP 3	Female	-		-	20050829	Other health professional	-	UNITED STATES
4817146	GROUP 3	Female	-		-	20050829	Physician	-	UNITED STATES
4817148		Male	-		-	20050829	Physician	-	UNITED STATES
4817149	GROUP 3	Male	-		-	20050829	Physician	-	UNITED STATES
4817159	GROUP 3	Female	-		-	20050829	Physician	-	UNITED STATES
4817167		Female	-		-	20050829	Physician	-	UNITED STATES
4819355	GROUP 3	Male	222	Pounds	100	20051014	Consumer	-	UNITED STATES
4820164		Male	74	Kilograms	74	20051020	Other health professional	-	UNITED STATES
4821833	GROUP 3	Male	-		-	20051107	Physician	-	GERMANY
4826267		Missing	92	Kilograms	92	-	Other health professional	-	UNITED STATES
4826274		Male	75	Kilograms	75	20051024	Other health professional	-	UNITED STATES
4826360	GROUP 3	Male	77.1	Kilograms	77	20051031	Other health professional	20050215	UNITED STATES
4828303	GROUP 2	Male	67	Kilograms	67	20051115	Physician	-	JAPAN
4832882	GROUP 3	Male	96.8	Kilograms	96	20051121	Physician	-	NETHERLANDS
4833762	GROUP 2	Female	117	Pounds	53	20051117	Consumer	-	UNITED STATES
4833775		Male	103	Kilograms	103	20051114	Other health professional	20051110	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4834797	GROUP 3	Male	170	Pounds	77	20051111	Physician	20050215	UNITED STATES
4838069		Male	96	Kilograms	96	20051110	Other health professional	-	UNITED STATES
4840105	GROUP 2	Male	130	Pounds	58	20051122	Consumer	-	UNITED STATES
4843170	GROUP 3	Female	-		-	20051004		-	UNITED STATES
4846119	GROUP 1	Female	270	Pounds	122	20051129	Other health professional	-	UNITED STATES
4846435		Male	-		-	20051201	Consumer	20051106	UNITED STATES
4847003		Missing	-		-	20051201		-	FRANCE
4847053		Male	-		-	20051207	Other health professional	-	UNITED STATES
4847638	GROUP 1	Female	-		-	20051202	Other health professional	-	UNITED KINGDOM
4847706	GROUP 1	Female	-		-	20051123	Physician	-	MEXICO
4852120		Female	-		-	20051104	Other health professional	-	UNITED STATES
4852895	GROUP 3	Missing	-		-	20051206	Physician	20040101	UNITED STATES
4854233	GROUP 4	Male	-		-	20051108	Physician	-	UNITED STATES
4865588	GROUP 2	Female	148	Pounds	67	20051214		-	UNITED STATES
4867362		Unknown	-		-	20051221	Physician	-	UNITED STATES
4867364		Unknown	-		-	20051221	Physician	-	UNITED STATES
4867367		Missing	-		-	20051221	Physician	-	UNITED STATES
4867370		Missing	-		-	20051221	Physician	-	UNITED STATES
4867373		Missing	-		-	20051221	Physician	-	UNITED STATES
4867375		Missing	-		-	20051221	Physician	-	UNITED STATES
4867377		Missing	-		-	20051221	Physician	-	UNITED STATES
4867384		Missing	-		-	20051221	Physician	-	UNITED STATES
4867390		Missing	-		-	20051221	Physician	-	UNITED STATES
4867392		Missing	-		-	20051221	Physician	-	UNITED STATES
4867604		Unknown	-		-	20051221	Physician	-	UNITED STATES
4867630		Unknown	-		-	20051221	Physician	-	UNITED STATES
4869006	GROUP 3	Female	45	Kilograms	45	20051207	Physician	-	JAPAN

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870242	GROUP 3	Female	80	Kilograms	80	20060102	Other health professional	-	PORTUGAL
4870243	GROUP 3	Male	53	Kilograms	53	20060102	Physician	20051129	JAPAN
4870244	GROUP 1	Male	-		-	20060102	Other health professional	-	GERMANY
4870245	GROUP 2	Female	63.5	Kilograms	63	20060102	Physician	-	UNITED STATES
4870246	GROUP 3	Male	-		-	20060102	Physician	-	NETHERLANDS
4870247	GROUP 4	Female	65	Kilograms	65	20060102	Consumer	-	AUSTRALIA
4870248	GROUP 3	Male	72	Kilograms	72	20060102	Physician	20051120	BELGIUM
4870249		Missing	-		-	20060102	Pharmacist	-	UNITED STATES
4870250	GROUP 2	Female	57	Kilograms	57	20060102	Physician	-	JAPAN
4870251	GROUP 2	Female	-		-	20060102	Physician	-	BELGIUM
4870252	GROUP 2	Female	-		-	20060102	Other health professional	-	JAPAN
4870253	GROUP 3	Female	-		-	20060102	Physician	-	UNITED KINGDOM
4870254		Male	-		-	20051230	Physician	-	UNITED STATES
4870255		Male	-		-	20060102	Physician	20051219	GERMANY
4870256	GROUP 3	Male	-		-	20060102	Other health professional	-	UNITED KINGDOM
4870257		Male	75	Kilograms	75	20060102	Other health professional	20050928	KOREA, REPUBLIC OF
4870258	GROUP 3	Female	127	Kilograms	127	20060102		-	UNITED STATES
4870272		Female	54.48	Kilograms	54	20060103	Physician	-	UNITED STATES
4870302	GROUP 1	Female	-		-	20060103	Physician	-	FRANCE
4870303	GROUP 2	Male	-		-	20060103	Other health professional	-	CANADA
4870304		Male	62.5	Kilograms	62	20060103	Physician	-	JAPAN
4870305	GROUP 3	Male	-		-	20060103	Other health professional	-	NETHERLANDS
4870313		Male	-		-	20051215	Physician	-	UNITED KINGDOM
4870319		Female	-		-	20060103	Other health professional	-	UNITED STATES
4870320		Male	-		-	20060103	Other health professional	-	UNITED STATES
4870321		Male	-		-	20060103	Other health professional	-	UNITED STATES
4870322		Male	67.59	Kilograms	67	20060103	Other health professional	-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870323		Male	60	Kilograms	60	20060103	Physician	20041230	UNITED STATES
4870324		Female	52.8	Kilograms	52	20060103	Physician	-	KOREA, REPUBLIC OF
4870325	GROUP 2	Male	-		-	20060103	Physician	20050701	UNITED STATES
4870326		Female	46.27	Kilograms	46	20060103	Other health professional	-	UNITED STATES
4870327	GROUP 3	Female	-		-	20060103	Other health professional	-	UNITED STATES
4870328		Male	-		-	20060103	Physician	-	JAPAN
4870329		Female	67.59	Kilograms	67	20060103	Physician	-	UNITED STATES
4870330	GROUP 3	Male	-		-	20060103	Other health professional	-	NETHERLANDS
4870331		Male	74.39	Kilograms	74	20060103	Physician	-	UNITED STATES
4870332		Female	68.04	Kilograms	68	20060103	Physician	-	UNITED STATES
4870333		Male	126.1	Kilograms	126	20060103	Physician	-	UNITED STATES
4870334		Male	82.56	Kilograms	82	20060103	Physician	-	UNITED STATES
4870335		Male	-		-	20060103	Physician	-	UNITED STATES
4870336		Female	-		-	20060103	Consumer	-	UNITED STATES
4870343		Female	60	Kilograms	60	20060103	Physician	-	
4870344		Female	92	Kilograms	92	20060103		-	UNITED KINGDOM
4870345		Male	-		-	20060103	Physician	-	UNITED STATES
4870346		Female	65	Kilograms	65	20060103	Physician	-	JAPAN
4870347	GROUP 4	Female	60.78	Kilograms	60	20060103		-	UNITED STATES
4870348		Female	67.6	Kilograms	67	20060103		-	UNITED STATES
4870349		Female	72.7	Kilograms	72	20060103		-	UNITED STATES
4870350		Female	-		-	20060103	Consumer	-	UNITED STATES
4870351		Female	45	Kilograms	45	20060103	Physician	-	JAPAN
4870352		Male	-		-	20060103	Other health professional	-	
4870353		Female	-		-	20060103	Physician	-	JAPAN
4870354		Female	-		-	20060103	Physician	-	JAPAN
4870355		Female	-		-	20060103	Consumer	-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870356		Male	-		-	20060103	Physician		- JAPAN
4870357		Male	-		-	20060103	Other health professional		- JAPAN
4870358	GROUP 1	Female	-		-	20060103			- JAPAN
4870359		Female	75	Kilograms	75	20060103			- UNITED KINGDOM
4870360		Female	-		-	20060103			-
4870362		Female	-		-	20060103	Physician		- UNITED STATES
4870363		Female	54.43	Kilograms	54	20060103	Consumer		- UNITED STATES
4870364		Male	-		-	20060103	Physician		- UNITED STATES
4870365		Female	-		-	20060103	Physician		- UNITED STATES
4870366		Male	88.45	Kilograms	88	20060103	Physician	20050816	UNITED STATES
4870367		Male	-		-	20060103	Physician		- UNITED STATES
4870370	GROUP 3	Female	65	Kilograms	65	20060103	Physician		- UNITED STATES
4870372	GROUP 4	Male	74	Kilograms	74	20060103	Physician		- CANADA
4870379	GROUP 3	Female	70	Kilograms	70	20060103	Physician		- INDIA
4870385		Female	-		-	20060103	Physician		- UNITED STATES
4870386		Female	99.79	Kilograms	99	20060103	Physician		- UNITED STATES
4870387		Female	-		-	20060103	Physician		- UNITED STATES
4870388		Female	69.85	Kilograms	69	20060103	Physician		- UNITED STATES
4870389		Female	56.7	Kilograms	56	20060103	Physician		- UNITED STATES
4870390		Female	-		-	20060103	Physician		- UNITED STATES
4870391		Male	51.71	Kilograms	51	20060103	Physician	20050704	UNITED STATES
4870392		Female	73.48	Kilograms	73	20060103	Consumer		- UNITED STATES
4870393		Female	129.28	Kilograms	129	20060103	Consumer	20050101	UNITED STATES
4870414	GROUP 3	Female	53	Kilograms	53	20060103	Physician		- UNITED STATES
4870415	GROUP 3	Female	70	Kilograms	70	20060103	Consumer		- UNITED STATES
4870416	GROUP 4	Female	-		-	20060103	Physician		- UNITED STATES
4870417		Missing	-		-	20060103	Physician		- UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870418		Female	-		-	20060103	Consumer	-	UNITED STATES
4870419	GROUP 2	Female	79	Kilograms	79	20060103	Consumer	-	UNITED STATES
4870420	GROUP 1	Male	82	Kilograms	82	20060103	Other health professional	-	UNITED STATES
4870421	GROUP 2	Female	-		-	20060103	Physician	-	UNITED STATES
4870422	GROUP 3	Female	82	Kilograms	82	20060103	Consumer	-	UNITED STATES
4870423	GROUP 3	Female	-		-	20060103	Consumer	-	UNITED STATES
4870424		Female	-		-	20060103	Pharmacist	-	UNITED STATES
4870425	GROUP 2	Female	43	Kilograms	43	20060103	Other health professional	-	UNITED STATES
4870426		Male	59	Kilograms	59	20060103	Consumer	-	UNITED STATES
4870427		Female	-		-	20060103	Consumer	-	UNITED STATES
4870428		Female	-		-	20060103	Consumer	-	UNITED STATES
4870429		Missing	-		-	20060103	Consumer	-	UNITED STATES
4870430	GROUP 2	Female	59	Kilograms	59	20060103	Consumer	-	UNITED STATES
4870431		Female	-		-	20060103	Consumer	-	UNITED STATES
4870432	GROUP 2	Male	76	Kilograms	76	20060103	Consumer	-	UNITED STATES
4870433	GROUP 3	Male	-		-	20060103	Pharmacist	-	UNITED STATES
4870434	GROUP 2	Male	77	Kilograms	77	20060103	Consumer	-	UNITED STATES
4870435		Female	-		-	20060103	Consumer	-	UNITED STATES
4870436		Female	-		-	20060103	Consumer	-	UNITED STATES
4870437		Female	-		-	20060103	Consumer	-	UNITED STATES
4870438	GROUP 3	Female	54	Kilograms	54	20060103	Consumer	-	UNITED STATES
4870439	GROUP 4	Male	-		-	20060103	Physician	-	UNITED STATES
4870440	GROUP 2	Male	-		-	20060103	Physician	-	UNITED STATES
4870441	GROUP 1	Female	52	Kilograms	52	20060103	Physician	-	UNITED STATES
4870442	GROUP 4	Male	69	Kilograms	69	20060103	Consumer	-	UNITED STATES
4870443		Female	-		-	20060103	Consumer	-	UNITED STATES
4870444		Female	-		-	20060103	Consumer	-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870445		Male	-		-	20060103	Consumer	-	UNITED STATES
4870446		Missing	-		-	20060103	Physician	-	UNITED STATES
4870447		Male	-		-	20060103	Physician	-	UNITED STATES
4870448	GROUP 3	Female	-		-	20060103	Consumer	-	UNITED STATES
4870449	GROUP 3	Female	138	Kilograms	138	20060103	Consumer	-	UNITED STATES
4870450		Missing	-		-	20060103	Physician	-	UNITED STATES
4870451		Missing	-		-	20060103	Physician	-	UNITED STATES
4870452	GROUP 1	Male	-		-	20060103	Consumer	-	UNITED STATES
4870453	GROUP 2	Male	107	Kilograms	107	20060103	Consumer	-	UNITED STATES
4870454		Male	73	Kilograms	73	20060103	Consumer	-	UNITED STATES
4870455	GROUP 3	Female	-		-	20060103	Physician	-	UNITED STATES
4870456	GROUP 3	Female	-		-	20060103	Consumer	-	UNITED STATES
4870457	GROUP 3	Male	73	Kilograms	73	20060103	Physician	-	UNITED STATES
4870458		Female	61	Kilograms	61	20060103	Physician	20051006	GERMANY
4870459	GROUP 2	Male	68.1	Kilograms	68	20060103	Physician	-	UNITED STATES
4870460		Female	73	Kilograms	73	20060103	Physician	-	UNITED STATES
4870461		Male	63	Kilograms	63	20060103	Physician	20051014	GERMANY
4870462		Missing	-		-	20060103	Consumer	-	UNITED STATES
4870463		Female	48.7	Kilograms	48	20060103	Physician	-	CANADA
4870464		Female	-		-	20060103	Other health professional	-	UNITED STATES
4870465		Male	-		-	20060103	Physician	-	UNITED STATES
4870466		Female	-		-	20060103	Pharmacist	-	UNITED STATES
4870467	GROUP 2	Male	110	Kilograms	110	20060103	Physician	-	SWITZERLAND
4870468		Male	75.5	Kilograms	75	20060103	Physician	-	GERMANY
4870469		Male	85	Kilograms	85	20060103	Physician	-	FRANCE
4870478		Female	-		-	20060103	Physician	-	UNITED STATES
4870480	GROUP 4	Female	-		-	20060103	Other health professional	-	FRANCE

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870481		Male	-		-	20060103	Consumer	-	UNITED STATES
4870482	GROUP 3	Female	-		-	20060103	Physician	20051222	JAPAN
4870483	GROUP 3	Male	-		-	20060103	Physician	-	JAPAN
4870484	GROUP 3	Male	80	Kilograms	80	20060103	Other health professional	-	SWITZERLAND
4870486		Female	80	Kilograms	80	20060103	Physician	20050805	GERMANY
4870512	GROUP 1	Male	-		-	20060103	Other health professional	-	GERMANY
4870529	GROUP 3	Male	90	Kilograms	90	20060103	Physician	-	GERMANY
4870534		Female	-		-	20060103		20051118	UNITED STATES
4870535	GROUP 3	Male	64	Kilograms	64	20060103	Physician	-	JAPAN
4870550	GROUP 3	Male	-		-	20060103		-	UNITED KINGDOM
4870552	GROUP 2	Female	-		-	20051230		-	FRANCE
4870553	GROUP 2	Male	58	Kilograms	58	20060103	Physician	-	JAPAN
4870566	GROUP 4	Female	-		-	20060103	Physician	-	ISRAEL
4870567	GROUP 2	Male	90	Kilograms	90	20051230	Physician	-	JAPAN
4870568	GROUP 4	Female	50	Kilograms	50	20060102		-	
4870569	GROUP 4	Male	93	Kilograms	93	20060102		-	
4870570		Female	60.7	Kilograms	60	20060102	Physician	-	UNITED STATES
4870571	GROUP 2	Male	-		-	20060102	Physician	-	FRANCE
4870572	GROUP 3	Female	46	Kilograms	46	20060102	Other health professional	-	JAPAN
4870573	GROUP 4	Female	41	Kilograms	41	20060103	Consumer	20051221	UNITED STATES
4870574	GROUP 3	Male	-		-	20060102		-	
4870575	GROUP 2	Female	-		-	20060102		-	
4870576	GROUP 2	Male	-		-	20060102	Physician	-	JAPAN
4870577	GROUP 3	Female	67	Kilograms	67	20060102		-	FRANCE
4870578	GROUP 1	Female	112	Kilograms	112	20060102		-	
4870579	GROUP 2	Female	-		-	20060102		-	
4870580	GROUP 4	Male	-		-	20060102	Other health professional	-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870581	GROUP 3	Missing	-		-	20060103	Physician	-	JAPAN
4870582	GROUP 2	Female	-		-	20060103	Other health professional	20051013	AUSTRALIA
4870583	GROUP 4	Male	-		-	20060102		-	
4870584	GROUP 4	Male	-		-	20060102		-	
4870585	GROUP 3	Male	-		-	20060103	Physician	-	AUSTRALIA
4870586	GROUP 3	Male	-		-	20060103	Other health professional	-	UNITED STATES
4870587	GROUP 2	Male	-		-	20060103	Physician	-	FRANCE
4870588	GROUP 4	Female	-		-	20060103	Other health professional	20051109	FRANCE
4870589	GROUP 3	Male	-		-	20060103	Physician	-	UNITED STATES
4870591	GROUP 2	Male	-		-	20060103	Other health professional	-	JAPAN
4870592		Female	-		-	20060103	Physician	-	JAPAN
4870593	GROUP 4	Female	64	Kilograms	64	20051230	Physician	-	UNITED STATES
4870594	GROUP 1	Male	0	Kilograms	0	20060103	Physician	20050126	JAPAN
4870604	GROUP 4	Female	0	Kilograms	0	20060103	Physician	20050918	JAPAN
4870618	GROUP 3	Male	85.3	Kilograms	85	20060103	Consumer	-	UNITED STATES
4870623	GROUP 1	Male	-		-	20060103	Other health professional	-	UNITED STATES
4870624		Missing	-		-	20060103	Other health professional	-	UNITED STATES
4870651		Female	-		-	20060103	Pharmacist	-	UNITED STATES
4870659		Male	-		-	20060103	Physician	-	CANADA
4870660	GROUP 3	Male	-		-	20060103	Physician	-	FRANCE
4870661	GROUP 1	Male	-		-	20060103	Physician	-	AUSTRIA
4870662		Female	-		-	20060103	Physician	-	UNITED KINGDOM
4870663		Male	78.93	Kilograms	78	20060103	Consumer	-	UNITED STATES
4870667		Female	54.2	Kilograms	54	20060103	Physician	-	FRANCE
4870668		Female	67	Kilograms	67	20060103	Pharmacist	-	CANADA
4870669		Female	50	Kilograms	50	20060103	Physician	-	BELGIUM
4870670	GROUP 3	Female	-		-	20060103	Consumer	-	CHINA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870671	GROUP 4	Male	-		-	20060103	Other health professional	-	UNITED KINGDOM
4870672	GROUP 2	Male	-		-	20060103	Physician	-	UNITED STATES
4870673	GROUP 2	Male	-		-	20060103	Physician	-	JAPAN
4870674	GROUP 3	Female	90	Kilograms	90	20060103	Physician	20051227	GERMANY
4870684	GROUP 3	Female	-		-	20060103	Consumer	-	UNITED STATES
4870685	GROUP 3	Male	-		-	20060103	Consumer	-	UNITED STATES
4870686	GROUP 2	Female	-		-	20060103	Consumer	-	UNITED STATES
4870687	GROUP 1	Male	-		-	20060103	Consumer	-	FRANCE
4870688		Female	-		-	20060103	Physician	20040108	UNITED KINGDOM
4870689		Male	-		-	20060103	Physician	-	UNITED KINGDOM
4870690	GROUP 1	Female	-		-	20060103	Physician	-	AUSTRALIA
4870691	GROUP 2	Female	-		-	20060103	Pharmacist	-	JAPAN
4870692	GROUP 4	Female	40	Kilograms	40	20060103	Physician	20050913	JAPAN
4870693	GROUP 2	Male	-		-	20060103	Physician	-	JAPAN
4870694	GROUP 1	Male	12	Kilograms	12	20060103	Physician	20050901	JAPAN
4870695	GROUP 2	Male	-		-	20060103	Physician	20031015	JAPAN
4870696	GROUP 2	Male	-		-	20060103	Consumer	-	NETHERLANDS
4870697	GROUP 2	Male	-		-	20060103	Pharmacist	-	UNITED KINGDOM
4870698	GROUP 2	Male	89	Kilograms	89	20060103	Physician	20051211	JAPAN
4870699	GROUP 3	Female	-		-	20060103	Consumer	-	JAPAN
4870700	GROUP 3	Male	70	Kilograms	70	20060103	Physician	-	LATVIA
4870701	GROUP 1	Male	-		-	20060103	Other health professional	-	JAPAN
4870702	GROUP 3	Male	-		-	20060103	Other health professional	-	FRANCE
4870703		Missing	-		-	20060103	Physician	-	JAPAN
4870704		Missing	-		-	20060103	Physician	-	KENYA
4870705	GROUP 4	Male	82	Kilograms	82	20060103	Consumer	-	UNITED KINGDOM
4870706	GROUP 3	Male	-		-	20060103	Physician	-	JAPAN

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870707	GROUP 3	Female	-		-	20060103	Physician	-	JAPAN
4870708	GROUP 2	Male	-		-	20060103	Physician	-	FRANCE
4870709	GROUP 1	Female	-		-	20060103	Consumer	-	FRANCE
4870710	GROUP 2	Female	-		-	20060103	Physician	20041007	JAPAN
4870711		Female	-		-	20060103	Physician	-	UNITED KINGDOM
4870712		Female	-		-	20060103	Physician	-	SOUTH AFRICA
4870714	GROUP 1	Male	-		-	20060103	Consumer	-	SOUTH AFRICA
4870715	GROUP 2	Male	-		-	20060103	Consumer	-	ITALY
4870716	GROUP 2	Male	-		-	20060103	Consumer	-	UNITED KINGDOM
4870717	GROUP 3	Female	-		-	20060103	Consumer	-	FRANCE
4870718	GROUP 2	Female	-		-	20060103	Other health professional	-	NETHERLANDS
4870719	GROUP 2	Female	-		-	20060103	Physician	-	GERMANY
4870720	GROUP 2	Female	88	Kilograms	88	20060103	Physician	-	GERMANY
4870721	GROUP 2	Female	-		-	20060103	Other health professional	-	GERMANY
4870722		Male	-		-	20060103	Other health professional	20041211	GERMANY
4870723	GROUP 3	Female	-		-	20060103		-	
4870724	GROUP 3	Female	-		-	20060103		-	
4870725	GROUP 2	Male	-		-	20060103	Pharmacist	-	BRAZIL
4870728	GROUP 4	Female	-		-	20060103		-	
4870732		Male	-		-	20060103	Consumer	20051209	UNITED STATES
4870733	GROUP 3	Female	-		-	20060103	Physician	-	KOREA, REPUBLIC OF
4870734		Female	-		-	20060103	Physician	-	FRANCE
4870735		Male	-		-	20060103	Other health professional	-	UNITED KINGDOM
4870736		Missing	-		-	20060103	Physician	-	JAPAN
4870737	GROUP 3	Female	70	Kilograms	70	20060103	Other health professional	-	GERMANY
4870738		Female	-		-	20060103	Physician	-	JAPAN
4870739		Missing	-		-	20060103	Physician	-	JAPAN

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870741	GROUP 2	Female	70	Kilograms	70	20060103	Physician	-	UNITED STATES
4870753		Missing	-		-	20060103	Pharmacist	-	UNITED STATES
4870754		Female	-		-	20060103	Consumer	-	UNITED STATES
4870755	GROUP 3	Male	70.7	Kilograms	70	20060103	Physician	-	CANADA
4870756	GROUP 3	Female	-		-	20060103	Physician	-	UNITED STATES
4870757	GROUP 3	Female	-		-	20060103	Consumer	-	UNITED STATES
4870758	GROUP 2	Female	86.4	Kilograms	86	20060103	Physician	-	UNITED STATES
4870763	GROUP 3	Female	-		-	20060103	Lawyer	20000503	UNITED STATES
4870764	GROUP 3	Male	67	Kilograms	67	20060103	Physician	-	UNITED STATES
4870765	GROUP 3	Male	90	Kilograms	90	20060103	Physician	-	UNITED STATES
4870766	GROUP 4	Female	65	Kilograms	65	20060103	Physician	-	UNITED STATES
4870767	GROUP 3	Male	164	Kilograms	164	20060103	Physician	-	UNITED STATES
4870768	GROUP 3	Female	89	Kilograms	89	20060103	Lawyer	-	UNITED STATES
4870769	GROUP 3	Female	91	Kilograms	91	20060103	Physician	-	UNITED STATES
4870770	GROUP 3	Male	105	Kilograms	105	20060103	Physician	-	UNITED STATES
4870771	GROUP 3	Male	80	Kilograms	80	20060103	Physician	-	UNITED STATES
4870772	GROUP 3	Female	105	Kilograms	105	20060103	Lawyer	-	UNITED STATES
4870773		Female	-		-	20060103	Lawyer	-	UNITED STATES
4870774	GROUP 3	Male	89	Kilograms	89	20060103	Physician	-	UNITED STATES
4870775	GROUP 3	Male	84	Kilograms	84	20060103	Lawyer	-	UNITED STATES
4870776	GROUP 3	Male	107	Kilograms	107	20060103	Lawyer	-	UNITED STATES
4870777	GROUP 4	Female	53	Kilograms	53	20060103	Physician	20040308	UNITED STATES
4870778	GROUP 3	Female	-		-	20060103	Consumer	-	GERMANY
4870779	GROUP 3	Male	87	Kilograms	87	20060103	Physician	-	UNITED STATES
4870780	GROUP 3	Female	68	Kilograms	68	20060103	Physician	20040425	UNITED STATES
4870781	GROUP 4	Male	91	Kilograms	91	20060103	Physician	20040130	UNITED STATES
4870782	GROUP 3	Female	56	Kilograms	56	20060103	Lawyer	-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870783	GROUP 2	Female	135	Kilograms	135	20060103	Physician	-	UNITED STATES
4870784	GROUP 3	Male	-		-	20060103	Physician	-	UNITED STATES
4870785	GROUP 3	Male	81	Kilograms	81	20060103	Physician	20030516	UNITED STATES
4870786	GROUP 3	Male	95	Kilograms	95	20060103	Physician	-	UNITED STATES
4870787	GROUP 3	Female	72	Kilograms	72	20060103	Physician	-	UNITED STATES
4870788	GROUP 3	Female	82	Kilograms	82	20060103	Lawyer	-	UNITED STATES
4870789	GROUP 2	Male	100	Kilograms	100	20060103	Physician	-	UNITED STATES
4870790	GROUP 2	Male	-		-	20060103	Consumer	-	UNITED STATES
4870791	GROUP 4	Male	88	Kilograms	88	20060103	Physician	20050923	UNITED STATES
4870792	GROUP 2	Male	89	Kilograms	89	20060103	Lawyer	-	UNITED STATES
4870793	GROUP 3	Female	123	Kilograms	123	20060103	Physician	20000918	UNITED STATES
4870794	GROUP 2	Female	80	Kilograms	80	20060103	Physician	-	UNITED STATES
4870795	GROUP 3	Female	143	Kilograms	143	20060103	Physician	20050901	UNITED STATES
4870796	GROUP 3	Female	57	Kilograms	57	20060103	Lawyer	-	UNITED STATES
4870797	GROUP 1	Female	74	Kilograms	74	20060103	Other health professional	-	UNITED KINGDOM
4870798	GROUP 2	Male	129	Kilograms	129	20060103	Physician	-	UNITED STATES
4870799	GROUP 3	Female	100	Kilograms	100	20060103	Lawyer	-	UNITED STATES
4870800	GROUP 2	Female	-		-	20060103	Consumer	-	CHINA
4870801	GROUP 3	Male	77	Kilograms	77	20060103	Lawyer	-	UNITED STATES
4870802	GROUP 3	Male	-		-	20060103	Other health professional	20051107	UNITED STATES
4870803		Male	-		-	20060103	Physician	-	FRANCE
4870804	GROUP 2	Male	-		-	20060103	Physician	-	NETHERLANDS
4870805	GROUP 1	Female	82	Kilograms	82	20060103	Other health professional	-	FRANCE
4870806	GROUP 1	Male	-		-	20060103	Physician	-	AUSTRALIA
4870807	GROUP 3	Female	-		-	20060103	Consumer	20050515	UNITED STATES
4870808	GROUP 2	Male	55	Kilograms	55	20060103	Physician	20050314	JAPAN
4870809		Female	3	Kilograms	3	20060103	Physician	-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870810	GROUP 3	Female	70	Kilograms	70	20060103	Other health professional	-	GERMANY
4870811	GROUP 2	Male	-		-	20060103	Physician	-	CHINA
4870812	GROUP 2	Male	-		-	20060103	Consumer	-	UNITED STATES
4870813	GROUP 2	Female	74	Kilograms	74	20060103	Physician	-	UNITED STATES
4870814	GROUP 2	Female	-		-	20060103	Other health professional	-	GERMANY
4870816	GROUP 3	Female	106	Kilograms	106	20060103	Lawyer	-	UNITED STATES
4870817	GROUP 3	Female	50	Kilograms	50	20060103	Lawyer	20040329	UNITED STATES
4870818	GROUP 3	Male	130	Kilograms	130	20060103	Physician	-	UNITED STATES
4870819	GROUP 3	Female	-		-	20060103	Physician	20010808	UNITED STATES
4870821	GROUP 2	Male	81	Kilograms	81	20060103	Lawyer	-	UNITED STATES
4870822		Female	-		-	20060103	Lawyer	-	UNITED STATES
4870823	GROUP 2	Male	100	Kilograms	100	20060103	Physician	-	UNITED STATES
4870824	GROUP 3	Male	89	Kilograms	89	20060103	Physician	-	UNITED STATES
4870825	GROUP 2	Male	82	Kilograms	82	20060103	Physician	20050128	UNITED STATES
4870826	GROUP 3	Female	-		-	20060103	Lawyer	-	UNITED STATES
4870827	GROUP 1	Female	-		-	20060103	Physician	-	UNITED STATES
4870828	GROUP 3	Male	77	Kilograms	77	20060103	Physician	20030519	UNITED STATES
4870829	GROUP 3	Male	82	Kilograms	82	20060103	Physician	-	UNITED STATES
4870830	GROUP 3	Male	94	Kilograms	94	20060103	Physician	20010429	UNITED STATES
4870831	GROUP 3	Male	114	Kilograms	114	20060103	Lawyer	-	UNITED STATES
4870832	GROUP 4	Female	61	Kilograms	61	20060103	Physician	20030903	UNITED STATES
4870833	GROUP 2	Female	-		-	20060103	Lawyer	-	UNITED STATES
4870834	GROUP 2	Male	110	Kilograms	110	20060103	Physician	-	UNITED STATES
4870835	GROUP 3	Female	132	Kilograms	132	20060103	Lawyer	-	UNITED STATES
4870836	GROUP 3	Male	-		-	20060103	Consumer	-	UNITED STATES
4870837	GROUP 2	Female	75	Kilograms	75	20060103	Lawyer	-	UNITED STATES
4870838	GROUP 2	Male	81	Kilograms	81	20060103	Lawyer	20030717	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870839	GROUP 3	Female	-		-	20060103	Physician	20021007	UNITED STATES
4870840	GROUP 3	Female	-		-	20060103	Lawyer	20020513	UNITED STATES
4870841	GROUP 3	Male	-		-	20060103	Other health professional	-	UNITED KINGDOM
4870842	GROUP 4	Male	-		-	20060103	Physician	20040530	UNITED STATES
4870843		Male	-		-	20060103	Lawyer	-	UNITED STATES
4870844		Male	-		-	20060103	Consumer	-	UNITED STATES
4870845		Female	-		-	20060103	Lawyer	-	UNITED STATES
4870846	GROUP 4	Female	84	Kilograms	84	20060103	Physician	-	UNITED STATES
4870847	GROUP 4	Female	-		-	20060103	Consumer	-	UNITED STATES
4870848	GROUP 3	Female	-		-	20060103	Lawyer	-	UNITED STATES
4870849	GROUP 3	Male	86	Kilograms	86	20060103	Physician	-	UNITED STATES
4870850	GROUP 3	Female	-		-	20060103	Lawyer	-	UNITED STATES
4870851		Male	-		-	20060103	Lawyer	-	UNITED STATES
4870852	GROUP 3	Female	-		-	20060103	Lawyer	-	UNITED STATES
4870853	GROUP 3	Male	70	Kilograms	70	20060103	Physician	20040209	UNITED STATES
4870855	GROUP 2	Female	45	Kilograms	45	20060103	Consumer	-	UNITED STATES
4870856	GROUP 3	Female	-		-	20060103	Lawyer	-	UNITED STATES
4870857	GROUP 2	Male	-		-	20060103	Lawyer	-	UNITED STATES
4870858	GROUP 2	Male	102	Kilograms	102	20060103	Physician	-	UNITED STATES
4870859		Female	-		-	20060103	Consumer	-	UNITED STATES
4870860		Male	-		-	20060103	Lawyer	-	UNITED STATES
4870861	GROUP 2	Male	-		-	20060103	Lawyer	-	UNITED STATES
4870862	GROUP 3	Male	91	Kilograms	91	20060103	Lawyer	20041111	UNITED STATES
4870863	GROUP 3	Male	-		-	20060103	Lawyer	-	UNITED STATES
4870864		Female	-		-	20060103	Lawyer	20031117	UNITED STATES
4870865	GROUP 3	Female	59	Kilograms	59	20060103	Physician	-	UNITED STATES
4870866	GROUP 3	Male	-		-	20060103	Lawyer	-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870867	GROUP 3	Male	82	Kilograms	82	20060103	Lawyer	20020621	UNITED STATES
4870868	GROUP 2	Male	107	Kilograms	107	20060103	Physician	-	UNITED STATES
4870869	GROUP 3	Male	102	Kilograms	102	20060103	Lawyer	-	UNITED STATES
4870870	GROUP 3	Male	102	Kilograms	102	20060103	Physician	-	UNITED STATES
4870871	GROUP 3	Female	-		-	20060103	Lawyer	-	UNITED STATES
4870872	GROUP 3	Female	56	Kilograms	56	20060103	Physician	-	UNITED STATES
4870873	GROUP 3	Female	82	Kilograms	82	20060103	Lawyer	-	UNITED STATES
4870874	GROUP 2	Female	-		-	20060103	Other health professional	-	UNITED STATES
4870875	GROUP 2	Male	120	Kilograms	120	20060103	Lawyer	-	UNITED STATES
4870876		Male	-		-	20060103	Lawyer	20040323	UNITED STATES
4870877	GROUP 3	Female	-		-	20060103	Lawyer	-	UNITED STATES
4870878	GROUP 3	Male	98	Kilograms	98	20060103	Lawyer	-	UNITED STATES
4870879		Female	-		-	20060103	Other health professional	-	FRANCE
4870880	GROUP 3	Female	-		-	20060103	Lawyer	-	UNITED STATES
4870886		Male	106.7	Kilograms	106	20060103	Other health professional	20050602	UNITED STATES
4870888	GROUP 4	Female	104.3	Kilograms	104	20060103		-	UNITED STATES
4870890	GROUP 3	Male	-		-	20060103	Other health professional	-	UNITED KINGDOM
4870891	GROUP 3	Male	47	Kilograms	47	20060103	Other health professional	20051002	JAPAN
4870892		Female	55	Kilograms	55	20060103	Other health professional	-	
4870894		Female	-		-	20060103	Physician	-	UNITED STATES
4870898	GROUP 2	Female	-		-	20060103	Physician	-	FRANCE
4870900		Female	-		-	20060103	Physician	-	ITALY
4870901		Male	-		-	20060103	Physician	-	AUSTRALIA
4870902	GROUP 4	Male	-		-	20060103	Other health professional	-	KOREA, REPUBLIC OF
4870903	GROUP 3	Female	84	Kilograms	84	20060103	Other health professional	-	GERMANY
4870904	GROUP 3	Female	-		-	20060103	Pharmacist	-	UNITED STATES
4870917	GROUP 2	Female	40	Kilograms	40	20060103	Other health professional	-	SPAIN

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4870921		Missing	-		-	20060103	Physician	-	JAPAN
4870922	GROUP 3	Male	-		-	20060103	Consumer	-	AUSTRALIA
4870923	GROUP 1	Female	-		-	20060103	Physician	-	JAPAN
4870976	GROUP 3	Female	56	Kilograms	56	20060103	Other health professional	-	UNITED STATES
4870977	GROUP 2	Female	-		-	20060103	Pharmacist	-	UNITED STATES
4870978		Male	-		-	20060103	Physician	-	UNITED STATES
4870979	GROUP 3	Male	-		-	20060103	Consumer	20051201	CANADA
4870993		Female	-		-	20060103	Consumer	-	UNITED STATES
4870994	GROUP 3	Female	50	Kilograms	50	20060103	Other health professional	-	UNITED STATES
4871004		Female	-		-	20060103	Lawyer	20031217	UNITED STATES
4871005		Female	-		-	20060103	Consumer	-	UNITED STATES
4871006	GROUP 2	Female	99.79	Kilograms	99	20060103	Physician	-	UNITED STATES
4871016	GROUP 1	Female	-		-	20060103	Physician	-	JAPAN
4871017		Male	-		-	20060103	Physician	-	UNITED STATES
4871018		Female	-		-	20060103	Other health professional	-	UNITED STATES
4871019		Male	-		-	20060103	Physician	20050101	UNITED STATES
4871040		Male	35.412	Kilograms	35	20060103	Other health professional	-	UNITED STATES
4871057	GROUP 3	Female	70	Kilograms	70	20060103	Consumer	-	FRANCE
4871073	GROUP 4	Female	-		-	20060103	Other health professional	20051206	NETHERLANDS
4871074		Male	47.7	Kilograms	47	20060103	Consumer	-	UNITED STATES
4871086		Male	-		-	20060103		-	AUSTRALIA
4871087		Female	-		-	20060103		-	AUSTRALIA
4871088		Male	-		-	20060103		-	AUSTRALIA
4871089		Male	-		-	20060103		-	AUSTRALIA
4871101		Male	-		-	20060103		-	AUSTRALIA
4871102		Male	-		-	20060103		-	AUSTRALIA
4871103		Male	-		-	20060103		-	AUSTRALIA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871105		Female	-		-	20060103		-	AUSTRALIA
4871106	GROUP 3	Male	-		-	20060103	Physician	-	UNITED STATES
4871127		Female	85	Kilograms	85	20060103		-	
4871134	GROUP 3	Female	0	Kilograms	0	20060103	Pharmacist	-	JAPAN
4871141	GROUP 1	Male	46	Kilograms	46	20060103	Physician	-	ISRAEL
4871146	GROUP 3	Male	0	Kilograms	0	20060103	Physician	-	AUSTRALIA
4871160	GROUP 3	Male	135	Kilograms	135	20060103	Consumer	-	AUSTRALIA
4871180	GROUP 2	Male	68	Kilograms	68	20060103	Other health professional	-	FRANCE
4871210		Female	-		-	20060103		-	AUSTRALIA
4871211		Male	-		-	20060103		-	FINLAND
4871212		Female	-		-	20060103		-	FRANCE
4871213		Male	-		-	20060103		-	FINLAND
4871214		Female	-		-	20060103		-	JAPAN
4871220		Male	-		-	20060103		-	JAPAN
4871221		Male	-		-	20060103		-	AUSTRALIA
4871222		Male	-		-	20060103		-	FRANCE
4871223		Female	-		-	20060103		-	NEW ZEALAND
4871224		Male	-		-	20060103		-	NEW ZEALAND
4871225		Male	-		-	20060103		20010608	AUSTRALIA
4871226		Female	-		-	20060103		-	FRANCE
4871227		Male	-		-	20060103		-	FRANCE
4871229		Male	-		-	20060103		20020319	FRANCE
4871230		Female	-		-	20060103		-	FRANCE
4871231		Female	-		-	20060103		-	FRANCE
4871232		Male	-		-	20060103		-	FRANCE
4871233		Female	-		-	20060103		-	FRANCE
4871235		Female	-		-	20060103		-	FRANCE

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871236	GROUP 2	Female	-		-	20060103		-	JAPAN
4871237		Male	-		-	20060103		-	AUSTRALIA
4871238		Male	20	Kilograms	20	20060103		-	JAPAN
4871239		Female	-		-	20060103		-	FINLAND
4871240		Male	-		-	20060103		-	FRANCE
4871241		Male	-		-	20060103		-	FRANCE
4871242		Female	-		-	20060103		-	FRANCE
4871243		Male	-		-	20060103		20000908	FRANCE
4871244		Male	-		-	20060103		-	FINLAND
4871249		Female	-		-	20060103		-	FRANCE
4871250		Male	-		-	20060103		-	FRANCE
4871338	GROUP 4	Female	50	Kilograms	50	20060104	Other health professional	-	FRANCE
4871339	GROUP 3	Female	-		-	20060104	Physician	-	UNITED STATES
4871340	GROUP 3	Male	98	Kilograms	98	20060104	Physician	-	UNITED STATES
4871341	GROUP 3	Male	96	Kilograms	96	20060104	Physician	-	UNITED STATES
4871342	GROUP 3	Male	98	Kilograms	98	20060104	Lawyer	-	UNITED STATES
4871344		Male	-		-	20060104	Lawyer	-	UNITED STATES
4871345	GROUP 3	Female	99	Kilograms	99	20060104	Lawyer	-	UNITED STATES
4871346	GROUP 3	Male	89	Kilograms	89	20060104	Physician	20050516	UNITED STATES
4871353	GROUP 3	Male	-		-	20060104	Lawyer	-	UNITED STATES
4871354	GROUP 3	Female	65	Kilograms	65	20060104	Lawyer	-	UNITED STATES
4871355	GROUP 3	Male	-		-	20060104	Lawyer	-	UNITED STATES
4871356	GROUP 3	Female	97	Kilograms	97	20060104	Physician	-	UNITED STATES
4871357	GROUP 3	Female	84	Kilograms	84	20060104	Physician	-	UNITED STATES
4871359	GROUP 3	Male	80	Kilograms	80	20060104	Lawyer	-	UNITED STATES
4871360	GROUP 3	Male	-		-	20060104	Lawyer	-	AUSTRALIA
4871361	GROUP 3	Female	68	Kilograms	68	20060104	Physician	-	IRELAND

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871362		Female	83	Kilograms	83	20060104	Lawyer	-	UNITED STATES
4871363		Male	-		-	20060104	Lawyer	20030804	UNITED STATES
4871364		Female	-		-	20060104	Lawyer	-	UNITED STATES
4871365	GROUP 3	Female	77	Kilograms	77	20060104	Physician	-	UNITED STATES
4871367	GROUP 3	Female	55	Kilograms	55	20060104	Physician	-	JAPAN
4871368	GROUP 3	Female	57	Kilograms	57	20060104	Lawyer	-	UNITED STATES
4871369	GROUP 2	Male	105	Kilograms	105	20060104	Physician	-	UNITED STATES
4871370	GROUP 4	Female	-		-	20060104	Physician	20040507	UNITED STATES
4871371	GROUP 3	Male	101	Kilograms	101	20060104	Physician	-	UNITED STATES
4871373	GROUP 4	Male	-		-	20060104	Physician	-	GERMANY
4871374		Male	-		-	20060104	Lawyer	-	UNITED STATES
4871375	GROUP 2	Male	107	Kilograms	107	20060104	Physician	-	UNITED STATES
4871376	GROUP 3	Male	91	Kilograms	91	20060104	Physician	-	UNITED STATES
4871377	GROUP 3	Female	-		-	20060104	Physician	-	FRANCE
4871378	GROUP 3	Male	77	Kilograms	77	20060104	Lawyer	-	UNITED STATES
4871379	GROUP 3	Male	73	Kilograms	73	20060104	Lawyer	-	UNITED STATES
4871380	GROUP 3	Female	55	Kilograms	55	20060104	Physician	-	UNITED STATES
4871382	GROUP 3	Female	-		-	20060104	Lawyer	20041005	UNITED STATES
4871383	GROUP 3	Female	70	Kilograms	70	20060104	Lawyer	-	UNITED STATES
4871384	GROUP 3	Male	114	Kilograms	114	20060104	Lawyer	-	UNITED STATES
4871385	GROUP 2	Male	82	Kilograms	82	20060104	Lawyer	-	UNITED STATES
4871386	GROUP 2	Male	105	Kilograms	105	20060104	Lawyer	-	UNITED STATES
4871387	GROUP 3	Male	86	Kilograms	86	20060104	Lawyer	-	UNITED STATES
4871405	GROUP 2	Female	-		-	20060104	Lawyer	-	UNITED STATES
4871406	GROUP 2	Male	109	Kilograms	109	20060104	Physician	-	UNITED STATES
4871407	GROUP 1	Female	-		-	20060104	Other health professional	-	SWEDEN
4871408	GROUP 2	Male	132	Kilograms	132	20060104	Physician	-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871409	GROUP 2	Male	-		-	20060104	Pharmacist	-	MALAYSIA
4871411	GROUP 3	Female	90	Kilograms	90	20060104	Other health professional	-	UNITED STATES
4871412	GROUP 3	Female	60	Kilograms	60	20060104	Other health professional	-	FRANCE
4871413		Male	-		-	20060104	Physician	20030915	UNITED STATES
4871415	GROUP 3	Male	75	Kilograms	75	20060104	Physician	-	AUSTRALIA
4871416	GROUP 3	Male	50	Kilograms	50	20060104	Physician	-	JAPAN
4871417	GROUP 3	Female	59	Kilograms	59	20060104	Physician	-	UNITED STATES
4871419	GROUP 3	Male	78	Kilograms	78	20060104	Physician	-	UNITED STATES
4871432	GROUP 3	Female	107	Kilograms	107	20060104	Physician	-	UNITED STATES
4871448	GROUP 3	Female	80	Kilograms	80	20060104	Physician	-	FRANCE
4871560		Female	65.4	Kilograms	65	20060103	Physician	-	UNITED STATES
4871561		Female	-		-	20060104	Physician	-	ITALY
4871562		Female	-		-	20060104	Physician	20040719	SPAIN
4871573	GROUP 2	Male	-		-	20060104	Physician	-	ITALY
4871574		Missing	-		-	20060104	Physician	-	UNITED STATES
4871582		Female	-		-	20060104	Physician	20051116	GERMANY
4871583		Male	106.6	Kilograms	106	20060104	Consumer	-	UNITED STATES
4871584		Female	-		-	20060104	Consumer	-	UNITED STATES
4871585		Female	53.52	Kilograms	53	20060104	Consumer	-	UNITED STATES
4871587		Female	53.52	Kilograms	53	20060104	Consumer	-	UNITED STATES
4871592		Male	-		-	20060104	Physician	20010925	ITALY
4871598	GROUP 3	Female	-		-	20060104		-	
4871599	GROUP 3	Male	-		-	20060104		-	
4871600	GROUP 3	Female	90	Kilograms	90	20060104	Physician	-	FRANCE
4871601	GROUP 3	Male	-		-	20060104		-	
4871602		Male	-		-	20060104	Pharmacist	-	UNITED STATES
4871614	GROUP 4	Female	-		-	20060104	Physician	-	COLOMBIA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871615		Female	73.03	Kilograms	73	20060104	Physician		- UNITED STATES
4871616		Female	-		-	20060104	Pharmacist		- UNITED STATES
4871617	GROUP 3	Female	-		-	20060104	Other health professional		- JAPAN
4871622	GROUP 4	Female	-		-	20060104			-
4871623	GROUP 4	Female	-		-	20060104			- UNITED KINGDOM
4871624		Female	-		-	20060104	Consumer	20051025	UNITED STATES
4871625	GROUP 3	Male	83	Kilograms	83	20060104	Physician		- FRANCE
4871626		Missing	-		-	20060104	Pharmacist		- UNITED KINGDOM
4871627	GROUP 3	Male	-		-	20060104	Consumer		- FRANCE
4871628		Female	-		-	20060104	Physician		- NETHERLANDS
4871629		Male	69	Kilograms	69	20060104	Physician		- UNITED STATES
4871630		Female	62	Kilograms	62	20060104	Pharmacist		- UNITED STATES
4871631	GROUP 2	Male	-		-	20060103	Physician		- GERMANY
4871632		Male	-		-	20060104	Physician		- GERMANY
4871633		Female	65.3	Kilograms	65	20060104	Physician		- UNITED STATES
4871634	GROUP 2	Male	-		-	20060103	Other health professional		- UNITED KINGDOM
4871635		Missing	-		-	20051230	Consumer		- UNITED STATES
4871636	GROUP 2	Male	72.562	Kilograms	72	20060103	Physician		- UNITED STATES
4871637		Missing	-		-	20051230			- UNITED STATES
4871638		Female	-		-	20051230			- INDIA
4871639	GROUP 2	Female	-		-	20051230			- UNITED STATES
4871640	GROUP 3	Male	-		-	20060104			- CHINA
4871641	GROUP 4	Female	58.956	Kilograms	58	20051230			- UNITED STATES
4871642	GROUP 3	Male	-		-	20051230	Physician		- ITALY
4871643	GROUP 4	Female	-		-	20051230	Physician		- ITALY
4871644		Female	-		-	20060103	Physician		- JAPAN
4871645	GROUP 4	Female	73	Kilograms	73	20060103			- FRANCE

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871646	GROUP 2	Female	-		-	20051230	Consumer	-	UNITED KINGDOM
4871648	GROUP 1	Female	3.124	Kilograms	3	20060104	Physician	-	JAPAN
4871649	GROUP 4	Male	65	Kilograms	65	20060104	Pharmacist	20051216	JAPAN
4871651	GROUP 4	Male	-		-	20060104	Other health professional	-	AUSTRALIA
4871654		Male	92	Kilograms	92	20060104	Other health professional	-	SWITZERLAND
4871655		Male	-		-	20060104	Consumer	-	UNITED STATES
4871656	GROUP 4	Male	43	Kilograms	43	20060104	Physician	-	JAPAN
4871659	GROUP 2	Female	56	Kilograms	56	20060103		-	FRANCE
4871660	GROUP 3	Female	-		-	20060103	Pharmacist	-	GERMANY
4871661		Female	-		-	20060103	Consumer	-	AUSTRALIA
4871662	GROUP 2	Female	62.4	Kilograms	62	20060103		-	JAPAN
4871663	GROUP 3	Male	-		-	20060103	Physician	-	JAPAN
4871664	GROUP 4	Male	-		-	20060103	Physician	-	UNITED STATES
4871665		Missing	-		-	20060102	Physician	-	JAPAN
4871666		Male	-		-	20060104	Pharmacist	-	GERMANY
4871667		Male	-		-	20060104	Other health professional	-	ITALY
4871668		Male	-		-	20060103	Pharmacist	-	GERMANY
4871669	GROUP 3	Male	-		-	20060104	Consumer	20051219	UNITED STATES
4871670	GROUP 3	Female	-		-	20060104	Other health professional	20041216	BELGIUM
4871671		Male	75	Kilograms	75	20060103	Physician	-	GERMANY
4871672		Male	60	Kilograms	60	20060104		-	GERMANY
4871673	GROUP 1	Male	50	Kilograms	50	20060103	Pharmacist	-	JAPAN
4871674	GROUP 2	Female	-		-	20060104	Consumer	-	TAIWAN, PROVINCE OF CHINA
4871675		Female	-		-	20060104	Consumer	-	UNITED STATES
4871676	GROUP 2	Male	70	Kilograms	70	20060104	Physician	-	FRANCE
4871677	GROUP 3	Male	-		-	20060104	Physician	-	AUSTRALIA
4871678	GROUP 3	Missing	-		-	20060104	Other health professional	20051115	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871681		Male	-		-	20060103		-	FRANCE
4871682	GROUP 3	Male	-		-	20060104	Physician	20041125	IRELAND
4871685		Male	68	Kilograms	68	20060104	Physician	-	FRANCE
4871686		Female	-		-	20060104	Other health professional	-	NETHERLANDS
4871687		Male	-		-	20060104	Physician	-	UNITED STATES
4871689		Male	-		-	20060103		20051015	UNITED KINGDOM
4871692	GROUP 3	Male	-		-	20060104	Consumer	-	UNITED KINGDOM
4871693		Male	63.6	Kilograms	63	20060104	Physician	-	UNITED STATES
4871694	GROUP 3	Female	-		-	20060104	Physician	-	GERMANY
4871695		Female	-		-	20060104	Physician	-	JAPAN
4871706	GROUP 4	Male	68	Kilograms	68	20060104	Physician	-	AUSTRIA
4871707	GROUP 4	Female	-		-	20060104	Other health professional	-	PORTUGAL
4871708	GROUP 3	Male	70	Kilograms	70	20060104	Physician	20050415	GERMANY
4871709	GROUP 3	Female	-		-	20060104	Other health professional	-	DENMARK
4871712	GROUP 3	Male	-		-	20060104	Physician	-	JAPAN
4871713	GROUP 2	Female	89	Kilograms	89	20060104	Physician	-	LITHUANIA
4871714	GROUP 2	Female	-		-	20060104	Other health professional	-	FRANCE
4871720	GROUP 3	Female	53	Kilograms	53	20060104	Physician	-	UNITED STATES
4871721	GROUP 3	Female	70	Kilograms	70	20060104	Consumer	-	UNITED STATES
4871722	GROUP 4	Female	-		-	20060104	Physician	-	UNITED STATES
4871723		Missing	-		-	20060104	Physician	-	UNITED STATES
4871724		Female	-		-	20060104	Consumer	-	UNITED STATES
4871725	GROUP 2	Female	79	Kilograms	79	20060104	Consumer	-	UNITED STATES
4871726	GROUP 1	Male	82	Kilograms	82	20060104	Other health professional	-	UNITED STATES
4871727	GROUP 2	Female	-		-	20060104	Physician	-	UNITED STATES
4871728	GROUP 3	Female	82	Kilograms	82	20060104	Consumer	-	UNITED STATES
4871729	GROUP 3	Female	-		-	20060104	Consumer	-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871730		Female	-		-	20060104	Pharmacist	-	UNITED STATES
4871731	GROUP 2	Female	43	Kilograms	43	20060104	Other health professional	-	UNITED STATES
4871733		Male	59	Kilograms	59	20060104	Consumer	-	UNITED STATES
4871734		Female	-		-	20060104	Consumer	-	UNITED STATES
4871735		Female	-		-	20060104	Consumer	-	UNITED STATES
4871736		Missing	-		-	20060104	Consumer	-	UNITED STATES
4871737	GROUP 2	Female	59	Kilograms	59	20060104	Consumer	-	UNITED STATES
4871738		Female	-		-	20060104	Consumer	-	UNITED STATES
4871739	GROUP 2	Male	76	Kilograms	76	20060104	Consumer	-	UNITED STATES
4871740	GROUP 3	Male	-		-	20060104	Pharmacist	-	UNITED STATES
4871741	GROUP 2	Male	77	Kilograms	77	20060104	Consumer	-	UNITED STATES
4871742		Female	-		-	20060104	Consumer	-	UNITED STATES
4871743		Female	-		-	20060104	Consumer	-	UNITED STATES
4871744		Female	-		-	20060104	Consumer	-	UNITED STATES
4871745	GROUP 3	Female	54	Kilograms	54	20060104	Consumer	-	UNITED STATES
4871746	GROUP 4	Male	-		-	20060104	Physician	-	UNITED STATES
4871747	GROUP 2	Male	-		-	20060104	Physician	-	UNITED STATES
4871748	GROUP 1	Female	52	Kilograms	52	20060104	Physician	-	UNITED STATES
4871749	GROUP 4	Male	69	Kilograms	69	20060104	Consumer	-	UNITED STATES
4871750		Female	-		-	20060104	Consumer	-	UNITED STATES
4871751		Female	-		-	20060104	Consumer	-	UNITED STATES
4871752		Male	-		-	20060104	Consumer	-	UNITED STATES
4871753		Missing	-		-	20060104	Physician	-	UNITED STATES
4871754		Male	-		-	20060104	Physician	-	UNITED STATES
4871755	GROUP 3	Female	-		-	20060104	Consumer	-	UNITED STATES
4871756	GROUP 3	Female	138	Kilograms	138	20060104	Consumer	-	UNITED STATES
4871757		Missing	-		-	20060104	Physician	-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871758		Missing	-		-	20060104	Physician	-	UNITED STATES
4871759	GROUP 1	Male	-		-	20060104	Consumer	-	UNITED STATES
4871760	GROUP 2	Male	107	Kilograms	107	20060104	Consumer	-	UNITED STATES
4871761		Male	73	Kilograms	73	20060104	Consumer	-	UNITED STATES
4871762	GROUP 3	Female	-		-	20060104	Physician	-	UNITED STATES
4871763	GROUP 3	Female	-		-	20060104	Consumer	-	UNITED STATES
4871764	GROUP 3	Male	73	Kilograms	73	20060104	Physician	-	UNITED STATES
4871766	GROUP 3	Male	77	Kilograms	77	20060104	Consumer	-	UNITED STATES
4871773	GROUP 2	Female	-		-	20060103	Physician	-	JAPAN
4871774		Female	59	Kilograms	59	20060104		-	SPAIN
4871775	GROUP 2	Female	-		-	20060103	Pharmacist	-	JAPAN
4871776	GROUP 3	Female	-		-	20060103		-	UNITED STATES
4871777	GROUP 4	Female	-		-	20060103	Pharmacist	-	JAPAN
4871778		Female	-		-	20060104	Consumer	-	UNITED STATES
4871779	GROUP 2	Male	-		-	20060104	Consumer	-	CANADA
4871780	GROUP 2	Male	-		-	20060104	Consumer	20050101	CANADA
4871781		Female	-		-	20060104	Consumer	-	UNITED STATES
4871782	GROUP 2	Male	-		-	20060104	Physician	-	UNITED STATES
4871783		Male	87.09	Kilograms	87	20060104	Physician	-	UNITED STATES
4871784	GROUP 4	Female	-		-	20060104	Consumer	-	UNITED STATES
4871785		Female	-		-	20060104	Consumer	-	UNITED STATES
4871786	GROUP 1	Female	-		-	20060104	Consumer	-	UNITED STATES
4871787	GROUP 3	Female	-		-	20060104	Consumer	-	UNITED STATES
4871788	GROUP 2	Male	-		-	20060104	Consumer	-	UNITED STATES
4871789	GROUP 1	Female	-		-	20060104	Consumer	-	UNITED STATES
4871790		Female	-		-	20060104	Consumer	-	UNITED STATES
4871791		Female	-		-	20060104	Consumer	20051210	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871792		Female	-		-	20060104	Consumer		UNITED STATES
4871793		Missing	-		-	20060104	Other health professional		UNITED STATES
4871794	GROUP 3	Female	38	Kilograms	38	20060104	Physician	20050824	JAPAN
4871795	GROUP 2	Female	52	Kilograms	52	20060104	Consumer		FRANCE
4871796	GROUP 2	Missing	-		-	20060104	Physician		INDIA
4871797		Male	2.5	Kilograms	2	20060104	Physician		JAPAN
4871798	GROUP 3	Female	54	Kilograms	54	20060104	Physician		JAPAN
4871799		Female	-		-	20060104	Physician		UNITED KINGDOM
4871800	GROUP 4	Female	-		-	20060104	Consumer		FRANCE
4871801	GROUP 3	Female	48	Kilograms	48	20060104	Physician		JAPAN
4871802	GROUP 2	Female	-		-	20060104	Consumer		NETHERLANDS
4871803	GROUP 3	Female	36	Kilograms	36	20060104	Pharmacist		JAPAN
4871804		Male	-		-	20060104	Consumer		JAPAN
4871805	GROUP 4	Female	-		-	20060104	Consumer		FRANCE
4871806	GROUP 3	Male	-		-	20060104	Consumer		FRANCE
4871807	GROUP 2	Female	-		-	20060104	Physician		FRANCE
4871808	GROUP 2	Male	-		-	20060104	Consumer		FRANCE
4871809	GROUP 3	Missing	-		-	20060104	Consumer		UNITED KINGDOM
4871810	GROUP 2	Female	-		-	20060104	Consumer		UNITED KINGDOM
4871811	GROUP 3	Female	-		-	20060104	Consumer		UNITED KINGDOM
4871812	GROUP 3	Female	-		-	20060104	Consumer		FRANCE
4871813	GROUP 3	Female	-		-	20051230	Consumer		GERMANY
4871814		Female	-		-	20060104	Other health professional		NORWAY
4871815	GROUP 4	Male	-		-	20060104	Other health professional		SWEDEN
4871816		Female	54.2	Kilograms	54	20060104	Physician		FRANCE
4871817	GROUP 2	Male	-		-	20060104	Other health professional		JAPAN
4871818	GROUP 3	Male	95	Kilograms	95	20060104	Lawyer		UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871819	GROUP 3	Male	89	Kilograms	89	20060104	Lawyer	-	UNITED STATES
4871820	GROUP 3	Female	64	Kilograms	64	20060104	Physician	20040415	UNITED STATES
4871821	GROUP 2	Female	111	Kilograms	111	20060104	Lawyer	-	UNITED STATES
4871822		Female	-		-	20060104	Lawyer	-	UNITED STATES
4871823	GROUP 3	Female	117	Kilograms	117	20060104	Physician	-	UNITED STATES
4871824	GROUP 2	Male	84	Kilograms	84	20060104	Lawyer	-	UNITED STATES
4871825	GROUP 4	Male	-		-	20060104	Other health professional	-	JAPAN
4871826	GROUP 4	Male	70	Kilograms	70	20060104	Lawyer	-	UNITED STATES
4871827	GROUP 4	Female	-		-	20060104	Physician	-	FRANCE
4871828	GROUP 2	Male	65	Kilograms	65	20060104	Other health professional	-	FRANCE
4871829	GROUP 3	Female	100	Kilograms	100	20060104	Lawyer	-	UNITED STATES
4871830	GROUP 3	Male	82	Kilograms	82	20060104	Lawyer	-	UNITED STATES
4871831	GROUP 3	Male	91	Kilograms	91	20060104	Physician	-	UNITED STATES
4871833	GROUP 3	Male	95	Kilograms	95	20060104	Physician	20040108	UNITED STATES
4871834	GROUP 4	Male	100	Kilograms	100	20060104	Lawyer	20040216	UNITED STATES
4871835	GROUP 2	Female	73	Kilograms	73	20060104	Physician	-	UNITED STATES
4871836		Male	58	Kilograms	58	20060104	Lawyer	-	UNITED STATES
4871837	GROUP 3	Male	136	Kilograms	136	20060104	Physician	-	UNITED STATES
4871838	GROUP 3	Female	107	Kilograms	107	20060104	Lawyer	-	UNITED STATES
4871839	GROUP 3	Male	-		-	20060104	Lawyer	-	UNITED STATES
4871840		Male	-		-	20060104	Lawyer	-	UNITED STATES
4871841	GROUP 3	Male	175	Kilograms	175	20060104	Lawyer	-	UNITED STATES
4871842	GROUP 3	Female	58	Kilograms	58	20060104	Physician	20000926	UNITED STATES
4871843	GROUP 3	Male	82	Kilograms	82	20060104	Physician	-	UNITED STATES
4871844	GROUP 3	Female	118	Kilograms	118	20060104	Physician	20040718	UNITED STATES
4871845	GROUP 3	Male	-		-	20060104	Other health professional	-	FRANCE
4871846	GROUP 3	Male	86	Kilograms	86	20060104	Lawyer	-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871847	GROUP 2	Female	66	Kilograms	66	20060104	Lawyer	-	UNITED STATES
4871848	GROUP 3	Male	75	Kilograms	75	20060104	Consumer	-	POLAND
4871849	GROUP 2	Male	79	Kilograms	79	20060104	Physician	-	UNITED STATES
4871850	GROUP 2	Male	109	Kilograms	109	20060104	Physician	-	UNITED STATES
4871851	GROUP 3	Male	100	Kilograms	100	20060104	Physician	-	UNITED STATES
4871852	GROUP 2	Female	90	Kilograms	90	20060104	Lawyer	-	UNITED STATES
4871853	GROUP 4	Female	52	Kilograms	52	20060104	Physician	-	UNITED STATES
4871854	GROUP 2	Male	-		-	20060104	Physician	-	UNITED STATES
4871856	GROUP 3	Male	-		-	20060104	Physician	-	UNITED STATES
4871857	GROUP 3	Female	-		-	20060104	Physician	-	GERMANY
4871858	GROUP 3	Male	100	Kilograms	100	20060104	Physician	-	UNITED STATES
4871859	GROUP 2	Male	84	Kilograms	84	20060104	Lawyer	-	UNITED STATES
4871860	GROUP 3	Female	80	Kilograms	80	20060104	Physician	-	UNITED STATES
4871861		Female	-		-	20060104	Lawyer	-	UNITED STATES
4871862	GROUP 4	Female	53	Kilograms	53	20060104	Physician	-	UNITED STATES
4871863		Male	-		-	20060104	Lawyer	-	UNITED STATES
4871864	GROUP 3	Male	-		-	20060104		-	SWEDEN
4871865	GROUP 3	Male	75	Kilograms	75	20060104	Physician	-	UNITED STATES
4871866	GROUP 3	Female	77	Kilograms	77	20060104	Physician	-	UNITED STATES
4871867	GROUP 2	Female	55	Kilograms	55	20060104	Physician	-	UNITED STATES
4871870	GROUP 3	Female	58	Kilograms	58	20060104	Physician	-	UNITED STATES
4871871	GROUP 3	Female	-		-	20060104	Physician	-	UNITED STATES
4871873		Female	-		-	20060104	Lawyer	20041022	UNITED STATES
4871874	GROUP 3	Male	85	Kilograms	85	20060104	Physician	-	UNITED STATES
4871875	GROUP 3	Male	105	Kilograms	105	20060104	Lawyer	-	UNITED STATES
4871876	GROUP 3	Female	-		-	20060104	Physician	20000211	UNITED STATES
4871877	GROUP 3	Female	132	Kilograms	132	20060104	Physician	-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871878	GROUP 3	Male	80	Kilograms	80	20060104	Physician	-	UNITED STATES
4871879	GROUP 4	Female	64	Kilograms	64	20060104	Physician	-	UNITED STATES
4871880		Male	-		-	20060104	Lawyer	-	UNITED STATES
4871881	GROUP 3	Male	95	Kilograms	95	20060104	Physician	-	UNITED STATES
4871882	GROUP 3	Male	98	Kilograms	98	20060104	Lawyer	-	UNITED STATES
4871883	GROUP 3	Female	-		-	20060104	Lawyer	-	UNITED STATES
4871884	GROUP 3	Female	91	Kilograms	91	20060104	Physician	-	UNITED STATES
4871885	GROUP 3	Male	119	Kilograms	119	20060104	Physician	-	UNITED STATES
4871886		Male	-		-	20060104	Lawyer	20041020	UNITED STATES
4871887	GROUP 4	Male	82	Kilograms	82	20060104	Physician	20031211	UNITED STATES
4871888	GROUP 3	Female	-		-	20060104	Lawyer	-	UNITED STATES
4871889	GROUP 4	Male	95	Kilograms	95	20060104	Physician	-	UNITED STATES
4871890		Female	-		-	20060104	Lawyer	-	UNITED STATES
4871891	GROUP 3	Male	116	Kilograms	116	20060104	Lawyer	-	UNITED STATES
4871892	GROUP 3	Female	50	Kilograms	50	20060104	Physician	20030217	UNITED STATES
4871893	GROUP 3	Female	91	Kilograms	91	20060104	Physician	-	UNITED STATES
4871894		Female	-		-	20060104	Lawyer	-	UNITED STATES
4871895	GROUP 3	Male	78	Kilograms	78	20060104	Physician	20040531	UNITED STATES
4871897	GROUP 2	Female	-		-	20060103		-	UNITED STATES
4871899	GROUP 3	Male	83.9	Kilograms	83	20060104		-	UNITED STATES
4871900	GROUP 3	Male	-		-	20060104		-	CHINA
4871901	GROUP 3	Male	91	Kilograms	91	20060104	Physician	-	UNITED STATES
4871902	GROUP 3	Female	-		-	20060104	Physician	-	JAPAN
4871903	GROUP 1	Female	-		-	20060103	Physician	-	TURKEY
4871904	GROUP 3	Female	-		-	20060104	Other health professional	-	GERMANY
4871905	GROUP 4	Female	-		-	20060104	Physician	-	JAPAN
4871906	GROUP 1	Female	-		-	20060104		-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871907	GROUP 2	Male	77	Kilograms	77	20060104	Physician	-	UNITED STATES
4871908		Missing	-		-	20060104	Physician	-	UNITED STATES
4871909	GROUP 3	Female	89.9	Kilograms	89	20060104	Pharmacist	-	UNITED STATES
4871912		Female	-		-	20060103	Physician	-	CHILE
4871917		Male	-		-	20060104	Consumer	-	UNITED STATES
4871918	GROUP 2	Male	-		-	20060104	Other health professional	-	UNITED STATES
4871919	GROUP 2	Female	-		-	20060104	Other health professional	-	UNITED STATES
4871920	GROUP 3	Male	-		-	20060104	Other health professional	-	GERMANY
4871921	GROUP 2	Female	-		-	20060104	Other health professional	-	UNITED STATES
4871922	GROUP 3	Male	-		-	20060104	Physician	20051213	JAPAN
4871923		Female	-		-	20060104	Physician	-	JAPAN
4871924	GROUP 3	Male	80	Kilograms	80	20060104	Other health professional	-	SWITZERLAND
4871927	GROUP 4	Female	56.8	Kilograms	56	20051229	Physician	-	FINLAND
4871928		Male	60	Kilograms	60	20060104		-	GERMANY
4871929	GROUP 3	Female	-		-	20060104	Other health professional	-	GERMANY
4871930	GROUP 2	Male	70	Kilograms	70	20060104	Physician	-	FRANCE
4871934	GROUP 2	Male	-		-	20060104	Lawyer	-	UNITED STATES
4871935	GROUP 1	Female	72.6	Kilograms	72	20060104	Lawyer	-	UNITED STATES
4871937	GROUP 3	Female	-		-	20060104	Other health professional	20051016	UNITED STATES
4871938	GROUP 1	Male	88.5	Kilograms	88	20060104	Lawyer	-	UNITED STATES
4871939	GROUP 1	Male	-		-	20060104	Physician	-	GERMANY
4871940	GROUP 2	Male	81.6	Kilograms	81	20060104	Lawyer	-	UNITED STATES
4871941	GROUP 1	Male	67.3	Kilograms	67	20060104	Lawyer	-	UNITED STATES
4871942	GROUP 3	Male	82	Kilograms	82	20060104	Physician	-	CANADA
4871943	GROUP 2	Male	-		-	20060104	Physician	-	JAPAN
4871949	GROUP 2	Male	94.8	Kilograms	94	20060104	Lawyer	-	UNITED STATES
4871950	GROUP 1	Female	-		-	20060104	Physician	-	GERMANY

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4871957	GROUP 4	Male	-		-	20060104	Physician	-	JAPAN
4871969	GROUP 2	Male	68	Kilograms	68	20060104	Other health professional	-	UNITED STATES
4871971		Male	2.3	Kilograms	2	20060104	Physician	-	JAPAN
4871972	GROUP 3	Female	47	Kilograms	47	20060104	Physician	-	JAPAN
4871973	GROUP 2	Female	71.7	Kilograms	71	20060104	Pharmacist	-	UNITED STATES
4871974	GROUP 3	Missing	82	Kilograms	82	20060104	Physician	-	GERMANY
4871976	GROUP 3	Female	-		-	20060104	Consumer	20051204	UNITED STATES
4871977	GROUP 3	Male	-		-	20060104	Consumer	-	UNITED STATES
4871978	GROUP 2	Male	-		-	20060104	Consumer	-	UNITED STATES
4871979	GROUP 2	Male	56	Kilograms	56	20060104	Physician	-	UNITED STATES
4871980	GROUP 3	Female	-		-	20060104	Physician	-	GERMANY
4871988	GROUP 3	Female	65	Kilograms	65	20060104	Other health professional	20051003	UNITED KINGDOM
4872010	GROUP 2	Female	174	Pounds	78	20051228	Consumer	-	UNITED STATES
4872016		Male	-		-	20060104	Consumer	-	UNITED STATES
4872017	GROUP 2	Female	-		-	20060104	Consumer	-	JAPAN
4872018		Female	62	Kilograms	62	20060104	Physician	-	JAPAN
4872021		Female	-		-	20060104	Consumer	-	UNITED STATES
4872030	GROUP 3	Female	-		-	20060104	Other health professional	20031101	UNITED STATES
4872033	GROUP 2	Female	-		-	20060104	Physician	-	JAPAN
4872034	GROUP 4	Male	42	Kilograms	42	20060104	Physician	20051202	JAPAN
4872043	GROUP 2	Female	-		-	20060104	Other health professional	-	GERMANY
4872044	GROUP 3	Female	-		-	20060104	Other health professional	-	UNITED STATES
4872072	GROUP 3	Female	-		-	20060104	Physician	-	ITALY
4872074	GROUP 3	Male	-		-	20060104	Physician	-	ISRAEL
4872075		Female	-		-	20060104	Physician	-	GERMANY
4872076	GROUP 3	Female	67	Kilograms	67	20060103	Consumer	-	GERMANY
4872077	GROUP 4	Female	-		-	20060104		-	FRANCE

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4872086		Missing	-		-	20060104		-	FRANCE
4872087	GROUP 1	Female	-		-	20060104	Physician	-	UNITED STATES
4872123		Male	60	Kilograms	60	20060104	Physician	-	GERMANY
4872134	GROUP 3	Female	150	Kilograms	150	20060104	Physician	20050901	RUSSIAN FEDERATION
4872153		Female	-		-	20051201	Pharmacist	-	UNITED STATES
4872155	GROUP 3	Female	-		-	20051229		-	UNITED STATES
4872156	GROUP 3	Female	-		-	20060104	Other health professional	-	UNITED STATES
4872157	GROUP 4	Female	-		-	20051229		-	UNITED STATES
4872159	GROUP 1	Male	74.8	Kilograms	74	20051229	Consumer	-	UNITED STATES
4872161		Female	-		-	20051222	Consumer	20051001	UNITED STATES
4872163	GROUP 2	Female	-		-	20051229		-	UNITED STATES
4872165	GROUP 3	Male	-		-	20051229	Consumer	-	UNITED STATES
4872166	GROUP 3	Male	-		-	20051222	Physician	-	UNITED STATES
4872168	GROUP 1	Male	81.6	Kilograms	81	20060104	Lawyer	-	UNITED STATES
4872169	GROUP 1	Female	45.8	Kilograms	45	20060104	Lawyer	-	UNITED STATES
4872170	GROUP 3	Male	-		-	20051230	Other health professional	-	FRANCE
4872171		Male	-		-	20051230	Other health professional	20051217	PORTUGAL
4872172	GROUP 1	Female	-		-	20051229	Other health professional	-	FRANCE
4872173		Male	-		-	20051230	Other health professional	-	PORTUGAL
4872174		Male	-		-	20051230	Other health professional	20051217	PORTUGAL
4872175	GROUP 2	Female	145	Pounds	65	20051230	Consumer	-	CANADA
4872176	GROUP 2	Female	105	Pounds	47	20051230	Consumer	-	CANADA
4872178	GROUP 1	Male	-		-	20051228		-	FRANCE
4872179	GROUP 3	Male	-		-	20051230		-	JAPAN
4872180	GROUP 3	Male	-		-	20051230		-	JAPAN
4872181		Female	57.885	Kilograms	57	20060104		-	UNITED STATES
4872182		Female	75.137	Kilograms	75	20060104		-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4872183		Male	-		-	20051230	Physician	-	AUSTRALIA
4872184	GROUP 3	Female	-		-	20051230		-	UNITED KINGDOM
4872186	GROUP 3	Male	-		-	20051230	Physician	-	JAPAN
4872187	GROUP 3	Male	-		-	20051230	Physician	-	JAPAN
4872188	GROUP 3	Male	-		-	20051227	Physician	-	UNITED KINGDOM
4872190	GROUP 4	Female	-		-	20051230		-	FRANCE
4872191	GROUP 3	Male	-		-	20051230		-	JAPAN
4872193	GROUP 4	Female	-		-	20051230		-	GERMANY
4872194		Female	-		-	20060104	Consumer	20030705	GERMANY
4872195	GROUP 3	Male	-		-	20060104	Physician	20050517	JAPAN
4872196		Female	-		-	20060104	Physician	-	UNITED STATES
4872197	GROUP 3	Male	-		-	20060104	Other health professional	20050527	UNITED STATES
4872198	GROUP 2	Female	-		-	20060104	Consumer	-	FRANCE
4872203	GROUP 1	Male	-		-	20060104	Physician	-	UNITED STATES
4872220	GROUP 3	Female	44	Kilograms	44	20060104	Pharmacist	-	JAPAN
4872266	GROUP 3	Male	52	Kilograms	52	20060104	Physician	20040201	JAPAN
4872267	GROUP 3	Male	-		-	20060104	Physician	20051201	UNITED KINGDOM
4872268	GROUP 3	Male	-		-	20060104	Other health professional	20051201	UNITED KINGDOM
4872319	GROUP 3	Female	93	Kilograms	93	20060104	Pharmacist	20051116	NETHERLANDS
4872382		Male	-		-	20060105	Lawyer	-	UNITED STATES
4872383	GROUP 2	Female	88	Kilograms	88	20060105	Lawyer	-	UNITED STATES
4872384	GROUP 4	Female	69	Kilograms	69	20060105	Lawyer	-	UNITED STATES
4872385		Female	-		-	20060105	Consumer	20051126	AUSTRALIA
4872386	GROUP 3	Female	95	Kilograms	95	20060105	Physician	-	GERMANY
4872388		Female	-		-	20060105	Lawyer	-	UNITED STATES
4872389	GROUP 3	Female	-		-	20060105	Consumer	-	UNITED STATES
4872390		Female	-		-	20060105	Lawyer	20031215	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4872398	GROUP 2	Female	86	Kilograms	86	20060105	Lawyer	-	UNITED STATES
4872399	GROUP 3	Male	80	Kilograms	80	20060105	Physician	-	UNITED STATES
4872400		Male	-		-	20060105	Lawyer	-	UNITED STATES
4872401		Male	-		-	20060105	Consumer	-	UNITED STATES
4872402	GROUP 3	Female	77	Kilograms	77	20060105	Lawyer	-	UNITED STATES
4872403	GROUP 2	Male	120	Kilograms	120	20060105	Physician	-	UNITED STATES
4872404	GROUP 3	Male	105	Kilograms	105	20060105	Physician	20040629	UNITED STATES
4872405		Female	-		-	20060105	Lawyer	-	UNITED STATES
4872406	GROUP 3	Male	77	Kilograms	77	20060105	Physician	-	UNITED STATES
4872407	GROUP 4	Female	80	Kilograms	80	20060105	Other health professional	-	UNITED KINGDOM
4872408	GROUP 1	Female	-		-	20060105	Physician	-	JAPAN
4872409	GROUP 3	Female	107	Kilograms	107	20060105	Lawyer	-	UNITED STATES
4872410	GROUP 3	Female	-		-	20060105	Lawyer	-	UNITED STATES
4872411	GROUP 3	Male	86	Kilograms	86	20060105	Physician	20010121	UNITED STATES
4872412	GROUP 4	Male	100	Kilograms	100	20060105	Lawyer	-	UNITED STATES
4872414	GROUP 3	Female	82	Kilograms	82	20060105	Lawyer	-	UNITED STATES
4872415	GROUP 3	Female	50	Kilograms	50	20060105	Physician	20041004	UNITED STATES
4872416	GROUP 3	Female	59	Kilograms	59	20060105	Lawyer	-	UNITED STATES
4872417	GROUP 3	Female	-		-	20060105	Physician	-	GREECE
4872418	GROUP 3	Male	68	Kilograms	68	20060105	Physician	-	UNITED STATES
4872419	GROUP 3	Female	62	Kilograms	62	20060105	Physician	-	GERMANY
4872420	GROUP 2	Female	-		-	20060105	Other health professional	-	CANADA
4872421	GROUP 2	Female	96	Kilograms	96	20060105	Lawyer	-	UNITED STATES
4872430		Male	-		-	20060105	Lawyer	-	UNITED STATES
4872431	GROUP 3	Male	84	Kilograms	84	20060105	Lawyer	-	UNITED STATES
4872437	GROUP 1	Missing	-		-	20060105	Lawyer	-	UNITED STATES
4872439		Male	-		-	20060105	Lawyer	-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4872440	GROUP 2	Male	120	Kilograms	120	20060105	Lawyer	-	UNITED STATES
4872441	GROUP 3	Female	86	Kilograms	86	20060105	Lawyer	-	UNITED STATES
4872442		Female	-		-	20060105	Lawyer	20031209	UNITED STATES
4872443		Female	-		-	20060105	Lawyer	-	UNITED STATES
4872444		Male	-		-	20060105	Pharmacist	-	AUSTRALIA
4872445	GROUP 3	Female	68	Kilograms	68	20060105	Lawyer	20050408	UNITED STATES
4872446		Female	-		-	20060105	Lawyer	20040829	UNITED STATES
4872447	GROUP 4	Female	63	Kilograms	63	20060105	Lawyer	-	UNITED STATES
4872448		Missing	-		-	20060105	Lawyer	-	UNITED STATES
4872449	GROUP 3	Male	100	Kilograms	100	20060105	Lawyer	20030319	UNITED STATES
4872450	GROUP 4	Male	-		-	20060105	Lawyer	-	UNITED STATES
4872452	GROUP 3	Male	82	Kilograms	82	20060105	Other health professional	-	FRANCE
4872453	GROUP 3	Male	93	Kilograms	93	20060105	Lawyer	20040910	UNITED STATES
4872454	GROUP 3	Female	-		-	20060105	Lawyer	-	UNITED STATES
4872455	GROUP 3	Male	98	Kilograms	98	20060105	Lawyer	-	UNITED STATES
4872456	GROUP 3	Female	-		-	20060105	Consumer	-	AUSTRALIA
4872457	GROUP 2	Female	73	Kilograms	73	20060105	Lawyer	-	UNITED STATES
4872462	GROUP 3	Female	81	Kilograms	81	20060105	Lawyer	-	UNITED STATES
4872463		Male	-		-	20060105	Lawyer	-	UNITED STATES
4872464		Female	-		-	20060105	Consumer	-	UNITED STATES
4872465		Female	-		-	20060105	Lawyer	-	CANADA
4872466	GROUP 2	Female	135	Kilograms	135	20060105	Physician	-	UNITED STATES
4872467	GROUP 3	Female	83	Kilograms	83	20060105	Physician	-	FRANCE
4872468	GROUP 1	Female	74	Kilograms	74	20060105	Other health professional	-	UNITED KINGDOM
4872469	GROUP 3	Female	70	Kilograms	70	20060105	Lawyer	-	UNITED STATES
4872470	GROUP 2	Male	76	Kilograms	76	20060105	Physician	-	FRANCE
4872481		Female	88.2	Kilograms	88	20060104		-	UNITED STATES

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4872482		Male	-		-	20060104	Physician	-	FRANCE
4872483		Male	73	Kilograms	73	20060104	Physician	20051024	GERMANY
4872484		Male	68	Kilograms	68	20060104	Other health professional	-	KOREA, REPUBLIC OF
4872485		Female	-		-	20060104	Consumer	20050725	UNITED STATES
4872486		Missing	-		-	20060104	Physician	-	UNITED STATES
4872487	GROUP 3	Male	-		-	20060104	Physician	-	UNITED KINGDOM
4872488		Female	58	Kilograms	58	20060104	Physician	20051101	GERMANY
4872489	GROUP 3	Male	-		-	20060104	Physician	-	FRANCE
4872490		Male	54	Kilograms	54	20060104	Other health professional	20051207	ITALY
4872491		Male	75	Kilograms	75	20060104	Other health professional	-	SOUTH AFRICA
4872492	GROUP 3	Male	60	Kilograms	60	20060104	Physician	-	SWITZERLAND
4872493		Male	-		-	20060104		-	
4872494		Female	-		-	20060104		-	FRANCE
4872495		Female	-		-	20060104		-	FINLAND
4872496		Male	-		-	20060104		-	AUSTRALIA
4872497		Male	-		-	20060104		-	FRANCE
4872498		Male	-		-	20060104		-	AUSTRALIA
4872499		Female	-		-	20060104		-	FRANCE
4872500		Male	-		-	20060104		-	FRANCE
4872501		Male	-		-	20060104		-	FINLAND
4872502		Female	-		-	20060104		-	FRANCE
4872535	GROUP 3	Female	-		-	20051229	Consumer	-	FRANCE
4872536		Female	-		-	20051229		-	FINLAND
4872537	GROUP 2	Male	-		-	20051229	Physician	-	UNITED KINGDOM
4872538	GROUP 2	Male	-		-	20051223		20000226	AUSTRALIA
4872539	GROUP 1	Male	-		-	20051228	Physician	-	GERMANY

ADVERSE EVENT REPORTING SYSTEM (AERS)
Demographic Listings

<i>Report's unique number</i>	<i>Derived age group</i>	<i>Code for patient's sex</i>	<i>Numeric value of patient's weight</i>	<i>Unit abbreviation for patient's weight</i>	<i>Derived weight</i>	<i>Date report was sent</i>	<i>Abbreviation for initial reporter's type of occupation</i>	<i>Date patient died</i>	<i>Reports Country</i>
4872540	GROUP 3	Female	-		-	20051228	Physician	-	GERMANY
4872541	GROUP 3	Female	79	Kilograms	79	20060105	Other health professional	-	UNITED KINGDOM

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4793437	1006499909	Primary Suspect Drug	GLUCOPHAGE XR	Validated trade name used	ORAL		
4793437	1006499910	Secondary Suspect Drug	EDTA	Verbatim name used			
4793437	1006499911	Concomitant	AVANDAMET	Validated trade name used			
4799889	1006520185	Primary Suspect Drug	EFFEXOR	Validated trade name used	ORAL	ORAL	Does not apply
4799889	1006533234	Secondary Suspect Drug	ETHANOL (ETHANOL,)	Verbatim name used	ORAL	1 BOTTLE OF PORT ORAL	Does not apply
4799889	1006533235	Secondary Suspect Drug	TEMAZEPAM (TEMAZEPAM, CAPSULE)	Verbatim name used		4 TABLET 1X PER 1 DAY	Does not apply
4802758	1006528830	Primary Suspect Drug	MYLOTARG	Validated trade name used	INTRAVENOUS	15.5 MG OVER 2 HOURS, INTRAVENOUS	Does not apply
4802758	1006542743	Concomitant	VANCOMYCIN	Validated trade name used			
4802758	1006542744	Concomitant	LEVAQUIN	Validated trade name used			
4802758	1006542745	Concomitant	DIFLUCAN	Validated trade name used			
4802758	1006542746	Concomitant	VALTREX	Validated trade name used			
4802758	1006542747	Concomitant	AMBIEN	Validated trade name used			
4802758	1006542748	Concomitant	TAMOXIFEN CITRATE	Validated trade name used			
4802758	1006542749	Concomitant	SENOKOT	Validated trade name used			
4806822	1006543212	Primary Suspect Drug	TISSUES, NOS	Validated trade name used			

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4807735	1006546441	Primary Suspect Drug	SOTALOL HYDROCHLORIDE	Validated trade name used	ORAL	1X/DAY, ORAL	Positive dechallenge
4807735	1006576213	Secondary Suspect Drug	AUGMENTIN '125'	Validated trade name used		1G,2X/DAY	
4807884	1006546701	Primary Suspect Drug	STALEVO 100	Validated trade name used	ORAL	300 MG, 3 IN 1 D, ORAL	Does not apply
4810789	1006557089	Primary Suspect Drug	DETROL LA	Validated trade name used	ORAL	4 MG (4 MG, 1 IN 1 D), ORAL	Does not apply
4810789	1006588338	Secondary Suspect Drug	VESICARE	Validated trade name used			Does not apply
4810789	1006588339	Concomitant	VITAMINS	Verbatim name used			
4811786	1006562404	Primary Suspect Drug	CISPLATIN	Validated trade name used	INTRAVENOUS	150MG	Positive dechallenge
4811786	1006580006	Secondary Suspect Drug	PEMETREXED	Verbatim name used			
4811786	1006580007	Concomitant	ATENOLOL	Validated trade name used			
4811786	1006580008	Concomitant	BISACODYL	Verbatim name used			
4811786	1006580009	Concomitant	DOCUSATE NA	Verbatim name used			
4811786	1006580010	Concomitant	CLOTRIMAZOLE	Validated trade name used			
4811786	1006580011	Concomitant	FUROSEMIDE	Validated trade name used			
4811786	1006580012	Concomitant	HYDROCODONE 5/ACETAMINOPHEN	Verbatim name used			
4811786	1006580013	Concomitant	MORPHINE	Validated trade name used			

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4811786	1006580014	Concomitant	SPIRONOLACTONE	Validated trade name used			
4811786	1006580015	Concomitant	TEMAZEPAM	Validated trade name used			
4813034	1006566431	Primary Suspect Drug	PHENYTOIN SODIUM	Validated trade name used	ORAL	300 MG (100 MG, 3 IN 1 D), ORAL	Does not apply
4813034	1006601168	Secondary Suspect Drug	DONEPEZIL HCL	Validated trade name used		5 MG (1 IN 1 D),	Positive dechallenge
4813034	1006601169	Secondary Suspect Drug	LAMOTRIGINE	Validated trade name used	ORAL	125 MG (1 IN 1 D), ORAL	Positive dechallenge
4815387	1006574695	Primary Suspect Drug	ARELIA	Validated trade name used			
4815387	1006596772	Secondary Suspect Drug	ZOLEDRONIC ACID	Verbatim name used			
4815387	1006596773	Concomitant	DOXORUBICIN HCL	Validated trade name used			
4815387	1006596775	Concomitant	VINCRIStINE	Validated trade name used			
4815387	1006596777	Concomitant	DEXAMETHASONE	Validated trade name used			
4815387	1006596785	Concomitant	ANABOLIC STEROIDS	Verbatim name used			
4815387	1006596787	Concomitant	THALIDOMIDE	Verbatim name used			
4815387	1006596788	Concomitant	CYCLOPHOSPHAMIDE	Validated trade name used			
4815387	1006596790	Secondary Suspect Drug	REVLIMID	Validated trade name used			
4817144	1006582227	Primary Suspect Drug	ZOMETA	Validated trade name used	INTRAVENOUS	4 MG, QMO, INTRAVENOUS	Negative dechallenge

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
		-	-	
		-	-	
Does not apply		-	84349	
Does not apply		-	-	
Does not apply		-	-	
		-	75841	
		-	-	
		-	-	
		-	-	
		-	-	
		-	-	
		-	-	
		-	-	
Does not apply		-	21223	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4817145	1006582228	Primary Suspect Drug	ZOMETA	Validated trade name used			Unknown
4817146	1006582230	Primary Suspect Drug	ZOMETA	Validated trade name used		4 MG PER MONTH, INFUSION	Does not apply
4817146	1006612746	Concomitant	PREDNISONE TAB	Validated trade name used			
4817148	1006582233	Primary Suspect Drug	ZOMETA	Validated trade name used			Unknown
4817149	1006582234	Primary Suspect Drug	ZOMETA	Validated trade name used	INTRAVENOUS	4 MG, ONCE/SINGLE, INTRAVENOUS	Positive dechallenge
4817149	1006612769	Concomitant	ATENOLOL	Validated trade name used			
4817149	1006612771	Concomitant	CASODEX	Validated trade name used			
4817149	1006612773	Concomitant	LISINOPRIL	Validated trade name used			
4817149	1006612777	Concomitant	PERCOCET	Validated trade name used			
4817159	1006582292	Primary Suspect Drug	ZOMETA	Validated trade name used	INTRAVENOUS	4 MG IN JAN, FEB AND MAR 2005, INTRAVENOUS	Negative dechallenge
4817159	1006612783	Concomitant	MEGASTROL (MEGESTROL)	Verbatim name used			
4817159	1006612784	Concomitant	LIPITOR	Validated trade name used			
4817159	1006612785	Concomitant	TAXOL	Validated trade name used			
4817167	1006582324	Primary Suspect Drug	ZOMETA	Validated trade name used	INTRAVENOUS	4 MG, INTRAVENOUS	Unknown
4819355	1006590009	Primary Suspect Drug	SYMLIN	Validated trade name used	SUBCUTANEOUS	30 MCG;TID;SC	Does not apply

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
Unknown		-	21223	
Does not apply		-	21223	
		-	-	
Unknown		-	21223	
Does not apply		-	21223	
		-	-	
		-	-	
		-	-	
		-	-	
Does not apply		-	21223	
		-	-	
		-	-	
		-	-	
Unknown		-	21223	
Does not apply		-	21332	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

Report's unique number	Number for identifying drug from Report's unique number	Code for the role drug played in event	Name of drug	Code for source of drug name	Route of drug administration	Exact text for dose, frequency and route	Dechallenge code (reaction when drug therapy stopped)	Rechallenge code (reaction when drug therapy restarted)
4819355	1006713366	Concomitant	HUMALOG	Validated trade name used				
4820164	1006592680	Primary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		2.41 X 10 ^6 CD34/KG 041	Does not apply	Does not apply
4820164	1006612262	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		4.62 X 10 ^6 CD34/KG 041	Does not apply	Does not apply
4821833	1006599623	Primary Suspect Drug	LAMISIL	Validated trade name used	ORAL	250 MG, QD		
4826267	1006616466	Primary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		13.61 X10 ^6 CD34/KG 041	Does not apply	Does not apply
4826267	1006627645	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		14.89 X10 ^6 CD34/KG 041	Does not apply	Does not apply
4826274	1006616477	Primary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		6.77 X 10 ^6 CD34/KG 041	Does not apply	Does not apply
4826360	1006616799	Primary Suspect Drug	DOLOPHINE HCL	Validated trade name used	ORAL	PO	Does not apply	Does not apply
4826360	1006646257	Secondary Suspect Drug	ALPRAZOLAM	Validated trade name used	ORAL	PO	Does not apply	Does not apply
4826360	1006646259	Secondary Suspect Drug	BIVALIRUDIN	Verbatim name used	INTRAVENOUS	SEE TEXT, IV	Does not apply	Does not apply
4826360	1006646263	Secondary Suspect Drug	ONDANSETRON HCL	Validated trade name used	ORAL	PO	Does not apply	Does not apply

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
	-	-	
KO19846	20051001	-	
KO19853	20051001	-	
	-	20539	
K019835	20051001	-	
K019843	20051001	-	
KO19882	20051001	-	
	-	6134	
	-	-	
	-	-	
	-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>	<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>
4826360	1006646285	Concomitant	OMEPRAZOLE	Validated trade name used					
4826360	1006646287	Concomitant	QUINAPRIL	Validated trade name used					
4826360	1006646291	Concomitant	DILTIAZEM	Validated trade name used					
4826360	1006646292	Concomitant	WARFARIN SODIUM	Validated trade name used					
4826360	1006646294	Concomitant	HYDROXYZINE	Validated trade name used					
4826360	1006646295	Concomitant	INSULIN	Validated trade name used					
4826360	1006646297	Concomitant	METOCLOPRAMIDE	Validated trade name used					
4826360	1006646299	Concomitant	PANOCASE	Verbatim name used					
4826360	1006646300	Concomitant	QUININE	Verbatim name used					
4826360	1006646303	Concomitant	MIRTAZAPINE	Validated trade name used					
4826360	1006646304	Concomitant	LEVOTHYROXINE SODIUM	Validated trade name used					

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>
4826360	1006646310	Concomitant	PENTOXIFYLLINE	Validated trade name used						-
4826360	1006646314	Concomitant	TERAZOSIN HCL	Validated trade name used						-
4826360	1006646315	Concomitant	SIMVASTATIN	Validated trade name used						-
4828303	1006624790	Primary Suspect Drug	MARCAINE	Validated trade name used	EPIDURAL					-
4828303	1006624791	Secondary Suspect Drug	DIPRIVAN	Validated trade name used	INTRAVENOUS	INDUCTION				-
4828303	1006624792	Secondary Suspect Drug	DIPRIVAN	Validated trade name used	INTRAVENOUS	INDUCTION				-
4828303	1006624793	Secondary Suspect Drug	DIPRIVAN	Validated trade name used	INTRAVENOUS	MAINTENANCE				-
4828303	1006624794	Secondary Suspect Drug	DIPRIVAN	Validated trade name used	INTRAVENOUS	MAINTENANCE				-

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>NDA number</i>	<i>Derived Drug Name</i>
-	
-	
-	
18304	
19627	
19627	
19627	
19627	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>
4828303	1006624795	Secondary Suspect Drug	CEFAMEZIN ALPHA	Verbatim name used	INTRAVENOUS					-
4828303	1006624796	Secondary Suspect Drug	MUSCULAX	Verbatim name used	INTRAVENOUS					-
4828303	1006624797	Secondary Suspect Drug	MUSCULAX	Verbatim name used	INTRAVENOUS					-
4828303	1006624798	Secondary Suspect Drug	AUTOLOGOUS BLOOD TRANSFUSION	Verbatim name used						-
4828303	1006624799	Concomitant	CONTRAST MEDIA	Verbatim name used						-
4828303	1006624800	Concomitant	XYLOCAINE	Validated trade name used	EPIDURAL					-
4828303	1006624801	Concomitant	XYLOCAINE	Validated trade name used	OTHER	TEST DOSE				-
4828303	1006624802	Concomitant	MORPHINE	Validated trade name used	EPIDURAL					-
4828303	1006624803	Concomitant	ATROPINE SULFATE	Validated trade name used	INTRAVENOUS					-

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

NDA number	Derived Drug Name
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>
4828303	1006624804	Concomitant	VAGOSTIGMIN	Verbatim name used	INTRAVENOUS					-
4828303	1006624805	Concomitant	PENTCILLIN	Verbatim name used	INTRAVENOUS					-
4828303	1006624806	Concomitant	FENTANEST	Verbatim name used	INTRAVENOUS					-
4828303	1006624807	Concomitant	GASTER	Verbatim name used	INTRAVENOUS					-
4832882	1006644304	Concomitant	GW679769	Verbatim name used	ORAL					-
4832882	1006644305	Primary Suspect Drug	ONDANSETRON HCL	Validated trade name used	INTRAVENOUS	32MG SINGLE DOSE				-
4832882	1006644306	Secondary Suspect Drug	DEXAMETHASONE TAB	Validated trade name used	ORAL					-
4832882	1006644307	Concomitant	CISPLATIN	Validated trade name used	INTRAVENOUS					-
4832882	1006644308	Concomitant	VINORELBINE	Verbatim name used	INTRAVENOUS					-

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

NDA number		Derived Drug Name	
		-	
		-	
		-	
		-	
		-	
20007			
		-	
		-	
		-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>
4833762	1006646649	Primary Suspect Drug	DEPO-PROVERA SUSPENSION/INJ	Validated trade name used	INTRAMUSCULAR	EVERY 3 MOS. IM	Negative dechallenge	Does not apply		-
4833775	1006646665	Primary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used						-
4834797	1006650318	Primary Suspect Drug	ALPRAZOLAM	Validated trade name used	ORAL	ORAL	Unknown	Unknown		-
4834797	1006674751	Secondary Suspect Drug	BIVALIRUDIN	Verbatim name used	INTRAVENOUS	3.2ML BOLUS THEN 4 ML/HR TO 28 ML/HR), INTRAVENOUS	Does not apply	Does not apply		-
4834797	1006674753	Secondary Suspect Drug	DOLOPHINE HCL	Validated trade name used	ORAL	ORAL	Unknown	Unknown		-
4834797	1006674755	Secondary Suspect Drug	ONDANSETRON HCL	Validated trade name used	ORAL	ORAL	Unknown	Unknown		-
4834797	1006674756	Concomitant	ACCUPRIL	Validated trade name used						-
4834797	1006674757	Concomitant	CARDIZEM	Validated trade name used						-

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

NDA number	Derived Drug Name
-	
-	
18276	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>
4834797	1006674759	Concomitant	WARFARIN SODIUM	Validated trade name used						-
4834797	1006674761	Concomitant	HYDROXYZINE	Validated trade name used						-
4834797	1006674762	Concomitant	REGLAN	Validated trade name used						-
4834797	1006674763	Concomitant	INSULIN	Validated trade name used						-
4834797	1006674766	Concomitant	PANCRELIPASE	Verbatim name used						-
4834797	1006674770	Concomitant	QUININE	Verbatim name used						-
4834797	1006674787	Concomitant	REMERON	Validated trade name used						-
4834797	1006674793	Concomitant	SYNTHROID	Validated trade name used						-
4834797	1006674829	Concomitant	PENTOXYPHYLLINE	Verbatim name used						-

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

NDA number	Derived Drug Name
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

Report's unique number	Number for identifying drug from Report's unique number	Code for the role drug played in event	Name of drug	Code for source of drug name	Route of drug administration	Exact text for dose, frequency and route	Dechalleng e code (reaction when drug therapy stopped)	Rechalleng e code (reaction when drug therapy restarted)	Lot number of drug	Expiration date of drug
4834797	1006674851	Concomitant	TERAZOSIN HCL	Validated trade name used						-
4834797	1006674867	Concomitant	ZOCOR	Validated trade name used						-
4838069	1006664089	Primary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		5.97 X 10 ^6 CD34/KG 041	Does not apply	Does not apply		-
4838069	1006690892	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		4.82 X 10 ^6 CD34/KG 041	Does not apply	Does not apply	KO2004 0	20051101
4840105	1006670788	Primary Suspect Drug	BENADRYL	Validated trade name used	ORAL	6 OR 7 TABS, ONCE, ORAL	Does not apply	Does not apply	04213S	20060930
4840105	1006693739	Secondary Suspect Drug	MOTRIN	Validated trade name used	ORAL	ONE, ONCE, ORAL	Does not apply	Does not apply		-
4840105	1006693817	Secondary Suspect Drug	THERAFLU	Verbatim name used	ORAL	2, ONCE, ORAL	Does not apply	Does not apply		-
4840105	1006693842	Secondary Suspect Drug	MEDINITE (DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, EPHEDRI	Verbatim name used	ORAL	ONCE, ORAL	Does not apply	Does not apply		-

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

NDA number		Derived Drug Name	
		-	
		-	
		-	
		-	
5845			
		-	
		-	
		-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4843170	1006681888	Primary Suspect Drug	PREMARIN	Validated trade name used			Does not apply
4843170	1006687377	Secondary Suspect Drug	MEDROXYPROGESTERONE	Validated trade name used			Does not apply
4843170	1006687378	Secondary Suspect Drug	PROVERA	Validated trade name used			Does not apply
4846119	1006693270	Primary Suspect Drug	DEPO-PROVERA SUSPENSION/INJ	Validated trade name used	INTRAMUSCULAR	150 MG (150 MG, EVERY 90 DAYS, 1ST INJECTION), INTRAMUSCULAR	Does not apply
4846119	1006720722	Concomitant	NUVARING (ETHINYLESTRADIOL, ETONOGESTREL)	Verbatim name used			
4846435	1006694159	Primary Suspect Drug	DEPO-PROVERA SUSPENSION/INJ	Validated trade name used	INTRAMUSCULAR	SEE IMAGE	Does not apply
4847003	1006696440	Primary Suspect Drug	RAPAMUNE	Validated trade name used			Does not apply
4847003	1006725071	Concomitant	CORTICOSTEROID NOS	Verbatim name used			
4847053	1006696663	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS	RECEIVED SIX DOSES	
4847053	1006696664	Concomitant	METHOTREXATE	Validated trade name used			
4847638	1006698536	Primary Suspect Drug	DEPO-PROVERA SUSPENSION/INJ	Validated trade name used	INTRAMUSCULAR	150 MG (150 MG, SINGLE INJECTION), INTRAMUSCULAR	Positive dechallenge

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
Does not apply		-	4782	
Does not apply		-	-	
Does not apply		-	-	
Does not apply	05K703	20070831	20246	
		-	-	
Does not apply		-	20246	
Does not apply		-	21083	
		-	-	
		-	-	
		-	-	
Does not apply		-	20246	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>
4847706	1006698669	Primary Suspect Drug	NAPROXEN	Validated trade name used	ORAL	ORAL
4847706	1006723545	Concomitant	SERVICEF (CEFALEXIN)	Verbatim name used		
4847706	1006723548	Concomitant	CEFUROXIME	Validated trade name used		
4847706	1006723549	Concomitant	RANITIDINE	Validated trade name used		
4847706	1006723550	Concomitant	METOCLOPRAMIDE	Validated trade name used		
4847706	1006723551	Concomitant	NIMESULIDE (NIMESULIDE)	Verbatim name used		
4847706	1006723553	Concomitant	NAPROXEN	Validated trade name used		
4847706	1006723558	Secondary Suspect Drug	ACETAMINOPHEN	Validated trade name used		
4852120	1006715372	Primary Suspect Drug	RAPTIVA	Validated trade name used		
4852895	1006718379	Primary Suspect Drug	CODEINE PHOSPHATE AND ACETAMINOPHEN	Validated trade name used		
4852895	1006759277	Secondary Suspect Drug	NAPROXEN	Validated trade name used		
4852895	1007311837	Secondary Suspect Drug	IBUPROFEN	Validated trade name used		
4854233	1006722432	Primary Suspect Drug	EYE TISSUE HUMAN	Validated trade name used		
4865588	1006759846	Primary Suspect Drug	MYOBLOC	Validated trade name used	INTRAMUSCULAR	SEE IMAGE
4865588	1006774466	Concomitant	ZELNORM /USA/	Verbatim name used		
4867362	1006767685	Primary Suspect Drug	ALKERAN	Validated trade name used		
4867362	1006789786	Secondary Suspect Drug	FLUDARABINE PHOSPHATE	Validated trade name used	INTRAVENOUS	INTRAVENOUS
4867362	1006789787	Secondary Suspect Drug	ALEMTUZUMAB	Verbatim name used	INTRAVENOUS	INTRAVENOUS
4867362	1006789789	Secondary Suspect Drug	TACROLIMUS	Verbatim name used		
4867362	1006789792	Secondary Suspect Drug	ACETAMINOPHEN	Validated trade name used		
4867362	1006789793	Secondary Suspect Drug	DIPHENHYDRAMINE HCL	Validated trade name used		
4867362	1006789795	Concomitant	GLUCOCORTICOID	Verbatim name used		
4867362	1006789797	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		
4867362	1006789798	Secondary Suspect Drug	FILGRASTIM	Verbatim name used	SUBCUTANEOUS	SUBCUTANEOUS

ADVERSE EVENT REPORTING SYSTEM (AERS)

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>
4867362	1006789799	Concomitant	ANTIBACTERIAL	Verbatim name used	ORAL	ORAL
4867362	1006789802	Concomitant	ANTIFUNGAL	Verbatim name used		
4867362	1006789803	Concomitant	ANTI-VIRAL MEDICATION	Verbatim name used		
4867362	1006789806	Secondary Suspect Drug	COTRIM DS	Validated trade name used	ORAL	ORAL
4867364	1006767690	Primary Suspect Drug	ALKERAN	Validated trade name used		
4867364	1006789905	Secondary Suspect Drug	FLUDARABINE PHOSPHATE	Validated trade name used	INTRAVENOUS	INTRAVENOUS
4867364	1006789922	Secondary Suspect Drug	ALEMTUZUMAB	Verbatim name used	INTRAVENOUS	INTRAVENOUS
4867364	1006789939	Secondary Suspect Drug	TACROLIMUS	Verbatim name used		
4867364	1006789940	Secondary Suspect Drug	ACETAMINOPHEN	Validated trade name used		
4867364	1006789941	Secondary Suspect Drug	DIPHENHYDRAMINE HCL	Validated trade name used		
4867364	1006789942	Concomitant	GLUCOCORTICOID	Verbatim name used		
4867364	1006789944	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		
4867364	1006789946	Secondary Suspect Drug	FILGRASTIM	Verbatim name used	SUBCUTANEOUS	SUBCUTANEOUS
4867364	1006789947	Concomitant	ANTIBACTERIAL	Verbatim name used	ORAL	ORAL
4867364	1006789948	Concomitant	ANTIFUNGAL	Verbatim name used		
4867364	1006789949	Concomitant	ANTI-VIRAL MEDICATION	Verbatim name used		
4867364	1006789959	Secondary Suspect Drug	COTRIM DS	Validated trade name used	ORAL	ORAL
4867367	1006767694	Primary Suspect Drug	ALKERAN	Validated trade name used		
4867367	1006790043	Secondary Suspect Drug	FLUDARABINE PHOSPHATE	Validated trade name used	INTRAVENOUS	INTRAVENOUS
4867367	1006790044	Secondary Suspect Drug	ALEMTUZUMAB	Verbatim name used	INTRAVENOUS	INTRAVENOUS
4867367	1006790045	Secondary Suspect Drug	TACROLIMUS	Verbatim name used		
4867367	1006790047	Secondary Suspect Drug	ACETAMINOPHEN	Validated trade name used		
4867367	1006790048	Secondary Suspect Drug	DIPHENHYDRAMINE HCL	Validated trade name used		
4867367	1006790049	Concomitant	GLUCOCORTICOID	Verbatim name used		

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>
4867367	1006790051	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		
4867367	1006790052	Secondary Suspect Drug	FILGRASTIM	Verbatim name used	SUBCUTANEOUS	SUBCUTANEOUS
4867367	1006790053	Concomitant	ANTIBACTERIAL	Verbatim name used	ORAL	ORAL
4867367	1006790054	Concomitant	ANTIFUNGAL	Verbatim name used		
4867367	1006790056	Concomitant	ANTI-VIRAL MEDICATION	Verbatim name used		
4867367	1006790058	Secondary Suspect Drug	COTRIM DS	Validated trade name used	ORAL	ORAL
4867370	1006767702	Primary Suspect Drug	ALKERAN	Validated trade name used		
4867370	1006790098	Secondary Suspect Drug	FLUDARABINE PHOSPHATE	Validated trade name used	INTRAVENOUS	INTRAVENOUS
4867370	1006790102	Secondary Suspect Drug	ALEMTUZUMAB	Verbatim name used	INTRAVENOUS	INTRAVENOUS
4867370	1006790105	Secondary Suspect Drug	TACROLIMUS	Verbatim name used		
4867370	1006790107	Secondary Suspect Drug	ACETAMINOPHEN	Validated trade name used		
4867370	1006790109	Secondary Suspect Drug	DIPHENHYDRAMINE HCL	Validated trade name used		
4867370	1006790111	Concomitant	GLUCOCORTICOID	Verbatim name used		
4867370	1006790113	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		
4867370	1006790115	Secondary Suspect Drug	FILGRASTIM	Verbatim name used	SUBCUTANEOUS	SUBCUTANEOUS
4867370	1006790117	Concomitant	ANTIBACTERIAL	Verbatim name used	ORAL	ORAL
4867370	1006790118	Concomitant	ANTIFUNGAL	Verbatim name used		
4867370	1006790120	Concomitant	ANTI-VIRAL MEDICATION	Verbatim name used		
4867370	1006790122	Secondary Suspect Drug	COTRIM DS	Validated trade name used	ORAL	ORAL
4867373	1006767712	Primary Suspect Drug	ALKERAN	Validated trade name used		
4867373	1006790138	Secondary Suspect Drug	FLUDARABINE PHOSPHATE	Validated trade name used	INTRAVENOUS	INTRAVENOUS
4867373	1006790140	Secondary Suspect Drug	ALEMTUZUMAB	Verbatim name used	INTRAVENOUS	INTRAVENOUS
4867373	1006790141	Secondary Suspect Drug	TACROLIMUS	Verbatim name used		
4867373	1006790142	Secondary Suspect Drug	ACETAMINOPHEN	Validated trade name used		

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Dechallenge code (reaction when drug therapy stopped)</i>	<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
			-		-
			-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-	14691	
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
			-		-
			-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-	14691	
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>
4867373	1006790145	Secondary Suspect Drug	DIPHENHYDRAMINE HCL	Validated trade name used		
4867373	1006790148	Concomitant	GLUCOCORTICOID	Verbatim name used		
4867373	1006790149	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		
4867373	1006790150	Secondary Suspect Drug	FILGRASTIM	Verbatim name used	SUBCUTANEOUS	SUBCUTANEOUS
4867373	1006790151	Concomitant	ANTIBACTERIAL	Verbatim name used	ORAL	ORAL
4867373	1006790152	Concomitant	ANTIFUNGAL	Verbatim name used		
4867373	1006790153	Concomitant	ANTI-VIRAL MEDICATION	Verbatim name used		
4867373	1006790158	Secondary Suspect Drug	COTRIM DS	Validated trade name used	ORAL	ORAL
4867375	1006767714	Primary Suspect Drug	ALKERAN	Validated trade name used		
4867375	1006790176	Secondary Suspect Drug	FLUDARABINE PHOSPHATE	Validated trade name used	INTRAVENOUS	INTRAVENOUS
4867375	1006790178	Secondary Suspect Drug	ALEMTUZUMAB	Verbatim name used	INTRAVENOUS	INTRAVENOUS
4867375	1006790181	Secondary Suspect Drug	TACROLIMUS	Verbatim name used		
4867375	1006790183	Secondary Suspect Drug	ACETAMINOPHEN	Validated trade name used		
4867375	1006790194	Secondary Suspect Drug	DIPHENHYDRAMINE HCL	Validated trade name used		
4867375	1006790217	Concomitant	GLUCOCORTICOID	Verbatim name used		
4867375	1006790219	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		
4867375	1006790220	Secondary Suspect Drug	FILGRASTIM	Verbatim name used	SUBCUTANEOUS	SUBCUTANEOUS
4867375	1006790221	Concomitant	ANTIBACTERIAL	Verbatim name used	ORAL	ORAL
4867375	1006790222	Concomitant	ANTIFUNGAL	Verbatim name used		
4867375	1006790411	Concomitant	ANTI-VIRAL MEDICATION	Verbatim name used		
4867375	1006790414	Secondary Suspect Drug	COTRIM DS	Validated trade name used	ORAL	ORAL
4867377	1006767717	Primary Suspect Drug	ALKERAN	Validated trade name used		
4867377	1006790542	Secondary Suspect Drug	FLUDARABINE PHOSPHATE	Validated trade name used		
4867377	1006790543	Secondary Suspect Drug	ALEMTUZUMAB	Verbatim name used	INTRAVENOUS	INTRAVENOUS

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Dechallenge code (reaction when drug therapy stopped)</i>	<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
	Does not apply		-		-
	Does not apply		-		-
			-		-
			-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-	14691	-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-		-
	Does not apply		-	14691	-
	Does not apply		-		-
	Does not apply		-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>
4867377	1006790544	Secondary Suspect Drug	TACROLIMUS	Verbatim name used		
4867377	1006790545	Secondary Suspect Drug	ACETAMINOPHEN	Validated trade name used		
4867377	1006790547	Secondary Suspect Drug	DIPHENHYDRAMINE HCL	Validated trade name used		
4867377	1006790548	Concomitant	GLUCOCORTICOID	Verbatim name used		
4867377	1006790550	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		
4867377	1006790551	Secondary Suspect Drug	FILGRASTIM	Verbatim name used	SUBCUTANEOUS	SUBCUTANEOUS
4867377	1006790552	Concomitant	ANTIBACTERIAL	Verbatim name used	ORAL	ORAL
4867377	1006790553	Concomitant	ANTIFUNGAL	Verbatim name used		
4867377	1006790554	Concomitant	ANTI-VIRAL MEDICATION	Verbatim name used		
4867377	1006790555	Secondary Suspect Drug	COTRIM DS	Validated trade name used	ORAL	ORAL
4867384	1006767733	Primary Suspect Drug	ALKERAN	Validated trade name used		
4867384	1006790724	Secondary Suspect Drug	FLUDARABINE PHOSPHATE	Validated trade name used	INTRAVENOUS	INTRAVENOUS
4867384	1006790725	Secondary Suspect Drug	ALEMTUZUMAB	Verbatim name used	INTRAVENOUS	INTRAVENOUS
4867384	1006790726	Secondary Suspect Drug	TACROLIMUS	Verbatim name used		
4867384	1006790727	Secondary Suspect Drug	ACETAMINOPHEN	Validated trade name used		
4867384	1006790730	Secondary Suspect Drug	DIPHENHYDRAMINE HCL	Validated trade name used		
4867384	1006790731	Concomitant	GLUCOCORTICOID	Verbatim name used		
4867384	1006790732	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used		
4867384	1006790733	Secondary Suspect Drug	FILGRASTIM	Verbatim name used	SUBCUTANEOUS	SUBCUTANEOUS
4867384	1006790734	Concomitant	ANTIBACTERIAL	Verbatim name used	ORAL	ORAL
4867384	1006790736	Concomitant	ANTIFUNGAL	Verbatim name used		
4867384	1006790738	Concomitant	ANTI-VIRAL MEDICATION	Verbatim name used		
4867384	1006790740	Secondary Suspect Drug	COTRIM DS	Validated trade name used	ORAL	ORAL
4867390	1006767761	Primary Suspect Drug	ALKERAN	Validated trade name used		

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>
4867390	1006790064	Secondary Suspect Drug	FLUDARABINE PHOSPHATE	Validated trade name used	INTRAVENOUS
4867390	1006790066	Secondary Suspect Drug	ALEMTUZUMAB	Verbatim name used	INTRAVENOUS
4867390	1006790082	Secondary Suspect Drug	TACROLIMUS	Verbatim name used	
4867390	1006790083	Secondary Suspect Drug	ACETAMINOPHEN	Validated trade name used	
4867390	1006790085	Secondary Suspect Drug	DIPHENHYDRAMINE HCL	Validated trade name used	
4867390	1006790086	Concomitant	GLUCOCORTICOID	Verbatim name used	
4867390	1006790087	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used	
4867390	1006790088	Concomitant	ANTI-VIRAL MEDICATION	Verbatim name used	
4867392	1006767776	Primary Suspect Drug	ALKERAN	Validated trade name used	
4867392	1006790882	Secondary Suspect Drug	FLUDARABINE PHOSPHATE	Validated trade name used	INTRAVENOUS
4867392	1006790885	Secondary Suspect Drug	ALEMTUZUMAB	Verbatim name used	
4867392	1006790887	Secondary Suspect Drug	TACROLIMUS	Verbatim name used	
4867392	1006790892	Secondary Suspect Drug	ACETAMINOPHEN	Validated trade name used	
4867392	1006790895	Secondary Suspect Drug	DIPHENHYDRAMINE HCL	Validated trade name used	
4867392	1006790897	Concomitant	GLUCOCORTICOID	Verbatim name used	
4867392	1006790899	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used	
4867392	1006790900	Secondary Suspect Drug	FILGRASTIM	Verbatim name used	SUBCUTANEOUS
4867392	1006790902	Concomitant	ANTIBACTERIAL	Verbatim name used	ORAL
4867392	1006790931	Concomitant	ANTIFUNGAL	Verbatim name used	
4867392	1006790934	Concomitant	ANTI-VIRAL MEDICATION	Verbatim name used	
4867392	1006790942	Secondary Suspect Drug	COTRIM DS	Validated trade name used	ORAL
4867604	1006768378	Primary Suspect Drug	ALKERAN	Validated trade name used	
4867604	1006790096	Secondary Suspect Drug	FLUDARABINE PHOSPHATE	Validated trade name used	INTRAVENOUS
4867604	1006790100	Secondary Suspect Drug	ALEMTUZUMAB	Verbatim name used	INTRAVENOUS
4867604	1006790101	Secondary Suspect Drug	TACROLIMUS	Verbatim name used	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>	<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
INTRAVENOUS		Does not apply		-	-	
INTRAVENOUS		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	14691	
INTRAVENOUS		Does not apply		-	-	
		Does not apply		-	-	
DAYS		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	-	
SUBCUTANEOUS				-	-	
ORAL/MONTHS		Does not apply		-	-	
MONTHS		Does not apply		-	-	
MONTHS		Does not apply		-	-	
2 TABLET/ORAL		Does not apply		-	-	
		Does not apply		-	14691	
INTRAVENOUS		Does not apply		-	-	
INTRAVENOUS		Does not apply		-	-	
		Does not apply		-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>
4867604	1006790104	Secondary Suspect Drug	ACETAMINOPHEN	Validated trade name used	
4867604	1006790106	Secondary Suspect Drug	DIPHENHYDRAMINE HCL	Validated trade name used	
4867604	1006790108	Concomitant	GLUCORTICOID	Verbatim name used	
4867604	1006790110	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used	
4867604	1006790112	Secondary Suspect Drug	FILGRASTIM	Verbatim name used	SUBCUTANEOUS
4867604	1006790114	Concomitant	ANTIBACTERIAL	Verbatim name used	ORAL
4867604	1006790119	Concomitant	ANTIFUNGAL	Verbatim name used	
4867604	1006790121	Concomitant	ANTI-VIRAL MEDICATION	Verbatim name used	
4867604	1006790123	Secondary Suspect Drug	COTRIM DS	Validated trade name used	ORAL
4867630	1006768432	Primary Suspect Drug	ALKERAN	Validated trade name used	
4867630	1006790806	Concomitant	FLUDARABINE PHOSPHATE	Validated trade name used	INTRAVENOUS
4867630	1006790809	Secondary Suspect Drug	ALEMTUZUMAB	Verbatim name used	INTRAVENOUS
4867630	1006790810	Secondary Suspect Drug	TACROLIMUS	Verbatim name used	
4867630	1006790811	Secondary Suspect Drug	ACETAMINOPHEN	Validated trade name used	
4867630	1006790813	Secondary Suspect Drug	DIPHENHYDRAMINE HCL	Validated trade name used	
4867630	1006790816	Concomitant	GLUCOCORTICOID	Verbatim name used	
4867630	1006790818	Secondary Suspect Drug	HEMATOPOETIC PROGENITOR CELLS HUMAN	Validated trade name used	
4867630	1006790819	Secondary Suspect Drug	FILGRASTIM	Verbatim name used	
4867630	1006790820	Concomitant	ANTIBACTERIAL	Verbatim name used	ORAL
4867630	1006790822	Concomitant	ANTIFUNGAL	Verbatim name used	
4867630	1006790823	Concomitant	ANTI-VIRAL MEDICATION	Verbatim name used	
4867630	1006790825	Secondary Suspect Drug	COTRIM DS	Validated trade name used	ORAL
4869006	1006773747	Primary Suspect Drug	RALOXIFENE HCL	Validated trade name used	ORAL
4869006	1006795874	Concomitant	SUCRALFATE	Validated trade name used	
4869006	1006795876	Concomitant	BAYSPIRIN (ACETYLSALICYLIC ACID)	Verbatim name used	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>	<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
		Does not apply		-	-	
		Does not apply		-	-	
	Does not apply			-	-	
				-	-	
SUBCUTANEOUS				-	-	
ORAL		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	-	
ORAL		Does not apply		-	-	
		Does not apply		-	14691	
INTRAVENOUS		Does not apply		-	-	
INTRAVENOUS		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	-	
SUBCUTANEOUS				-	-	
ORAL		Does not apply		-	-	
		Does not apply		-	-	
		Does not apply		-	-	
ORAL		Does not apply		-	-	
60 MG, DAILY (1/D), ORAL	Does not apply	Does not apply		-	20815	
				-	-	
				-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>
4869006	1006795877	Concomitant	LANSOPRAZOLE	Validated trade name used	
4869006	1006795880	Concomitant	SELBEX (TEPRENONE)	Verbatim name used	
4869006	1006795881	Concomitant	ASPARA-CA (ASPARTATE CALCIUM)	Verbatim name used	
4870242	1006778880	Primary Suspect Drug	MARCAINE	Validated trade name used	INTRATHECAL
4870242	1006778881	Concomitant	MIDAZOLAM HYDROCHLORIDE	Validated trade name used	INTRAVENOUS
4870242	1006778882	Concomitant	VALSARTAN + HYDROCHLOROTHIAZIDE	Verbatim name used	ORAL
4870242	1006778883	Concomitant	FLAVONOIDES	Verbatim name used	ORAL
4870242	1006778884	Concomitant	FUROSEMIDE	Validated trade name used	ORAL
4870242	1006778885	Concomitant	ATORVASTATIN	Verbatim name used	ORAL
4870243	1006778886	Primary Suspect Drug	IRESSA	Validated trade name used	ORAL
4870243	1006778887	Secondary Suspect Drug	IRESSA	Validated trade name used	ORAL
4870243	1006778888	Concomitant	LUVOX	Validated trade name used	ORAL
4870243	1006778889	Concomitant	ERYTHROCIN	Validated trade name used	ORAL
4870243	1006778890	Concomitant	VERAPAMIL	Validated trade name used	ORAL
4870243	1006778891	Concomitant	HYPEN	Verbatim name used	ORAL
4870243	1006778892	Concomitant	PRIMPERAN INJ	Validated trade name used	ORAL
4870243	1006778893	Concomitant	FRANDOL S	Verbatim name used	ORAL
4870243	1006778894	Concomitant	DILTIAZEM HCL	Validated trade name used	ORAL
4870243	1006778895	Concomitant	BUFFERIN	Validated trade name used	ORAL
4870243	1006778896	Concomitant	ROCORNAL	Verbatim name used	ORAL
4870243	1006778897	Concomitant	RADIO THERAPY	Verbatim name used	
4870243	1006778898	Concomitant	DOCETAXEL	Verbatim name used	
4870243	1006778899	Concomitant	CARBOPLATIN	Validated trade name used	
4870244	1006778900	Primary Suspect Drug	SEROQUEL	Validated trade name used	ORAL
4870244	1006778901	Secondary Suspect Drug	SEROQUEL	Validated trade name used	ORAL
4870244	1006778902	Secondary Suspect Drug	SEROQUEL	Validated trade name used	ORAL

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Exact text for dose, frequency and route	Dechallenge code (reaction when drug therapy stopped)	Rechallenge code (reaction when drug therapy restarted)	Lot number of drug	Expiration date of drug	NDA number	Derived Drug Name
					-	-
					-	-
					-	-
			GE23011		-	71202
					-	-
					-	-
					-	-
					-	-
					-	-
					-	-
					-	21399
					-	21399
					-	-
					-	-
					-	-
					-	-
					-	-
					-	-
					-	-
					-	-
1 COURSE					-	-
1 COURSE					-	-
					-	20639
					-	20639
					-	20639

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>
4870244	1006778903	Secondary Suspect Drug	SEROQUEL	Validated trade name used	ORAL	
4870244	1006778904	Secondary Suspect Drug	SEROQUEL	Validated trade name used	ORAL	
4870244	1006778905	Secondary Suspect Drug	SEROQUEL	Validated trade name used	ORAL	
4870244	1006778906	Secondary Suspect Drug	SEROQUEL	Validated trade name used	ORAL	
4870244	1006778907	Secondary Suspect Drug	SEROQUEL	Validated trade name used	ORAL	
4870244	1006778908	Secondary Suspect Drug	SEROQUEL	Validated trade name used	ORAL	
4870244	1006778909	Secondary Suspect Drug	SEROQUEL	Validated trade name used	ORAL	
4870244	1006778910	Secondary Suspect Drug	SEROQUEL	Validated trade name used	ORAL	
4870244	1006778911	Secondary Suspect Drug	SEROQUEL	Validated trade name used	ORAL	
4870244	1006778912	Secondary Suspect Drug	SOLIAN	Verbatim name used		
4870244	1006778913	Concomitant	ERGENYL	Verbatim name used	ORAL	
4870244	1006778914	Concomitant	ERGENYL	Verbatim name used	ORAL	
4870244	1006778915	Concomitant	TAXILAN	Verbatim name used	ORAL	
4870244	1006778916	Concomitant	TAXILAN	Verbatim name used	ORAL	
4870244	1006778917	Concomitant	TAXILAN	Verbatim name used	ORAL	
4870245	1006778918	Primary Suspect Drug	BONIVA	Validated trade name used	ORAL	
4870246	1006778919	Primary Suspect Drug	MYCOPHENOLATE MOFETIL	Verbatim name used	ORAL	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Dechallenge code (reaction when drug therapy stopped)</i>	<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
			-	20639	
			-	20639	
			-	20639	
			-	20639	
			-	20639	
			-	20639	
			-	20639	
			-	20639	
			-	-	
			-	-	
			-	-	
			-	-	
			-	-	
			-	21455	
			-	50722	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4870246	1006778920	Secondary Suspect Drug	TACROLIMUS	Verbatim name used	ORAL		
4870247	1006778921	Primary Suspect Drug	XELODA	Validated trade name used	ORAL	DOSING FREQUENCY: CYCLICAL.	
4870247	1006778922	Secondary Suspect Drug	PYRIDOXINE HYDROCHLORIDE INJ	Validated trade name used	UNKNOWN		
4870247	1006778923	Secondary Suspect Drug	BONEFOS	Verbatim name used	ORAL		
4870248	1006778924	Primary Suspect Drug	IRESSA	Validated trade name used	ORAL		
4870249	1006778925	Primary Suspect Drug	DIPRIVAN	Validated trade name used	INTRAVENOUS	UNSPECIFIED	
4870249	1006778926	Secondary Suspect Drug	DIPRIVAN	Validated trade name used	INTRAVENOUS	UNSPECIFIED	
4870250	1006778927	Primary Suspect Drug	ANAPEINE	Verbatim name used	EPIDURAL		
4870250	1006778928	Secondary Suspect Drug	ANAPEINE	Verbatim name used	EPIDURAL		
4870250	1006778929	Concomitant	MARCAINE	Validated trade name used	INTRATHECAL		
4870250	1006778930	Concomitant	PROCAINE HYDROCHLORIDE INJ	Validated trade name used	SUBCUTANEOUS		
4870251	1006778931	Primary Suspect Drug	XYLOCAINE	Validated trade name used			
4870251	1006778932	Secondary Suspect Drug	XYLOCAINE	Validated trade name used			
4870251	1006778933	Secondary Suspect Drug	LINISOL	Verbatim name used			
4870252	1006778934	Primary Suspect Drug	SEROQUEL	Validated trade name used	ORAL		

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
		-	-	
		-	20896	
		-	20896	
		-	-	
		-	21399	
		-	19627	
		-	19627	
		-	20533	
		-	20533	
		-	-	
		-	-	
		-	6488	
		-	6488	
		-	-	
		-	20639	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4870252	1006778935	Secondary Suspect Drug	SEROQUEL	Validated trade name used	ORAL		
4870252	1006778936	Secondary Suspect Drug	SEROQUEL	Validated trade name used	ORAL	}300MG DAILY	
4870252	1006778937	Concomitant	TEGRETOL	Validated trade name used	ORAL	0.8-2.6G DIVIDED IN 2 OR 3 DOSES	
4870252	1006778938	Concomitant	ALEVIATIN	Verbatim name used	INTRAVENOUS		
4870252	1006778939	Concomitant	ALEVIATIN	Verbatim name used	INTRAVENOUS		
4870252	1006778940	Concomitant	ALEVIATIN	Verbatim name used	ORAL	1-2G THREE TIMES DAILY	
4870252	1006778941	Concomitant	ALEVIATIN	Verbatim name used	ORAL	1-2G THREE TIMES DAILY	
4870252	1006778942	Concomitant	MYSTAN	Verbatim name used	ORAL		
4870252	1006778943	Concomitant	EXCEGRAN	Verbatim name used	ORAL		
4870252	1006778944	Concomitant	THIOPENTAL SODIUM	Validated trade name used	INTRAVENOUS DRIP	1-10G	
4870252	1006778945	Concomitant	DALACIN	Verbatim name used	INTRAVENOUS		
4870252	1006778946	Concomitant	PENTCILLIN	Verbatim name used	INTRAVENOUS		
4870252	1006778947	Concomitant	GAster D	Verbatim name used		DIVIDED INTO 3 DOSES	
4870252	1006778948	Concomitant	LAXOBERON	Verbatim name used		10-30 DROPS/DAY	
4870252	1006778949	Concomitant	DORMICUM	Verbatim name used	INTRAVENOUS DRIP		

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>	<i>Rechallenge code (reaction when drug therapy restarted)</i>
4870252	1006778950	Concomitant	CERCINE	Verbatim name used		10-15 MG DAILY IN 1-5 DOSES		
4870252	1006778951	Concomitant	PHENOBAL	Verbatim name used	INTRAMUSCULAR			
4870253	1006778952	Primary Suspect Drug	LISINOPRIL	Validated trade name used	ORAL			
4870254	1006778953	Primary Suspect Drug	AMBIEN CR	Validated trade name used	ORAL	UNK		
4870255	1006778954	Primary Suspect Drug	ELOXATIN	Validated trade name used	INTRAVENOUS DRIP			
4870255	1006778955	Secondary Suspect Drug	CAPECITABIN	Verbatim name used	ORAL			
4870255	1006778956	Secondary Suspect Drug	CETUXIMAB	Verbatim name used	INTRAVENOUS DRIP			
4870256	1006778957	Primary Suspect Drug	ALFUZOSIN	Validated trade name used	ORAL			
4870257	1006778958	Primary Suspect Drug	PLAVIX	Validated trade name used	ORAL			
4870257	1006778959	Concomitant	ASPIRIN	Validated trade name used	ORAL			
4870257	1006778960	Concomitant	DILTIAZEM HCL	Validated trade name used	ORAL			
4870257	1006778961	Concomitant	AMIODARONE	Verbatim name used	ORAL			
4870258	1006778963	Primary Suspect Drug	TOPROL-XL	Validated trade name used	ORAL			
4870258	1006778964	Secondary Suspect Drug	TOPROL-XL	Validated trade name used	ORAL			
4870258	1006778965	Secondary Suspect Drug	AVALIDE	Validated trade name used				

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Lot number of drug		Expiration date of drug	NDA number	Derived Drug Name
UNKNOWN		-	-	
		-	-	
		-	19777	
		-	21774	
		-	21492	
		-	-	
		-	-	
		-	21287	
		-	20839	
		-	-	
		-	-	
		-	-	
		-	19962	
		-	19962	
		-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4870258	1006778966	Concomitant	FUROSEMIDE	Validated trade name used			
4870258	1006778967	Concomitant	ESTRACE	Validated trade name used			
4870258	1006778968	Concomitant	NEXIUM	Validated trade name used	ORAL		
4870258	1006778969	Concomitant	SINGULAIR	Validated trade name used			
4870258	1006778970	Concomitant	ZYRTEC	Validated trade name used			
4870272	1006779201	Primary Suspect Drug	SUBOXONE	Validated trade name used	SUBLINGUAL		
4870272	1006779202	Concomitant	CLONAZEPAM	Validated trade name used	ORAL		
4870302	1006779257	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS		
4870302	1006779258	Concomitant	IMUREL	Verbatim name used			
4870303	1006779259	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS		
4870304	1006779260	Secondary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS		
4870304	1006779261	Secondary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS		
4870304	1006779262	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS		
4870304	1006779263	Concomitant	COLCHICINE	Verbatim name used	ORAL	START DATE: BEFORE STUDY	
4870304	1006779264	Concomitant	LOCOID	Validated trade name used	TOPICAL	ADEQUATE DOSE	

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4870304	1006779265	Concomitant	ISODINE GARGLE	Verbatim name used		ADEQUATE DOSE	
4870304	1006779266	Concomitant	GASTER D	Verbatim name used	ORAL		
4870304	1006779267	Concomitant	GASTER D	Verbatim name used	ORAL		
4870304	1006779268	Concomitant	NEORAL	Validated trade name used	ORAL		
4870304	1006779269	Concomitant	APLACE	Verbatim name used	ORAL		
4870304	1006779270	Concomitant	PREDONINE	Verbatim name used	ORAL		
4870304	1006779271	Concomitant	MYDRIN P	Verbatim name used	OPHTHALMIC	START DATE: BEFORE STUDY, 3 TIMES DAILY, RIGHT EYE	
4870304	1006779272	Concomitant	MYDRIN P	Verbatim name used	OPHTHALMIC	START DATE: BEFORE STUDY, 3 TIMES DAILY, LEFT EYE	
4870304	1006779273	Concomitant	TIMOPTIC	Validated trade name used	OPHTHALMIC	START DATE: BEFORE STUDY, TWICE DAILY, RIGHT EYE	
4870304	1006779274	Concomitant	TIMOPTIC	Validated trade name used	OPHTHALMIC	START DATE: BEFORE STUDY, TWICE DAILY, LEFT EYE	
4870304	1006779275	Concomitant	TRUSOPT	Validated trade name used	OPHTHALMIC	START DATE: BEFORE STUDY, 3 TIMES DAILY, RIGHT EYE	
4870304	1006779276	Concomitant	TRUSOPT	Validated trade name used	OPHTHALMIC	START DATE: BEFORE STUDY, 3 TIMES DAILY, LEFT EYE	
4870304	1006779277	Concomitant	CRAVIT	Verbatim name used	OPHTHALMIC	START DATE: BEFORE STUDY, TWICE DAILY, RIGHT EYE	
4870304	1006779278	Concomitant	CRAVIT	Verbatim name used	OPHTHALMIC	START DATE: BEFORE STUDY, TWICE DAILY, LEFT EYE	
4870304	1006779279	Concomitant	BETAMETHASONE SODIUM PHOSPHATE	Validated trade name used	OPHTHALMIC	NINE TIMES DAILY, LEFT EYE	

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4870304	1006779280	Concomitant	BETAMETHASONE SODIUM PHOSPHATE	Validated trade name used	OPHTHALMIC	FOUR TIMES DAILY, LEFT EYE	
4870304	1006779281	Concomitant	FLUMETHOLON	Verbatim name used	OPHTHALMIC	4 TIMES DAILY, RIGHT EYE	
4870304	1006779282	Concomitant	DIAMOX	Validated trade name used	ORAL		
4870304	1006779283	Concomitant	DIAMOX	Validated trade name used	ORAL		
4870304	1006779284	Concomitant	ASPARA K	Verbatim name used	ORAL		
4870304	1006779285	Concomitant	XALATAN	Validated trade name used	OPHTHALMIC	ONCE DAILY, RIGHT EYE	
4870305	1006779286	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS	WEEKS 0, 2, 6 AND THEN EVERY 6 WEEKS	
4870305	1006779287	Concomitant	METHOTREXATE	Validated trade name used			
4870305	1006779288	Concomitant	PREDNISOLONE	Validated trade name used			
4870305	1006779289	Concomitant	FOLIC ACID	Validated trade name used			
4870313	1006779327	Primary Suspect Drug	STRATTERA	Validated trade name used			Positive dechallenge
4870319	1006779354	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS		
4870320	1006779355	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS		
4870321	1006779356	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS		
4870322	1006779357	Secondary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS		

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
		-		-
		-		-
		-		-
		-		-
		-		-
		-		-
		-		-
		-		-
		-		-
Unknown		-	21411	
		-		-
		-		-
		-		-
	04F093A	-		-

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>
4870322	1006779358	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS	
4870322	1006779359	Secondary Suspect Drug	INH	Validated trade name used		
4870322	1006779360	Concomitant	ZOLOFT	Validated trade name used		
4870322	1006779361	Concomitant	MESALAMINE	Validated trade name used		
4870322	1006779362	Concomitant	VITAMIN B6	Validated trade name used		
4870322	1006779363	Concomitant	ZYRTEC	Validated trade name used		
4870322	1006779364	Concomitant	SINGULAIR	Validated trade name used		
4870322	1006779365	Concomitant	ZANTAC	Validated trade name used		
4870322	1006779366	Concomitant	FOLIC ACID	Validated trade name used		
4870322	1006779367	Concomitant	METHYLPREDNISOLONE	Validated trade name used	ORAL	
4870323	1006779368	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS	TOTAL OF 3 INFUSIONS
4870323	1006779369	Concomitant	IMURAN	Validated trade name used		
4870323	1006779370	Concomitant	PENTASA	Validated trade name used		
4870324	1006779371	Secondary Suspect Drug	BLINDED; INFLIXIMAB, RECOMBINANT	Verbatim name used	INTRAVENOUS	
4870324	1006779372	Secondary Suspect Drug	BLINDED; INFLIXIMAB, RECOMBINANT	Verbatim name used	INTRAVENOUS	
4870324	1006779373	Primary Suspect Drug	BLINDED; INFLIXIMAB, RECOMBINANT	Verbatim name used	INTRAVENOUS	
4870324	1006779374	Secondary Suspect Drug	PLACEBO	Verbatim name used	INTRAVENOUS	
4870324	1006779375	Secondary Suspect Drug	PLACEBO	Verbatim name used	INTRAVENOUS	
4870324	1006779376	Secondary Suspect Drug	PLACEBO	Verbatim name used	INTRAVENOUS	
4870324	1006779377	Concomitant	FOLIC ACID	Validated trade name used	ORAL	
4870324	1006779378	Concomitant	SOLOLONDO	Verbatim name used	ORAL	
4870324	1006779379	Concomitant	RECOMIDE	Verbatim name used	ORAL	
4870324	1006779380	Concomitant	TYLENOL ER	Verbatim name used	ORAL	
4870324	1006779381	Concomitant	GANATON	Verbatim name used	ORAL	

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot numbe r of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870324	1006779382	Concomitant	MOBIC	Validated trade name used	ORAL					-	-	
4870324	1006779383	Concomitant	METHOTREXATE	Validated trade name used	ORAL					-	-	
4870325	1006779384	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS					-	-	
4870326	1006779385	Primary Suspect Drug	REMICADE	Verbatim name used	INTRAVENOUS					-	-	
4870327	1006779386	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS					-	-	
4870327	1006779387	Concomitant	IMURAN	Validated trade name used						-	-	
4870328	1006779388	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS					-	-	
4870328	1006779389	Concomitant	PREDONINE	Verbatim name used						-	-	
4870328	1006779390	Concomitant	RHEUMATREX	Validated trade name used	ORAL					-	-	
4870329	1006779391	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS					-	-	
4870329	1006779392	Concomitant	METHOTREXATE	Validated trade name used						-	-	
4870329	1006779393	Concomitant	OCUVITE	Verbatim name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot numbe r of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870329	1006779394	Concomitant	OCUVITE	Verbatim name used						-	-	
4870329	1006779395	Concomitant	OCUVITE	Verbatim name used						-	-	
4870329	1006779396	Concomitant	DARVOCET	Validated trade name used						-	-	
4870329	1006779397	Concomitant	DARVOCET	Validated trade name used						-	-	
4870329	1006779398	Concomitant	VIACTIVE	Verbatim name used						-	-	
4870329	1006779399	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870329	1006779400	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870329	1006779401	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870329	1006779402	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870329	1006779403	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870329	1006779404	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870329	1006779405	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870329	1006779406	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870330	1006779407	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS					-	-	
4870330	1006779408	Secondary Suspect Drug	METHOTREXATE	Validated trade name used						-	-	
4870330	1006779409	Secondary Suspect Drug	FOLIC ACID	Validated trade name used	ORAL					-	-	
4870330	1006779410	Concomitant	CELEBREX	Validated trade name used	ORAL					-	-	
4870331	1006779411	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS					-	-	
4870331	1006779412	Concomitant	INSULIN	Validated trade name used						-	-	
4870331	1006779413	Concomitant	FUROSEMIDE	Validated trade name used						-	-	
4870331	1006779414	Concomitant	CYTOXAN	Validated trade name used						-	-	
4870331	1006779415	Concomitant	ATACAND	Validated trade name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequenc y and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870331	1006779416	Concomitant	CRESTOR	Validated trade name used						-	-	
4870331	1006779417	Concomitant	PLAVIX	Validated trade name used						-	-	
4870331	1006779418	Concomitant	VERELAN PM	Validated trade name used						-	-	
4870331	1006779419	Concomitant	ISOSORBIDE	Validated trade name used						-	-	
4870331	1006779420	Concomitant	MINOCYCLINE HCL	Validated trade name used						-	-	
4870331	1006779421	Concomitant	NEXIUM	Validated trade name used						-	-	
4870331	1006779422	Concomitant	ALBUTEROL	Validated trade name used						-	-	
4870331	1006779423	Concomitant	IPRATROPIUM BROMIDE	Validated trade name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>
4870331	1006779424	Concomitant	ADVAIR DISKUS 250/50	Validated trade name used		
4870331	1006779425	Concomitant	ADVAIR DISKUS 250/50	Validated trade name used		
4870331	1006779426	Concomitant	PAMIDRONATE DISODIUM	Validated trade name used		
4870331	1006779427	Concomitant	AMBIEN	Validated trade name used		
4870331	1006779428	Concomitant	CALCIUM+D	Verbatim name used		
4870331	1006779429	Concomitant	CALCIUM+D	Verbatim name used		
4870331	1006779430	Concomitant	MULTIVITAMIN	Validated trade name used		
4870331	1006779431	Concomitant	MULTIVITAMIN	Validated trade name used		
4870331	1006779432	Concomitant	MULTIVITAMIN	Validated trade name used		
4870331	1006779433	Concomitant	MULTIVITAMIN	Validated trade name used		
4870331	1006779434	Concomitant	MULTIVITAMIN	Validated trade name used		
4870331	1006779435	Concomitant	MULTIVITAMIN	Validated trade name used		
4870331	1006779436	Concomitant	MULTIVITAMIN	Validated trade name used		
4870331	1006779437	Concomitant	MULTIVITAMIN	Validated trade name used		
4870332	1006779438	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS	
4870332	1006779439	Concomitant	AMITRIPTYLINE	Verbatim name used		
4870332	1006779440	Concomitant	CALTRATE	Verbatim name used		
4870332	1006779441	Concomitant	CLINORIL	Validated trade name used		
4870332	1006779442	Concomitant	FOLIC ACID	Validated trade name used		
4870332	1006779443	Concomitant	IMODIUM	Validated trade name used		2 IN 1 DAY, AS NEEDED
4870332	1006779444	Concomitant	LACTAID	Verbatim name used		
4870332	1006779445	Concomitant	PENTASA	Validated trade name used		
4870332	1006779446	Concomitant	PEPCID	Validated trade name used		
4870332	1006779447	Concomitant	SINEMET	Validated trade name used		

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>
4870332	1006779448	Concomitant	SINEMET	Validated trade name used		
4870332	1006779449	Concomitant	METHOTREXATE	Validated trade name used		
4870332	1006779450	Concomitant	NEXIUM	Validated trade name used		
4870332	1006779451	Concomitant	TRICOR	Validated trade name used		
4870332	1006779452	Concomitant	ZOMIG	Validated trade name used		
4870332	1006779453	Concomitant	MULTI-VITAMIN	Validated trade name used		
4870332	1006779454	Concomitant	MULTI-VITAMIN	Validated trade name used		
4870332	1006779455	Concomitant	MULTI-VITAMIN	Validated trade name used		
4870332	1006779456	Concomitant	MULTI-VITAMIN	Validated trade name used		
4870332	1006779457	Concomitant	MULTI-VITAMIN	Validated trade name used		
4870332	1006779458	Concomitant	MULTI-VITAMIN	Validated trade name used		
4870332	1006779459	Concomitant	MULTI-VITAMIN	Validated trade name used		
4870332	1006779460	Concomitant	MULTI-VITAMIN	Validated trade name used		
4870333	1006779461	Secondary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS	
4870333	1006779462	Secondary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS	

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>
4870333	1006779463	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS	4-5 MG/KG
4870333	1006779464	Concomitant	METHOTREXATE	Validated trade name used		
4870334	1006779465	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS	
4870334	1006779466	Concomitant	CIPRO	Validated trade name used		
4870334	1006779467	Concomitant	IMODIUM	Validated trade name used		
4870334	1006779468	Concomitant	PREVACID	Validated trade name used		
4870334	1006779469	Concomitant	ROWASA	Validated trade name used		
4870335	1006779470	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS	
4870335	1006779471	Concomitant	DARVOCET-N 100	Validated trade name used		
4870335	1006779472	Concomitant	DARVOCET-N 100	Validated trade name used		
4870335	1006779473	Concomitant	METFORMIN	Validated trade name used		
4870335	1006779474	Concomitant	HYDROCHLOROTHIAZIDE	Validated trade name used		
4870335	1006779475	Concomitant	INSULIN	Validated trade name used		
4870335	1006779476	Concomitant	NEORAL	Validated trade name used		
4870336	1006779477	Primary Suspect Drug	REMICADE	Verbatim name used	INTRAVENOUS	

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>
4870336	1006779478	Concomitant	METHOTREXATE	Validated trade name used		} 6 MONTHS
4870336	1006779479	Concomitant	AZATHIOPRINE	Verbatim name used		
4870343	1006779487	Primary Suspect Drug	SIFROL	Verbatim name used	ORAL	
4870343	1006779488	Concomitant	DOMINAL	Verbatim name used		
4870344	1006779489	Primary Suspect Drug	TIPRANAVIR/RITONAVIR	Verbatim name used	ORAL	TIPRANAVIR 500MG / RITONAVIR 200MG BD
4870344	1006779490	Concomitant	KALETRA	Validated trade name used	ORAL	
4870344	1006779491	Concomitant	TENOFOVIR	Verbatim name used	ORAL	
4870344	1006779492	Concomitant	ABACAVIR	Verbatim name used	ORAL	
4870344	1006779493	Concomitant	ATAZANAVIR	Verbatim name used	ORAL	
4870345	1006779494	Primary Suspect Drug	MICARDIS	Validated trade name used		
4870346	1006779495	Primary Suspect Drug	MICARDIS	Validated trade name used	ORAL	
4870346	1006779496	Secondary Suspect Drug	ZYLORIC	Verbatim name used	ORAL	
4870346	1006779497	Concomitant	SERMION	Verbatim name used	ORAL	
4870346	1006779498	Concomitant	ADALAT	Validated trade name used	ORAL	
4870346	1006779499	Concomitant	PAXIL	Validated trade name used	ORAL	
4870346	1006779500	Concomitant	ALPRAZOLAM	Validated trade name used	ORAL	
4870346	1006779501	Concomitant	ACTOS	Validated trade name used	ORAL	
4870346	1006779502	Concomitant	PANALDINE	Verbatim name used	ORAL	

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>
4870347	1006779503	Primary Suspect Drug	ATROVENT	Validated trade name used	RESPIRATORY (INHALATION)	
4870347	1006779504	Secondary Suspect Drug	AROMASIN	Validated trade name used	ORAL	
4870347	1006779505	Concomitant	M.V.I.	Validated trade name used		
4870347	1006779506	Concomitant	VITAMIN E	Validated trade name used		
4870347	1006779507	Concomitant	FEMOVIRIN	Verbatim name used		
4870347	1006779508	Concomitant	ZOCOR	Validated trade name used		
4870347	1006779509	Concomitant	ESTRA C	Verbatim name used		
4870348	1006779510	Primary Suspect Drug	MICARDIS	Validated trade name used	ORAL	
4870348	1006779511	Secondary Suspect Drug	MICARDIS	Validated trade name used	ORAL	
4870348	1006779512	Concomitant	LANOXIN	Validated trade name used	ORAL	
4870348	1006779513	Concomitant	ALENDRONATE SODIUM	Validated trade name used		
4870348	1006779514	Concomitant	FLUTICASONE PROPIONATE	Validated trade name used		
4870348	1006779515	Concomitant	FLUVASTATIN	Verbatim name used		
4870348	1006779516	Concomitant	MAXAIR	Validated trade name used		
4870348	1006779517	Concomitant	MAXAIR	Validated trade name used		
4870348	1006779518	Concomitant	SYNTHROID	Validated trade name used		
4870349	1006779519	Primary Suspect Drug	MICARDIS	Validated trade name used	ORAL	
4870349	1006779520	Secondary Suspect Drug	MICARDIS	Validated trade name used	ORAL	
4870349	1006779521	Concomitant	LEVOXYL	Validated trade name used	ORAL	
4870349	1006779522	Concomitant	PREMARIN	Validated trade name used	ORAL	
4870349	1006779523	Concomitant	CITRACAL	Verbatim name used		
4870350	1006779524	Primary Suspect Drug	MOBIC	Validated trade name used	ORAL	
4870350	1006779525	Secondary Suspect Drug	MOBIC	Validated trade name used	ORAL	
4870350	1006779526	Secondary Suspect Drug	COUMADIN	Validated trade name used		
4870350	1006779527	Secondary Suspect Drug	COUMADIN	Validated trade name used		

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Dechallenge code (reaction when drug therapy stopped)</i>	<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
		NOT REPORTED	-	19085	
			-	-	
			-	-	
			-	-	
			-	-	
			-	-	
			-	-	
			-	20850	
			-	20850	
			-	-	
			-	-	
			-	-	
			-	-	
			-	-	
			-	-	
			-	-	
			-	20850	
			-	20850	
			-	-	
			-	-	
			-	-	
		552607	-	20938	
		552607	-	20938	
			-	-	
			-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>
4870350	1006779528	Concomitant	DILTIAZEM HCL	Validated trade name used	
4870350	1006779529	Concomitant	SYNTHROID	Validated trade name used	
4870350	1006779530	Concomitant	DIGITEK	Verbatim name used	
4870350	1006779531	Concomitant	FUROSEMIDE	Validated trade name used	
4870350	1006779532	Concomitant	TYLENOL	Validated trade name used	
4870350	1006779533	Concomitant	SUCRALFATE	Validated trade name used	
4870350	1006779534	Concomitant	PROTONIX	Validated trade name used	
4870351	1006779535	Primary Suspect Drug	MICARDIS	Validated trade name used	ORAL
4870351	1006779536	Concomitant	MEVALOTIN	Verbatim name used	ORAL
4870351	1006779537	Concomitant	ADALAT	Validated trade name used	ORAL
4870351	1006779538	Concomitant	ASPIRIN	Validated trade name used	ORAL
4870351	1006779539	Concomitant	MEXITIL	Validated trade name used	ORAL
4870351	1006779540	Concomitant	EUGLUCON	Verbatim name used	ORAL
4870351	1006779541	Concomitant	RIVOTRIL	Verbatim name used	ORAL
4870352	1006779542	Primary Suspect Drug	VIRAMUNE	Validated trade name used	INTRA-UTERINE
4870353	1006779543	Primary Suspect Drug	MOBIC	Validated trade name used	ORAL
4870353	1006779544	Concomitant	THYRADIN	Verbatim name used	ORAL
4870354	1006779545	Primary Suspect Drug	MICARDIS	Validated trade name used	ORAL
4870354	1006779546	Secondary Suspect Drug	EUGLUCON	Verbatim name used	ORAL
4870355	1006779547	Primary Suspect Drug	MOBIC	Validated trade name used	ORAL
4870355	1006779548	Secondary Suspect Drug	MOBIC	Validated trade name used	
4870355	1006779549	Secondary Suspect Drug	MOBIC	Validated trade name used	
4870355	1006779550	Concomitant	DIOVAN	Validated trade name used	
4870355	1006779551	Concomitant	ASPIRIN	Validated trade name used	
4870355	1006779552	Concomitant	VITAMIN PILL	Verbatim name used	
4870355	1006779553	Concomitant	NEXIUM	Validated trade name used	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Exact text for dose, frequency and route	Dechallenge code (reaction when drug therapy stopped)	Rechallenge code (reaction when drug therapy restarted)	Lot number of drug	Expiration date of drug	NDA number	Derived Drug Name
				-	-	
				-	-	
				-	-	
				-	-	
				-	-	
				-	-	
				-	-	
				-	20850	
				-	-	
				-	-	
				-	-	
				-	-	
				-	-	
				-	-	
				-	20636	
				-	20938	
				-	-	
				-	20850	
				-	-	
		NOT REPORTED		-	20938	
		NOT REPORTED		-	20938	
		NOT REPORTED		-	20938	
				-	-	
				-	-	
				-	-	
				-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>
4870355	1006779554	Concomitant	SPIRONOLACTONE	Validated trade name used	
4870356	1006779555	Primary Suspect Drug	VIRAMUNE	Validated trade name used	ORAL
4870356	1006779556	Secondary Suspect Drug	EPIVIR	Validated trade name used	ORAL
4870356	1006779557	Secondary Suspect Drug	ZIAGEN	Validated trade name used	ORAL
4870357	1006779558	Primary Suspect Drug	VIRAMUNE	Validated trade name used	INTRA-UTERINE
4870357	1006779559	Secondary Suspect Drug	VIRAMUNE	Validated trade name used	INTRA-UTERINE
4870357	1006779560	Secondary Suspect Drug	ZIDOVUDINE	Validated trade name used	INTRA-UTERINE
4870357	1006779561	Secondary Suspect Drug	LAMIVUDINE + ZIDOVUDINE	Validated trade name used	INTRA-UTERINE
4870358	1006779562	Primary Suspect Drug	VIRAMUNE	Validated trade name used	ORAL
4870358	1006779563	Secondary Suspect Drug	RETROVIR	Validated trade name used	ORAL
4870358	1006779564	Secondary Suspect Drug	EPIVIR	Validated trade name used	ORAL
4870359	1006779565	Primary Suspect Drug	AGGRENOX	Validated trade name used	ORAL
4870359	1006779566	Secondary Suspect Drug	MICARDIS	Validated trade name used	ORAL
4870359	1006779567	Secondary Suspect Drug	CLOPIDOGREL BISULFATE	Validated trade name used	ORAL
4870359	1006779568	Concomitant	SIMVASTATIN	Validated trade name used	ORAL
4870359	1006779569	Concomitant	DOSULEPIN	Verbatim name used	ORAL
4870360	1006779570	Primary Suspect Drug	NEVIRAPINE	Validated trade name used	
4870360	1006779571	Secondary Suspect Drug	NEVIRAPINE	Validated trade name used	
4870360	1006779572	Concomitant	COMBIVIR	Validated trade name used	
4870360	1006779573	Concomitant	INDINAVIR	Verbatim name used	
4870360	1006779574	Concomitant	STEROIDS	Verbatim name used	
4870362	1006779587	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS
4870362	1006779588	Concomitant	ASPIRIN	Validated trade name used	
4870362	1006779589	Concomitant	ENBREL	Validated trade name used	
4870362	1006779590	Concomitant	ZOCOR	Validated trade name used	
4870362	1006779591	Concomitant	COREG	Validated trade name used	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequenc y and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot numbe r of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870362	1006779592	Concomitant	LIBRIUM	Validated trade name used						-	-	
4870362	1006779593	Concomitant	PAXIL	Validated trade name used						-	-	
4870362	1006779594	Concomitant	PLAVIX	Validated trade name used						-	-	
4870362	1006779595	Concomitant	PREVACID	Validated trade name used						-	-	
4870362	1006779596	Concomitant	SYNTHROID	Validated trade name used						-	-	
4870362	1006779597	Concomitant	TRAMADOL HCL	Validated trade name used						-	-	
4870362	1006779598	Concomitant	LESCOL	Validated trade name used						-	-	
4870363	1006779599	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS					-	-	
4870363	1006779600	Concomitant	IMURAN	Validated trade name used						-	-	
4870364	1006779601	Secondary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS					-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequenc y and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot numbe r of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870364	1006779602	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOUS					-	-	
4870364	1006779603	Concomitant	ATARAX	Validated trade name used						-	-	
4870364	1006779604	Concomitant	FLEXERIL	Validated trade name used						-	-	
4870364	1006779605	Concomitant	AMBIEN	Validated trade name used						-	-	
4870364	1006779606	Concomitant	ASACOL	Validated trade name used						-	-	
4870364	1006779607	Concomitant	PREDNISONE	Validated trade name used						-	-	
4870364	1006779608	Concomitant	PROTONIX	Validated trade name used						-	-	
4870364	1006779609	Concomitant	PERCOCET	Validated trade name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequenc y and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot numbe r of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870364	1006779610	Concomitant	PERCOCET	Validated trade name used						-	-	
4870364	1006779611	Concomitant	IMODIUM	Validated trade name used						-	-	
4870364	1006779612	Concomitant	VICODIN	Validated trade name used						-	-	
4870364	1006779613	Concomitant	VICODIN	Validated trade name used						-	-	
4870364	1006779614	Concomitant	CELEBREX	Validated trade name used						-	-	
4870364	1006779615	Concomitant	COUMADIN	Validated trade name used						-	-	
4870364	1006779616	Concomitant	AVANDAMENT	Verbatim name used						-	-	
4870365	1006779617	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS					-	-	
4870365	1006779618	Concomitant	OSCAL 500-D	Verbatim name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequenc y and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot numbe r of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870365	1006779619	Concomitant	OSCAL 500-D	Verbatim name used						-	-	
4870365	1006779620	Concomitant	ASPIRIN	Validated trade name used						-	-	
4870365	1006779621	Concomitant	AVAPRO	Validated trade name used						-	-	
4870365	1006779622	Concomitant	FLEXERIL	Validated trade name used						-	-	
4870365	1006779623	Concomitant	FOLIC ACID	Validated trade name used						-	-	
4870365	1006779624	Concomitant	METHOTREXATE	Validated trade name used						-	-	
4870365	1006779625	Concomitant	NASACORT	Validated trade name used						-	-	
4870365	1006779626	Concomitant	NITROGLYCERIN	Validated trade name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>
4870365	1006779627	Concomitant	PREDNISONE	Validated trade name used	
4870365	1006779628	Concomitant	PREVACID	Validated trade name used	
4870365	1006779629	Concomitant	SYNTHROID	Validated trade name used	
4870365	1006779630	Concomitant	TENORMIN	Validated trade name used	
4870365	1006779631	Concomitant	ULTRAM	Validated trade name used	
4870365	1006779632	Concomitant	MULTIVITAMIN	Validated trade name used	
4870365	1006779633	Concomitant	MULTIVITAMIN	Validated trade name used	
4870365	1006779634	Concomitant	MULTIVITAMIN	Validated trade name used	
4870365	1006779635	Concomitant	MULTIVITAMIN	Validated trade name used	
4870365	1006779636	Concomitant	MULTIVITAMIN	Validated trade name used	
4870365	1006779637	Concomitant	MULTIVITAMIN	Validated trade name used	
4870365	1006779638	Concomitant	MULTIVITAMIN	Validated trade name used	
4870365	1006779639	Concomitant	MULTIVITAMIN	Validated trade name used	
4870366	1006779640	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS
4870366	1006779641	Concomitant	ASPIRIN	Validated trade name used	
4870366	1006779642	Concomitant	CALCIUM GLUCONATE	Validated trade name used	
4870366	1006779643	Concomitant	CELEBREX	Validated trade name used	
4870366	1006779644	Concomitant	DIGOXIN	Validated trade name used	
4870366	1006779645	Concomitant	LEUCOVORIN CALCIUM	Validated trade name used	
4870366	1006779646	Concomitant	LISINOPRIL	Validated trade name used	
4870366	1006779647	Concomitant	SIMVASTATIN	Validated trade name used	
4870366	1006779648	Concomitant	MULTI-VITAMIN	Validated trade name used	
4870366	1006779649	Concomitant	MULTI-VITAMIN	Validated trade name used	
4870366	1006779650	Concomitant	MULTI-VITAMIN	Validated trade name used	
4870366	1006779651	Concomitant	MULTI-VITAMIN	Validated trade name used	
4870366	1006779652	Concomitant	MULTI-VITAMIN	Validated trade name used	

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>
4870366	1006779653	Concomitant	MULTI-VITAMIN	Validated trade name used	
4870366	1006779654	Concomitant	MULTI-VITAMIN	Validated trade name used	
4870366	1006779655	Concomitant	MULTI-VITAMIN	Validated trade name used	
4870367	1006779656	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS
4870367	1006779657	Concomitant	DARVOCET-N 100	Validated trade name used	
4870367	1006779658	Concomitant	DARVOCET-N 100	Validated trade name used	
4870367	1006779659	Concomitant	METFORMIN	Validated trade name used	
4870367	1006779660	Concomitant	HYDROCHLOROTHIAZIDE	Validated trade name used	
4870367	1006779661	Concomitant	INSULIN	Validated trade name used	
4870367	1006779662	Concomitant	NEORAL	Validated trade name used	
4870370	1006779665	Primary Suspect Drug	IRESSA	Validated trade name used	ORAL
4870370	1006779666	Secondary Suspect Drug	ARIMIDEX	Validated trade name used	ORAL
4870370	1006779667	Secondary Suspect Drug	LISINOPRIL	Validated trade name used	ORAL
4870370	1006779668	Secondary Suspect Drug	COUMADIN	Validated trade name used	ORAL
4870370	1006779669	Secondary Suspect Drug	ASPIRIN	Validated trade name used	ORAL
4870370	1006779670	Concomitant	DYST-ESE	Verbatim name used	ORAL
4870370	1006779671	Concomitant	ZOCOR	Validated trade name used	ORAL
4870370	1006779672	Concomitant	FOSAMAX	Validated trade name used	ORAL
4870370	1006779673	Concomitant	FAMOTIDINE	Validated trade name used	ORAL
4870370	1006779674	Concomitant	INSULIN	Validated trade name used	
4870370	1006779675	Concomitant	ULTRAM	Validated trade name used	ORAL
4870372	1006779677	Primary Suspect Drug	IRESSA	Validated trade name used	ORAL
4870372	1006779678	Concomitant	METOPROLOL	Verbatim name used	ORAL
4870372	1006779679	Concomitant	METOPROLOL	Verbatim name used	ORAL
4870372	1006779680	Concomitant	AMLODIPINE BESYLATE	Validated trade name used	ORAL
4870372	1006779681	Concomitant	ASPIRIN	Validated trade name used	ORAL

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>	<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
				-	-	
				-	-	
				-	-	
				-	-	
				-	-	
				-	-	
				-	-	
				-	-	
				-	-	
				-	21399	
				-	20541	
				-	19777	
				-	-	
				-	-	
				-	-	
				-	-	
				-	-	
				-	-	
				-	-	
				-	-	
				-	21399	
				-	-	
				-	-	
				-	-	
				-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>
4870372	1006779682	Concomitant	NITROGLYCERINE TRANSDERMAL	Verbatim name used	TRANSDERMAL
4870372	1006779683	Concomitant	NITROGLYCERINE AEROSOL	Verbatim name used	ORAL
4870379	1006779698	Primary Suspect Drug	HUMAN MIXTARD 30	Verbatim name used	
4870379	1006779699	Concomitant	DILTIAZEM HCL	Validated trade name used	ORAL
4870379	1006779700	Concomitant	ARKAMIN	Verbatim name used	ORAL
4870379	1006779701	Concomitant	APRESOLINE	Validated trade name used	
4870379	1006779702	Concomitant	LASIX	Validated trade name used	
4870379	1006779703	Concomitant	BUDECORT ^ASTRA^	Verbatim name used	
4870379	1006779704	Concomitant	CLEXANE	Verbatim name used	SUBCUTANEOUS
4870379	1006779705	Concomitant	ATORVASTATIN	Verbatim name used	
4870379	1006779706	Concomitant	PANTOPRAZOLE	Verbatim name used	
4870379	1006779707	Concomitant	DOMSTAL	Verbatim name used	
4870379	1006779708	Concomitant	VASYLOX	Verbatim name used	
4870379	1006779709	Concomitant	NITRAZEPAM	Validated trade name used	
4870379	1006779710	Concomitant	AMARYL	Validated trade name used	
4870379	1006779711	Concomitant	PRAZOSIN	Verbatim name used	
4870385	1006779719	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS
4870385	1006779720	Concomitant	HUMIRA	Validated trade name used	
4870385	1006779721	Concomitant	CALCIUM GLUCONATE	Validated trade name used	
4870385	1006779722	Concomitant	FOLIC ACID	Validated trade name used	
4870385	1006779723	Concomitant	LOVASTATIN	Validated trade name used	
4870385	1006779724	Concomitant	METOPROLOL	Verbatim name used	
4870385	1006779725	Concomitant	NIFEDIPINE	Validated trade name used	
4870385	1006779726	Concomitant	OMEPRAZOLE	Validated trade name used	
4870385	1006779727	Concomitant	PREDNISONE	Validated trade name used	
4870385	1006779728	Concomitant	RELAFEN	Validated trade name used	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequenc y and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot numbe r of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870385	1006779729	Concomitant	VICODIN	Validated trade name used						-	-	
4870385	1006779730	Concomitant	VICODIN	Validated trade name used						-	-	
4870385	1006779731	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870385	1006779732	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870385	1006779733	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870385	1006779734	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870385	1006779735	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870385	1006779736	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequenc y and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot numbe r of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870385	1006779737	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870385	1006779738	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870386	1006779739	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS					-	-	
4870386	1006779740	Concomitant	CALTRATE	Verbatim name used						-	-	
4870386	1006779741	Concomitant	CELEBREX	Validated trade name used						-	-	
4870386	1006779742	Concomitant	FOLIC ACID	Validated trade name used						-	-	
4870386	1006779743	Concomitant	HYDROCHLOROTHIAZIDE	Validated trade name used						-	-	
4870386	1006779744	Concomitant	LEVOXYL	Validated trade name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot numbe r of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870386	1006779745	Concomitant	K-DUR 10	Validated trade name used						-	-	
4870386	1006779746	Concomitant	METHOTREXATE	Validated trade name used						-	-	
4870386	1006779747	Concomitant	PAXIL	Validated trade name used						-	-	
4870386	1006779748	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870386	1006779749	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870386	1006779750	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870386	1006779751	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870386	1006779752	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot numbe r of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870386	1006779753	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870386	1006779754	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870386	1006779755	Concomitant	MULTI-VITAMIN	Validated trade name used						-	-	
4870387	1006779756	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS					-	-	
4870387	1006779757	Concomitant	ARAVA	Validated trade name used						-	-	
4870387	1006779758	Concomitant	CALCIUM GLUCONATE	Validated trade name used						-	-	
4870387	1006779759	Concomitant	CLINDAMYCIN	Validated trade name used						-	-	
4870387	1006779760	Concomitant	ENBREL	Validated trade name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4870387	1006779761	Concomitant	LEVOTHYROXINE SODIUM	Validated trade name used			
4870387	1006779762	Concomitant	PREDNISONE	Validated trade name used			
4870387	1006779763	Concomitant	ULTRACET	Validated trade name used			
4870387	1006779764	Concomitant	ACTONEL	Validated trade name used			
4870387	1006779765	Concomitant	GLUCOSAMINE WITH CHONDROITIN	Verbatim name used			
4870387	1006779766	Concomitant	GLUCOSAMINE WITH CHONDROITIN	Verbatim name used			
4870387	1006779767	Concomitant	GLUCOSAMINE WITH CHONDROITIN	Verbatim name used			
4870387	1006779768	Concomitant	GLUCOSAMINE WITH CHONDROITIN	Verbatim name used			
4870387	1006779769	Concomitant	FENTANYL	Validated trade name used		^	
4870387	1006779770	Concomitant	MULTIVITAMIN	Validated trade name used			
4870387	1006779771	Concomitant	MULTIVITAMIN	Validated trade name used			

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4870387	1006779772	Concomitant	MULTIVITAMIN	Validated trade name used			
4870387	1006779773	Concomitant	MULTIVITAMIN	Validated trade name used			
4870387	1006779774	Concomitant	MULTIVITAMIN	Validated trade name used			
4870387	1006779775	Concomitant	MULTIVITAMIN	Validated trade name used			
4870387	1006779776	Concomitant	MULTIVITAMIN	Validated trade name used			
4870387	1006779777	Concomitant	MULTIVITAMIN	Validated trade name used			
4870388	1006779778	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOU S		
4870388	1006779779	Concomitant	CYCLOBENZAPRINE HCL	Validated trade name used			
4870388	1006779780	Concomitant	ESTRADIOL INJ	Validated trade name used			
4870388	1006779781	Concomitant	FOLIC ACID	Validated trade name used			
4870388	1006779782	Concomitant	PHENYTOIN	Validated trade name used	ORAL		

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4870388	1006779783	Concomitant	PROPRANOLOL	Validated trade name used			
4870388	1006779784	Concomitant	SALSALATE	Verbatim name used			
4870388	1006779785	Concomitant	SYNTHROID	Validated trade name used			
4870388	1006779786	Concomitant	TYLENOL	Validated trade name used			
4870388	1006779787	Concomitant	METHOTREXATE	Validated trade name used			
4870388	1006779788	Concomitant	ZETIA	Validated trade name used			
4870388	1006779789	Concomitant	RESTASIS	Validated trade name used			
4870388	1006779790	Concomitant	CALCIUM WITH VITAMIN D	Verbatim name used	ORAL		
4870388	1006779791	Concomitant	CALCIUM WITH VITAMIN D	Verbatim name used	ORAL		
4870388	1006779792	Concomitant	CALCIUM WITH VITAMIN D	Verbatim name used	ORAL		
4870389	1006779793	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOU S		
4870389	1006779794	Concomitant	METHOTREXATE	Validated trade name used			

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4870389	1006779795	Concomitant	WELLBUTRIN	Validated trade name used			
4870390	1006779796	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS		
4870390	1006779797	Concomitant	PLAQUENIL	Validated trade name used			
4870390	1006779798	Concomitant	CALCIUM WITH VITAMIN D	Verbatim name used			
4870390	1006779799	Concomitant	CALCIUM WITH VITAMIN D	Verbatim name used			
4870390	1006779800	Concomitant	CALCIUM WITH VITAMIN D	Verbatim name used			
4870390	1006779801	Concomitant	MOTRIN	Validated trade name used			
4870391	1006779802	Primary Suspect Drug	INFLIXIMAB	Verbatim name used	INTRAVENOUS	STOPPED MONTHS BEFORE DEATH	
4870391	1006779803	Concomitant	METHOTREXATE	Validated trade name used			
4870391	1006779804	Concomitant	ARAVA	Validated trade name used			
4870391	1006779805	Concomitant	PREDNISONE	Validated trade name used			
4870391	1006779806	Concomitant	FOSAMAX	Validated trade name used			

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4870391	1006779807	Concomitant	NEURONTIN	Validated trade name used			
4870391	1006779808	Concomitant	REMERON	Validated trade name used			
4870391	1006779809	Concomitant	AMITRIPTYLINE	Verbatim name used			
4870391	1006779810	Concomitant	LASIX	Validated trade name used			
4870391	1006779811	Concomitant	POTASSIUM	Verbatim name used			
4870391	1006779812	Concomitant	VICODIN ES	Validated trade name used			
4870391	1006779813	Concomitant	VICODIN ES	Validated trade name used			
4870391	1006779814	Concomitant	MS CONTIN	Validated trade name used			
4870392	1006779815	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOU S		
4870392	1006779816	Concomitant	PREDNISONE	Validated trade name used			
4870392	1006779817	Concomitant	METHOTREXATE	Validated trade name used			
4870392	1006779818	Concomitant	ANALGESICS	Verbatim name used			
4870392	1006779819	Concomitant	NSAID'S	Verbatim name used			
4870392	1006779820	Concomitant	LEFLUNOMIDE	Validated trade name used			
4870393	1006779821	Primary Suspect Drug	REMICADE	Validated trade name used	INTRAVENOU S	3 VIALS	

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administration</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4870414	1006779896	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used	ORAL	PHYSICIAN REPORTED DRUG WAS STOPPED IN RESPONSE TO EVENT IN ^?7/04 ^ AND CONTINUED TO RESENT^	
4870414	1006779897	Concomitant	VERELAN	Validated trade name used			
4870414	1006779898	Concomitant	SYNTHROID	Validated trade name used			
4870414	1006779899	Concomitant	VALIUM	Validated trade name used			
4870415	1006779901	Primary Suspect Drug	DESYREL	Validated trade name used	ORAL		
4870415	1006779902	Secondary Suspect Drug	HEPARIN	Validated trade name used	PARENTERAL		
4870415	1006779903	Secondary Suspect Drug	PLAVIX	Validated trade name used	ORAL		
4870415	1006779904	Secondary Suspect Drug	PLAVIX	Validated trade name used	ORAL		
4870415	1006779905	Concomitant	EFFEXOR	Validated trade name used			
4870415	1006779906	Concomitant	ALDACTAZIDE	Validated trade name used			

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
		-	18207	
		-	-	
		-	-	
		-	-	
		-	18207	
		-	-	
		-	-	
		-	-	
		-	-	
		-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administratio n</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4870415	1006779907	Concomitant	VALIUM	Validated trade name used			
4870415	1006779908	Concomitant	PRILOSEC	Validated trade name used			
4870415	1006779909	Concomitant	OXYGEN	Verbatim name used	NASAL		
4870415	1006779910	Concomitant	PHENERGAN	Validated trade name used			
4870416	1006779912	Primary Suspect Drug	DESYREL	Validated trade name used			
4870416	1006779913	Secondary Suspect Drug	DESYREL	Validated trade name used			
4870416	1006779914	Secondary Suspect Drug	TRAZODONE HCL	Validated trade name used			
4870416	1006779915	Secondary Suspect Drug	TRAZODONE HCL	Validated trade name used			
4870417	1006779916	Primary Suspect Drug	DESYREL	Validated trade name used	ORAL		
4870418	1006779917	Primary Suspect Drug	DESYREL	Validated trade name used	ORAL		
4870419	1006779918	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used	ORAL		

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administratio n</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4870419	1006779919	Concomitant	TAMOXIFEN	Verbatim name used			
4870420	1006779920	Primary Suspect Drug	DESYREL	Validated trade name used			
4870420	1006779921	Concomitant	ELAVIL	Validated trade name used	AT BEDTIME		
4870421	1006779923	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used	ORAL	NIGHTLY	
4870421	1006779924	Secondary Suspect Drug	PERCOCET	Validated trade name used			
4870421	1006779925	Concomitant	LAMICTAL	Validated trade name used			
4870421	1006779926	Concomitant	XANAX	Validated trade name used			
4870421	1006779927	Concomitant	OXYCONTIN	Validated trade name used			
4870422	1006779928	Primary Suspect Drug	DESYREL	Validated trade name used	ORAL	DURATION OF THERAPY: ^A WHILE^	
4870422	1006779929	Secondary Suspect Drug	DESYREL	Validated trade name used	ORAL	DURATION OF THERAPY: ^A WHILE^	
4870422	1006779930	Secondary Suspect Drug	LEXAPRO	Validated trade name used			

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
		-	-	
		-	18207	
		-	-	
		-	18207	
		-	-	
		-	-	
		-	-	
		-	-	
		-	18207	
		-	18207	
		-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administratio n</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechallenge code (reaction when drug therapy stopped)</i>
4870422	1006779931	Concomitant	TOPROL-XL	Validated trade name used			
4870422	1006779932	Concomitant	LIPITOR	Validated trade name used			
4870422	1006779933	Concomitant	LOPID	Validated trade name used			
4870422	1006779934	Concomitant	FIORICET	Validated trade name used			
4870422	1006779935	Concomitant	LORTAB	Validated trade name used			
4870423	1006779936	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used		DOSE VALUE: 300 MG AM AND 150 MG PM. DOSE THEN CHANGED TO 150 MG TWICE DAILY IN DEC-2004.	
4870423	1006779937	Concomitant	WELLBUTRIN	Validated trade name used			
4870424	1006779939	Primary Suspect Drug	DESYREL	Validated trade name used			
4870425	1006779940	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used	ORAL	THERAPY DURATION - 1 TO 2 WEEKS TAKEN AT BEDTIME (HS); DISCONTINUED 5 WEEKS AGO	
4870425	1006779941	Secondary Suspect Drug	TRAZODONE HCL	Validated trade name used	ORAL	THERAPY DURATION - 1 TO 2 WEEKS TAKEN AT BEDTIME (HS); DISCONTINUED 5 WEEKS AGO	
4870425	1006779942	Secondary Suspect Drug	TRANQUILIZERS	Verbatim name used			

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Rechallenge code (reaction when drug therapy restarted)</i>	<i>Lot number of drug</i>	<i>Expiration date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
		-	-	
		-	-	
		-	-	
		-	-	
		-	-	
		-	18207	
		-	-	
		-	18207	
		-	18207	
		-	18207	
		-	-	

Report's unique number	Number for identifying drug from Report's unique number	Code for the role drug played in event	Name of drug	Code for source of drug name	Route of drug administratio n	Exact text for dose, frequency and route	Dechalleng e code (reaction when drug therapy stopped)	Rechalleng e code (reaction when drug therapy restarted)	Lot numbe r of drug	Expiratio n date of drug	NDA number	Derived Drug Name
4870425	1006779943	Concomitant	ATIVAN	Validated trade name used	ORAL					-	-	
4870426	1006779944	Primary Suspect Drug	DESYREL	Validated trade name used	ORAL					-	18207	
4870426	1006779945	Concomitant	TOPROL-XL	Validated trade name used						-	-	
4870426	1006779946	Concomitant	ZOLOFT	Validated trade name used						-	-	
4870426	1006779947	Concomitant	TAPAZOLE	Validated trade name used						-	-	
4870427	1006779948	Primary Suspect Drug	DESYREL	Validated trade name used						-	18207	
4870428	1006779949	Primary Suspect Drug	DESYREL	Validated trade name used						-	18207	
4870429	1006779950	Primary Suspect Drug	DESYREL	Validated trade name used						-	18207	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administratio n</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot numbe r of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870430	1006779951	Primary Suspect Drug	DESYREL	Validated trade name used						-	18207	
4870430	1006779952	Secondary Suspect Drug	SERZONE	Validated trade name used						-	20152	
4870430	1006779953	Concomitant	SINEQUAN	Validated trade name used						-	-	
4870431	1006779954	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used	ORAL					-	18207	
4870432	1006779955	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used						-	18207	
4870433	1006779956	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used						-	18207	
4870433	1006779957	Secondary Suspect Drug	PRINIVIL	Validated trade name used	ORAL					-	-	
4870433	1006779958	Secondary Suspect Drug	DIPHENHYDRAMINE HCL	Validated trade name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

Report's unique number	Number for identifying drug from Report's unique number	Code for the role drug played in event	Name of drug	Code for source of drug name	Route of drug administration	Exact text for dose, frequency and route	Dechallenge code (reaction when drug therapy stopped)	Rechallenge code (reaction when drug therapy restarted)	Lot number of drug	Expiration date of drug	NDA number	Derived Drug Name
4870433	1006779959	Secondary Suspect Drug	DILTIAZEM HCL	Validated trade name used						-	-	
4870433	1006779960	Secondary Suspect Drug	GABAPENTIN	Validated trade name used						-	-	
4870433	1006779961	Secondary Suspect Drug	SERTRALINE HCL	Validated trade name used						-	-	
4870433	1006779962	Concomitant	SYNTHROID	Validated trade name used						-	-	
4870433	1006779963	Concomitant	INSULIN ASPART	Validated trade name used						-	-	
4870433	1006779964	Concomitant	OMEPRAZOLE	Validated trade name used						-	-	
4870433	1006779965	Concomitant	SIMVASTATIN	Validated trade name used						-	-	
4870434	1006779966	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used						-	18207	
4870434	1006779967	Concomitant	WELLBUTRIN	Validated trade name used						-	-	
4870435	1006779968	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used						-	18207	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

Report's unique number	Number for identifying drug from Report's unique number	Code for the role drug played in event	Name of drug	Code for source of drug name	Route of drug administratio n	Exact text for dose, frequency and route	Dechalleng e code (reaction when drug therapy stopped)	Rechalleng e code (reaction when drug therapy restarted)	Lot numbe r of drug	Expiratio n date of drug	NDA number	Derived Drug Name
4870436	1006779969	Primary Suspect Drug	DESYREL	Validated trade name used		DURATION OF THERAPY: MANY YEARS			MAA15	-	18207	
4870437	1006779970	Primary Suspect Drug	DESYREL	Validated trade name used						-	18207	
4870438	1006779971	Primary Suspect Drug	DESYREL	Validated trade name used		INTERRUPTED X 1 NIGHT				-	18207	
4870439	1006779972	Primary Suspect Drug	DESYREL	Validated trade name used	ORAL					-	18207	
4870440	1006779973	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used						-	18207	
4870440	1006779974	Concomitant	AMBIEN	Validated trade name used						-	-	
4870441	1006779975	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used	ORAL					-	18207	
4870441	1006779976	Secondary Suspect Drug	TRAZODONE HCL	Validated trade name used	ORAL					-	18207	
4870441	1006779977	Secondary Suspect Drug	TRAZODONE HCL	Validated trade name used	ORAL					-	18207	
4870441	1006779978	Secondary Suspect Drug	TRAZODONE HCL	Validated trade name used	ORAL					-	18207	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

Report's unique number	Number for identifying drug from Report's unique number	Code for the role drug played in event	Name of drug	Code for source of drug name	Route of drug administratio n	Exact text for dose, frequency and route	Dechalleng e code (reaction when drug therapy stopped)	Rechalleng e code (reaction when drug therapy restarted)	Lot numbe r of drug	Expiratio n date of drug	NDA number	Derived Drug Name
4870441	1006779979	Concomitant	ZOLOFT	Validated trade name used						-	-	
4870441	1006779980	Concomitant	PROVIGIL	Validated trade name used						-	-	
4870441	1006779981	Concomitant	PROVENTIL	Validated trade name used						-	-	
4870441	1006779982	Concomitant	ADVAIR DISKUS 250/50	Validated trade name used						-	-	
4870442	1006779983	Primary Suspect Drug	SINEMET	Validated trade name used						-	17555	
4870442	1006779984	Secondary Suspect Drug	TRAZODONE HCL	Validated trade name used						-	18207	
4870442	1006779985	Secondary Suspect Drug	LEVOXYL	Validated trade name used						-	-	
4870443	1006779986	Primary Suspect Drug	DESYREL	Validated trade name used						-	18207	
4870443	1006779987	Concomitant	NOVOCAIN	Validated trade name used						-	-	
4870443	1006779988	Concomitant	NITROUS OXIDE W/ OXYGEN	Validated trade name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administratio n</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot numbe r of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870444	1006779989	Primary Suspect Drug	DESYREL	Validated trade name used							- 18207	
4870445	1006779990	Primary Suspect Drug	DESYREL	Validated trade name used							- 18207	
4870445	1006779991	Secondary Suspect Drug	ALCOHOL	Verbatim name used							- -	
4870446	1006779992	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used							- 18207	
4870447	1006779993	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used							- 18207	
4870447	1006779994	Secondary Suspect Drug	ZOLOFT	Validated trade name used							- -	
4870448	1006779995	Primary Suspect Drug	DESYREL	Validated trade name used	ORAL						- 18207	
4870449	1006779996	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used	ORAL						- 18207	
4870449	1006779997	Concomitant	ZANAFLEX	Validated trade name used							- -	
4870449	1006779998	Concomitant	MOBIC	Validated trade name used							- -	
4870449	1006779999	Concomitant	K-DUR 10	Validated trade name used							- -	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administratio n</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot numbe r of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870449	1006780000	Concomitant	ANTIVERT	Validated trade name used						-	-	
4870449	1006780001	Concomitant	AVANDIA	Validated trade name used						-	-	
4870449	1006780002	Concomitant	SYNTHROID	Validated trade name used						-	-	
4870449	1006780003	Concomitant	NORVASC	Validated trade name used						-	-	
4870449	1006780004	Concomitant	PREVACID	Validated trade name used						-	-	
4870449	1006780005	Concomitant	XANAX	Validated trade name used						-	-	
4870449	1006780006	Concomitant	ZOLOFT	Validated trade name used						-	-	
4870449	1006780007	Concomitant	IMITREX	Validated trade name used						-	-	
4870449	1006780008	Concomitant	SOMA	Validated trade name used						-	-	
4870449	1006780009	Concomitant	TALWIN	Validated trade name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Report's unique number</i>	<i>Number for identifying drug from Report's unique number</i>	<i>Code for the role drug played in event</i>	<i>Name of drug</i>	<i>Code for source of drug name</i>	<i>Route of drug administratio n</i>	<i>Exact text for dose, frequency and route</i>	<i>Dechalleng e code (reaction when drug therapy stopped)</i>	<i>Rechalleng e code (reaction when drug therapy restarted)</i>	<i>Lot numbe r of drug</i>	<i>Expiratio n date of drug</i>	<i>NDA number</i>	<i>Derived Drug Name</i>
4870449	1006780010	Concomitant	REGLAN	Validated trade name used						-	-	
4870449	1006780011	Concomitant	CARAFATE	Validated trade name used						-	-	
4870449	1006780012	Concomitant	COLACE	Verbatim name used						-	-	
4870449	1006780013	Concomitant	PROVIGIL	Validated trade name used						-	-	
4870449	1006780014	Concomitant	LASIX	Validated trade name used						-	-	
4870449	1006780015	Concomitant	BETASERON	Validated trade name used						-	-	
4870449	1006780016	Concomitant	VITAMIN B-12	Validated trade name used						-	-	
4870449	1006780017	Concomitant	ZETIA	Validated trade name used						-	-	
4870449	1006780018	Concomitant	FOLIC ACID	Validated trade name used						-	-	
4870449	1006780019	Concomitant	REGULAR INSULIN	Validated trade name used						-	-	
4870449	1006780020	Concomitant	LANTUS	Validated trade name used						-	-	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

Report's unique number	Number for identifying drug from Report's unique number	Code for the role drug played in event	Name of drug	Code for source of drug name	Route of drug administration	Exact text for dose, frequency and route	Dechallenge code (reaction when drug therapy stopped)	Rechallenge code (reaction when drug therapy restarted)	Lot number of drug	Expiration date of drug	NDA number	Derived Drug Name
4870449	1006780021	Concomitant	MULTIVITAMIN	Validated trade name used						-	-	
4870449	1006780022	Concomitant	ZELNORM	Validated trade name used						-	-	
4870449	1006780023	Concomitant	SUDAL	Verbatim name used						-	-	
4870449	1006780024	Concomitant	SUDAL-DM	Verbatim name used						-	-	
4870450	1006780025	Primary Suspect Drug	TRAZODONE HCL	Validated trade name used	ORAL					-	18207	
4870451	1006780026	Primary Suspect Drug	DESYREL	Validated trade name used	ORAL					-	18207	
4870451	1006780027	Concomitant	ENBREL	Validated trade name used						-	-	
4870451	1006780028	Concomitant	METHOTREXATE	Validated trade name used						-	86358	
4870451	1006780029	Concomitant	PREDNISONE	Validated trade name used						-	-	
4870452	1006780030	Primary Suspect Drug	ABILIFY	Validated trade name used						-	21436	
4870452	1006780031	Secondary Suspect Drug	TRAZODONE HCL	Validated trade name used						-	18207	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4793437	BLOOD GLUCOSE INCREASED
4799889	AGGRESSION
4799889	HALLUCINATION, AUDITORY
4799889	INTENTIONAL SELF-INJURY
4799889	PSYCHOTIC DISORDER
4799889	SUICIDAL IDEATION
4802758	BLOOD UREA INCREASED
4802758	CELLULITIS
4802758	DEEP VEIN THROMBOSIS
4802758	DISEASE PROGRESSION
4802758	HAEMOGLOBIN DECREASED
4802758	WHITE BLOOD CELL COUNT DECREASED
4806822	PHARMACEUTICAL PRODUCT COMPLAINT
4807735	HEPATITIS CHOLESTATIC
4807735	PRURIGO
4807884	LUNG NEOPLASM MALIGNANT
4810789	DRUG INEFFECTIVE
4810789	GLAUCOMA
4810789	URINARY INCONTINENCE
4810789	VISION BLURRED
4811786	HYPERKALAEMIA
4811786	HYPERPHOSPHATAEMIA
4811786	HYPERURICAEMIA
4811786	NAUSEA
4811786	RENAL FAILURE ACUTE
4811786	VOMITING
4813034	CONDITION AGGRAVATED
4813034	CONVULSION

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4815387	INFECTION
4815387	OSTEONECROSIS
4817144	BONE DISORDER
4817145	RENAL FAILURE ACUTE
4817146	ALVEOLOPLASTY
4817146	BONE DISORDER
4817146	TOOTH EXTRACTION
4817148	BLOOD CREATININE INCREASED
4817148	RENAL FAILURE
4817149	BLOOD CREATININE INCREASED
4817149	FEELING ABNORMAL
4817149	RENAL FAILURE ACUTE
4817159	ARTHRALGIA
4817159	BONE PAIN
4817159	MYALGIA
4817167	BLOOD ALBUMIN DECREASED
4817167	BLOOD CALCIUM DECREASED
4819355	BLOOD GLUCOSE INCREASED
4819355	DECREASED APPETITE
4819355	WEIGHT DECREASED
4820164	CHILLS
4820164	FLUSHING
4820164	HEADACHE
4820164	INFUSION RELATED REACTION
4820164	NAUSEA
4820164	PROCEDURAL COMPLICATION
4820164	VOMITING
4821833	ANAL HAEMORRHAGE

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4821833	ARTHRALGIA
4821833	EPISTAXIS
4821833	INSOMNIA
4821833	JOINT SWELLING
4821833	LABORATORY TEST ABNORMAL
4821833	MOBILITY DECREASED
4821833	PAIN
4826267	BLOOD PRESSURE DECREASED
4826267	CHILLS
4826267	INFUSION RELATED REACTION
4826267	PYREXIA
4826267	VOMITING
4826267	WHEEZING
4826274	CHILLS
4826274	INFUSION RELATED REACTION
4826274	MUSCLE TIGHTNESS
4826360	ANOXIC ENCEPHALOPATHY
4826360	CARDIO-RESPIRATORY ARREST
4826360	OVERDOSE
4826360	PAIN
4826360	SYNCOPE
4828303	HEPATIC FUNCTION ABNORMAL
4828303	POST PROCEDURAL COMPLICATION
4832882	NAUSEA
4832882	PAIN
4833762	AMENORRHOEA
4833762	ASTHENIA
4833762	BALANCE DISORDER

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4833762	GAIT DISTURBANCE
4833762	HIP FRACTURE
4833762	JOINT RANGE OF MOTION DECREASED
4833762	LOWER LIMB DEFORMITY
4833762	MOBILITY DECREASED
4833762	OSTEOPENIA
4833762	OSTEOPOROSIS
4833762	POST PROCEDURAL COMPLICATION
4833762	STRESS FRACTURE
4833775	DISEASE PROGRESSION
4833775	DISEASE RECURRENCE
4833775	HAEMORRHAGE
4833775	HEPATIC FUNCTION ABNORMAL
4833775	RESPIRATORY FAILURE
4834797	ANOXIC ENCEPHALOPATHY
4834797	CARDIO-RESPIRATORY ARREST
4834797	NAUSEA
4834797	OVERDOSE
4834797	PAIN
4834797	SYNCOPE
4838069	CHILLS
4838069	INFUSION RELATED REACTION
4838069	NAUSEA
4838069	VOMITING
4840105	DIZZINESS
4840105	OVERDOSE
4840105	RETCHING
4843170	BREAST CANCER

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4846119	HYPOAESTHESIA
4846119	PARAESTHESIA ORAL
4846119	PRURITUS GENERALISED
4846435	BLOOD GLUCOSE DECREASED
4846435	DRUG EXPOSURE DURING PREGNANCY
4846435	UMBILICAL CORD ABNORMALITY
4847003	BENIGN INTRACRANIAL HYPERTENSION
4847053	BRONCHITIS
4847053	HIP ARTHROPLASTY
4847053	TUBERCULOSIS
4847638	CEREBRAL HAEMORRHAGE
4847706	STEVENS-JOHNSON SYNDROME
4847706	VOMITING
4852120	ARTHRITIS
4852120	FUNGAL INFECTION
4852895	COMPLETED SUICIDE
4854233	CULTURE WOUND POSITIVE
4854233	INFECTION
4854233	POST PROCEDURAL COMPLICATION
4865588	ABDOMINAL PAIN
4865588	ACCIDENTAL OVERDOSE
4865588	CONSTIPATION
4865588	DRUG EXPOSURE DURING PREGNANCY
4865588	DRY MOUTH
4865588	DYSPHAGIA
4865588	OFF LABEL USE
4865588	PAIN
4865588	PREGNANCY

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4865588	VISION BLURRED
4867362	DRUG TOXICITY
4867362	PNEUMONIA
4867364	CARDIAC FAILURE CONGESTIVE
4867364	CARDIOMYOPATHY
4867367	GRAFT VERSUS HOST DISEASE
4867367	SEPSIS
4867370	MULTI-ORGAN FAILURE
4867370	PNEUMONIA CYTOMEGALOVIRAL
4867373	HAEMOLYTIC URAEMIC SYNDROME
4867373	SUDDEN CARDIAC DEATH
4867373	THROMBOTIC THROMBOCYTOPENIC PURPURA
4867375	DEMENTIA
4867377	CARDIAC FAILURE CONGESTIVE
4867377	MYOCARDIAL INFARCTION
4867377	SUDDEN CARDIAC DEATH
4867384	COMPLICATIONS OF TRANSPLANT SURGERY
4867384	VENOOCCLUSIVE DISEASE
4867390	CARDIAC ARREST
4867390	COMPLICATIONS OF TRANSPLANT SURGERY
4867392	HAEMOLYTIC URAEMIC SYNDROME
4867392	PNEUMONIA
4867392	THROMBOTIC THROMBOCYTOPENIC PURPURA
4867604	GRAFT VERSUS HOST DISEASE
4867604	PNEUMONIA
4867630	ENCEPHALOPATHY
4867630	MYELITIS
4867630	NEUTROPHIL COUNT ABNORMAL

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4867630	STEM CELL TRANSPLANT
4869006	CEREBRAL INFARCTION
4870242	BRADYCARDIA
4870242	HYPOTENSION
4870242	NERVE BLOCK
4870243	DRUG INEFFECTIVE
4870243	HYPOXIA
4870243	INTERSTITIAL LUNG DISEASE
4870243	PLEURAL EFFUSION
4870244	AGRANULOCYTOSIS
4870244	DRUG SCREEN POSITIVE
4870244	NEUTROPHIL COUNT DECREASED
4870245	ARTHRITIS
4870245	CONNECTIVE TISSUE DISORDER
4870245	DYSPEPSIA
4870245	INSOMNIA
4870245	JOINT SWELLING
4870245	MUSCULOSKELETAL PAIN
4870245	MYALGIA
4870245	OEDEMA PERIPHERAL
4870245	PAIN
4870245	PAIN IN EXTREMITY
4870245	PRURITUS
4870245	RASH
4870245	SHOULDER PAIN
4870246	CYTOMEGALOVIRUS INFECTION
4870246	HYPERCALCAEMIA
4870246	HYPERNATRAEMIA

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870246	HYPERTENSION
4870246	KIDNEY TRANSPLANT REJECTION
4870246	PYREXIA
4870246	RENAL HAEMATOMA
4870246	URINARY TRACT INFECTION
4870246	WOUND
4870247	OEDEMA
4870247	RASH ERYTHEMATOUS
4870247	RASH GENERALISED
4870247	SKIN EXFOLIATION
4870248	MYOCARDIAL INFARCTION
4870248	PNEUMONIA
4870248	RESPIRATORY FAILURE
4870249	CIRCULATORY COLLAPSE
4870249	PROPOFOL INFUSION SYNDROME
4870249	RHABDOMYOLYSIS
4870250	CONVULSION
4870250	DEPRESSED LEVEL OF CONSCIOUSNESS
4870250	DRUG TOXICITY
4870250	DYSPNOEA
4870250	FEELING ABNORMAL
4870250	MUSCULOSKELETAL STIFFNESS
4870250	SOMNOLENCE
4870251	DIZZINESS
4870251	FATIGUE
4870251	MUSCLE SPASMS
4870251	MUSCULOSKELETAL STIFFNESS
4870252	APHONIA

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870252	CONFUSIONAL STATE
4870252	DEEP VEIN THROMBOSIS
4870252	OEDEMA PERIPHERAL
4870252	PNEUMONIA
4870252	RESPIRATORY DISORDER
4870252	STATUS EPILEPTICUS
4870253	CROUP INFECTIOUS
4870254	FALL
4870254	RIB FRACTURE
4870254	UPPER LIMB FRACTURE
4870255	ACUTE RESPIRATORY DISTRESS SYNDROME
4870255	ANAEMIA
4870255	CARDIAC FAILURE
4870255	DEHYDRATION
4870255	DYSPHAGIA
4870255	ENTERITIS
4870255	FEBRILE NEUTROPENIA
4870255	HYPERTHYROIDISM
4870255	HYPOTENSION
4870255	INTESTINAL HAEMORRHAGE
4870255	LEUKOPENIA
4870255	MUCOSAL INFLAMMATION
4870255	MULTI-ORGAN FAILURE
4870255	PERITONITIS
4870255	RESPIRATORY FAILURE
4870255	SEPSIS
4870255	TACHYARRHYTHMIA
4870255	THROMBOCYTOPENIA

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870256	CATARACT OPERATION COMPLICATION
4870256	IRIS DISORDER
4870257	CEREBROVASCULAR ACCIDENT
4870257	SUDDEN DEATH
4870257	SYNCOPE
4870258	ABDOMINAL PAIN UPPER
4870258	COUGH
4870258	DIARRHOEA
4870258	DYSPNOEA
4870272	AMNESIA
4870272	BACK PAIN
4870272	DYSARTHRIA
4870302	APHTHOUS STOMATITIS
4870302	ARTHRALGIA
4870302	ASCITES
4870302	CONVERSION DISORDER
4870302	DEPRESSION
4870302	GENERAL PHYSICAL CONDITION
4870302	PLEURISY
4870302	PSYCHOTIC DISORDER
4870302	RASH
4870302	RAYNAUD'S PHENOMENON
4870302	SYSTEMIC LUPUS ERYTHEMATOSUS
4870302	TACHYCARDIA
4870303	PSORIASIS
4870304	CATARACT
4870304	GLAUCOMA
4870305	DRUG INEFFECTIVE

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870305	PNEUMOCYSTIS JIROVECI PNEUMONIA
4870305	PNEUMONIA
4870313	CONVULSION
4870313	HEAD INJURY
4870319	TUBERCULOSIS
4870320	TUBERCULOSIS
4870321	TUBERCULOSIS
4870322	CROHN'S DISEASE
4870322	CUTANEOUS TUBERCULOSIS
4870322	PANCREATITIS
4870323	HISTIOCYTOSIS HAEMATOPHAGIC
4870323	PANCYTOPENIA
4870323	RESPIRATORY FAILURE
4870323	TUBERCULOSIS
4870324	FIBROCYSTIC BREAST DISEASE
4870325	ANOREXIA
4870325	CHILLS
4870325	DEATH
4870325	DIARRHOEA
4870325	DYSGEUSIA
4870325	GRANULOMA
4870325	HIV INFECTION
4870325	LIVER FUNCTION TEST ABNORMAL
4870325	PYREXIA
4870325	WEIGHT DECREASED
4870326	TUBERCULOSIS
4870327	LEUKAEMIA
4870328	ATRIAL FIBRILLATION

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870328	BLOOD PRESSURE DECREASED
4870328	C-REACTIVE PROTEIN INCREASED
4870328	INFUSION RELATED REACTION
4870328	TACHYCARDIA
4870328	WHITE BLOOD CELL COUNT INCREASED
4870329	CHRONIC OBSTRUCTIVE PULMONARY DISEASE
4870329	PNEUMONIA
4870330	LISTERIOSIS
4870331	GASTRITIS
4870331	GASTROOESOPHAGITIS
4870331	NOCARDIOSIS
4870331	PNEUMONIA
4870332	BASAL CELL CARCINOMA
4870333	INFLUENZA LIKE ILLNESS
4870333	LYMPHOCYTOSIS
4870334	ARTHRALGIA
4870334	BACK PAIN
4870334	JOINT EFFUSION
4870334	JOINT STIFFNESS
4870334	PYREXIA
4870335	BRONCHIOLOALVEOLAR CARCINOMA
4870335	POST PROCEDURAL HAEMATOMA
4870336	DEHYDRATION
4870336	SYSTEMIC LUPUS ERYTHEMATOSUS
4870343	ABDOMINAL PAIN
4870343	UTERINE CANCER
4870344	DIARRHOEA
4870344	DRUG INEFFECTIVE

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870344	PRURITUS
4870344	RASH
4870345	BIPOLAR DISORDER
4870345	OVERDOSE
4870345	TACHYCARDIA
4870346	ERYTHEMA
4870346	GENERALISED OEDEMA
4870346	LIVER DISORDER
4870346	RASH
4870346	RENAL DISORDER
4870346	SWELLING
4870346	URINE OUTPUT DECREASED
4870347	ANAEMIA POSTOPERATIVE
4870347	ATELECTASIS
4870347	CARDIAC FAILURE CONGESTIVE
4870347	HEPATIC MASS
4870347	PYREXIA
4870348	ANAEMIA
4870348	ATRIAL FIBRILLATION
4870348	CELLULITIS
4870348	RENAL FAILURE ACUTE
4870349	ASTHENIA
4870349	DEHYDRATION
4870349	MYALGIA
4870349	PYREXIA
4870349	SUPRAVENTRICULAR TACHYCARDIA
4870349	TACHYCARDIA
4870350	HAEMATOCHESIA

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870350	OEDEMA
4870350	SWELLING
4870350	ULCER HAEMORRHAGE
4870351	CEREBRAL INFARCTION
4870351	CONSTIPATION
4870352	DRUG EXPOSURE DURING PREGNANCY
4870352	VENTRICULAR HYPERTROPHY
4870353	ULCER HAEMORRHAGE
4870354	HYPOGLYCAEMIA
4870355	BLOOD PRESSURE FLUCTUATION
4870355	CHILLS
4870355	CONFUSIONAL STATE
4870355	DIZZINESS
4870355	HYPONATRAEMIA
4870355	MEMORY IMPAIRMENT
4870355	RASH
4870355	VISION BLURRED
4870356	ALANINE AMINOTRANSFERASE INCREASED
4870356	ASPARTATE AMINOTRANSFERASE INCREASED
4870356	CARDIAC MURMUR
4870356	HYPERTENSION
4870357	ACCESSORY AURICLE
4870357	CONGENITAL ANOMALY
4870357	DRUG EXPOSURE DURING PREGNANCY
4870357	PREMATURE BABY
4870358	ANAEMIA
4870358	DRUG EXPOSURE DURING PREGNANCY
4870358	PREMATURE LABOUR

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870359	HEAD INJURY
4870359	ORTHOSTATIC HYPOTENSION
4870359	SKIN LACERATION
4870359	SYNCOPE VASOVAGAL
4870360	ABDOMINAL PAIN
4870360	ANOREXIA
4870360	CHILLS
4870360	COAGULOPATHY
4870360	EOSINOPHILIA
4870360	HEPATIC ENCEPHALOPATHY
4870360	HEPATOTOXICITY
4870360	JAUNDICE
4870360	LEUKOCYTOSIS
4870360	MALAISE
4870360	PANCREATITIS
4870360	PYREXIA
4870360	RASH MACULO-PAPULAR
4870360	STEVENS-JOHNSON SYNDROME
4870360	THROMBOCYTOPENIA
4870362	BIOPSY LUNG
4870363	CHRONIC MYELOID LEUKAEMIA
4870364	ANAPLASTIC LARGE CELL LYMPHOMA T- AND NULL-CELL TYPES
4870365	RENAL ARTERY STENT PLACEMENT
4870366	OESOPHAGEAL CARCINOMA
4870367	HYPOGLYCAEMIA
4870367	HYPOTENSION
4870370	ISCHAEMIC STROKE
4870370	LACUNAR INFARCTION

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870370	TREMOR
4870372	PNEUMOTHORAX
4870372	POST PROCEDURAL COMPLICATION
4870379	BLOOD GLUCOSE INCREASED
4870379	CARDIAC FAILURE ACUTE
4870379	DRUG INEFFECTIVE
4870385	ANGINA PECTORIS
4870385	CORONARY ARTERY DISEASE
4870385	SUPRAVENTRICULAR TACHYCARDIA
4870386	BASAL CELL CARCINOMA
4870387	BASAL CELL CARCINOMA
4870388	SKIN CANCER
4870389	BASAL CELL CARCINOMA
4870390	MALIGNANT MELANOMA
4870391	CHRONIC OBSTRUCTIVE PULMONARY DISEASE
4870391	DEATH
4870391	EMPHYSEMA
4870391	PULMONARY MYCOSIS
4870392	RENAL DISORDER
4870393	DEATH
4870393	INFECTION
4870393	RENAL FAILURE
4870414	NOREPINEPHRINE INCREASED
4870415	ABDOMINAL MASS
4870415	ABDOMINAL PAIN
4870415	CLOSTRIDIAL INFECTION
4870415	CONTUSION
4870416	DRUG INEFFECTIVE

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870417	ALOPECIA
4870418	DYSURIA
4870418	INSOMNIA
4870418	NIGHTMARE
4870419	ALOPECIA
4870419	INSOMNIA
4870420	PRIAPISM
4870421	PREGNANCY
4870422	DIZZINESS
4870423	ARTHRALGIA
4870424	BLOOD TEST ABNORMAL
4870425	CRYING
4870425	DEPRESSION
4870425	DISTURBANCE IN ATTENTION
4870425	MOOD SWINGS
4870426	COUGH
4870427	PREGNANCY
4870428	INSOMNIA
4870429	DRUG SCREEN POSITIVE
4870430	THINKING ABNORMAL
4870431	PHOTOSENSITIVITY REACTION
4870432	DRY SKIN
4870433	DIZZINESS
4870434	ERECTILE DYSFUNCTION
4870435	PSORIASIS
4870436	DRUG ADMINISTRATION ERROR
4870436	IMPAIRED DRIVING ABILITY
4870437	CHEST PAIN

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870437	DRY MOUTH
4870437	HEADACHE
4870438	ARTHRALGIA
4870439	ASTHENIA
4870439	BLOOD PRESSURE DECREASED
4870439	DISORIENTATION
4870440	SUICIDAL IDEATION
4870441	MYALGIA
4870442	AGITATION
4870442	DYSSTASIA
4870442	PARKINSON'S DISEASE
4870442	SOMNOLENCE
4870443	HEADACHE
4870444	ARRHYTHMIA
4870445	SUICIDE ATTEMPT
4870446	NEUTROPENIA
4870447	PRIAPISM
4870448	DEATH
4870449	DYSPEPSIA
4870449	SLEEP DISORDER
4870450	SALIVARY HYPERSECRETION
4870451	DRUG LEVEL INCREASED
4870452	ACCIDENTAL EXPOSURE
4870452	DRUG TOXICITY
4870453	DRUG SCREEN FALSE POSITIVE
4870454	PRIAPISM
4870455	VAGINAL PAIN
4870456	DRUG INEFFECTIVE

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870457	AMNESIA
4870458	COR PULMONALE
4870458	MULTI-ORGAN FAILURE
4870458	PULMONARY EMBOLISM
4870458	SEPSIS
4870458	WHITE BLOOD CELL COUNT DECREASED
4870459	APLASIA PURE RED CELL
4870459	BONE MARROW TRANSPLANT
4870459	STAPHYLOCOCCAL BACTERAEemia
4870460	APLASIA PURE RED CELL
4870460	LUNG DISORDER
4870460	PLEURAL EFFUSION
4870461	DEHYDRATION
4870461	DEMYELINATION
4870461	DEPRESSED LEVEL OF CONSCIOUSNESS
4870461	DIARRHOEA
4870461	KORSAKOFF'S PSYCHOSIS NON-ALCOHOLIC
4870462	OVERDOSE
4870463	BONE MARROW FAILURE
4870463	EYE ALLERGY
4870463	INFECTION
4870463	MOUTH ULCERATION
4870463	THERAPEUTIC RESPONSE DECREASED
4870464	BONE MARROW FAILURE
4870464	FATIGUE
4870464	PNEUMONIA
4870464	THERAPEUTIC RESPONSE DECREASED
4870465	BONE MARROW FAILURE

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870465	TREATMENT NONCOMPLIANCE
4870466	DEATH
4870467	CARDIAC FAILURE
4870468	ASTHENIA
4870468	DEPRESSION
4870468	FATIGUE
4870468	HEPATIC STEATOSIS
4870469	ABDOMINAL PAIN
4870469	COLITIS
4870469	CONSTIPATION
4870469	DIARRHOEA
4870469	ENTERITIS
4870469	WEIGHT DECREASED
4870478	DEATH
4870480	ANAEMIA
4870480	DEHYDRATION
4870480	DIARRHOEA
4870480	HAEMATOMA
4870481	DEATH
4870482	RENAL FAILURE ACUTE
4870482	SEPSIS
4870483	INTERSTITIAL LUNG DISEASE
4870484	LEUKOCYTOCLASTIC VASCULITIS
4870486	PNEUMOCYSTIS JIROVECI INFECTION
4870486	SEPTIC SHOCK
4870512	AGRANULOCYTOSIS
4870512	DRUG ABUSER
4870512	DRUG SCREEN POSITIVE

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870529	BRAIN OEDEMA
4870534	MULTI-ORGAN FAILURE
4870535	PROSTATE CANCER
4870550	GASTROINTESTINAL HAEMORRHAGE
4870550	INTERNATIONAL NORMALISED RATIO INCREASED
4870552	APHTHOUS STOMATITIS
4870552	BODY TEMPERATURE INCREASED
4870552	C-REACTIVE PROTEIN INCREASED
4870552	DERMATITIS BULLOUS
4870552	GENITAL ULCERATION
4870552	PHARYNGITIS
4870552	RASH PAPULAR
4870552	WHITE BLOOD CELL COUNT INCREASED
4870553	ARTERIOSPASM CORONARY
4870553	CHEST DISCOMFORT
4870553	CHEST PAIN
4870553	ELECTROCARDIOGRAM Q WAVE ABNORMAL
4870553	ELECTROCARDIOGRAM ST SEGMENT ELEVATION
4870553	MYOCARDIAL INFARCTION
4870566	ANAEMIA
4870566	PNEUMONIA
4870566	PURPURA
4870566	RENAL IMPAIRMENT
4870567	FOLLICULITIS
4870567	GALLBLADDER POLYP
4870567	INFLUENZA
4870567	POLYPECTOMY
4870567	UPPER RESPIRATORY TRACT INFECTION

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870568	BRADYCARDIA
4870568	DEHYDRATION
4870568	HYPERKALAEMIA
4870568	HYPONATRAEMIA
4870568	RENAL FAILURE
4870569	DEHYDRATION
4870569	ENCEPHALOPATHY
4870569	HYPOKALAEMIA
4870570	CONTUSION
4870570	DIARRHOEA
4870570	EPISTAXIS
4870570	FAECES DISCOLOURED
4870570	HAEMOPTYSIS
4870570	HEADACHE
4870570	IDIOPATHIC THROMBOCYTOPENIC PURPURA
4870570	INJECTION SITE HAEMORRHAGE
4870570	MEGAKARYOCYTES ABNORMAL
4870570	PLATELET COUNT DECREASED
4870570	PYREXIA
4870570	SINUSITIS
4870570	VOMITING
4870571	AMAUROSIS FUGAX
4870572	ALANINE AMINOTRANSFERASE INCREASED
4870572	ASPARTATE AMINOTRANSFERASE INCREASED
4870572	CONDITION AGGRAVATED
4870572	DIABETES MELLITUS
4870572	GAMMA-GLUTAMYLTRANSFERASE INCREASED
4870572	PARAESTHESIA

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870572	RHEUMATOID ARTHRITIS
4870573	DEATH
4870574	ANAEMIA
4870574	ASTHENIA
4870574	CLOSTRIDIAL INFECTION
4870574	DRUG INTERACTION
4870574	INTERNATIONAL NORMALISED RATIO INCREASED
4870574	MELAENA
4870575	ABORTION
4870575	DRUG EXPOSURE DURING PREGNANCY
4870576	DERMATITIS EXFOLIATIVE
4870576	DIZZINESS
4870576	RASH
4870576	URTICARIA
4870577	PRURITUS
4870577	RASH MACULO-PAPULAR
4870577	TOXIC SKIN ERUPTION
4870578	CARDIAC ARREST
4870578	CARDIO-RESPIRATORY ARREST
4870578	PARESIS
4870579	ANAPHYLACTOID REACTION
4870579	ERYTHEMA
4870579	OXYGEN SATURATION DECREASED
4870579	SHOCK
4870580	DEEP VEIN THROMBOSIS
4870580	EROSIVE OESOPHAGITIS
4870580	FEBRILE NEUTROPENIA
4870580	GASTROINTESTINAL HAEMORRHAGE

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870580	LETHARGY
4870580	ORTHOSTATIC HYPOTENSION
4870581	DRUG ERUPTION
4870581	ERYTHEMA MULTIFORME
4870581	FEBRILE NEUTROPENIA
4870582	ASTHENIA
4870582	CARDIAC ARREST
4870582	GASTRITIS
4870582	MALaise
4870582	NEUTROPENIA
4870582	PLATELET COUNT DECREASED
4870582	PYREXIA
4870582	VOMITING
4870583	DIZZINESS
4870583	DYSKINESIA
4870583	HYPOGLYCAEMIA
4870583	NEUROLOGICAL SYMPTOM
4870583	VISUAL DISTURBANCE
4870583	VISUAL FIELD DEFECT
4870584	DIZZINESS
4870584	DYSKINESIA
4870584	HYPOGLYCAEMIA
4870584	NEUROLOGICAL SYMPTOM
4870584	VISUAL FIELD DEFECT
4870585	DIABETES MELLITUS
4870585	DRUG INEFFECTIVE
4870585	TREATMENT NONCOMPLIANCE
4870585	WEIGHT DECREASED

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870586	IMMUNE RECONSTITUTION SYNDROME
4870586	SARCOIDOSIS
4870587	COMPLETED SUICIDE
4870588	CARDIAC FAILURE ACUTE
4870588	MELAENA
4870588	PROTHROMBIN LEVEL DECREASED
4870588	RENAL FAILURE ACUTE
4870589	DEATH
4870591	LEUKAEMIA
4870591	MYELODYSPLASTIC SYNDROME
4870591	REFRACTORY ANAEMIA WITH EXCESS BLASTS IN TRANSFORMATION
4870591	TREATMENT RELATED SECONDARY MALIGNANCY
4870592	DIARRHOEA
4870592	DISSEMINATED INTRAVASCULAR COAGULATION
4870592	LEUKOPENIA
4870592	LIVER DISORDER
4870592	PYREXIA
4870592	RASH
4870592	STOMATITIS
4870592	THROMBOCYTOPENIA
4870593	ACUTE PRERENAL FAILURE
4870593	CARDIAC FAILURE CONGESTIVE
4870593	DIALYSIS
4870593	EJECTION FRACTION DECREASED
4870593	FLUID RETENTION
4870593	OEDEMA
4870593	ORTHOSTATIC HYPOTENSION
4870593	RENAL IMPAIRMENT

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870594	ENCEPHALOPATHY
4870604	BRAIN DEATH
4870604	SHOCK
4870618	PULMONARY FIBROSIS
4870623	COMPLETED SUICIDE
4870623	HEPATIC FAILURE
4870623	INTENTIONAL OVERDOSE
4870623	RENAL FAILURE
4870624	HEPATOTOXICITY
4870651	MEDICATION ERROR
4870659	AMYLOIDOSIS
4870659	CHRONIC OBSTRUCTIVE PULMONARY DISEASE
4870659	CONSTIPATION
4870659	DIZZINESS
4870659	HYPERHIDROSIS
4870659	NAUSEA
4870659	PNEUMONIA
4870659	PYREXIA
4870659	RENAL FAILURE
4870660	URTICARIA
4870661	DRUG INTERACTION
4870661	RESPIRATORY DEPRESSION
4870662	NEUTROPENIA
4870663	DRUG INEFFECTIVE
4870663	INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION
4870663	MYOCARDIAL INFARCTION
4870663	NAUSEA
4870667	FEMORAL NECK FRACTURE

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870668	BRADYCARDIA
4870668	NAUSEA
4870668	OVERDOSE
4870668	SINUS ARRHYTHMIA
4870668	SYNCOPE
4870668	VOMITING
4870669	SHOULDER PAIN
4870670	ROSEOLA
4870670	SWELLING FACE
4870671	CONTUSION
4870671	DRUG INTERACTION
4870671	INTERNATIONAL NORMALISED RATIO INCREASED
4870672	EXTRADURAL HAEMATOMA
4870672	HAEMORRHAGE
4870673	NEPHRITIS INTERSTITIAL
4870674	BRADYCARDIA
4870674	CARDIAC ARREST
4870674	PULMONARY EMBOLISM
4870684	BRONCHITIS
4870685	ALOPECIA
4870685	PNEUMONIA
4870686	ABNORMAL DREAMS
4870686	AMNESIA
4870686	DYSARTHRIA
4870686	FACIAL PALSY
4870686	INSOMNIA
4870687	ANGIONEUROTIC OEDEMA
4870687	BRONCHOSPASM

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870687	INFLAMMATION
4870687	LYMPH NODE PAIN
4870687	OEDEMA
4870687	PAINFUL RESPIRATION
4870687	PYREXIA
4870687	RASH MACULO-PAPULAR
4870688	AORTIC INJURY
4870688	CARDIAC ARREST
4870688	HAEMORRHAGE
4870688	LOSS OF CONSCIOUSNESS
4870688	RIB FRACTURE
4870688	ROAD TRAFFIC ACCIDENT
4870688	SUDDEN ONSET OF SLEEP
4870689	AFFECTIVE DISORDER
4870689	AGITATION
4870689	ANXIETY
4870689	CHEST PAIN
4870689	COMPLETED SUICIDE
4870689	DEPRESSED MOOD
4870689	DRUG WITHDRAWAL SYNDROME
4870689	IRRITABILITY
4870689	MALaise
4870690	ASTHMA
4870690	DYSпноEA
4870690	FATIGUE
4870690	HYPERGLYCAEMIA
4870690	HYPOKALAEMIA
4870690	LACTIC ACIDOSIS

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870690	METABOLIC ACIDOSIS
4870690	RESPIRATORY ACIDOSIS
4870690	RESPIRATORY FAILURE
4870690	RESPIRATORY RATE DECREASED
4870690	SOMNOLENCE
4870690	TACHYPNOEA
4870691	ERYTHEMA MULTIFORME
4870692	ARRHYTHMIA
4870692	ATRIAL FIBRILLATION
4870692	CARDIAC FAILURE CONGESTIVE
4870692	DISSEMINATED INTRAVASCULAR COAGULATION
4870692	HEPATITIS FULMINANT
4870692	HYPOXIA
4870692	INFECTION
4870692	MALaise
4870692	METABOLIC ACIDOSIS
4870692	MULTI-ORGAN FAILURE
4870692	PLEURAL EFFUSION
4870692	PNEUMONIA
4870692	SEPSIS
4870693	DEPRESSED LEVEL OF CONSCIOUSNESS
4870693	DIALYSIS
4870693	DIFFICULTY IN WALKING
4870693	DYSPHORIA
4870693	GAIT DISTURBANCE
4870693	HEADACHE
4870693	ILL-DEFINED DISORDER
4870693	NAUSEA

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870693	NERVOUS SYSTEM DISORDER
4870693	NEUROPATHY
4870693	NUCHAL RIGIDITY
4870694	ACUTE RESPIRATORY DISTRESS SYNDROME
4870694	C-REACTIVE PROTEIN INCREASED
4870694	DIARRHOEA
4870694	HAEMATOCHESIA
4870694	HYPERBILIRUBINAEMIA
4870694	LIVER DISORDER
4870694	PYREXIA
4870694	RASH
4870694	SEPSIS
4870694	THROMBOTIC MICROANGIOPATHY
4870694	VENOOCCLUSIVE LIVER DISEASE
4870695	HEPATIC CIRRHOSIS
4870695	HEPATIC FAILURE
4870696	CHOLESTASIS
4870696	CHROMATURIA
4870696	FAECES DISCOLOURED
4870696	JAUNDICE
4870696	PRURITUS
4870697	HYPERTHYROIDISM
4870698	ALANINE AMINOTRANSFERASE INCREASED
4870698	AMMONIA INCREASED
4870698	ASCITES
4870698	ASPARTATE AMINOTRANSFERASE INCREASED
4870698	BLOOD ALKALINE PHOSPHATASE INCREASED
4870698	BLOOD CREATININE INCREASED

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870698	BLOOD UREA INCREASED
4870698	GAMMA-GLUTAMYLTRANSFERASE INCREASED
4870698	GASTRIC ULCER HAEMORRHAGE
4870698	HAEMATEMESIS
4870698	HAEMATOCRIT DECREASED
4870698	HAEMOGLOBIN DECREASED
4870698	PLATELET COUNT DECREASED
4870698	PYREXIA
4870698	RED BLOOD CELL COUNT DECREASED
4870698	RENAL FAILURE ACUTE
4870698	WHITE BLOOD CELL COUNT INCREASED
4870699	DRUG INTERACTION
4870699	EXTRAPYRAMIDAL DISORDER
4870699	SOMNOLENCE
4870700	BRADYCARDIA
4870700	CARDIAC FAILURE CHRONIC
4870700	CORONARY ARTERY DISEASE
4870700	MITRAL VALVE INCOMPETENCE
4870700	TRICUSPID VALVE INCOMPETENCE
4870700	VENTRICULAR EXTRASYSTOLES
4870701	CSF PRESSURE INCREASED
4870701	GAIT DISTURBANCE
4870702	INTERNATIONAL NORMALISED RATIO INCREASED
4870703	RESPIRATORY DEPRESSION
4870704	DRUG EXPOSURE DURING PREGNANCY
4870704	DRUG EXPOSURE VIA BREAST MILK
4870704	NEUTROPHIL COUNT ABNORMAL
4870705	HEPATITIS

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870706	CARDIAC MURMUR
4870706	FATIGUE
4870706	HYPERHIDROSIS
4870707	EOSINOPHIL COUNT INCREASED
4870707	HEPATIC FUNCTION ABNORMAL
4870708	ACCOMMODATION DISORDER
4870708	DIABETES MELLITUS
4870708	POLYDIPSIA
4870708	POLYURIA
4870708	WEIGHT DECREASED
4870709	ASCITES
4870709	CHOLANGIOLITIS
4870709	CHOLANGITIS
4870709	CHOLESTASIS
4870709	HEPATIC FIBROSIS
4870709	HEPATITIS
4870709	HEPATOCELLULAR DAMAGE
4870709	HEPATOMEGALY
4870709	JAUNDICE
4870709	PORTAL HYPERTENSION
4870709	SPLENOMEGALY
4870710	DEATH
4870711	AGGRESSION
4870711	COMPLETED SUICIDE
4870711	DRUG WITHDRAWAL SYNDROME
4870711	MYALGIA
4870711	NERVOUSNESS
4870711	PARAESTHESIA

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870711	THINKING ABNORMAL
4870712	ASTHENIA
4870712	BLOOD CREATININE INCREASED
4870712	BLOOD THYROID STIMULATING HORMONE DECREASED
4870712	DYSTONIA
4870712	FACIAL PALSY
4870712	MUSCLE SPASMS
4870712	MUSCLE TWITCHING
4870714	CRYPTOCOCCOSIS
4870714	ENCEPHALITIS
4870714	FACIAL PALSY
4870714	FACIAL PARESIS
4870714	HEADACHE
4870714	HERPES SIMPLEX
4870714	IMMUNE RECONSTITUTION SYNDROME
4870714	INTRACRANIAL PRESSURE INCREASED
4870714	NECK PAIN
4870714	RASH VESICULAR
4870714	VISUAL DISTURBANCE
4870714	VOMITING
4870715	ABDOMINAL DISCOMFORT
4870715	DRUG INTERACTION
4870715	FATIGUE
4870715	HEADACHE
4870715	NEPHROPATHY TOXIC
4870716	ACUTE RESPIRATORY FAILURE
4870716	CREPITATIONS
4870716	CYANOSIS

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870716	DYSпноEA
4870716	IMMUNE RECONSTITUTION SYNDROME
4870716	MYCOBACTERIUM KANSASII INFECTION
4870716	PYREXIA
4870716	TACHYPNOEA
4870717	PRURITUS
4870717	RASH MACULAR
4870717	SKIN LESION
4870718	ABORTION SPONTANEOUS
4870718	DRUG EXPOSURE DURING PREGNANCY
4870719	GINGIVITIS
4870719	GINGIVITIS ULCERATIVE
4870719	MUCOSAL INFLAMMATION
4870719	NECROTISING ULCERATIVE GINGIVOSTOMATITIS
4870719	STOMATITIS
4870719	TOOTH LOSS
4870720	RASH
4870721	DRUG EXPOSURE DURING PREGNANCY
4870721	PREMATURE LABOUR
4870722	DRUG EXPOSURE DURING PREGNANCY
4870722	STILLBIRTH
4870722	UMBILICAL CORD AROUND NECK
4870723	ALANINE AMINOTRANSFERASE INCREASED
4870723	DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS
4870723	EOSINOPHILIA
4870723	ERYTHEMA
4870723	HUMAN HERPES VIRUS 6 SEROLOGY POSITIVE
4870723	LYMPHADENOPATHY

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870723	PYREXIA
4870723	RENAL FAILURE ACUTE
4870724	PANCYTOPENIA
4870725	ANOSMIA
4870728	ACCIDENTAL OVERDOSE
4870728	ANAEMIA
4870728	COAGULATION TIME PROLONGED
4870728	HAEMATOMA
4870728	INTERNATIONAL NORMALISED RATIO INCREASED
4870732	ABASIA
4870732	AGITATION
4870732	DYSKINESIA
4870732	DYSPNOEA
4870732	HEART RATE INCREASED
4870732	HYPERTENSION
4870732	MUSCLE CONTRACTIONS INVOLUNTARY
4870732	PYREXIA
4870732	RESPIRATORY ARREST
4870733	AGRANULOCYTOSIS
4870734	ACCOMMODATION DISORDER
4870734	VISUAL FIELD DEFECT
4870735	DIFFICULTY IN WALKING
4870735	DISORIENTATION
4870735	DISSOCIATION
4870735	DYSARTHRIA
4870735	DYSSTASIA
4870735	FATIGUE
4870735	INCOHERENT

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Report's unique number</i>	<i>Preferred term to describe the event</i>
4870736	RHABDOMYOLYSIS
4870737	ACIDOSIS
4870737	SHOCK
4870738	DRUG INTERACTION
4870738	NEUROLEPTIC MALIGNANT SYNDROME
4870739	FALL
4870739	STEVENS-JOHNSON SYNDROME
4870741	FEBRILE NEUTROPENIA
4870741	LEUKOPENIA
4870741	NEUTROPENIA
4870741	SOMNOLENCE
4870741	THROMBOCYTOPENIA
4870741	THROMBOSIS
4870753	PANCREATITIS
4870754	BENIGN INTRACRANIAL HYPERTENSION
4870755	ANASTOMOTIC COMPLICATION
4870755	ANASTOMOTIC STENOSIS
4870755	GASTROENTERITIS VIRAL
4870755	RENAL FAILURE ACUTE
4870755	URINARY TRACT INFECTION

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4799889	Hospitalization - Initial or Prolonged
4802758	Death
4802758	Hospitalization - Initial or Prolonged
4807735	Hospitalization - Initial or Prolonged
4807884	Hospitalization - Initial or Prolonged
4810789	Hospitalization - Initial or Prolonged
4810789	Other
4811786	Hospitalization - Initial or Prolonged
4811786	Required Intervention to Prevent Permanent Impairment/Damage
4813034	Disability
4813034	Other
4815387	Other
4817144	Other
4817145	Other
4817146	Other
4817148	Other
4817149	Hospitalization - Initial or Prolonged
4817159	Disability
4817167	Other
4820164	Required Intervention to Prevent Permanent Impairment/Damage
4821833	Other
4826267	Required Intervention to Prevent Permanent Impairment/Damage
4826274	Required Intervention to Prevent Permanent Impairment/Damage
4826360	Death
4826360	Hospitalization - Initial or Prolonged
4828303	Other
4832882	Hospitalization - Initial or Prolonged
4833762	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4833762	Other
4833775	Death
4834797	Death
4834797	Hospitalization - Initial or Prolonged
4834797	Other
4838069	Required Intervention to Prevent Permanent Impairment/Damage
4840105	Other
4843170	Other
4846119	Hospitalization - Initial or Prolonged
4846119	Other
4846435	Death
4847003	Other
4847053	Hospitalization - Initial or Prolonged
4847638	Hospitalization - Initial or Prolonged
4847706	Hospitalization - Initial or Prolonged
4852895	Death
4854233	Required Intervention to Prevent Permanent Impairment/Damage
4865588	Other
4867362	Death
4867364	Death
4867367	Death
4867370	Death
4867373	Death
4867375	Death
4867377	Death
4867384	Death
4867390	Death
4867392	Death

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4867604	Death
4867630	Death
4869006	Hospitalization - Initial or Prolonged
4870242	Life-Threatening
4870243	Death
4870243	Life-Threatening
4870243	Other
4870245	Other
4870246	Hospitalization - Initial or Prolonged
4870247	Hospitalization - Initial or Prolonged
4870248	Death
4870248	Disability
4870248	Hospitalization - Initial or Prolonged
4870248	Life-Threatening
4870248	Other
4870249	Death
4870250	Other
4870251	Disability
4870252	Life-Threatening
4870253	Hospitalization - Initial or Prolonged
4870254	Other
4870255	Death
4870255	Hospitalization - Initial or Prolonged
4870255	Life-Threatening
4870256	Other
4870257	Death
4870257	Other
4870258	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870272	Hospitalization - Initial or Prolonged
4870302	Hospitalization - Initial or Prolonged
4870303	Other
4870304	Hospitalization - Initial or Prolonged
4870305	Hospitalization - Initial or Prolonged
4870313	Other
4870319	Other
4870320	Other
4870321	Other
4870322	Hospitalization - Initial or Prolonged
4870322	Other
4870323	Death
4870323	Hospitalization - Initial or Prolonged
4870323	Other
4870324	Hospitalization - Initial or Prolonged
4870324	Other
4870325	Death
4870325	Hospitalization - Initial or Prolonged
4870326	Death
4870327	Other
4870328	Hospitalization - Initial or Prolonged
4870329	Hospitalization - Initial or Prolonged
4870330	Hospitalization - Initial or Prolonged
4870331	Hospitalization - Initial or Prolonged
4870332	Other
4870333	Other
4870334	Hospitalization - Initial or Prolonged
4870334	Other

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870335	Hospitalization - Initial or Prolonged
4870336	Other
4870343	Hospitalization - Initial or Prolonged
4870344	Disability
4870345	Hospitalization - Initial or Prolonged
4870346	Hospitalization - Initial or Prolonged
4870347	Hospitalization - Initial or Prolonged
4870348	Hospitalization - Initial or Prolonged
4870349	Hospitalization - Initial or Prolonged
4870350	Hospitalization - Initial or Prolonged
4870351	Disability
4870352	Congenital Anomaly
4870353	Hospitalization - Initial or Prolonged
4870354	Hospitalization - Initial or Prolonged
4870355	Hospitalization - Initial or Prolonged
4870356	Hospitalization - Initial or Prolonged
4870357	Congenital Anomaly
4870358	Hospitalization - Initial or Prolonged
4870359	Hospitalization - Initial or Prolonged
4870360	Hospitalization - Initial or Prolonged
4870362	Hospitalization - Initial or Prolonged
4870363	Other
4870364	Other
4870365	Hospitalization - Initial or Prolonged
4870366	Death
4870367	Hospitalization - Initial or Prolonged
4870370	Hospitalization - Initial or Prolonged
4870372	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870379	Hospitalization - Initial or Prolonged
4870385	Hospitalization - Initial or Prolonged
4870386	Other
4870387	Other
4870388	Other
4870389	Other
4870390	Other
4870391	Death
4870392	Hospitalization - Initial or Prolonged
4870393	Death
4870393	Hospitalization - Initial or Prolonged
4870420	Hospitalization - Initial or Prolonged
4870433	Hospitalization - Initial or Prolonged
4870435	Other
4870445	Other
4870447	Hospitalization - Initial or Prolonged
4870448	Death
4870452	Hospitalization - Initial or Prolonged
4870454	Other
4870458	Death
4870459	Other
4870460	Hospitalization - Initial or Prolonged
4870460	Other
4870461	Hospitalization - Initial or Prolonged
4870461	Life-Threatening
4870463	Hospitalization - Initial or Prolonged
4870463	Other
4870464	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870464	Other
4870465	Other
4870466	Death
4870467	Other
4870468	Hospitalization - Initial or Prolonged
4870469	Hospitalization - Initial or Prolonged
4870478	Death
4870480	Hospitalization - Initial or Prolonged
4870481	Death
4870482	Death
4870483	Death
4870484	Hospitalization - Initial or Prolonged
4870486	Death
4870486	Hospitalization - Initial or Prolonged
4870529	Life-Threatening
4870534	Death
4870535	Hospitalization - Initial or Prolonged
4870550	Life-Threatening
4870552	Hospitalization - Initial or Prolonged
4870553	Hospitalization - Initial or Prolonged
4870553	Life-Threatening
4870566	Other
4870567	Other
4870568	Hospitalization - Initial or Prolonged
4870569	Hospitalization - Initial or Prolonged
4870570	Hospitalization - Initial or Prolonged
4870570	Life-Threatening
4870570	Other

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870571	Hospitalization - Initial or Prolonged
4870572	Hospitalization - Initial or Prolonged
4870572	Other
4870573	Death
4870574	Hospitalization - Initial or Prolonged
4870575	Hospitalization - Initial or Prolonged
4870576	Hospitalization - Initial or Prolonged
4870577	Hospitalization - Initial or Prolonged
4870578	Life-Threatening
4870579	Life-Threatening
4870580	Hospitalization - Initial or Prolonged
4870581	Hospitalization - Initial or Prolonged
4870582	Death
4870582	Other
4870583	Other
4870584	Other
4870585	Hospitalization - Initial or Prolonged
4870586	Hospitalization - Initial or Prolonged
4870587	Death
4870588	Death
4870588	Hospitalization - Initial or Prolonged
4870588	Life-Threatening
4870589	Death
4870591	Other
4870592	Hospitalization - Initial or Prolonged
4870593	Hospitalization - Initial or Prolonged
4870594	Death
4870604	Death

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870618	Hospitalization - Initial or Prolonged
4870623	Death
4870623	Hospitalization - Initial or Prolonged
4870624	Hospitalization - Initial or Prolonged
4870651	Hospitalization - Initial or Prolonged
4870659	Hospitalization - Initial or Prolonged
4870659	Other
4870660	Hospitalization - Initial or Prolonged
4870661	Hospitalization - Initial or Prolonged
4870661	Life-Threatening
4870662	Other
4870663	Hospitalization - Initial or Prolonged
4870663	Other
4870667	Hospitalization - Initial or Prolonged
4870668	Hospitalization - Initial or Prolonged
4870670	Other
4870671	Hospitalization - Initial or Prolonged
4870672	Other
4870673	Other
4870674	Death
4870684	Hospitalization - Initial or Prolonged
4870685	Hospitalization - Initial or Prolonged
4870686	Other
4870687	Hospitalization - Initial or Prolonged
4870688	Death
4870689	Other
4870690	Hospitalization - Initial or Prolonged
4870691	Other

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870692	Death
4870692	Life-Threatening
4870693	Hospitalization - Initial or Prolonged
4870693	Life-Threatening
4870694	Death
4870694	Hospitalization - Initial or Prolonged
4870694	Life-Threatening
4870695	Death
4870696	Hospitalization - Initial or Prolonged
4870697	Other
4870698	Death
4870699	Other
4870700	Hospitalization - Initial or Prolonged
4870701	Hospitalization - Initial or Prolonged
4870702	Hospitalization - Initial or Prolonged
4870703	Life-Threatening
4870704	Other
4870705	Other
4870706	Hospitalization - Initial or Prolonged
4870707	Hospitalization - Initial or Prolonged
4870708	Hospitalization - Initial or Prolonged
4870709	Hospitalization - Initial or Prolonged
4870710	Death
4870711	Other
4870712	Other
4870714	Hospitalization - Initial or Prolonged
4870715	Other
4870716	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870717	Hospitalization - Initial or Prolonged
4870718	Other
4870719	Disability
4870720	Other
4870721	Other
4870722	Death
4870723	Hospitalization - Initial or Prolonged
4870724	Hospitalization - Initial or Prolonged
4870725	Other
4870728	Hospitalization - Initial or Prolonged
4870732	Death
4870733	Hospitalization - Initial or Prolonged
4870734	Other
4870735	Other
4870736	Hospitalization - Initial or Prolonged
4870737	Other
4870738	Disability
4870738	Hospitalization - Initial or Prolonged
4870739	Other
4870741	Hospitalization - Initial or Prolonged
4870753	Hospitalization - Initial or Prolonged
4870754	Other
4870755	Hospitalization - Initial or Prolonged
4870756	Hospitalization - Initial or Prolonged
4870757	Other
4870758	Hospitalization - Initial or Prolonged
4870763	Death
4870763	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870764	Hospitalization - Initial or Prolonged
4870765	Hospitalization - Initial or Prolonged
4870766	Disability
4870766	Hospitalization - Initial or Prolonged
4870767	Hospitalization - Initial or Prolonged
4870768	Hospitalization - Initial or Prolonged
4870769	Hospitalization - Initial or Prolonged
4870769	Other
4870770	Hospitalization - Initial or Prolonged
4870771	Hospitalization - Initial or Prolonged
4870772	Hospitalization - Initial or Prolonged
4870773	Hospitalization - Initial or Prolonged
4870774	Disability
4870774	Hospitalization - Initial or Prolonged
4870775	Hospitalization - Initial or Prolonged
4870775	Other
4870776	Hospitalization - Initial or Prolonged
4870777	Death
4870777	Hospitalization - Initial or Prolonged
4870778	Hospitalization - Initial or Prolonged
4870779	Hospitalization - Initial or Prolonged
4870779	Other
4870780	Death
4870780	Hospitalization - Initial or Prolonged
4870780	Other
4870781	Death
4870781	Hospitalization - Initial or Prolonged
4870782	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870782	Other
4870783	Hospitalization - Initial or Prolonged
4870783	Other
4870784	Hospitalization - Initial or Prolonged
4870785	Death
4870786	Disability
4870786	Hospitalization - Initial or Prolonged
4870787	Disability
4870787	Hospitalization - Initial or Prolonged
4870788	Hospitalization - Initial or Prolonged
4870789	Disability
4870789	Hospitalization - Initial or Prolonged
4870790	Death
4870790	Other
4870791	Death
4870791	Hospitalization - Initial or Prolonged
4870791	Other
4870792	Other
4870793	Death
4870794	Hospitalization - Initial or Prolonged
4870795	Death
4870795	Hospitalization - Initial or Prolonged
4870795	Other
4870796	Hospitalization - Initial or Prolonged
4870796	Other
4870797	Disability
4870797	Other
4870798	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870798	Other
4870799	Hospitalization - Initial or Prolonged
4870800	Hospitalization - Initial or Prolonged
4870801	Disability
4870801	Hospitalization - Initial or Prolonged
4870802	Death
4870802	Hospitalization - Initial or Prolonged
4870803	Hospitalization - Initial or Prolonged
4870804	Other
4870805	Hospitalization - Initial or Prolonged
4870805	Other
4870806	Other
4870807	Death
4870807	Other
4870808	Death
4870809	Congenital Anomaly
4870810	Disability
4870810	Hospitalization - Initial or Prolonged
4870811	Death
4870812	Death
4870813	Disability
4870814	Hospitalization - Initial or Prolonged
4870814	Life-Threatening
4870816	Hospitalization - Initial or Prolonged
4870816	Other
4870817	Death
4870817	Disability
4870817	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870818	Hospitalization - Initial or Prolonged
4870818	Other
4870819	Death
4870819	Hospitalization - Initial or Prolonged
4870821	Other
4870822	Other
4870823	Hospitalization - Initial or Prolonged
4870824	Hospitalization - Initial or Prolonged
4870824	Other
4870825	Death
4870825	Disability
4870826	Other
4870827	Disability
4870828	Death
4870828	Other
4870829	Disability
4870829	Hospitalization - Initial or Prolonged
4870830	Death
4870831	Hospitalization - Initial or Prolonged
4870832	Death
4870832	Hospitalization - Initial or Prolonged
4870833	Other
4870834	Other
4870835	Disability
4870836	Other
4870837	Disability
4870837	Hospitalization - Initial or Prolonged
4870837	Other

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870838	Death
4870839	Death
4870840	Death
4870840	Other
4870841	Hospitalization - Initial or Prolonged
4870842	Death
4870843	Other
4870844	Other
4870845	Other
4870846	Hospitalization - Initial or Prolonged
4870846	Other
4870847	Hospitalization - Initial or Prolonged
4870848	Other
4870849	Hospitalization - Initial or Prolonged
4870849	Other
4870850	Other
4870851	Other
4870852	Other
4870853	Death
4870853	Hospitalization - Initial or Prolonged
4870855	Other
4870856	Other
4870857	Other
4870858	Disability
4870858	Hospitalization - Initial or Prolonged
4870859	Other
4870860	Other
4870861	Other

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870862	Death
4870862	Hospitalization - Initial or Prolonged
4870862	Other
4870863	Other
4870864	Death
4870865	Disability
4870866	Other
4870867	Death
4870867	Hospitalization - Initial or Prolonged
4870868	Hospitalization - Initial or Prolonged
4870869	Hospitalization - Initial or Prolonged
4870869	Other
4870870	Disability
4870870	Hospitalization - Initial or Prolonged
4870871	Other
4870872	Hospitalization - Initial or Prolonged
4870873	Hospitalization - Initial or Prolonged
4870874	Disability
4870874	Hospitalization - Initial or Prolonged
4870875	Disability
4870875	Hospitalization - Initial or Prolonged
4870876	Death
4870876	Other
4870877	Other
4870878	Hospitalization - Initial or Prolonged
4870879	Hospitalization - Initial or Prolonged
4870880	Other
4870886	Death

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4870886	Hospitalization - Initial or Prolonged
4870886	Life-Threatening
4870888	Other
4870890	Other
4870891	Other
4870892	Hospitalization - Initial or Prolonged
4870898	Other
4870900	Hospitalization - Initial or Prolonged
4870901	Disability
4870901	Other
4870902	Hospitalization - Initial or Prolonged
4870903	Hospitalization - Initial or Prolonged
4870903	Life-Threatening
4870904	Other
4870917	Life-Threatening
4870921	Other
4870922	Other
4870923	Other
4870976	Other
4870977	Hospitalization - Initial or Prolonged
4870978	Other
4870979	Death
4870993	Hospitalization - Initial or Prolonged
4870994	Hospitalization - Initial or Prolonged
4871004	Death
4871005	Hospitalization - Initial or Prolonged
4871005	Other
4871006	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871016	Hospitalization - Initial or Prolonged
4871016	Other
4871017	Other
4871018	Death
4871019	Death
4871040	Other
4871057	Hospitalization - Initial or Prolonged
4871073	Death
4871074	Hospitalization - Initial or Prolonged
4871086	Hospitalization - Initial or Prolonged
4871087	Other
4871088	Hospitalization - Initial or Prolonged
4871089	Hospitalization - Initial or Prolonged
4871101	Other
4871102	Hospitalization - Initial or Prolonged
4871103	Hospitalization - Initial or Prolonged
4871105	Hospitalization - Initial or Prolonged
4871106	Other
4871127	Hospitalization - Initial or Prolonged
4871134	Hospitalization - Initial or Prolonged
4871141	Hospitalization - Initial or Prolonged
4871146	Hospitalization - Initial or Prolonged
4871160	Hospitalization - Initial or Prolonged
4871180	Hospitalization - Initial or Prolonged
4871210	Hospitalization - Initial or Prolonged
4871211	Hospitalization - Initial or Prolonged
4871212	Hospitalization - Initial or Prolonged
4871213	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871214	Hospitalization - Initial or Prolonged
4871220	Hospitalization - Initial or Prolonged
4871221	Hospitalization - Initial or Prolonged
4871222	Hospitalization - Initial or Prolonged
4871222	Other
4871223	Hospitalization - Initial or Prolonged
4871224	Other
4871225	Death
4871226	Hospitalization - Initial or Prolonged
4871227	Hospitalization - Initial or Prolonged
4871229	Death
4871229	Hospitalization - Initial or Prolonged
4871229	Other
4871230	Hospitalization - Initial or Prolonged
4871231	Hospitalization - Initial or Prolonged
4871232	Hospitalization - Initial or Prolonged
4871233	Hospitalization - Initial or Prolonged
4871235	Hospitalization - Initial or Prolonged
4871236	Life-Threatening
4871237	Hospitalization - Initial or Prolonged
4871238	Hospitalization - Initial or Prolonged
4871239	Hospitalization - Initial or Prolonged
4871240	Hospitalization - Initial or Prolonged
4871241	Hospitalization - Initial or Prolonged
4871242	Hospitalization - Initial or Prolonged
4871242	Other
4871243	Death
4871244	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871249	Hospitalization - Initial or Prolonged
4871250	Hospitalization - Initial or Prolonged
4871338	Hospitalization - Initial or Prolonged
4871339	Hospitalization - Initial or Prolonged
4871340	Hospitalization - Initial or Prolonged
4871341	Hospitalization - Initial or Prolonged
4871342	Hospitalization - Initial or Prolonged
4871344	Other
4871345	Other
4871346	Death
4871346	Disability
4871346	Hospitalization - Initial or Prolonged
4871353	Other
4871354	Hospitalization - Initial or Prolonged
4871355	Other
4871356	Hospitalization - Initial or Prolonged
4871357	Hospitalization - Initial or Prolonged
4871359	Hospitalization - Initial or Prolonged
4871360	Disability
4871360	Hospitalization - Initial or Prolonged
4871361	Hospitalization - Initial or Prolonged
4871362	Hospitalization - Initial or Prolonged
4871363	Death
4871363	Other
4871364	Hospitalization - Initial or Prolonged
4871365	Disability
4871365	Hospitalization - Initial or Prolonged
4871367	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871368	Disability
4871368	Hospitalization - Initial or Prolonged
4871369	Disability
4871369	Hospitalization - Initial or Prolonged
4871370	Death
4871370	Hospitalization - Initial or Prolonged
4871371	Hospitalization - Initial or Prolonged
4871371	Life-Threatening
4871373	Death
4871373	Other
4871374	Other
4871375	Hospitalization - Initial or Prolonged
4871376	Other
4871377	Hospitalization - Initial or Prolonged
4871377	Life-Threatening
4871378	Hospitalization - Initial or Prolonged
4871379	Disability
4871379	Hospitalization - Initial or Prolonged
4871380	Disability
4871380	Hospitalization - Initial or Prolonged
4871382	Death
4871383	Hospitalization - Initial or Prolonged
4871384	Hospitalization - Initial or Prolonged
4871385	Hospitalization - Initial or Prolonged
4871386	Other
4871387	Hospitalization - Initial or Prolonged
4871405	Other
4871406	Disability

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871406	Hospitalization - Initial or Prolonged
4871407	Hospitalization - Initial or Prolonged
4871408	Disability
4871409	Death
4871411	Disability
4871411	Other
4871412	Disability
4871413	Death
4871413	Hospitalization - Initial or Prolonged
4871415	Disability
4871416	Other
4871417	Hospitalization - Initial or Prolonged
4871419	Disability
4871419	Hospitalization - Initial or Prolonged
4871432	Disability
4871432	Hospitalization - Initial or Prolonged
4871448	Hospitalization - Initial or Prolonged
4871448	Life-Threatening
4871560	Hospitalization - Initial or Prolonged
4871560	Life-Threatening
4871561	Death
4871561	Hospitalization - Initial or Prolonged
4871561	Other
4871562	Death
4871562	Life-Threatening
4871573	Other
4871574	Other
4871582	Death

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871582	Other
4871583	Hospitalization - Initial or Prolonged
4871584	Other
4871585	Hospitalization - Initial or Prolonged
4871587	Other
4871592	Death
4871592	Hospitalization - Initial or Prolonged
4871592	Life-Threatening
4871592	Other
4871598	Hospitalization - Initial or Prolonged
4871599	Hospitalization - Initial or Prolonged
4871600	Hospitalization - Initial or Prolonged
4871600	Life-Threatening
4871601	Hospitalization - Initial or Prolonged
4871602	Hospitalization - Initial or Prolonged
4871614	Hospitalization - Initial or Prolonged
4871615	Hospitalization - Initial or Prolonged
4871616	Other
4871617	Hospitalization - Initial or Prolonged
4871622	Hospitalization - Initial or Prolonged
4871623	Hospitalization - Initial or Prolonged
4871624	Death
4871624	Hospitalization - Initial or Prolonged
4871625	Other
4871626	Hospitalization - Initial or Prolonged
4871627	Other
4871628	Hospitalization - Initial or Prolonged
4871629	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871630	Hospitalization - Initial or Prolonged
4871631	Hospitalization - Initial or Prolonged
4871632	Hospitalization - Initial or Prolonged
4871633	Other
4871634	Other
4871635	Death
4871636	Hospitalization - Initial or Prolonged
4871637	Death
4871638	Life-Threatening
4871639	Other
4871640	Hospitalization - Initial or Prolonged
4871641	Other
4871642	Hospitalization - Initial or Prolonged
4871643	Disability
4871644	Hospitalization - Initial or Prolonged
4871645	Hospitalization - Initial or Prolonged
4871646	Hospitalization - Initial or Prolonged
4871648	Congenital Anomaly
4871649	Death
4871651	Hospitalization - Initial or Prolonged
4871651	Other
4871654	Hospitalization - Initial or Prolonged
4871655	Other
4871656	Other
4871659	Hospitalization - Initial or Prolonged
4871660	Other
4871661	Other
4871662	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871663	Other
4871664	Hospitalization - Initial or Prolonged
4871664	Other
4871665	Other
4871666	Other
4871667	Other
4871668	Other
4871669	Death
4871670	Death
4871670	Hospitalization - Initial or Prolonged
4871670	Other
4871671	Hospitalization - Initial or Prolonged
4871672	Hospitalization - Initial or Prolonged
4871673	Hospitalization - Initial or Prolonged
4871674	Disability
4871675	Death
4871676	Other
4871677	Other
4871678	Death
4871681	Other
4871682	Death
4871682	Hospitalization - Initial or Prolonged
4871682	Life-Threatening
4871682	Other
4871685	Hospitalization - Initial or Prolonged
4871686	Other
4871687	Other
4871689	Death

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871689	Other
4871692	Other
4871693	Other
4871694	Hospitalization - Initial or Prolonged
4871695	Hospitalization - Initial or Prolonged
4871706	Death
4871707	Disability
4871707	Other
4871708	Death
4871708	Hospitalization - Initial or Prolonged
4871709	Hospitalization - Initial or Prolonged
4871709	Life-Threatening
4871712	Hospitalization - Initial or Prolonged
4871713	Hospitalization - Initial or Prolonged
4871714	Hospitalization - Initial or Prolonged
4871726	Hospitalization - Initial or Prolonged
4871740	Hospitalization - Initial or Prolonged
4871742	Other
4871752	Other
4871754	Hospitalization - Initial or Prolonged
4871755	Death
4871759	Hospitalization - Initial or Prolonged
4871761	Other
4871773	Hospitalization - Initial or Prolonged
4871774	Disability
4871775	Hospitalization - Initial or Prolonged
4871776	Hospitalization - Initial or Prolonged
4871776	Other

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871777	Hospitalization - Initial or Prolonged
4871778	Hospitalization - Initial or Prolonged
4871779	Other
4871780	Death
4871781	Other
4871782	Hospitalization - Initial or Prolonged
4871783	Other
4871784	Hospitalization - Initial or Prolonged
4871785	Other
4871786	Hospitalization - Initial or Prolonged
4871787	Disability
4871787	Hospitalization - Initial or Prolonged
4871788	Hospitalization - Initial or Prolonged
4871789	Hospitalization - Initial or Prolonged
4871790	Other
4871791	Death
4871792	Other
4871793	Other
4871794	Death
4871794	Life-Threatening
4871795	Life-Threatening
4871796	Hospitalization - Initial or Prolonged
4871797	Hospitalization - Initial or Prolonged
4871798	Hospitalization - Initial or Prolonged
4871798	Life-Threatening
4871799	Other
4871800	Hospitalization - Initial or Prolonged
4871801	Disability

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871802	Life-Threatening
4871803	Life-Threatening
4871804	Other
4871805	Hospitalization - Initial or Prolonged
4871806	Hospitalization - Initial or Prolonged
4871807	Other
4871808	Hospitalization - Initial or Prolonged
4871809	Other
4871810	Life-Threatening
4871810	Other
4871811	Other
4871812	Hospitalization - Initial or Prolonged
4871813	Disability
4871813	Other
4871814	Hospitalization - Initial or Prolonged
4871815	Other
4871816	Hospitalization - Initial or Prolonged
4871817	Other
4871818	Hospitalization - Initial or Prolonged
4871818	Other
4871819	Hospitalization - Initial or Prolonged
4871820	Death
4871820	Hospitalization - Initial or Prolonged
4871821	Disability
4871821	Hospitalization - Initial or Prolonged
4871822	Hospitalization - Initial or Prolonged
4871822	Other
4871823	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871824	Disability
4871824	Hospitalization - Initial or Prolonged
4871825	Hospitalization - Initial or Prolonged
4871826	Hospitalization - Initial or Prolonged
4871827	Hospitalization - Initial or Prolonged
4871828	Hospitalization - Initial or Prolonged
4871829	Disability
4871829	Hospitalization - Initial or Prolonged
4871830	Hospitalization - Initial or Prolonged
4871830	Other
4871831	Disability
4871831	Hospitalization - Initial or Prolonged
4871833	Death
4871833	Hospitalization - Initial or Prolonged
4871834	Death
4871834	Hospitalization - Initial or Prolonged
4871835	Hospitalization - Initial or Prolonged
4871836	Disability
4871836	Hospitalization - Initial or Prolonged
4871837	Disability
4871837	Hospitalization - Initial or Prolonged
4871838	Disability
4871838	Hospitalization - Initial or Prolonged
4871839	Other
4871840	Other
4871841	Disability
4871841	Hospitalization - Initial or Prolonged
4871842	Death

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871843	Hospitalization - Initial or Prolonged
4871844	Death
4871844	Hospitalization - Initial or Prolonged
4871845	Hospitalization - Initial or Prolonged
4871846	Disability
4871846	Hospitalization - Initial or Prolonged
4871847	Disability
4871847	Hospitalization - Initial or Prolonged
4871848	Hospitalization - Initial or Prolonged
4871849	Disability
4871849	Hospitalization - Initial or Prolonged
4871850	Hospitalization - Initial or Prolonged
4871851	Disability
4871851	Hospitalization - Initial or Prolonged
4871852	Disability
4871852	Hospitalization - Initial or Prolonged
4871853	Death
4871853	Hospitalization - Initial or Prolonged
4871854	Hospitalization - Initial or Prolonged
4871854	Other
4871856	Hospitalization - Initial or Prolonged
4871857	Hospitalization - Initial or Prolonged
4871858	Hospitalization - Initial or Prolonged
4871859	Disability
4871859	Hospitalization - Initial or Prolonged
4871860	Disability
4871860	Hospitalization - Initial or Prolonged
4871860	Other

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871861	Other
4871862	Hospitalization - Initial or Prolonged
4871863	Other
4871864	Other
4871865	Disability
4871865	Hospitalization - Initial or Prolonged
4871866	Hospitalization - Initial or Prolonged
4871867	Disability
4871867	Hospitalization - Initial or Prolonged
4871870	Hospitalization - Initial or Prolonged
4871870	Other
4871871	Hospitalization - Initial or Prolonged
4871871	Other
4871873	Death
4871873	Other
4871874	Hospitalization - Initial or Prolonged
4871875	Disability
4871875	Other
4871876	Death
4871876	Hospitalization - Initial or Prolonged
4871877	Hospitalization - Initial or Prolonged
4871877	Other
4871878	Hospitalization - Initial or Prolonged
4871878	Other
4871879	Hospitalization - Initial or Prolonged
4871880	Other
4871881	Disability
4871881	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871882	Hospitalization - Initial or Prolonged
4871882	Other
4871883	Other
4871884	Disability
4871884	Hospitalization - Initial or Prolonged
4871884	Other
4871885	Disability
4871885	Hospitalization - Initial or Prolonged
4871885	Other
4871886	Death
4871886	Other
4871887	Death
4871887	Hospitalization - Initial or Prolonged
4871887	Other
4871888	Other
4871889	Hospitalization - Initial or Prolonged
4871890	Hospitalization - Initial or Prolonged
4871891	Hospitalization - Initial or Prolonged
4871892	Death
4871892	Hospitalization - Initial or Prolonged
4871892	Other
4871893	Disability
4871893	Hospitalization - Initial or Prolonged
4871893	Other
4871894	Other
4871895	Death
4871895	Hospitalization - Initial or Prolonged
4871897	Life-Threatening

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871897	Other
4871899	Hospitalization - Initial or Prolonged
4871900	Hospitalization - Initial or Prolonged
4871901	Disability
4871901	Hospitalization - Initial or Prolonged
4871901	Life-Threatening
4871901	Other
4871902	Other
4871903	Hospitalization - Initial or Prolonged
4871904	Hospitalization - Initial or Prolonged
4871905	Hospitalization - Initial or Prolonged
4871906	Hospitalization - Initial or Prolonged
4871907	Disability
4871907	Hospitalization - Initial or Prolonged
4871908	Other
4871909	Hospitalization - Initial or Prolonged
4871912	Other
4871917	Death
4871918	Other
4871919	Other
4871920	Hospitalization - Initial or Prolonged
4871920	Life-Threatening
4871921	Other
4871922	Death
4871923	Other
4871924	Hospitalization - Initial or Prolonged
4871927	Hospitalization - Initial or Prolonged
4871927	Other

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871927	Required Intervention to Prevent Permanent Impairment/Damage
4871928	Hospitalization - Initial or Prolonged
4871929	Other
4871930	Other
4871934	Disability
4871934	Hospitalization - Initial or Prolonged
4871935	Disability
4871935	Hospitalization - Initial or Prolonged
4871937	Death
4871937	Hospitalization - Initial or Prolonged
4871938	Disability
4871938	Hospitalization - Initial or Prolonged
4871939	Hospitalization - Initial or Prolonged
4871940	Disability
4871940	Hospitalization - Initial or Prolonged
4871941	Disability
4871941	Hospitalization - Initial or Prolonged
4871942	Hospitalization - Initial or Prolonged
4871943	Other
4871949	Disability
4871949	Hospitalization - Initial or Prolonged
4871950	Hospitalization - Initial or Prolonged
4871957	Hospitalization - Initial or Prolonged
4871957	Other
4871969	Disability
4871971	Hospitalization - Initial or Prolonged
4871972	Other
4871973	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4871974	Hospitalization - Initial or Prolonged
4871976	Death
4871977	Other
4871978	Other
4871979	Hospitalization - Initial or Prolonged
4871980	Hospitalization - Initial or Prolonged
4871988	Death
4871988	Hospitalization - Initial or Prolonged
4872010	Required Intervention to Prevent Permanent Impairment/Damage
4872016	Hospitalization - Initial or Prolonged
4872016	Other
4872017	Death
4872018	Hospitalization - Initial or Prolonged
4872021	Other
4872030	Death
4872030	Hospitalization - Initial or Prolonged
4872033	Hospitalization - Initial or Prolonged
4872033	Other
4872034	Death
4872034	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4799889	Foreign
4799889	Health Professional
4799889	Other
4802758	Study
4807735	Foreign
4807735	Health Professional
4807735	Other
4807884	Health Professional
4807884	Study
4810789	Consumer
4813034	Foreign
4813034	Health Professional
4813034	Other
4815387	Health Professional
4815387	Literature
4817144	Company Representative
4817144	Health Professional
4817145	Health Professional
4817146	Company Representative
4817146	Health Professional
4817148	Health Professional
4817149	Health Professional
4817159	Health Professional
4817167	Company Representative
4817167	Health Professional
4819355	Consumer
4826360	Health Professional
4826360	Study

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4834797	Health Professional
4838069	Health Professional
4840105	Consumer
4843170	Consumer
4846119	Health Professional
4846435	Consumer
4847003	Literature
4847003	Study
4847638	Foreign
4847638	Health Professional
4847706	Foreign
4847706	Health Professional
4847706	Other
4852120	Health Professional
4852895	Health Professional
4852895	Literature
4854233	Health Professional
4865588	Company Representative
4865588	Consumer
4867362	Health Professional
4867362	Literature
4867362	Study
4867364	Health Professional
4867364	Literature
4867364	Study
4867367	Health Professional
4867367	Literature
4867367	Study

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4867370	Health Professional
4867370	Literature
4867370	Study
4867373	Health Professional
4867373	Literature
4867373	Study
4867375	Health Professional
4867375	Literature
4867375	Study
4867377	Health Professional
4867377	Literature
4867377	Study
4867384	Health Professional
4867384	Literature
4867384	Study
4867390	Health Professional
4867390	Literature
4867390	Study
4867392	Health Professional
4867392	Literature
4867392	Study
4867604	Health Professional
4867604	Literature
4867604	Study
4867630	Health Professional
4867630	Literature
4867630	Study
4869006	Foreign

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4869006	Health Professional
4869006	Other
4869006	Study
4870313	Foreign
4870313	Health Professional
4870313	Other
4871927	Foreign
4871927	Health Professional
4871927	Study
4872010	Health Professional
4872010	Other
4872153	Health Professional
4872155	Consumer
4872157	Consumer
4872159	Consumer
4872161	Consumer
4872165	Consumer
4872166	Health Professional
4872166	Literature
4872170	Foreign
4872170	Health Professional
4872170	Other
4872171	Foreign
4872171	Health Professional
4872171	Other
4872172	Foreign
4872172	Health Professional
4872172	Other

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4872173	Foreign
4872173	Health Professional
4872173	Other
4872174	Foreign
4872174	Health Professional
4872174	Other
4872175	Consumer
4872175	Foreign
4872176	Consumer
4872176	Foreign
4872176	Other
4872178	Health Professional
4872179	Foreign
4872179	Health Professional
4872179	Study
4872180	Foreign
4872180	Health Professional
4872180	Study
4872183	Foreign
4872183	Health Professional
4872184	Foreign
4872184	Other
4872186	Foreign
4872186	Health Professional
4872186	Literature
4872186	Other
4872187	Foreign
4872187	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4872187	Literature
4872187	Other
4872188	Foreign
4872188	Health Professional
4872188	Literature
4872188	Other
4872190	Foreign
4872190	Health Professional
4872190	Other
4872191	Foreign
4872191	Health Professional
4872191	Other
4872191	Study
4872193	Foreign
4872193	Health Professional
4872193	Other
4872193	Study
4872535	Consumer
4872535	Foreign
4872535	Other
4872536	Consumer
4872536	Foreign
4872536	Other
4872537	Foreign
4872537	Health Professional
4872537	Other
4872538	Foreign
4872538	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4872538	Other
4872539	Foreign
4872539	Health Professional
4872539	Other
4872540	Foreign
4872540	Health Professional
4872540	Other
4872548	Foreign
4872548	Health Professional
4872548	Other
4872549	Foreign
4872549	Health Professional
4872549	Other
4872571	Foreign
4872571	Health Professional
4872571	Other
4872572	Foreign
4872572	Health Professional
4872572	Other
4872573	Foreign
4872573	Health Professional
4872573	Other
4872574	Foreign
4872574	Health Professional
4872574	Other
4872575	Foreign
4872575	Health Professional
4872575	Other

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4872576	Foreign
4872576	Health Professional
4872576	Other
4872577	Foreign
4872577	Health Professional
4872577	Other
4872578	Consumer
4872578	Foreign
4872578	Other
4872579	Foreign
4872579	Health Professional
4872579	Other
4872586	Consumer
4872586	Foreign
4872586	Other
4872592	Foreign
4872592	Health Professional
4872592	Other
4872593	Foreign
4872593	Health Professional
4872593	Literature
4872593	Other
4872619	Foreign
4872619	Health Professional
4872619	Other
4872641	Foreign
4872641	Health Professional
4872641	Other

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4872652	Foreign
4872652	Health Professional
4872652	Other
4872653	Foreign
4872653	Health Professional
4872653	Other
4872654	Foreign
4872654	Health Professional
4872654	Literature
4872654	Other
4872655	Foreign
4872655	Health Professional
4872655	Other
4872657	Foreign
4872657	Health Professional
4872657	Literature
4872657	Other
4872659	Foreign
4872659	Health Professional
4872659	Other
4872660	Foreign
4872660	Health Professional
4872661	Consumer
4872661	Foreign
4872661	Other
4872663	Foreign
4872663	Health Professional
4872663	Literature

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4872663	Other
4872664	Foreign
4872664	Other
4872665	Foreign
4872665	Other
4872666	Foreign
4872666	Health Professional
4872666	Other
4872676	Consumer
4872677	Health Professional
4872678	Health Professional
4872679	Foreign
4872679	Health Professional
4872679	Other
4872679	Study
4872680	Foreign
4872680	Health Professional
4872680	Other
4872681	Foreign
4872681	Health Professional
4872681	Other
4872682	Health Professional
4872683	Literature
4872684	Foreign
4872684	Health Professional
4872684	Other
4872685	Consumer
4872685	Foreign

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4872685	Other
4872686	Company Representative
4872686	Health Professional
4872688	Foreign
4872688	Health Professional
4872688	Other
4872690	Consumer
4872693	Company Representative
4872693	Health Professional
4872696	Consumer
4872698	Health Professional
4872698	Other
4872698	Study
4872700	Consumer
4872701	Health Professional
4872702	Consumer
4872704	Consumer
4872705	Consumer
4872707	Consumer
4872711	Consumer
4872712	Consumer
4872713	Consumer
4872714	Consumer
4872715	Consumer
4872716	Health Professional
4872717	Consumer
4872721	Consumer
4872722	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4872723	Company Representative
4872724	Health Professional
4872725	Health Professional
4872726	Consumer
4872727	Consumer
4872730	Consumer
4872732	Health Professional
4872733	Foreign
4872733	Health Professional
4872733	Other
4872734	Health Professional
4872735	Consumer
4872736	Health Professional
4872737	Foreign
4872737	Health Professional
4872737	Other
4872738	Health Professional
4872739	Health Professional
4872740	Consumer
4872742	Foreign
4872742	Health Professional
4872742	Other
4872743	Health Professional
4872744	Health Professional
4872745	Consumer
4872746	Foreign
4872746	Health Professional
4872746	Other

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4872747	Foreign
4872747	Health Professional
4872747	Other
4872748	Foreign
4872748	Health Professional
4872748	Other
4872749	Consumer
4872750	Foreign
4872750	Health Professional
4872750	Other
4872751	Consumer
4872753	Consumer
4872755	Company Representative
4872758	Consumer
4872759	Consumer
4872759	Foreign
4872759	Other
4872760	Health Professional
4872761	Consumer
4872763	Foreign
4872763	Health Professional
4872763	Other
4872764	Consumer
4872766	Foreign
4872766	Health Professional
4872766	Other
4872767	Foreign
4872767	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4872767	Other
4872778	Consumer
4872778	Health Professional
4872778	Other
4872779	Consumer
4872779	Health Professional
4872779	Other
4872780	Consumer
4872780	Health Professional
4872780	Other
4872781	Consumer
4872782	Consumer
4872783	Foreign
4872783	Health Professional
4872783	Literature
4872783	Other
4872785	Health Professional
4872787	Consumer
4872788	Consumer
4872789	Foreign
4872789	Health Professional
4872789	Other
4872790	Foreign
4872790	Health Professional
4872790	Literature
4872790	Other
4872794	Foreign
4872794	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4872794	Other
4872795	Foreign
4872795	Health Professional
4872795	Other
4873279	Consumer
4873280	Consumer
4873281	Health Professional
4873282	Consumer
4873328	Foreign
4873328	Health Professional
4873328	Other
4873329	Consumer
4873329	Foreign
4873329	Health Professional
4873329	Other
4873330	Foreign
4873330	Health Professional
4873330	Other
4873330	Study
4873331	Foreign
4873331	Health Professional
4873331	Other
4873332	Foreign
4873332	Health Professional
4873332	Other
4873333	Foreign
4873333	Health Professional
4873333	Other

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4873334	Foreign
4873334	Health Professional
4873334	Other
4873334	Study
4873335	Foreign
4873335	Health Professional
4873335	Other
4873342	Foreign
4873342	Health Professional
4873342	Other
4873343	Foreign
4873343	Health Professional
4873343	Study
4873345	Foreign
4873345	Health Professional
4873345	Study
4873354	Foreign
4873354	Health Professional
4873366	Foreign
4873366	Health Professional
4873366	Study
4873367	Foreign
4873367	Health Professional
4873367	Study
4873368	Foreign
4873368	Health Professional
4873368	Study
4873369	Foreign

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4873369	Health Professional
4873737	Consumer
4873737	Health Professional
4873738	Consumer
4873738	Health Professional
4873738	Study
4873743	Consumer
4873743	Health Professional
4873744	Consumer
4873744	Health Professional
4873745	Consumer
4873745	Study
4873746	Consumer
4873746	Health Professional
4873746	Study
4873747	Consumer
4873748	Consumer
4873748	Health Professional
4873749	Consumer
4873749	Health Professional
4873749	Study
4873750	Consumer
4873750	Study
4873751	Consumer
4873751	Study
4873752	Consumer
4873753	Consumer
4873753	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4873753	Study
4873754	Consumer
4873755	Consumer
4873755	Health Professional
4873757	Company Representative
4873757	Health Professional
4873760	Health Professional
4873769	Company Representative
4873769	Health Professional
4873771	Health Professional
4873776	Health Professional
4873776	Study
4873781	Consumer
4873781	Study
4873782	Consumer
4873782	Study
4873783	Consumer
4873784	Health Professional
4873784	Study
4873785	Consumer
4873786	Company Representative
4873786	Health Professional
4873787	Health Professional
4873787	Study
4873788	Consumer
4873789	Consumer
4873790	Company Representative
4873790	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4873791	Consumer
4873791	Health Professional
4873797	Consumer
4873799	Consumer
4873800	Consumer
4873800	Health Professional
4873801	Consumer
4873801	Health Professional
4873804	Health Professional
4873804	Other
4873804	Study
4873808	Consumer
4873808	Study
4873809	Consumer
4873809	Study
4873810	Health Professional
4873811	Health Professional
4873811	Study
4873812	Consumer
4873812	Study
4873813	Health Professional
4873813	Other
4873813	Study
4873814	Consumer
4873814	Study
4873818	Consumer
4873819	Consumer
4873819	Study

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4873820	Health Professional
4873821	Consumer
4873821	Health Professional
4873822	Health Professional
4873822	Other
4873822	Study
4873824	Health Professional
4873825	Health Professional
4873827	Consumer
4873829	Consumer
4873831	Health Professional
4873832	Other
4873833	Other
4873835	Other
4873839	Other
4873843	Health Professional
4873846	Literature
4873850	Consumer
4873853	Health Professional
4873853	Other
4873853	Study
4873855	Consumer
4873857	Health Professional
4873857	Study
4873858	Health Professional
4873859	Health Professional
4873860	Consumer
4873862	Other

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4873864	Other
4873865	Health Professional
4873867	Consumer
4873868	Other
4873870	Health Professional
4873871	Consumer
4873871	Health Professional
4873874	Consumer
4873875	Health Professional
4873878	Health Professional
4873878	Study
4873879	Consumer
4873881	Consumer
4873881	Health Professional
4873882	Consumer
4873883	Consumer
4873884	Consumer
4873885	Consumer
4873886	Consumer
4873886	Health Professional
4873886	Study
4873888	Consumer
4873889	Consumer
4873891	Consumer
4873899	Consumer
4873901	Consumer
4873904	Consumer
4873906	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4873907	Consumer
4873911	Consumer
4873912	Consumer
4873912	Health Professional
4873913	Consumer
4873913	Health Professional
4873915	Consumer
4873915	Health Professional
4873919	Consumer
4873921	Consumer
4873923	Consumer
4873924	Consumer
4873927	Consumer
4873932	Consumer
4873932	Health Professional
4873941	Health Professional
4873944	Consumer
4873944	Health Professional
4873945	Consumer
4873947	Consumer
4873948	Consumer
4873950	Consumer
4873952	Consumer
4873954	Consumer
4873957	Consumer
4873959	Consumer
4873960	Consumer
4873961	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4873966	Consumer
4873966	Study
4873967	Consumer
4873968	Consumer
4873968	Health Professional
4873969	Consumer
4873970	Consumer
4873970	Health Professional
4873970	Study
4873971	Consumer
4873972	Consumer
4873972	Health Professional
4873973	Consumer
4873973	Health Professional
4873973	Study
4873974	Consumer
4873975	Consumer
4873976	Consumer
4873977	Consumer
4873977	Health Professional
4873977	Study
4873978	Consumer
4873979	Health Professional
4873979	Other
4873979	Study
4873980	Consumer
4873980	Health Professional
4873980	Study

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4873981	Health Professional
4873981	Other
4873981	Study
4873982	Consumer
4873983	Consumer
4873984	Consumer
4873984	Study
4873985	Consumer
4873985	Health Professional
4873986	Consumer
4873986	Study
4873987	Consumer
4873987	Study
4873988	Consumer
4873988	Study
4873989	Consumer
4873989	Study
4873994	Consumer
4873994	Study
4873995	Health Professional
4873996	Consumer
4873997	Health Professional
4873997	Literature
4873998	Consumer
4873998	Study
4873999	Consumer
4873999	Study
4874000	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4874000	Study
4874001	Consumer
4874001	Study
4874002	Consumer
4874002	Study
4874003	Consumer
4874003	Study
4874004	Consumer
4874004	Study
4874009	Consumer
4874009	Study
4874011	Consumer
4874011	Health Professional
4874012	Consumer
4874012	Study
4874013	Consumer
4874013	Health Professional
4874020	Consumer
4874020	Study
4874021	Consumer
4874021	Study
4874022	Consumer
4874022	Study
4874023	Consumer
4874023	Study
4874024	Consumer
4874024	Study
4874025	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4874025	Study
4874026	Consumer
4874026	Study
4874031	Consumer
4874032	Consumer
4874033	Company Representative
4874033	Health Professional
4874034	Consumer
4874040	Consumer
4874041	Health Professional
4874043	Consumer
4874044	Consumer
4874045	Consumer
4874049	Health Professional
4874050	Health Professional
4874051	Health Professional
4874052	Consumer
4874054	Health Professional
4874056	Health Professional
4874057	Company Representative
4874057	Health Professional
4874059	Consumer
4874062	Consumer
4874064	Consumer
4874066	Consumer
4874069	Consumer
4874072	Consumer
4874074	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4874076	Consumer
4874077	Health Professional
4874077	Other
4874077	Study
4874079	Consumer
4874080	Health Professional
4874080	Other
4874080	Study
4874081	Consumer
4874082	Consumer
4874083	Consumer
4874084	Consumer
4874086	Consumer
4874088	Consumer
4874089	Consumer
4874091	Consumer
4874092	Consumer
4874093	Health Professional
4874093	Study
4874094	Consumer
4874096	Company Representative
4874096	Foreign
4874096	Health Professional
4874096	Other
4874097	Consumer
4874100	Consumer
4874102	Consumer
4874103	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4874105	Consumer
4874110	Consumer
4874111	Consumer
4874113	Consumer
4874114	Consumer
4874115	Consumer
4874116	Consumer
4874119	Consumer
4874120	Consumer
4874122	Company Representative
4874122	Health Professional
4874123	Health Professional
4874125	Consumer
4874149	Consumer
4874174	Consumer
4874175	Consumer
4874177	Consumer
4874184	Consumer
4874192	Consumer
4874193	Consumer
4874194	Consumer
4874198	Consumer
4874324	Health Professional
4874330	Consumer
4874332	Company Representative
4874332	Health Professional
4874333	Consumer
4874335	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4874338	Consumer
4874341	Consumer
4874343	Consumer
4874344	Consumer
4874345	Consumer
4874351	Consumer
4874352	Consumer
4874354	Consumer
4874356	Consumer
4874356	Health Professional
4874357	Consumer
4874363	Consumer
4874369	Consumer
4874370	Consumer
4874371	Consumer
4874373	Consumer
4874375	Consumer
4874378	Consumer
4874380	Health Professional
4874381	Consumer
4874382	Consumer
4874384	Consumer
4874389	Consumer
4874392	Health Professional
4874395	Consumer
4874395	Health Professional
4874402	Health Professional
4874406	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4874406	Health Professional
4874418	Consumer
4874418	Health Professional
4874419	Consumer
4874421	Company Representative
4874421	Health Professional
4874425	Health Professional
4874427	Consumer
4874427	Health Professional
4874442	Distributor
4874445	Distributor
4874447	Health Professional
4874447	Other
4874455	Health Professional
4874455	Other
4874759	Consumer
4874759	Foreign
4874761	Consumer
4874761	Foreign
4874763	Consumer
4874763	Foreign
4874765	Foreign
4874765	Health Professional
4874766	Foreign
4874766	Health Professional
4874766	Study
4874770	Foreign
4874770	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4874775	Foreign
4874775	Health Professional
4874776	Foreign
4874776	Health Professional
4874785	Foreign
4874785	Health Professional
4874787	Company Representative
4874787	Foreign
4874787	Health Professional
4874790	Foreign
4874790	Health Professional
4874793	Consumer
4874793	Foreign
4874795	Company Representative
4874795	Foreign
4874795	Health Professional
4874797	Company Representative
4874797	Foreign
4874797	Health Professional
4874798	Company Representative
4874798	Foreign
4874798	Health Professional
4874799	Company Representative
4874799	Foreign
4874799	Health Professional
4874800	Foreign
4874800	Health Professional
4874800	Literature

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4874800	Other
4874804	Foreign
4874804	Health Professional
4874804	Other
4874805	Foreign
4874805	Health Professional
4874805	Literature
4874805	Other
4874807	Foreign
4874807	Health Professional
4874811	Company Representative
4874811	Foreign
4874811	Health Professional
4874813	Company Representative
4874813	Foreign
4874813	Health Professional
4874815	Consumer
4874815	Foreign
4874819	Consumer
4874819	Foreign
4874820	Foreign
4874820	Health Professional
4874822	Company Representative
4874822	Foreign
4874822	Health Professional
4874829	Company Representative
4874829	Foreign
4874829	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4874830	Company Representative
4874830	Foreign
4874830	Health Professional
4874831	Foreign
4874831	Health Professional
4874831	Study
4874832	Foreign
4874832	Health Professional
4874832	Study
4874833	Foreign
4874833	Health Professional
4874834	Company Representative
4874834	Foreign
4874834	Health Professional
4874835	Company Representative
4874835	Foreign
4874835	Health Professional
4874836	Company Representative
4874836	Consumer
4874836	Foreign
4874837	Foreign
4874837	Health Professional
4874837	Literature
4874838	Foreign
4874838	Health Professional
4874839	Foreign
4874839	Health Professional
4874840	Foreign

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4874840	Health Professional
4874841	Company Representative
4874841	Foreign
4874841	Health Professional
4874842	Foreign
4874842	Health Professional
4874843	Company Representative
4874843	Foreign
4874843	Health Professional
4874844	Company Representative
4874844	Foreign
4874844	Health Professional
4874846	Foreign
4874846	Health Professional
4874847	Literature
4874848	Consumer
4874848	Foreign
4874849	Health Professional
4874850	Consumer
4874850	Foreign
4874851	Health Professional
4874852	Foreign
4874852	Health Professional
4874853	Foreign
4874853	Health Professional
4874854	Company Representative
4874854	Foreign
4874854	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4874860	Consumer
4874860	Foreign
4874861	Foreign
4874861	Health Professional
4874862	Other
4874862	Study
4874863	Company Representative
4874863	Foreign
4874863	Health Professional
4874864	Foreign
4874864	Health Professional
4874865	Foreign
4874865	Health Professional
4874866	Health Professional
4874866	Other
4874867	Foreign
4874867	Health Professional
4874868	Foreign
4874868	Health Professional
4874869	Other
4874869	Study
4874870	Foreign
4874870	Health Professional
4874871	Company Representative
4874871	Foreign
4874871	Health Professional
4874872	Health Professional
4874873	Foreign

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Report's unique number</i>	<i>Code for patient outcomes</i>
4874873	Health Professional
4874874	Consumer
4874876	Consumer
4874876	Health Professional
4874877	Consumer
4874877	Foreign
4874878	Consumer
4874879	Company Representative
4874879	Health Professional
4874885	Health Professional
4874886	Health Professional
4874890	Consumer
4874891	Health Professional
4874892	Consumer
4874892	Health Professional
4874892	Other
4874893	Consumer
4874893	Health Professional
4874893	Other
4874894	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4793437	1006499910	20040101	20040101	0
4802758	1006528830	20040326	20040326	0
4807735	1006546441	20040626	20050527	0
4807735	1006576213	20050201	20050214	0
4807884	1006546701	20050707	20050707	0
4810789	1006588338	20050101	20050101	0
4811786	1006562404	20050624	20050624	0
4813034	1006566431	20050101	20050101	0
4813034	1006601168	20041213	20050101	0
4813034	1006601169	19970101	19970101	0
4817144	1006582227	20041221	20050316	0
4817146	1006582230	20020601	20020601	0
4817149	1006582234	20050318	20050318	0
4817159	1006582292	20050125	20050301	0
4819355	1006590009	20050725	20050725	0
4820164	1006592680	20051005	20051005	0
4820164	1006612262	20051005	20051005	0
4821833	1006599623	20041223	20050127	0
4826267	1006616466	20051004	20051004	0
4826267	1006627645	20051004	20051004	0
4826274	1006616477	20051012	20051012	0
4826360	1006616799	20050201	20050201	0
4826360	1006646257	20050215	20050215	0
4826360	1006646259	20040720	20040720	0
4826360	1006646263	20050215	20050215	0
4828303	1006624790	20050809	20050809	0
4828303	1006624791	20050809	20050809	0
4828303	1006624792	20050809	20050809	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4828303	1006624793	20050809	20050809	0
4828303	1006624794	20050809	20050809	0
4828303	1006624795	20050809	20050809	0
4828303	1006624796	20050809	20050809	0
4828303	1006624797	20050809	20050809	0
4828303	1006624800	20050809	20050809	0
4828303	1006624802	20050809	20050809	0
4828303	1006624803	20050809	20050809	0
4828303	1006624804	20050809	20050809	0
4828303	1006624805	20050809	20050810	0
4828303	1006624806	20050809	20050809	0
4828303	1006624807	20050809	20050809	0
4832882	1006644304	20050525	20050527	0
4832882	1006644305	20050525	20050525	0
4832882	1006644306	20050525	20050528	0
4832882	1006644307	20050525	20050525	0
4832882	1006644308	20050525	20050525	0
4833762	1006646649	19930901	20040520	10
4834797	1006650318	20050215	20050215	0
4834797	1006674751	20040720	20040720	0
4834797	1006674753	20050201	20050201	0
4834797	1006674755	20050215	20050215	0
4838069	1006664089	20051103	20051103	0
4838069	1006690892	20051103	20051103	0
4840105	1006670788	20051114	20051114	0
4840105	1006693739	20051114	20051114	0
4840105	1006693817	20051114	20051114	0
4840105	1006693842	20051114	20051114	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4846119	1006693270	20050916	20050916	0
4846119	1006693270	20051024	20051024	0
4846435	1006694159	20010101	20010101	0
4846435	1006694159	20010701	20010701	0
4846435	1006694159	20011001	20011001	0
4847638	1006698536	20050302	20050302	0
4852895	1006718379	20040101	20040101	0
4865588	1006759846	20050501	20050501	0
4865588	1006759846	20050715	20050715	0
4867362	1006767685	-	-	0
4867362	1006789786	-	-	0
4867362	1006789787	-	-	0
4867364	1006767690	-	-	0
4867364	1006789905	-	-	0
4867364	1006789922	-	-	0
4867367	1006767694	-	-	0
4867367	1006790043	-	-	0
4867367	1006790044	-	-	0
4867370	1006767702	-	-	0
4867370	1006790098	-	-	0
4867370	1006790102	-	-	0
4867373	1006767712	-	-	0
4867373	1006790138	-	-	0
4867373	1006790140	-	-	0
4867375	1006767714	-	-	0
4867375	1006790176	-	-	0
4867375	1006790178	-	-	0
4867377	1006767717	-	-	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4867377	1006790542	-	-	0
4867377	1006790543	-	-	0
4867384	1006767733	-	-	0
4867384	1006790724	-	-	0
4867384	1006790725	-	-	0
4867390	1006767761	-	-	0
4867390	1006790064	-	-	0
4867390	1006790066	-	-	0
4867390	1006790082	-	-	0
4867392	1006767776	-	-	0
4867392	1006790882	-	-	0
4867392	1006790885	-	-	0
4867604	1006768378	-	-	0
4867604	1006790096	-	-	0
4867604	1006790100	-	-	0
4867630	1006768432	-	-	0
4867630	1006790806	-	-	0
4867630	1006790809	-	-	0
4869006	1006773747	20050527	20050527	0
4870242	1006778880	20051205	20051205	0
4870242	1006778881	20051205	20051205	0
4870242	1006778883	20050101	20050101	0
4870243	1006778886	20051023	20051123	0
4870243	1006778887	20051023	20051123	0
4870243	1006778888	20051002	20051028	0
4870243	1006778889	20051003	20051003	0
4870243	1006778890	20051012	20051120	0
4870243	1006778891	20051104	20051104	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870243	1006778892	20051113	20051113	0
4870243	1006778898	20051011	20051020	0
4870243	1006778899	20051011	20051021	0
4870244	1006778900	20040201	20040301	0
4870244	1006778901	20040501	20040927	0
4870244	1006778902	20040928	20050301	0
4870244	1006778903	20050511	20050513	0
4870244	1006778904	20050514	20050514	0
4870244	1006778905	20050515	20050516	0
4870244	1006778906	20050517	20050517	0
4870244	1006778907	20050518	20050522	0
4870244	1006778908	20050523	20050523	0
4870244	1006778909	20050524	20050530	0
4870244	1006778910	20050531	20050531	0
4870244	1006778911	20050601	20050705	0
4870244	1006778913	20040904	20041004	0
4870244	1006778914	20050621	20050705	0
4870244	1006778915	20040420	20040424	0
4870244	1006778916	20040425	20040427	0
4870244	1006778917	20040428	20040512	0
4870245	1006778918	20051112	20051112	0
4870246	1006778919	20050929	20050929	0
4870246	1006778920	20050915	20050915	0
4870247	1006778921	20040503	20040503	0
4870247	1006778922	20040503	20040503	0
4870248	1006778924	20050819	20051119	0
4870250	1006778927	20051216	20051216	0
4870250	1006778928	20051216	20051216	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870250	1006778929	20051216	20051216	0
4870250	1006778930	20051216	20051216	0
4870252	1006778934	20020101	20051005	3
4870252	1006778935	20051009	20051109	0
4870252	1006778936	20051110	20051116	0
4870252	1006778937	20051007	20051026	0
4870252	1006778938	20051008	20051009	0
4870252	1006778939	20051008	20051009	0
4870252	1006778940	20051010	20051010	0
4870252	1006778941	20051010	20051010	0
4870252	1006778942	20051016	20051016	0
4870252	1006778944	20051006	20051008	0
4870252	1006778945	20051010	20051017	0
4870252	1006778946	20051009	20051018	0
4870252	1006778947	20051009	20051009	0
4870252	1006778948	20051017	20051017	0
4870252	1006778949	20051006	20051007	0
4870252	1006778950	20051007	20051008	0
4870252	1006778951	20051007	20051007	0
4870255	1006778954	20051207	20051207	0
4870255	1006778955	20051130	20051130	0
4870255	1006778956	20051207	20051207	0
4870256	1006778957	20050301	20050301	0
4870257	1006778958	20050104	20050928	0
4870257	1006778959	20050504	20050928	0
4870257	1006778960	20050301	20050928	0
4870257	1006778961	20050501	20050928	0
4870258	1006778963	20020101	20020101	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870258	1006778964	20030701	20030701	0
4870258	1006778965	20030701	20030701	0
4870272	1006779201	20051129	20051129	0
4870319	1006779354	-	-	1
4870329	1006779391	20010319	20010319	0
4870343	1006779487	20051007	20051007	0
4870343	1006779488	20051007	20051007	0
4870344	1006779489	20040513	20040816	0
4870344	1006779490	20010604	20040816	3
4870344	1006779491	20020425	20040425	2
4870344	1006779492	20001102	20050414	4
4870344	1006779493	20040819	20040819	0
4870346	1006779495	20051011	20051122	0
4870346	1006779496	20051011	20051122	0
4870346	1006779497	19990406	20051122	6
4870346	1006779498	19990406	20051128	6
4870346	1006779499	20040329	20051128	1
4870346	1006779500	20040329	20051122	1
4870346	1006779501	20040427	20051122	1
4870346	1006779502	19990406	20051122	6
4870347	1006779503	20000901	20000901	0
4870347	1006779504	20020417	20020417	0
4870347	1006779506	20000101	20000101	0
4870347	1006779507	20000101	20000101	0
4870347	1006779508	20050401	20050601	0
4870347	1006779509	20000101	20000101	0
4870348	1006779510	20030520	20030530	0
4870348	1006779511	20030505	20030519	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870348	1006779512	19950101	20030529	8
4870349	1006779519	20030401	20030403	0
4870349	1006779520	20030318	20030401	0
4870350	1006779524	20051123	20051123	0
4870350	1006779525	20051125	20051127	0
4870351	1006779535	20031214	20041116	0
4870351	1006779536	19991117	19991117	0
4870351	1006779537	20030215	20030215	0
4870351	1006779538	20021012	20021012	0
4870351	1006779539	20020514	20020514	0
4870351	1006779540	20030927	20030927	0
4870351	1006779541	19991130	19991130	0
4870352	1006779542	20050709	20051124	0
4870353	1006779543	20050625	20051117	0
4870354	1006779545	20051226	20051226	0
4870354	1006779546	20051223	20051223	0
4870355	1006779547	20050801	20050901	0
4870356	1006779555	19990629	19990629	0
4870356	1006779556	19990622	19990622	0
4870356	1006779557	20040820	20040820	0
4870357	1006779558	20010201	20010214	0
4870357	1006779559	20010215	20010627	0
4870357	1006779560	20010201	20010627	0
4870357	1006779561	20010201	20010627	0
4870358	1006779562	20010201	20010201	0
4870358	1006779563	20010201	20010201	0
4870358	1006779564	20010201	20010201	0
4870359	1006779565	20050405	20050405	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870359	1006779566	20050405	20051107	0
4870359	1006779567	20050405	20050405	0
4870359	1006779568	20050311	20050311	0
4870359	1006779569	20050311	20050311	0
4870360	1006779570	20031104	20031118	0
4870360	1006779571	20031118	20031129	0
4870360	1006779572	19961113	19961113	0
4870360	1006779573	20031104	20031104	0
4870365	1006779617	20030421	20030421	0
4870370	1006779665	20050315	20050818	0
4870370	1006779666	20050315	20050818	0
4870370	1006779667	20021001	20021001	0
4870370	1006779668	20050315	20050315	0
4870370	1006779669	19980101	19980101	0
4870370	1006779670	20021001	20021001	0
4870370	1006779671	20021001	20021001	0
4870370	1006779672	20021001	20021001	0
4870370	1006779673	20040101	20040101	0
4870370	1006779674	20050101	20050101	0
4870370	1006779675	20050803	20050803	0
4870372	1006779677	20050523	20050619	0
4870372	1006779678	19980401	19980401	0
4870372	1006779679	19980401	19980401	0
4870372	1006779680	19980401	19980401	0
4870372	1006779681	20050401	20050401	0
4870372	1006779682	19980401	19980401	0
4870372	1006779683	19980401	19980401	0
4870379	1006779698	20051119	20051119	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870385	1006779719	20010409	20040601	3
4870387	1006779756	20011004	20020301	0
4870392	1006779816	-	-	0
4870392	1006779817	-	-	0
4870392	1006779818	-	-	0
4870392	1006779819	-	-	0
4870392	1006779820	-	-	0
4870414	1006779896	20040112	20040112	0
4870415	1006779901	20041001	20041001	0
4870415	1006779903	20040904	20040904	0
4870415	1006779904	20040904	20040904	0
4870415	1006779905	20041004	20041004	0
4870418	1006779917	20041205	20041205	0
4870419	1006779918	20030701	20030701	0
4870421	1006779923	20031201	20031201	0
4870423	1006779936	20041201	20041201	0
4870423	1006779937	20041201	20041201	0
4870425	1006779940	20040101	20040101	0
4870425	1006779941	20040101	20040101	0
4870426	1006779944	20040101	20040101	0
4870430	1006779951	20040901	20040901	0
4870430	1006779952	19980101	19980101	0
4870431	1006779954	20020101	20041201	2
4870433	1006779956	20040501	20040501	0
4870433	1006779957	20040501	20040501	0
4870433	1006779958	20040501	20040501	0
4870433	1006779959	20040621	20040621	0
4870433	1006779961	20040501	20040501	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870434	1006779966	20050301	20050325	0
4870438	1006779971	-	-	2
4870439	1006779972	-	-	0
4870440	1006779973	20050310	20050310	0
4870440	1006779974	20050311	20050311	0
4870442	1006779983	-	-	4
4870446	1006779992	-	-	5
4870448	1006779995	20041013	20041013	0
4870449	1006779996	20050709	20050709	0
4870453	1006780033	20050601	20050601	0
4870455	1006780039	20050915	20050915	0
4870457	1006780045	20050922	20050922	0
4870458	1006780056	20050729	20050729	0
4870458	1006780057	20050728	20050728	0
4870458	1006780058	20050728	20050728	0
4870458	1006780059	20050728	20050728	0
4870459	1006780060	20020601	20051127	3
4870459	1006780069	20020101	20040818	2
4870459	1006780070	20020101	20040818	2
4870460	1006780071	20051003	20051215	0
4870460	1006780072	20051206	20051206	0
4870460	1006780073	20051223	20051223	0
4870460	1006780075	20050826	20050826	0
4870460	1006780076	20050826	20050826	0
4870460	1006780077	20050826	20050826	0
4870460	1006780078	20050826	20051206	0
4870460	1006780079	20051206	20051206	0
4870460	1006780081	20051223	20051223	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870461	1006780082	20040819	20040930	0
4870461	1006780084	20020624	20040927	2
4870461	1006780085	20040610	20040915	0
4870463	1006780087	20050723	20050723	0
4870463	1006780088	19990629	20050723	6
4870463	1006780090	20050620	20050620	0
4870463	1006780091	20010307	20010307	0
4870463	1006780092	20050620	20050620	0
4870463	1006780093	20050605	20050605	0
4870463	1006780094	20050706	20050706	0
4870463	1006780095	20050620	20050620	0
4870463	1006780096	19990828	19990828	0
4870464	1006780097	20030404	20051112	2
4870465	1006780110	20050801	20050801	0
4870468	1006780116	20020904	20020904	0
4870468	1006780117	20020824	20021209	0
4870469	1006780121	20050704	20051010	0
4870480	1006780170	20051128	20051128	0
4870480	1006780171	20051128	20051128	0
4870480	1006780172	20051128	20051128	0
4870480	1006780173	20051128	20051128	0
4870480	1006780174	20051128	20051128	0
4870480	1006780175	20051128	20051128	0
4870480	1006780176	20051202	20051202	0
4870480	1006780177	20051202	20051202	0
4870480	1006780178	20051202	20051202	0
4870484	1006780188	20051003	20051003	0
4870484	1006780189	20051001	20051001	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870484	1006780190	20050301	20050301	0
4870484	1006780191	20051001	20051001	0
4870512	1006780283	20040201	20040301	0
4870512	1006780284	20040501	20040927	0
4870512	1006780285	20040928	20050301	0
4870512	1006780286	20050511	20050513	0
4870512	1006780287	20050514	20050514	0
4870512	1006780288	20050515	20050516	0
4870512	1006780289	20050517	20050517	0
4870512	1006780290	20050518	20050522	0
4870512	1006780291	20050523	20050523	0
4870512	1006780292	20050524	20050530	0
4870512	1006780293	20050531	20050531	0
4870512	1006780294	20050601	20050705	0
4870512	1006780296	20040904	20041004	0
4870512	1006780297	20050621	20050705	0
4870512	1006780298	20040420	20040424	0
4870512	1006780299	20040425	20040427	0
4870512	1006780300	20040428	20040512	0
4870529	1006780356	20051107	20051107	0
4870529	1006780357	20051107	20051107	0
4870529	1006780358	20051107	20051107	0
4870529	1006780359	20051113	20051113	0
4870529	1006780360	20051108	20051108	0
4870529	1006780361	20051113	20051113	0
4870529	1006780362	20051108	20051108	0
4870529	1006780363	20051108	20051108	0
4870529	1006780364	20051109	20051109	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870529	1006780365	20051110	20051117	0
4870529	1006780366	20051112	20051112	0
4870529	1006780367	20051117	20051126	0
4870529	1006780368	20051108	20051108	0
4870529	1006780369	20051116	20051116	0
4870529	1006780370	20051119	20051119	0
4870529	1006780371	20051115	20051115	0
4870529	1006780372	20051117	20051117	0
4870529	1006780373	20051108	20051112	0
4870529	1006780374	20051108	20051130	0
4870529	1006780375	20051108	20051130	0
4870529	1006780376	20051116	20051116	0
4870529	1006780377	20051120	20051120	0
4870529	1006780378	20051112	20051123	0
4870529	1006780379	20051120	20051126	0
4870535	1006780400	20021109	20021109	0
4870535	1006780402	19930508	19930508	0
4870535	1006780403	19980101	19980101	0
4870535	1006780404	19930508	19930508	0
4870535	1006780405	20020101	20020101	0
4870550	1006780462	20051101	20051201	0
4870552	1006780473	20050501	20051105	0
4870552	1006780474	20051010	20051108	0
4870552	1006780475	20051010	20051010	0
4870552	1006780476	-	-	0
4870552	1006780478	20051105	20051105	0
4870552	1006780479	20051102	20051104	0
4870552	1006780480	20051010	20051105	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870552	1006780481	20050501	20051105	0
4870553	1006780482	20050401	20050401	0
4870553	1006780483	20050101	20050101	0
4870553	1006780484	20051118	20051209	0
4870553	1006780485	20021008	20021008	0
4870553	1006780486	19970826	19970826	0
4870553	1006780487	20000125	20000125	0
4870553	1006780488	19970908	19970908	0
4870553	1006780489	19990304	19990304	0
4870567	1006780536	20040729	20040901	0
4870567	1006780537	20040902	20040902	0
4870568	1006780549	20051022	20051120	0
4870568	1006780550	20051120	20051120	0
4870568	1006780551	20051022	20051120	0
4870568	1006780552	20051022	20051120	0
4870569	1006780553	20051005	20051106	0
4870569	1006780554	20051005	20051106	0
4870570	1006780555	20030101	20050101	2
4870571	1006780556	20050901	20050912	0
4870571	1006780557	20050901	20050912	0
4870572	1006780558	20031219	20031219	0
4870572	1006780559	20031220	20040122	0
4870572	1006780560	20040123	20040205	0
4870572	1006780561	20031205	20041203	0
4870572	1006780562	20031204	20040204	0
4870572	1006780563	20031204	20040204	0
4870572	1006780564	20021205	20031203	0
4870572	1006780565	20040205	20040205	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870572	1006780566	20021205	20021205	0
4870572	1006780567	20021205	20021205	0
4870572	1006780568	20021205	20021205	0
4870572	1006780569	20051205	20051205	0
4870572	1006780570	20030508	20030508	0
4870572	1006780571	20021205	20021205	0
4870572	1006780572	20030508	20030508	0
4870572	1006780573	20030508	20030508	0
4870572	1006780574	20031225	20040105	0
4870572	1006780575	20030225	20030225	0
4870572	1006780577	20040510	20040510	0
4870576	1006780598	20051125	20051125	0
4870577	1006780599	20051030	20051104	0
4870577	1006780601	20051031	20051104	0
4870578	1006780602	20041027	20041027	0
4870578	1006780603	20041027	20041027	0
4870578	1006780604	20041027	20041027	0
4870578	1006780605	20041027	20041027	0
4870578	1006780606	20041027	20041027	0
4870579	1006780607	20050422	20050422	0
4870579	1006780608	20050422	20050422	0
4870579	1006780609	20050422	20050422	0
4870579	1006780610	20050422	20050422	0
4870580	1006780611	20050721	20050822	0
4870580	1006780612	20050721	20050721	0
4870581	1006780613	20051117	20051117	0
4870581	1006780614	20051117	20051117	0
4870581	1006780615	20051118	20051128	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870582	1006780620	20050908	20051006	0
4870582	1006780621	20050908	20051006	0
4870582	1006780622	20050908	20050908	0
4870582	1006780623	20051006	20051006	0
4870582	1006780624	20050908	20050908	0
4870582	1006780625	20051006	20051006	0
4870582	1006780626	20050908	20050908	0
4870582	1006780627	20050908	20050908	0
4870583	1006780631	20050329	20051130	0
4870583	1006780632	20050329	20050329	0
4870583	1006780636	20050301	20050301	0
4870584	1006780638	20050329	20051130	0
4870584	1006780640	20050329	20050329	0
4870584	1006780644	20050301	20050301	0
4870585	1006780645	20050201	20050201	0
4870586	1006780648	20020501	20020501	0
4870586	1006780649	20020501	20020501	0
4870586	1006780650	20020501	20020501	0
4870588	1006780653	-	-	3
4870592	1006780677	20051129	20051129	0
4870592	1006780678	20051129	20051129	0
4870592	1006780679	20051128	20051202	0
4870593	1006780687	20051129	20051129	0
4870594	1006780689	20050105	20050105	0
4870594	1006780690	20050105	20050105	0
4870594	1006780691	20050501	20050501	0
4870594	1006780692	20050105	20050105	0
4870604	1006780724	20050918	20050918	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870604	1006780725	20050917	20050917	0
4870604	1006780726	20050917	20050917	0
4870618	1006780754	20050101	20050101	0
4870618	1006780755	20040101	20050101	1
4870667	1006780970	20051116	20051208	0
4870667	1006780971	20051116	20051208	0
4870667	1006780972	20041031	20041031	0
4870669	1006780978	20040519	20040616	0
4870669	1006780979	20040519	20040616	0
4870671	1006780985	20051130	20051130	0
4870674	1006780989	20051218	20051218	0
4870684	1006781027	20030101	20050901	2
4870685	1006781029	-	-	1
4870686	1006781035	20051101	20051228	0
4870687	1006781037	20040101	20040701	0
4870688	1006781038	20040108	20040108	0
4870689	1006781039	20001214	20030101	2
4870691	1006781043	20050817	20050829	0
4870691	1006781044	20050817	20050829	0
4870691	1006781045	20050817	20050817	0
4870692	1006781046	20050901	20050904	0
4870692	1006781047	20050907	20050913	0
4870692	1006781048	20050827	20050905	0
4870692	1006781049	20050827	20050905	0
4870692	1006781050	20050827	20050905	0
4870692	1006781051	20050906	20050907	0
4870692	1006781052	20050907	20050913	0
4870692	1006781053	20050907	20050913	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870692	1006781054	20050907	20050913	0
4870692	1006781055	20050908	20050913	0
4870692	1006781056	20050909	20050913	0
4870692	1006781057	20050908	20050913	0
4870692	1006781058	20050603	20050603	0
4870692	1006781059	20050603	20050603	0
4870692	1006781060	20050603	20050603	0
4870692	1006781061	20050603	20050603	0
4870693	1006781062	20020905	20020905	0
4870693	1006781063	20050907	20050907	0
4870694	1006781064	20050521	20050523	0
4870694	1006781066	20050604	20050818	0
4870694	1006781067	20050524	20050626	0
4870694	1006781068	20050526	20050605	0
4870694	1006781069	20050625	20050901	0
4870694	1006781070	20050518	20050530	0
4870694	1006781071	20050521	20050713	0
4870694	1006781072	20050531	20050901	0
4870694	1006781073	20050603	20050712	0
4870694	1006781074	20050605	20050822	0
4870694	1006781075	20050605	20050901	0
4870694	1006781076	20050525	20050901	0
4870694	1006781077	20050518	20050524	0
4870695	1006781078	20030916	20031008	0
4870695	1006781079	20020220	20031008	1
4870696	1006781090	20050919	20050926	0
4870696	1006781091	19980101	19980101	0
4870696	1006781092	19980101	19980101	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870696	1006781093	19980101	19980101	0
4870696	1006781094	19980101	19980101	0
4870697	1006781095	-	-	2
4870698	1006781096	20051107	20051204	0
4870698	1006781097	20051107	20051107	0
4870698	1006781098	20051112	20051112	0
4870698	1006781099	20051107	20051107	0
4870698	1006781100	20051107	20051109	0
4870698	1006781101	20051107	20051115	0
4870698	1006781102	20051117	20051120	0
4870698	1006781103	20051122	20051128	0
4870698	1006781104	20051115	20051128	0
4870698	1006781105	20051115	20051202	0
4870700	1006781113	20040505	20040505	0
4870701	1006781114	20051207	20051209	0
4870701	1006781115	20051209	20051209	0
4870702	1006781117	20051111	20051116	0
4870702	1006781118	20030215	20051117	2
4870702	1006781119	20051117	20051121	0
4870704	1006781125	20040825	20040825	0
4870704	1006781126	20040825	20040825	0
4870705	1006781127	20050719	20050726	0
4870705	1006781128	20050624	20050819	0
4870706	1006781129	19990622	19990622	0
4870706	1006781130	20040820	20040820	0
4870706	1006781131	19990629	19990629	0
4870706	1006781132	19990622	20040819	5
4870707	1006781133	20051107	20051110	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870707	1006781134	20051114	20051119	0
4870708	1006781137	20051001	20051101	0
4870709	1006781138	20050908	20051014	0
4870709	1006781139	20050913	20051017	0
4870709	1006781140	20050912	20051014	0
4870709	1006781141	20050908	20051014	0
4870709	1006781142	20051009	20051009	0
4870709	1006781143	20050913	20050928	0
4870710	1006781144	20040612	20041007	0
4870710	1006781145	20000101	20030201	2
4870710	1006781146	20040401	20041007	0
4870711	1006781151	19970326	19970326	0
4870712	1006781154	20051216	20051220	0
4870717	1006781171	20051208	20051216	0
4870717	1006781172	20051208	20051216	0
4870717	1006781173	20051208	20051216	0
4870718	1006781177	20000108	20000108	0
4870719	1006781178	20041001	20050213	0
4870720	1006781180	20051124	20051129	0
4870721	1006781181	20040825	20040825	0
4870721	1006781182	20040825	20040825	0
4870722	1006781183	20040825	20040825	0
4870722	1006781184	20040825	20040825	0
4870723	1006781185	20050527	20050705	0
4870723	1006781186	20050527	20050705	0
4870723	1006781187	20050616	20050704	0
4870723	1006781188	20050616	20050704	0
4870723	1006781189	20050527	20050703	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870723	1006781190	20050527	20050703	0
4870723	1006781191	20050527	20050703	0
4870724	1006781192	20051031	20051105	0
4870724	1006781193	20051031	20051105	0
4870724	1006781194	20051117	20051122	0
4870724	1006781195	20051117	20051117	0
4870724	1006781196	20051031	20051105	0
4870724	1006781197	20051117	20051117	0
4870724	1006781198	20051012	20051012	0
4870724	1006781199	20051012	20051012	0
4870724	1006781200	20051012	20051012	0
4870724	1006781201	20051012	20051012	0
4870724	1006781202	20051022	20051112	0
4870724	1006781203	20051022	20051022	0
4870724	1006781204	20051031	20051031	0
4870724	1006781205	20051122	20051122	0
4870725	1006781206	20050824	20050828	0
4870725	1006781207	20050824	20050826	0
4870732	1006781240	20051208	20051209	0
4870733	1006781246	-	-	1
4870733	1006781247	-	-	1
4870733	1006781248	-	-	1
4870733	1006781249	-	-	0
4870733	1006781250	-	-	0
4870741	1006781281	20051117	20051130	0
4870741	1006781282	20051117	20051130	0
4870755	1006781312	20041005	20041005	0
4870755	1006781313	20041006	20041202	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870755	1006781314	20041006	20041114	0
4870755	1006781320	20041006	20041006	0
4870755	1006781321	20041113	20041113	0
4870755	1006781325	20041012	20041012	0
4870755	1006781328	20041011	20041011	0
4870755	1006781329	20041215	20041215	0
4870755	1006781330	20050115	20050115	0
4870755	1006781331	20041014	20041014	0
4870755	1006781332	20041009	20041009	0
4870755	1006781333	20041014	20041014	0
4870755	1006781334	20041007	20041007	0
4870755	1006781336	20041009	20041009	0
4870755	1006781338	20041127	20041127	0
4870755	1006781340	20041118	20041125	0
4870755	1006781341	20050210	20050225	0
4870755	1006781342	20041012	20041012	0
4870755	1006781343	20050305	20050307	0
4870756	1006781344	20050831	20050908	0
4870756	1006781345	20030615	20030615	0
4870757	1006781346	20051207	20051207	0
4870757	1006781347	20051207	20051207	0
4870758	1006781348	20010220	20010220	0
4870758	1006781349	20010221	20010221	0
4870758	1006781350	20010328	20010328	0
4870758	1006781351	20010330	20010330	0
4870758	1006781352	20010223	20010223	0
4870758	1006781353	20010221	20010221	0
4870758	1006781354	20010306	20010306	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870758	1006781355	20010221	20010221	0
4870758	1006781356	20010401	20010401	0
4870758	1006781357	20010227	20010227	0
4870758	1006781358	20010220	20010220	0
4870758	1006781359	20010401	20010401	0
4870758	1006781360	20010223	20010223	0
4870758	1006781361	20010303	20010303	0
4870763	1006781377	20000503	20000503	0
4870764	1006781378	20030101	20040901	1
4870764	1006781379	20030101	20040901	1
4870764	1006781380	20040101	20040101	0
4870764	1006781382	20030101	20030101	0
4870765	1006781383	20001001	20040901	3
4870765	1006781390	20010101	20030101	2
4870765	1006781391	20010101	20030501	2
4870765	1006781392	20030101	20030401	0
4870765	1006781393	20010101	20030101	2
4870765	1006781394	20030101	20030101	0
4870765	1006781395	19960101	19960101	0
4870766	1006781396	20010701	20040101	2
4870767	1006781401	19990101	20040901	5
4870767	1006781402	19990101	20040101	14
4870767	1006781403	19990101	20040101	14
4870767	1006781404	19990101	20040101	14
4870767	1006781405	19990101	20040101	14
4870767	1006781406	19990101	20040101	14
4870767	1006781407	19950101	19950101	0
4870767	1006781408	19980101	19980101	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870767	1006781409	19990101	20040101	5
4870767	1006781410	19700101	19700101	0
4870767	1006781411	19700101	19700101	0
4870767	1006781412	19900101	20040101	14
4870767	1006781413	19900101	19900101	0
4870767	1006781414	19950101	19950101	0
4870767	1006781415	19950101	19950101	0
4870768	1006781416	20020101	20040901	2
4870769	1006781418	19990901	20030720	4
4870769	1006781419	19990901	20030720	4
4870770	1006781425	20010801	20041104	3
4870770	1006781426	20010801	20041104	3
4870771	1006781431	19990801	20040901	5
4870772	1006781440	19990601	19990901	0
4870772	1006781441	19990601	19990901	0
4870773	1006781442	20040701	20040701	0
4870774	1006781443	20010801	20030901	2
4870775	1006781447	20010315	20040929	3
4870776	1006781448	20000101	20020101	2
4870777	1006781451	20031106	20040115	0
4870778	1006781458	20040501	20040501	0
4870779	1006781461	20010126	20010430	0
4870779	1006781462	20030815	20031125	0
4870779	1006781463	20010126	20010430	0
4870779	1006781464	20030815	20031125	0
4870780	1006781474	20000710	20000710	0
4870780	1006781475	19991101	19991101	2
4870780	1006781476	20000710	20020901	2

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870780	1006781477	20000710	20000710	0
4870780	1006781478	19991101	19991101	2
4870780	1006781479	20000710	20020901	2
4870781	1006781507	20000405	20031217	3
4870782	1006781521	19990911	19990911	0
4870783	1006781522	20010101	20030101	3
4870783	1006781523	19780702	20050201	26
4870783	1006781527	19780702	20050201	26
4870783	1006781528	19750101	19750101	0
4870784	1006781530	20020101	20020101	0
4870785	1006781538	20020401	20020401	0
4870786	1006781548	19990723	20040319	4
4870786	1006781549	19990723	20040319	4
4870786	1006781550	20021101	20021101	0
4870786	1006781551	20021101	20040801	1
4870786	1006781552	20020301	20020301	0
4870787	1006781559	20000328	20011001	1
4870788	1006781565	20000501	20040101	3
4870788	1006781566	20001101	20001101	0
4870788	1006781567	20000501	20020101	1
4870788	1006781568	20020201	20020201	0
4870789	1006781574	20010601	20010601	0
4870789	1006781575	20040601	20040601	0
4870789	1006781576	20010601	20010601	0
4870789	1006781577	20040601	20040601	0
4870791	1006781584	20010703	20020211	0
4870791	1006781585	20010703	20020211	0
4870791	1006781587	20010912	20020201	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870791	1006781589	20010716	20020301	0
4870791	1006781590	20010827	20040701	2
4870791	1006781592	20010926	20020301	0
4870792	1006781593	19990501	20020101	2
4870792	1006781594	19990501	20020101	2
4870792	1006781595	19990501	20020101	2
4870792	1006781596	19990501	20020101	2
4870793	1006781600	20000908	20000918	0
4870794	1006781609	20000101	20000401	0
4870794	1006781613	20000301	20000301	0
4870795	1006781617	20000510	20020530	2
4870795	1006781618	19990713	19990917	0
4870796	1006781644	20000101	20000101	0
4870797	1006781648	20051119	20051119	0
4870797	1006781650	20051119	20051119	0
4870797	1006781651	20051118	20051119	0
4870799	1006781664	20010101	20040901	3
4870800	1006781666	19990101	20051001	6
4870800	1006781667	20051001	20051001	0
4870800	1006781668	19780101	19780101	0
4870802	1006781670	20050919	20050919	0
4870802	1006781671	20050808	20050808	0
4870802	1006781672	20050531	20050919	0
4870802	1006781673	20050515	20050515	0
4870802	1006781674	20050510	20050510	0
4870803	1006781675	20050901	20051220	0
4870803	1006781676	20050901	20050901	0
4870803	1006781677	20050901	20051220	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870804	1006781678	20051009	20051009	0
4870805	1006781679	20051118	20051118	0
4870805	1006781680	20051118	20051118	0
4870806	1006781683	-	-	0
4870807	1006781684	20050509	20050510	0
4870807	1006781688	20050509	20050510	0
4870808	1006781697	20050313	20050314	0
4870808	1006781698	20050310	20050314	0
4870808	1006781699	20050312	20050314	0
4870809	1006781700	20041001	20041111	0
4870810	1006781701	20050805	20050805	0
4870810	1006781702	20050802	20050802	0
4870810	1006781703	20050413	20050806	0
4870810	1006781704	20050413	20050413	0
4870810	1006781705	20050413	20050805	0
4870810	1006781706	20050608	20050803	0
4870810	1006781707	20050608	20050803	0
4870813	1006781710	20000101	20010701	1
4870814	1006781711	20050322	20050322	0
4870814	1006781712	20050322	20050322	0
4870814	1006781713	20050322	20050322	0
4870816	1006781715	20030219	20040915	1
4870817	1006781716	20010401	20010706	0
4870818	1006781721	20000101	20040101	4
4870819	1006781727	20010727	20010727	0
4870822	1006781773	20030101	20040101	1
4870823	1006781775	20040613	20040930	0
4870824	1006781779	20030301	20040611	1

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870825	1006781783	20020201	20030601	1
4870827	1006781785	20051101	20051101	0
4870827	1006781786	20040101	20051101	1
4870828	1006781788	20030201	20030519	0
4870828	1006781789	20000901	20030519	2
4870828	1006781790	20000901	20030519	2
4870828	1006781791	20000929	20030519	2
4870828	1006781792	20000901	20030519	2
4870829	1006781794	19990901	20000601	0
4870829	1006781795	19990901	20000601	0
4870830	1006781796	20010416	20010416	0
4870831	1006781806	20030101	20030101	0
4870832	1006781809	20030825	20030903	0
4870832	1006781810	20030825	20030903	0
4870834	1006781814	20040706	20040706	0
4870834	1006781820	20040624	20040624	0
4870836	1006781835	20020101	20040101	2
4870838	1006781839	20030519	20030717	0
4870839	1006781840	20010101	20021001	1
4870840	1006781841	20040101	20040101	0
4870842	1006781845	20010101	20010101	0
4870843	1006781846	20000601	20031201	3
4870846	1006781849	19990201	20000101	0
4870847	1006781850	20040101	20040101	0
4870849	1006781858	20010806	20040901	3
4870849	1006781859	20010806	20040901	3
4870851	1006781865	20010101	20031201	2
4870853	1006781867	20030630	20040209	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870853	1006781868	20030630	20040209	0
4870855	1006781873	20010501	20010501	0
4870855	1006781874	20010501	20010501	0
4870858	1006781877	20040929	20040929	0
4870859	1006781879	19990101	19990101	0
4870860	1006781880	20030601	20041001	1
4870862	1006781885	20000320	20041111	4
4870862	1006781886	20000320	20041111	4
4870865	1006781903	19991102	20011109	2
4870865	1006781904	19991102	20011109	2
4870865	1006781905	19800101	19800101	0
4870867	1006781908	20000101	20020101	2
4870868	1006781911	20010701	20030809	2
4870868	1006781912	20010701	20030809	2
4870869	1006781914	19980101	20040101	6
4870870	1006781916	20010101	20030621	2
4870872	1006781921	20020401	20040701	2
4870873	1006781930	20020112	20031023	1
4870873	1006781931	19990101	20031023	4
4870873	1006781932	19990101	20031023	4
4870873	1006781933	20020112	20031023	1
4870873	1006781934	19990101	20031023	4
4870873	1006781935	19990101	20031023	4
4870873	1006781939	19980101	20020101	4
4870873	1006781940	19960101	19960101	0
4870873	1006781941	19980101	19980101	0
4870873	1006781942	19980101	19980101	0
4870873	1006781943	19980101	19980101	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870873	1006781944	19990101	19990101	0
4870873	1006781945	19990101	19990101	0
4870874	1006781946	19990101	19991201	0
4870875	1006781948	20030101	20040101	1
4870878	1006781952	20010301	20040930	3
4870886	1006781988	20050513	20050513	0
4870886	1006781989	20050513	20050513	0
4870886	1006781990	20050513	20050515	0
4870886	1006781991	20050513	20050514	0
4870886	1006781992	20050419	20050419	0
4870886	1006781993	20050419	20050419	0
4870886	1006781994	20050420	20050424	0
4870886	1006781995	20050511	20050512	0
4870886	1006781996	20050424	20050424	0
4870886	1006781997	20050420	20050420	0
4870886	1006781998	20050511	20050511	0
4870886	1006781999	20050511	20050511	0
4870886	1006782000	20050111	20050602	0
4870886	1006782001	20050111	20050602	0
4870886	1006782002	20050602	20050602	0
4870886	1006782004	20011120	20050601	3
4870886	1006782005	20050406	20050406	0
4870886	1006782006	20050406	20050406	0
4870886	1006782007	20050406	20050406	0
4870886	1006782008	20050406	20050406	0
4870886	1006782009	20050406	20050406	0
4870886	1006782010	20050420	20050420	0
4870886	1006782011	20050413	20050413	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870888	1006782014	20050501	20051213	0
4870891	1006782034	20050922	20050922	0
4870891	1006782035	20050922	20050923	0
4870891	1006782036	20050922	20050923	0
4870892	1006782037	20050214	20050309	0
4870892	1006782039	20050214	20050214	0
4870892	1006782040	20050218	20050303	0
4870892	1006782041	20050210	20050210	0
4870892	1006782042	20050222	20050223	0
4870892	1006782043	20050214	20050214	0
4870892	1006782044	20050219	20050219	0
4870892	1006782045	20050215	20050218	0
4870892	1006782046	20050223	20050223	0
4870892	1006782047	20050216	20050221	0
4870892	1006782048	20050222	20050227	0
4870892	1006782049	20050216	20050223	0
4870892	1006782050	20050228	20050303	0
4870892	1006782051	20050221	20050221	0
4870892	1006782052	20050216	20050216	0
4870892	1006782053	20050215	20050219	0
4870892	1006782054	20050215	20050215	0
4870892	1006782055	20050221	20050221	0
4870892	1006782056	20050222	20050222	0
4870892	1006782057	20050222	20050225	0
4870892	1006782058	20050224	20050227	0
4870892	1006782059	20050213	20050213	0
4870892	1006782060	20050214	20050216	0
4870892	1006782061	20050218	20050223	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870892	1006782062	20050219	20050219	0
4870892	1006782063	20050225	20050303	0
4870892	1006782064	20050217	20050217	0
4870892	1006782065	20050215	20050303	0
4870892	1006782066	20050221	20050221	0
4870892	1006782067	20050222	20050222	0
4870892	1006782068	20050215	20050215	0
4870892	1006782069	20050216	20050216	0
4870892	1006782070	20050218	20050218	0
4870892	1006782071	20050214	20050214	0
4870892	1006782072	20050213	20050219	0
4870892	1006782073	20050224	20050225	0
4870892	1006782074	20050224	20050224	0
4870892	1006782075	20050223	20050223	0
4870892	1006782076	20050309	20050309	0
4870892	1006782077	20050306	20050306	0
4870892	1006782078	20050305	20050305	0
4870892	1006782079	20050304	20050304	0
4870892	1006782080	20050303	20050303	0
4870892	1006782082	20050302	20050302	0
4870892	1006782083	20050228	20050228	0
4870892	1006782084	20050224	20050224	0
4870892	1006782085	20050216	20050216	0
4870892	1006782086	20050224	20050224	0
4870892	1006782087	20050213	20050214	0
4870892	1006782088	20050216	20050216	0
4870892	1006782089	20050218	20050218	0
4870892	1006782090	20050220	20050220	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870892	1006782091	20050219	20050219	0
4870892	1006782092	20050228	20050306	0
4870892	1006782093	20050228	20050228	0
4870892	1006782094	20050227	20050227	0
4870892	1006782095	20050226	20050226	0
4870892	1006782096	20050224	20050224	0
4870892	1006782097	20050225	20050225	0
4870892	1006782098	20050223	20050223	0
4870892	1006782099	20050222	20050222	0
4870892	1006782100	20050217	20050217	0
4870892	1006782101	20050216	20050216	0
4870892	1006782102	20050214	20050214	0
4870892	1006782103	20050215	20050215	0
4870892	1006782104	20050215	20050215	0
4870892	1006782105	20050222	20050222	0
4870892	1006782106	20050228	20050228	0
4870892	1006782107	20050301	20050301	0
4870892	1006782108	20050216	20050218	0
4870892	1006782109	20050216	20050222	0
4870892	1006782110	20050228	20050228	0
4870892	1006782111	20050223	20050301	0
4870892	1006782112	20050217	20050217	0
4870892	1006782113	20050219	20050223	0
4870892	1006782114	20050218	20050218	0
4870892	1006782115	20050219	20050221	0
4870892	1006782116	20050302	20050302	0
4870892	1006782117	20050218	20050218	0
4870892	1006782118	20050223	20050223	0

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870892	1006782119	20050304	20050304	0
4870892	1006782120	20050305	20050305	0
4870892	1006782121	20050223	20050223	0
4870892	1006782122	20050306	20050306	0
4870892	1006782123	20050309	20050309	0
4870892	1006782124	20050308	20050308	0
4870892	1006782125	20050307	20050307	0
4870892	1006782126	20050306	20050306	0
4870892	1006782127	20050303	20050303	0
4870892	1006782128	20050225	20050225	0
4870892	1006782129	20050224	20050224	0
4870892	1006782130	20050224	20050226	0
4870892	1006782131	20050302	20050302	0
4870892	1006782132	20050228	20050228	0
4870892	1006782133	20050214	20050214	0
4870892	1006782134	20050221	20050221	0
4870892	1006782135	20050214	20050214	0
4870892	1006782136	20050214	20050214	0
4870892	1006782137	20050223	20050223	0
4870892	1006782138	20050223	20050223	0
4870892	1006782139	20050214	20050214	0
4870892	1006782140	20050215	20050215	0
4870892	1006782141	20050215	20050215	0
4870892	1006782142	20050214	20050214	0
4870892	1006782143	20050218	20050222	0
4870894	1006782147	20050101	20050101	0
4870898	1006782159	20050201	20051001	0
4870900	1006782163	20040101	20051030	1

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Date when drug therapy started</i>	<i>Date when drug therapy ended</i>	<i>Derived duration</i>
4870902	1006782168	20051221	20051221	0
4870903	1006782169	20051012	20051123	0
4870903	1006782170	20051214	20051214	0
4870903	1006782171	20051012	20051123	0
4870903	1006782172	20051012	20051012	0
4870903	1006782173	20051214	20051214	0
4870903	1006782177	20051012	20051012	0
4870903	1006782178	20051012	20051012	0
4870903	1006782179	20051012	20051012	0
4870903	1006782180	20051012	20051012	0
4870903	1006782181	20051010	20051010	0
4870904	1006782183	20051011	20051011	0
4870904	1006782184	20051011	20051011	0
4870917	1006782244	20020722	20020722	0
4870917	1006782245	20020722	20020722	0
4870917	1006782246	20020722	20020722	0
4870922	1006782268	20030801	20030804	0
4870922	1006782269	20030805	20030805	0
4870922	1006782270	20030801	20030808	0
4870976	1006782436	20050711	20050822	0

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4793437	1006499909	DIABETES MELLITUS
4802758	1006528830	ACUTE MYELOID LEUKAEMIA
4807735	1006576213	LUNG DISORDER
4807884	1006546701	PARKINSON'S DISEASE
4810789	1006557089	HYPERTONIC BLADDER
4810789	1006588338	HYPERTONIC BLADDER
4811786	1006562404	MESOTHELIOMA
4813034	1006566431	EPILEPSY
4813034	1006601168	DEMENTIA
4813034	1006601169	EPILEPSY
4815387	1006596772	METASTASES TO BONE
4817144	1006582227	MULTIPLE MYELOMA
4817145	1006582228	METASTASES TO BONE
4817146	1006582230	METASTASES TO BONE
4817148	1006582233	PROSTATE CANCER METASTATIC
4817149	1006582234	METASTASES TO BONE
4817159	1006582292	OSTEOPOROSIS
4817167	1006582324	MULTIPLE MYELOMA
4819355	1006590009	DIABETES MELLITUS INSULIN-DEPENDENT
4820164	1006592680	HODGKIN'S DISEASE
4820164	1006612262	HODGKIN'S DISEASE
4821833	1006599623	ONYCHOMYCOSIS
4826267	1006616466	LEUKAEMIA PLASMACYTIC
4826267	1006627645	LEUKAEMIA PLASMACYTIC
4826274	1006616477	MYELOYDYSPLASTIC SYNDROME
4826360	1006616799	ALCOHOL WITHDRAWAL SYNDROME
4826360	1006646257	ANXIETY
4826360	1006646263	NAUSEA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4828303	1006624790	ANAESTHESIA
4828303	1006624791	INDUCTION OF ANAESTHESIA
4828303	1006624792	MAINTENANCE OF ANAESTHESIA
4828303	1006624795	PREMEDICATION
4828303	1006624796	ANAESTHESIA
4828303	1006624797	HYPOTONIA
4828303	1006624800	ANALGESIC THERAPY
4828303	1006624802	ANALGESIC THERAPY
4828303	1006624803	ANAESTHESIA
4828303	1006624804	ANAESTHESIA
4828303	1006624806	ANAESTHESIA
4828303	1006624807	PREMEDICATION
4832882	1006644307	CHEMOTHERAPY
4832882	1006644308	CHEMOTHERAPY
4833762	1006646649	CONTRACEPTION
4834797	1006650318	ANXIETY
4834797	1006674751	ILL-DEFINED DISORDER
4834797	1006674753	ALCOHOL WITHDRAWAL SYNDROME
4834797	1006674755	NAUSEA
4838069	1006664089	CHRONIC MYELOID LEUKAEMIA
4838069	1006690892	CHRONIC MYELOID LEUKAEMIA
4846119	1006693270	MENORRHAGIA
4846435	1006694159	CONTRACEPTION
4847003	1006696440	PROPHYLAXIS AGAINST TRANSPLANT REJECTION
4847053	1006696663	RHEUMATOID ARTHRITIS
4847638	1006698536	CONTRACEPTION
4852120	1006715372	DRUG USE FOR UNKNOWN INDICATION
4865588	1006759846	HYPERHIDROSIS

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4867362	1006767685	ACUTE MYELOID LEUKAEMIA
4867362	1006789786	ACUTE MYELOID LEUKAEMIA
4867362	1006789787	ACUTE MYELOID LEUKAEMIA
4867362	1006789792	PROPHYLAXIS
4867362	1006789793	PROPHYLAXIS
4867362	1006789795	PROPHYLAXIS
4867362	1006789803	PROPHYLAXIS
4867364	1006767690	MYELOYDYSPLASTIC SYNDROME
4867364	1006789905	MYELOYDYSPLASTIC SYNDROME
4867364	1006789922	MYELOYDYSPLASTIC SYNDROME
4867364	1006789940	PROPHYLAXIS
4867364	1006789941	PROPHYLAXIS
4867364	1006789942	PROPHYLAXIS
4867364	1006789949	PROPHYLAXIS
4867367	1006767694	ACUTE MYELOID LEUKAEMIA
4867367	1006790043	ACUTE MYELOID LEUKAEMIA
4867367	1006790044	ACUTE MYELOID LEUKAEMIA
4867367	1006790047	PROPHYLAXIS
4867367	1006790048	PROPHYLAXIS
4867367	1006790049	PROPHYLAXIS
4867367	1006790056	PROPHYLAXIS
4867370	1006767702	REFRACTORY ANAEMIA WITH AN EXCESS OF BLASTS
4867370	1006790098	REFRACTORY ANAEMIA WITH AN EXCESS OF BLASTS
4867370	1006790102	REFRACTORY ANAEMIA WITH AN EXCESS OF BLASTS
4867370	1006790107	PROPHYLAXIS
4867370	1006790109	PROPHYLAXIS
4867370	1006790111	PROPHYLAXIS
4867370	1006790120	PROPHYLAXIS

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4867373	1006767712	ACUTE MYELOID LEUKAEMIA
4867373	1006790138	ACUTE MYELOID LEUKAEMIA
4867373	1006790140	ACUTE MYELOID LEUKAEMIA
4867373	1006790142	PROPHYLAXIS
4867373	1006790145	PROPHYLAXIS
4867373	1006790148	PROPHYLAXIS
4867373	1006790153	PROPHYLAXIS
4867375	1006767714	ACUTE MYELOID LEUKAEMIA
4867375	1006790176	ACUTE MYELOID LEUKAEMIA
4867375	1006790178	ACUTE MYELOID LEUKAEMIA
4867375	1006790183	PROPHYLAXIS
4867375	1006790194	PROPHYLAXIS
4867375	1006790217	PROPHYLAXIS
4867375	1006790411	PROPHYLAXIS
4867377	1006767717	REFRACTORY ANAEMIA WITH AN EXCESS OF BLASTS
4867377	1006790542	REFRACTORY ANAEMIA WITH AN EXCESS OF BLASTS
4867377	1006790543	REFRACTORY ANAEMIA WITH AN EXCESS OF BLASTS
4867377	1006790545	PROPHYLAXIS
4867377	1006790547	PROPHYLAXIS
4867377	1006790548	PROPHYLAXIS
4867377	1006790554	PROPHYLAXIS
4867384	1006767733	ACUTE MYELOID LEUKAEMIA
4867384	1006790724	ACUTE MYELOID LEUKAEMIA
4867384	1006790725	ACUTE MYELOID LEUKAEMIA
4867384	1006790727	PROPHYLAXIS
4867384	1006790730	PROPHYLAXIS
4867384	1006790731	PROPHYLAXIS
4867384	1006790738	PROPHYLAXIS

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4867390	1006767761	ACUTE MYELOID LEUKAEMIA
4867390	1006790064	ACUTE MYELOID LEUKAEMIA
4867390	1006790066	ACUTE MYELOID LEUKAEMIA
4867390	1006790083	PROPHYLAXIS
4867390	1006790085	PROPHYLAXIS
4867390	1006790086	PROPHYLAXIS
4867392	1006767776	ACUTE MYELOID LEUKAEMIA
4867392	1006790882	ACUTE MYELOID LEUKAEMIA
4867392	1006790885	ACUTE MYELOID LEUKAEMIA
4867392	1006790892	PROPHYLAXIS
4867392	1006790895	PROPHYLAXIS
4867392	1006790897	PROPHYLAXIS
4867392	1006790934	PROPHYLAXIS
4867604	1006768378	ACUTE MYELOID LEUKAEMIA
4867604	1006790096	ACUTE MYELOID LEUKAEMIA
4867604	1006790100	ACUTE MYELOID LEUKAEMIA
4867604	1006790104	PROPHYLAXIS
4867604	1006790106	PROPHYLAXIS
4867630	1006768432	ACUTE MYELOID LEUKAEMIA
4867630	1006790806	ACUTE MYELOID LEUKAEMIA
4867630	1006790811	PROPHYLAXIS
4867630	1006790813	PROPHYLAXIS
4867630	1006790816	PROPHYLAXIS
4867630	1006790823	PROPHYLAXIS
4869006	1006773747	OSTEOPOROSIS
4870242	1006778880	ANAESTHESIA
4870242	1006778881	SEDATIVE THERAPY
4870242	1006778882	HYPERTENSION

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870242	1006778884	HYPERTENSION
4870242	1006778885	BLOOD CHOLESTEROL INCREASED
4870243	1006778886	LUNG ADENOCARCINOMA
4870243	1006778887	NON-SMALL CELL LUNG CANCER
4870243	1006778888	DEPRESSION
4870243	1006778889	CHRONIC OBSTRUCTIVE PULMONARY DISEASE
4870243	1006778890	TACHYARRHYTHMIA
4870243	1006778891	CANCER PAIN
4870243	1006778892	NAUSEA
4870243	1006778893	ANGINA PECTORIS
4870243	1006778894	TACHYARRHYTHMIA
4870243	1006778895	ANGINA PECTORIS
4870243	1006778896	ANGINA PECTORIS
4870243	1006778897	NON-SMALL CELL LUNG CANCER
4870243	1006778898	NON-SMALL CELL LUNG CANCER
4870243	1006778899	NON-SMALL CELL LUNG CANCER
4870245	1006778918	OSTEOPOROSIS
4870247	1006778921	DRUG USE FOR UNKNOWN INDICATION
4870247	1006778922	DRUG USE FOR UNKNOWN INDICATION
4870247	1006778923	OSTEOPOROSIS
4870248	1006778924	NON-SMALL CELL LUNG CANCER
4870249	1006778925	SEDATION
4870249	1006778926	ANAESTHESIA
4870250	1006778927	EPIDURAL ANAESTHESIA
4870250	1006778928	CAESAREAN SECTION
4870250	1006778929	SPINAL ANAESTHESIA
4870250	1006778930	LOCAL ANAESTHESIA
4870252	1006778934	SCHIZOPHRENIA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870252	1006778937	EPILEPSY
4870252	1006778938	EPILEPSY
4870252	1006778939	LIVER DISORDER
4870252	1006778942	EPILEPSY
4870252	1006778944	EPILEPSY
4870252	1006778945	PNEUMONIA
4870252	1006778946	PNEUMONIA
4870252	1006778949	EPILEPSY
4870252	1006778950	EPILEPSY
4870252	1006778951	EPILEPSY
4870253	1006778952	HYPERTENSION
4870254	1006778953	INSOMNIA
4870255	1006778954	RECTAL CANCER
4870255	1006778955	RECTAL CANCER
4870255	1006778956	RECTAL CANCER
4870256	1006778957	BENIGN PROSTATIC HYPERPLASIA
4870257	1006778958	THROMBOSIS
4870257	1006778959	THROMBOSIS
4870257	1006778960	HYPERTENSION
4870257	1006778961	ARRHYTHMIA
4870258	1006778963	HYPERTENSION
4870302	1006779257	CROHN'S DISEASE
4870302	1006779258	CROHN'S DISEASE
4870303	1006779259	RHEUMATOID ARTHRITIS
4870304	1006779262	RETINITIS
4870304	1006779265	VIRAL INFECTION
4870304	1006779267	PROPHYLAXIS
4870304	1006779269	PROPHYLAXIS

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870304	1006779272	UVEITIS
4870304	1006779274	GLAUCOMA
4870304	1006779276	GLAUCOMA
4870304	1006779278	INFECTION PROPHYLAXIS
4870304	1006779281	UVEITIS
4870305	1006779286	CROHN'S DISEASE
4870305	1006779287	CROHN'S DISEASE
4870305	1006779288	CROHN'S DISEASE
4870319	1006779354	CROHN'S DISEASE
4870320	1006779355	CROHN'S DISEASE
4870321	1006779356	DRUG USE FOR UNKNOWN INDICATION
4870322	1006779358	CROHN'S DISEASE
4870323	1006779368	CROHN'S DISEASE
4870323	1006779369	CROHN'S DISEASE
4870323	1006779370	CROHN'S DISEASE
4870324	1006779373	RHEUMATOID ARTHRITIS
4870324	1006779376	RHEUMATOID ARTHRITIS
4870324	1006779377	RHEUMATOID ARTHRITIS
4870324	1006779378	RHEUMATOID ARTHRITIS
4870324	1006779379	RHEUMATOID ARTHRITIS
4870324	1006779380	RHEUMATOID ARTHRITIS
4870324	1006779381	RHEUMATOID ARTHRITIS
4870324	1006779382	RHEUMATOID ARTHRITIS
4870324	1006779383	RHEUMATOID ARTHRITIS
4870325	1006779384	RHEUMATOID ARTHRITIS
4870326	1006779385	DRUG USE FOR UNKNOWN INDICATION
4870327	1006779386	CROHN'S DISEASE
4870328	1006779388	RHEUMATOID ARTHRITIS

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870329	1006779391	RHEUMATOID ARTHRITIS
4870330	1006779407	RHEUMATOID ARTHRITIS
4870330	1006779408	DRUG USE FOR UNKNOWN INDICATION
4870330	1006779409	DRUG USE FOR UNKNOWN INDICATION
4870331	1006779411	RHEUMATOID ARTHRITIS
4870332	1006779438	RHEUMATOID ARTHRITIS
4870333	1006779463	RHEUMATOID ARTHRITIS
4870333	1006779464	RHEUMATOID ARTHRITIS
4870334	1006779465	CROHN'S DISEASE
4870335	1006779470	RHEUMATOID ARTHRITIS
4870336	1006779477	RHEUMATOID ARTHRITIS
4870336	1006779478	RHEUMATOID ARTHRITIS
4870343	1006779487	RESTLESS LEGS SYNDROME
4870343	1006779488	SLEEP DISORDER
4870344	1006779489	HIV INFECTION
4870344	1006779490	HIV INFECTION
4870344	1006779491	HIV INFECTION
4870344	1006779492	HIV INFECTION
4870344	1006779493	HIV INFECTION
4870346	1006779495	HYPERTENSION
4870347	1006779503	CHRONIC OBSTRUCTIVE PULMONARY DISEASE
4870347	1006779504	BREAST CANCER
4870348	1006779510	ESSENTIAL HYPERTENSION
4870348	1006779512	ARRHYTHMIA
4870348	1006779516	WHEEZING
4870348	1006779517	DYSPNOEA
4870349	1006779519	ESSENTIAL HYPERTENSION
4870349	1006779521	HYPOTHYROIDISM

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870349	1006779522	HORMONE REPLACEMENT THERAPY
4870350	1006779524	SCIATICA
4870350	1006779526	ATRIAL FIBRILLATION
4870350	1006779527	CARDIAC ASSISTANCE DEVICE USER
4870350	1006779528	HYPERTENSION
4870350	1006779529	THYROID DISORDER
4870350	1006779530	ATRIAL FIBRILLATION
4870350	1006779532	ARTHRITIS
4870351	1006779535	ESSENTIAL HYPERTENSION
4870351	1006779536	HYPERLIPIDAEMIA
4870351	1006779537	ESSENTIAL HYPERTENSION
4870351	1006779538	CEREBRAL INFARCTION
4870351	1006779539	HEMIPLEGIA
4870351	1006779540	DIABETES MELLITUS
4870351	1006779541	CONVULSION
4870352	1006779542	HIV INFECTION
4870353	1006779543	OSTEOARTHRITIS
4870355	1006779547	INTERVERTEBRAL DISC PROTRUSION
4870355	1006779548	SCIATICA
4870355	1006779549	ACCIDENT
4870355	1006779550	HYPERTENSION
4870355	1006779552	VITAMIN SUPPLEMENTATION
4870355	1006779554	BLOOD PRESSURE
4870356	1006779555	HIV INFECTION
4870356	1006779556	HIV INFECTION
4870356	1006779557	HIV INFECTION
4870358	1006779562	HIV INFECTION
4870358	1006779563	HIV INFECTION

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870358	1006779564	HIV INFECTION
4870359	1006779565	CEREBROVASCULAR ACCIDENT PROPHYLAXIS
4870359	1006779566	CEREBROVASCULAR ACCIDENT PROPHYLAXIS
4870359	1006779567	CEREBROVASCULAR ACCIDENT PROPHYLAXIS
4870359	1006779568	BLOOD CHOLESTEROL INCREASED
4870359	1006779569	DEPRESSION
4870360	1006779570	HIV TEST POSITIVE
4870360	1006779572	HIV TEST POSITIVE
4870360	1006779573	HIV TEST POSITIVE
4870362	1006779587	RHEUMATOID ARTHRITIS
4870363	1006779599	CROHN'S DISEASE
4870364	1006779602	CROHN'S DISEASE
4870365	1006779617	RHEUMATOID ARTHRITIS
4870366	1006779640	RHEUMATOID ARTHRITIS
4870367	1006779656	RHEUMATOID ARTHRITIS
4870370	1006779665	BREAST CANCER METASTATIC
4870370	1006779666	BREAST CANCER METASTATIC
4870370	1006779667	HYPERTENSION
4870370	1006779668	THROMBOSIS PROPHYLAXIS
4870370	1006779669	HYPERTENSION
4870370	1006779670	OSTEOPOROSIS
4870370	1006779671	HYPERCHOLESTEROLAEMIA
4870370	1006779672	OSTEOPOROSIS
4870370	1006779673	DYSPEPSIA
4870370	1006779674	DIABETES MELLITUS
4870370	1006779675	MUSCULOSKELETAL CHEST PAIN
4870372	1006779677	NON-SMALL CELL LUNG CANCER
4870372	1006779678	HYPERTENSION

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870372	1006779679	ANGINA PECTORIS
4870372	1006779680	HYPERTENSION
4870372	1006779681	PROPHYLAXIS
4870372	1006779682	ANGINA PECTORIS
4870372	1006779683	ANGINA PECTORIS
4870379	1006779698	DIABETES MELLITUS
4870385	1006779719	RHEUMATOID ARTHRITIS
4870386	1006779739	RHEUMATOID ARTHRITIS
4870387	1006779756	RHEUMATOID ARTHRITIS
4870388	1006779778	RHEUMATOID ARTHRITIS
4870389	1006779793	RHEUMATOID ARTHRITIS
4870390	1006779796	RHEUMATOID ARTHRITIS
4870391	1006779802	RHEUMATOID ARTHRITIS
4870392	1006779815	RHEUMATOID ARTHRITIS
4870393	1006779821	RHEUMATOID ARTHRITIS
4870414	1006779896	MAJOR DEPRESSION
4870415	1006779901	DEPRESSION
4870415	1006779903	STENT PLACEMENT
4870415	1006779904	CORONARY ARTERY OCCLUSION
4870415	1006779905	DEPRESSION
4870416	1006779912	PSEUDODEMENTIA
4870416	1006779913	SLEEP DISORDER
4870416	1006779914	PSEUDODEMENTIA
4870416	1006779915	SLEEP DISORDER
4870418	1006779917	DEPRESSION
4870419	1006779918	SLEEP DISORDER
4870421	1006779923	INSOMNIA
4870422	1006779928	DEPRESSION

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870422	1006779929	SLEEP DISORDER
4870425	1006779940	ANXIETY
4870425	1006779941	INSOMNIA
4870426	1006779944	INSOMNIA
4870430	1006779952	INSOMNIA
4870432	1006779955	SLEEP DISORDER
4870434	1006779966	SLEEP DISORDER
4870438	1006779971	INSOMNIA
4870440	1006779973	DEPRESSION
4870441	1006779975	PANIC DISORDER
4870441	1006779976	DEPRESSION
4870441	1006779977	ANXIETY
4870441	1006779978	SLEEP DISORDER
4870442	1006779983	PARKINSON'S DISEASE
4870444	1006779989	INSOMNIA
4870446	1006779992	DEPRESSION
4870449	1006779996	DEPRESSION
4870453	1006780033	INSOMNIA
4870454	1006780037	INSOMNIA
4870454	1006780038	DEPRESSION
4870455	1006780039	INSOMNIA
4870457	1006780045	ANXIETY
4870458	1006780056	CHEMOTHERAPY
4870459	1006780060	HIV INFECTION
4870460	1006780071	ANAEMIA OF MALIGNANT DISEASE
4870461	1006780082	ANKYLOSING SPONDYLITIS
4870461	1006780083	CROHN'S DISEASE
4870461	1006780084	ANKYLOSING SPONDYLITIS

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870461	1006780085	CROHN'S DISEASE
4870463	1006780087	ANAEMIA
4870463	1006780088	ANAEMIA
4870464	1006780097	RENAL TRANSPLANT
4870465	1006780110	MYELOYDYSPLASTIC SYNDROME
4870466	1006780112	DRUG USE FOR UNKNOWN INDICATION
4870467	1006780113	DRUG USE FOR UNKNOWN INDICATION
4870468	1006780116	ANKYLOSING SPONDYLITIS
4870469	1006780121	PSORIASIS
4870482	1006780184	LUNG NEOPLASM MALIGNANT
4870482	1006780185	LUNG NEOPLASM MALIGNANT
4870483	1006780186	NON-SMALL CELL LUNG CANCER
4870483	1006780187	INTERSTITIAL LUNG DISEASE
4870484	1006780188	RHEUMATOID ARTHRITIS
4870484	1006780189	RHEUMATOID ARTHRITIS
4870484	1006780190	RHEUMATOID ARTHRITIS
4870486	1006780197	POLYARTHRITIS
4870486	1006780198	ATRIAL FIBRILLATION
4870486	1006780200	RHEUMATOID ARTHRITIS
4870529	1006780356	CEREBRAL HAEMORRHAGE
4870529	1006780357	HYPERTENSION
4870529	1006780358	HYPOKALAEMIA
4870529	1006780359	HYPERTENSION
4870529	1006780360	PROPHYLAXIS
4870529	1006780361	HYPERTENSION
4870529	1006780362	HYPERLIPIDAEMIA
4870529	1006780363	DIABETES MELLITUS
4870529	1006780364	DIURETIC THERAPY

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870529	1006780365	INFLAMMATION
4870529	1006780366	HYPERTENSION
4870529	1006780367	PYREXIA
4870529	1006780368	PROPHYLAXIS
4870529	1006780369	PROPHYLAXIS
4870529	1006780371	HYPERTENSION
4870529	1006780372	ANALGESIC EFFECT
4870529	1006780373	GASTRIC ULCER
4870529	1006780374	PROPHYLAXIS
4870529	1006780375	PROPHYLAXIS
4870529	1006780376	ANXIETY DISORDER
4870529	1006780377	DIABETES MELLITUS
4870529	1006780378	IMPAIRED GASTRIC EMPTYING
4870529	1006780379	INFECTION
4870529	1006780380	INFECTION
4870534	1006780399	DRUG USE FOR UNKNOWN INDICATION
4870535	1006780400	HYPERTENSION
4870535	1006780401	HYPERTENSION
4870535	1006780402	HYPERTENSION
4870535	1006780403	DIABETES MELLITUS NON-INSULIN-DEPENDENT
4870535	1006780404	DIABETES MELLITUS NON-INSULIN-DEPENDENT
4870535	1006780405	HYPERLIPIDAEMIA
4870550	1006780462	ATRIAL FIBRILLATION
4870550	1006780465	ANALGESIC EFFECT
4870552	1006780479	PHARYNGITIS
4870553	1006780482	ARTHRALGIA
4870553	1006780485	DIABETES MELLITUS
4870553	1006780486	HYPERURICAEMIA

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870553	1006780487	DIABETES MELLITUS
4870553	1006780488	TINEA INFECTION
4870553	1006780489	HYPERKERATOSIS
4870566	1006780533	HYPERTENSION
4870567	1006780536	HYPERTENSION
4870567	1006780538	HYPERTENSION
4870567	1006780539	INSOMNIA
4870568	1006780549	ESSENTIAL HYPERTENSION
4870568	1006780550	ESSENTIAL HYPERTENSION
4870568	1006780551	ATRIAL FIBRILLATION
4870568	1006780552	ATRIAL FLUTTER
4870569	1006780553	OEDEMA PERIPHERAL
4870569	1006780554	OEDEMA PERIPHERAL
4870570	1006780555	RHEUMATOID ARTHRITIS
4870571	1006780556	POLYURIA
4870571	1006780557	POLYDIPSIA
4870572	1006780558	RHEUMATOID ARTHRITIS
4870572	1006780561	RHEUMATOID ARTHRITIS
4870572	1006780566	RHEUMATOID ARTHRITIS
4870572	1006780567	PROPHYLAXIS AGAINST GASTROINTESTINAL ULCER
4870572	1006780568	INTESTINAL FUNCTIONAL DISORDER
4870572	1006780569	PROPHYLAXIS AGAINST GASTROINTESTINAL ULCER
4870572	1006780570	ANAEMIA
4870572	1006780571	RHEUMATOID ARTHRITIS
4870572	1006780572	BRONCHIECTASIS
4870572	1006780573	OSTEOPOROSIS
4870572	1006780574	INSOMNIA
4870572	1006780575	PARAESTHESIA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870572	1006780576	PARAESTHESIA
4870572	1006780578	DIABETES MELLITUS
4870574	1006780586	CLOSTRIDIAL INFECTION
4870577	1006780599	TONSILLITIS
4870577	1006780601	TONSILLITIS
4870579	1006780607	PERITONITIS
4870579	1006780608	GENERAL ANAESTHESIA
4870579	1006780609	GENERAL ANAESTHESIA
4870579	1006780610	GENERAL ANAESTHESIA
4870580	1006780611	PROSTATE CANCER
4870581	1006780613	NON-SMALL CELL LUNG CANCER
4870581	1006780614	NON-SMALL CELL LUNG CANCER
4870581	1006780615	NON-SMALL CELL LUNG CANCER
4870582	1006780620	BLADDER NEOPLASM
4870582	1006780621	BLADDER NEOPLASM
4870583	1006780631	DIABETES MELLITUS
4870583	1006780632	DIABETES MELLITUS
4870583	1006780634	MYOCARDIAL ISCHAEMIA
4870583	1006780635	BLOOD CHOLESTEROL INCREASED
4870583	1006780636	BLOOD PRESSURE INCREASED
4870583	1006780637	MYOCARDIAL ISCHAEMIA
4870584	1006780638	DIABETES MELLITUS
4870584	1006780639	DIABETES MELLITUS
4870584	1006780641	MYOCARDIAL ISCHAEMIA
4870584	1006780642	BLOOD CHOLESTEROL INCREASED
4870584	1006780643	MYOCARDIAL ISCHAEMIA
4870584	1006780644	BLOOD PRESSURE INCREASED
4870586	1006780648	HIV INFECTION

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870586	1006780649	HIV INFECTION
4870586	1006780650	HIV INFECTION
4870587	1006780651	SCHIZOPHRENIA
4870589	1006780657	DIABETES MELLITUS
4870591	1006780666	TESTICULAR MASS
4870591	1006780667	TESTICULAR MASS
4870591	1006780668	TESTICULAR MASS
4870591	1006780669	TESTICULAR MASS
4870591	1006780670	TESTICULAR MASS
4870591	1006780671	TESTICULAR MASS
4870591	1006780672	TESTICULAR MASS
4870591	1006780673	TESTICULAR MASS
4870591	1006780674	TESTICULAR MASS
4870591	1006780675	TESTICULAR MASS
4870592	1006780677	UTERINE CANCER
4870592	1006780678	UTERINE CANCER
4870593	1006780687	BLOOD IRON INCREASED
4870594	1006780689	HAEMORRHAGE
4870604	1006780724	TRAUMATIC HAEMORRHAGE
4870618	1006780754	MYOCARDIAL INFARCTION
4870623	1006780773	SUICIDE ATTEMPT
4870623	1006780774	EPILEPSY
4870624	1006780776	DRUG USE FOR UNKNOWN INDICATION
4870659	1006780918	NAUSEA
4870659	1006780919	GASTROINTESTINAL DISORDER
4870659	1006780921	GOUT
4870659	1006780922	PROPHYLAXIS
4870659	1006780923	MEMORY IMPAIRMENT

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870659	1006780925	PAIN
4870659	1006780927	SLEEP DISORDER THERAPY
4870659	1006780932	CONSTIPATION
4870659	1006780933	CONSTIPATION
4870661	1006780941	PAIN MANAGEMENT
4870661	1006780942	DRUG USE FOR UNKNOWN INDICATION
4870661	1006780943	DRUG USE FOR UNKNOWN INDICATION
4870661	1006780944	DRUG USE FOR UNKNOWN INDICATION
4870661	1006780945	DRUG USE FOR UNKNOWN INDICATION
4870661	1006780948	DRUG USE FOR UNKNOWN INDICATION
4870661	1006780949	DRUG USE FOR UNKNOWN INDICATION
4870661	1006780950	DRUG USE FOR UNKNOWN INDICATION
4870662	1006780951	MULTIPLE SCLEROSIS
4870663	1006780954	HYPOTHYROIDISM
4870663	1006780955	ANXIETY
4870663	1006780956	HYPERTENSION
4870663	1006780957	FLUID RETENTION
4870663	1006780959	ANGINA PECTORIS
4870663	1006780960	ANXIETY
4870663	1006780965	NAUSEA
4870667	1006780972	ANXIETY
4870668	1006780973	DEMENTIA ALZHEIMER'S TYPE
4870668	1006780974	HYPERTENSION
4870668	1006780976	AFFECTIVE DISORDER
4870668	1006780977	VITAMIN B12 DEFICIENCY
4870669	1006780982	MEMORY IMPAIRMENT
4870669	1006780983	OSTEOPOROSIS
4870671	1006780985	ORAL INFECTION

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870671	1006780986	DRUG USE FOR UNKNOWN INDICATION
4870672	1006780987	DRUG USE FOR UNKNOWN INDICATION
4870673	1006780988	NAIL TINEA
4870674	1006780989	CEREBRAL HAEMORRHAGE
4870684	1006781027	CHRONIC OBSTRUCTIVE PULMONARY DISEASE
4870685	1006781029	HYPERTENSION
4870686	1006781035	BIPOLAR DISORDER
4870689	1006781039	DEPRESSION
4870690	1006781040	ASTHMA
4870691	1006781043	ASTHMA
4870691	1006781044	ASTHMA
4870692	1006781046	HERPES ZOSTER
4870692	1006781047	GASTRIC ULCER
4870692	1006781048	NUTRITIONAL SUPPORT
4870692	1006781049	NUTRITIONAL SUPPORT
4870692	1006781050	NUTRITIONAL SUPPORT
4870692	1006781051	NUTRITIONAL SUPPORT
4870692	1006781052	NUTRITIONAL SUPPORT
4870692	1006781053	PNEUMONIA
4870692	1006781054	PNEUMONIA
4870692	1006781055	DISSEMINATED INTRAVASCULAR COAGULATION
4870692	1006781056	CARDIAC FAILURE
4870692	1006781057	CARDIAC FAILURE
4870692	1006781058	CHEMOTHERAPY
4870692	1006781059	CHEMOTHERAPY
4870692	1006781060	CHEMOTHERAPY
4870692	1006781061	CHEMOTHERAPY
4870693	1006781062	HERPES ZOSTER

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870693	1006781063	HERPES ZOSTER
4870694	1006781064	ALLOGENIC BONE MARROW TRANSPLANTATION THERAPY
4870694	1006781067	IMMUNOSUPPRESSANT DRUG THERAPY
4870694	1006781068	IMMUNOSUPPRESSANT DRUG THERAPY
4870694	1006781069	IMMUNOSUPPRESSANT DRUG THERAPY
4870695	1006781078	HEPATIC CIRRHOSIS
4870696	1006781090	EAR INFECTION
4870697	1006781095	DEPRESSION
4870698	1006781096	HEPATITIS B
4870698	1006781099	HEPATITIS B
4870698	1006781104	ASCITES
4870698	1006781105	ASCITES
4870700	1006781113	NEOPLASM PROPHYLAXIS
4870702	1006781119	DRUG RESISTANCE
4870703	1006781122	PAIN
4870704	1006781124	ANTIVIRAL PROPHYLAXIS
4870704	1006781125	ANTIVIRAL PROPHYLAXIS
4870705	1006781128	PARKINSON'S DISEASE
4870706	1006781129	HIV INFECTION
4870706	1006781130	HIV INFECTION
4870706	1006781131	HIV INFECTION
4870706	1006781132	HIV INFECTION
4870707	1006781133	PANCREATITIS
4870710	1006781144	HEPATIC CIRRHOSIS
4870710	1006781145	HEPATIC CIRRHOSIS
4870712	1006781153	DEPRESSION
4870714	1006781156	HIV INFECTION
4870714	1006781157	HIV INFECTION

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870714	1006781158	HIV INFECTION
4870715	1006781159	HIV INFECTION
4870715	1006781160	HIV INFECTION
4870715	1006781161	HIV INFECTION
4870716	1006781165	HIV INFECTION
4870716	1006781166	HIV INFECTION
4870716	1006781167	HIV INFECTION
4870716	1006781168	HIV INFECTION
4870717	1006781176	SLEEP DISORDER
4870719	1006781178	ASTHMA
4870721	1006781181	HIV INFECTION
4870721	1006781182	HIV INFECTION
4870722	1006781183	HIV INFECTION
4870722	1006781184	HIV INFECTION
4870723	1006781185	INFECTION
4870723	1006781185	PACEMAKER COMPLICATION
4870723	1006781186	ENDOCARDITIS
4870723	1006781187	INFECTION
4870723	1006781187	PACEMAKER COMPLICATION
4870723	1006781188	ENDOCARDITIS
4870723	1006781190	INFECTION
4870723	1006781190	PACEMAKER COMPLICATION
4870723	1006781191	ENDOCARDITIS
4870724	1006781192	GASTROENTERITIS
4870724	1006781193	GASTROENTERITIS
4870724	1006781194	GASTROENTERITIS
4870724	1006781195	GASTROENTERITIS
4870724	1006781196	GASTROENTERITIS

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870724	1006781197	GASTROENTERITIS
4870724	1006781198	INFLUENZA
4870724	1006781202	CERVICAL ROOT PAIN
4870724	1006781203	CERVICAL ROOT PAIN
4870724	1006781204	GASTROENTERITIS
4870725	1006781206	SINUSITIS
4870725	1006781207	SINUSITIS
4870732	1006781242	DRUG USE FOR UNKNOWN INDICATION
4870733	1006781245	PSYCHOTIC DISORDER
4870733	1006781246	DIABETES MELLITUS
4870733	1006781247	HYPERTENSION
4870733	1006781248	HYPERTENSION
4870733	1006781249	CEREBRAL INFARCTION
4870733	1006781250	CEREBRAL INFARCTION
4870735	1006781252	DRUG USE FOR UNKNOWN INDICATION
4870736	1006781254	SCHIZOPHRENIA
4870736	1006781255	SCHIZOPHRENIA
4870737	1006781256	DRUG USE FOR UNKNOWN INDICATION
4870737	1006781257	DRUG USE FOR UNKNOWN INDICATION
4870738	1006781259	SCHIZOPHRENIA
4870738	1006781260	SCHIZOPHRENIA
4870738	1006781262	SCHIZOPHRENIA
4870738	1006781263	SCHIZOPHRENIA
4870738	1006781264	SCHIZOPHRENIA
4870738	1006781265	SCHIZOPHRENIA
4870738	1006781266	SCHIZOPHRENIA
4870738	1006781267	SCHIZOPHRENIA
4870739	1006781268	DRUG USE FOR UNKNOWN INDICATION

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870739	1006781270	DRUG USE FOR UNKNOWN INDICATION
4870741	1006781283	DRUG USE FOR UNKNOWN INDICATION
4870753	1006781310	DRUG USE FOR UNKNOWN INDICATION
4870754	1006781311	HEPATITIS C
4870756	1006781344	BREAST CANCER
4870763	1006781377	ARTHRITIS
4870764	1006781378	OSTEOARTHRITIS
4870764	1006781379	ARTHRALGIA
4870765	1006781383	ARTHRALGIA
4870765	1006781387	GASTROOESOPHAGEAL REFLUX DISEASE
4870766	1006781396	ARTHRITIS
4870766	1006781397	HYPOTHYROIDISM
4870766	1006781398	HYPERTENSION
4870766	1006781399	HYPERTENSION
4870766	1006781400	DIABETES MELLITUS NON-INSULIN-DEPENDENT
4870767	1006781401	ARTHRITIS
4870767	1006781403	HYPERTENSION
4870767	1006781404	OEDEMA PERIPHERAL
4870767	1006781408	ARTHRALGIA
4870767	1006781410	LETHARGY
4870767	1006781411	VITAMIN SUPPLEMENTATION
4870767	1006781413	FEELING OF RELAXATION
4870767	1006781414	DYSPEPSIA
4870767	1006781415	GASTROOESOPHAGEAL REFLUX DISEASE
4870768	1006781416	ARTHRITIS
4870769	1006781418	OSTEOARTHRITIS
4870770	1006781425	ROTATOR CUFF SYNDROME
4870770	1006781426	OSTEOARTHRITIS

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870771	1006781431	ARTHRALGIA
4870772	1006781440	RHEUMATOID ARTHRITIS
4870773	1006781442	PAIN
4870774	1006781443	BACK PAIN
4870774	1006781444	ANXIETY DISORDER
4870775	1006781447	ARTHRITIS
4870776	1006781448	PAIN
4870777	1006781451	BACK PAIN
4870778	1006781458	BREAST CANCER
4870778	1006781459	BREAST CANCER
4870779	1006781461	MONARTHRITIS
4870779	1006781463	LIMB DISCOMFORT
4870780	1006781474	INTERVERTEBRAL DISC DEGENERATION
4870780	1006781477	OSTEOARTHRITIS
4870781	1006781507	ARTHRITIS
4870782	1006781521	PAIN
4870783	1006781522	ARTHRALGIA
4870784	1006781530	GOUT
4870784	1006781531	BIPOLAR DISORDER
4870784	1006781533	BIPOLAR DISORDER
4870785	1006781538	ARTHRITIS
4870785	1006781542	DIZZINESS
4870785	1006781547	HYPERLIPIDAEMIA
4870786	1006781548	OSTEOARTHRITIS
4870786	1006781549	MUSCULOSKELETAL PAIN
4870786	1006781550	HYPERTENSION
4870786	1006781551	BLOOD CHOLESTEROL
4870786	1006781552	BLOOD CHOLESTEROL

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870786	1006781553	BENIGN PROSTATIC HYPERPLASIA
4870786	1006781557	HYPERTENSION
4870786	1006781558	CARDIAC DISORDER
4870787	1006781559	FIBROMYALGIA
4870788	1006781565	ARTHRITIS
4870789	1006781574	RHEUMATOID ARTHRITIS
4870789	1006781576	ARTHRITIS
4870790	1006781582	PAIN
4870790	1006781583	PAIN
4870791	1006781584	SPINAL OSTEOARTHRITIS
4870791	1006781585	BACK PAIN
4870791	1006781590	BLOOD CHOLESTEROL INCREASED
4870792	1006781593	NEURALGIA
4870792	1006781595	PAIN
4870793	1006781600	PAIN IN EXTREMITY
4870794	1006781609	PERIARTHRITIS
4870795	1006781617	OSTEOARTHRITIS
4870796	1006781644	ARTHRITIS
4870797	1006781648	PREMATURE LABOUR
4870797	1006781649	ASTHMA
4870797	1006781650	DYSPEPSIA
4870797	1006781651	PREMATURE LABOUR
4870799	1006781664	SPONDYLITIS
4870800	1006781666	HYPERTENSION
4870800	1006781668	DIABETES MELLITUS INSULIN-DEPENDENT
4870801	1006781669	ARTHRALGIA
4870802	1006781670	NON-SMALL CELL LUNG CANCER
4870802	1006781671	NON-SMALL CELL LUNG CANCER

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870803	1006781675	SCHIZOPHRENIA
4870803	1006781676	ANXIETY
4870803	1006781677	ANXIETY
4870805	1006781679	NEPHROBLASTOMA
4870805	1006781680	NEPHROBLASTOMA
4870806	1006781683	DRUG USE FOR UNKNOWN INDICATION
4870807	1006781684	BLADDER CANCER RECURRENT
4870808	1006781698	DIABETES MELLITUS
4870808	1006781699	DIABETES MELLITUS
4870809	1006781700	ACNE
4870810	1006781701	BREAST CANCER
4870810	1006781702	BREAST CANCER
4870810	1006781705	PREMEDICATION
4870810	1006781706	PREMEDICATION
4870810	1006781707	PREMEDICATION
4870811	1006781708	SCHIZOPHRENIA
4870813	1006781710	SHOULDER PAIN
4870814	1006781711	NON-SMALL CELL LUNG CANCER
4870814	1006781712	NON-SMALL CELL LUNG CANCER
4870814	1006781713	NON-SMALL CELL LUNG CANCER
4870817	1006781716	ARTHRITIS
4870817	1006781717	ARTHRITIS
4870817	1006781718	ARTHRITIS
4870817	1006781719	ARTHRITIS
4870817	1006781720	UPPER RESPIRATORY TRACT INFECTION
4870818	1006781721	OSTEOARTHRITIS
4870819	1006781727	ARTHRITIS
4870821	1006781771	NECK PAIN

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870823	1006781775	INTERVERTEBRAL DISC PROTRUSION
4870824	1006781779	OSTEOPOROSIS
4870825	1006781783	RHEUMATOID ARTHRITIS
4870827	1006781785	MIGRAINE
4870827	1006781786	MIGRAINE
4870828	1006781788	ARTHRITIS
4870828	1006781789	BLOOD CHOLESTEROL INCREASED
4870828	1006781790	HYPERTENSION
4870828	1006781791	HYPERTENSION
4870828	1006781792	PROPHYLAXIS
4870829	1006781794	ARTHRALGIA
4870829	1006781795	BACK PAIN
4870830	1006781796	OSTEOARTHRITIS
4870831	1006781806	PAIN
4870832	1006781809	BACK PAIN
4870832	1006781810	ARTHRITIS
4870834	1006781814	BACK PAIN
4870835	1006781822	ARTHRALGIA
4870836	1006781835	ARTHRITIS
4870837	1006781837	VASCULITIS
4870838	1006781839	SHOULDER PAIN
4870839	1006781840	ARTHRITIS
4870840	1006781841	ARTHRITIS
4870842	1006781845	ARTHRITIS
4870846	1006781849	ARTHROPATHY
4870847	1006781850	ARTHRALGIA
4870849	1006781858	OSTEOARTHRITIS
4870849	1006781859	COSTOCHONDRITIS

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870853	1006781867	ARTHRITIS
4870853	1006781869	ARTHRITIS
4870853	1006781870	BLOOD PRESSURE
4870855	1006781873	ARTHRITIS
4870855	1006781874	LIMB INJURY
4870858	1006781877	MUSCLE STRAIN
4870862	1006781885	ARTHRITIS
4870865	1006781903	CARPAL TUNNEL SYNDROME
4870865	1006781904	ARTHRITIS
4870865	1006781905	HORMONE REPLACEMENT THERAPY
4870867	1006781908	ARTHRALGIA
4870868	1006781911	CARPAL TUNNEL SYNDROME
4870868	1006781912	ROTATOR CUFF SYNDROME
4870869	1006781914	ARTHRITIS
4870870	1006781916	ARTHRITIS
4870872	1006781921	ARTHRITIS
4870873	1006781930	ROTATOR CUFF SYNDROME
4870873	1006781933	TENDONITIS
4870873	1006781936	INSOMNIA
4870873	1006781937	ALLERGIC SINUSITIS
4870873	1006781938	WHEEZING
4870873	1006781939	MENOPAUSE
4870873	1006781940	DEPRESSION
4870873	1006781944	DEPRESSION
4870874	1006781946	ARTHRITIS
4870875	1006781948	BACK PAIN
4870878	1006781952	RHEUMATOID ARTHRITIS
4870879	1006781960	DRUG USE FOR UNKNOWN INDICATION

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870886	1006781988	GASTROINTESTINAL CANCER METASTATIC
4870886	1006781989	OESOPHAGEAL ADENOCARCINOMA STAGE IV
4870888	1006782014	LOSS OF CONSCIOUSNESS
4870891	1006782034	COLON CANCER
4870892	1006782037	ELECTROCARDIOGRAM ST SEGMENT ELEVATION
4870892	1006782040	ANGINA PECTORIS
4870892	1006782041	HYPERTENSION
4870892	1006782043	HYPERTENSION
4870892	1006782046	POLYURIA
4870892	1006782047	DIABETES MELLITUS
4870892	1006782049	AZOTAEMIA
4870892	1006782051	ANGINA PECTORIS
4870892	1006782052	INFECTION PROPHYLAXIS
4870892	1006782053	RESTLESSNESS
4870892	1006782055	HYPERTENSION
4870892	1006782059	THROMBOSIS
4870892	1006782060	ANAEMIA
4870892	1006782062	CONSTIPATION
4870892	1006782064	CONSTIPATION
4870892	1006782065	HYPERLIPIDAEMIA
4870892	1006782066	PROPHYLAXIS
4870892	1006782067	POLYURIA
4870892	1006782070	CONSTIPATION
4870892	1006782071	THROMBOSIS PROPHYLAXIS
4870892	1006782085	GASTROINTESTINAL DISORDER
4870892	1006782087	ANGINA PECTORIS
4870892	1006782104	ANAEMIA
4870892	1006782108	INFECTION PROPHYLAXIS

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870892	1006782109	ANAEMIA
4870892	1006782111	INFECTION PROPHYLAXIS
4870892	1006782112	CARDIAC FAILURE
4870892	1006782115	INFECTION PROPHYLAXIS
4870892	1006782117	CARDIAC FAILURE
4870892	1006782118	SEDATIVE THERAPY
4870892	1006782130	COAGULATION TIME
4870892	1006782133	ANGINA PECTORIS
4870892	1006782135	GASTROINTESTINAL DISORDER
4870892	1006782136	ACIDOSIS
4870892	1006782138	INFECTION
4870892	1006782140	RESTLESSNESS
4870892	1006782141	RESTLESSNESS
4870892	1006782142	SLEEP DISORDER
4870894	1006782147	DRUG USE FOR UNKNOWN INDICATION
4870898	1006782159	JESSNER'S LYMPHOCYTIC INFILTRATION
4870900	1006782163	RHEUMATOID ARTHRITIS
4870900	1006782164	DRUG USE FOR UNKNOWN INDICATION
4870902	1006782168	BENIGN PROSTATIC HYPERPLASIA
4870903	1006782169	BREAST CANCER
4870903	1006782170	BREAST CANCER
4870903	1006782171	BREAST CANCER
4870903	1006782172	ERYTHROPENIA
4870903	1006782173	BREAST CANCER
4870903	1006782174	DEPRESSION
4870903	1006782175	DIABETES MELLITUS
4870903	1006782176	DEPRESSION
4870903	1006782178	PREMEDICATION

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4870903	1006782179	PREMEDICATION
4870903	1006782180	PREMEDICATION
4870904	1006782183	COLORECTAL CANCER
4870917	1006782244	HIV INFECTION
4870917	1006782245	HIV INFECTION
4870917	1006782246	HIV INFECTION
4870922	1006782268	DRUG USE FOR UNKNOWN INDICATION
4870922	1006782269	DRUG USE FOR UNKNOWN INDICATION
4870922	1006782270	DRUG USE FOR UNKNOWN INDICATION
4870923	1006782277	GASTROINTESTINAL HAEMORRHAGE
4870976	1006782436	ADENOCARCINOMA PANCREAS
4870976	1006782437	ADENOCARCINOMA PANCREAS
4870976	1006782438	ADENOCARCINOMA PANCREAS
4870976	1006782439	ADENOCARCINOMA PANCREAS
4870976	1006782440	PANCREATIC ENZYMES
4870976	1006782441	NAUSEA
4870976	1006782445	DIARRHOEA
4870976	1006782446	NAUSEA
4870977	1006782447	HIV INFECTION
4870977	1006782448	FUNGAL INFECTION
4870977	1006782449	HIV INFECTION
4870977	1006782450	HIV INFECTION
4870977	1006782451	HIV INFECTION
4870979	1006782456	HYPERTHYROIDISM
4870994	1006782489	OVARIAN CANCER
4870994	1006782490	OVARIAN CANCER
4870994	1006782491	ANAEMIA
4871004	1006782514	DRUG USE FOR UNKNOWN INDICATION

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4871006	1006782517	NEUROPATHY
4871006	1006782518	DRUG USE FOR UNKNOWN INDICATION
4871006	1006782519	DRUG USE FOR UNKNOWN INDICATION
4871006	1006782520	PAIN
4871006	1006782521	DRUG USE FOR UNKNOWN INDICATION
4871016	1006782541	SCHIZOPHRENIA
4871017	1006782542	SCHIZOPHRENIA
4871018	1006782543	AGITATION
4871018	1006782544	DEMENTIA
4871018	1006782545	DEPRESSION
4871018	1006782546	BLOOD PRESSURE
4871018	1006782547	ANTICOAGULANT THERAPY
4871018	1006782548	INSOMNIA
4871019	1006782550	ANXIETY
4871040	1006782573	HIV INFECTION
4871040	1006782574	HIV INFECTION
4871057	1006782593	HYPERTENSION
4871057	1006782594	HYPERTENSION
4871057	1006782595	PROPHYLAXIS
4871074	1006782619	DIABETES MELLITUS
4871074	1006782621	DIABETES MELLITUS
4871074	1006782622	DIABETES MELLITUS
4871086	1006782646	DYSLIPIDAEMIA
4871086	1006782648	DRUG USE FOR UNKNOWN INDICATION
4871086	1006782649	DRUG USE FOR UNKNOWN INDICATION
4871086	1006782650	DRUG USE FOR UNKNOWN INDICATION
4871086	1006782651	DRUG USE FOR UNKNOWN INDICATION
4871087	1006782652	DYSLIPIDAEMIA

ADVERSE EVENT REPORTING SYSTEM (AERS)**Indication Listings**

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4871087	1006782653	DRUG USE FOR UNKNOWN INDICATION
4871087	1006782654	DRUG USE FOR UNKNOWN INDICATION
4871087	1006782655	DRUG USE FOR UNKNOWN INDICATION
4871087	1006782656	DRUG USE FOR UNKNOWN INDICATION
4871087	1006782657	DRUG USE FOR UNKNOWN INDICATION
4871087	1006782658	DRUG USE FOR UNKNOWN INDICATION
4871088	1006782660	DYSLIPIDAEMIA
4871088	1006782661	DRUG USE FOR UNKNOWN INDICATION
4871088	1006782662	DRUG USE FOR UNKNOWN INDICATION
4871088	1006782663	DRUG USE FOR UNKNOWN INDICATION
4871088	1006782664	DRUG USE FOR UNKNOWN INDICATION
4871089	1006782665	DYSLIPIDAEMIA
4871089	1006782666	DRUG USE FOR UNKNOWN INDICATION
4871089	1006782667	DRUG USE FOR UNKNOWN INDICATION
4871089	1006782668	DRUG USE FOR UNKNOWN INDICATION
4871089	1006782669	DRUG USE FOR UNKNOWN INDICATION
4871089	1006782670	DRUG USE FOR UNKNOWN INDICATION
4871089	1006782672	DRUG USE FOR UNKNOWN INDICATION
4871089	1006782673	DRUG USE FOR UNKNOWN INDICATION
4871089	1006782674	DRUG USE FOR UNKNOWN INDICATION
4871089	1006782675	DRUG USE FOR UNKNOWN INDICATION
4871089	1006782676	DRUG USE FOR UNKNOWN INDICATION
4871089	1006782677	DRUG USE FOR UNKNOWN INDICATION
4871089	1006782678	DRUG USE FOR UNKNOWN INDICATION
4871089	1006782680	DRUG USE FOR UNKNOWN INDICATION
4871089	1006782681	DRUG USE FOR UNKNOWN INDICATION
4871101	1006782699	DYSLIPIDAEMIA
4871101	1006782700	DRUG USE FOR UNKNOWN INDICATION

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4871101	1006782701	DRUG USE FOR UNKNOWN INDICATION
4871101	1006782702	DRUG USE FOR UNKNOWN INDICATION
4871102	1006782703	DYSLIPIDAEMIA
4871103	1006782704	HYPERLIPIDAEMIA
4871103	1006782705	DRUG USE FOR UNKNOWN INDICATION
4871103	1006782706	DRUG USE FOR UNKNOWN INDICATION
4871103	1006782707	DRUG USE FOR UNKNOWN INDICATION
4871103	1006782708	DRUG USE FOR UNKNOWN INDICATION
4871105	1006782710	DYSLIPIDAEMIA
4871105	1006782711	DRUG USE FOR UNKNOWN INDICATION
4871105	1006782712	DRUG USE FOR UNKNOWN INDICATION
4871105	1006782713	DRUG USE FOR UNKNOWN INDICATION
4871105	1006782714	DRUG USE FOR UNKNOWN INDICATION
4871105	1006782715	DRUG USE FOR UNKNOWN INDICATION
4871105	1006782717	DRUG USE FOR UNKNOWN INDICATION
4871106	1006782718	CONSTIPATION
4871106	1006782719	BLOOD CHOLESTEROL INCREASED
4871106	1006782721	SINUS DISORDER
4871127	1006782755	THROMBOSIS PROPHYLAXIS
4871127	1006782757	EMPHYSEMA
4871127	1006782758	EMPHYSEMA
4871127	1006782759	INSOMNIA
4871127	1006782760	EMPHYSEMA
4871127	1006782761	DIABETES MELLITUS
4871127	1006782762	EMPHYSEMA
4871134	1006782772	DIABETES MELLITUS
4871134	1006782775	DIABETES MELLITUS
4871141	1006782789	DIABETES MELLITUS

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Report's unique number</i>	<i>Number for identifying drug from ISR</i>	<i>Preferred term to describe the event</i>
4871141	1006782790	ILL-DEFINED DISORDER
4871146	1006782801	DIABETES MELLITUS
4871160	1006782819	DIABETES MELLITUS
4871160	1006782820	DIABETES MELLITUS
4871180	1006782857	OPERATIVE HAEMORRHAGE
4871210	1006782896	DYSLIPIDAEMIA
4871210	1006782897	DRUG USE FOR UNKNOWN INDICATION
4871210	1006782898	DRUG USE FOR UNKNOWN INDICATION
4871210	1006782899	DRUG USE FOR UNKNOWN INDICATION
4871210	1006782900	DRUG USE FOR UNKNOWN INDICATION
4871210	1006782901	DRUG USE FOR UNKNOWN INDICATION
4871210	1006782902	DRUG USE FOR UNKNOWN INDICATION
4871210	1006782903	DRUG USE FOR UNKNOWN INDICATION
4871211	1006782904	HYPERLIPIDAEMIA
4871211	1006782905	DRUG USE FOR UNKNOWN INDICATION
4871211	1006782906	DRUG USE FOR UNKNOWN INDICATION
4871212	1006782907	HYPERLIPIDAEMIA
4871212	1006782909	DRUG USE FOR UNKNOWN INDICATION
4871212	1006782910	DRUG USE FOR UNKNOWN INDICATION
4871212	1006782911	DRUG USE FOR UNKNOWN INDICATION

Summary Tables

The Summary Tables section presents aggregated safety data to support pharmacovigilance signal detection and risk evaluation. These tables include analyses of adverse events by System Organ Class (SOC) and Preferred Term (PT), drug-event frequencies, patient outcomes (e.g., death, hospitalization), and demographic trends (e.g., gender, age groups).

The data are summarized to provide a high-level overview of potential safety concerns and reporting patterns across the database.

Demographic Summary Table Derived Age Group

		<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
Gender	Female	3128 (52.91)	10127 (59.37)	15944 (52.71)	4464 (57.56)	33663 (55.21)
	Male	2616 (44.25)	6716 (39.37)	14022 (46.35)	3223 (41.56)	26577 (43.59)
	Missing	146 (2.47)	179 (1.05)	239 (0.79)	60 (0.77)	624 (1.02)
	Not Specified	3 (0.05)	9 (0.05)	4 (0.01)	1 (0.01)	17 (0.03)
	Unknown	19 (0.32)	27 (0.16)	42 (0.14)	7 (0.09)	95 (0.16)
Report Code	Direct	383 (6.48)	1044 (6.12)	1698 (5.61)	572 (7.38)	3697 (6.06)
	Expedited	4286 (72.50)	11553 (67.73)	22426 (74.13)	5751 (74.16)	44016 (72.19)
	Periodic	1243 (21.03)	4461 (26.15)	6127 (20.25)	1432 (18.47)	13263 (21.75)
Occupation Code	Consumer	1495 (25.29)	4776 (28.00)	6116 (20.22)	1553 (20.03)	13940 (22.86)
	Lawyer	287 (4.85)	1557 (9.13)	3619 (11.96)	551 (7.11)	6014 (9.86)
	Physician	1958 (33.12)	5071 (29.73)	10420 (34.45)	2519 (32.48)	19968 (32.75)
	Missing	1013 (17.13)	2569 (15.06)	4848 (16.03)	1457 (18.79)	9887 (16.21)
	Other Health Professional	846 (14.31)	2226 (13.05)	3588 (11.86)	1040 (13.41)	7700 (12.63)
	Pharmacist	313 (5.29)	859 (5.04)	1660 (5.49)	635 (8.19)	3467 (5.69)
Age (Years)	Number	5912	17058	30251	7755	60976
	Mean	14.86	40.62	62.37	81.47	54.11
	Median	17.00	42.00	62.00	80.00	56.00
	Geometric Mean	14.86	40.62	62.37	81.47	54.11
	Minimum	0.00	26.00	51.00	76.00	0.00
	Maximum	25.00	50.00	75.00	108.0	108.0
	Standard Deviation	7.71	6.97	7.04	4.66	19.39
	Range	0-25	26-50	51-75	76-108	0-108
Weight (Kilograms)	Number	2366	7638	15651	3368	29023

Demographic Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
Mean	52.45	81.79	82.70	70.06	78.53
Median	54.00	79.00	80.00	69.00	77.00
Geometric Mean	52.45	81.79	82.70	70.06	78.53
Minimum	0.00	0.00	0.00	0.00	0.00
Maximum	771.0	267.0	876.0	183.0	876.0
Standard Deviation	34.43	25.36	24.33	17.62	26.40
Range	0-771	0-267	0-876	0-183	0-876

Drug Summary Table Derived Age Group

		<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
Drug Role	Primary Suspect Drug	3349 (56.65)	8573 (50.26)	13041 (43.11)	3122 (40.26)	28085 (46.06)
	Secondary Suspect Drug	75 (1.27)	159 (0.93)	317 (1.05)	90 (1.16)	641 (1.05)
	Concomitant	2465 (41.69)	8307 (48.70)	16871 (55.77)	4540 (58.54)	32183 (52.78)
	Interacting	23 (0.39)	19 (0.11)	22 (0.07)	3 (0.04)	67 (0.11)
Drug Name Source	Validated name used	4504 (76.18)	13647 (80.00)	23971 (79.24)	6090 (78.53)	48212 (79.07)
	Verbatim name used	1408 (23.82)	3411 (20.00)	6280 (20.76)	1665 (21.47)	12764 (20.93)
Dechallenge Code	Does Not Apply	988 (16.71)	2810 (16.47)	4332 (14.32)	999 (12.88)	9129 (14.97)
	Missing	4095 (69.27)	12545 (73.54)	23314 (77.07)	5929 (76.45)	45883 (75.25)
	Negative dechallenge	115 (1.95)	263 (1.54)	365 (1.21)	120 (1.55)	863 (1.42)
	Unknown	307 (5.19)	594 (3.48)	983 (3.25)	274 (3.53)	2158 (3.54)
	Positive dechallenge	407 (6.88)	846 (4.96)	1257 (4.16)	433 (5.58)	2943 (4.83)
Rechallenge Code	Does Not Apply	1431 (24.21)	3754 (22.01)	5722 (18.92)	1450 (18.70)	12357 (20.27)
	Missing	4127 (69.81)	12669 (74.27)	23551 (77.85)	6019 (77.61)	46366 (76.04)
	Negative dechallenge	19 (0.32)	63 (0.37)	106 (0.35)	32 (0.41)	220 (0.36)
	Unknown	280 (4.74)	469 (2.75)	739 (2.44)	227 (2.93)	1715 (2.81)
	Positive dechallenge	55 (0.93)	103 (0.60)	133 (0.44)	27 (0.35)	318 (0.52)
Route	AURICULAR (OTIC)	1 (0.02)	4 (0.02)	2 (0.01)		7 (0.01)
	BUCCAL	1 (0.02)	12 (0.07)	13 (0.04)	1 (0.01)	27 (0.04)
	CUTANEOUS	1 (0.02)	10 (0.06)	1 (0.00)		12 (0.02)
	DENTAL		3 (0.02)	1 (0.00)	1 (0.01)	5 (0.01)
	ENDOTRACHEAL			2 (0.01)		2 (0.00)
	EPIDURAL	3 (0.05)	11 (0.06)	11 (0.04)	6 (0.08)	31 (0.05)
	INTRA CORPUS CAVERNOSU		1 (0.01)			1 (0.00)
	INTRA-ARTERIAL	4 (0.07)	3 (0.02)	10 (0.03)		17 (0.03)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
INTRA-ARTICULAR	1 (0.02)		1 (0.00)	3 (0.04)	5 (0.01)
INTRA-UTERINE	58 (0.98)	182 (1.07)	6 (0.02)	1 (0.01)	247 (0.41)
INTRACAVERNOUS		2 (0.01)	1 (0.00)		3 (0.00)
INTRACEREBRAL			1 (0.00)		1 (0.00)
INTRADERMAL	7 (0.12)	7 (0.04)	6 (0.02)		20 (0.03)
INTRADISCAL (INTRASPIN		2 (0.01)	1 (0.00)		3 (0.00)
INTRAMENINGEAL			1 (0.00)		1 (0.00)
INTRAMUSCULAR	90 (1.52)	617 (3.62)	691 (2.28)	36 (0.46)	1434 (2.35)
INTRAOCULAR		4 (0.02)	14 (0.05)	3 (0.04)	21 (0.03)
INTRAPERITONEAL		1 (0.01)	4 (0.01)		5 (0.01)
INTRAPLEURAL			1 (0.00)		1 (0.00)
INTRASYNOVIAL		1 (0.01)			1 (0.00)
INTRATHECAL	7 (0.12)	9 (0.05)	13 (0.04)		29 (0.05)
INTRATHORACIC			1 (0.00)		1 (0.00)
INTRATUMOR	1 (0.02)			1 (0.01)	2 (0.00)
INTRAVENOUS	235 (3.97)	627 (3.68)	1396 (4.61)	308 (3.97)	2566 (4.21)
INTRAVENOUS BOLUS	2 (0.03)	8 (0.05)	41 (0.14)	9 (0.12)	60 (0.10)
INTRAVENOUS DRIP	8 (0.14)	64 (0.38)	149 (0.49)	35 (0.45)	256 (0.42)
INTRAVESICAL		4 (0.02)	35 (0.12)	18 (0.23)	57 (0.09)
MISSING	2600 (43.98)	7368 (43.19)	13008 (43.00)	3785 (48.81)	26761 (43.89)
NASAL	11 (0.19)	44 (0.26)	28 (0.09)	7 (0.09)	90 (0.15)
OPHTHALMIC	3 (0.05)	22 (0.13)	32 (0.11)	22 (0.28)	79 (0.13)
ORAL	2060 (34.84)	5332 (31.26)	9459 (31.27)	2606 (33.60)	19457 (31.91)
OROPHARINGEAL	3 (0.05)	4 (0.02)	5 (0.02)	1 (0.01)	13 (0.02)
OTHER	9 (0.15)	18 (0.11)	24 (0.08)	12 (0.15)	63 (0.10)
PARENTERAL	8 (0.14)	6 (0.04)	18 (0.06)	4 (0.05)	36 (0.06)
PERIARTICULAR		1 (0.01)			1 (0.00)
PERINEURAL			3 (0.01)	3 (0.04)	6 (0.01)

Drug Summary Table

Derived Age Group

		Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
	RECTAL	8 (0.14)	6 (0.04)	9 (0.03)	4 (0.05)	27 (0.04)
	RESPIRATORY (INHALATIO	70 (1.18)	51 (0.30)	94 (0.31)	31 (0.40)	246 (0.40)
	RETROBULBAR		1 (0.01)			1 (0.00)
	SUBCONJUNCTIVAL		2 (0.01)	2 (0.01)		4 (0.01)
	SUBCUTANEOUS	132 (2.23)	553 (3.24)	869 (2.87)	120 (1.55)	1674 (2.75)
	SUBDERMAL		1 (0.01)	1 (0.00)		2 (0.00)
	SUBLINGUAL	10 (0.17)	8 (0.05)	4 (0.01)	2 (0.03)	24 (0.04)
	TOPICAL	57 (0.96)	60 (0.35)	49 (0.16)	10 (0.13)	176 (0.29)
	TRANSDERMAL	72 (1.22)	112 (0.66)	62 (0.20)	15 (0.19)	261 (0.43)
	TRANSMAMMARY	4 (0.07)				4 (0.01)
	TRANSPLACENTAL	62 (1.05)	3 (0.02)			65 (0.11)
	UNKNOWN	193 (3.26)	1555 (9.12)	4153 (13.73)	707 (9.12)	6608 (10.84)
	URETHRAL		1 (0.01)		1 (0.01)	2 (0.00)
	VAGINAL	191 (3.23)	338 (1.98)	29 (0.10)	3 (0.04)	561 (0.92)
Drugname	(HURICANE BENZOCAINE T			1 (0.00)		1 (0.00)
	(HURRICAIN) BENZOCAIN			1 (0.00)		1 (0.00)
	1 CONCOMITANT DRUG	2 (0.03)	2 (0.01)	3 (0.01)		7 (0.01)
	100% OXYGEN (OXYGEN)	1 (0.02)				1 (0.00)
	13 CIS-RETINOINC ACID			1 (0.00)		1 (0.00)
	2% LIDOCAINE (LIDOCAIN	1 (0.02)				1 (0.00)
	2MG CERCINE TABLETS		1 (0.01)			1 (0.00)
	3TC		2 (0.01)			2 (0.00)
	4 WAY FAST ACTING NASA			1 (0.00)		1 (0.00)
	49653			1 (0.00)		1 (0.00)
	5% DEXTROSE, 0.2% SODI	1 (0.02)				1 (0.00)
	5'FEC			1 (0.00)		1 (0.00)
	5-HTP		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
506U78		2 (0.01)			2 (0.00)
6-MP		2 (0.01)			2 (0.00)
6MP	1 (0.02)				1 (0.00)
70% NPH HUMAN INSULIN			1 (0.00)		1 (0.00)
A AND D ORIGINAL (LANO	1 (0.02)				1 (0.00)
A AND D ORIGINAL (LANO	1 (0.02)				1 (0.00)
ABACAVIR		6 (0.04)	3 (0.01)		9 (0.01)
ABATACEPT		3 (0.02)	2 (0.01)		5 (0.01)
ABCIXIMAB			1 (0.00)		1 (0.00)
ABELCET		1 (0.01)	2 (0.01)		3 (0.00)
ABILIFY	24 (0.41)	40 (0.23)	17 (0.06)	3 (0.04)	84 (0.14)
ABILIT			1 (0.00)		1 (0.00)
ABRAXANE (PACLITAXEL)			1 (0.00)		1 (0.00)
ACARBOSE			4 (0.01)	1 (0.01)	5 (0.01)
ACARBOSE (ACARBOSE)			1 (0.00)		1 (0.00)
ACARD			2 (0.01)		2 (0.00)
ACC 200			3 (0.01)		3 (0.00)
ACCOLATE		4 (0.02)	7 (0.02)	1 (0.01)	12 (0.02)
ACCUPAQUE (IOHEXOL)			1 (0.00)		1 (0.00)
ACCUPRIL		11 (0.06)	46 (0.15)	7 (0.09)	64 (0.10)
ACCUPRIN			1 (0.00)		1 (0.00)
ACCURETIC			1 (0.00)	1 (0.01)	2 (0.00)
ACUTANE	206 (3.48)	46 (0.27)	4 (0.01)		256 (0.42)
ACE INHIBITOR		1 (0.01)	5 (0.02)		6 (0.01)
ACE INHIBITOR NOS			4 (0.01)	1 (0.01)	5 (0.01)
ACEBUTOLOL			9 (0.03)		9 (0.01)
ACECLOFENAC (ACECLOFEN		1 (0.01)			1 (0.00)
ACECOL			3 (0.01)	7 (0.09)	10 (0.02)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ACECOL (TEMOCAPRIL HYD				1 (0.01)	1 (0.00)
ACEDICONE			2 (0.01)		2 (0.00)
ACEMETACIN	1 (0.02)				1 (0.00)
ACENOCOUMAROL			2 (0.01)		2 (0.00)
ACENOCOUMAROL				1 (0.01)	1 (0.00)
ACENOCOUMAROL (ACENOCO			1 (0.00)		1 (0.00)
ACENOCOUMAROL (ACENOCO			1 (0.00)		1 (0.00)
ACENOCOUMEROL			1 (0.00)		1 (0.00)
ACEON			1 (0.00)		1 (0.00)
ACERCOMP (HYDROCHLOROT			1 (0.00)		1 (0.00)
ACETADOTE	1 (0.02)	2 (0.01)			3 (0.00)
ACETAMINOPHEN	58 (0.98)	75 (0.44)	125 (0.41)	40 (0.52)	298 (0.49)
ACETAMINOPHEN -ESTRA			1 (0.00)		1 (0.00)
ACETAMINOPHEN (+) CODE			1 (0.00)		1 (0.00)
ACETAMINOPHEN + SALICY				1 (0.01)	1 (0.00)
ACETAMINOPHEN AND CODE		1 (0.01)	2 (0.01)	3 (0.04)	6 (0.01)
ACETAMINOPHEN AND CODE			2 (0.01)		2 (0.00)
ACETAMINOPHEN AND DIHY			1 (0.00)		1 (0.00)
ACETAMINOPHEN AND HYDR	5 (0.08)	33 (0.19)	14 (0.05)	4 (0.05)	56 (0.09)
ACETAMINOPHEN AND ORPH			1 (0.00)		1 (0.00)
ACETAMINOPHEN AND OXYC			3 (0.01)		3 (0.00)
ACETAMINOPHEN AND OXYC				1 (0.01)	1 (0.00)
ACETAMINOPHEN AND PROP		3 (0.02)		2 (0.03)	5 (0.01)
ACETAMINOPHEN AND PROP		1 (0.01)	3 (0.01)	1 (0.01)	5 (0.01)
ACETAMINOPHEN AND TRAM			1 (0.00)		1 (0.00)
ACETAMINOPHEN W/ CODEI		3 (0.02)	2 (0.01)	1 (0.01)	6 (0.01)
ACETAMINOPHEN W/ CODEI			1 (0.00)		1 (0.00)
ACETAMINOPHEN W/ CODEI	1 (0.02)				1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ACETAMINOPHEN W/ PROPO		1 (0.01)	3 (0.01)	1 (0.01)	5 (0.01)
ACETAMINOPHEN/CODEINE			1 (0.00)		1 (0.00)
ACETAZOLAMIDE	1 (0.02)		1 (0.00)		2 (0.00)
ACETOSAL (ACETYLSALICY			1 (0.00)		1 (0.00)
ACETYLCHOLINE CHLORIDE				2 (0.03)	2 (0.00)
ACETYLCYSTEINE	4 (0.07)	3 (0.02)	2 (0.01)	2 (0.03)	11 (0.02)
ACETYLSALICYLATE			2 (0.01)	2 (0.03)	4 (0.01)
ACETYLSALICYLATE LYSIN		1 (0.01)			1 (0.00)
ACETYLSALICYLATE LYSIN				1 (0.01)	1 (0.00)
ACETYLSALICYLIC ACID			3 (0.01)		3 (0.00)
ACETYLSALICYLIC ACID (1 (0.01)	1 (0.00)
ACETYLSALICYLIC ACID +			1 (0.00)		1 (0.00)
ACETYLSALICYLIC ACID S	1 (0.02)	6 (0.04)	43 (0.14)	29 (0.37)	79 (0.13)
ACETYLSALICYLIC ACID/		1 (0.01)			1 (0.00)
ACETYLSCYSTEINE				1 (0.01)	1 (0.00)
ACETYSALICYLIC ACID (A			1 (0.00)		1 (0.00)
ACFOL		1 (0.01)			1 (0.00)
ACHILLES TENDON MUSCUL			1 (0.00)		1 (0.00)
ACIDUM FOLICUM	2 (0.03)				2 (0.00)
ACIFLUX (ALGITEC)				1 (0.01)	1 (0.00)
ACINON			4 (0.01)		4 (0.01)
ACIPEX			1 (0.00)		1 (0.00)
ACIPHEX		13 (0.08)	29 (0.10)	8 (0.10)	50 (0.08)
ACITERTIN			1 (0.00)		1 (0.00)
ACITRETIN	1 (0.02)	1 (0.01)	4 (0.01)	1 (0.01)	7 (0.01)
ACITRETIN (ACITRETIN)	1 (0.02)	1 (0.01)			2 (0.00)
ACLARUBICIN HYDROCHLOR				1 (0.01)	1 (0.00)
ACLARUBICIN HYDROCHLOR			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ACLOTINE		2 (0.01)			2 (0.00)
ACLOVATE			1 (0.00)		1 (0.00)
ACLOVATE OINTMENT			1 (0.00)	1 (0.01)	2 (0.00)
ACNE MEDICATION	1 (0.02)				1 (0.00)
ACOVIL				1 (0.01)	1 (0.00)
ACTIDUE GIORNO + NOTTE		1 (0.01)			1 (0.00)
ACTIFED	1 (0.02)		1 (0.00)		2 (0.00)
ACTIFED JOUR ET NUIT (1 (0.00)		1 (0.00)
ACTIGALL			1 (0.00)		1 (0.00)
ACTIMAX (MOXIFLOXACIN)		1 (0.01)	2 (0.01)		3 (0.00)
ACTIMMUNE	1 (0.02)		1 (0.00)		2 (0.00)
ACTIMMUNE (INTERFERON			1 (0.00)		1 (0.00)
ACTINAL			1 (0.00)		1 (0.00)
ACTIQ	2 (0.03)	1 (0.01)	2 (0.01)		5 (0.01)
ACTIRA		1 (0.01)			1 (0.00)
ACTIT (MAGNESIUM CHLOR			1 (0.00)		1 (0.00)
ACTIVACIN (ALTEPLASE)			1 (0.00)		1 (0.00)
ACTIVACIN (ALTEPLASE)P				1 (0.01)	1 (0.00)
ACTIVACIN(ALTEPLASE) P			1 (0.00)		1 (0.00)
ACTIVACIN(ALTEPLASE) P			1 (0.00)		1 (0.00)
ACTIVASE		1 (0.01)	3 (0.01)	3 (0.04)	7 (0.01)
ACTIVASE 1 MG/ML GENEN			1 (0.00)		1 (0.00)
ACTIVELLA			1 (0.00)		1 (0.00)
ACTIVELLA (OESTRANORM)			1 (0.00)		1 (0.00)
ACTLIYSE (ALTEPLASE) P				1 (0.01)	1 (0.00)
ACTO /METFORMIN			1 (0.00)		1 (0.00)
ACTONEL		10 (0.06)	43 (0.14)	14 (0.18)	67 (0.11)
ACTOPLUS MET				1 (0.01)	1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ACTOPLUS MET (PIOGLITA		1 (0.01)			1 (0.00)
ACTOS		30 (0.18)	164 (0.54)	26 (0.34)	220 (0.36)
ACTOS (PIOGLITAZONE HC		3 (0.02)			3 (0.00)
ACTOS (PIOGLITAZONE HY			1 (0.00)		1 (0.00)
ACTOS ^LILLY ^			3 (0.01)		3 (0.00)
ACTOS(PIOGLITAZONE HYR			1 (0.00)		1 (0.00)
ACTRAPHANE 30 NOVOLET			1 (0.00)		1 (0.00)
ACTRAPID		3 (0.02)	10 (0.03)		13 (0.02)
ACTRAPID NOVOLET		2 (0.01)			2 (0.00)
ACUATIM			3 (0.01)		3 (0.00)
ACUPAN		4 (0.02)	1 (0.00)		5 (0.01)
ACYCLOVIR	7 (0.12)	16 (0.09)	31 (0.10)	5 (0.06)	59 (0.10)
ACYCLOVIR (ACICLOVIR)		2 (0.01)			2 (0.00)
ACYCLOVIR SODIUM	2 (0.03)	1 (0.01)	7 (0.02)	1 (0.01)	11 (0.02)
ADAFERON (A643-INTERFE		1 (0.01)			1 (0.00)
ADAGEN	3 (0.05)				3 (0.00)
ADALAT	3 (0.05)	4 (0.02)	48 (0.16)	16 (0.21)	71 (0.12)
ADALAT CC	1 (0.02)		1 (0.00)	1 (0.01)	3 (0.00)
ADALAT XL (NIFEDIPINE)			1 (0.00)		1 (0.00)
ADANCOR				5 (0.06)	5 (0.01)
ADANCOR (NICORANDIL)				1 (0.01)	1 (0.00)
ADAPALENE	1 (0.02)				1 (0.00)
ADCAL D3			1 (0.00)	1 (0.01)	2 (0.00)
ADDERAL (AMFETAMINE AS	1 (0.02)				1 (0.00)
ADDERALL (AMFETAMINE A	4 (0.07)				4 (0.01)
ADDERALL (AMPHETAMINE	2 (0.03)				2 (0.00)
ADDERALL (OBETROL/0134	1 (0.02)	1 (0.01)			2 (0.00)
ADDERALL 10	20 (0.34)	9 (0.05)	1 (0.00)		30 (0.05)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
ADDERALL 15	1 (0.02)				1 (0.00)
ADDERALL 20	1 (0.02)				1 (0.00)
ADDERALL 30	2 (0.03)				2 (0.00)
ADDERALL TABLETS		1 (0.01)			1 (0.00)
ADDERALL XR (AMFETAMIN		1 (0.01)			1 (0.00)
ADDERALL XR 10	12 (0.20)	4 (0.02)			16 (0.03)
ADDERALL XR 15	1 (0.02)				1 (0.00)
ADDERALL XR 20	2 (0.03)				2 (0.00)
ADDERALL XR 25	1 (0.02)				1 (0.00)
ADDERALL XR 30	8 (0.14)	1 (0.01)			9 (0.01)
ADEFOVIR DIPIVOXIL			1 (0.00)		1 (0.00)
ADEFOVIR DIPIVOXIL (AD	1 (0.02)				1 (0.00)
ADEFOVIR DIPIVOXIL (AD	1 (0.02)				1 (0.00)
ADEFOVIR DIPIVOXIL KIT			1 (0.00)		1 (0.00)
ADELT		1 (0.01)			1 (0.00)
ADENOCK			1 (0.00)		1 (0.00)
ADENOSCAN		2 (0.01)	2 (0.01)	6 (0.08)	10 (0.02)
ADENOSINE	1 (0.02)		2 (0.01)	1 (0.01)	4 (0.01)
ADENOSINE 5- TRIPHOSPH	1 (0.02)				1 (0.00)
ADEPAL (LEVONORGESTREL	1 (0.02)				1 (0.00)
ADETPHOS (AD			1 (0.00)		1 (0.00)
ADIPEX			1 (0.00)		1 (0.00)
ADIRO				1 (0.01)	1 (0.00)
ADIRO 100 (ACETYLSALIC			1 (0.00)		1 (0.00)
ADOLONTA			1 (0.00)		1 (0.00)
ADONA			7 (0.02)	1 (0.01)	8 (0.01)
ADONA (CARBAZOCHRO				1 (0.01)	1 (0.00)
ADONA (CARBAZOCHROME S			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ADOXA		1 (0.01)			1 (0.00)
ADRENAL CORTEX EXTRACT	1 (0.02)				1 (0.00)
ADRENAL HORMONE PREPAR			1 (0.00)		1 (0.00)
ADRIACIN	1 (0.02)				1 (0.00)
ADRIAMYCIN (DOXORUBICI			1 (0.00)		1 (0.00)
ADRIAMYCIN PFS	3 (0.05)		6 (0.02)	1 (0.01)	10 (0.02)
ADRIBLASTINE (DOXORUBI			1 (0.00)		1 (0.00)
ADRONAT			1 (0.00)		1 (0.00)
ADVACAR			1 (0.00)		1 (0.00)
ADVAFERON		1 (0.01)			1 (0.00)
ADVAIR (FLUTICASONE PR		1 (0.01)			1 (0.00)
ADVAIR (FLUTICASONE)		2 (0.01)			2 (0.00)
ADVAIR (SALMETEROL XIN		1 (0.01)			1 (0.00)
ADVAIR (SALMETEROL/FLU			1 (0.00)		1 (0.00)
ADVAIR (SERETIDE)			11 (0.04)	4 (0.05)	15 (0.02)
ADVAIR DISKUS (FLUTICA	1 (0.02)				1 (0.00)
ADVAIR DISKUS (FLUTICA	1 (0.02)				1 (0.00)
ADVAIR DISKUS 100/50	10 (0.17)	14 (0.08)	51 (0.17)	6 (0.08)	81 (0.13)
ADVAIR DISKUS 250/50	1 (0.02)	4 (0.02)	5 (0.02)	1 (0.01)	11 (0.02)
ADVAIR INHALER		1 (0.01)			1 (0.00)
ADVANDAMET		1 (0.01)			1 (0.00)
ADVATE (OCTOCOG ALFA)		1 (0.01)	3 (0.01)		4 (0.01)
ADVAUR		1 (0.01)			1 (0.00)
ADVICOR			2 (0.01)		2 (0.00)
ADVIL	20 (0.34)	42 (0.25)	40 (0.13)	9 (0.12)	111 (0.18)
ADVIL /00109201/		1 (0.01)			1 (0.00)
ADVIL COLD AND SINUS	1 (0.02)	3 (0.02)			4 (0.01)
ADVIL COLD AND SINUS (1 (0.02)				1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ADVIL ENFANTS ET NOURR	1 (0.02)				1 (0.00)
ADVODART			1 (0.00)		1 (0.00)
AERIUS			1 (0.00)		1 (0.00)
AERIUS	1 (0.02)				1 (0.00)
AERIUS (DESLORATADINE)	1 (0.02)				1 (0.00)
AERIUS (DESLORATADINE)		1 (0.01)			1 (0.00)
AERIUS TABLETS (DESLOR		1 (0.01)			1 (0.00)
AEROLIN		1 (0.01)			1 (0.00)
AFEDITAB CR			1 (0.00)		1 (0.00)
AFRIN			1 (0.00)		1 (0.00)
AGGRASTAT		3 (0.02)	7 (0.02)	5 (0.06)	15 (0.02)
AGGRENOX		2 (0.01)	3 (0.01)	4 (0.05)	9 (0.01)
AGIOMAX (BIVALIRUDIN)I			1 (0.00)		1 (0.00)
AGRYLIN		1 (0.01)	3 (0.01)		4 (0.01)
AGRYLIN (ANAGRELIDE HY			1 (0.00)		1 (0.00)
AI: BONE TISSUE HUMAN		1 (0.01)			1 (0.00)
AI: MUSCULOSKELETAL SO		1 (0.01)			1 (0.00)
AI:BONE TISSUE HUMAN T		1 (0.01)			1 (0.00)
AIRBORNE FORMULA 1X EV		1 (0.01)			1 (0.00)
AK-FLUOR, 10%, AKORN			3 (0.01)		3 (0.00)
AKARIN (CITALOPRAM)				1 (0.01)	1 (0.00)
AKINETON	1 (0.02)	2 (0.01)	3 (0.01)		6 (0.01)
AKNE-MYCIN	1 (0.02)				1 (0.00)
AKNEFUG MINO (MINOCYCL	1 (0.02)				1 (0.00)
ALAVERT		1 (0.01)			1 (0.00)
ALAVERT D-12 (LORATADI			1 (0.00)		1 (0.00)
ALAVERT D-12 (LORATADI			4 (0.01)		4 (0.01)
ALB. INH			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ALBENDAZOLE	4 (0.07)		1 (0.00)		5 (0.01)
ALBENZA	1 (0.02)				1 (0.00)
ALBUMIN (HUMAN)			3 (0.01)	1 (0.01)	4 (0.01)
ALBUMINAR-5			1 (0.00)		1 (0.00)
ALBUTEROL	44 (0.74)	34 (0.20)	55 (0.18)	19 (0.25)	152 (0.25)
ALBUTEROL (ALBUTEROL S	1 (0.02)				1 (0.00)
ALBUTEROL IHL			1 (0.00)		1 (0.00)
ALBUTEROL SULATE				1 (0.01)	1 (0.00)
ALBUTEROL SULFATE	2 (0.03)		2 (0.01)		4 (0.01)
ALBUTEROL SULFATE (+			1 (0.00)		1 (0.00)
ALBUTEROL SULFATE AND	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
ALBUTEROL SULFATE AUTO	7 (0.12)	3 (0.02)	12 (0.04)	4 (0.05)	26 (0.04)
ALBUTEROL/PRATROPIUM M		1 (0.01)			1 (0.00)
ALBYL-E (ACETYLSALICYL				1 (0.01)	1 (0.00)
ALCOHOL	4 (0.07)	14 (0.08)	2 (0.01)		20 (0.03)
ALCOHOL (ETHANOL)		3 (0.02)			3 (0.00)
ALDACTACINE			1 (0.00)		1 (0.00)
ALDACTAZIDE			1 (0.00)		1 (0.00)
ALDACTAZIDE (ALDACTAZI			1 (0.00)		1 (0.00)
ALDACTAZINE			1 (0.00)	3 (0.04)	4 (0.01)
ALDACTON (SPIRONOLACTO			1 (0.00)		1 (0.00)
ALDACTONE	2 (0.03)	5 (0.03)	23 (0.08)	30 (0.39)	60 (0.10)
ALDALIX				1 (0.01)	1 (0.00)
ALDARA		6 (0.04)	2 (0.01)		8 (0.01)
ALDESLEUKIN 18 MILLION			1 (0.00)		1 (0.00)
ALDOMET	1 (0.02)	2 (0.01)			3 (0.00)
ALDORIL 15			1 (0.00)		1 (0.00)
ALDURAZYME	5 (0.08)				5 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ALEMTUZUMAB	1 (0.02)	2 (0.01)			3 (0.00)
ALENDRONATE SODIUM		2 (0.01)	12 (0.04)	3 (0.04)	17 (0.03)
ALENDRONATE SODIUM (AL				1 (0.01)	1 (0.00)
ALENDRONATE(ALENDRONAT			1 (0.00)		1 (0.00)
ALENDRONIC ACID		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)
ALEPSAL			1 (0.00)		1 (0.00)
ALERTEC		1 (0.01)			1 (0.00)
ALESION			2 (0.01)	1 (0.01)	3 (0.00)
ALESION (1 (0.00)		1 (0.00)
ALESION (EPINASTINE)	1 (0.02)		1 (0.00)		2 (0.00)
ALESSE		4 (0.02)			4 (0.01)
ALESSE 21 (ETHINYL EST	1 (0.02)				1 (0.00)
ALEVE	7 (0.12)	50 (0.29)	63 (0.21)	5 (0.06)	125 (0.20)
ALEVE /00256202/ (N				1 (0.01)	1 (0.00)
ALEVE (CAPLET)	5 (0.08)	11 (0.06)	15 (0.05)	9 (0.12)	40 (0.07)
ALEVE COLD + SINUS CAP			1 (0.00)		1 (0.00)
ALEXAN (SPIRONOLACTONE			1 (0.00)		1 (0.00)
ALFACALCIDOL			2 (0.01)	1 (0.01)	3 (0.00)
ALFACALCIDOL (ALFACALC			2 (0.01)		2 (0.00)
ALFACALCIDOL (ALFACALC			1 (0.00)		1 (0.00)
ALFADIL BPH			1 (0.00)		1 (0.00)
ALFAROL	1 (0.02)		1 (0.00)	1 (0.01)	3 (0.00)
ALFAROL (ALFACALCIDOL)			2 (0.01)		2 (0.00)
ALFAROL (ALFACALCIDOL)			1 (0.00)		1 (0.00)
ALFUZOSIN			1 (0.00)		1 (0.00)
ALFUZOSIN HYDROCHLORID				1 (0.01)	1 (0.00)
ALIMPTA	1 (0.02)				1 (0.00)
ALIMTA		1 (0.01)	13 (0.04)	1 (0.01)	15 (0.02)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ALIMTA (PEMETREXID)			1 (0.00)		1 (0.00)
ALINIA			1 (0.00)		1 (0.00)
ALKA-SELTZER			1 (0.00)		1 (0.00)
ALKA-SELTZER PLUS COLD		1 (0.01)			1 (0.00)
ALKA-SELTZER PLUS COLD		2 (0.01)			2 (0.00)
ALKALI THERAPY NOS (AL	1 (0.02)				1 (0.00)
ALKALI THERAPY NOS (AL	1 (0.02)				1 (0.00)
ALKERAN			6 (0.02)	6 (0.08)	12 (0.02)
ALL AD HD DRUGS	1 (0.02)				1 (0.00)
ALL OTHER THERAPEUTIC		1 (0.01)	6 (0.02)	3 (0.04)	10 (0.02)
ALL OTHER THERAPEUTIC			1 (0.00)		1 (0.00)
ALL OTHER THERAPEUTIC	2 (0.03)	10 (0.06)	19 (0.06)	6 (0.08)	37 (0.06)
ALL OTHER THERAPEUTIC			1 (0.00)		1 (0.00)
ALLEGRA	10 (0.17)	31 (0.18)	34 (0.11)	8 (0.10)	83 (0.14)
ALLEGRA (FEXOFANADINE		1 (0.01)			1 (0.00)
ALLELOCK		1 (0.01)	4 (0.01)	2 (0.03)	7 (0.01)
ALLELOCK (OLOPATADINE		1 (0.01)			1 (0.00)
ALLELOCK (OLOPATADINE		1 (0.01)			1 (0.00)
ALLEREST (PHENYLEPHRIN	2 (0.03)				2 (0.00)
ALLERGENIC EXTRACT			3 (0.01)		3 (0.00)
ALLERGENIC EXTRACT -DI		1 (0.01)			1 (0.00)
ALLERGIN (CHLORPHENAMI		1 (0.01)			1 (0.00)
ALLERGY MEDICINE			1 (0.00)		1 (0.00)
ALLERGY SHOTS (NOS)		1 (0.01)			1 (0.00)
ALLERTEC	1 (0.02)				1 (0.00)
ALLOGRAFT, BONE BONE		1 (0.01)			1 (0.00)
ALLOPUR (ALLOPURINOL)				1 (0.01)	1 (0.00)
ALLOPURINOL	2 (0.03)	14 (0.08)	73 (0.24)	22 (0.28)	111 (0.18)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ALLOPURINOL (200 MG) A			1 (0.00)		1 (0.00)
ALLOPURINOL MSD			1 (0.00)		1 (0.00)
ALLOPUSINOL				1 (0.01)	1 (0.00)
ALMAGATE			1 (0.00)		1 (0.00)
ALMAGATE (ALMAGATE)			1 (0.00)		1 (0.00)
ALMAGEL		2 (0.01)			2 (0.00)
ALOH/MGOH/SIMTH XTRA S		1 (0.01)			1 (0.00)
ALOH/MGOH/SIMTH XTRA S			1 (0.00)		1 (0.00)
ALOSENN			3 (0.01)		3 (0.00)
ALOXI		4 (0.02)	9 (0.03)	4 (0.05)	17 (0.03)
ALPHA GLUCOSIDASE INHI			1 (0.00)		1 (0.00)
ALPHA LIPOIC ACID (THI			1 (0.00)		1 (0.00)
ALPHA-LIPON (THIOCTIC			1 (0.00)		1 (0.00)
ALPHAGAN			14 (0.05)	4 (0.05)	18 (0.03)
ALPHAGAN (BRIMONIDINE				1 (0.01)	1 (0.00)
ALPHAGAN P		1 (0.01)		1 (0.01)	2 (0.00)
ALPRAZOLAM	7 (0.12)	25 (0.15)	25 (0.08)	5 (0.06)	62 (0.10)
ALPRESS				1 (0.01)	1 (0.00)
ALPROSTADIL	2 (0.03)	1 (0.01)	2 (0.01)	5 (0.06)	10 (0.02)
ALREX			1 (0.00)		1 (0.00)
ALREX (LOTEPREDNOL ETA			1 (0.00)		1 (0.00)
ALTACE	4 (0.07)	15 (0.09)	51 (0.17)	26 (0.34)	96 (0.16)
ALTAT				4 (0.05)	4 (0.01)
ALTENOLOL			1 (0.00)		1 (0.00)
ALTHIAZIDE		1 (0.01)			1 (0.00)
ALTHIAZIDE AND SPIRONO			1 (0.00)		1 (0.00)
ALUMINUM HYDROXIDE AND			1 (0.00)		1 (0.00)
ALUMINUM HYDROXIDE GEL		2 (0.01)			2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ALVEDON		2 (0.01)	1 (0.00)		3 (0.00)
ALVEDON (PARACETAMOL)		1 (0.01)			1 (0.00)
ALVEDON (PARACETAMOL)			1 (0.00)		1 (0.00)
ALVERINE			1 (0.00)		1 (0.00)
ALVERINE CITRATE			1 (0.00)		1 (0.00)
AMANTADINE		1 (0.01)			1 (0.00)
AMANTADINE (AMANTADINE		1 (0.01)			1 (0.00)
AMANTADINE HCL		7 (0.04)	13 (0.04)	1 (0.01)	21 (0.03)
AMANTADINE SULFATE				3 (0.04)	3 (0.00)
AMARYL		28 (0.16)	143 (0.47)	28 (0.36)	199 (0.33)
AMBIEN	8 (0.14)	82 (0.48)	96 (0.32)	14 (0.18)	200 (0.33)
AMBIEN (ZOLPIDEM TART			1 (0.00)		1 (0.00)
AMBIEN (ZOLPIDEM TARTR		1 (0.01)			1 (0.00)
AMBIEN (ZOLPIDEM TATRA			1 (0.00)		1 (0.00)
AMBIEN CR		3 (0.02)	4 (0.01)	1 (0.01)	8 (0.01)
AMBISOME	2 (0.03)	5 (0.03)	2 (0.01)		9 (0.01)
AMBROXOL (AMBROXOL)	1 (0.02)				1 (0.00)
AMERGE		2 (0.01)	1 (0.00)		3 (0.00)
AMERICAN FARE NICOTINE			1 (0.00)		1 (0.00)
AMERIDE			2 (0.01)		2 (0.00)
AMEVIVE	1 (0.02)	5 (0.03)	9 (0.03)	5 (0.06)	20 (0.03)
AMEVIVE (AL		1 (0.01)			1 (0.00)
AMIAS 2MG TABLETS				1 (0.01)	1 (0.00)
AMICAR			2 (0.01)		2 (0.00)
AMIDRINE GENERIC		1 (0.01)			1 (0.00)
AMIFOSTINE			1 (0.00)		1 (0.00)
AMIKACIN	1 (0.02)	2 (0.01)	4 (0.01)		7 (0.01)
AMIKACIN (AMIKICAN)	1 (0.02)				1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
AMIKACIN BANYU	1 (0.02)				1 (0.00)
AMIKACIN SULFATE		4 (0.02)			4 (0.01)
AMIKIN			2 (0.01)		2 (0.00)
AMIKLIN	1 (0.02)		1 (0.00)		2 (0.00)
AMIKLIN INJ	1 (0.02)				1 (0.00)
AMILORID NM PHARMA			1 (0.00)		1 (0.00)
AMILORIDE CHLORTHALIDO		1 (0.01)			1 (0.00)
AMILORIDE HCL			1 (0.00)		1 (0.00)
AMILORIDE HCL AND HYDR				1 (0.01)	1 (0.00)
AMILORIDE HYDROCHLORID				1 (0.01)	1 (0.00)
AMILORIDE HYDROCHLORID				1 (0.01)	1 (0.00)
AMINO ACIDS		1 (0.01)			1 (0.00)
AMINOFILINA (AMINOPHYL	1 (0.02)				1 (0.00)
AMINOGLYCOSIDE ANTIBAC		1 (0.01)			1 (0.00)
AMINOHIPPURATE SODIUM	2 (0.03)				2 (0.00)
AMINOPHYLLIN	2 (0.03)				2 (0.00)
AMINOPHYLLINE		4 (0.02)			4 (0.01)
AMINOSALICYLIC ACID AN		1 (0.01)			1 (0.00)
AMIODARON HYDROCHLORID	1 (0.02)				1 (0.00)
AMIODARONE	1 (0.02)		17 (0.06)	7 (0.09)	25 (0.04)
AMIODARONE			1 (0.00)		1 (0.00)
AMIODARONE (AMIODARON			1 (0.00)		1 (0.00)
AMIODARONE 200MG			2 (0.01)		2 (0.00)
AMIODARONE 400 MG, TH			1 (0.00)		1 (0.00)
AMIODARONE (AMIODARONE				1 (0.01)	1 (0.00)
AMIODARONE (AMIODARONE				1 (0.01)	1 (0.00)
AMIODARONE (AMIODARONE				1 (0.01)	1 (0.00)
AMIODARONE 150 MG /3 M			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
AMIODARONE 200 MG			2 (0.01)	1 (0.01)	3 (0.00)
AMIODARONE HCL	2 (0.03)		9 (0.03)	12 (0.15)	23 (0.04)
AMIODARONE HYDROCHLORI			5 (0.02)	2 (0.03)	7 (0.01)
AMIODARONE;;;ANTIARRHY				1 (0.01)	1 (0.00)
AMISALIN (PROCAINAMIDE				1 (0.01)	1 (0.00)
AMISULPRIDE		1 (0.01)	17 (0.06)	1 (0.01)	19 (0.03)
AMISULPRIDE (AMISULPRI			1 (0.00)		1 (0.00)
AMITRIPTYLIN		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
AMITRIPTYLINE	1 (0.02)		3 (0.01)	1 (0.01)	5 (0.01)
AMITRIPTYLINE (AMITRIP	1 (0.02)	2 (0.01)	1 (0.00)		4 (0.01)
AMITRIPTYLINE HCL	5 (0.08)	12 (0.07)	22 (0.07)	7 (0.09)	46 (0.08)
AMITRIPTYLINE HCL 100M		1 (0.01)			1 (0.00)
AMITRIPTYLINE HYDROCHL		1 (0.01)	16 (0.05)	2 (0.03)	19 (0.03)
AMLODIN			7 (0.02)	2 (0.03)	9 (0.01)
AMLODIPINE	4 (0.07)	7 (0.04)	51 (0.17)	15 (0.19)	77 (0.13)
AMLODIPINE BESILATE (A			1 (0.00)		1 (0.00)
AMLODIPINE BESILATE TA			2 (0.01)		2 (0.00)
AMLODIPINE BESYLATE		4 (0.02)	26 (0.09)	11 (0.14)	41 (0.07)
AMLODIPINE MESYLATE			1 (0.00)		1 (0.00)
AMLOR			5 (0.02)	7 (0.09)	12 (0.02)
AMMONIUM LACTATE			1 (0.00)		1 (0.00)
AMNESTEEM	7 (0.12)	6 (0.04)			13 (0.02)
AMOBAN		3 (0.02)	1 (0.00)	2 (0.03)	6 (0.01)
AMOBAN (ZOPICLONE)			2 (0.01)		2 (0.00)
AMOBARBITAL SODIUM			1 (0.00)		1 (0.00)
AMOCILLIN	4 (0.07)				4 (0.01)
AMOCLAV	2 (0.03)	1 (0.01)			3 (0.00)
AMOKSIKLAV	1 (0.02)				1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
AMOKSIKLAV (NGX) (AMOX	1 (0.02)				1 (0.00)
AMOXAN	1 (0.02)				1 (0.00)
AMOXAPINE		1 (0.01)			1 (0.00)
AMOXICILLIN	17 (0.29)	24 (0.14)	18 (0.06)	3 (0.04)	62 (0.10)
AMOXICILLIN (AMOXICILL		1 (0.01)			1 (0.00)
AMOXICILLIN + CLAVULAN	1 (0.02)	2 (0.01)	5 (0.02)	1 (0.01)	9 (0.01)
AMOXICILLIN + CLAVULAN		1 (0.01)			1 (0.00)
AMOXICILLIN / CLAVULAN			1 (0.00)		1 (0.00)
AMOXICILLIN AND CLAVUL	1 (0.02)	4 (0.02)	2 (0.01)		7 (0.01)
AMOXICILLIN CLAVULANAT				1 (0.01)	1 (0.00)
AMOXICILLIN SODIUM	1 (0.02)				1 (0.00)
AMOXICILLIN TRIHYDRATE	2 (0.03)	3 (0.02)	3 (0.01)	1 (0.01)	9 (0.01)
AMOXICILLIN-CLAVULANIC		1 (0.01)			1 (0.00)
AMOXICILLIN/SULBACTAM				1 (0.01)	1 (0.00)
AMOXICILLINE + AC CLAV		1 (0.01)			1 (0.00)
AMOXICILLINE RPG				1 (0.01)	1 (0.00)
AMOXIL	7 (0.12)	2 (0.01)			9 (0.01)
AMOXIL ^BEECHAM PHARM^		1 (0.01)			1 (0.00)
AMPCILLIN	1 (0.02)				1 (0.00)
AMPHETAMINE SULFATE		1 (0.01)			1 (0.00)
AMPHO-MORONAL (AMPHOTE	1 (0.02)				1 (0.00)
AMPHOTERICIN B	1 (0.02)	5 (0.03)	5 (0.02)		11 (0.02)
AMPICILLIN	3 (0.05)		2 (0.01)		5 (0.01)
AMPICILLIN AND SULBACT			1 (0.00)		1 (0.00)
AMPICILLIN IV			1 (0.00)		1 (0.00)
AMPICILLIN SODIUM	4 (0.07)	1 (0.01)		2 (0.03)	7 (0.01)
AMPICILLIN SODIUM W/SU		1 (0.01)			1 (0.00)
AMPICILLIN SODIUM/SULB		2 (0.01)			2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
AMPRENAVIR		1 (0.01)			1 (0.00)
ANABOLIC STEROIDS		1 (0.01)			1 (0.00)
ANACIN			5 (0.02)		5 (0.01)
ANACIN PAIN RELIEVER (1 (0.02)				1 (0.00)
ANADIN IBUPROFEN (IBUP	1 (0.02)		1 (0.00)		2 (0.00)
ANAESTHETIC			1 (0.00)		1 (0.00)
ANAESTHETIC (UNSPECIFI	1 (0.02)				1 (0.00)
ANAFRANIL	2 (0.03)	3 (0.02)	1 (0.00)		6 (0.01)
ANAGRELIDE (NGX) (ANAG		1 (0.01)			1 (0.00)
ANAGRELIDE HCL		2 (0.01)	1 (0.00)		3 (0.00)
ANALGESIC OR ANESTHETI		2 (0.01)	7 (0.02)	1 (0.01)	10 (0.02)
ANALGESICS			2 (0.01)	3 (0.04)	5 (0.01)
ANALGESICS (ANALGESICS	1 (0.02)		1 (0.00)		2 (0.00)
ANALGETICS		1 (0.01)			1 (0.00)
ANAPEINE		1 (0.01)			1 (0.00)
ANAPROX		1 (0.01)	1 (0.00)		2 (0.00)
ANASTRAZOL		2 (0.01)			2 (0.00)
ANASTROZOLE			1 (0.00)		1 (0.00)
ANASTROZOLE			1 (0.00)		1 (0.00)
ANCARON (AMIODARONE, T		2 (0.01)	5 (0.02)	1 (0.01)	8 (0.01)
ANCEF	1 (0.02)	3 (0.02)	6 (0.02)		10 (0.02)
ANCORON			1 (0.00)		1 (0.00)
ANDOL (ACETYLSALICYLIC			1 (0.00)		1 (0.00)
ANDRODERM		1 (0.01)	1 (0.00)		2 (0.00)
ANDROGEL		1 (0.01)	6 (0.02)		7 (0.01)
ANDROGEL 5.0 G			1 (0.00)		1 (0.00)
ANDROGEL GEL 1% SOLVAY		1 (0.01)			1 (0.00)
ANEMET		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
ANEXATE				2 (0.03)	2 (0.00)
ANGELIQ			4 (0.01)		4 (0.01)
ANGIOMAX		4 (0.02)	16 (0.05)	10 (0.13)	30 (0.05)
ANGIOTENSIN II ANTAGON			1 (0.00)		1 (0.00)
ANGIPRESS			1 (0.00)		1 (0.00)
ANOPYRIN			1 (0.00)	1 (0.01)	2 (0.00)
ANPLAG			1 (0.00)		1 (0.00)
ANTABUSE		3 (0.02)			3 (0.00)
ANTACID TAB		1 (0.01)	3 (0.01)		4 (0.01)
ANTALVIC (DEXTROPOROPO			1 (0.00)		1 (0.00)
ANTARA			1 (0.00)		1 (0.00)
ANTARA (MICRONIZED)			2 (0.01)		2 (0.00)
ANTI DEPRESSANTS			1 (0.00)		1 (0.00)
ANTI HIV		1 (0.01)			1 (0.00)
ANTI-ASTHMATICS			1 (0.00)		1 (0.00)
ANTI-CHOLESTEROL MEDIC		1 (0.01)			1 (0.00)
ANTI-COMMON COLD DRUGS			2 (0.01)		2 (0.00)
ANTI-DIABETES (ANTI-DI			1 (0.00)		1 (0.00)
ANTI-DIABETICS	2 (0.03)				2 (0.00)
ANTI-HYPERTENSIVE			1 (0.00)		1 (0.00)
ANTI-HYPERTENSIVE MEDI				1 (0.01)	1 (0.00)
ANTI-HYPERTENSIVES				1 (0.01)	1 (0.00)
ANTI-INFLAMMATORIES			1 (0.00)		1 (0.00)
ANTI-PARATHYROID HORMO		1 (0.01)			1 (0.00)
ANTI-PYSCHOTICS		1 (0.01)			1 (0.00)
ANTI-TUBERCULOSIS MEDI		2 (0.01)			2 (0.00)
ANTI-ASTHMATICS			1 (0.00)		1 (0.00)
ANTIBIOTIC	2 (0.03)	5 (0.03)	1 (0.00)		8 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ANTIBIOTIC (ANTIBIOTIC		1 (0.01)			1 (0.00)
ANTIBIOTIC (NOS)			1 (0.00)		1 (0.00)
ANTIBIOTIC OINTMENT			1 (0.00)		1 (0.00)
ANTIBIOTICS	5 (0.08)	10 (0.06)	9 (0.03)	2 (0.03)	26 (0.04)
ANTIBIOTICS (ANTIBIOTI		1 (0.01)	1 (0.00)		2 (0.00)
ANTIBIOTICS (ANTIBIOTI		1 (0.01)	1 (0.00)		2 (0.00)
ANTIBIOTICS (NOT SPECI			1 (0.00)		1 (0.00)
ANTIBIOTICS FOR TOPICA			1 (0.00)		1 (0.00)
ANTIBIOTICS NOS			1 (0.00)		1 (0.00)
ANTICOAGULANT (ANTICOA		1 (0.01)			1 (0.00)
ANTICOAGULANT 4% SODIU	1 (0.02)	1 (0.01)			2 (0.00)
ANTICOAGULANT CITRATE				1 (0.01)	1 (0.00)
ANTICOAGULANT THERAPY			1 (0.00)		1 (0.00)
ANTICOAGULANTS (ANTICO				1 (0.01)	1 (0.00)
ANTICOAGULANTS (ANTITH	1 (0.02)	1 (0.01)			2 (0.00)
ANTICONVULSANT		1 (0.01)	1 (0.00)		2 (0.00)
ANTICONVULSANT MEDICAT	1 (0.02)				1 (0.00)
ANTICONVULSANTS	1 (0.02)	1 (0.01)			2 (0.00)
ANTIDEPRESSANT	2 (0.03)				2 (0.00)
ANTIDEPRESSANT (ANTIDE		1 (0.01)			1 (0.00)
ANTIDEPRESSANTS		2 (0.01)	6 (0.02)		8 (0.01)
ANTIDEPRESSANTS (ANTID	1 (0.02)		2 (0.01)		3 (0.00)
ANTIDEPRESSANTS (NOS)			1 (0.00)		1 (0.00)
ANTIDIABETIC		2 (0.01)			2 (0.00)
ANTIDIABETIC DRUGS			1 (0.00)		1 (0.00)
ANTIFUNGAL TREATMENT	1 (0.02)				1 (0.00)
ANTIHISTAMINE		1 (0.01)			1 (0.00)
ANTIHISTAMINES	3 (0.05)	1 (0.01)	2 (0.01)		6 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ANTIHYPERTENSIVE		2 (0.01)	2 (0.01)		4 (0.01)
ANTIHYPERTENSIVE (ANTI		1 (0.01)			1 (0.00)
ANTIHYPERTENSIVE AGENT			1 (0.00)		1 (0.00)
ANTIHYPERTENSIVE AGENT			1 (0.00)		1 (0.00)
ANTIHYPERTENSIVE DRUG			1 (0.00)		1 (0.00)
ANTIHYPERTENSIVE DRUGS			1 (0.00)		1 (0.00)
ANTIHYPERTENSIVE MEDIC				1 (0.01)	1 (0.00)
ANTIHYPERTENSIVE MEDIC			1 (0.00)		1 (0.00)
ANTIHYPERTENSIVES	1 (0.02)	4 (0.02)	8 (0.03)	5 (0.06)	18 (0.03)
ANTIHYPERTENSIVES (ANT	2 (0.03)				2 (0.00)
ANTIHYPERTENSIVES (ANT	1 (0.02)				1 (0.00)
ANTIHYPERTENSIVES (ANT		2 (0.01)	6 (0.02)	4 (0.05)	12 (0.02)
ANTIHYPERTENSIVES			1 (0.00)		1 (0.00)
ANTIINFLAMMATORY/ANTIR		1 (0.01)			1 (0.00)
ANTIMICROBIAL (UNSPECI		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
ANTIMIGRAINE PREPARATI		1 (0.01)			1 (0.00)
ANTINEOPLASTIC			1 (0.00)		1 (0.00)
ANTINEOPLASTIC (UNSPEC			1 (0.00)		1 (0.00)
ANTINEOPLASTIC AGENTS			2 (0.01)		2 (0.00)
ANTIPLATELET AGENTS				1 (0.01)	1 (0.00)
ANTIPSYCHOTIC AGENT (A			1 (0.00)		1 (0.00)
ANTIPSYCHOTIC AGENT (N	1 (0.02)				1 (0.00)
ANTIRETROVIRALS (ANTIR		1 (0.01)			1 (0.00)
ANTITHROMBIN III (ANTI			1 (0.00)		1 (0.00)
ANTITHYMOCYTE IMMUNOGL	1 (0.02)				1 (0.00)
ANTITUSSIVE NOS	2 (0.03)				2 (0.00)
ANTIVERT				2 (0.03)	2 (0.00)
ANTIVERT PFIZER (MECL			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ANTIVIRAL (ANTIVIRALS			1 (0.00)		1 (0.00)
ANTIVIRALS FOR SYSTEMI		1 (0.01)			1 (0.00)
ANTRA			1 (0.00)		1 (0.00)
ANYRUME	2 (0.03)				2 (0.00)
ANZEMET		7 (0.04)	3 (0.01)	1 (0.01)	11 (0.02)
AOTAL (ACAMPROSATE)	1 (0.02)	3 (0.02)			4 (0.01)
APAP 500 MG/ HYDROCODO				1 (0.01)	1 (0.00)
APAP TAB			2 (0.01)		2 (0.00)
APLISOL DIAGNOSTIC ANT	1 (0.02)	1 (0.01)			2 (0.00)
APO-GO		1 (0.01)			1 (0.00)
APO-LEFLUNOMIDE (LEFLU			1 (0.00)		1 (0.00)
APO-LEVOCARB				1 (0.01)	1 (0.00)
APO-NADOL			1 (0.00)		1 (0.00)
APO-PAROXETINE (PAROXE	1 (0.02)				1 (0.00)
APO-PREDNISONE			1 (0.00)		1 (0.00)
APOMORPHINE HYDROCHLOR			1 (0.00)		1 (0.00)
APOMORPHINE HYDROCHLOR			1 (0.00)		1 (0.00)
APPROVEL				1 (0.01)	1 (0.00)
APREPITANT		1 (0.01)	1 (0.00)		2 (0.00)
APRESOLINE			1 (0.00)		1 (0.00)
APRI		2 (0.01)			2 (0.00)
APRINDINE HYDROCHLORID			3 (0.01)		3 (0.00)
APROTIN		1 (0.01)			1 (0.00)
APROTININ			4 (0.01)		4 (0.01)
APROVEL		1 (0.01)	1 (0.00)	3 (0.04)	5 (0.01)
APROVEL TABS 150 MG		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
APTIVUS		5 (0.03)	3 (0.01)		8 (0.01)
AQUAFRESH EXTREME CLEA		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
AQUAFRESH EXTREME CLEA		1 (0.01)			1 (0.00)
AQUAMEPHYTON			1 (0.00)		1 (0.00)
AQUAPHOR			1 (0.00)		1 (0.00)
AQUAPHOR (XIPAMIDE FOR			1 (0.00)		1 (0.00)
AQUEOUS CREAM (EMULSIF			1 (0.00)		1 (0.00)
AQUEOUS CREAM (EMULSIF			1 (0.00)		1 (0.00)
AQUILEA		1 (0.01)			1 (0.00)
AQUPLA		1 (0.01)			1 (0.00)
ARA-C (CYTARBINE)		1 (0.01)			1 (0.00)
ARALEN	1 (0.02)				1 (0.00)
ARANESP	1 (0.02)	3 (0.02)	13 (0.04)	4 (0.05)	21 (0.03)
ARASENA-A			1 (0.00)		1 (0.00)
ARAVA		9 (0.05)	11 (0.04)		20 (0.03)
ARBKACIN SULFATE			2 (0.01)		2 (0.00)
ARCOXIA			1 (0.00)	1 (0.01)	2 (0.00)
ARDINEX			1 (0.00)		1 (0.00)
AREDIA		2 (0.01)	26 (0.09)	10 (0.13)	38 (0.06)
ARELIX ACE (RAMIPRIL,				1 (0.01)	1 (0.00)
ARESTIN		2 (0.01)		1 (0.01)	3 (0.00)
ARGATROBAN			2 (0.01)	1 (0.01)	3 (0.00)
ARICEPT		1 (0.01)	36 (0.12)	70 (0.90)	107 (0.18)
ARICEPT (CONEPEZIL HYD				1 (0.01)	1 (0.00)
ARICEPT (DONEPEZIL HYD				1 (0.01)	1 (0.00)
ARICEPT (DONEPEZILE HY				1 (0.01)	1 (0.00)
ARICEPT /JPN/ (DONEPEZ			1 (0.00)		1 (0.00)
ARICFEPT (DONEPEZIL HY				1 (0.01)	1 (0.00)
ARIFON (INDAPAMIDE)			1 (0.00)		1 (0.00)
ARIMIDEX		5 (0.03)	34 (0.11)	11 (0.14)	50 (0.08)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ARIPIRAZOLE	3 (0.05)	8 (0.05)	3 (0.01)	1 (0.01)	15 (0.02)
ARIPIRAZOLE (ARIPIRA		4 (0.02)	1 (0.00)		5 (0.01)
ARIPIRAZOLE 30 MG TAB			1 (0.00)		1 (0.00)
ARIPIRAZOLE 5 MG	1 (0.02)				1 (0.00)
ARIXTRA			6 (0.02)		6 (0.01)
ARMOUR THYROID 120 MG			1 (0.00)		1 (0.00)
ARMOUR THYROID TABLETS			5 (0.02)		5 (0.01)
AROMASIN		4 (0.02)	17 (0.06)	3 (0.04)	24 (0.04)
AROMASIN (EXEMESTNE)				1 (0.01)	1 (0.00)
AROMYCIN				2 (0.03)	2 (0.00)
AROPAX		1 (0.01)			1 (0.00)
ARSENIC TRIOXIDE	2 (0.03)	3 (0.02)	8 (0.03)	4 (0.05)	17 (0.03)
ARSENIC TRIOXIDE 10MG/				1 (0.01)	1 (0.00)
ARTANE			6 (0.02)	1 (0.01)	7 (0.01)
ARTHROTEC		5 (0.03)	8 (0.03)	4 (0.05)	17 (0.03)
ARTICIAL TEARS				1 (0.01)	1 (0.00)
ARTIFICIAL TEARS			1 (0.00)		1 (0.00)
ARTIST		1 (0.01)	10 (0.03)		11 (0.02)
ASA (ASPIRIN (ACETYLSA			1 (0.00)		1 (0.00)
ASA (ASPIRIN (ACETYLSA			2 (0.01)		2 (0.00)
ASA TABS (ACETYLSALICY			1 (0.00)		1 (0.00)
ASACOL	7 (0.12)	9 (0.05)	6 (0.02)	3 (0.04)	25 (0.04)
ASAFLOW			3 (0.01)		3 (0.00)
ASANTIN				1 (0.01)	1 (0.00)
ASASANTIN				1 (0.01)	1 (0.00)
ASASANTIN - SLOW RELEA				2 (0.03)	2 (0.00)
ASASANTIN SR (CAPSULE,			1 (0.00)		1 (0.00)
ASCAL			2 (0.01)		2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ASCAL CARDIO			1 (0.00)		1 (0.00)
ASCORBIC ACID	1 (0.02)	7 (0.04)	5 (0.02)	3 (0.04)	16 (0.03)
ASCRIPITIN (ACETYLSALIC				1 (0.01)	1 (0.00)
ASM981			1 (0.00)		1 (0.00)
ASMANEX TWISTHALER	1 (0.02)	1 (0.01)			2 (0.00)
ASORBIC ACID			1 (0.00)		1 (0.00)
ASPARA-CA (ASPARTATE				1 (0.01)	1 (0.00)
ASPARTIC ACID	1 (0.02)				1 (0.00)
ASPARTIC ACID (ASPARTI	1 (0.02)				1 (0.00)
ASPEGIC		1 (0.01)	2 (0.01)	2 (0.03)	5 (0.01)
ASPEGIC 1000			1 (0.00)	1 (0.01)	2 (0.00)
ASPENON CAPSULES			1 (0.00)		1 (0.00)
ASPERCREME			1 (0.00)		1 (0.00)
ASPERGIC			1 (0.00)		1 (0.00)
ASPIRIN	14 (0.24)	165 (0.97)	911 (3.01)	266 (3.43)	1356 (2.22)
ASPIRIN ENTERIC COATED				1 (0.01)	1 (0.00)
ASPIRIN FREE EXCEDRIN			2 (0.01)		2 (0.00)
ASPIRIN LYSINE			2 (0.01)	2 (0.03)	4 (0.01)
ASPIRIN TAB			1 (0.00)		1 (0.00)
ASPIRINE 9ACETYLSALICY		1 (0.01)			1 (0.00)
ASPRIN (ACETYLSALICYLI		1 (0.01)			1 (0.00)
ASTELIN		4 (0.02)	4 (0.01)	1 (0.01)	9 (0.01)
ASTHMA MEDICATION		2 (0.01)		1 (0.01)	3 (0.00)
ASTHMAXINE				1 (0.01)	1 (0.00)
ASTOMIN			1 (0.00)	1 (0.01)	2 (0.00)
ASTRIX (ACETYLSALICYLI				2 (0.03)	2 (0.00)
ASVERIN	18 (0.30)	2 (0.01)			20 (0.03)
ASVERN (TIPEPIDINE HIB	1 (0.02)				1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ATACAND		4 (0.02)	28 (0.09)	11 (0.14)	43 (0.07)
ATACAND HCT		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
ATARAX	6 (0.10)	9 (0.05)	15 (0.05)	7 (0.09)	37 (0.06)
ATARAX (TABLET) (HYDO		1 (0.01)			1 (0.00)
ATAZANAVIR	1 (0.02)	5 (0.03)			6 (0.01)
ATAZANAVIR (ATAZANAVIR			1 (0.00)		1 (0.00)
ATAZANAVIR (REYATAZ)			1 (0.00)		1 (0.00)
ATELEC		1 (0.01)	9 (0.03)		10 (0.02)
ATELEC (CILNIDIPINE)			1 (0.00)		1 (0.00)
ATELEC (CLINIDIPINE)			1 (0.00)		1 (0.00)
ATENILON				1 (0.01)	1 (0.00)
ATENOL			1 (0.00)		1 (0.00)
ATENOLO			2 (0.01)		2 (0.00)
ATENOLOL	7 (0.12)	48 (0.28)	230 (0.76)	84 (1.08)	369 (0.61)
ATENOMEL (ATENOLOL)			1 (0.00)		1 (0.00)
ATGAM	1 (0.02)				1 (0.00)
ATHYMIL				1 (0.01)	1 (0.00)
ATHYMIL (MIANSERIN)			1 (0.00)		1 (0.00)
ATIVAN	4 (0.07)	35 (0.21)	57 (0.19)	7 (0.09)	103 (0.17)
ATMADISC MITE	1 (0.02)				1 (0.00)
ATOMOXETINE HYDROCHLOR	2 (0.03)				2 (0.00)
ATOMOXETINE HYDROCHLOR	1 (0.02)				1 (0.00)
ATOMOXETINE HYDROCHLOR	1 (0.02)				1 (0.00)
ATOMOXETINE HYDROCHLOR	1 (0.02)	1 (0.01)			2 (0.00)
ATOMOXETINE HYDROCHLOR	1 (0.02)				1 (0.00)
ATOMOXETINE HYDROCHLOR	1 (0.02)				1 (0.00)
ATORVASTATIN		1 (0.01)	4 (0.01)	1 (0.01)	6 (0.01)
ATORVASTATIN 80 MG		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ATORVASTATIN 40 MG PFI			1 (0.00)		1 (0.00)
ATORVASTATIN CALCIUM		13 (0.08)	71 (0.23)	18 (0.23)	102 (0.17)
ATRACURIUM BESYLATE	1 (0.02)	1 (0.01)			2 (0.00)
ATROPINE	2 (0.03)		1 (0.00)		3 (0.00)
ATROPINE SULFATE			1 (0.00)		1 (0.00)
ATROPINE W/DIPHENOXYLA		1 (0.01)			1 (0.00)
ATROVENT		3 (0.02)	13 (0.04)	4 (0.05)	20 (0.03)
ATROVENT HFA			1 (0.00)		1 (0.00)
ATUSS DM			1 (0.00)		1 (0.00)
AUGEMENTIN	1 (0.02)				1 (0.00)
AUGMENTIN		2 (0.01)	4 (0.01)	1 (0.01)	7 (0.01)
AUGMENTIN '125'	14 (0.24)	25 (0.15)	17 (0.06)	12 (0.15)	68 (0.11)
AUGMENTIN '250'	2 (0.03)	2 (0.01)			4 (0.01)
AUGMENTIN '500'			1 (0.00)		1 (0.00)
AUGMENTIN '875'	1 (0.02)				1 (0.00)
AUGMENTIN /UNK/		1 (0.01)			1 (0.00)
AULIN				1 (0.01)	1 (0.00)
AULIN (NIMESULIDE)				1 (0.01)	1 (0.00)
AUTOLOGOUS TRANSPLANTA			1 (0.00)		1 (0.00)
AVALI				1 (0.01)	1 (0.00)
AVALIDE		1 (0.01)	12 (0.04)	1 (0.01)	14 (0.02)
AVALIDE (IRBESARTAN)				1 (0.01)	1 (0.00)
AVANDAMET		13 (0.08)	26 (0.09)	1 (0.01)	40 (0.07)
AVANDAMET (METFORMIN H			1 (0.00)		1 (0.00)
AVANDAMET (METFORMIN H			1 (0.00)		1 (0.00)
AVANDAMET (ROSIGLITAZO		1 (0.01)			1 (0.00)
AVANDARYL			1 (0.00)	3 (0.04)	4 (0.01)
AVANDIA	1 (0.02)	32 (0.19)	115 (0.38)	13 (0.17)	161 (0.26)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
AVANDIA (ROSIGLITAZONE			1 (0.00)		1 (0.00)
AVANZA (MIRTAZAPINE)			1 (0.00)		1 (0.00)
AVAPRO		9 (0.05)	29 (0.10)	10 (0.13)	48 (0.08)
AVASTIN	2 (0.03)	52 (0.30)	112 (0.37)	21 (0.27)	187 (0.31)
AVASTIN (BAVACIZUMAB)		1 (0.01)			1 (0.00)
AVASTIN (BEVACIZUMAB)			1 (0.00)		1 (0.00)
AVASTIN (BEVACIZUMAB)			4 (0.01)		4 (0.01)
AVASTIN (INJECTION FOR			1 (0.00)		1 (0.00)
AVASTIN(BEVACIZUMAB) P		1 (0.01)			1 (0.00)
AVEENO			1 (0.00)		1 (0.00)
AVELOX	5 (0.08)	24 (0.14)	25 (0.08)	18 (0.23)	72 (0.12)
AVENTYL HCL			1 (0.00)		1 (0.00)
AVILAC (GALACTOSE, LAC		2 (0.01)			2 (0.00)
AVINZA		2 (0.01)	4 (0.01)		6 (0.01)
AVLOCARDYL	1 (0.02)	2 (0.01)	2 (0.01)	4 (0.05)	9 (0.01)
AVODART			7 (0.02)	6 (0.08)	13 (0.02)
AVONEX	18 (0.30)	497 (2.91)	601 (1.99)	8 (0.10)	1124 (1.84)
AVONEX		1 (0.01)			1 (0.00)
AVONEX LIQUID		18 (0.11)	19 (0.06)	1 (0.01)	38 (0.06)
AVONEX LIQUID (INTERFE		3 (0.02)	2 (0.01)		5 (0.01)
AVONEX LYOPHILIZED		11 (0.06)	27 (0.09)	1 (0.01)	39 (0.06)
AXEPIM (CEFEPIME HYDRO		1 (0.01)			1 (0.00)
AXID			6 (0.02)		6 (0.01)
AYGESTIN	1 (0.02)		1 (0.00)		2 (0.00)
AZACITIDINE (AZACITIDI			4 (0.01)	2 (0.03)	6 (0.01)
AZACITIDINE (VIDAZA) (1 (0.01)	1 (0.00)
AZACTAM			3 (0.01)		3 (0.00)
AZAMUN		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
AZANIN		3 (0.02)			3 (0.00)
AZATHIOPRINE	11 (0.19)	31 (0.18)	14 (0.05)		56 (0.09)
AZATHIOPINE			1 (0.00)		1 (0.00)
AZELASTINE HCL		1 (0.01)			1 (0.00)
AZITHROMYCIN	8 (0.14)	14 (0.08)	5 (0.02)	6 (0.08)	33 (0.05)
AZMACORT		5 (0.03)	4 (0.01)	3 (0.04)	12 (0.02)
AZOPT			1 (0.00)	2 (0.03)	3 (0.00)
AZT		1 (0.01)			1 (0.00)
AZTREONAM				1 (0.01)	1 (0.00)
AZULFIDINE		5 (0.03)	3 (0.01)	1 (0.01)	9 (0.01)
AZULFIDINE EN-TABS			2 (0.01)		2 (0.00)
B-VOLTAREN			1 (0.00)		1 (0.00)
B12		1 (0.01)	1 (0.00)		2 (0.00)
B4Z-MC-LYBX COMORBID O	1 (0.02)				1 (0.00)
BAACTRIM (SULFAMETHOXA		1 (0.01)			1 (0.00)
BABY ASPIRIN (ACETYLSA			1 (0.00)		1 (0.00)
BACITRACIN			1 (0.00)		1 (0.00)
BACLOFEN	3 (0.05)	26 (0.15)	31 (0.10)	4 (0.05)	64 (0.10)
BACOFEN				1 (0.01)	1 (0.00)
BACTRIM	12 (0.20)	15 (0.09)	8 (0.03)	3 (0.04)	38 (0.06)
BACTRIM (SULFAMETHOXAZ	1 (0.02)				1 (0.00)
BACTRIM DS	9 (0.15)	7 (0.04)	11 (0.04)		27 (0.04)
BAKTAR		1 (0.01)	1 (0.00)		2 (0.00)
BAKTAR (SULFAMETHOXAZO				1 (0.01)	1 (0.00)
BALANCED SALT SOLUTION		7 (0.04)	1 (0.00)		8 (0.01)
BANAN	4 (0.07)				4 (0.01)
BARACLUDE		1 (0.01)	2 (0.01)		3 (0.00)
BARBITURATES		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
BARNIDIPINE				1 (0.01)	1 (0.00)
BASEN			6 (0.02)	1 (0.01)	7 (0.01)
BASEN			1 (0.00)		1 (0.00)
BASEN TABLETS (VOGLIBO			1 (0.00)		1 (0.00)
BASEN TABLETS 0.3			2 (0.01)		2 (0.00)
BASILIXIMAB	1 (0.02)				1 (0.00)
BAVACIZAMALS		1 (0.01)			1 (0.00)
BAY43-9006 (SO			1 (0.00)		1 (0.00)
BAY43-9006 (SORAFENIB)			2 (0.01)		2 (0.00)
BAYASPIRIN		1 (0.01)			1 (0.00)
BAYCARON				1 (0.01)	1 (0.00)
BAYCOL		2 (0.01)	5 (0.02)		7 (0.01)
BAYER ENTERIC ASPIRIN			1 (0.00)		1 (0.00)
BAYNAS			1 (0.00)		1 (0.00)
BC ALLERGY SINUS HEADA		1 (0.01)			1 (0.00)
BC PAIN RELIEF ARTHRIT		1 (0.01)			1 (0.00)
BC POWDER (NEW FORMULA			1 (0.00)		1 (0.00)
BC POWDER (OLD FORMULA		1 (0.01)			1 (0.00)
BCG THERAPEUTICS		2 (0.01)	4 (0.01)		6 (0.01)
BCG VACCINE (BCG VACCI			1 (0.00)		1 (0.00)
BECLAZONE (BECLOMETASO		1 (0.01)			1 (0.00)
BECLOMETHASONE DIPROPI	1 (0.02)	4 (0.02)	2 (0.01)	3 (0.04)	10 (0.02)
BECLOVENT			1 (0.00)		1 (0.00)
BECODISKS				2 (0.03)	2 (0.00)
BECOSULES CAPSULE (ASC			1 (0.00)		1 (0.00)
BECOSYM FORTE (PYRIDOX			1 (0.00)		1 (0.00)
BECOTIDE	3 (0.05)		2 (0.01)		5 (0.01)
BECOTIDE INHALER		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
BEFACT FORTE			1 (0.00)		1 (0.00)
BELLADONNA (BELLADONNA			1 (0.00)		1 (0.00)
BELLERGAL-S TABLETS			1 (0.00)		1 (0.00)
BELOC			2 (0.01)		2 (0.00)
BELOC MITE				1 (0.01)	1 (0.00)
BELOC ZOK			1 (0.00)		1 (0.00)
BELOC ZOK MITE		1 (0.01)			1 (0.00)
BELOC-ZOC COMP (HYDROC		1 (0.01)			1 (0.00)
BELOC-ZOK MITE (METOPR			2 (0.01)		2 (0.00)
BEMIPARIN SODIUM			1 (0.00)		1 (0.00)
BEN-GAY			1 (0.00)		1 (0.00)
BENACAR			1 (0.00)		1 (0.00)
BENADRYL	18 (0.30)	27 (0.16)	45 (0.15)	6 (0.08)	96 (0.16)
BENADRYL ALLERGY/SINUS	1 (0.02)				1 (0.00)
BENADRYL CREAM EXTRA S			1 (0.00)		1 (0.00)
BENZAEPRIIL (BENZAEPRIIL			1 (0.00)		1 (0.00)
BENZAEPRIIL + AMLODIPIN			1 (0.00)		1 (0.00)
BENZAEPRIIL 20MG NOVART			1 (0.00)		1 (0.00)
BENZAEPRIIL HCL		3 (0.02)	1 (0.00)	1 (0.01)	5 (0.01)
BENZAEPRIIL HYDROCHLORI			2 (0.01)		2 (0.00)
BENDROFLUAZIDE			7 (0.02)		7 (0.01)
BENDROFLUAZIDE				1 (0.01)	1 (0.00)
BENDROFLUAZIDE (BENDR			1 (0.00)		1 (0.00)
BENDROFLUAZIDE (BENDRO			5 (0.02)		5 (0.01)
BENDROFLUMETHIAZIDE			5 (0.02)	8 (0.10)	13 (0.02)
BENDROFLUMETHIAZIDE (B			1 (0.00)		1 (0.00)
BENDROFLUMETHIAZIDUM			1 (0.00)		1 (0.00)
BENECAR			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
BENECOL		1 (0.01)			1 (0.00)
BENEFIX	4 (0.07)	3 (0.02)			7 (0.01)
BENERVA		2 (0.01)	2 (0.01)		4 (0.01)
BENERVA (THIAMINE HYDR			1 (0.00)		1 (0.00)
BENEXATE HYDROCHLORIDE			1 (0.00)		1 (0.00)
BENGAY (MENTHOL)				1 (0.01)	1 (0.00)
BENGAY PAIN RELIEVING		1 (0.01)			1 (0.00)
BENGAY ULTRA STRENGTH		3 (0.02)			3 (0.00)
BENICAR	2 (0.03)	2 (0.01)	29 (0.10)	4 (0.05)	37 (0.06)
BENICAR HCT			1 (0.00)	2 (0.03)	3 (0.00)
BENICARE (OLMESARTAN M			1 (0.00)		1 (0.00)
BENSERAZIDE HYDROCHLOR			1 (0.00)		1 (0.00)
BENTYL		2 (0.01)	2 (0.01)		4 (0.01)
BENYLIN 1 ALL-IN-ONE C	1 (0.02)				1 (0.00)
BENZALIN		3 (0.02)			3 (0.00)
BENZAMYCIN	1 (0.02)				1 (0.00)
BENZATROPINE		2 (0.01)			2 (0.00)
BENZATROPINE (BENZATRO		1 (0.01)			1 (0.00)
BENZOCAINE (HURRICAIN			1 (0.00)		1 (0.00)
BENZOCAINE -HURRICAIN		1 (0.01)			1 (0.00)
BENZOCAINE -HURRICAIN			1 (0.00)		1 (0.00)
BENZOCAINE 20%			1 (0.00)		1 (0.00)
BENZOCAINE SPRAY 20%			1 (0.00)		1 (0.00)
BENZOCAINE TOPICAL 20%			1 (0.00)		1 (0.00)
BENZOCAINE TOPICAL 20%			1 (0.00)		1 (0.00)
BENZOCAINE, BUTAMBEN,	1 (0.02)				1 (0.00)
BENZOCAINE-HURRICAIN-	1 (0.02)				1 (0.00)
BENZODIAZEPINE		1 (0.01)	3 (0.01)		4 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
BENZODIAZEPINE DERIVAT			1 (0.00)		1 (0.00)
BENZODIAZEPINE DERIVAT		2 (0.01)			2 (0.00)
BENZODIAZEPINES	2 (0.03)		1 (0.00)		3 (0.00)
BENZODIAZEPRINE			1 (0.00)		1 (0.00)
BENZONATATE				1 (0.01)	1 (0.00)
BENZTROPINE MESYLATE	1 (0.02)	5 (0.03)	1 (0.00)		7 (0.01)
BENZTROPINE MESYLATE (1 (0.00)		1 (0.00)
BERACHIN	1 (0.02)				1 (0.00)
BERAPROST SODIUM			1 (0.00)		1 (0.00)
BERAPROST SODIUM (BERA		1 (0.01)	2 (0.01)		3 (0.00)
BERIZYM			2 (0.01)		2 (0.00)
BEROCCA			1 (0.00)		1 (0.00)
BEROCCA PLUS TABLETS			1 (0.00)		1 (0.00)
BERODUAL			1 (0.00)		1 (0.00)
BERODUAL (IPRATROPIUM			1 (0.00)		1 (0.00)
BESITRAN				1 (0.01)	1 (0.00)
BESPAR	1 (0.02)				1 (0.00)
BESTATIN (UBENIMEX)		2 (0.01)			2 (0.00)
BETA BLOCKER		1 (0.01)	2 (0.01)		3 (0.00)
BETA BLOCKING AGENTS			6 (0.02)		6 (0.01)
BETA BLOCKING AGENTS (1 (0.00)		1 (0.00)
BETA-BLOCKER		1 (0.01)			1 (0.00)
BETA-BLOCKER (NOS)				1 (0.01)	1 (0.00)
BETABLOCKER			1 (0.00)		1 (0.00)
BETADINE		1 (0.01)	9 (0.03)	1 (0.01)	11 (0.02)
BETAFERON	1 (0.02)	1 (0.01)			2 (0.00)
BETAFERON		1 (0.01)			1 (0.00)
BETAFERON (BETAFERON (1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
BETA FERON (INTERFERON	1 (0.02)	1 (0.01)			2 (0.00)
BETA FERON (INTERFERON	1 (0.02)	2 (0.01)			3 (0.00)
BETA FERON (INTERFERON	3 (0.05)	3 (0.02)			6 (0.01)
BETA FERON (INTERFERON		1 (0.01)			1 (0.00)
BETA FERON (INTERFERON			1 (0.00)		1 (0.00)
BETA FERON (INTERFERON		1 (0.01)			1 (0.00)
BETA FERON (INTERFERON		1 (0.01)			1 (0.00)
BETA FERON (INTERFERON		3 (0.02)			3 (0.00)
BETA FERON 250 ?G, 500	1 (0.02)				1 (0.00)
BETA FERON 250 UG, 500		1 (0.01)			1 (0.00)
BETA FERON 250 UG, 500	1 (0.02)				1 (0.00)
BETA FERON 250 UG, 500		1 (0.01)			1 (0.00)
BETA FERON(BETA FERON (S			1 (0.00)		1 (0.00)
BETA FERON(INTEREFERON	1 (0.02)				1 (0.00)
BETA FERON(INTERFERON B		2 (0.01)			2 (0.00)
BETA FERON(INTERFERON B			1 (0.00)		1 (0.00)
BETA FERON(INTERFERON B		1 (0.01)			1 (0.00)
BETA FERONE		1 (0.01)			1 (0.00)
BETAGAN			2 (0.01)		2 (0.00)
BETA HISTINE (BETA HISTI				2 (0.03)	2 (0.00)
BETALOC		2 (0.01)			2 (0.00)
BETAMAC				1 (0.01)	1 (0.00)
BETAMETASONE		1 (0.01)			1 (0.00)
BETAMETHASONE	5 (0.08)		3 (0.01)	1 (0.01)	9 (0.01)
BETAMETHASONE DIPROPIO			1 (0.00)		1 (0.00)
BETAMETHASONE SODIUM P		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
BETAMETHASONE VALERATE		1 (0.01)			1 (0.00)
BETAMETHASONE/CALCIPOT			2 (0.01)		2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
BETANOL		1 (0.01)			1 (0.00)
BETAPACE			3 (0.01)	2 (0.03)	5 (0.01)
BETAPRED		1 (0.01)			1 (0.00)
BETASERC		2 (0.01)			2 (0.00)
BETASERC (BETAHISTINE			1 (0.00)		1 (0.00)
BETASERC /NET/ (BETAHI				1 (0.01)	1 (0.00)
BETASERON	5 (0.08)	88 (0.52)	93 (0.31)	3 (0.04)	189 (0.31)
BETASERON (INTERFERON			1 (0.00)		1 (0.00)
BETASERON (INTERFERON		2 (0.01)	2 (0.01)		4 (0.01)
BETASERON (INTERFERON			1 (0.00)		1 (0.00)
BETASERON (INTERFERON		1 (0.01)			1 (0.00)
BETASERON(INTERFERON B		1 (0.01)	2 (0.01)		3 (0.00)
BETATOP			2 (0.01)		2 (0.00)
BETAXA			1 (0.00)		1 (0.00)
BETAXOLOL	3 (0.05)		1 (0.00)		4 (0.01)
BETESERON (INTERFERON			1 (0.00)		1 (0.00)
BETNESOL-N EYE OINTMEN			1 (0.00)		1 (0.00)
BETNOVATE (BET		1 (0.01)			1 (0.00)
BETNOVATE (BETAMETHASO		1 (0.01)			1 (0.00)
BETOPIC (BETAMETHASONE			1 (0.00)		1 (0.00)
BETOPTIC			1 (0.00)		1 (0.00)
BEVACIZUMAB		2 (0.01)	10 (0.03)	2 (0.03)	14 (0.02)
BEVACIZUMAB 15MG/KG		1 (0.01)			1 (0.00)
BEVACIZUMAB GENENTEC		1 (0.01)			1 (0.00)
BEVACIZUMAB 0R PLACEBO		1 (0.01)			1 (0.00)
BEVACIZUMAB 1252 MG IV			1 (0.00)		1 (0.00)
BEVACIZUMAB 15MG/KG		1 (0.01)			1 (0.00)
BEVACIZUMAB GENENTECH		1 (0.01)			1 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
BEVACIZUMAB OR PLACEBO			1 (0.00)		1 (0.00)
BEVACIZUMAB OR PLACEBO			1 (0.00)		1 (0.00)
BEVACIZUMAB OR PLACEBO			1 (0.00)		1 (0.00)
BEVACIZUMAB OR PLACEBO			2 (0.01)		2 (0.00)
BEVACIZUMAB, 15 MG/KG				1 (0.01)	1 (0.00)
BEXTRA	1 (0.02)	27 (0.16)	47 (0.16)	19 (0.25)	94 (0.15)
BEXXAR		1 (0.01)			1 (0.00)
BEZAFIBRATE		2 (0.01)	1 (0.00)	4 (0.05)	7 (0.01)
BEZALIP			1 (0.00)		1 (0.00)
BEZATOL			2 (0.01)		2 (0.00)
BEZATOL - SLOW RELEASE				1 (0.01)	1 (0.00)
BH-AC		1 (0.01)			1 (0.00)
BI-SIFROL TABLETS			1 (0.00)		1 (0.00)
BIAPENEM			1 (0.00)		1 (0.00)
BIAXIN	3 (0.05)	1 (0.01)	6 (0.02)	2 (0.03)	12 (0.02)
BIAXIN XL	2 (0.03)		4 (0.01)		6 (0.01)
BICALUTAMIDE			1 (0.00)	1 (0.01)	2 (0.00)
BICARBONATED RINGER'S			1 (0.00)		1 (0.00)
BICLAR (C			1 (0.00)		1 (0.00)
BIFITERAL		1 (0.01)			1 (0.00)
BIGOMET			1 (0.00)		1 (0.00)
BIODINE		1 (0.01)			1 (0.00)
BIOFERMIN	7 (0.12)	1 (0.01)			8 (0.01)
BIOFERMIN R		1 (0.01)			1 (0.00)
BIOFERMIN R (STREPTOCO			1 (0.00)		1 (0.00)
BIOTIN	1 (0.02)	1 (0.01)			2 (0.00)
BIPERIDEN HYDROCHLORID	2 (0.03)	1 (0.01)	3 (0.01)		6 (0.01)
BIPERIDENI		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
BIPHOSPHONATE (BISPHOS		1 (0.01)			1 (0.00)
BIPRETERAX			1 (0.00)		1 (0.00)
BIPROFENID			1 (0.00)		1 (0.00)
BIRODOGYL	1 (0.02)		3 (0.01)		4 (0.01)
BIRTH CONTROL	3 (0.05)	3 (0.02)			6 (0.01)
BIRTH CONTROL NAME UNK	1 (0.02)				1 (0.00)
BIRTH CONTROL NOS	1 (0.02)				1 (0.00)
BIRTH CONTROL PILL	1 (0.02)				1 (0.00)
BIRTH CONTROL PILLS	8 (0.14)	8 (0.05)	2 (0.01)		18 (0.03)
BIRTH CONTROL PILLS NO	3 (0.05)				3 (0.00)
BISACODY			1 (0.00)		1 (0.00)
BISACODYL			1 (0.00)		1 (0.00)
BISOLVON	2 (0.03)				2 (0.00)
BISOMERCK				1 (0.01)	1 (0.00)
BISOPROLOL		3 (0.02)	5 (0.02)	5 (0.06)	13 (0.02)
BISOPROLOL (BISOPROLOL			2 (0.01)	1 (0.01)	3 (0.00)
BISOPROLOL (NGX) (BISO			1 (0.00)		1 (0.00)
BISOPROLOL 5 MG			1 (0.00)		1 (0.00)
BISOPROLOL ALPHARMA			1 (0.00)		1 (0.00)
BISOPROLOL FUMARATE		4 (0.02)	8 (0.03)	10 (0.13)	22 (0.04)
BISOPROLOL FUMARATE AN			1 (0.00)		1 (0.00)
BISULFAN (BUSULFAN)			1 (0.00)		1 (0.00)
BIVALIRUDIN			1 (0.00)		1 (0.00)
BIVALIRUDIN INJECTABLE				1 (0.01)	1 (0.00)
BLACK COHOSH			5 (0.02)		5 (0.01)
BLADDERON			1 (0.00)		1 (0.00)
BLEOMYCIN	1 (0.02)	6 (0.04)	4 (0.01)		11 (0.02)
BLINDED ADEFOVIR DIPIV	1 (0.02)				1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
BLINDED THEAPY (INTERF			1 (0.00)		1 (0.00)
BLINDED THERAPY (INTER			2 (0.01)		2 (0.00)
BLINDED THERAPY (INTER			16 (0.05)	2 (0.03)	18 (0.03)
BLINDED: CETUXIMAB			1 (0.00)		1 (0.00)
BLINDED: IRBESARTAN			1 (0.00)		1 (0.00)
BLINDED; RISPERIDONE		1 (0.01)			1 (0.00)
BLOOD PESSURE MEDICATI				1 (0.01)	1 (0.00)
BLOOD PRESSURE MEDICAT		3 (0.02)	13 (0.04)	2 (0.03)	18 (0.03)
BLOOD PRESSURE MEDICAT				1 (0.01)	1 (0.00)
BLOOD PRESSURE MEDICAT				1 (0.01)	1 (0.00)
BLOOD PRESSURE MEDICAT			1 (0.00)		1 (0.00)
BLOOD PRESSURE MEDICAT			1 (0.00)		1 (0.00)
BLOOD PRESSURE MEDS			1 (0.00)		1 (0.00)
BLOOD THINNER (UNSPECI			2 (0.01)		2 (0.00)
BLOOD TRANSFUSION (BLO			1 (0.00)		1 (0.00)
BLOOD TRANSFUSION, AUX	2 (0.03)				2 (0.00)
BLOPRESS	1 (0.02)		8 (0.03)	1 (0.01)	10 (0.02)
BLOPRESS			1 (0.00)		1 (0.00)
BLOPRESS (CANDESARTAN			4 (0.01)	1 (0.01)	5 (0.01)
BLOPRESS PLUS			1 (0.00)		1 (0.00)
BLOPRESS TABLETS 4	1 (0.02)	1 (0.01)			2 (0.00)
BLOPRESS TABLETS 8			2 (0.01)		2 (0.00)
BONDRONAT			1 (0.00)		1 (0.00)
BONE GRAFT MATERIAL BO			1 (0.00)		1 (0.00)
BONE TISSUE HUMAN		1 (0.01)			1 (0.00)
BONEFOS BOEHRINGER I			1 (0.00)		1 (0.00)
BONEFOS (CLODRONATE DI			1 (0.00)		1 (0.00)
BONIVA		22 (0.13)	115 (0.38)	37 (0.48)	174 (0.29)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
BONIVA (IBANDRONIC ACI				1 (0.01)	1 (0.00)
BONVIVA			1 (0.00)		1 (0.00)
BOOSTRIX			1 (0.00)		1 (0.00)
BORTEZOMIB 3MG			1 (0.00)		1 (0.00)
BORTEZOMIB (BORTEZOMIB			1 (0.00)		1 (0.00)
BOSENTAN	1 (0.02)	1 (0.01)	3 (0.01)		5 (0.01)
BOSENTAN (BOSENTAN L.			1 (0.00)		1 (0.00)
BOSENTAN(BOSENTAN I,PH			1 (0.00)		1 (0.00)
BOSENTAN(BOSENTAN, BOS	1 (0.02)				1 (0.00)
BOTOX		8 (0.05)	5 (0.02)		13 (0.02)
BOTOX A 100 UNITS (ALL		1 (0.01)			1 (0.00)
BOTOX COSMETIC		5 (0.03)	4 (0.01)		9 (0.01)
BOTULINUM TOXIN TYPE A		1 (0.01)			1 (0.00)
BOTULINUM TOXIN TYPE B			1 (0.00)	1 (0.01)	2 (0.00)
BOTULISM ANTITOXIN E			1 (0.00)		1 (0.00)
BREDININ			1 (0.00)		1 (0.00)
BREMON TABLETS	1 (0.02)				1 (0.00)
BRICANYL		1 (0.01)	3 (0.01)		4 (0.01)
BRICANYL (GU			1 (0.00)		1 (0.00)
BRIMONIDINE TARTRATE				3 (0.04)	3 (0.00)
BRIPLATIN		1 (0.01)	2 (0.01)		3 (0.00)
BROCIN		2 (0.01)		1 (0.01)	3 (0.00)
BROMAZEPAM		1 (0.01)	4 (0.01)	3 (0.04)	8 (0.01)
BROMOCRIPTINE MESYLATE		3 (0.02)	4 (0.01)		7 (0.01)
BROMODRIPTINE (BROMOCR	1 (0.02)				1 (0.00)
BROMOKIN		1 (0.01)			1 (0.00)
BRONCHORETARD				1 (0.01)	1 (0.00)
BRONDILAT	1 (0.02)		1 (0.00)		2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
BROTIZOLAM				1 (0.01)	1 (0.00)
BRUFEN (IBUPROFEN)			5 (0.02)		5 (0.01)
BRUFEN ^ABBOTT^ (IBUPR		1 (0.01)			1 (0.00)
BRUFEN ^ABBOT^ (IBUPRO		1 (0.01)			1 (0.00)
BSS			1 (0.00)		1 (0.00)
BUCILLAMINE				1 (0.01)	1 (0.00)
BUDES			1 (0.00)		1 (0.00)
BUDESONID			1 (0.00)		1 (0.00)
BUDESONIDE	4 (0.07)	5 (0.03)	6 (0.02)	11 (0.14)	26 (0.04)
BUDESONIDE AND FORMOTE		1 (0.01)	2 (0.01)		3 (0.00)
BUFFERIN	2 (0.03)		2 (0.01)	5 (0.06)	9 (0.01)
BUFFERIN/JPN/ (ACETYLS				1 (0.01)	1 (0.00)
BUFLOMEDIL 600			1 (0.00)		1 (0.00)
BUFLOMEDIL HYDROCHLORI				2 (0.03)	2 (0.00)
BUMETADINE INJ. USP 1.			1 (0.00)		1 (0.00)
BUMETANIDE			5 (0.02)	1 (0.01)	6 (0.01)
BUMEX			2 (0.01)		2 (0.00)
BUP-4	1 (0.02)				1 (0.00)
BUPIVACAINE	1 (0.02)		5 (0.02)		6 (0.01)
BUPIVACAINE HCL		4 (0.02)			4 (0.01)
BUPIVACAINE HYDROCHLOR			1 (0.00)		1 (0.00)
BUPRENORPHINE (BUPRENO			2 (0.01)		2 (0.00)
BUPRENORPHINE HCL	34 (0.58)	53 (0.31)	2 (0.01)	1 (0.01)	90 (0.15)
BUPRENORPHINE HYDROCHL				1 (0.01)	1 (0.00)
BUPRENORPHINE/NALOXONE			3 (0.01)		3 (0.00)
BUPROPION	1 (0.02)	3 (0.02)			4 (0.01)
BUPROPION HCL	2 (0.03)	14 (0.08)	8 (0.03)		24 (0.04)
BUPROPION HYDROCHLORID	1 (0.02)	4 (0.02)	2 (0.01)		7 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
BUPROPION HYDROCHLORID		1 (0.01)			1 (0.00)
BUPROPION SR -TEVA-			1 (0.00)		1 (0.00)
BUPROPION SR 150 MG TE			1 (0.00)		1 (0.00)
BUPROPION HCL			1 (0.00)		1 (0.00)
BURANA (IBUPROFEN)		2 (0.01)			2 (0.00)
BURINEX	1 (0.02)				1 (0.00)
BUSCOPAN		2 (0.01)			2 (0.00)
BUSCOPAN (SCOPOLAMINE		1 (0.01)			1 (0.00)
BUSPAR	6 (0.10)	8 (0.05)	17 (0.06)	1 (0.01)	32 (0.05)
BUSPIRONE		1 (0.01)			1 (0.00)
BUSPIRONE HCL		1 (0.01)	1 (0.00)		2 (0.00)
BUSULFAN	2 (0.03)	1 (0.01)			3 (0.00)
BUSULFAN (BUSULFAN)			1 (0.00)		1 (0.00)
BUSULFAN UMBILICAL COR		1 (0.01)			1 (0.00)
BUTALBITAL			3 (0.01)		3 (0.00)
BUTALBITAL + ACETAMINO		1 (0.01)			1 (0.00)
BUTALBITAL + CAFFEINE		1 (0.01)			1 (0.00)
BUTALBITAL ACETAMINOPH		2 (0.01)			2 (0.00)
BUTETANIDE			1 (0.00)		1 (0.00)
BUTISOL SODIUM		1 (0.01)			1 (0.00)
BUTYLSCOPOLAMIN (HYOSC	1 (0.02)				1 (0.00)
BYETTA	1 (0.02)	111 (0.65)	311 (1.03)	24 (0.31)	447 (0.73)
BYETTA INJECTION (0.35		1 (0.01)			1 (0.00)
C-PAP			1 (0.00)		1 (0.00)
CA. GLUCONATE			1 (0.00)		1 (0.00)
CABASER				1 (0.01)	1 (0.00)
CABASERIL		1 (0.01)			1 (0.00)
CABERGOLINE	2 (0.03)	6 (0.04)	17 (0.06)	4 (0.05)	29 (0.05)

Drug Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
CADUET		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
CAELYX		2 (0.01)	3 (0.01)		5 (0.01)
CAFFEINE CITRATE (CAFF	1 (0.02)				1 (0.00)
CALAN		2 (0.01)	11 (0.04)		13 (0.02)
CALCET			1 (0.00)		1 (0.00)
CALCICHEW		1 (0.01)	1 (0.00)		2 (0.00)
CALCICHEW (CALCIUM CAR			1 (0.00)		1 (0.00)
CALCICHEW-D3 (COLECALC			1 (0.00)		1 (0.00)
CALCICHEW-D3 FORTE		1 (0.01)			1 (0.00)
CALCIDIA (CALCIUM CARB				1 (0.01)	1 (0.00)
CALCIMED D3			1 (0.00)		1 (0.00)
CALCIORAL			2 (0.01)		2 (0.00)
CALCIPARINE				2 (0.03)	2 (0.00)
CALCIPARINE ^SANOFI^ (1 (0.01)	1 (0.00)
CALCIPOTRIENE		1 (0.01)	1 (0.00)		2 (0.00)
CALCIPOTRIOL (CALCIPOT		1 (0.01)			1 (0.00)
CALCIPOTRIOL (CALCIPRO		1 (0.01)			1 (0.00)
CALCIPRANE			1 (0.00)		1 (0.00)
CALCITONIN SALMON				2 (0.03)	2 (0.00)
CALCITONIN-SALMON			1 (0.00)		1 (0.00)
CALCITRIOL		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
CALCIUM (CALCIUM)		3 (0.02)	4 (0.01)		7 (0.01)
CALCIUM (UNSPECIFIED)			13 (0.04)	5 (0.06)	18 (0.03)
CALCIUM (UNSPECIFIED)		2 (0.01)		2 (0.03)	4 (0.01)
CALCIUM ACETATE		1 (0.01)	1 (0.00)		2 (0.00)
CALCIUM ANTAGONIST (CA				2 (0.03)	2 (0.00)
CALCIUM CARBONATE			6 (0.02)	1 (0.01)	7 (0.01)
CALCIUM CARBONATE (CAL			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CALCIUM CARBONATE (FOR	1 (0.02)				1 (0.00)
CALCIUM CARBONATE + CH				1 (0.01)	1 (0.00)
CALCIUM CARBONATE AND			3 (0.01)	1 (0.01)	4 (0.01)
CALCIUM CARBONATE TABL			3 (0.01)		3 (0.00)
CALCIUM CARBONATE TABL			1 (0.00)		1 (0.00)
CALCIUM CHANNEL BLOCKE		1 (0.01)		2 (0.03)	3 (0.00)
CALCIUM CHLORIDE (CA			1 (0.00)		1 (0.00)
CALCIUM CITRATE (CALCI			1 (0.00)		1 (0.00)
CALCIUM FOLINATE		1 (0.01)			1 (0.00)
CALCIUM GLUCONATE	2 (0.03)	2 (0.01)	20 (0.07)	8 (0.10)	32 (0.05)
CALCIUM LACTOGLUCONATE		1 (0.01)			1 (0.00)
CALCIUM LEVOFOLINATE		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
CALCIUM LEVOFOLINATE (3 (0.01)		3 (0.00)
CALCIUM SANDOZ		1 (0.01)	1 (0.00)		2 (0.00)
CALCIUM SANDOZ FORTE D			1 (0.00)		1 (0.00)
CALCIUM SUPPLEMENT				1 (0.01)	1 (0.00)
CALCIUM WITH MAGNESIUM			1 (0.00)		1 (0.00)
CALCIUM WITH VITAMIN D				1 (0.01)	1 (0.00)
CALCORT				1 (0.01)	1 (0.00)
CALONAL	3 (0.05)		2 (0.01)		5 (0.01)
CALONAL (1 (0.01)	1 (0.00)
CALONAL (ACETAMINOPHEN				3 (0.04)	3 (0.00)
CALTAN		2 (0.01)			2 (0.00)
CALTAN (CALCIUM CARBON		2 (0.01)	1 (0.00)		3 (0.00)
CALTIN (CALCIUM CARBON			1 (0.00)		1 (0.00)
CALTRATE			1 (0.00)		1 (0.00)
CAM	1 (0.02)	1 (0.01)			2 (0.00)
CAMOMILE TEA	1 (0.02)				1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CAMPATH	1 (0.02)	2 (0.01)	4 (0.01)	3 (0.04)	10 (0.02)
CAMPATH (ALEMTUZUMAB)		1 (0.01)			1 (0.00)
CAMPAZINE			1 (0.00)		1 (0.00)
CAMPRAL		4 (0.02)	1 (0.00)	1 (0.01)	6 (0.01)
CAMPTOSAR		1 (0.01)	10 (0.03)		11 (0.02)
CANCER VACCINE INJECTA			1 (0.00)		1 (0.00)
CANCIDAS	2 (0.03)	7 (0.04)	3 (0.01)		12 (0.02)
CANDESARTAN			3 (0.01)	2 (0.03)	5 (0.01)
CANDESARTAN (CANDESARTAN)	2 (0.03)		1 (0.00)		3 (0.00)
CANDESARTAN CILEXETIL			2 (0.01)		2 (0.00)
CANDESARTAN CILEXETIL				1 (0.01)	1 (0.00)
CANDESARTAN CILEXETIL			4 (0.01)		4 (0.01)
CANESTEN		1 (0.01)			1 (0.00)
CANFERON			2 (0.01)		2 (0.00)
CANNABINOIDS	1 (0.02)				1 (0.00)
CANNABIS (CANNABIS)	1 (0.02)				1 (0.00)
CANNBIS VAPORIZED AD L			1 (0.00)		1 (0.00)
CANSIDAS			1 (0.00)		1 (0.00)
CAPASTA (CAPREOMYCIN S)				1 (0.01)	1 (0.00)
CAPECITABINE		14 (0.08)	27 (0.09)	2 (0.03)	43 (0.07)
CAPECITABINE (CAPECITABINE)			5 (0.02)		5 (0.01)
CAPECITABINE 1500 MG/M			1 (0.00)		1 (0.00)
CAPECITABINE PO		1 (0.01)	1 (0.00)		2 (0.00)
CAPOTEN		1 (0.01)	1 (0.00)		2 (0.00)
CAPREOMYCIN		1 (0.01)			1 (0.00)
CAPSAICIN			1 (0.00)		1 (0.00)
CAPTOPRIL	3 (0.05)	4 (0.02)	21 (0.07)	9 (0.12)	37 (0.06)
CAPTOPRIL			1 (0.00)		1 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CAPTOPRIL MSD			1 (0.00)		1 (0.00)
CAPZASIN HP 0.1		1 (0.01)			1 (0.00)
CARAFATE		3 (0.02)	4 (0.01)		7 (0.01)
CARBA (CARBAMAZEPINE)			1 (0.00)		1 (0.00)
CARBAMAZEPINE	24 (0.41)	26 (0.15)	20 (0.07)	2 (0.03)	72 (0.12)
CARBATROL	2 (0.03)	6 (0.04)	3 (0.01)		11 (0.02)
CARBAZOCHROME SODIUM S			3 (0.01)		3 (0.00)
CARBENIN	2 (0.03)		1 (0.00)		3 (0.00)
CARBENIN (BETAMIPRON,				1 (0.01)	1 (0.00)
CARBENIN (BETAMIPRON/P			1 (0.00)		1 (0.00)
CARBIDOPA + LEVODOPA	1 (0.02)		3 (0.01)		4 (0.01)
CARBIDOPA + LEVODOPA C			1 (0.00)		1 (0.00)
CARBIDOPA AND LEVODOPA	1 (0.02)		6 (0.02)	1 (0.01)	8 (0.01)
CARBIDOPA/LEVODOPA ER			1 (0.00)		1 (0.00)
CARBIMAZOLE		2 (0.01)			2 (0.00)
CARBIMAZOLE (CARBIMAZO				1 (0.01)	1 (0.00)
CARBOCAIN			1 (0.00)		1 (0.00)
CARBOCAINA		3 (0.02)	1 (0.00)		4 (0.01)
CARBOCAINA + ADRENALIN		1 (0.01)			1 (0.00)
CARBOCAINE			1 (0.00)		1 (0.00)
CARBOCISTEINE			1 (0.00)		1 (0.00)
CARBOCISTEINE LYSINE			1 (0.00)		1 (0.00)
CARBOFED DM DROPS 1MG	1 (0.02)				1 (0.00)
CARBOLITIUM		1 (0.01)			1 (0.00)
CARBON DIOXIDE GAS GRE		1 (0.01)			1 (0.00)
CARBOPLATIN	2 (0.03)	12 (0.07)	73 (0.24)	13 (0.17)	100 (0.16)
CARBOPLATIN (NGX) (CAR			1 (0.00)		1 (0.00)
CARBOPLATIN 50 MG VIAL			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CARBOPLATINE			2 (0.01)		2 (0.00)
CARBOPLATINE TEVA			1 (0.00)		1 (0.00)
CARDENALIN			1 (0.00)	5 (0.06)	6 (0.01)
CARDENALIN (DOXAZOSIN)			8 (0.03)		8 (0.01)
CARDENSIEL (FILM-COATE				1 (0.01)	1 (0.00)
CARDIAC MEDICATION NOS			1 (0.00)		1 (0.00)
CARDIAC THERAPY (CARDI			1 (0.00)	2 (0.03)	3 (0.00)
CARDIAC TISSUE HUMAN				3 (0.04)	3 (0.00)
CARDIKET				1 (0.01)	1 (0.00)
CARDILATE			1 (0.00)		1 (0.00)
CARDIOLITE		6 (0.04)	6 (0.02)	1 (0.01)	13 (0.02)
CARDIOVASCULAR SYSTEM			1 (0.00)		1 (0.00)
CARDIOVASCULAR SYSTEM			1 (0.00)		1 (0.00)
CARDIOVASCULAR SYSTEM				1 (0.01)	1 (0.00)
CARDISER - SLOW RELEAS			1 (0.00)		1 (0.00)
CARDIZEM		8 (0.05)	35 (0.12)	19 (0.25)	62 (0.10)
CARDIZEM (DILATIAZEM)			1 (0.00)		1 (0.00)
CARDIZEM CD		2 (0.01)	11 (0.04)	2 (0.03)	15 (0.02)
CARDIZEM LA				1 (0.01)	1 (0.00)
CARDURA			18 (0.06)	5 (0.06)	23 (0.04)
CARDYL			1 (0.00)		1 (0.00)
CARDYL (ATORVASTATIN)			1 (0.00)		1 (0.00)
CARIMUNE			3 (0.01)		3 (0.00)
CARISOPRODOL		8 (0.05)	5 (0.02)		13 (0.02)
CARMEN			3 (0.01)		3 (0.00)
CARMENT (LERCANIDIPINE			1 (0.00)		1 (0.00)
CARMUSTINE		1 (0.01)	1 (0.00)		2 (0.00)
CARTEOLOL HCL		1 (0.01)			1 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
CARTEOLOL HYDROCHLORID			1 (0.00)		1 (0.00)
CARTIA XG			1 (0.00)		1 (0.00)
CARTIA XT			6 (0.02)	1 (0.01)	7 (0.01)
CARTIA/AUS/				1 (0.01)	1 (0.00)
CARTICEL		2 (0.01)			2 (0.00)
CARVEDILOL	1 (0.02)	1 (0.01)	15 (0.05)	17 (0.22)	34 (0.06)
CARVIDELOL			1 (0.00)		1 (0.00)
CASODEX			11 (0.04)	13 (0.17)	24 (0.04)
CASPOFUNGIN		1 (0.01)	3 (0.01)		4 (0.01)
CATAFLAM		3 (0.02)	1 (0.00)		4 (0.01)
CATAPRES		4 (0.02)	5 (0.02)	2 (0.03)	11 (0.02)
CATAPRES /USA/		1 (0.01)			1 (0.00)
CATAPRES-TTS-1	1 (0.02)		3 (0.01)		4 (0.01)
CATHFLO ACTIVASE			1 (0.00)		1 (0.00)
CAVERJECT		1 (0.01)	3 (0.01)	2 (0.03)	6 (0.01)
CBV (ZIODUVINDE W/LAMI		1 (0.01)			1 (0.00)
CC-5013 REVLIMID			1 (0.00)		1 (0.00)
CC-5013 (CAPSULES) REV				2 (0.03)	2 (0.00)
CDDP		1 (0.01)			1 (0.00)
CEBUTID			1 (0.00)		1 (0.00)
CECLOR	1 (0.02)	2 (0.01)			3 (0.00)
CEDAX	1 (0.02)				1 (0.00)
CEFACIDAL	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)
CEFACLOR	1 (0.02)		1 (0.00)		2 (0.00)
CEFADROXIL		2 (0.01)			2 (0.00)
CEFALIUM (CAFFEINE, DI		1 (0.01)			1 (0.00)
CEFAMEZIN	2 (0.03)				2 (0.00)
CEFAZOLIN	3 (0.05)	8 (0.05)	17 (0.06)	3 (0.04)	31 (0.05)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CEFAZOLIN FOR INJECTIO			1 (0.00)		1 (0.00)
CEFAZOLIN SODIUM		3 (0.02)			3 (0.00)
CEFAZOLIN SODIUM		1 (0.01)			1 (0.00)
CEFAZOLIN SODIUM (KEFZ		1 (0.01)			1 (0.00)
CEFAZOLIN SODIUM IN DE			1 (0.00)		1 (0.00)
CEFCAPENE PIVOXIL HYDR				3 (0.04)	3 (0.00)
CEFDITOREN PIVOXIL			2 (0.01)		2 (0.00)
CEFDITOREN PIVOXIL (CE	1 (0.02)				1 (0.00)
CEFDITOREN PIVOXIL (CE			1 (0.00)		1 (0.00)
CEFDITOREN PIVOXIL (SI	1 (0.02)				1 (0.00)
CEFDITOREN PIVOXIL (SI	1 (0.02)	1 (0.01)			2 (0.00)
CEFEPIME		1 (0.01)	2 (0.01)		3 (0.00)
CEFEPIME DIHYDROCHLORI			1 (0.00)		1 (0.00)
CEFEPIME HCL			2 (0.01)	1 (0.01)	3 (0.00)
CEFEPIME, ELAN LABORAT				1 (0.01)	1 (0.00)
CEFIPEM		1 (0.01)			1 (0.00)
CEFIXIME CHEWABLE	1 (0.02)		1 (0.00)		2 (0.00)
CEFMETAZON			2 (0.01)	1 (0.01)	3 (0.00)
CEFMETAZON (CEFMETAZOL		1 (0.01)			1 (0.00)
CEFOBID	1 (0.02)				1 (0.00)
CEFOPERAZONE				1 (0.01)	1 (0.00)
CEFOPERAZONE SODIUM			1 (0.00)		1 (0.00)
CEFOPERAZONE SODIUM/SU			1 (0.00)		1 (0.00)
CEFOPERAZONE SODIUM/SU			1 (0.00)		1 (0.00)
CEFOPERAZONE/SULBACTAM			1 (0.00)		1 (0.00)
CEFOTAXIME	3 (0.05)				3 (0.00)
CEFOTAXIME SODIUM	6 (0.10)				6 (0.01)
CEFOTIAM HYDROCHLORIDE			1 (0.00)		1 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
CEFOTIAM HYDROCHLORIDE			1 (0.00)		1 (0.00)
CEFPIROME			1 (0.00)		1 (0.00)
CEFPODOXIME PROXETIL	1 (0.02)	2 (0.01)			3 (0.00)
CEFPROZIL	1 (0.02)				1 (0.00)
CEFRADINE		1 (0.01)			1 (0.00)
CEFSPAN (CEFIXIME)	1 (0.02)				1 (0.00)
CEFTAZIDIME	1 (0.02)		2 (0.01)	2 (0.03)	5 (0.01)
CEFTAZIDIME SODIUM	1 (0.02)			1 (0.01)	2 (0.00)
CEFTAZIDMINE PENTAHYDR				2 (0.03)	2 (0.00)
CEFTIBUTEN	1 (0.02)				1 (0.00)
CEFTIN			1 (0.00)	1 (0.01)	2 (0.00)
CEFTRIAZONE	4 (0.07)	4 (0.02)	8 (0.03)	5 (0.06)	21 (0.03)
CEFTRIAZONE SODIUM	2 (0.03)	2 (0.01)	4 (0.01)	2 (0.03)	10 (0.02)
CEFURIM ECO 500 (CEFU			1 (0.00)		1 (0.00)
CEFUROXIM			2 (0.01)		2 (0.00)
CEFUROXIME	1 (0.02)	4 (0.02)	11 (0.04)	3 (0.04)	19 (0.03)
CEFUROXIME AXETIL	1 (0.02)		3 (0.01)		4 (0.01)
CEFUROXIME SODIUM				1 (0.01)	1 (0.00)
CEFZIL	9 (0.15)				9 (0.01)
CEFZON	2 (0.03)	1 (0.01)	2 (0.01)	1 (0.01)	6 (0.01)
CELCEPT			1 (0.00)		1 (0.00)
CELEBRA			1 (0.00)		1 (0.00)
CELEBREX	4 (0.07)	51 (0.30)	151 (0.50)	35 (0.45)	241 (0.40)
CELEBREX (CELECOXIB)				1 (0.01)	1 (0.00)
CELECOXIB		4 (0.02)	3 (0.01)	4 (0.05)	11 (0.02)
CELECOXIB 200MG				1 (0.01)	1 (0.00)
CELECOXIB (CELECOXIB)		1 (0.01)	3 (0.01)	1 (0.01)	5 (0.01)
CELECOXIB 200 MG PFIZE			1 (0.00)		1 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CELECTOL				2 (0.03)	2 (0.00)
CELESDEPOT INJECTABLE			1 (0.00)		1 (0.00)
CELESTAMINE (BETAMETHA			3 (0.01)		3 (0.00)
CELESTAMINE TAB			2 (0.01)		2 (0.00)
CELESTENE	2 (0.03)	1 (0.01)			3 (0.00)
CELESTENE (BET			1 (0.00)		1 (0.00)
CELESTENE (BETAMETHASO			1 (0.00)		1 (0.00)
CELESTONE	6 (0.10)	2 (0.01)	1 (0.00)		9 (0.01)
CELESTONE TAB			1 (0.00)		1 (0.00)
CELEXA	7 (0.12)	41 (0.24)	22 (0.07)	4 (0.05)	74 (0.12)
CELLCEPT	7 (0.12)	17 (0.10)	28 (0.09)	1 (0.01)	53 (0.09)
CELLCEPT/RAPAMUNE		1 (0.01)			1 (0.00)
CELLUVISE			1 (0.00)		1 (0.00)
CELOCURINE		1 (0.01)			1 (0.00)
CELTECT			1 (0.00)		1 (0.00)
CELTECT (OXATOMIDE)		1 (0.01)			1 (0.00)
CENESTIN		1 (0.01)	2 (0.01)		3 (0.00)
CENTOLIN (SALBUTAMOL)				1 (0.01)	1 (0.00)
CENTRUM	1 (0.02)	2 (0.01)	2 (0.01)	1 (0.01)	6 (0.01)
CENTRUM (MINERALS NOS,		1 (0.01)			1 (0.00)
CENTRUM (MINERALS NOS,		1 (0.01)			1 (0.00)
CENTRUM (MULTIVITAMIN/			1 (0.00)		1 (0.00)
CENTRUM A TO ZINC (MIN			1 (0.00)		1 (0.00)
CENTRUM PERFORMANCE			1 (0.00)		1 (0.00)
CENTRUM SILVER			3 (0.01)	2 (0.03)	5 (0.01)
CENTRUM SILVER (CENTRU			1 (0.00)		1 (0.00)
CENTYL (BENDROFLUMETHI		1 (0.01)			1 (0.00)
CENTYL MITE W/POTASSIU		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CENTYL WITH POTASSIUM			1 (0.00)		1 (0.00)
CEPHALEXIN	1 (0.02)	4 (0.02)	10 (0.03)	2 (0.03)	17 (0.03)
CEPHALOSPORIN			2 (0.01)		2 (0.00)
CEPRANDAL		2 (0.01)			2 (0.00)
CERAZETTE		2 (0.01)			2 (0.00)
CERCINE		2 (0.01)	1 (0.00)		3 (0.00)
CEREBYX	1 (0.02)		3 (0.01)		4 (0.01)
CEREZYME	12 (0.20)	7 (0.04)	14 (0.05)	6 (0.08)	39 (0.06)
CERNILTON		1 (0.01)			1 (0.00)
CEROCRAL			1 (0.00)	3 (0.04)	4 (0.01)
CERUCAL		1 (0.01)			1 (0.00)
CERVIDIL	1 (0.02)	2 (0.01)			3 (0.00)
CETIRIZIN			1 (0.00)		1 (0.00)
CETIRIZINE	1 (0.02)		1 (0.00)		2 (0.00)
CETIRIZINE HCL	1 (0.02)	1 (0.01)		1 (0.01)	3 (0.00)
CETIRIZINE HCL AND PSE			1 (0.00)		1 (0.00)
CETIRIZINE HYDROCHLORI	1 (0.02)				1 (0.00)
CETROTIDE		2 (0.01)			2 (0.00)
CETROTIDE (CETRORELIX		1 (0.01)			1 (0.00)
CETUXIMAB		25 (0.15)	99 (0.33)	9 (0.12)	133 (0.22)
CETUXIMAB 100 MG VIA		1 (0.01)			1 (0.00)
CETUXIMAB (MERCK AND C			1 (0.00)		1 (0.00)
CHEMOTHERAPEUTICS,OTHE		3 (0.02)	12 (0.04)	2 (0.03)	17 (0.03)
CHEMOTHERAPY	1 (0.02)	2 (0.01)	4 (0.01)	2 (0.03)	9 (0.01)
CHEMOTHERAPY (CHEMOTHE		2 (0.01)			2 (0.00)
CHEMOTHERAPY REGIMENS				1 (0.01)	1 (0.00)
CHILDREN'S ADVIL	6 (0.10)				6 (0.01)
CHILDREN'S CLARITIN	1 (0.02)				1 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
CHILDREN'S IBUPROFEN S	1 (0.02)				1 (0.00)
CHILDREN'S MOTRIN	2 (0.03)				2 (0.00)
CHILDREN'S PANADOL COL	1 (0.02)				1 (0.00)
CHILDREN'S PEDIACARE M	1 (0.02)				1 (0.00)
CHILDREN'S PEDIACARE M	1 (0.02)				1 (0.00)
CHILDREN'S PEDIACARE N	2 (0.03)				2 (0.00)
CHILDREN'S PEDICARE MU	1 (0.02)				1 (0.00)
CHILDREN'S SUDAFED NAS	1 (0.02)				1 (0.00)
CHINESE MEDICINES	1 (0.02)				1 (0.00)
CHLORAL HYDRATE				1 (0.01)	1 (0.00)
CHLORAL HYDRATE (CHLOR			2 (0.01)		2 (0.00)
CHLORAL HYDRATE LIQUID			1 (0.00)		1 (0.00)
CHLORALDURAT			1 (0.00)		1 (0.00)
CHLORAMPHENICOL		1 (0.01)	2 (0.01)		3 (0.00)
CHLORAPREP			1 (0.00)		1 (0.00)
CHLORAPREP 26ML WITH T			1 (0.00)		1 (0.00)
CHLORAPREP ONE-STEP SE	1 (0.02)				1 (0.00)
CHLORAPREP WITH TINT			2 (0.01)		2 (0.00)
CHLORDIAZEPOXIDE		1 (0.01)	2 (0.01)		3 (0.00)
CHLORMADINONE ACETATE		1 (0.01)			1 (0.00)
CHLORMADINONE ACETATE			5 (0.02)		5 (0.01)
CHLOROTHIAZIDE			2 (0.01)		2 (0.00)
CHLORPHENIRAMINE MALEA		2 (0.01)	2 (0.01)		4 (0.01)
CHLORPHENIRAMINE, D-PS			1 (0.00)		1 (0.00)
CHLORPHENIRAMINE/PARAC		2 (0.01)			2 (0.00)
CHLORPROMAZINE	1 (0.02)	3 (0.02)	1 (0.00)	2 (0.03)	7 (0.01)
CHLORPROMAZINE HCL		2 (0.01)			2 (0.00)
CHLORTHALIDONE			2 (0.01)		2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CHOLEBINE (COLESTILAN)			1 (0.00)		1 (0.00)
CHOLECALCIFEROL				2 (0.03)	2 (0.00)
CHOLESTEROL			1 (0.00)		1 (0.00)
CHOLESTEROL MEDCIATION			1 (0.00)		1 (0.00)
CHOLESTEROL MEDICATION		1 (0.01)		1 (0.01)	2 (0.00)
CHOLESTEROL- AND TRIGL			2 (0.01)		2 (0.00)
CHOLESTYRAMINAL			1 (0.00)		1 (0.00)
CHOLESTYRAMINAL (COLES			1 (0.00)		1 (0.00)
CHOLESTYRAMINE			2 (0.01)		2 (0.00)
CHOLINESTERASE INHIBIT				3 (0.04)	3 (0.00)
CHONDROITIN / GLUCOSAM		1 (0.01)			1 (0.00)
CHONDROSULF (CHONDROIT				1 (0.01)	1 (0.00)
CHORIONIC GONADOTROPIN		3 (0.02)			3 (0.00)
CHRONADALATE			2 (0.01)		2 (0.00)
CIALIS	3 (0.05)	31 (0.18)	70 (0.23)	6 (0.08)	110 (0.18)
CIBLOR	1 (0.02)		1 (0.00)		2 (0.00)
CICLESONIDE		1 (0.01)			1 (0.00)
CIFLOX	1 (0.02)		2 (0.01)	1 (0.01)	4 (0.01)
CIFLOX (CIPROFLOXACIN)			1 (0.00)		1 (0.00)
CIFLOX (MOXIFLOXACIN)			1 (0.00)		1 (0.00)
CIKLOSPORIN			1 (0.00)		1 (0.00)
CILAZAPRIL			1 (0.00)		1 (0.00)
CILAZAPRIL (CILAZAPRIL				1 (0.01)	1 (0.00)
CILEST		2 (0.01)			2 (0.00)
CILIFT (CITALOPRAM)		1 (0.01)			1 (0.00)
CILOSTAZOL			5 (0.02)	5 (0.06)	10 (0.02)
CIMETIDINE		1 (0.01)	5 (0.02)	1 (0.01)	7 (0.01)
CINACALCET		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CINAL TABLETS			1 (0.00)		1 (0.00)
CIORDINOL (CLOPENTHIXO		1 (0.01)			1 (0.00)
CIPRALEX	1 (0.02)	2 (0.01)			3 (0.00)
CIPRALEX (ESCITALOPRAM	3 (0.05)	9 (0.05)	8 (0.03)	3 (0.04)	23 (0.04)
CIPRAMIL	2 (0.03)	2 (0.01)			4 (0.01)
CIPRAMIL		1 (0.01)			1 (0.00)
CIPRO	6 (0.10)	9 (0.05)	17 (0.06)	7 (0.09)	39 (0.06)
CIPRO /00697201/		1 (0.01)	2 (0.01)		3 (0.00)
CIPRO XR	2 (0.03)	1 (0.01)			3 (0.00)
CIPROFIBRATE				1 (0.01)	1 (0.00)
CIPROFLAXACIN		4 (0.02)	4 (0.01)	2 (0.03)	10 (0.02)
CIPROFLOXACIN	8 (0.14)	12 (0.07)	22 (0.07)	18 (0.23)	60 (0.10)
CIPROFLOXACIN 500 MG		1 (0.01)			1 (0.00)
CIPROFLOXACIN 250		1 (0.01)			1 (0.00)
CIPROFLOXACIN HCL		1 (0.01)	9 (0.03)	5 (0.06)	15 (0.02)
CIPROFLOXACIN HYDROCHL		1 (0.01)	2 (0.01)		3 (0.00)
CIPROXAN (CIPROFLOXACI		1 (0.01)			1 (0.00)
CIPROXAN (CIPROFLOXACI			1 (0.00)		1 (0.00)
CIPROXAN(CIPROFLOXACIN			1 (0.00)		1 (0.00)
CIPROXIN 500MG		1 (0.01)			1 (0.00)
CIPROXIN (CIPROFLOXACI			2 (0.01)		2 (0.00)
CIRPO (CIPROFLOXACIN H		1 (0.01)			1 (0.00)
CIRRUS			1 (0.00)		1 (0.00)
CISAPRIDE			1 (0.00)		1 (0.00)
CISATRACURIUM BESYLATE			1 (0.00)		1 (0.00)
CISDYNE	1 (0.02)				1 (0.00)
CISORDINOL (CLOPENTHIX		2 (0.01)			2 (0.00)
CISORDINOL - SLOW RELE			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CISPLATIN	3 (0.05)	25 (0.15)	75 (0.25)	6 (0.08)	109 (0.18)
CISPLATIN (CISPLATIN U			1 (0.00)		1 (0.00)
CISPLATIN (CISPLATIN)	1 (0.02)		1 (0.00)		2 (0.00)
CITALOPRAM	3 (0.05)	10 (0.06)	6 (0.02)	2 (0.03)	21 (0.03)
CITALOPRAM (CITALOPRAM	2 (0.03)	4 (0.02)	3 (0.01)		9 (0.01)
CITALOPRAM 20 MG DR. R		1 (0.01)			1 (0.00)
CITALOPRAM 20 MG IVAX		1 (0.01)			1 (0.00)
CITALOPRAM HYDROBROMID	18 (0.30)	26 (0.15)	24 (0.08)	7 (0.09)	75 (0.12)
CITALOPRAM HYDROBROMII	1 (0.02)				1 (0.00)
CITROLOPRAM			1 (0.00)		1 (0.00)
CLACID				1 (0.01)	1 (0.00)
CLACIUM CHLORIDE (CALC			1 (0.00)		1 (0.00)
CLADRIBINE		1 (0.01)	2 (0.01)		3 (0.00)
CLAFORAN	2 (0.03)	2 (0.01)			4 (0.01)
CLAMOXYL		3 (0.02)	4 (0.01)	1 (0.01)	8 (0.01)
CLARAVIS	20 (0.34)	10 (0.06)			30 (0.05)
CLARINEX	1 (0.02)	6 (0.04)	4 (0.01)	2 (0.03)	13 (0.02)
CLARINEX/USA/(DESLORAT		1 (0.01)			1 (0.00)
CLARITHROMYCIN	8 (0.14)	13 (0.08)	17 (0.06)	5 (0.06)	43 (0.07)
CLARITIN	7 (0.12)	15 (0.09)	23 (0.08)	6 (0.08)	51 (0.08)
CLARITIN-D	2 (0.03)	3 (0.02)	4 (0.01)		9 (0.01)
CLARITIN-D ALLERGY/CON			1 (0.00)		1 (0.00)
CLASTOBAN			1 (0.00)		1 (0.00)
CLAVENTIN		1 (0.01)			1 (0.00)
CLAVURION	1 (0.02)				1 (0.00)
CLEANAL				2 (0.03)	2 (0.00)
CLEAR CARE 120Z BOTTLE			1 (0.00)		1 (0.00)
CLEAR CARE CIBA VISION		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CLEAR EYES FOR DRY EYE			1 (0.00)		1 (0.00)
CLEMASTINE		1 (0.01)	1 (0.00)		2 (0.00)
CLEMASTINE FUMARATE		2 (0.01)			2 (0.00)
CLEOCIN	2 (0.03)	1 (0.01)			3 (0.00)
CLEOCIN T GEL (CLINDAM	1 (0.02)				1 (0.00)
CLEXANE			1 (0.00)	2 (0.03)	3 (0.00)
CLEXANE /GFR/(HEPARI			1 (0.00)		1 (0.00)
CLIMAGEST (ESTRADIOL V			1 (0.00)		1 (0.00)
CLIMARA		6 (0.04)	7 (0.02)		13 (0.02)
CLINDAMICYN		1 (0.01)			1 (0.00)
CLINDAMYCIN	2 (0.03)	5 (0.03)	6 (0.02)	5 (0.06)	18 (0.03)
CLINDAMYCIN HCL	6 (0.10)	3 (0.02)	4 (0.01)	1 (0.01)	14 (0.02)
CLINDAMYCIN HYDROCHLOR	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)
CLINDAMYCIN PHOSPHATE	3 (0.05)	1 (0.01)	2 (0.01)	2 (0.03)	8 (0.01)
CLINORIL			2 (0.01)	3 (0.04)	5 (0.01)
CLOBAZAM				1 (0.01)	1 (0.00)
CLOBETASOL			1 (0.00)		1 (0.00)
CLOBETASOL OINTMENT (C		1 (0.01)			1 (0.00)
CLOBETASOL PROPIONATE			1 (0.00)	1 (0.01)	2 (0.00)
CLOBEX		2 (0.01)			2 (0.00)
CLODRONATE DISODIUM (C			2 (0.01)		2 (0.00)
CLODRONATE DISODIUM (C			1 (0.00)		1 (0.00)
CLOFARABINE	14 (0.24)	2 (0.01)	8 (0.03)	5 (0.06)	29 (0.05)
CLOFARABINE GENZYM			1 (0.00)		1 (0.00)
CLOFARABINE GENZYME			1 (0.00)		1 (0.00)
CLOFAZIMINE		1 (0.01)			1 (0.00)
CLOLAR	2 (0.03)	1 (0.01)	2 (0.01)		5 (0.01)
CLOMID	2 (0.03)	4 (0.02)			6 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CLOMIPHENE		1 (0.01)			1 (0.00)
CLOMIPHENE CITRATE		2 (0.01)			2 (0.00)
CLOMIPRAMINE HCL		1 (0.01)	3 (0.01)		4 (0.01)
CLONAZEPAM	13 (0.22)	37 (0.22)	36 (0.12)	5 (0.06)	91 (0.15)
CLONAZEPAM			1 (0.00)		1 (0.00)
CLONAZEPAM (CLONAZEPAM		1 (0.01)			1 (0.00)
CLONIDINE	15 (0.25)	13 (0.08)	16 (0.05)	5 (0.06)	49 (0.08)
CLONIDINE HCL			2 (0.01)		2 (0.00)
CLONIDINE HCL (CLONIDI				1 (0.01)	1 (0.00)
CLONIDINE HYDROCHLORID			1 (0.00)		1 (0.00)
CLONIDINIE (CLONIDINE)			1 (0.00)		1 (0.00)
CLONOPIN		5 (0.03)			5 (0.01)
CLOPIDOGREL		2 (0.01)	15 (0.05)	6 (0.08)	23 (0.04)
CLOPIDOGREL (CLOPIDOGR				1 (0.01)	1 (0.00)
CLOPIDOGREL BISULFATE			11 (0.04)	5 (0.06)	16 (0.03)
CLOPIXOL		1 (0.01)	1 (0.00)		2 (0.00)
CLOPIXOL (HYDROCHLORID				1 (0.01)	1 (0.00)
CLORANA				1 (0.01)	1 (0.00)
CLORAZEPATE DIPOTASSIU		6 (0.04)	3 (0.01)		9 (0.01)
CLOSTRIDIUM BUTYRICUM	1 (0.02)				1 (0.00)
CLOTIAPINE		1 (0.01)			1 (0.00)
CLOTRIMAZOLE		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
CLOXAZOLAM				2 (0.03)	2 (0.00)
CLOZAPINE	45 (0.76)	425 (2.49)	336 (1.11)	62 (0.80)	868 (1.42)
CLOZAPINE (CLOZAPNE) (1 (0.00)		1 (0.00)
CLOZAPINE TABLETS, 12.		1 (0.01)			1 (0.00)
CLOZARIL	5 (0.08)	25 (0.15)	11 (0.04)	4 (0.05)	45 (0.07)
CO-AMILOFRUSE			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CO-BENELDOPA			1 (0.00)		1 (0.00)
CO-CARELDOPA			1 (0.00)		1 (0.00)
CO-CODAMOL		2 (0.01)	2 (0.01)		4 (0.01)
CO-DIOVAN			1 (0.00)	1 (0.01)	2 (0.00)
CO-DIOVAN (VALSARTAN/H			2 (0.01)		2 (0.00)
CO-DYDRAMOL			2 (0.01)	1 (0.01)	3 (0.00)
CO-DYDRAMOL (DIHYDROCO			1 (0.00)		1 (0.00)
CO-PHENOTROPE		1 (0.01)			1 (0.00)
CO-RENITEN			1 (0.00)		1 (0.00)
CO-TRIMAZOLE	1 (0.02)				1 (0.00)
CO-TRIMAZOLE 800 MG/16		1 (0.01)			1 (0.00)
CO-TRIMAZOLE ^DAKOTA P			1 (0.00)		1 (0.00)
CO-TRIMOXAZOLE	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
CO-TRIMOXAZOLE (SULFA		1 (0.01)			1 (0.00)
COAPROVEL			2 (0.01)	1 (0.01)	3 (0.00)
COAPROVEL (HYDROCHLORO				2 (0.03)	2 (0.00)
COAPROVEL (IRBESARTAN)				1 (0.01)	1 (0.00)
COAPROVEL TABS				1 (0.01)	1 (0.00)
COAPROVEL TABS 300MG/1		1 (0.01)		2 (0.03)	3 (0.00)
COCAINE		2 (0.01)			2 (0.00)
COCAINE (COCAINE)	2 (0.03)				2 (0.00)
COCAINE(COCAINE)		1 (0.01)			1 (0.00)
COCARL	3 (0.05)				3 (0.00)
COD LIVER OIL			1 (0.00)		1 (0.00)
CODATEN		2 (0.01)			2 (0.00)
CODE UNBROKEN				2 (0.03)	2 (0.00)
CODEINE		6 (0.04)	4 (0.01)		10 (0.02)
CODEINE (CODEINE)		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CODEINE PHOSPHATE			1 (0.00)		1 (0.00)
CODEINE PHOSPHATE (COD		2 (0.01)			2 (0.00)
CODEINE PHOSPHATE/PARA			1 (0.00)		1 (0.00)
CODEINE/GUAIFENESIN		1 (0.01)			1 (0.00)
COGENTIN		1 (0.01)	1 (0.00)		2 (0.00)
COLACE		2 (0.01)	3 (0.01)		5 (0.01)
COLACE (DOCUSATE SODIU		1 (0.01)	2 (0.01)		3 (0.00)
COLACE (DOSCUATE SODIU		1 (0.01)			1 (0.00)
COLCHICINE		7 (0.04)	3 (0.01)		10 (0.02)
COLCHICINE (WATSON LAB			1 (0.00)		1 (0.00)
COLCHICUM JTL LIQ		1 (0.01)	1 (0.00)		2 (0.00)
COLD MEDICINE (UNSPECI	1 (0.02)				1 (0.00)
COLECALCIFEROL (COLCAL				1 (0.01)	1 (0.00)
COLECALCIFEROL (COLECA				1 (0.01)	1 (0.00)
COLESTID			1 (0.00)		1 (0.00)
COLESTIPOL HYDROCHLORI			1 (0.00)		1 (0.00)
COLISTIN (COLISTIN)				2 (0.03)	2 (0.00)
COLISTIN SULFATE		2 (0.01)			2 (0.00)
COLISTIN SULFATE (COLI		5 (0.03)			5 (0.01)
COLOXYL WITH SENNA			2 (0.01)		2 (0.00)
COMBIPATCH			1 (0.00)		1 (0.00)
COMBIVENT			10 (0.03)	5 (0.06)	15 (0.02)
COMBIVENT (ALBUTEROL			1 (0.00)		1 (0.00)
COMBIVENT (ALBUTEROL,			1 (0.00)		1 (0.00)
COMBIVIR	6 (0.10)	20 (0.12)	4 (0.01)		30 (0.05)
COMELIAN				3 (0.04)	3 (0.00)
COMMIT	1 (0.02)	2 (0.01)	1 (0.00)		4 (0.01)
COMMIT NICOTINE POLACR			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
COMPAT	1 (0.02)				1 (0.00)
COMPAZINE		3 (0.02)	8 (0.03)	1 (0.01)	12 (0.02)
COMPD W WART REMOVAL S			1 (0.00)		1 (0.00)
COMTAN			1 (0.00)	2 (0.03)	3 (0.00)
COMTESS (ENTACAPONE)				1 (0.01)	1 (0.00)
COMTRES		1 (0.01)			1 (0.00)
COMTRES DAY + NIGHT CO			1 (0.00)		1 (0.00)
CONCERIA	1 (0.02)				1 (0.00)
CONCERTA	53 (0.90)	10 (0.06)	8 (0.03)		71 (0.12)
CONCERTA OROS	1 (0.02)				1 (0.00)
CONCOR		1 (0.01)	6 (0.02)	3 (0.04)	10 (0.02)
CONCOR (BISOPROLOL)			3 (0.01)		3 (0.00)
CONCOR 10 MG(10 MG)(BI			1 (0.00)		1 (0.00)
CONCOR COR			2 (0.01)		2 (0.00)
CONCURRENT MEDICATIONS			1 (0.00)		1 (0.00)
CONDIUREN			1 (0.00)		1 (0.00)
CONIEL			3 (0.01)	9 (0.12)	12 (0.02)
CONIEL (BENIDIPINE HYD			2 (0.01)	2 (0.03)	4 (0.01)
CONJUGATED ESTROGENS/M			1 (0.00)		1 (0.00)
CONTACT 12-HOUR COLD CA			2 (0.01)		2 (0.00)
CONTACT COLD AND FLU		1 (0.01)			1 (0.00)
CONTOMIN		2 (0.01)			2 (0.00)
CONTRACEPTIVE	69 (1.17)	63 (0.37)			132 (0.22)
CONTRACEPTIVE DRUG NOS	2 (0.03)				2 (0.00)
CONTRACEPTIVE NOS		1 (0.01)			1 (0.00)
CONTRACEPTIVE PILL NOS		2 (0.01)			2 (0.00)
CONTRACEPTIVE, UNSPECI		1 (0.01)			1 (0.00)
CONTRACEPTIVES		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CONTRAMAL	1 (0.02)				1 (0.00)
CONTRAMAL RETARD				1 (0.01)	1 (0.00)
CONTRAST MEDIA		1 (0.01)			1 (0.00)
COOL MINT LISTERINE (M	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
COPAXONE	4 (0.07)	41 (0.24)	30 (0.10)		75 (0.12)
COPEGUS	4 (0.07)	8 (0.05)	3 (0.01)		15 (0.02)
COPROXAMOL		1 (0.01)			1 (0.00)
COQUELUSEDAL	1 (0.02)				1 (0.00)
CORDARONE			27 (0.09)	16 (0.21)	43 (0.07)
CORDERON			1 (0.00)		1 (0.00)
CORDIPATCH				1 (0.01)	1 (0.00)
COREG		7 (0.04)	33 (0.11)	18 (0.23)	58 (0.10)
COREG (CAREDILOL)			1 (0.00)		1 (0.00)
COREG (CARVEDIOL)		1 (0.01)			1 (0.00)
CORGARD		2 (0.01)	5 (0.02)		7 (0.01)
CORICIDIN	1 (0.02)	1 (0.01)			2 (0.00)
CORICIDIN (ACETAMINOPH			1 (0.00)		1 (0.00)
CORICIDIN D TABLETS			1 (0.00)		1 (0.00)
CORICIDIN HBP COUGH +	1 (0.02)				1 (0.00)
CORICIDIN HBP COUGH AN	1 (0.02)				1 (0.00)
CORICIDIN SINUS H/A(X-		1 (0.01)			1 (0.00)
CORICIDINE HBP COUGH A	2 (0.03)				2 (0.00)
CORINAE			1 (0.00)		1 (0.00)
CORINAE L			1 (0.00)		1 (0.00)
CORINAEL (NIFEDIPINE)			1 (0.00)		1 (0.00)
CORMAX (CLOBETASOL PRO			1 (0.00)		1 (0.00)
CORODARONE		1 (0.01)			1 (0.00)
CORODIL		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
COROPRES		1 (0.01)			1 (0.00)
CORTANCYL	2 (0.03)	15 (0.09)	9 (0.03)	5 (0.06)	31 (0.05)
CORTANCYL (PREDNISONE)		2 (0.01)	1 (0.00)		3 (0.00)
CORTANSYL			1 (0.00)		1 (0.00)
CORTEF	6 (0.10)	2 (0.01)		1 (0.01)	9 (0.01)
CORTICOID			1 (0.00)	1 (0.01)	2 (0.00)
CORTICOIDS		4 (0.02)			4 (0.01)
CORTICOSTERIODS	1 (0.02)				1 (0.00)
CORTICOSTEROID	1 (0.02)		1 (0.00)		2 (0.00)
CORTICOSTEROID NOS	2 (0.03)		1 (0.00)		3 (0.00)
CORTICOSTEROID NOS (CO		3 (0.02)	1 (0.00)		4 (0.01)
CORTICOSTEROIDS		2 (0.01)	7 (0.02)	1 (0.01)	10 (0.02)
CORTICOSTEROIDS (CORTI		1 (0.01)	2 (0.01)		3 (0.00)
CORTICOSTEROIDS (NO IN			1 (0.00)		1 (0.00)
CORTICOSTEROIDS (UNSPE	2 (0.03)	1 (0.01)	5 (0.02)		8 (0.01)
CORTICOTROPIN	1 (0.02)				1 (0.00)
CORTISOL	1 (0.02)				1 (0.00)
CORTISONE ACETATE	1 (0.02)	1 (0.01)	5 (0.02)	1 (0.01)	8 (0.01)
CORTISONE ACETATE TAB			2 (0.01)	3 (0.04)	5 (0.01)
CORTIL				1 (0.01)	1 (0.00)
CORTIL (HYDROCORTISON				1 (0.01)	1 (0.00)
CORUNO -MOLSIDOMINE				1 (0.01)	1 (0.00)
CORVASAL		1 (0.01)	1 (0.00)	3 (0.04)	5 (0.01)
CORVASAL (MOLSIDOMINE)				1 (0.01)	1 (0.00)
COSMEGEN			1 (0.00)		1 (0.00)
COSMO INSULIN PUMP	1 (0.02)				1 (0.00)
COSOPT		1 (0.01)	3 (0.01)	3 (0.04)	7 (0.01)
COTAREG		1 (0.01)	6 (0.02)		7 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
COTAZYM	1 (0.02)				1 (0.00)
COTIRMOXAZOLE		1 (0.01)			1 (0.00)
COTRIM	4 (0.07)	4 (0.02)	5 (0.02)		13 (0.02)
COUAMDINE (WARFARIN SO		1 (0.01)			1 (0.00)
COUGH AND COLD PREPARA		2 (0.01)			2 (0.00)
COUGH SYRUP			1 (0.00)		1 (0.00)
COUGH, COLD, AND FLU T		2 (0.01)	2 (0.01)		4 (0.01)
COUMADIN	3 (0.05)	28 (0.16)	109 (0.36)	79 (1.02)	219 (0.36)
COUMARIN			1 (0.00)		1 (0.00)
COVERA-HS			2 (0.01)	3 (0.04)	5 (0.01)
COVEREX			1 (0.00)		1 (0.00)
COVERSUM				1 (0.01)	1 (0.00)
COVERSUM COMBI				1 (0.01)	1 (0.00)
COVERSYL			3 (0.01)	9 (0.12)	12 (0.02)
COVERSYL (PERINDOPRIL			1 (0.00)		1 (0.00)
COVERSYL (PERINDOPRIL			1 (0.00)		1 (0.00)
COVERSYL (PERINDOPRIL)			1 (0.00)	4 (0.05)	5 (0.01)
COVERSYL/BEL/(PERINDOP			1 (0.00)		1 (0.00)
COXTRAL (NIMESULIDE)		1 (0.01)			1 (0.00)
COZAAR		13 (0.08)	63 (0.21)	22 (0.28)	98 (0.16)
COZAAR (LOSAETAN POTAS			1 (0.00)		1 (0.00)
CRAVIT	2 (0.03)	3 (0.02)	1 (0.00)	1 (0.01)	7 (0.01)
CRAVIT OPHTHALMIC SOLU				1 (0.01)	1 (0.00)
CRBOPLATIN				1 (0.01)	1 (0.00)
CREATINE MONOHYDRATE		1 (0.01)			1 (0.00)
CREON	3 (0.05)		3 (0.01)		6 (0.01)
CREST W/ FLUORIDE	1 (0.02)			1 (0.01)	2 (0.00)
CRESTOR		14 (0.08)	37 (0.12)	3 (0.04)	54 (0.09)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CRESTOR (ROSUVATATIN)			1 (0.00)		1 (0.00)
CRINONE		2 (0.01)			2 (0.00)
CRIXIVAN	1 (0.02)	10 (0.06)	3 (0.01)		14 (0.02)
CSE INHIBITOR NOS			1 (0.00)		1 (0.00)
CSF	1 (0.02)				1 (0.00)
CUBICIN		4 (0.02)	6 (0.02)	3 (0.04)	13 (0.02)
CUPRIMINE		1 (0.01)			1 (0.00)
CYAMEMAZINE		2 (0.01)			2 (0.00)
CYAMEMAZINE (CYAMEMAZI				1 (0.01)	1 (0.00)
CYANOCOBALAMIN	1 (0.02)	4 (0.02)	6 (0.02)	1 (0.01)	12 (0.02)
CYANOCOBALAMIN/PYRIDOX				1 (0.01)	1 (0.00)
CYCLIZINE		1 (0.01)	4 (0.01)	1 (0.01)	6 (0.01)
CYCLOBENZAPRINE 10 MG		1 (0.01)			1 (0.00)
CYCLOBENZAPRINE HCL		3 (0.02)	1 (0.00)		4 (0.01)
CYCLOBENZAPRINE HYDROC	1 (0.02)	3 (0.02)	1 (0.00)		5 (0.01)
CYCLOBENZAPRINE PO			1 (0.00)		1 (0.00)
CYCLOCORT				1 (0.01)	1 (0.00)
CYCLONAMINE (ETAMSILAT			1 (0.00)		1 (0.00)
CYCLOPENTOLATE HCL				1 (0.01)	1 (0.00)
CYCLOPHOSPHAMIDE	8 (0.14)	14 (0.08)	55 (0.18)	3 (0.04)	80 (0.13)
CYCLOPHOSPHAMIDE + DOX			1 (0.00)		1 (0.00)
CYCLOPHOSPHAMIDE 9CYCL	1 (0.02)				1 (0.00)
CYCLOPORINE (CYCLOSPOR	1 (0.02)				1 (0.00)
CYCLORCATE			1 (0.00)		1 (0.00)
CYCLOSPORINE	17 (0.29)	31 (0.18)	21 (0.07)	5 (0.06)	74 (0.12)
CYCLOSPORINWE		1 (0.01)			1 (0.00)
CYCRIN			1 (0.00)		1 (0.00)
CYLERT			1 (0.00)	1 (0.01)	2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CYMAMEMAZINE		2 (0.01)			2 (0.00)
CYMBALTA	10 (0.17)	88 (0.52)	67 (0.22)	14 (0.18)	179 (0.29)
CYMERIN		2 (0.01)	2 (0.01)		4 (0.01)
CYMEVEN	1 (0.02)				1 (0.00)
CYMEVENE		1 (0.01)	2 (0.01)		3 (0.00)
CYNBALTA		1 (0.01)			1 (0.00)
CYNT ^BEIERSDORF^			2 (0.01)		2 (0.00)
CYPHER			1 (0.00)		1 (0.00)
CYPHER CORONARY STENT			1 (0.00)		1 (0.00)
CYPHER DES			1 (0.00)		1 (0.00)
CYPHER DES CARDIAC STE			2 (0.01)		2 (0.00)
CYPHER SIROLIMUS-ELITI			1 (0.00)		1 (0.00)
CYPHER STENT CORDIS JO			1 (0.00)		1 (0.00)
CYPROHEPTADINE HCL			1 (0.00)		1 (0.00)
CYPROHEPTADINE HYDROCH				1 (0.01)	1 (0.00)
CYPROTERONE ACETATE +	1 (0.02)				1 (0.00)
CYSTEX			2 (0.01)		2 (0.00)
CYTARABINE	4 (0.07)	11 (0.06)	24 (0.08)	2 (0.03)	41 (0.07)
CYTOGAM	1 (0.02)				1 (0.00)
CYTOMEL			2 (0.01)		2 (0.00)
CYTOSINE ARABINOSIDE		6 (0.04)	4 (0.01)		10 (0.02)
CYTOTEC		1 (0.01)	3 (0.01)		4 (0.01)
CYTOXAN	1 (0.02)	4 (0.02)	8 (0.03)	2 (0.03)	15 (0.02)
D FOSFENAL			1 (0.00)		1 (0.00)
D-VIS-SOL (COLECALCIFE	1 (0.02)				1 (0.00)
D.H.E. 45			1 (0.00)		1 (0.00)
D5W 500			1 (0.00)		1 (0.00)
DACARBAZINE		3 (0.02)	16 (0.05)	1 (0.01)	20 (0.03)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DACLIZUMAB	1 (0.02)	1 (0.01)	3 (0.01)		5 (0.01)
DAFALGAN		2 (0.01)			2 (0.00)
DAFLON (DIOSMIN)		1 (0.01)	3 (0.01)		4 (0.01)
DAFLON 500		1 (0.01)			1 (0.00)
DAFORIN	1 (0.02)				1 (0.00)
DAI-KENCHU-TO ORAL POW			1 (0.00)		1 (0.00)
DAIVOBET			1 (0.00)		1 (0.00)
DAIVOCET			1 (0.00)		1 (0.00)
DAIVONEX				1 (0.01)	1 (0.00)
DALACIN			3 (0.01)		3 (0.00)
DALACIN C	2 (0.03)				2 (0.00)
DALACIN VAGINAL CREAM		2 (0.01)			2 (0.00)
DALMANE		3 (0.02)	1 (0.00)	1 (0.01)	5 (0.01)
DALTEPARIN (DALTEPARIN			1 (0.00)		1 (0.00)
DANAPAROID SODIUM	1 (0.02)		3 (0.01)	4 (0.05)	8 (0.01)
DANATROL				1 (0.01)	1 (0.00)
DANAZOL			3 (0.01)	1 (0.01)	4 (0.01)
DANTOIN	1 (0.02)				1 (0.00)
DANTRIUM		1 (0.01)	2 (0.01)		3 (0.00)
DAONIL	2 (0.03)		5 (0.02)	1 (0.01)	8 (0.01)
DAPOTUM/SCH/ (FLUPHENA			1 (0.00)		1 (0.00)
DAPSONE	1 (0.02)	7 (0.04)	9 (0.03)		17 (0.03)
DAPTOMYCIN		1 (0.01)	1 (0.00)		2 (0.00)
DARBEPOETIN ALFA			9 (0.03)		9 (0.01)
DARBEPOETIN ALFA (ARAN			1 (0.00)		1 (0.00)
DARVO ET (DEXTROPPOX			1 (0.00)		1 (0.00)
DARVOCET		12 (0.07)	12 (0.04)	4 (0.05)	28 (0.05)
DARVOCET-N (PROPACET)			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DARVOCET-N 100			7 (0.02)	1 (0.01)	8 (0.01)
DARVOCET-N 50		11 (0.06)	9 (0.03)	1 (0.01)	21 (0.03)
DARVOCETT			1 (0.00)		1 (0.00)
DAUNORUBICIN		1 (0.01)			1 (0.00)
DAUNORUBICIN HCL	4 (0.07)		3 (0.01)		7 (0.01)
DAUNORUBICIN HYDROCHLO			2 (0.01)		2 (0.00)
DAYQUIL		1 (0.01)			1 (0.00)
DDAVP	3 (0.05)	1 (0.01)	1 (0.00)		5 (0.01)
DECA-DURABOLIN		2 (0.01)			2 (0.00)
DECADRON	8 (0.14)	14 (0.08)	19 (0.06)	5 (0.06)	46 (0.08)
DECADRON (DEXAMETHAOSN			1 (0.00)		1 (0.00)
DECADRON PHOSPHATE		3 (0.02)	8 (0.03)		11 (0.02)
DECADRON SRC		10 (0.06)	19 (0.06)	2 (0.03)	31 (0.05)
DECAPEPTYL		1 (0.01)			1 (0.00)
DECAPEPTYL (GONADORELI		2 (0.01)			2 (0.00)
DECONGESTANT	1 (0.02)				1 (0.00)
DECORTIN	1 (0.02)	1 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)
DECORTIN H			1 (0.00)		1 (0.00)
DEDROGYL			1 (0.00)		1 (0.00)
DEDROGYL (CALCIFEDIOL)			1 (0.00)		1 (0.00)
DEFINITY			4 (0.01)		4 (0.01)
DEFLAZACORT		2 (0.01)	4 (0.01)		6 (0.01)
DEFOBIN	1 (0.02)				1 (0.00)
DELFLEX W/ DEXTROSE 1.			2 (0.01)		2 (0.00)
DELIX			1 (0.00)		1 (0.00)
DELSYM	2 (0.03)		1 (0.00)		3 (0.00)
DELTASONE			1 (0.00)		1 (0.00)
DELURSAN			1 (0.00)		1 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DEMADEX		3 (0.02)	7 (0.02)	1 (0.01)	11 (0.02)
DEMEROL	3 (0.05)	4 (0.02)	1 (0.00)		8 (0.01)
DEMOXEPAM		1 (0.01)			1 (0.00)
DEMULEN 1/35-21		2 (0.01)			2 (0.00)
DENAVIR		1 (0.01)			1 (0.00)
DENOSINE		1 (0.01)	1 (0.00)		2 (0.00)
DEPAKEN (VALPROATE SOD	1 (0.02)				1 (0.00)
DEPAKENE	15 (0.25)	24 (0.14)	10 (0.03)	6 (0.08)	55 (0.09)
DEPAKENE-R (VALPOATE S			1 (0.00)		1 (0.00)
DEPAKINE /00228502/	1 (0.02)				1 (0.00)
DEPAKINE CHRONO SUSPEN	1 (0.02)				1 (0.00)
DEPAKOTE	29 (0.49)	57 (0.33)	29 (0.10)	8 (0.10)	123 (0.20)
DEPAKOTE - SLOW RELEAS		1 (0.01)		1 (0.01)	2 (0.00)
DEPAKOTE ER	2 (0.03)	2 (0.01)	2 (0.01)		6 (0.01)
DEPAKOTE ER (TABLETS)			1 (0.00)		1 (0.00)
DEPAS	2 (0.03)	4 (0.02)		1 (0.01)	7 (0.01)
DEPAS (ETIZOLAM)			3 (0.01)	1 (0.01)	4 (0.01)
DEPO-ESTRADIOL		1 (0.01)	2 (0.01)		3 (0.00)
DEPO-MEDROL	1 (0.02)	7 (0.04)	7 (0.02)	1 (0.01)	16 (0.03)
DEPO-PROVERA	32 (0.54)	39 (0.23)	2 (0.01)		73 (0.12)
DEPO-PROVERA SUSPENSIO	2 (0.03)	3 (0.02)			5 (0.01)
DEPO-TESTOSTERONE			4 (0.01)		4 (0.01)
DEPO-TESTOSTERONE (TES		1 (0.01)			1 (0.00)
DEPOCYT			1 (0.00)		1 (0.00)
DEPODUR			2 (0.01)	1 (0.01)	3 (0.00)
DEPRAKINE	3 (0.05)				3 (0.00)
DEPROMEL 25				1 (0.01)	1 (0.00)
DERINOX			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DERMATOLOGIC (UNSPECIF			2 (0.01)		2 (0.00)
DERMOVATE		1 (0.01)	2 (0.01)		3 (0.00)
DEROXAT	1 (0.02)	6 (0.04)	7 (0.02)	4 (0.05)	18 (0.03)
DESFERAL	3 (0.05)	4 (0.02)	1 (0.00)		8 (0.01)
DESFERAL (DEFEROXAMINE			1 (0.00)		1 (0.00)
DESFLURANE		1 (0.01)			1 (0.00)
DESIPRAMINE HCL		2 (0.01)			2 (0.00)
DESIPRAMINE HYDROCHLOR			1 (0.00)		1 (0.00)
DES Loratadine		1 (0.01)			1 (0.00)
DESMOPRESSIN			1 (0.00)		1 (0.00)
DESMOPRESSIN ACETATE	3 (0.05)	2 (0.01)	1 (0.00)		6 (0.01)
DESMOSPRAY	1 (0.02)				1 (0.00)
DESMOTABS	1 (0.02)				1 (0.00)
DESOGESTREL AND ETHINY		1 (0.01)			1 (0.00)
DESOWEN			1 (0.00)		1 (0.00)
DESOXYN		2 (0.01)			2 (0.00)
DESYREL		2 (0.01)	6 (0.02)	5 (0.06)	13 (0.02)
DETENSIEL			1 (0.00)		1 (0.00)
DETENSIEL			1 (0.00)		1 (0.00)
DETROL		2 (0.01)	10 (0.03)	5 (0.06)	17 (0.03)
DETROL - SLOW RELEASE			1 (0.00)		1 (0.00)
DETROL /01350202/ (TOL				1 (0.01)	1 (0.00)
DETROL LA			17 (0.06)	14 (0.18)	31 (0.05)
DETROL LA (TOLTERODINE		1 (0.01)			1 (0.00)
DETRUSITOL			1 (0.00)		1 (0.00)
DETURGYLONE		1 (0.01)			1 (0.00)
DEXAMETASON TABLETS		1 (0.01)			1 (0.00)
DEXAMETHASONE	3 (0.05)	11 (0.06)	42 (0.14)	2 (0.03)	58 (0.10)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DEXAMETHASONE (DEXMETH		1 (0.01)			1 (0.00)
DEXAMETHASONE ACETATE	1 (0.02)				1 (0.00)
DEXAMETHASONE PO			1 (0.00)		1 (0.00)
DEXAMETHASONE SODIUM P	3 (0.05)	5 (0.03)	9 (0.03)	1 (0.01)	18 (0.03)
DEXAMETHASONE TAB	1 (0.02)	7 (0.04)	22 (0.07)	5 (0.06)	35 (0.06)
DEXAMETHASONE/DOXORUBI			1 (0.00)		1 (0.00)
DEXAMFETAMINE (DEXAMFE	1 (0.02)				1 (0.00)
DEXAMYTREX AUGENSALBE		1 (0.01)			1 (0.00)
DEXAVEN (DEXAMETHASONE	1 (0.02)				1 (0.00)
DEXCHLORPHENIRAMINE MA			1 (0.00)		1 (0.00)
DEXEDRINE	3 (0.05)				3 (0.00)
DEXMEDETOMIDENE			1 (0.00)		1 (0.00)
DEXMEDETOMIDINE				1 (0.01)	1 (0.00)
DEXTROAMPHETAMINE 10 M	1 (0.02)				1 (0.00)
DEXTROMETHORPHAN (DEXT	1 (0.02)				1 (0.00)
DEXTROMETHORPHAN (NGX)	1 (0.02)				1 (0.00)
DEXTROMETHORPHAN HYDRO	4 (0.07)			1 (0.01)	5 (0.01)
DEXTROPROPOXYPHENE			1 (0.00)		1 (0.00)
DEXTROPROPOXYPHENE HYD			1 (0.00)		1 (0.00)
DEXTROSE	1 (0.02)				1 (0.00)
DEXTROSE 5%		1 (0.01)	1 (0.00)		2 (0.00)
DEXTROSE 5% AND SODIUM	1 (0.02)				1 (0.00)
DF118			1 (0.00)		1 (0.00)
DHEA			1 (0.00)		1 (0.00)
DI HYDAN				1 (0.01)	1 (0.00)
DI-ANTALVIC			1 (0.00)	1 (0.01)	2 (0.00)
DI-ANTALVIC (APOREX)		2 (0.01)			2 (0.00)
DI-ANTALVIC (DEXTROPOP			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DI-HYDAN (PHENYTOIN) T			1 (0.00)		1 (0.00)
DIABETA		1 (0.01)	3 (0.01)		4 (0.01)
DIABETES MEDICATION		1 (0.01)	1 (0.00)		2 (0.00)
DIABETES MELLITUS THER			1 (0.00)		1 (0.00)
DIABETICINE			1 (0.00)		1 (0.00)
DIABINESE		2 (0.01)			2 (0.00)
DIAFUSOR				2 (0.03)	2 (0.00)
DIALYSIS			2 (0.01)		2 (0.00)
DIALYSIS (DIALYSIS TRE	1 (0.02)				1 (0.00)
DIAMICRON			5 (0.02)	1 (0.01)	6 (0.01)
DIAMICRON (GLICLAZIDE)		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
DIAMICRON (GLICLAZIDE)			1 (0.00)		1 (0.00)
DIAMICRON MR			2 (0.01)		2 (0.00)
DIAMORPHINE (DIAMORPHI		1 (0.01)			1 (0.00)
DIAMOX		2 (0.01)	2 (0.01)	3 (0.04)	7 (0.01)
DIANE (CYPROTERONE ACE		2 (0.01)			2 (0.00)
DIANEAL		1 (0.01)	7 (0.02)	1 (0.01)	9 (0.01)
DIANEAL PD-2 2.5			1 (0.00)		1 (0.00)
DIANEAL PD-4 1.5			2 (0.01)		2 (0.00)
DIANEAL PD4 ULTRABAG			1 (0.00)		1 (0.00)
DIANETTE	2 (0.03)	2 (0.01)			4 (0.01)
DIART	1 (0.02)				1 (0.00)
DIART			1 (0.00)		1 (0.00)
DIART (AZOSEMIDE)			1 (0.00)		1 (0.00)
DIASTAT ACUDIAL	1 (0.02)				1 (0.00)
DIATRIZOATE ORAL SOLN				1 (0.01)	1 (0.00)
DIAVAN			1 (0.00)	1 (0.01)	2 (0.00)
DIAZEAM (DIAZEPAM)	1 (0.02)				1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DIAZEPAM	5 (0.08)	29 (0.17)	28 (0.09)	2 (0.03)	64 (0.10)
DIAZIDE		1 (0.01)	2 (0.01)		3 (0.00)
DIAZIDE (GLICLAZIDE)			1 (0.00)		1 (0.00)
DIAZOXIDE	1 (0.02)				1 (0.00)
DICLAC		2 (0.01)			2 (0.00)
DICLOCIL	1 (0.02)				1 (0.00)
DICLOFENAC	4 (0.07)	6 (0.04)	15 (0.05)	6 (0.08)	31 (0.05)
DICLOFENAC 75MG			1 (0.00)		1 (0.00)
DICLOFENAC (NGX) (DICL			1 (0.00)		1 (0.00)
DICLOFENAC 75 MG			2 (0.01)		2 (0.00)
DICLOFENAC EPOLAMINE P		1 (0.01)	1 (0.00)		2 (0.00)
DICLOFENAC NA			1 (0.00)		1 (0.00)
DICLOFENAC POTASSIUM	1 (0.02)				1 (0.00)
DICLOFENAC RATIOPHARM		1 (0.01)			1 (0.00)
DICLOFENAC SODIUM	1 (0.02)	7 (0.04)	19 (0.06)	3 (0.04)	30 (0.05)
DICLOFENAC-RATIOPHARM		1 (0.01)			1 (0.00)
DICLONEFAC (DICLOFENAC			1 (0.00)		1 (0.00)
DICLOXACILLIN		1 (0.01)			1 (0.00)
DICYCLOMINE				2 (0.03)	2 (0.00)
DICYCLOMINE HYDROCHLOR				1 (0.01)	1 (0.00)
DICYCLOVIR			1 (0.00)		1 (0.00)
DICYLOMINE (ALL OTHER			1 (0.00)		1 (0.00)
DIDANOSINE	4 (0.07)	10 (0.06)	2 (0.01)	1 (0.01)	17 (0.03)
DIDROCAL			1 (0.00)	2 (0.03)	3 (0.00)
DIDRONEL		1 (0.01)			1 (0.00)
DIFFERIN	2 (0.03)				2 (0.00)
DIFFU K			1 (0.00)	6 (0.08)	7 (0.01)
DIFLUCAN		6 (0.04)	13 (0.04)	8 (0.10)	27 (0.04)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DIFLUCAN (FLUCONAZOLE)		3 (0.02)	1 (0.00)	1 (0.01)	5 (0.01)
DIFORMIN RETARD			2 (0.01)		2 (0.00)
DIFOSFONAL			1 (0.00)		1 (0.00)
DIGESTIVES, INCL ENZYM			1 (0.00)		1 (0.00)
DIGIMERCK MINOR			1 (0.00)		1 (0.00)
DIGITALIS			3 (0.01)		3 (0.00)
DIGITALIS CAP			1 (0.00)		1 (0.00)
DIGITEK		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
DIGITEK 0.25 MG			1 (0.00)		1 (0.00)
DIGITEX			2 (0.01)		2 (0.00)
DIGITOXIN TAB			2 (0.01)	2 (0.03)	4 (0.01)
DIGOXIN	2 (0.03)	7 (0.04)	46 (0.15)	42 (0.54)	97 (0.16)
DIGOXIN			1 (0.00)		1 (0.00)
DIGOXIN (DIOXIN)	1 (0.02)				1 (0.00)
DIGOXIN SEMI			1 (0.00)		1 (0.00)
DIGOXINA	1 (0.02)				1 (0.00)
DIHYDROCODEINE		1 (0.01)	4 (0.01)		5 (0.01)
DIHYDROCODEINE (DIHYDR			2 (0.01)		2 (0.00)
DIHYDROCODRINE (DIHYDR			1 (0.00)		1 (0.00)
DIHYDROERGOTAMINE MESY	1 (0.02)	2 (0.01)			3 (0.00)
DILACOR XR			1 (0.00)		1 (0.00)
DILANDID		2 (0.01)			2 (0.00)
DILANTIN	3 (0.05)	23 (0.13)	27 (0.09)	4 (0.05)	57 (0.09)
DILANTIN (PHENYTOIN /O		1 (0.01)			1 (0.00)
DILANTIN /AUS/ (PHENYT			1 (0.00)		1 (0.00)
DILANTIN /AUS/(PHENYTO			1 (0.00)		1 (0.00)
DILANTIN /CAN/ (PHENYT			1 (0.00)		1 (0.00)
DILANTIN KAPSEAL	3 (0.05)	1 (0.01)	6 (0.02)	3 (0.04)	13 (0.02)

Drug Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
DILATREND		2 (0.01)	4 (0.01)	2 (0.03)	8 (0.01)
DILAUDID	2 (0.03)	4 (0.02)	14 (0.05)		20 (0.03)
DILAUDIND (HYDROMORPHO			1 (0.00)		1 (0.00)
DILTIA				1 (0.01)	1 (0.00)
DILTIAZEM	1 (0.02)	1 (0.01)	13 (0.04)	6 (0.08)	21 (0.03)
DILTIAZEM HCL	1 (0.02)	10 (0.06)	11 (0.04)	13 (0.17)	35 (0.06)
DILTIAZEM HYDROCHLORID		1 (0.01)	3 (0.01)	5 (0.06)	9 (0.01)
DILTIAZEM HYDROCHLORID		1 (0.01)			1 (0.00)
DILTIAZEM MALATE				3 (0.04)	3 (0.00)
DILTIAZEM RETARD		1 (0.01)			1 (0.00)
DIMENHYDRINATE			4 (0.01)		4 (0.01)
DIMETHYL SULFONE			2 (0.01)		2 (0.00)
DINOPROSTONE GEL (DINO	2 (0.03)				2 (0.00)
DIOCOMB SI			1 (0.00)		1 (0.00)
DIOSMIN			2 (0.01)		2 (0.00)
DIOSMINE, HESPERIDINE			1 (0.00)		1 (0.00)
DIOVAN	1 (0.02)	35 (0.21)	138 (0.46)	32 (0.41)	206 (0.34)
DIOVAN AMLO		1 (0.01)			1 (0.00)
DIOVAN HCT		6 (0.04)	19 (0.06)	1 (0.01)	26 (0.04)
DIOVAN HCT (CO-DIOVAN)			1 (0.00)		1 (0.00)
DIOVAN TABLETS			1 (0.00)		1 (0.00)
DIOVAN ^CIBA-GEIGY ^ (V			1 (0.00)	1 (0.01)	2 (0.00)
DIOVANCE (VALSARTAN)			1 (0.00)		1 (0.00)
DIOVANE			2 (0.01)		2 (0.00)
DIPENTUM		3 (0.02)			3 (0.00)
DIPHANTOINE		1 (0.01)			1 (0.00)
DIPHENHYDRAMINE		1 (0.01)	5 (0.02)		6 (0.01)
DIPHENHYDRAMINE CITRAT			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DIPHENHYDRAMINE HCL	1 (0.02)	2 (0.01)	8 (0.03)		11 (0.02)
DIPHENHYDRAMINE HYDROC	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)
DIPHENOXYLATE			1 (0.00)		1 (0.00)
DIPHThERIA AND TETANUS		2 (0.01)			2 (0.00)
DIPHThERIA, PERTUSSIS,	1 (0.02)				1 (0.00)
DIPIDOLOR			1 (0.00)		1 (0.00)
DIPIDOLOR (PIRITRAMIDE				1 (0.01)	1 (0.00)
DIPRIVAN	1 (0.02)	13 (0.08)	6 (0.02)		20 (0.03)
DIPROGENTA CREAM	1 (0.02)		1 (0.00)		2 (0.00)
DIPROLENE		2 (0.01)			2 (0.00)
DIPROLENE CREAM (BETAM			1 (0.00)		1 (0.00)
DIPROSONE			1 (0.00)		1 (0.00)
DIPThERIA AND TETANUS		1 (0.01)			1 (0.00)
DIPYRIDAMOLE		1 (0.01)	8 (0.03)	2 (0.03)	11 (0.02)
DIPYRONE (METAMIZOLE S		1 (0.01)			1 (0.00)
DIPYRONE AND VITAMIN B			2 (0.01)		2 (0.00)
DIPYRONE TAB		4 (0.02)	5 (0.02)	1 (0.01)	10 (0.02)
DISCOTRINE (GLYCERYL T				1 (0.01)	1 (0.00)
DISENTRONIC H_TRON PLU		1 (0.01)			1 (0.00)
DISOPYRAMIDE				1 (0.01)	1 (0.00)
DISPERSIBLE ASPIRIN TA				1 (0.01)	1 (0.00)
DISPRIN		1 (0.01)			1 (0.00)
DISTRANEURIN				2 (0.03)	2 (0.00)
DISTRANEURINE				1 (0.01)	1 (0.00)
DITHRANOL			1 (0.00)		1 (0.00)
DITROPAN		2 (0.01)	8 (0.03)	2 (0.03)	12 (0.02)
DITROPAN XL		1 (0.01)	3 (0.01)	5 (0.06)	9 (0.01)
DIURETIC			2 (0.01)	3 (0.04)	5 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DIURETIC (UNSPECIFIED)			5 (0.02)	1 (0.01)	6 (0.01)
DIURETICS				1 (0.01)	1 (0.00)
DIURETICS (DIURETICS)				1 (0.01)	1 (0.00)
DIVALPROEX SODIUM	1 (0.02)	5 (0.03)	2 (0.01)	1 (0.01)	9 (0.01)
DIVALPROIC ACID		1 (0.01)			1 (0.00)
DIVAN			1 (0.00)		1 (0.00)
DLANTIN -PHENYTOIN-		1 (0.01)			1 (0.00)
DMSO 70% LYN COURT PHAR		1 (0.01)			1 (0.00)
DOBUTAMINE HCL	2 (0.03)		2 (0.01)	1 (0.01)	5 (0.01)
DOCETAXEL		4 (0.02)	11 (0.04)	1 (0.01)	16 (0.03)
DOCETAXEL (DOCETAXEL)		1 (0.01)	1 (0.00)		2 (0.00)
DOCETAXEL 35 MG/M2			1 (0.00)		1 (0.00)
DOCETAXEL 75 MG/M2 (DO			1 (0.00)		1 (0.00)
DOCETAXEL, 80 MG INJEC			1 (0.00)		1 (0.00)
DOCETAXEL/75MG/M2			1 (0.00)		1 (0.00)
DOCTTAXEL 25 MG/ML AVE			1 (0.00)		1 (0.00)
DOCUSATE SODIUM		1 (0.01)	5 (0.02)		6 (0.01)
DOCUSATE SODIUM (DOCUS		1 (0.01)			1 (0.00)
DOCUSATE SODIUM CAPSUL			2 (0.01)		2 (0.00)
DOCUSATE SODIUM/SENNA				1 (0.01)	1 (0.00)
DOCUSATE/ SENNOSIDES				1 (0.01)	1 (0.00)
DOGMATYL		7 (0.04)		1 (0.01)	8 (0.01)
DOGMATYL (SULPIRIDE)			1 (0.00)		1 (0.00)
DOGMATYL (SULPIRIDE) (1 (0.00)		1 (0.00)
DOGMATYL CAPSULES			1 (0.00)		1 (0.00)
DOLASETRON 100 MG /5ML				1 (0.01)	1 (0.00)
DOLCONTIN (MORPHINE SU			2 (0.01)		2 (0.00)
DOLIPRANE		2 (0.01)	3 (0.01)	1 (0.01)	6 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DOLONEX DT (PIROXICAM		1 (0.01)			1 (0.00)
DOLOREX FORTE			1 (0.00)		1 (0.00)
DOMEBORO			1 (0.00)		1 (0.00)
DOMINAL		1 (0.01)			1 (0.00)
DOMINAL FORTE			1 (0.00)		1 (0.00)
DOMPERIDON			2 (0.01)		2 (0.00)
DOMPERIDONE	1 (0.02)		5 (0.02)	1 (0.01)	7 (0.01)
DOMPERIDONE (DOMPERIDO			2 (0.01)		2 (0.00)
DONEPEZIL HCL				3 (0.04)	3 (0.00)
DONEPEZIL HYDROCHLORID				2 (0.03)	2 (0.00)
DOPAMINE	2 (0.03)		4 (0.01)		6 (0.01)
DOPAMINE HCL	3 (0.05)				3 (0.00)
DOPAMINERGIC AGENTS				2 (0.03)	2 (0.00)
DOPASTON			1 (0.00)		1 (0.00)
DOPRAM	1 (0.02)				1 (0.00)
DORAL	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
DORAL (QUAZEPAM) (QUAZ			1 (0.00)		1 (0.00)
DORMICUM (NITRAZEPAM)			1 (0.00)		1 (0.00)
DORMONID		1 (0.01)			1 (0.00)
DORSPAN		1 (0.01)			1 (0.00)
DORYX		4 (0.02)			4 (0.01)
DORZOLAMIDE (DORZOLAMI			1 (0.00)		1 (0.00)
DOSTINEX	1 (0.02)	3 (0.02)			4 (0.01)
DOTAREM DOTAREM		1 (0.01)			1 (0.00)
DOTAREM UNKNOWN		1 (0.01)			1 (0.00)
DOTAREM -MEGLUMINE GAD		1 (0.01)			1 (0.00)
DOTHIEPIN HYDROCHLORID		3 (0.02)			3 (0.00)
DOVONEX		1 (0.01)		1 (0.01)	2 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DOVONEX CREAM			1 (0.00)		1 (0.00)
DOXABEN				1 (0.01)	1 (0.00)
DOXAZOSIN			5 (0.02)	2 (0.03)	7 (0.01)
DOXAZOSIN (DOXAZOSIN)			10 (0.03)	1 (0.01)	11 (0.02)
DOXAZOSIN MESYLATE		1 (0.01)	5 (0.02)	2 (0.03)	8 (0.01)
DOXAZOSIN MESYLATE TAB	2 (0.03)				2 (0.00)
DOXAZOSIN TABLET 4MG (1 (0.01)	1 (0.00)
DOXAZOSIN;; ZENITH ; A			1 (0.00)		1 (0.00)
DOXEPIN		1 (0.01)	2 (0.01)		3 (0.00)
DOXEPIN HCL		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
DOXEPIN HYDROCHLORIDE		1 (0.01)	2 (0.01)		3 (0.00)
DOXIDAN (CASANTHRANOL,		1 (0.01)			1 (0.00)
DOXIL		9 (0.05)	28 (0.09)	5 (0.06)	42 (0.07)
DOXIL (DOXORUBICIN HYD		1 (0.01)	3 (0.01)	3 (0.04)	7 (0.01)
DOXORUBICIN	1 (0.02)	1 (0.01)			2 (0.00)
DOXORUBICIN (DOXORUBIC			4 (0.01)		4 (0.01)
DOXORUBICIN (NGX) (DOX	1 (0.02)				1 (0.00)
DOXORUBICIN HCL		7 (0.04)	13 (0.04)		20 (0.03)
DOXORUBICIN HYDROCHLOR		3 (0.02)	4 (0.01)		7 (0.01)
DOXORUBICIN(DOXORUBICI			1 (0.00)		1 (0.00)
DOXYCLINE	1 (0.02)				1 (0.00)
DOXYCYCLINE	6 (0.10)	7 (0.04)	7 (0.02)	1 (0.01)	21 (0.03)
DOXYCYCLINE +AMBROXOL			1 (0.00)		1 (0.00)
DOXYCYCLINE HCL			1 (0.00)		1 (0.00)
DOXYCYCLINE HYCLATE	1 (0.02)			1 (0.01)	2 (0.00)
DOXYCYINE		1 (0.01)			1 (0.00)
DR. SCHOLL'S EXTRA THI			1 (0.00)		1 (0.00)
DR.SCHOLL'S EXTRA THIC			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DRAMAMINE	11 (0.19)	1 (0.01)			12 (0.02)
DREISACARB			1 (0.00)		1 (0.00)
DRIPTANE (OXYBUTYNIN H		1 (0.01)			1 (0.00)
DROPERIDOL	1 (0.02)				1 (0.00)
DROSPIRENONE + ETHINYL	1 (0.02)				1 (0.00)
DROTRECOGIN			1 (0.00)		1 (0.00)
DROXIDOPA			1 (0.00)		1 (0.00)
DRUG (DRUG)			1 (0.00)		1 (0.00)
DRUG (DRUG)UNSPECIFIED				1 (0.01)	1 (0.00)
DRUG, UNSPECIFIED			1 (0.00)		1 (0.00)
DRUG, UNSPECIFIED (DRU				2 (0.03)	2 (0.00)
DUCENE		1 (0.01)			1 (0.00)
DUET DHA (PRENATAL VIT	1 (0.02)				1 (0.00)
DULCOLAX	3 (0.05)	1 (0.01)			4 (0.01)
DULOXETINE			1 (0.00)	1 (0.01)	2 (0.00)
DULOXETINE HYDROCHLORI			1 (0.00)		1 (0.00)
DULOXETINE HYDROCHLORI			3 (0.01)		3 (0.00)
DULOXETINE HYDROCHLORI	1 (0.02)				1 (0.00)
DULOXETINE HYDROCHLORI	1 (0.02)				1 (0.00)
DUONEB			1 (0.00)		1 (0.00)
DUOVENT (FENOTEROL HYD			1 (0.00)		1 (0.00)
DUPHALAC			1 (0.00)	2 (0.03)	3 (0.00)
DURACLON			1 (0.00)		1 (0.00)
DURAGESIC		1 (0.01)	3 (0.01)		4 (0.01)
DURAGESIC-100	1 (0.02)	18 (0.11)	22 (0.07)	7 (0.09)	48 (0.08)
DURAGESIC-25		3 (0.02)			3 (0.00)
DURAGESIC-50	1 (0.02)	1 (0.01)			2 (0.00)
DURAMORPH PF		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DURAPATITE			1 (0.00)		1 (0.00)
DURAPREP			1 (0.00)		1 (0.00)
DURATEARS			1 (0.00)		1 (0.00)
DURCEF (CEFADROXIL)		1 (0.01)			1 (0.00)
DUREFERON DURETT			1 (0.00)		1 (0.00)
DUROFERON			2 (0.01)		2 (0.00)
DUROGESIC MATRIX		1 (0.01)			1 (0.00)
DUROTEP			8 (0.03)		8 (0.01)
DUTASTERIDE			8 (0.03)		8 (0.01)
DYAZIDE		4 (0.02)	12 (0.04)	2 (0.03)	18 (0.03)
DYAZIDE (HYDROCHLOROTH			1 (0.00)		1 (0.00)
DYDROGESTERONE AND EST			1 (0.00)		1 (0.00)
DYNACIRC			2 (0.01)		2 (0.00)
DYPHYLLINE			1 (0.00)		1 (0.00)
DYSPORE (BOTULINUM TOX			2 (0.01)		2 (0.00)
DYST-ESE			1 (0.00)		1 (0.00)
DYTIDE				1 (0.01)	1 (0.00)
E.S. BAYER BACK + BODY			1 (0.00)		1 (0.00)
EBRANTIL				1 (0.01)	1 (0.00)
ECOPIRIN			2 (0.01)		2 (0.00)
ECOTRIN		2 (0.01)	12 (0.04)	8 (0.10)	22 (0.04)
ECOTRIN (ACETYLSALICYL			2 (0.01)		2 (0.00)
EDARAVONE (EDARAVONE)			1 (0.00)		1 (0.00)
EDETATE DISODIUM	2 (0.03)				2 (0.00)
EDEX		1 (0.01)	1 (0.00)		2 (0.00)
EFALIZUMAB (EFALIZUMAB			1 (0.00)		1 (0.00)
EFALIZUMAB (EFALIZUMAB		4 (0.02)	9 (0.03)		13 (0.02)
EFALIZUMAB (EFALIZUMAB		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
EFALIZUMAB(EFALIZUMAB)			1 (0.00)		1 (0.00)
EFALIZUMAB(EFALIZUMAB)		1 (0.01)	1 (0.00)		2 (0.00)
EFAVIRENZ	4 (0.07)	14 (0.08)	5 (0.02)		23 (0.04)
EFFECTIN (VEN		1 (0.01)			1 (0.00)
EFFECTIN (VENLAFAXINE H		1 (0.01)			1 (0.00)
EFFECTIN (VENLAFAXINE H			1 (0.00)		1 (0.00)
EFEROX			2 (0.01)		2 (0.00)
EFEXOR		1 (0.01)	1 (0.00)		2 (0.00)
EFEXOR (VENLAFAXINE HY	1 (0.02)				1 (0.00)
EFEXOR 9VENLAFAXINE HY		1 (0.01)			1 (0.00)
EFFEOR (VENLAFAXINE HY			1 (0.00)		1 (0.00)
EFFERALGAN		2 (0.01)		1 (0.01)	3 (0.00)
EFFERALGAN (PARACETAMO		1 (0.01)			1 (0.00)
EFFERALGAN CODEINE			4 (0.01)		4 (0.01)
EFFEXOR	22 (0.37)	84 (0.49)	65 (0.21)	4 (0.05)	175 (0.29)
EFFEXOR (VENLAFAXINE H			1 (0.00)		1 (0.00)
EFFEXOR XR	14 (0.24)	37 (0.22)	40 (0.13)	6 (0.08)	97 (0.16)
EFUDEX			2 (0.01)		2 (0.00)
ELAVIL	3 (0.05)	10 (0.06)	14 (0.05)	6 (0.08)	33 (0.05)
ELCITONIN				1 (0.01)	1 (0.00)
ELCITONIN (ELCATONIN)			3 (0.01)	1 (0.01)	4 (0.01)
ELDEPRYL			2 (0.01)		2 (0.00)
ELECTROLYTES (UNSPECIF				1 (0.01)	1 (0.00)
ELETRIPTAN	1 (0.02)				1 (0.00)
ELIDEL	16 (0.27)	3 (0.02)	4 (0.01)	2 (0.03)	25 (0.04)
ELIGARD			2 (0.01)		2 (0.00)
ELISOR			1 (0.00)	2 (0.03)	3 (0.00)
ELISOR TABS		1 (0.01)	3 (0.01)		4 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ELISOR TABS 20 MG			2 (0.01)	2 (0.03)	4 (0.01)
ELLENCE			2 (0.01)		2 (0.00)
ELMIRON		2 (0.01)			2 (0.00)
ELOCON	3 (0.05)				3 (0.00)
ELOXATIN		2 (0.01)	4 (0.01)	4 (0.05)	10 (0.02)
ELOXATIN - CARBOPLATIN		1 (0.01)			1 (0.00)
ELOXATIN /GFR/ (OXALIP		1 (0.01)	1 (0.00)		2 (0.00)
ELOXATINE /FRA/ (OXALI				1 (0.01)	1 (0.00)
ELSPAR	2 (0.03)				2 (0.00)
ELSPAR (ASPARAGINASE/M				1 (0.01)	1 (0.00)
ELTROXIN			3 (0.01)		3 (0.00)
EMCONCOR			1 (0.00)		1 (0.00)
EMCONCOR (BISOPROLOL)				2 (0.03)	2 (0.00)
EMCYT				1 (0.01)	1 (0.00)
EMEND		1 (0.01)	4 (0.01)		5 (0.01)
EMETROL			1 (0.00)		1 (0.00)
EMETROL (GLUCOSE, FRUC			2 (0.01)		2 (0.00)
EMLA	2 (0.03)				2 (0.00)
EMOLLENT CREAM	1 (0.02)				1 (0.00)
EMOLLIENTS AND PROTECT	2 (0.03)				2 (0.00)
EMSELEX EXTENDED RELEA		1 (0.01)			1 (0.00)
EMTRICITABINE (EMTRICI		1 (0.01)			1 (0.00)
EMTRICITABINE/TENOFOVI		1 (0.01)			1 (0.00)
EMTRICITABINE/TENOFOVI		2 (0.01)			2 (0.00)
EMTRIVA		4 (0.02)			4 (0.01)
ENABLEX		4 (0.02)	31 (0.10)	32 (0.41)	67 (0.11)
ENALAPRIL	1 (0.02)	2 (0.01)	16 (0.05)	4 (0.05)	23 (0.04)
ENALAPRIL MALEATE	4 (0.07)	4 (0.02)	54 (0.18)	19 (0.25)	81 (0.13)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ENALAPRIL MALEATE AND			1 (0.00)		1 (0.00)
ENALAPRIL MALEATE TABL			1 (0.00)		1 (0.00)
ENALAPRIL MERCK + CO.			1 (0.00)		1 (0.00)
ENALAPRIL+HYDROCHLOROT			1 (0.00)		1 (0.00)
ENALOC			1 (0.00)		1 (0.00)
ENANTONE LP (LEUPROLI			1 (0.00)		1 (0.00)
ENAP			3 (0.01)		3 (0.00)
ENARMON DEPOT (TESTOST			2 (0.01)		2 (0.00)
ENBREL	9 (0.15)	26 (0.15)	36 (0.12)	5 (0.06)	76 (0.12)
ENBREL 50 MG-PFS- AMGE			1 (0.00)		1 (0.00)
ENCADE CAPS 25 MG			1 (0.00)		1 (0.00)
ENDOBULIN/IVEEGAM S/D	2 (0.03)	2 (0.01)		1 (0.01)	5 (0.01)
ENDOCET		1 (0.01)	4 (0.01)		5 (0.01)
ENDOCET (OXYCOCET)			1 (0.00)		1 (0.00)
ENDOCET 10MG/650MG END			1 (0.00)		1 (0.00)
ENDOCET 7.5/500 MG END		1 (0.01)			1 (0.00)
ENDOCORT EC				1 (0.01)	1 (0.00)
ENDOSOL EXTRA				1 (0.01)	1 (0.00)
ENDOXAN	1 (0.02)	6 (0.04)	13 (0.04)	2 (0.03)	22 (0.04)
ENDOXAN (CYCLOPHOSPHAM		1 (0.01)	1 (0.00)		2 (0.00)
ENDRATE	1 (0.02)		1 (0.00)		2 (0.00)
ENFUVIRTIDE 90 MG		1 (0.01)			1 (0.00)
ENKAID				2 (0.03)	2 (0.00)
ENLON-PLUS			1 (0.00)		1 (0.00)
ENOCITABINE		1 (0.01)			1 (0.00)
ENOXACIN			1 (0.00)		1 (0.00)
ENOXAPARIN (ENOXAPARIN				1 (0.01)	1 (0.00)
ENOXAPARIN SODIUM		7 (0.04)	15 (0.05)	8 (0.10)	30 (0.05)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ENOXIMONE				2 (0.03)	2 (0.00)
ENTACAPONE			1 (0.00)		1 (0.00)
ENTECAVIR		4 (0.02)			4 (0.01)
ENTEX CAP		4 (0.02)	1 (0.00)		5 (0.01)
ENTOCORT			2 (0.01)		2 (0.00)
ENTOCORT (BUDESONIDE)	1 (0.02)				1 (0.00)
ENVACAR (AMLODIPINE/AT			1 (0.00)		1 (0.00)
EPADEL			2 (0.01)	1 (0.01)	3 (0.00)
EPADEL (ETHYL ICOSAPEN				1 (0.01)	1 (0.00)
EPALRESTAT			1 (0.00)		1 (0.00)
EPELIN KAPSEALS (PHENY			1 (0.00)		1 (0.00)
EPHEDRINE			1 (0.00)		1 (0.00)
EPHYNAL				3 (0.04)	3 (0.00)
EPI DRIP			1 (0.00)		1 (0.00)
EPIDURAL			1 (0.00)		1 (0.00)
EPILIM	2 (0.03)	1 (0.01)	2 (0.01)		5 (0.01)
EPILIM (VALPROATE SODI		1 (0.01)			1 (0.00)
EPILIM CHRONO TABLETS	2 (0.03)	2 (0.01)			4 (0.01)
EPILIM TABLETS	1 (0.02)	1 (0.01)			2 (0.00)
EPINEPHRINE	3 (0.05)	2 (0.01)	3 (0.01)		8 (0.01)
EPINEPHRINE 0.3MG	1 (0.02)				1 (0.00)
EPIPEN	1 (0.02)		2 (0.01)		3 (0.00)
EPIRUBICIN		2 (0.01)	2 (0.01)		4 (0.01)
EPIRUBICIN HCL			1 (0.00)		1 (0.00)
EPIRUBICIN HYDROCHLORI		1 (0.01)			1 (0.00)
EPITOMAX	4 (0.07)				4 (0.01)
EPIVIR	1 (0.02)	23 (0.13)	13 (0.04)		37 (0.06)
EPIVIR-HBV		1 (0.01)			1 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
EPLERENONE (EPLERENONE	2 (0.03)				2 (0.00)
EPOCELIN (CEFTIZOXIME	1 (0.02)				1 (0.00)
EPOETIN			2 (0.01)	1 (0.01)	3 (0.00)
EPOETIN ALFA			1 (0.00)		1 (0.00)
EPOETIN BETA			2 (0.01)		2 (0.00)
EPOGEN		6 (0.04)	5 (0.02)		11 (0.02)
EPOPROSTENOL SODIUM	1 (0.02)				1 (0.00)
EPOPROSTENOL SODIUM (E	1 (0.02)				1 (0.00)
EPREX			1 (0.00)		1 (0.00)
EPREX /SCH	1 (0.02)				1 (0.00)
EPROSARTAN				1 (0.01)	1 (0.00)
EPTIFIBATIDE			1 (0.00)		1 (0.00)
EPZICOM		4 (0.02)	1 (0.00)		5 (0.01)
EPZICOM			1 (0.00)		1 (0.00)
EQUANIL		2 (0.01)		2 (0.03)	4 (0.01)
EQUATE MADE BY PERRIGO			1 (0.00)		1 (0.00)
EQUATE NICOTINE GUM 2M	2 (0.03)	13 (0.08)	10 (0.03)	1 (0.01)	26 (0.04)
EQUATE NICOTINE GUM 2M	2 (0.03)	5 (0.03)	3 (0.01)		10 (0.02)
EQUATE POWDER LAXATIVE				1 (0.01)	1 (0.00)
EQUETRO		2 (0.01)			2 (0.00)
ERBITUX		7 (0.04)	15 (0.05)	6 (0.08)	28 (0.05)
ERBITUX -CETUXIMAB-			1 (0.00)		1 (0.00)
ERBITUX-CETUXIMAB- 100		1 (0.01)			1 (0.00)
ERBTIUX		1 (0.01)			1 (0.00)
ERDOSTEINE			1 (0.00)		1 (0.00)
ERGENYL	2 (0.03)	3 (0.02)			5 (0.01)
ERGENYL CHRONO (VALPRO	1 (0.02)				1 (0.00)
ERGENYL CHRONO TABLETS		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ERITROPOIETIN			2 (0.01)		2 (0.00)
ERLOTINIB			1 (0.00)		1 (0.00)
ERLOTINIB HCL (TABLET			1 (0.00)		1 (0.00)
ERLOTINIB (ERLOTINIB)			2 (0.01)		2 (0.00)
ERLOTINIB (ERLOTINIB)			1 (0.00)		1 (0.00)
ERLOTINIB (ERLOTINIB)T			1 (0.00)		1 (0.00)
ERLOTINIB (ERLOTINIB)T			1 (0.00)		1 (0.00)
ERLOTINIB (TABLET)			1 (0.00)		1 (0.00)
ERLOTINIB 150 MG		1 (0.01)			1 (0.00)
ERLOTINIB 150MG			1 (0.00)		1 (0.00)
ERLOTINIB HCL (TABLET)		2 (0.01)	6 (0.02)	3 (0.04)	11 (0.02)
ERLOTINIB(ERLOTINIB) T			2 (0.01)		2 (0.00)
ERLOTINIB(ERLOTINIB) T			1 (0.00)		1 (0.00)
ERTAPENEM 1 GM VIAL ME		1 (0.01)			1 (0.00)
ERTAPENEM 1GM VIAL MER			1 (0.00)		1 (0.00)
ERY-TAB			2 (0.01)		2 (0.00)
ERYTHROCIN			1 (0.00)		1 (0.00)
ERYTHROMYCIN	6 (0.10)	6 (0.04)	1 (0.00)	1 (0.01)	14 (0.02)
ERYTHROMYCIN 2% TOPICA		2 (0.01)			2 (0.00)
ERYTHROMYCIN BASE	1 (0.02)				1 (0.00)
ERYTHROMYCIN GEL	1 (0.02)				1 (0.00)
ERYTHROPOIETIC FACTOR			2 (0.01)		2 (0.00)
ERYTHROPOIETIN			1 (0.00)		1 (0.00)
ERYTHROPOIETIN (ERYTHR			1 (0.00)		1 (0.00)
ESBERIVEN			1 (0.00)		1 (0.00)
ESCITALOIPRAM (ESCITAL		1 (0.01)			1 (0.00)
ESCITALOPRAM (ESCITALO	2 (0.03)	1 (0.01)	1 (0.00)		4 (0.01)
ESCITALOPRAM (OPEN-LAB			2 (0.01)		2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ESCITALOPRAM OXALATE	4 (0.07)	16 (0.09)	9 (0.03)	2 (0.03)	31 (0.05)
ESE 1000	1 (0.02)				1 (0.00)
ESGIC-PLUS		1 (0.01)			1 (0.00)
ESIDRIX		5 (0.03)	5 (0.02)	1 (0.01)	11 (0.02)
ESKALITH		4 (0.02)	2 (0.01)	1 (0.01)	7 (0.01)
ESKALITH AND ESKALITH		1 (0.01)			1 (0.00)
ESKALITH CR		2 (0.01)			2 (0.00)
ESKAZOLE		1 (0.01)			1 (0.00)
ESOMEPRAZOLE		6 (0.04)	5 (0.02)	2 (0.03)	13 (0.02)
ESOMEPRAZOLE (ESOMEPR			4 (0.01)		4 (0.01)
ESOMEPRAZOLE MAGNESIUM		4 (0.02)	4 (0.01)		8 (0.01)
ESOMEPRAZOLE MAGNESIUM			1 (0.00)		1 (0.00)
ESOMPERAZOLE		1 (0.01)			1 (0.00)
ESPUMISAN		1 (0.01)			1 (0.00)
ESTALIS SEQUI		1 (0.01)			1 (0.00)
ESTERIFIED ESTROGEN		1 (0.01)			1 (0.00)
ESTRACE		4 (0.02)	30 (0.10)		34 (0.06)
ESTRACYT			1 (0.00)		1 (0.00)
ESTRACYT				1 (0.01)	1 (0.00)
ESTRACYT (ESTRAMUSITIN			1 (0.00)		1 (0.00)
ESTRACYT (ESTRAMUSTINE			3 (0.01)		3 (0.00)
ESTRACYT (ESTRAMUSTINE			1 (0.00)		1 (0.00)
ESTRADERM			4 (0.01)		4 (0.01)
ESTRADERM TTS 25				1 (0.01)	1 (0.00)
ESTRADIOL		5 (0.03)	15 (0.05)		20 (0.03)
ESTRADIOL AND ESTRIOL			1 (0.00)		1 (0.00)
ESTRADIOL INJ		1 (0.01)	1 (0.00)		2 (0.00)
ESTRADIOL PATCH		1 (0.01)	1 (0.00)		2 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ESTRADOT			1 (0.00)		1 (0.00)
ESTRATEST		4 (0.02)	9 (0.03)		13 (0.02)
ESTREVA		2 (0.01)			2 (0.00)
ESTROGEN		2 (0.01)	2 (0.01)		4 (0.01)
ESTROGEN (ESTROGEN NOS		1 (0.01)			1 (0.00)
ESTROGEN PATCH		1 (0.01)	1 (0.00)		2 (0.00)
ESTROGEN REPLACEMENT			1 (0.00)		1 (0.00)
ESTROGENS			1 (0.00)		1 (0.00)
ESTROGENS (UNSPECIFIED		1 (0.01)	6 (0.02)	2 (0.03)	9 (0.01)
ESTROGENS CONJUGATED			2 (0.01)		2 (0.00)
ESTROGENS CONJUGATED W		1 (0.01)			1 (0.00)
ESTROGENS GEL		1 (0.01)			1 (0.00)
ESTROGENS SOL/INJ			2 (0.01)		2 (0.00)
ESTROPIPATE			1 (0.00)		1 (0.00)
ESTROSTEP FE		1 (0.01)			1 (0.00)
ESTROSTEP FE (ETHINYL	1 (0.02)				1 (0.00)
ETALPHA			1 (0.00)		1 (0.00)
ETANERCEPT		1 (0.01)	3 (0.01)		4 (0.01)
ETANERCEPT (AMGEN)			1 (0.00)		1 (0.00)
ETANERCEPT 25MG/VIAL A		1 (0.01)			1 (0.00)
ETHAMBUTOL 400 MGM			1 (0.00)		1 (0.00)
ETHAMBUTOL HCL			3 (0.01)		3 (0.00)
ETHAMBUTOL HYDROCHLORI		1 (0.01)			1 (0.00)
ETHANOL		2 (0.01)	1 (0.00)		3 (0.00)
ETHANOL (ETHANOL)			1 (0.00)		1 (0.00)
ETHINYL ESTRADIOL AND	2 (0.03)	2 (0.01)			4 (0.01)
ETHINYL ESTRADIOL TAB		2 (0.01)			2 (0.00)
ETHINYLESTRADIOL + GES		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ETHINYLESTRADIOL+GESTO		2 (0.01)			2 (0.00)
ETHOSUXIMIDE	2 (0.03)	2 (0.01)			4 (0.01)
ETHOSUXIMIDE (ZARONTIN			1 (0.00)		1 (0.00)
ETHYL ICOSAPENTATE				1 (0.01)	1 (0.00)
ETHYL LOFLAZEPATE	1 (0.02)				1 (0.00)
ETHYLENE GLYCOL (NO PR		1 (0.01)			1 (0.00)
ETHYOL		3 (0.02)	10 (0.03)	2 (0.03)	15 (0.02)
ETILEFRINE HYDROCHLORI			5 (0.02)		5 (0.01)
ETIZOLAM				2 (0.03)	2 (0.00)
ETODOLAC	1 (0.02)	3 (0.02)	13 (0.04)	1 (0.01)	18 (0.03)
ETOMIDATE			1 (0.00)		1 (0.00)
ETOPOPHOS (ETOPOSIDE)			1 (0.00)		1 (0.00)
ETOPOSIDE	1 (0.02)	2 (0.01)	7 (0.02)	1 (0.01)	11 (0.02)
ETORICOXIB			2 (0.01)		2 (0.00)
ETRETINATE		1 (0.01)			1 (0.00)
EUCALCIC (CALCIUM CARB				1 (0.01)	1 (0.00)
EUGLUAN			1 (0.00)		1 (0.00)
EUGLUCON			7 (0.02)		7 (0.01)
EUGLUCON (GLIBENCLAMID			1 (0.00)		1 (0.00)
EUGLUCON N			1 (0.00)		1 (0.00)
EUGYNON	2 (0.03)				2 (0.00)
EULEXIN			1 (0.00)		1 (0.00)
EUPANTOL				1 (0.01)	1 (0.00)
EUPHYLLINE				1 (0.01)	1 (0.00)
EUPHYTOSE	1 (0.02)				1 (0.00)
EUROBIOL			3 (0.01)		3 (0.00)
EUROCAL (COLECALCIFERO			1 (0.00)		1 (0.00)
EUTHYROX	1 (0.02)		5 (0.02)		6 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
EUTIROX		1 (0.01)			1 (0.00)
EVISTA		3 (0.02)	69 (0.23)	34 (0.44)	106 (0.17)
EVOXAC		1 (0.01)	1 (0.00)		2 (0.00)
EXCEDRIN		3 (0.02)	1 (0.00)		4 (0.01)
EXCEDRIN (ACETAMINOPHE		3 (0.02)	2 (0.01)		5 (0.01)
EXCEDRIN (MIGRAINE)		4 (0.02)	7 (0.02)	3 (0.04)	14 (0.02)
EXCEDRIN EXTRA STRENGT			2 (0.01)		2 (0.00)
EXCEDRIN EXTRA STRENGT			1 (0.00)		1 (0.00)
EXCEDRIN EXTRA STRENGT			1 (0.00)		1 (0.00)
EXCEGRAN	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
EXCEGRAN	1 (0.02)				1 (0.00)
EXCEGRAN (ZONISAMIDE)		2 (0.01)			2 (0.00)
EXCELAZE				3 (0.04)	3 (0.00)
EXELON		1 (0.01)	3 (0.01)	19 (0.25)	23 (0.04)
EXEMESTANE		1 (0.01)	2 (0.01)	2 (0.03)	5 (0.01)
EXENATIDE (EXENATIDE)			1 (0.00)		1 (0.00)
EXJADE	10 (0.17)	1 (0.01)	8 (0.03)	3 (0.04)	22 (0.04)
EXTENDED PHENYTOIN SOD	2 (0.03)	1 (0.01)			3 (0.00)
EXTRA STRENGTH TYLENOL	2 (0.03)	6 (0.04)	9 (0.03)	5 (0.06)	22 (0.04)
EXTRANEAL				2 (0.03)	2 (0.00)
EYE DROPS	1 (0.02)		2 (0.01)	1 (0.01)	4 (0.01)
EYE DROPS NOS (EYE DRO	1 (0.02)				1 (0.00)
EYE TISSUE HUMAN		1 (0.01)	2 (0.01)	3 (0.04)	6 (0.01)
EYE TISSUE HUMAN 10417				1 (0.01)	1 (0.00)
EZETIMIBE		2 (0.01)	4 (0.01)	1 (0.01)	7 (0.01)
EZETIMIBE (EZETIMIBE)			3 (0.01)		3 (0.00)
EZETIMIBE 10 MG MERCK/		1 (0.01)			1 (0.00)
EZETIMIBE/SIMVASTATIN			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
EZETIMIBE/SIMVASTATIN			1 (0.00)		1 (0.00)
EZETROL			1 (0.00)		1 (0.00)
EZETROL (EZETIMIBE)			2 (0.01)		2 (0.00)
EZETROL 10 MG MEDIMART			1 (0.00)		1 (0.00)
F6SO4			1 (0.00)		1 (0.00)
FABRAZYME	8 (0.14)	11 (0.06)	8 (0.03)		27 (0.04)
FACTIVE	6 (0.10)	37 (0.22)	16 (0.05)	4 (0.05)	63 (0.10)
FACTIVE	1 (0.02)				1 (0.00)
FACTOR VIII, RECOMBINA			2 (0.01)		2 (0.00)
FALITHROM		1 (0.01)	1 (0.00)		2 (0.00)
FAMCICLOVIR		2 (0.01)			2 (0.00)
FAMOTIDINE	1 (0.02)	7 (0.04)	17 (0.06)	4 (0.05)	29 (0.05)
FAMPRIDINE		1 (0.01)			1 (0.00)
FAMVIR		3 (0.02)		1 (0.01)	4 (0.01)
FANSIDAR		1 (0.01)			1 (0.00)
FARESTON			3 (0.01)	1 (0.01)	4 (0.01)
FASLODEX		2 (0.01)	5 (0.02)	3 (0.04)	10 (0.02)
FASTIC			2 (0.01)		2 (0.00)
FE SULFATE			1 (0.00)		1 (0.00)
FE-TINIC				2 (0.03)	2 (0.00)
FEIBA			1 (0.00)		1 (0.00)
FEIBA VH IMMUNO	1 (0.02)		1 (0.00)		2 (0.00)
FELDENE	1 (0.02)	2 (0.01)	10 (0.03)	1 (0.01)	14 (0.02)
FELODIPINE			18 (0.06)	2 (0.03)	20 (0.03)
FEMARA	1 (0.02)	7 (0.04)	22 (0.07)	4 (0.05)	34 (0.06)
FEMHRT			2 (0.01)		2 (0.00)
FEMHRT (ANOVLAR)			1 (0.00)		1 (0.00)
FEMRING		1 (0.01)			1 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
FEMULEN (ETYNODIOL		1 (0.01)			1 (0.00)
FEMULEN (ETYNODIOL DIA		5 (0.03)			5 (0.01)
FENOFIBRATE	1 (0.02)		8 (0.03)	2 (0.03)	11 (0.02)
FENOFIBRATE (MICRONIZE			1 (0.00)		1 (0.00)
FENOPROFEN CALCIUM			1 (0.00)		1 (0.00)
FENOTEROL HYDROBROMIDE	1 (0.02)				1 (0.00)
FENTANEST		1 (0.01)		1 (0.01)	2 (0.00)
FENTANYL	6 (0.10)	20 (0.12)	28 (0.09)	7 (0.09)	61 (0.10)
FENTANYL CITRATE	3 (0.05)	1 (0.01)	5 (0.02)		9 (0.01)
FENTANYL TRANSDERMAL S		3 (0.02)	9 (0.03)	1 (0.01)	13 (0.02)
FENYTOIN		1 (0.01)			1 (0.00)
FERRIC GLUCONATE		1 (0.01)	1 (0.00)		2 (0.00)
FERRIC PYROPHOSPHATE (1 (0.02)				1 (0.00)
FERRIMED	1 (0.02)				1 (0.00)
FERRLECIT		4 (0.02)	5 (0.02)	1 (0.01)	10 (0.02)
FERROMIA			2 (0.01)		2 (0.00)
FERROMIA (FERROUS CITR		1 (0.01)			1 (0.00)
FERROMIA (FERROUS CITR		1 (0.01)			1 (0.00)
FERROUS FUMARATE	2 (0.03)				2 (0.00)
FERROUS GLUCONATE			1 (0.00)	1 (0.01)	2 (0.00)
FERROUS SULFATE			1 (0.00)		1 (0.00)
FERROUS SULFATE (PREPA			1 (0.00)		1 (0.00)
FERROUS SULFATE TAB	1 (0.02)	6 (0.04)	7 (0.02)	1 (0.01)	15 (0.02)
FERRUM			1 (0.00)		1 (0.00)
FESO4			1 (0.00)		1 (0.00)
FEXADIN		1 (0.01)			1 (0.00)
FEXOFENADINE 180MG		1 (0.01)	1 (0.00)		2 (0.00)
FEXOFENADINE 180MG AVE			1 (0.00)		1 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
FEXOFENADINE HYDROCHLO		1 (0.01)			1 (0.00)
FEXOFENADINE TEVA	1 (0.02)				1 (0.00)
FIBERCON (POLYCARBOPHI		1 (0.01)			1 (0.00)
FILGRASTIM	1 (0.02)				1 (0.00)
FILGRASTIM (FILGRASTIM			1 (0.00)		1 (0.00)
FINASTERIDE				2 (0.03)	2 (0.00)
FIORCET (BUTALBITAL)	1 (0.02)				1 (0.00)
FIORICET			2 (0.01)	2 (0.03)	4 (0.01)
FIORICET TABLETS		1 (0.01)	6 (0.02)		7 (0.01)
FIORINAL			3 (0.01)		3 (0.00)
FIORINAL W/CODEINE		1 (0.01)			1 (0.00)
FISH (FISH OIL)		1 (0.01)			1 (0.00)
FISH OIL (FISH OIL)				1 (0.01)	1 (0.00)
FISH OIL SUPPLEMENT	1 (0.02)				1 (0.00)
FIV-ASA			1 (0.00)		1 (0.00)
FK506 (TACROLIMUS CAPS		3 (0.02)	3 (0.01)		6 (0.01)
FK506 (TACROLIMUS CAPS			1 (0.00)		1 (0.00)
FK506 (TACROLIMUS) CAP		3 (0.02)	7 (0.02)		10 (0.02)
FK506(TACROLIMUS CAPSU		1 (0.01)			1 (0.00)
FK506(TACROLIMUS) CAPS		1 (0.01)	1 (0.00)		2 (0.00)
FLAGYL	7 (0.12)	7 (0.04)	8 (0.03)	3 (0.04)	25 (0.04)
FLECAINIDE ACETATE	4 (0.07)	4 (0.02)	8 (0.03)	5 (0.06)	21 (0.03)
FLEET				1 (0.01)	1 (0.00)
FLEET ACCU-PREP			1 (0.00)		1 (0.00)
FLEETS PHOSPHASODA			1 (0.00)		1 (0.00)
FLEETS PHOSPHO SODA			1 (0.00)		1 (0.00)
FLEETS PHOSPHO- SODA				1 (0.01)	1 (0.00)
FLEETS PHOSPHOSODA			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
FLEMOXIN SOLUTAB	1 (0.02)				1 (0.00)
FLEXERIL	1 (0.02)	33 (0.19)	10 (0.03)	1 (0.01)	45 (0.07)
FLINSTONES (VITAMINS N		1 (0.01)			1 (0.00)
FLINTSTONES MULTIPLE V	1 (0.02)				1 (0.00)
FLIVAS			1 (0.00)		1 (0.00)
FLIVAS (NAFTOPIDIL) (T				1 (0.01)	1 (0.00)
FLIXONASE	2 (0.03)	1 (0.01)	1 (0.00)		4 (0.01)
FLIXOTIDE		4 (0.02)		1 (0.01)	5 (0.01)
FLIXOTIDE DISKUS			1 (0.00)		1 (0.00)
FLOLAN	5 (0.08)	3 (0.02)	3 (0.01)	1 (0.01)	12 (0.02)
FLOMAX		3 (0.02)	26 (0.09)	22 (0.28)	51 (0.08)
FLOMAX (MORNIFLUMATE)		1 (0.01)	11 (0.04)	2 (0.03)	14 (0.02)
FLOMOX	1 (0.02)	4 (0.02)			5 (0.01)
FLOMOX (CE		1 (0.01)			1 (0.00)
FLOMOX (CEFCAPENE PIVO		1 (0.01)			1 (0.00)
FLONASE	6 (0.10)	12 (0.07)	17 (0.06)	3 (0.04)	38 (0.06)
FLORID-F (MICONAZOLE)		1 (0.01)			1 (0.00)
FLORINEF	1 (0.02)				1 (0.00)
FLOVENT	4 (0.07)	12 (0.07)	9 (0.03)	5 (0.06)	30 (0.05)
FLOVENT 44 MDI			1 (0.00)		1 (0.00)
FLOXACILLIN			1 (0.00)	1 (0.01)	2 (0.00)
FLOXAL AUGENSALBE				1 (0.01)	1 (0.00)
FLOXIN		1 (0.01)		1 (0.01)	2 (0.00)
FLUANXOL		2 (0.01)			2 (0.00)
FLUCLOXACILLIN		1 (0.01)			1 (0.00)
FLUCLOXACILLIN			1 (0.00)		1 (0.00)
FLUCLOXACILLIN (FLUCLO	1 (0.02)		1 (0.00)		2 (0.00)
FLUCONAZOLE	3 (0.05)	15 (0.09)	19 (0.06)	4 (0.05)	41 (0.07)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
FLUCTIN (FLUOXETINE HY		1 (0.01)	1 (0.00)		2 (0.00)
FLUCTINE			2 (0.01)		2 (0.00)
FLUDARA	3 (0.05)		6 (0.02)	1 (0.01)	10 (0.02)
FLUDARA I.V. (FLUDARAB			1 (0.00)		1 (0.00)
FLUDARABINE		3 (0.02)	6 (0.02)		9 (0.01)
FLUDARABINE PHOSPHAT (1 (0.00)		1 (0.00)
FLUDARABINE PHOSPHATE	1 (0.02)	4 (0.02)	9 (0.03)		14 (0.02)
FLUDEX		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
FLUDROCORTISONE	1 (0.02)	3 (0.02)			4 (0.01)
FLUFENAZIN (FLUPHENAZI		1 (0.01)			1 (0.00)
FLUID			1 (0.00)		1 (0.00)
FLUINDIONE				1 (0.01)	1 (0.00)
FLUIR (FORMOTREOL		1 (0.01)			1 (0.00)
FLUITRAN			2 (0.01)		2 (0.00)
FLUMARIN		1 (0.01)			1 (0.00)
FLUMARIN (FLO		1 (0.01)			1 (0.00)
FLUMARIN (FLOMOXEF SOD		1 (0.01)			1 (0.00)
FLUMEZIN	1 (0.02)				1 (0.00)
FLUNCONAZOLE (FLUNCONA		1 (0.01)			1 (0.00)
FLUNISOLIDE			1 (0.00)		1 (0.00)
FLUNITRAZEPAM		1 (0.01)			1 (0.00)
FLUOCINOLONE ACETONIDE	1 (0.02)				1 (0.00)
FLUOCINOLONE ACETONIDE	1 (0.02)				1 (0.00)
FLUOCINONIDE			1 (0.00)	1 (0.01)	2 (0.00)
FLUOROURACIL	1 (0.02)	12 (0.07)	66 (0.22)	6 (0.08)	85 (0.14)
FLUOROURACIL INJ			1 (0.00)		1 (0.00)
FLUOROURACIL ^TEVA^ -			1 (0.00)		1 (0.00)
FLUOXETIN ^RATIOPHARM^		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
FLUOXETINA		1 (0.01)			1 (0.00)
FLUOXETINE	4 (0.07)	24 (0.14)	16 (0.05)	4 (0.05)	48 (0.08)
FLUOXETINE HCL	3 (0.05)	12 (0.07)	6 (0.02)	2 (0.03)	23 (0.04)
FLUOXETINE HYDROCHLORI	2 (0.03)	3 (0.02)	4 (0.01)		9 (0.01)
FLUOXETINIE (FLUOXETIN		1 (0.01)			1 (0.00)
FLUPHENAZINE		1 (0.01)	2 (0.01)		3 (0.00)
FLUPHENAZINE DECANOATE		3 (0.02)	1 (0.00)		4 (0.01)
FLUPHENAZINE HCL			1 (0.00)		1 (0.00)
FLUPREDNIDENE ACETATE		1 (0.01)			1 (0.00)
FLURAZEPAM		3 (0.02)			3 (0.00)
FLURBIPROPHEN		1 (0.01)			1 (0.00)
FLUROX			1 (0.00)		1 (0.00)
FLUSPI (FLUSPIRILENE)			1 (0.00)		1 (0.00)
FLUTAMIDE			6 (0.02)	1 (0.01)	7 (0.01)
FLUTICASON		1 (0.01)			1 (0.00)
FLUTICASONE	1 (0.02)				1 (0.00)
FLUTICASONE PROPIONATE	2 (0.03)	1 (0.01)	4 (0.01)		7 (0.01)
FLUTICASONE PROPIONATE	1 (0.02)		1 (0.00)		2 (0.00)
FLUTICASONE PROPIONATE			1 (0.00)		1 (0.00)
FLUTICASONE W/SALMETER			1 (0.00)		1 (0.00)
FLUTIDE	1 (0.02)				1 (0.00)
FLUVASTATIN			4 (0.01)	1 (0.01)	5 (0.01)
FLUVASTATIN SODIUM			2 (0.01)	2 (0.03)	4 (0.01)
FLUVOXAMINE			1 (0.00)		1 (0.00)
FLUVOXAMINE (FLUVOXAMI	1 (0.02)				1 (0.00)
FLUVOXAMINE MALEATE	2 (0.03)	5 (0.03)	3 (0.01)		10 (0.02)
FLUZONE		3 (0.02)			3 (0.00)
FOCALIN	7 (0.12)	1 (0.01)			8 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
FOCALIN XR	11 (0.19)				11 (0.02)
FOLACIN			2 (0.01)		2 (0.00)
FOLATE		2 (0.01)	2 (0.01)		4 (0.01)
FOLATE SODIUM	1 (0.02)				1 (0.00)
FOLFOX			1 (0.00)		1 (0.00)
FOLGARD			1 (0.00)		1 (0.00)
FOLIC ACID	4 (0.07)	19 (0.11)	59 (0.20)	10 (0.13)	92 (0.15)
FOLINIC ACID			4 (0.01)		4 (0.01)
FOLLITROPIN BETA		3 (0.02)			3 (0.00)
FONDAPARINUX			1 (0.00)		1 (0.00)
FONZYLANE				4 (0.05)	4 (0.01)
FONZYLANE (BULFOMEDIL				1 (0.01)	1 (0.00)
FORADIL	2 (0.03)	4 (0.02)	13 (0.04)	3 (0.04)	22 (0.04)
FORASEQ		3 (0.02)			3 (0.00)
FORMOTEROL		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
FORMOTEROL FUMARATE			1 (0.00)	1 (0.01)	2 (0.00)
FORMOTEROL INHALER				1 (0.01)	1 (0.00)
FORSTEO (T			1 (0.00)		1 (0.00)
FORSTEO PEN (FORSTEO			1 (0.00)		1 (0.00)
FORSTEO (TERIPARATIDE				1 (0.01)	1 (0.00)
FORSTEO(TERIPARATIDE U			1 (0.00)		1 (0.00)
FORTAMET		2 (0.01)	5 (0.02)		7 (0.01)
FORTAZ		1 (0.01)		1 (0.01)	2 (0.00)
FORTECORTIN			3 (0.01)		3 (0.00)
FORTECORTIN /00016001/			1 (0.00)		1 (0.00)
FORTECORTIN TABLETS			2 (0.01)		2 (0.00)
FORTEN PEN				1 (0.01)	1 (0.00)
FORTEO		29 (0.17)	257 (0.85)	274 (3.53)	560 (0.92)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
FORTEO PEN			1 (0.00)		1 (0.00)
FORTEO PEN (FOETEO PE				1 (0.01)	1 (0.00)
FORTEO PEN (250MCG/ML)		1 (0.01)			1 (0.00)
FORTEO PEN (FORTEO PEN		1 (0.01)			1 (0.00)
FORTEO PEN (FORTEO PEN		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
FORTEO PEN, 250MCG/ML			1 (0.00)		1 (0.00)
FORTOVASE	2 (0.03)				2 (0.00)
FORTZAAR			1 (0.00)		1 (0.00)
FOSAMAX		11 (0.06)	151 (0.50)	123 (1.59)	285 (0.47)
FOSAMAX (ALENDRONAE SO			1 (0.00)		1 (0.00)
FOSAMAX (ALLENDRONATE			1 (0.00)		1 (0.00)
FOSAMAX ONCE WEEKLY		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)
FOSAMAX PLUS D		1 (0.01)	3 (0.01)		4 (0.01)
FOSAMPRENAVIR		1 (0.01)			1 (0.00)
FOSCARNET	1 (0.02)				1 (0.00)
FOSCAVIR	1 (0.02)		2 (0.01)		3 (0.00)
FOSINOPRIL			1 (0.00)		1 (0.00)
FOSINOPRIL SODIUM		2 (0.01)	7 (0.02)	1 (0.01)	10 (0.02)
FOSPHENYTOIN SODIUM	2 (0.03)	2 (0.01)	1 (0.00)		5 (0.01)
FOSRENOL			5 (0.02)	1 (0.01)	6 (0.01)
FOY			1 (0.00)		1 (0.00)
FOY (GABEXATE MESILATE			2 (0.01)		2 (0.00)
FOY (GABEXATE MESILATE				2 (0.03)	2 (0.00)
FOZITEC TABS				1 (0.01)	1 (0.00)
FRACTAL			1 (0.00)	1 (0.01)	2 (0.00)
FRACTIONATED		1 (0.01)			1 (0.00)
FRAGMIN	2 (0.03)	6 (0.04)	6 (0.02)	1 (0.01)	15 (0.02)
FRAXIPARINE		1 (0.01)	1 (0.00)		2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
FRESH FROZEN PLASMA			1 (0.00)		1 (0.00)
FRESHBURST LISTERINE (1 (0.01)			1 (0.00)
FRISIUM		1 (0.01)			1 (0.00)
FROBEN (FLURBIPROFEN)		1 (0.01)			1 (0.00)
FROVA		1 (0.01)			1 (0.00)
FROZEN BONE TISSUE A		1 (0.01)			1 (0.00)
FRUSEMIDE		1 (0.01)	3 (0.01)	3 (0.04)	7 (0.01)
FRUSEMIDE TABLET BP (F				1 (0.01)	1 (0.00)
FUCIDINE CAP			2 (0.01)	1 (0.01)	3 (0.00)
FULCALIQ			1 (0.00)		1 (0.00)
FULVESTRANT 50MG/ML AS			1 (0.00)		1 (0.00)
FUNGIZONE	1 (0.02)	1 (0.01)		3 (0.04)	5 (0.01)
FUNGUARD (MICA FUNGIN I				1 (0.01)	1 (0.00)
FUNGUARD (MICA FUNGIN)	2 (0.03)	1 (0.01)	1 (0.00)	1 (0.01)	5 (0.01)
FUNGUARD(MICA FUNGIN) I			1 (0.00)		1 (0.00)
FURADANTIN			1 (0.00)		1 (0.00)
FURON			2 (0.01)		2 (0.00)
FURORESE			2 (0.01)		2 (0.00)
FUROSEM				1 (0.01)	1 (0.00)
FUROSEMIDE	8 (0.14)	23 (0.13)	82 (0.27)	47 (0.61)	160 (0.26)
FUROSEMIDE INJ SOLN				1 (0.01)	1 (0.00)
FUROSEMIDE TABLETS, US			1 (0.00)		1 (0.00)
FURSULTIAMINE				1 (0.01)	1 (0.00)
FURTULON		2 (0.01)	1 (0.00)		3 (0.00)
FUZEON		10 (0.06)	6 (0.02)		16 (0.03)
FYBOGEL				1 (0.01)	1 (0.00)
GABAPENTIN	1 (0.02)	20 (0.12)	22 (0.07)	7 (0.09)	50 (0.08)
GABEXATE MESILATE			3 (0.01)		3 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
GABEXATE MESILATE (REM				1 (0.01)	1 (0.00)
GABITRIL	3 (0.05)	12 (0.07)	4 (0.01)	1 (0.01)	20 (0.03)
GADOLINIUM			1 (0.00)		1 (0.00)
GALANTAMINE HYDROBROMI		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
GALFER	2 (0.03)				2 (0.00)
GAMIMUNE N 10%			1 (0.00)		1 (0.00)
GAMIMUNE N 5%	1 (0.02)				1 (0.00)
GAMMAGARD		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
GAMMAGARD S/D			5 (0.02)		5 (0.01)
GAMMAGARD SD (IMMUNOGL	1 (0.02)				1 (0.00)
GAMMAR-P I.V.	1 (0.02)				1 (0.00)
GAMUNEX	2 (0.03)	7 (0.04)	2 (0.01)	1 (0.01)	12 (0.02)
GAMUNEX (IMMUNOGLOBULI	1 (0.02)				1 (0.00)
GANCICLOVIR	1 (0.02)	1 (0.01)	4 (0.01)		6 (0.01)
GANCICLOVIR (GANCICLO			1 (0.00)		1 (0.00)
GARDENAL		3 (0.02)	1 (0.00)		4 (0.01)
GARDENALE (PHENOBARBIT		2 (0.01)			2 (0.00)
GARLIC		1 (0.01)			1 (0.00)
GASLON N (IRSOGLADINE	1 (0.02)				1 (0.00)
GASMOTIN			5 (0.02)		5 (0.01)
GASMOTIN (MOSAPRIDE CI			3 (0.01)		3 (0.00)
GASPORT (FAMOT				1 (0.01)	1 (0.00)
GAster		2 (0.01)	5 (0.02)	2 (0.03)	9 (0.01)
GAster D		2 (0.01)	9 (0.03)	6 (0.08)	17 (0.03)
GAster D /KOR/ (FAMOTI				1 (0.01)	1 (0.00)
GAster RAPIDLY-DISINTE		1 (0.01)			1 (0.00)
GAster TABLETS			1 (0.00)		1 (0.00)
GASTROCROM	1 (0.02)				1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
GASTROINTESTINAL PREPA			4 (0.01)		4 (0.01)
GASTROM	1 (0.02)				1 (0.00)
GASTROM (ECABET MONOSO			1 (0.00)		1 (0.00)
GASTROSIL (METOCLOPRAM			1 (0.00)		1 (0.00)
GATIFLOXACIN		1 (0.01)	7 (0.02)	12 (0.15)	20 (0.03)
GAVISCON		3 (0.02)			3 (0.00)
GAVISON (SODIUM ALGINA		1 (0.01)			1 (0.00)
GEFITINIB			4 (0.01)		4 (0.01)
GEFITINIB (GEFITINIB)			1 (0.00)		1 (0.00)
GEMCITABINE		2 (0.01)	9 (0.03)		11 (0.02)
GEMCITABINE HYDROCHLO		1 (0.01)			1 (0.00)
GEMCITABINE (MG/M2)			1 (0.00)		1 (0.00)
GEMCITABINE HYDROCHLOR				1 (0.01)	1 (0.00)
GEMCITABINE HYDROCHLOR			5 (0.02)		5 (0.01)
GEMCITABINE HYDROCHLOR			1 (0.00)		1 (0.00)
GEMCITABINE, CONTROL F			1 (0.00)		1 (0.00)
GEMFIBROZIL		8 (0.05)	14 (0.05)	2 (0.03)	24 (0.04)
GEMTUZUMAB OZOGAMICIN			1 (0.00)		1 (0.00)
GEMTUZUMAB OZOGAMICIN	1 (0.02)	1 (0.01)	13 (0.04)		15 (0.02)
GEMZAR	4 (0.07)	12 (0.07)	74 (0.24)	10 (0.13)	100 (0.16)
GEMZAR 750 MG/M2 E LIL			1 (0.00)		1 (0.00)
GEN NITRO (GLYCERYL TR				1 (0.01)	1 (0.00)
GENERAL ANAESTHETICS			1 (0.00)		1 (0.00)
GENERIC UNKNOWN		1 (0.01)			1 (0.00)
GENGRAF	1 (0.02)	1 (0.01)			2 (0.00)
GENOTONORM (SOMATROPIN		1 (0.01)			1 (0.00)
GENOTROPIN	31 (0.52)	6 (0.04)	7 (0.02)	1 (0.01)	45 (0.07)
GENOTROPIN (SOMATROPIN	1 (0.02)				1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
GENTACIN		3 (0.02)			3 (0.00)
GENTAMICIN	4 (0.07)	4 (0.02)	8 (0.03)	7 (0.09)	23 (0.04)
GENTAMICIN SULFATE		1 (0.01)	3 (0.01)		4 (0.01)
GENTEAL (NVO)			1 (0.00)	1 (0.01)	2 (0.00)
GENTEAL LUBRICANT EYE			1 (0.00)		1 (0.00)
GENTEAL LUBRICATING EY		1 (0.01)	1 (0.00)		2 (0.00)
GENTEAL MILD LUBRICANT				1 (0.01)	1 (0.00)
GENTIAN VIOLET		1 (0.01)			1 (0.00)
GENUINE BAYER CAPLETS				1 (0.01)	1 (0.00)
GEODON	15 (0.25)	30 (0.18)	6 (0.02)	1 (0.01)	52 (0.09)
GEODONE (ZIPRASIDONE H		1 (0.01)			1 (0.00)
GINGER			2 (0.01)		2 (0.00)
GINKGO BILOBA			1 (0.00)		1 (0.00)
GINKGO BILOBA EXTRACT		2 (0.01)			2 (0.00)
GINKOR FORT				1 (0.01)	1 (0.00)
GINKOR FORT (GINKGO BI			1 (0.00)		1 (0.00)
GLARGINE INSULIN			1 (0.00)		1 (0.00)
GLATIRAMER ACETATE		11 (0.06)			11 (0.02)
GLEEVEC	6 (0.10)	27 (0.16)	37 (0.12)	9 (0.12)	79 (0.13)
GLIADEL			2 (0.01)		2 (0.00)
GLIBENCLAMID				1 (0.01)	1 (0.00)
GLIBENCLAMIDE		1 (0.01)	6 (0.02)	2 (0.03)	9 (0.01)
GLIBENCLAMIDE/METFORMI			1 (0.00)		1 (0.00)
GLIBENKLAMID				1 (0.01)	1 (0.00)
GLIBOMET			2 (0.01)		2 (0.00)
GLICLAZIDE			11 (0.04)	4 (0.05)	15 (0.02)
GLICLAZIDE (GLICLAZIDE			1 (0.00)	1 (0.01)	2 (0.00)
GLIMEPIRIDE			13 (0.04)		13 (0.02)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
GLIMICRON			5 (0.02)	2 (0.03)	7 (0.01)
GLIMICRON			1 (0.00)		1 (0.00)
GLIMICRON (GLICLAZIDE)			1 (0.00)		1 (0.00)
GLIPERIMIDE			2 (0.01)		2 (0.00)
GLIPIZIDE		10 (0.06)	51 (0.17)	15 (0.19)	76 (0.12)
GLORIAMIN				1 (0.01)	1 (0.00)
GLUCADOL			1 (0.00)		1 (0.00)
GLUCAGON			1 (0.00)		1 (0.00)
GLUCAGON G NOVO				1 (0.01)	1 (0.00)
GLUCOBAY		3 (0.02)	4 (0.01)	2 (0.03)	9 (0.01)
GLUCOCORTICOIDS			1 (0.00)		1 (0.00)
GLUCOPHAG			3 (0.01)		3 (0.00)
GLUCOPHAGE	3 (0.05)	83 (0.49)	267 (0.88)	19 (0.25)	372 (0.61)
GLUCOPHAGE			1 (0.00)		1 (0.00)
GLUCOPHAGE XL			1 (0.00)		1 (0.00)
GLUCOPHAGE XR		7 (0.04)	14 (0.05)		21 (0.03)
GLUCOR			1 (0.00)		1 (0.00)
GLUCOSAMINE			16 (0.05)	2 (0.03)	18 (0.03)
GLUCOSAMINE / CHONDROT			1 (0.00)		1 (0.00)
GLUCOSAMINE CHONDROITI				1 (0.01)	1 (0.00)
GLUCOSAMINE W/CHONDROI				1 (0.01)	1 (0.00)
GLUCOSE		1 (0.01)			1 (0.00)
GLUCOSE (GLUCOSE)	1 (0.02)		1 (0.00)		2 (0.00)
GLUCOTROL		5 (0.03)	36 (0.12)	3 (0.04)	44 (0.07)
GLUCOTROL XL		3 (0.02)	16 (0.05)		19 (0.03)
GLUCOVANCE		15 (0.09)	47 (0.16)	11 (0.14)	73 (0.12)
GLUFAST			1 (0.00)		1 (0.00)
GLURENORM			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
GLYBURIDE	1 (0.02)	6 (0.04)	89 (0.29)	31 (0.40)	127 (0.21)
GLYBURIDE AND METFORMI		1 (0.01)	8 (0.03)		9 (0.01)
GLYBURIDE AND METFORMI			1 (0.00)		1 (0.00)
GLYBURIDE W/METFORMIN		1 (0.01)			1 (0.00)
GLYCEOL (FRUCTOSE, GLY			4 (0.01)		4 (0.01)
GLYCEROL (FRUCTOSE, GL			1 (0.00)		1 (0.00)
GLYCERYL TRINITRATE			2 (0.01)	1 (0.01)	3 (0.00)
GLYCERYL TRINITRATE (G			1 (0.00)	1 (0.01)	2 (0.00)
GLYCYRON	1 (0.02)		2 (0.01)		3 (0.00)
GLYNASE			3 (0.01)		3 (0.00)
GLYSET			1 (0.00)		1 (0.00)
GM-CSF (GM-CSF (N/A))		1 (0.01)			1 (0.00)
GOLD SALT (GOLD) (INJE			1 (0.00)		1 (0.00)
GOLYTELY		1 (0.01)			1 (0.00)
GONADORELIN INJ		2 (0.01)			2 (0.00)
GONADOTROPHINE CHORION	1 (0.02)				1 (0.00)
GONADOTROPIN RELEASING		1 (0.01)			1 (0.00)
GONAL-F		2 (0.01)			2 (0.00)
GOODMIN			1 (0.00)		1 (0.00)
GOPTEN			5 (0.02)	2 (0.03)	7 (0.01)
GOSERELIN			1 (0.00)	1 (0.01)	2 (0.00)
GOSERELIN ACETATE		1 (0.01)			1 (0.00)
GRAFTS/DEVICES (NOT FR		1 (0.01)			1 (0.00)
GRAMALIL			1 (0.00)		1 (0.00)
GRAN	5 (0.08)		1 (0.00)	1 (0.01)	7 (0.01)
GRANDAXIN			2 (0.01)	2 (0.03)	4 (0.01)
GRANISETRON		1 (0.01)	1 (0.00)		2 (0.00)
GRANISETRON HCL			4 (0.01)	1 (0.01)	5 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
GRANISETRON HCL			4 (0.01)	1 (0.01)	5 (0.01)
GRANOCYTE (LENOGRASTIM			2 (0.01)		2 (0.00)
GRANULOCYTE COLONY STI	6 (0.10)				6 (0.01)
GRANULOCYTE COLONY STI	1 (0.02)				1 (0.00)
GRAVOL TAB		1 (0.01)			1 (0.00)
GREAT GRAPE CHILDREN'S	1 (0.02)				1 (0.00)
GRIFULVIN V, UNSPECIFI	1 (0.02)				1 (0.00)
GROWTH HORMONE			1 (0.00)		1 (0.00)
GRTPA (ALTEPL			1 (0.00)		1 (0.00)
GRTPA (ALTEPLASE) PWDR			2 (0.01)	1 (0.01)	3 (0.00)
GUAIFENESIN			3 (0.01)	1 (0.01)	4 (0.01)
GUAIFENESIN SYRUP (RUG		1 (0.01)			1 (0.00)
GUAIFENEX LA			1 (0.00)		1 (0.00)
GUAIFENSIN				1 (0.01)	1 (0.00)
GUTRON				1 (0.01)	1 (0.00)
GW433908			1 (0.00)		1 (0.00)
GW679769			1 (0.00)		1 (0.00)
GYNERGENE CAFEINE		1 (0.01)			1 (0.00)
GYNO-DAKTARIN			1 (0.00)		1 (0.00)
GYNOKADIN GEL (ESTRADI			3 (0.01)		3 (0.00)
H-CORT			1 (0.00)		1 (0.00)
HABEKACIN				1 (0.01)	1 (0.00)
HABEKACIN (ARBEKACIN)			1 (0.00)		1 (0.00)
HABITROL	1 (0.02)	8 (0.05)	1 (0.00)		10 (0.02)
HAEMATE (FACTOT VIII		1 (0.01)			1 (0.00)
HALCION	1 (0.02)	2 (0.01)	8 (0.03)	1 (0.01)	12 (0.02)
HALDOL	6 (0.10)	6 (0.04)	12 (0.04)	1 (0.01)	25 (0.04)
HALDOL DECANOATE (HALO		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
HALDOL SOLUTAB		4 (0.02)	2 (0.01)		6 (0.01)
HALFLYTELY		1 (0.01)	1 (0.00)		2 (0.00)
HALOPERIDOL	3 (0.05)	17 (0.10)	5 (0.02)	6 (0.08)	31 (0.05)
HALOPERIDOL DECANOATE		2 (0.01)			2 (0.00)
HALOPERIDOL LACTATE		1 (0.01)			1 (0.00)
HARMONET	1 (0.02)	1 (0.01)			2 (0.00)
HARNAL			3 (0.01)	4 (0.05)	7 (0.01)
HARNAL (TAMSULOSIN HYD				1 (0.01)	1 (0.00)
HARNAL D (TAMSULOSIN H				2 (0.03)	2 (0.00)
HAVLANE		1 (0.01)			1 (0.00)
HC TUSSIVE		1 (0.01)			1 (0.00)
HCTZ (HYDROCHLOROTHIAZ			1 (0.00)	1 (0.01)	2 (0.00)
HCTZ 25 MG /LISINOPRIL			1 (0.00)		1 (0.00)
HCTZ 25/TRIAMTERENE				1 (0.01)	1 (0.00)
HEART MEDICATION		1 (0.01)		2 (0.03)	3 (0.00)
HEART MEDICATIONS (SPE			1 (0.00)		1 (0.00)
HEART MEDICINE				1 (0.01)	1 (0.00)
HEHPEARIN			1 (0.00)		1 (0.00)
HEMATOPOETIC PROGENITO	2 (0.03)		1 (0.00)		3 (0.00)
HEMODIALYSIS			1 (0.00)		1 (0.00)
HEMOFIL (FACTOR VIII (2 (0.03)				2 (0.00)
HEP B	1 (0.02)				1 (0.00)
HEPARIN	7 (0.12)	12 (0.07)	28 (0.09)	13 (0.17)	60 (0.10)
HEPARIN 300 UNITS			1 (0.00)		1 (0.00)
HEPARIN LOCK-FLUSH			1 (0.00)		1 (0.00)
HEPARIN SODIUM	2 (0.03)	2 (0.01)	7 (0.02)	3 (0.04)	14 (0.02)
HEPARIN SODIUM 20,000				1 (0.01)	1 (0.00)
HEPARIN SODIUM 25,000				2 (0.03)	2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
HEPARIN SODIUM 25,000				1 (0.01)	1 (0.00)
HEPARIN SODIUM INJECTI			1 (0.00)		1 (0.00)
HEPARIN SODIUM WITH SO				1 (0.01)	1 (0.00)
HEPARINE SODIQUE CHOAY		1 (0.01)			1 (0.00)
HEPATIL		1 (0.01)			1 (0.00)
HEPATITIS A/HEPATITIS	1 (0.02)				1 (0.00)
HEPSERA		4 (0.02)	6 (0.02)		10 (0.02)
HEPTAMINOL		1 (0.01)			1 (0.00)
HERBAL AND DIET MEDICA		1 (0.01)			1 (0.00)
HERBAL SUPPLEMENT WHIC		2 (0.01)			2 (0.00)
HERBESSER			2 (0.01)	2 (0.03)	4 (0.01)
HERBS			1 (0.00)		1 (0.00)
HERCEPTIN		20 (0.12)	41 (0.14)	2 (0.03)	63 (0.10)
HERCEPTIN (TRASTUZUMAB		1 (0.01)			1 (0.00)
HERCEPTIN (TRASTUZUMAB		1 (0.01)			1 (0.00)
HERCEPTIN (TRASTUZUMAB			1 (0.00)		1 (0.00)
HERCEPTIN(TRASTUZUMAB)			1 (0.00)		1 (0.00)
HERCEPTINE			2 (0.01)		2 (0.00)
HEROIN	1 (0.02)				1 (0.00)
HERPARIN			1 (0.00)		1 (0.00)
HIDANTAL		2 (0.01)			2 (0.00)
HIGH BLOOD PRESSURE ME			2 (0.01)		2 (0.00)
HIGH BLOOD PRESSURE ME			1 (0.00)		1 (0.00)
HIGH DOSE STEROIDS			1 (0.00)		1 (0.00)
HIPREX			1 (0.00)		1 (0.00)
HIRUDOID	1 (0.02)				1 (0.00)
HISTACOL TAB		1 (0.01)			1 (0.00)
HIV TREATMENTS (UNSPEC	2 (0.03)				2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
HOKUNALIN				3 (0.04)	3 (0.00)
HOME OXYGEN (OXYGEN)			1 (0.00)		1 (0.00)
HOMEOPATHIC MEDICATION			1 (0.00)		1 (0.00)
HOMEOPATHIC PREPARATIO	1 (0.02)	1 (0.01)			2 (0.00)
HOMEOPATHIC PREPARATIO	1 (0.02)				1 (0.00)
HOMEOPATIC PREPARATION			2 (0.01)		2 (0.00)
HOMEOPATIC PREPARATION			1 (0.00)		1 (0.00)
HONVAN			2 (0.01)		2 (0.00)
HORIZON	1 (0.02)			1 (0.01)	2 (0.00)
HORMONAL CONTRACEPTIVE		3 (0.02)			3 (0.00)
HORMONE AGENT			1 (0.00)		1 (0.00)
HORMONE REPLACEMENT TH			3 (0.01)		3 (0.00)
HORMONES		3 (0.02)	3 (0.01)		6 (0.01)
HORMONES (UNSPECIFIED)		1 (0.01)	1 (0.00)		2 (0.00)
HPC-C THAWED	1 (0.02)				1 (0.00)
HRF - GONADORELIN		1 (0.01)			1 (0.00)
HRT			1 (0.00)		1 (0.00)
HTN			1 (0.00)		1 (0.00)
HUMACART 30% REGULAR,				2 (0.03)	2 (0.00)
HUMAJECT - HUMULIN 70/		1 (0.01)			1 (0.00)
HUMAJECT - HUMULIN N (1 (0.00)		1 (0.00)
HUMALOG	10 (0.17)	23 (0.13)	61 (0.20)	11 (0.14)	105 (0.17)
HUMALOG (INSULIN ANALO		1 (0.01)			1 (0.00)
HUMALOG 25% LISPRO, 75				1 (0.01)	1 (0.00)
HUMALOG MIX 50/50			2 (0.01)		2 (0.00)
HUMALOG MIX 75/25		3 (0.02)	12 (0.04)	8 (0.10)	23 (0.04)
HUMALOG PEN	1 (0.02)		4 (0.01)		5 (0.01)
HUMALOG PEN (HUMALOG P			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
HUMAN ALBUMIN GRIFOLS			1 (0.00)	1 (0.01)	2 (0.00)
HUMAN BONE FOR TRANSPL			1 (0.00)		1 (0.00)
HUMAN BONE FOR TRANSPL		1 (0.01)			1 (0.00)
HUMAN INSULIN		1 (0.01)			1 (0.00)
HUMAN INSULIN (RDNA OR	1 (0.02)				1 (0.00)
HUMAN INSULIN (RDNA OR			1 (0.00)		1 (0.00)
HUMAN MIXTARD 30 HM(GE		1 (0.01)			1 (0.00)
HUMATROPE	16 (0.27)	8 (0.05)	7 (0.02)	1 (0.01)	32 (0.05)
HUMIBID L.A.			1 (0.00)		1 (0.00)
HUMIRA	1 (0.02)	17 (0.10)	29 (0.10)	4 (0.05)	51 (0.08)
HUMIRA 40 MG ABBOTT			1 (0.00)		1 (0.00)
HUMIRA 40 MG/ 0.8 ML P			1 (0.00)		1 (0.00)
HUMULIN		1 (0.01)	8 (0.03)		9 (0.01)
HUMULIN (HUMAN INSULIN		1 (0.01)			1 (0.00)
HUMULIN (INSULIN HUMAN				1 (0.01)	1 (0.00)
HUMULIN 70/30	2 (0.03)	15 (0.09)	27 (0.09)	11 (0.14)	55 (0.09)
HUMULIN 70/30 (HUMAN I			1 (0.00)		1 (0.00)
HUMULIN H INSULIN			1 (0.00)		1 (0.00)
HUMULIN INSULIN			1 (0.00)		1 (0.00)
HUMULIN L		2 (0.01)		2 (0.03)	4 (0.01)
HUMULIN N	1 (0.02)	7 (0.04)	34 (0.11)	10 (0.13)	52 (0.09)
HUMULIN NPH (HUMAN INS	1 (0.02)				1 (0.00)
HUMULIN NPH(HUMAN INSU			1 (0.00)		1 (0.00)
HUMULIN R	2 (0.03)	4 (0.02)	18 (0.06)	4 (0.05)	28 (0.05)
HUMULIN U ULTRALENTE		1 (0.01)			1 (0.00)
HUMULIN-N INSULIN			1 (0.00)		1 (0.00)
HUMULINE NPH			1 (0.00)		1 (0.00)
HUMULINI-N INSULIN (IN			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
HURRICAIN BENZOCAINE		1 (0.01)			1 (0.00)
HURRICAIN BENZOCAINE			2 (0.01)		2 (0.00)
HURRICAIN SPRAY 20%		1 (0.01)			1 (0.00)
HURRICAIN TOPICAL SPR			1 (0.00)		1 (0.00)
HURRICANE 20% BENZOCAI		1 (0.01)			1 (0.00)
HUSCODE				1 (0.01)	1 (0.00)
HUSTAZOL	1 (0.02)		2 (0.01)	2 (0.03)	5 (0.01)
HYCODAN		1 (0.01)			1 (0.00)
HYDERGINE			1 (0.00)	1 (0.01)	2 (0.00)
HYDRALAZINE		1 (0.01)	8 (0.03)	2 (0.03)	11 (0.02)
HYDRALAZINE 12.5 MG			1 (0.00)		1 (0.00)
HYDRALAZINE 50 MG PLIV				1 (0.01)	1 (0.00)
HYDRALAZINE HCL		2 (0.01)	2 (0.01)		4 (0.01)
HYDREA		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)
HYDREA (HYDROXYCABAMID				1 (0.01)	1 (0.00)
HYDREX SEMI (HYDROCHLO			1 (0.00)		1 (0.00)
HYDROCHLOROTHIAZID		1 (0.01)			1 (0.00)
HYDROCHLOROTHIAZIDE	1 (0.02)	23 (0.13)	107 (0.35)	28 (0.36)	159 (0.26)
HYDROCHLOROTHIAZIDE 25			1 (0.00)		1 (0.00)
HYDROCHLOROTHIAZIDE AN			2 (0.01)		2 (0.00)
HYDROCHLOROTHIAZIDE AN			2 (0.01)		2 (0.00)
HYDROCHLOROTHIAZIDE AN			2 (0.01)	1 (0.01)	3 (0.00)
HYDROCHLOROTHIAZIDE AN			1 (0.00)		1 (0.00)
HYDROCHLOROTHIAZIDE TA			1 (0.00)		1 (0.00)
HYDROCHLOROTHIAZIDE TA			1 (0.00)		1 (0.00)
HYDROCHLOROTHIAZIDE W/		2 (0.01)		1 (0.01)	3 (0.00)
HYDROCHLOROTHIAZIDE/OL			1 (0.00)		1 (0.00)
HYDROCHLOROTHIAZIDE/TR			2 (0.01)		2 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
HYDROCHLOROTHIAZIDEL			1 (0.00)		1 (0.00)
HYDROCODONE	1 (0.02)	5 (0.03)	4 (0.01)		10 (0.02)
HYDROCODONE + ACETAMIN		5 (0.03)			5 (0.01)
HYDROCODONE BITARTRATE		14 (0.08)	15 (0.05)	2 (0.03)	31 (0.05)
HYDROCODONE BITARTRATE		7 (0.04)	10 (0.03)		17 (0.03)
HYDROCODONE BITARTRATE		1 (0.01)			1 (0.00)
HYDROCODONE HYDROCHLOR		5 (0.03)	4 (0.01)	1 (0.01)	10 (0.02)
HYDROCODONE WITH APAP		1 (0.01)			1 (0.00)
HYDROCODONE/APAP (HYDR			1 (0.00)		1 (0.00)
HYDROCODONE/APAP (VICO				1 (0.01)	1 (0.00)
HYDROCORTISONE HEMISU			1 (0.00)		1 (0.00)
HYDROCORTISON			1 (0.00)		1 (0.00)
HYDROCORTISONE	13 (0.22)	7 (0.04)	11 (0.04)	1 (0.01)	32 (0.05)
HYDROCORTISONE AC		1 (0.01)			1 (0.00)
HYDROCORTISONE HEMISUC			1 (0.00)		1 (0.00)
HYDROCORTISONE HEMISUC		2 (0.01)	1 (0.00)		3 (0.00)
HYDROCORTONE			2 (0.01)		2 (0.00)
HYDROCORTONE PHOSPHATE	1 (0.02)				1 (0.00)
HYDRODIURIL			9 (0.03)	2 (0.03)	11 (0.02)
HYDROMORPH CONTIN			1 (0.00)		1 (0.00)
HYDROMORPH CONTIN (HYD			1 (0.00)		1 (0.00)
HYDROMORPHONE				1 (0.01)	1 (0.00)
HYDROMORPHONE HCL (HY				1 (0.01)	1 (0.00)
HYDROMORPHONE HCL		5 (0.03)	5 (0.02)	4 (0.05)	14 (0.02)
HYDROMORPHONE HCL CR				1 (0.01)	1 (0.00)
HYDROMORPHONE HCL CR C			1 (0.00)		1 (0.00)
HYDROMORPHONE HYDROCHL		1 (0.01)	1 (0.00)		2 (0.00)
HYDROMORPHONE;;;OPIOID			1 (0.00)		1 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
HYDROTALCITE		1 (0.01)			1 (0.00)
HYDROXOCOBALAMIN				1 (0.01)	1 (0.00)
HYDROXOCOBALAMIN (HYDR				1 (0.01)	1 (0.00)
HYDROXYCHLOROQUINE SUL	1 (0.02)	1 (0.01)	7 (0.02)		9 (0.01)
HYDROXYCOBALAMIN				1 (0.01)	1 (0.00)
HYDROXYUREA	1 (0.02)	2 (0.01)	6 (0.02)	2 (0.03)	11 (0.02)
HYDROXYZINE	1 (0.02)	2 (0.01)	5 (0.02)	1 (0.01)	9 (0.01)
HYDROXYZINE HCL		3 (0.02)	1 (0.00)		4 (0.01)
HYDROXYZINE HYDROCHLOR		3 (0.02)			3 (0.00)
HYDROXYZINE PAMOATE	1 (0.02)	1 (0.01)		1 (0.01)	3 (0.00)
HYOSCINE HBR HYT		2 (0.01)			2 (0.00)
HYOSCYAMINE	1 (0.02)		1 (0.00)		2 (0.00)
HYOSCYAMINE 0.375			1 (0.00)		1 (0.00)
HYOSCYAMINE-EXTENDED-R			1 (0.00)		1 (0.00)
HYPaque		1 (0.01)	2 (0.01)		3 (0.00)
HYPEN			2 (0.01)		2 (0.00)
HYPERHEP		1 (0.01)			1 (0.00)
HYPERHEP B S/D		1 (0.01)			1 (0.00)
HYPERICUM PERFORATUM (2 (0.03)				2 (0.00)
HYPERTENSION MED			2 (0.01)		2 (0.00)
HYPERTENSION MEDICATIO			3 (0.01)	2 (0.03)	5 (0.01)
HYPNOGEN (ZOLPID		1 (0.01)			1 (0.00)
HYPNOGEN (ZOLPIDEM TA		1 (0.01)			1 (0.00)
HYPNOVEL		1 (0.01)	1 (0.00)		2 (0.00)
HYPOGLYCEMICS			1 (0.00)		1 (0.00)
HYDROCOD/APAP -GENERI	1 (0.02)				1 (0.00)
HYSRON			2 (0.01)		2 (0.00)
HYSRON (MEDROXYPROGEST			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
HYTACAND				1 (0.01)	1 (0.00)
HYTRIN			15 (0.05)	6 (0.08)	21 (0.03)
HYTRIN (TERAZOSIN HYDR				1 (0.01)	1 (0.00)
HYTRIN 5MG (HYTRIN) (T				1 (0.01)	1 (0.00)
HYZAAR		10 (0.06)	47 (0.16)	8 (0.10)	65 (0.11)
HYZAAR (LOSARTAN/HYDRO				1 (0.01)	1 (0.00)
I-131			1 (0.00)		1 (0.00)
IBANDRONIC ACID			1 (0.00)		1 (0.00)
IBUPROFEN	47 (0.79)	91 (0.53)	89 (0.29)	17 (0.22)	244 (0.40)
IBUPROFEN TABLETS		1 (0.01)		1 (0.01)	2 (0.00)
IBUPROFENE MSD		1 (0.01)			1 (0.00)
ICA-17043 VS PLACEBO (1 (0.02)				1 (0.00)
ICA-17043 VS. PLACEBO		1 (0.01)			1 (0.00)
ICL670A	3 (0.05)				3 (0.00)
IDAPTAN				1 (0.01)	1 (0.00)
IDARUBICIN HCL		6 (0.04)		1 (0.01)	7 (0.01)
IDARUBICIN HYDROCHLORI			1 (0.00)		1 (0.00)
IDARUBICINE		1 (0.01)			1 (0.00)
IDROLAX (MACROGOL)		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
IFEX			1 (0.00)		1 (0.00)
IFOMIDE		1 (0.01)			1 (0.00)
IFOSFAMIDE	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)
IGIV GENERIC		2 (0.01)	8 (0.03)	1 (0.01)	11 (0.02)
IGIV GENERIC (IMMUNOGL		1 (0.01)	6 (0.02)	1 (0.01)	8 (0.01)
IKOREL			1 (0.00)		1 (0.00)
ILETIN	2 (0.03)	3 (0.02)			5 (0.01)
ILLICIT DRUGS		1 (0.01)			1 (0.00)
IMATINIB	3 (0.05)	5 (0.03)	2 (0.01)		10 (0.02)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
IMDIUM (LOPERAMIDE HYD			1 (0.00)		1 (0.00)
IMDUR			12 (0.04)	8 (0.10)	20 (0.03)
IMIGRAN		2 (0.01)			2 (0.00)
IMIGRANE		1 (0.01)			1 (0.00)
IMIJECT		2 (0.01)			2 (0.00)
IMIPENEM	1 (0.02)	1 (0.01)	3 (0.01)		5 (0.01)
IMIPENEM/CILASTATIN			2 (0.01)		2 (0.00)
IMIPRAMINE	5 (0.08)	10 (0.06)	4 (0.01)		19 (0.03)
IMIPRAMINE HCL	1 (0.02)		1 (0.00)		2 (0.00)
IMIPRAMINE HYDROCHLORI		1 (0.01)	2 (0.01)		3 (0.00)
IMIQUIMOD		2 (0.01)			2 (0.00)
IMIQUIMOD (IMIQUIMOD)			1 (0.00)		1 (0.00)
IMITREX	5 (0.08)	29 (0.17)	19 (0.06)		53 (0.09)
IMMUCYST		3 (0.02)	31 (0.10)	20 (0.26)	54 (0.09)
IMMUKIN (INTERFERON GA	1 (0.02)				1 (0.00)
IMMUNE CELLS HUMAN			2 (0.01)		2 (0.00)
IMMUNE GLOBULIN (HUMAN			1 (0.00)		1 (0.00)
IMMUNE GLOBULIN INTRAV	4 (0.07)	8 (0.05)	18 (0.06)	5 (0.06)	35 (0.06)
IMMUNE GLOBULIN TALECR	1 (0.02)				1 (0.00)
IMMUNOGLOBULIN (IMMUNO		1 (0.01)			1 (0.00)
IMMUNOGLOBULIN (NOS)				1 (0.01)	1 (0.00)
IMMUNOGLOBULIN G HUMAN			1 (0.00)		1 (0.00)
IMMUNOSUPPRESSIVE			1 (0.00)		1 (0.00)
IMMUNOSUPPRESSIVE AGEN		1 (0.01)			1 (0.00)
IMMUNOSUPPRESSIVE AGEN	1 (0.02)				1 (0.00)
IMODIUM	2 (0.03)	4 (0.02)	11 (0.04)		17 (0.03)
IMOVANE	1 (0.02)	1 (0.01)	4 (0.01)	2 (0.03)	8 (0.01)
IMOVANE				1 (0.01)	1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
IMPACTED CORTICAL WED			1 (0.00)		1 (0.00)
IMUKIN (INTERFERON GAM	1 (0.02)				1 (0.00)
IMURAN	3 (0.05)	6 (0.04)	6 (0.02)		15 (0.02)
IMUREK	1 (0.02)				1 (0.00)
IMUREL	6 (0.10)	4 (0.02)	5 (0.02)		15 (0.02)
INALADUO			1 (0.00)		1 (0.00)
INDAPAMIDE		2 (0.01)	4 (0.01)	6 (0.08)	12 (0.02)
INDERAL	1 (0.02)	4 (0.02)	13 (0.04)	4 (0.05)	22 (0.04)
INDERAL LA		4 (0.02)	7 (0.02)		11 (0.02)
INDINAVIR SULFATE		1 (0.01)			1 (0.00)
INDINIVIR SULFATE		1 (0.01)			1 (0.00)
INDOBUFEN			1 (0.00)		1 (0.00)
INDOCIN	1 (0.02)	2 (0.01)	3 (0.01)		6 (0.01)
INDOMETHACIN	3 (0.05)	3 (0.02)	5 (0.02)	1 (0.01)	12 (0.02)
INDREAL-LA (PROPRANOLO		1 (0.01)			1 (0.00)
INFANT'S FORMULA	1 (0.02)				1 (0.00)
INFANT'S PEDIACARE DEC	1 (0.02)				1 (0.00)
INFANT'S PEDIACARE DEC	1 (0.02)				1 (0.00)
INFANT'S PEDIACARE DEC	1 (0.02)				1 (0.00)
INFANT'S PEDIACARE DEC	1 (0.02)				1 (0.00)
INFANT'S PEDIACARE DEC	1 (0.02)				1 (0.00)
INFANT'S PEDICARE	1 (0.02)				1 (0.00)
INFANTS' PEDIACARE LON	2 (0.03)				2 (0.00)
INFED		2 (0.01)	1 (0.00)		3 (0.00)
INFERAX (INTERFERON AL			1 (0.00)		1 (0.00)
INFERGEN		2 (0.01)	3 (0.01)		5 (0.01)
INFLAMMATORY DRUG		1 (0.01)			1 (0.00)
INFLIXIMAB	3 (0.05)	18 (0.11)	18 (0.06)	1 (0.01)	40 (0.07)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
INFLUENZA VACCINE			1 (0.00)		1 (0.00)
INFLUENZA VIRUS VACCIN	1 (0.02)				1 (0.00)
INFLUENZA VIRUS VACCIN			1 (0.00)		1 (0.00)
INFLUENZA VIRUS VACCIN			1 (0.00)		1 (0.00)
INFLUSPLIT			1 (0.00)		1 (0.00)
INFLUSPLIT SSW		2 (0.01)			2 (0.00)
INFLUVAC			1 (0.00)		1 (0.00)
INFREE			1 (0.00)		1 (0.00)
INH			1 (0.00)		1 (0.00)
INHALER		1 (0.01)			1 (0.00)
INHALERS	1 (0.02)				1 (0.00)
INHALERS NOS			1 (0.00)		1 (0.00)
INHIBACE PLUS (CILAZAP			1 (0.00)		1 (0.00)
INIPOMP		2 (0.01)			2 (0.00)
INIPOMP (PANTOPRAZOLE)			2 (0.01)		2 (0.00)
INIPOMP (PANTOPRAZOLE,			1 (0.00)		1 (0.00)
INJECTABLE GOLD (UNSPE			1 (0.00)		1 (0.00)
INNOHEP			3 (0.01)		3 (0.00)
INSULATARD NPH HUMAN		2 (0.01)			2 (0.00)
INSULIIN(INSULIN)			1 (0.00)		1 (0.00)
INSULIN	7 (0.12)	48 (0.28)	101 (0.33)	15 (0.19)	171 (0.28)
INSULIN (I	1 (0.02)				1 (0.00)
INSULIN (INSULIN)	1 (0.02)	1 (0.01)	6 (0.02)		8 (0.01)
INSULIN (INSULIN) INJE			1 (0.00)		1 (0.00)
INSULIN (INSULIN, ANIM	1 (0.02)				1 (0.00)
INSULIN ASPART		1 (0.01)	1 (0.00)		2 (0.00)
INSULIN ASPART, BIPHAS		1 (0.01)			1 (0.00)
INSULIN DETEMIR PENFIL		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
INSULIN GLARGINE			2 (0.01)		2 (0.00)
INSULIN GLARGINE (INSU			1 (0.00)		1 (0.00)
INSULIN HUMALOG (LILLY	1 (0.02)				1 (0.00)
INSULIN HUMAN			2 (0.01)		2 (0.00)
INSULIN HUMAN (INSULIN			1 (0.00)		1 (0.00)
INSULIN HUMULIN 70/30			1 (0.00)		1 (0.00)
INSULIN INJECTION, BIP			1 (0.00)		1 (0.00)
INSULIN INJECTION, BIP			1 (0.00)		1 (0.00)
INSULIN LISPRO	2 (0.03)				2 (0.00)
INSULIN NORDISK MIXTAR		1 (0.01)			1 (0.00)
INSULIN NOS			1 (0.00)		1 (0.00)
INSULIN PUMP	2 (0.03)				2 (0.00)
INSULIN PUMP NOS			1 (0.00)		1 (0.00)
INSULIN, BIPHASIC ISOP			2 (0.01)		2 (0.00)
INSULIN, NEUTRAL			1 (0.00)		1 (0.00)
INSULINE			1 (0.00)		1 (0.00)
INSULINES			1 (0.00)		1 (0.00)
INSULINS			1 (0.00)		1 (0.00)
INSUMAN RAPID			1 (0.00)		1 (0.00)
INTEGRILIN			4 (0.01)	1 (0.01)	5 (0.01)
INTERFERON		4 (0.02)	8 (0.03)		12 (0.02)
INTERFERON ALFA			3 (0.01)		3 (0.00)
INTERFERON ALFA (INTER		1 (0.01)			1 (0.00)
INTERFERON ALFA-2A	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
INTERFERON ALFA-2B INJ		2 (0.01)			2 (0.00)
INTERFERON ALFACON-1			1 (0.00)		1 (0.00)
INTERFERON ALFACON-L (1 (0.00)		1 (0.00)
INTERFERON BETA-1B UNB		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
INTERFERON GAMMA (INTE	1 (0.02)				1 (0.00)
INTERFERON GAMMA-1B		3 (0.02)	25 (0.08)	4 (0.05)	32 (0.05)
INTERFERON INJECTABLE			1 (0.00)		1 (0.00)
INTRATECT (IMMUNOGLOBU			1 (0.00)		1 (0.00)
INTRAUTERINE COPPER CO	12 (0.20)	23 (0.13)			35 (0.06)
INTRAVENOUS IMMUNE GLO				2 (0.03)	2 (0.00)
INTRAVENOUS IMMUNE GLO				1 (0.01)	1 (0.00)
INTRON A		7 (0.04)	14 (0.05)	1 (0.01)	22 (0.04)
INTRON A (INTERFERON A		1 (0.01)			1 (0.00)
INTRON A (INTERFERON A			1 (0.00)		1 (0.00)
INTRON A (INTERFERON A		1 (0.01)	1 (0.00)		2 (0.00)
INTRON A (INTERFERON A			1 (0.00)		1 (0.00)
INTRON A (INTERFERON A			1 (0.00)		1 (0.00)
INTRONA (INJECTION) (I			1 (0.00)		1 (0.00)
INVANZ	2 (0.03)	2 (0.01)	3 (0.01)	2 (0.03)	9 (0.01)
INVIRASE		1 (0.01)	1 (0.00)		2 (0.00)
IOPAMIRO			2 (0.01)		2 (0.00)
IOPAMIRON		2 (0.01)	2 (0.01)		4 (0.01)
IOPIDENE		1 (0.01)			1 (0.00)
IOPROMIDE(IOPROMIDE) I			1 (0.00)		1 (0.00)
IPRATROPIUM BROMIDE			5 (0.02)	5 (0.06)	10 (0.02)
IPREN 400 MG			2 (0.01)		2 (0.00)
IRBESARTAN			9 (0.03)	8 (0.10)	17 (0.03)
IRBESARTAN AND HYDROCH			1 (0.00)		1 (0.00)
IRENAT (SODIUM PERCHLO			1 (0.00)		1 (0.00)
IRESSA		7 (0.04)	41 (0.14)	6 (0.08)	54 (0.09)
IRINOTECAN HCL	1 (0.02)	11 (0.06)	28 (0.09)	1 (0.01)	41 (0.07)
IRON	2 (0.03)	3 (0.02)	1 (0.00)		6 (0.01)

Drug Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
IRON (IRON)	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
IRON (UNSPECIFIED)			1 (0.00)		1 (0.00)
IRON DEXTRAN		2 (0.01)	3 (0.01)		5 (0.01)
IRON SALT	1 (0.02)				1 (0.00)
IRON SULFATETHIAMIN CO			1 (0.00)		1 (0.00)
IRON TABLETS	3 (0.05)				3 (0.00)
IRRADIATION		2 (0.01)			2 (0.00)
ISALON			1 (0.00)		1 (0.00)
ISCOTIN			1 (0.00)	1 (0.01)	2 (0.00)
ISDN				1 (0.01)	1 (0.00)
ISMN				1 (0.01)	1 (0.00)
ISMO			2 (0.01)		2 (0.00)
ISODINE		1 (0.01)			1 (0.00)
ISOFLURANE			1 (0.00)		1 (0.00)
ISONIAZID	2 (0.03)	3 (0.02)	12 (0.04)	2 (0.03)	19 (0.03)
ISOPHANE INSULIN			3 (0.01)		3 (0.00)
ISOPROTERENOL		1 (0.01)			1 (0.00)
ISOPTIN	1 (0.02)		1 (0.00)	3 (0.04)	5 (0.01)
ISOPTIN SR			3 (0.01)		3 (0.00)
ISORDIL			4 (0.01)	2 (0.03)	6 (0.01)
ISOSORBID MONONITRANS			1 (0.00)		1 (0.00)
ISOSORBID MONONITRATE			1 (0.00)		1 (0.00)
ISOSORBIDE			11 (0.04)	8 (0.10)	19 (0.03)
ISOSORBIDE (ISOSORBIDE				1 (0.01)	1 (0.00)
ISOSORBIDE DINITRATE			7 (0.02)	6 (0.08)	13 (0.02)
ISOSORBIDE MONONITRATE			16 (0.05)	5 (0.06)	21 (0.03)
ISOSORBIDE MONONITRATE			2 (0.01)		2 (0.00)
ISOTONIC SOLUTION			1 (0.00)		1 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
ISOTONIC SOLUTIONS			2 (0.01)		2 (0.00)
ISOTONIC SOLUTIONS INJ			1 (0.00)		1 (0.00)
ISOTRETINOIN	13 (0.22)	5 (0.03)			18 (0.03)
ISOVORIN		1 (0.01)			1 (0.00)
ISOVUE (IOPAMIDOL INJ.		1 (0.01)			1 (0.00)
ISOVUE-128		1 (0.01)	2 (0.01)		3 (0.00)
ISOVUE-300		5 (0.03)	3 (0.01)		8 (0.01)
ISRADIPINE			5 (0.02)		5 (0.01)
ITRACOL			1 (0.00)		1 (0.00)
ITRACONAZOLE	3 (0.05)	1 (0.01)	1 (0.00)	2 (0.03)	7 (0.01)
ITRIZOLE		4 (0.02)	3 (0.01)		7 (0.01)
IVERMECTIN			2 (0.01)		2 (0.00)
IXPRIM		2 (0.01)			2 (0.00)
JATROSOM (TRANLYCYPROM	3 (0.05)				3 (0.00)
JATROSOM (TRANLYCYPROP	1 (0.02)				1 (0.00)
JODETTEN		1 (0.01)			1 (0.00)
JODETTEN - SLOW RELEAS			1 (0.00)		1 (0.00)
JOSIR			1 (0.00)		1 (0.00)
JUNEL 1.5/30	1 (0.02)				1 (0.00)
JUVELA		1 (0.01)	1 (0.00)		2 (0.00)
JUVELA NICOTINATE			2 (0.01)		2 (0.00)
K-DUR 10		1 (0.01)	4 (0.01)	5 (0.06)	10 (0.02)
KADIAN	1 (0.02)	3 (0.02)	5 (0.02)		9 (0.01)
KAKKON	1 (0.02)				1 (0.00)
KAKKON-TO	3 (0.05)	1 (0.01)			4 (0.01)
KAKODIN			1 (0.00)		1 (0.00)
KALETRA	6 (0.10)	38 (0.22)	1 (0.00)		45 (0.07)
KALETRA (LOPINAVIR/RIT		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
KAMI-SHOYO-SAN	1 (0.02)				1 (0.00)
KAPANOL			1 (0.00)		1 (0.00)
KARDEGIC			8 (0.03)	5 (0.06)	13 (0.02)
KARIVA	4 (0.07)	2 (0.01)			6 (0.01)
KARVEA (IRBESARTAN)				1 (0.01)	1 (0.00)
KARVEZIDE (HYDROCHLORO			1 (0.00)		1 (0.00)
KARVEZIDE TABS			1 (0.00)		1 (0.00)
KASKADIL		1 (0.01)			1 (0.00)
KEFLEX	5 (0.08)	9 (0.05)	4 (0.01)		18 (0.03)
KEFLEX (CEFALEXIN MONH		1 (0.01)			1 (0.00)
KEFLEX (CEFALEXIN MONO				1 (0.01)	1 (0.00)
KEFZOL			1 (0.00)		1 (0.00)
KEISHIBUKURYOUGAN (HER			1 (0.00)		1 (0.00)
KEISHIBUKURYOUGAN (HER			1 (0.00)		1 (0.00)
KEKTOCONAZOLE (KETOCON				1 (0.01)	1 (0.00)
KENACORT-A OPHTHALMIC		2 (0.01)	3 (0.01)	1 (0.01)	6 (0.01)
KENALOG	1 (0.02)	5 (0.03)	6 (0.02)		12 (0.02)
KENALOG-10			2 (0.01)		2 (0.00)
KENTERA (WATSON LABORA			1 (0.00)	1 (0.01)	2 (0.00)
KENZEN		1 (0.01)	1 (0.00)		2 (0.00)
KENZEN 8 MG			1 (0.00)		1 (0.00)
KEPIVANCE			1 (0.00)		1 (0.00)
KEPPRA	20 (0.34)	21 (0.12)	12 (0.04)	3 (0.04)	56 (0.09)
KERLONE			1 (0.00)		1 (0.00)
KETAMINE HCl INJ. USP	1 (0.02)				1 (0.00)
KETAMINE HCL	1 (0.02)				1 (0.00)
KETAS (IBUDILAST) CAPS			1 (0.00)		1 (0.00)
KETEK	5 (0.08)	43 (0.25)	26 (0.09)	6 (0.08)	80 (0.13)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
KETEX (TELITHROMYCIN)			1 (0.00)		1 (0.00)
KETOCONAZOLE			3 (0.01)	1 (0.01)	4 (0.01)
KETODERM			2 (0.01)		2 (0.00)
KETOPROFEN		2 (0.01)	2 (0.01)		4 (0.01)
KETOROLAC TROMETHAMINE		1 (0.01)	3 (0.01)		4 (0.01)
KETOTIFEN FUMARATE				1 (0.01)	1 (0.00)
KEVATRIL			1 (0.00)		1 (0.00)
KEVATRIL (GRANISETRON			2 (0.01)		2 (0.00)
KINEDAK			2 (0.01)		2 (0.00)
KINERET	3 (0.05)	3 (0.02)			6 (0.01)
KININ				1 (0.01)	1 (0.00)
KIVEXA		4 (0.02)			4 (0.01)
KLACID			3 (0.01)		3 (0.00)
KLACID FORTE TABLETS	1 (0.02)				1 (0.00)
KLACID MR TABLETS			1 (0.00)		1 (0.00)
KLARICID	4 (0.07)	1 (0.01)			5 (0.01)
KLARICID TABLETS	1 (0.02)				1 (0.00)
KLIOFEM			1 (0.00)		1 (0.00)
KLONOPIN	5 (0.08)	65 (0.38)	28 (0.09)	4 (0.05)	102 (0.17)
KLONOPIN (BUPROPION HY		1 (0.01)			1 (0.00)
KLOR-CON		1 (0.01)	10 (0.03)		11 (0.02)
KN-MG3			3 (0.01)		3 (0.00)
KN3B				1 (0.01)	1 (0.00)
KOGENATE	1 (0.02)				1 (0.00)
KOGENATE FS	3 (0.05)				3 (0.00)
KOLANTYL (ALUMINIUM HY				1 (0.01)	1 (0.00)
KREDEX		1 (0.01)	1 (0.00)		2 (0.00)
KU-ZYME CAPSULES			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
KYORIN AP2	1 (0.02)				1 (0.00)
KYRTIL (GRANISETRON)			1 (0.00)		1 (0.00)
KYTRIL	1 (0.02)	2 (0.01)	14 (0.05)	2 (0.03)	19 (0.03)
L -THYROXINE		1 (0.01)			1 (0.00)
L-ASPARTATE POTASSIUM		1 (0.01)			1 (0.00)
L-DOPA				2 (0.03)	2 (0.00)
L-THYROXIN		1 (0.01)	3 (0.01)		4 (0.01)
L-THYROXIN ^HENNING BE	1 (0.02)				1 (0.00)
L-THYROXINE		1 (0.01)	11 (0.04)	1 (0.01)	13 (0.02)
L-THYROXINE (LEVOTHYRO	2 (0.03)				2 (0.00)
L-THYROXINE (LEVOTHYRO		1 (0.01)			1 (0.00)
LABETALOL	1 (0.02)			1 (0.01)	2 (0.00)
LABETALOL 20 MG			1 (0.00)		1 (0.00)
LABETALOL HCL	1 (0.02)	1 (0.01)	4 (0.01)	1 (0.01)	7 (0.01)
LABETALOL HYDROCHLORID		2 (0.01)	3 (0.01)	1 (0.01)	6 (0.01)
LABETOLOL			1 (0.00)		1 (0.00)
LAC B (LACTOBACILLUS B				1 (0.01)	1 (0.00)
LAC B (LACTOBACILLUS B				1 (0.01)	1 (0.00)
LAC-HYDRIN (AMMONIUM L			1 (0.00)		1 (0.00)
LACHESIS			1 (0.00)		1 (0.00)
LACTATE RINGER SOLUTIO	1 (0.02)				1 (0.00)
LACTATED RINGER'S	1 (0.02)	6 (0.04)	1 (0.00)		8 (0.01)
LACTATED RINGER'S (RIN			1 (0.00)		1 (0.00)
LACTATED RINGER'S IN P		1 (0.01)			1 (0.00)
LACTEC-G			1 (0.00)		1 (0.00)
LACTULOSE	1 (0.02)	4 (0.02)	3 (0.01)	2 (0.03)	10 (0.02)
LADOSE (FLUOXETINE HYD		1 (0.01)			1 (0.00)
LAMALINE SUPPOSITORIES				1 (0.01)	1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
LAMICTAL	103 (1.74)	128 (0.75)	57 (0.19)	3 (0.04)	291 (0.48)
LAMISIL	4 (0.07)	27 (0.16)	25 (0.08)	8 (0.10)	64 (0.10)
LAMIVUDINE	4 (0.07)	30 (0.18)	9 (0.03)		43 (0.07)
LAMIVUDINE + ZIDOVUDIN		1 (0.01)	1 (0.00)		2 (0.00)
LAMOTRIGIN (LAMOTRIGIN		1 (0.01)			1 (0.00)
LAMOTRIGINE	11 (0.19)	9 (0.05)	8 (0.03)		28 (0.05)
LANDEL			1 (0.00)		1 (0.00)
LANOXICAPS			1 (0.00)		1 (0.00)
LANOXIN	2 (0.03)	2 (0.01)	9 (0.03)	13 (0.17)	26 (0.04)
LANREOTIDE				1 (0.01)	1 (0.00)
LANSAP		1 (0.01)			1 (0.00)
LANSAP 400 (LANSOPRAZO		1 (0.01)			1 (0.00)
LANSAP 800 (LANSOPRAZO			1 (0.00)	1 (0.01)	2 (0.00)
LANSOPRAZOL (LANSOPRAZ		1 (0.01)			1 (0.00)
LANSOPRAZOLE		9 (0.05)	37 (0.12)	13 (0.17)	59 (0.10)
LANTAS (INSULIN GLARGI		1 (0.01)			1 (0.00)
LANTHANUM CARBONATE (L			1 (0.00)		1 (0.00)
LANTUS	10 (0.17)	25 (0.15)	155 (0.51)	23 (0.30)	213 (0.35)
LANVIS	3 (0.05)				3 (0.00)
LANZOPRAZOLE (LANSOPRA			1 (0.00)		1 (0.00)
LARIAM	6 (0.10)	12 (0.07)	2 (0.01)		20 (0.03)
LAROXYL		2 (0.01)	1 (0.00)		3 (0.00)
LARPOSE		1 (0.01)			1 (0.00)
LARPOSE (LORAZEPAM)		1 (0.01)			1 (0.00)
LASILIX	1 (0.02)		5 (0.02)	12 (0.15)	18 (0.03)
LASILIX RETARD				1 (0.01)	1 (0.00)
LASIX	4 (0.07)	19 (0.11)	82 (0.27)	50 (0.64)	155 (0.25)
LASIX (FUROSEMIDE /00			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
LASIX (FUROSEMIDE, FUR				1 (0.01)	1 (0.00)
LASTET			1 (0.00)		1 (0.00)
LATANOPROST			4 (0.01)	1 (0.01)	5 (0.01)
LAUBEEL		1 (0.01)			1 (0.00)
LECITHIN	3 (0.05)				3 (0.00)
LECITHIN (LECITHIN)			1 (0.00)		1 (0.00)
LEDERFOLINE			1 (0.00)		1 (0.00)
LEFLUNOMIDE		2 (0.01)	8 (0.03)		10 (0.02)
LEFTOSE		1 (0.01)			1 (0.00)
LEFTOSE (LYSOZYME)			1 (0.00)		1 (0.00)
LEIOS (LEVONORGESTREL/		1 (0.01)			1 (0.00)
LEKOVIT CA (COLECALCIF				1 (0.01)	1 (0.00)
LENALIDOMIDE			1 (0.00)	2 (0.03)	3 (0.00)
LENALIDOMIDE 25 MG, 5			1 (0.00)		1 (0.00)
LENALIDOMIDE 5 MG , 25			1 (0.00)		1 (0.00)
LENALIDOMIDE 5 MG CELG			1 (0.00)		1 (0.00)
LENALIDOMIDE 5 MG. 25M			1 (0.00)		1 (0.00)
LENDORM				2 (0.03)	2 (0.00)
LENDORMIN	1 (0.02)			1 (0.01)	2 (0.00)
LENTARON			1 (0.00)		1 (0.00)
LEPIRUDIN		1 (0.01)			1 (0.00)
LEPIRUDIN 100 MG IN D5			1 (0.00)		1 (0.00)
LEPONEX		7 (0.04)	4 (0.01)		11 (0.02)
LEPTICUR		1 (0.01)	1 (0.00)		2 (0.00)
LEPTOS		1 (0.01)			1 (0.00)
LERCAN			1 (0.00)		1 (0.00)
LERCANIDIPINE		1 (0.01)	2 (0.01)		3 (0.00)
LESCOL		4 (0.02)	5 (0.02)	7 (0.09)	16 (0.03)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
LESCOL XL			1 (0.00)	1 (0.01)	2 (0.00)
LETROZOLE		1 (0.01)	2 (0.01)		3 (0.00)
LEUCOVORIN			1 (0.00)	1 (0.01)	2 (0.00)
LEUCOVORIN CALCIUM			9 (0.03)	1 (0.01)	10 (0.02)
LEUCOVORIN CALCIUM FOR			1 (0.00)		1 (0.00)
LEUKERAN			1 (0.00)		1 (0.00)
LEUKINE		1 (0.01)			1 (0.00)
LEUKINE VS. PLACEBO (G		1 (0.01)			1 (0.00)
LEUKOTRAP RC SYSTEM, D		2 (0.01)			2 (0.00)
LEUPLIN				1 (0.01)	1 (0.00)
LEUPLIN INJECTABLE				2 (0.03)	2 (0.00)
LEUPROLIDE ACETATE	1 (0.02)	10 (0.06)	14 (0.05)	3 (0.04)	28 (0.05)
LEUPRORELIN (LEUPROREL			1 (0.00)		1 (0.00)
LEUPRORELIN ACETATE (E			1 (0.00)		1 (0.00)
LEVAQUIN	1 (0.02)	33 (0.19)	39 (0.13)	7 (0.09)	80 (0.13)
LEVAXIN		6 (0.04)	3 (0.01)		9 (0.01)
LEVEMIR	1 (0.02)		4 (0.01)		5 (0.01)
LEVENOX (HEPARIN-FRACT		1 (0.01)			1 (0.00)
LEVETIRACETAM	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
LEVITRA		35 (0.21)	72 (0.24)	10 (0.13)	117 (0.19)
LEVO-THYROXIN			2 (0.01)		2 (0.00)
LEVO-TIROXINA	1 (0.02)				1 (0.00)
LEVOBUPIVACAINE				1 (0.01)	1 (0.00)
LEVOCARB				2 (0.03)	2 (0.00)
LEVOCARNITIN		1 (0.01)			1 (0.00)
LEVODOPA			4 (0.01)	2 (0.03)	6 (0.01)
LEVODOPA+BENSERAZIDE				2 (0.03)	2 (0.00)
LEVOFLOXACIN	3 (0.05)	5 (0.03)	18 (0.06)	2 (0.03)	28 (0.05)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
LEVOFLOXACTIN			1 (0.00)		1 (0.00)
LEVOMEPRMAZINE			1 (0.00)		1 (0.00)
LEVOMEPRMAZINE (LEVOM			1 (0.00)		1 (0.00)
LEVONELLE		1 (0.01)			1 (0.00)
LEVONORGESTREL		7 (0.04)	2 (0.01)		9 (0.01)
LEVONORGESTREL + ETHIN	1 (0.02)				1 (0.00)
LEVONORGESTREL AND ETH	1 (0.02)	2 (0.01)			3 (0.00)
LEVOPHED			4 (0.01)		4 (0.01)
LEVOTHROID			12 (0.04)	1 (0.01)	13 (0.02)
LEVOTHROXIN			1 (0.00)		1 (0.00)
LEVOTHYROX		2 (0.01)	11 (0.04)	4 (0.05)	17 (0.03)
LEVOTHYROX 50 (TABLET)			1 (0.00)		1 (0.00)
LEVOTHYROXINE		2 (0.01)			2 (0.00)
LEVOTHYROXINE 0.15MG T			1 (0.00)		1 (0.00)
LEVOTHYROXINE SODIUM	8 (0.14)	35 (0.21)	83 (0.27)	25 (0.32)	151 (0.25)
LEVOTHYROXINE SODIUM A			1 (0.00)		1 (0.00)
LEVOTHYROXINE SODIUM T			1 (0.00)		1 (0.00)
LEVOTHYROXYINE		1 (0.01)			1 (0.00)
LEVOXYL	1 (0.02)	26 (0.15)	50 (0.17)	8 (0.10)	85 (0.14)
LEVSIN			1 (0.00)		1 (0.00)
LEXAPRO	35 (0.59)	96 (0.56)	45 (0.15)	11 (0.14)	187 (0.31)
LEXAPRO (ESCITALOPRAM			1 (0.00)		1 (0.00)
LEXAPRO /USA/ (ESCITAL		3 (0.02)			3 (0.00)
LEXAPRO/USA/(ESCITALOP			1 (0.00)		1 (0.00)
LEXIVA		8 (0.05)	2 (0.01)		10 (0.02)
LEXOMIL		3 (0.02)	1 (0.00)	3 (0.04)	7 (0.01)
LEXOMIL (BROMAZEPAM)		1 (0.01)			1 (0.00)
LEXOTAN		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
LEXOTAN (BROMAZEPAM)	1 (0.02)				1 (0.00)
LEXOTANIL		1 (0.01)			1 (0.00)
LIASOPHIN			1 (0.00)		1 (0.00)
LIBRAX			3 (0.01)		3 (0.00)
LIBRAX CAPSULES			1 (0.00)		1 (0.00)
LIBRIUM		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
LIDOCAINE	2 (0.03)	10 (0.06)	6 (0.02)	1 (0.01)	19 (0.03)
LIDOCAINE 1%		1 (0.01)			1 (0.00)
LIDOCAINE 2%		1 (0.01)			1 (0.00)
LIDOCAINE AND EPINEPHR	2 (0.03)				2 (0.00)
LIDOCAINE AND PRILOCAI			1 (0.00)		1 (0.00)
LIDOCAINE HCL	2 (0.03)				2 (0.00)
LIDOCAINE HYDROCHLORID		2 (0.01)			2 (0.00)
LIDOCAINE HYDROCHLORID				1 (0.01)	1 (0.00)
LIDODERM		2 (0.01)			2 (0.00)
LIGNOCAINE		1 (0.01)	3 (0.01)		4 (0.01)
LIGNOCAINE HYDROCHLORI		1 (0.01)			1 (0.00)
LIGNOCAINE HYDROCHLORI		1 (0.01)			1 (0.00)
LIMAS (LITHIUM CARBONA			1 (0.00)		1 (0.00)
LIMAS (LITHIUM CARBONA			2 (0.01)		2 (0.00)
LIMETHASON			1 (0.00)		1 (0.00)
LINEX		1 (0.01)			1 (0.00)
LINEZOLID	1 (0.02)		6 (0.02)	1 (0.01)	8 (0.01)
LINEZOLID 600 MG			1 (0.00)		1 (0.00)
LINEZOLID 600MG	1 (0.02)				1 (0.00)
LINEZOLID SOLUTION, ST			1 (0.00)		1 (0.00)
LIORESAL	4 (0.07)	3 (0.02)	4 (0.01)		11 (0.02)
LIORESAL NOVARTIS		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
LIOTHYRONINE SODIUM		1 (0.01)			1 (0.00)
LIPANTHYL		1 (0.01)	1 (0.00)		2 (0.00)
LIPANTHYL SUPRA 160 LM			1 (0.00)		1 (0.00)
LIPANTHYL ^FOURNIER^			1 (0.00)		1 (0.00)
LIPANTYL			1 (0.00)		1 (0.00)
LIPEMOL TABS 20 MG			1 (0.00)		1 (0.00)
LIPID LOWERING TREATME			1 (0.00)		1 (0.00)
LIPIDIL		1 (0.01)	1 (0.00)		2 (0.00)
LIPITOR	3 (0.05)	75 (0.44)	334 (1.10)	89 (1.15)	501 (0.82)
LIPLAT			1 (0.00)		1 (0.00)
LIPLAT TABS			1 (0.00)		1 (0.00)
LIPOSTAT 10%			1 (0.00)		1 (0.00)
LIPRAM			1 (0.00)		1 (0.00)
LISINOPRIL	4 (0.07)	35 (0.21)	142 (0.47)	44 (0.57)	225 (0.37)
LISINOPRIL AND HYDROCH			4 (0.01)	1 (0.01)	5 (0.01)
LISINOPRIL ORALS		1 (0.01)			1 (0.00)
LISINOPRIL W/HYDROCHLO		1 (0.01)			1 (0.00)
LISINOPRIL-BC			2 (0.01)		2 (0.00)
LISTERINE (MENTHOL, ME	3 (0.05)	2 (0.01)	2 (0.01)		7 (0.01)
LISTERINE ANTISEPTIC M		3 (0.02)			3 (0.00)
LISTERINE POCKET MIST			1 (0.00)		1 (0.00)
LITALIR			3 (0.01)		3 (0.00)
LITHIUM	5 (0.08)	35 (0.21)	14 (0.05)		54 (0.09)
LITHIUM		1 (0.01)			1 (0.00)
LITHIUM (LITHIUM)		1 (0.01)	2 (0.01)		3 (0.00)
LITHIUM (LITHIUM) CAPS		1 (0.01)			1 (0.00)
LITHIUM 300 MG			1 (0.00)		1 (0.00)
LITHIUM ASPARTATE			2 (0.01)		2 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
LITHIUM CARBONATE	6 (0.10)	20 (0.12)	15 (0.05)		41 (0.07)
LITHIUM CARBONATE CAPS			1 (0.00)		1 (0.00)
LITHIUM CITRATE			1 (0.00)		1 (0.00)
LITHIUM SULFATE		1 (0.01)	1 (0.00)		2 (0.00)
LITHOBID	1 (0.02)	3 (0.02)	3 (0.01)		7 (0.01)
LITHONATE			1 (0.00)		1 (0.00)
LITICARB		3 (0.02)			3 (0.00)
LITIPOR			1 (0.00)		1 (0.00)
LIVACT			1 (0.00)		1 (0.00)
LIVER HYDROLYSIS COMBI			1 (0.00)		1 (0.00)
LIVOSTIN NASAL SUSPENS	1 (0.02)				1 (0.00)
LIXACOL (MESALAZINE)			1 (0.00)		1 (0.00)
LO/OVRAL		3 (0.02)			3 (0.00)
LOBU			1 (0.00)		1 (0.00)
LOCHOL		1 (0.01)	1 (0.00)		2 (0.00)
LOCOL		1 (0.01)	3 (0.01)	2 (0.03)	6 (0.01)
LODINE		1 (0.01)	4 (0.01)	3 (0.04)	8 (0.01)
LODOPIN			2 (0.01)		2 (0.00)
LOESTRIN 21 1/20		1 (0.01)			1 (0.00)
LOESTRIN 24		1 (0.01)			1 (0.00)
LOGIMAT				1 (0.01)	1 (0.00)
LOMOTIL		5 (0.03)	3 (0.01)		8 (0.01)
LONAFARNIB OR PLACEBO			2 (0.01)		2 (0.00)
LONGES	2 (0.03)				2 (0.00)
LONOX			3 (0.01)		3 (0.00)
LONOXIN				1 (0.01)	1 (0.00)
LOPEMIN		3 (0.02)			3 (0.00)
LOPERAMID (LOPERAMIDE)	1 (0.02)				1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
LOPERAMIDE	1 (0.02)	1 (0.01)	8 (0.03)	2 (0.03)	12 (0.02)
LOPERAMIDE HCL		3 (0.02)	1 (0.00)		4 (0.01)
LOPERAMIDE HYDROCHLORI		1 (0.01)	2 (0.01)		3 (0.00)
LOPID		2 (0.01)	5 (0.02)	1 (0.01)	8 (0.01)
LOPINAVIR		1 (0.01)	1 (0.00)		2 (0.00)
LOPINAVIR + RITONAVIR		2 (0.01)			2 (0.00)
LOPINAVIR AND RITONAVI		1 (0.01)			1 (0.00)
LOPINAVIR/RITONAVIR		3 (0.02)			3 (0.00)
LOPRESSOR		6 (0.04)	34 (0.11)	14 (0.18)	54 (0.09)
LORA TAB		2 (0.01)	5 (0.02)		7 (0.01)
LORAMET			3 (0.01)		3 (0.00)
LORATADIN		1 (0.01)			1 (0.00)
LORATADINE	6 (0.10)	7 (0.04)	9 (0.03)	2 (0.03)	24 (0.04)
LORATADINE (CLARITIN)		1 (0.01)			1 (0.00)
LORAZEPAM	9 (0.15)	52 (0.30)	37 (0.12)	14 (0.18)	112 (0.18)
LORAZEPAN		1 (0.01)	1 (0.00)		2 (0.00)
LORCAM			1 (0.00)		1 (0.00)
LORCAM (LORNOXICAM)				2 (0.03)	2 (0.00)
LORCET-HD		10 (0.06)	4 (0.01)	1 (0.01)	15 (0.02)
LORMETAZEPAM			3 (0.01)		3 (0.00)
LORMETAZEPAM (LORMETAZ			2 (0.01)		2 (0.00)
LORTAB	4 (0.07)	27 (0.16)	22 (0.07)	1 (0.01)	54 (0.09)
LORZAAR PLUS			2 (0.01)		2 (0.00)
LOSARTAN			1 (0.00)	2 (0.03)	3 (0.00)
LOSARTAN (LOSARTAN POT			1 (0.00)		1 (0.00)
LOSARTAN MERCK AND CO	1 (0.02)				1 (0.00)
LOSARTAN POTASSIUM		3 (0.02)	13 (0.04)	9 (0.12)	25 (0.04)
LOSARTAN POTASSIUM AND			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
LOSEC		3 (0.02)	2 (0.01)		5 (0.01)
LOSEC (OMEPRazole)		1 (0.01)			1 (0.00)
LOTENSIN	1 (0.02)	6 (0.04)	31 (0.10)	4 (0.05)	42 (0.07)
LOTREL		13 (0.08)	55 (0.18)	12 (0.15)	80 (0.13)
LOTRISONE		1 (0.01)		1 (0.01)	2 (0.00)
LOVAN			1 (0.00)		1 (0.00)
LOVASTATIN		2 (0.01)	13 (0.04)	4 (0.05)	19 (0.03)
LOVENOX	3 (0.05)	2 (0.01)	24 (0.08)	13 (0.17)	42 (0.07)
LOVOXIL			1 (0.00)		1 (0.00)
LOW MOLECULAR WEIGHT H				1 (0.01)	1 (0.00)
LOW MOLECULAR WEIGHT H		1 (0.01)			1 (0.00)
LOXAPAC		1 (0.01)			1 (0.00)
LOXAPINE SUCCINATE			1 (0.00)		1 (0.00)
LOXEN			1 (0.00)	7 (0.09)	8 (0.01)
LOXEN LP				2 (0.03)	2 (0.00)
LOXONIN	4 (0.07)	4 (0.02)	12 (0.04)	2 (0.03)	22 (0.04)
LOXONIN				1 (0.01)	1 (0.00)
LOXONIN (LOXOPROFEN SO		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
LOXOPROFEN SODIUM (LOX		1 (0.01)			1 (0.00)
LOZIDE			1 (0.00)		1 (0.00)
LOZOL		1 (0.01)	6 (0.02)	1 (0.01)	8 (0.01)
LUBRIDERM SKIN RENEWAL		1 (0.01)			1 (0.00)
LUBRIDERM SKIN RENEWEL		1 (0.01)			1 (0.00)
LUCRIN			1 (0.00)		1 (0.00)
LUDIOMIL	2 (0.03)	1 (0.01)			3 (0.00)
LUDIOMIL 75				1 (0.01)	1 (0.00)
LULLAN	2 (0.03)	1 (0.01)			3 (0.00)
LULLAN (PEROSPIRONE HY		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
LUMIGAN			1 (0.00)	2 (0.03)	3 (0.00)
LUNESTA	12 (0.20)	187 (1.10)	255 (0.84)	99 (1.28)	553 (0.91)
LUNESTA (2 MG)			1 (0.00)		1 (0.00)
LUPRON	5 (0.08)		7 (0.02)	6 (0.08)	18 (0.03)
LUPRON DEPOT	2 (0.03)		1 (0.00)		3 (0.00)
LUPRON DEPOT-3	1 (0.02)	4 (0.02)			5 (0.01)
LUPRON DEPOT-PED		1 (0.01)			1 (0.00)
LUSTRAL		2 (0.01)			2 (0.00)
LUSTRAL (SERTRALINE)		1 (0.01)	1 (0.00)		2 (0.00)
LUTENYL		1 (0.01)			1 (0.00)
LUTENYL (NOMEGESTROL A		2 (0.01)			2 (0.00)
LUVOX	8 (0.14)	1 (0.01)	3 (0.01)	2 (0.03)	14 (0.02)
LY231514(PEMETREXED) V				1 (0.01)	1 (0.00)
LY317615(ENZASTAURIN (1 (0.00)		1 (0.00)
LYMPHAZURIN			1 (0.00)		1 (0.00)
LYRICA	7 (0.12)	57 (0.33)	84 (0.28)	49 (0.63)	197 (0.32)
LYRICA			1 (0.00)		1 (0.00)
LYSODREN	2 (0.03)	1 (0.01)			3 (0.00)
LYSOPAINE		1 (0.01)			1 (0.00)
LYSOZYME HYDROCHLORIDE	1 (0.02)				1 (0.00)
M.V.I.		6 (0.04)	1 (0.00)	1 (0.01)	8 (0.01)
MAALOX FAST BLOCKER		1 (0.01)	2 (0.01)		3 (0.00)
MABTHER			1 (0.00)		1 (0.00)
MABTHERA			1 (0.00)		1 (0.00)
MABTHERA			1 (0.00)		1 (0.00)
MABTHERA	1 (0.02)				1 (0.00)
MABTHERA (RITUX		1 (0.01)			1 (0.00)
MABTHERA (RITUXIMAB)C			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MABTHERA (RITUXIMAB) C			1 (0.00)		1 (0.00)
MABTHERA (RITUXIMAB) C	3 (0.05)	2 (0.01)	22 (0.07)	3 (0.04)	30 (0.05)
MABTHERA (RITUXIMAB) C			1 (0.00)		1 (0.00)
MABTHERA (RITUXIMAB)CO			1 (0.00)	3 (0.04)	4 (0.01)
MABTHERA(RITUXIMAB) CO		3 (0.02)	4 (0.01)	1 (0.01)	8 (0.01)
MACRO BID / NITROFURAN			1 (0.00)		1 (0.00)
MACROBID		3 (0.02)	2 (0.01)		5 (0.01)
MACRODANTIN			1 (0.00)	3 (0.04)	4 (0.01)
MACROLIN		2 (0.01)			2 (0.00)
MACUGEN	1 (0.02)		1 (0.00)	7 (0.09)	9 (0.01)
MADOPAR			7 (0.02)	4 (0.05)	11 (0.02)
MADOPAR CR		2 (0.01)			2 (0.00)
MADOPARK				1 (0.01)	1 (0.00)
MADOPARK TABLET				1 (0.01)	1 (0.00)
MAGIC MOUTHWASH			5 (0.02)		5 (0.01)
MAGISTROL (MEGESTROL)			1 (0.00)		1 (0.00)
MAGLAX	1 (0.02)	1 (0.01)			2 (0.00)
MAGMITT			4 (0.01)		4 (0.01)
MAGNEROT CLASSIC			2 (0.01)		2 (0.00)
MAGNESIUM	1 (0.02)	2 (0.01)	3 (0.01)	1 (0.01)	7 (0.01)
MAGNESIUM (MAGNESIUM)			2 (0.01)		2 (0.00)
MAGNESIUM HYDROXIDE TA		2 (0.01)			2 (0.00)
MAGNESIUM OROTATE			3 (0.01)		3 (0.00)
MAGNESIUM OXIDE	4 (0.07)	2 (0.01)	11 (0.04)		17 (0.03)
MAGNESIUM OXIDE (MAGNE		1 (0.01)	1 (0.00)		2 (0.00)
MAGNESIUM SULFATE			3 (0.01)	2 (0.03)	5 (0.01)
MAGNEVIST	3 (0.05)	4 (0.02)	6 (0.02)	1 (0.01)	14 (0.02)
MAGNEX		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MAGNEX (SULBACTAM, CEF		1 (0.01)			1 (0.00)
MAGNYL				1 (0.01)	1 (0.00)
MAIBASTAN				3 (0.04)	3 (0.00)
MAIBBASTAN (PRAVASTATI				1 (0.01)	1 (0.00)
MAINTATE			7 (0.02)		7 (0.01)
MAINTOWA			1 (0.00)		1 (0.00)
MALARONE	5 (0.08)	12 (0.07)	7 (0.02)	1 (0.01)	25 (0.04)
MANDELIC ACID			1 (0.00)		1 (0.00)
MANIDIPINE HYDROCHLORI			1 (0.00)		1 (0.00)
MANNITOL	3 (0.05)	1 (0.01)	1 (0.00)	1 (0.01)	6 (0.01)
MANSIL (OXAMNIQUINE)		1 (0.01)			1 (0.00)
MANTADIX (1 (0.01)	1 (0.00)
MANY CONCOMITANT MEDIC			1 (0.00)		1 (0.00)
MANY MEDICATIONS (NOS)				1 (0.01)	1 (0.00)
MARCAIN SPINAL (MARCAI			1 (0.00)		1 (0.00)
MARCAINE	1 (0.02)	4 (0.02)	1 (0.00)	1 (0.01)	7 (0.01)
MARCOUMAR				1 (0.01)	1 (0.00)
MARCUMAR	1 (0.02)	1 (0.01)	14 (0.05)	2 (0.03)	18 (0.03)
MAREVAN		2 (0.01)	3 (0.01)	1 (0.01)	6 (0.01)
MARIJUANA	2 (0.03)				2 (0.00)
MARIJUANA (CANNABIS)		1 (0.01)			1 (0.00)
MARKEVAN ^BRITISH DRUG			1 (0.00)		1 (0.00)
MARVELON	1 (0.02)	4 (0.02)			5 (0.01)
MARZULENE S				2 (0.03)	2 (0.00)
MARZULENE S GRANULES 3			1 (0.00)		1 (0.00)
MARZULENE-S				1 (0.01)	1 (0.00)
MAVIK		4 (0.02)	6 (0.02)	2 (0.03)	12 (0.02)
MAXAIR	1 (0.02)	3 (0.02)		1 (0.01)	5 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MAXALT	3 (0.05)	5 (0.03)			8 (0.01)
MAXALT-MLT	2 (0.03)		1 (0.00)		3 (0.00)
MAXAQUIN			3 (0.01)		3 (0.00)
MAXIDE AND POTASSIUM S		1 (0.01)			1 (0.00)
MAXIDEX (BENZALKONIUM		1 (0.01)			1 (0.00)
MAXIDEX (BENZALKONIUM		1 (0.01)			1 (0.00)
MAXIPIME	1 (0.02)	2 (0.01)	8 (0.03)	5 (0.06)	16 (0.03)
MAXITROL			1 (0.00)		1 (0.00)
MAXOLON		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
MAXZIDE		3 (0.02)	9 (0.03)	1 (0.01)	13 (0.02)
MD-GASTROVIEW	1 (0.02)				1 (0.00)
MD-GASTROVIEW INDONATE	1 (0.02)				1 (0.00)
MEBEVERINE HYDROCHLORI				2 (0.03)	2 (0.00)
MECLIZINE	1 (0.02)	5 (0.03)	3 (0.01)	3 (0.04)	12 (0.02)
MECOBALAMIN			1 (0.00)		1 (0.00)
MEDET			2 (0.01)		2 (0.00)
MEDIATENSYL			2 (0.01)		2 (0.00)
MEDIATOR			3 (0.01)		3 (0.00)
MEDICATION (NOS)		1 (0.01)			1 (0.00)
MEDICATION (NOT SPECIF			1 (0.00)		1 (0.00)
MEDICINALPRODUCT NOT S	1 (0.02)	9 (0.05)	1 (0.00)	1 (0.01)	12 (0.02)
MEDICON	5 (0.08)		1 (0.00)		6 (0.01)
MEDIUM-CHAIN TRIGLYCER	2 (0.03)				2 (0.00)
MEDROL	2 (0.03)	12 (0.07)	11 (0.04)	3 (0.04)	28 (0.05)
MEDROL ACETATE			2 (0.01)		2 (0.00)
MEDROXYPROGESTERONE AC		2 (0.01)	17 (0.06)	1 (0.01)	20 (0.03)
MEFENAMIC ACID		1 (0.01)	1 (0.00)		2 (0.00)
MEFLOQUINE				1 (0.01)	1 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MEFLOQUINE (NGX)(MEFLO			1 (0.00)		1 (0.00)
MEFLOQUINE HCL		2 (0.01)	1 (0.00)		3 (0.00)
MEFOXIN				1 (0.01)	1 (0.00)
MEGACE	4 (0.07)	3 (0.02)	10 (0.03)	4 (0.05)	21 (0.03)
MEGASTROL (MEGESTROL)			1 (0.00)		1 (0.00)
MEGESTROL ACETATE			3 (0.01)	1 (0.01)	4 (0.01)
MEILAX			1 (0.00)		1 (0.00)
MELATONIN (MELATONIN)	1 (0.02)		2 (0.01)		3 (0.00)
MELATONIN (MELATONIN)			1 (0.00)		1 (0.00)
MELATONINA	1 (0.02)				1 (0.00)
MELLARIL	2 (0.03)				2 (0.00)
MELOXICAM			4 (0.01)	5 (0.06)	9 (0.01)
MELOXICAM (MELOXICAM)		1 (0.01)	1 (0.00)		2 (0.00)
MELPERON			1 (0.00)		1 (0.00)
MELPERONE			1 (0.00)		1 (0.00)
MELPERONE-G-MPHD+LIQ(M				1 (0.01)	1 (0.00)
MELPHALAN		1 (0.01)	14 (0.05)	2 (0.03)	17 (0.03)
MEMANTINE (OPEN LABEL,				1 (0.01)	1 (0.00)
MEMANTINE (OPEN-LABEL)			1 (0.00)		1 (0.00)
MEMANTINE HCL			5 (0.02)	21 (0.27)	26 (0.04)
MEMBERS MARK NICOTINE	1 (0.02)	2 (0.01)			3 (0.00)
MENATETRENONE CAPSULES			2 (0.01)		2 (0.00)
MENESIT			5 (0.02)		5 (0.01)
MENOTROPINS	1 (0.02)	1 (0.01)			2 (0.00)
MENTAX			1 (0.00)		1 (0.00)
MEPERIDINE		1 (0.01)			1 (0.00)
MEPERIDINE 75MG/ML		1 (0.01)			1 (0.00)
MEPERIDINE HCL	1 (0.02)	1 (0.01)			2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MEPERIDINE HYDROCHLORI			1 (0.00)		1 (0.00)
MEPIVACAINE HYDROCHLOR		1 (0.01)			1 (0.00)
MEPIVACAINE HYDROCHLOR			1 (0.00)		1 (0.00)
MEPROBAMATE		1 (0.01)	1 (0.00)		2 (0.00)
MEPRON		1 (0.01)	1 (0.00)		2 (0.00)
MEPRONIZINE (ACEPROMET			1 (0.00)		1 (0.00)
MEPROZINE			1 (0.00)		1 (0.00)
MEPROZINE 50/25 CAPSUL			1 (0.00)		1 (0.00)
MERCAPTOPURINE	2 (0.03)	2 (0.01)	1 (0.00)		5 (0.01)
MERCAZOLE	1 (0.02)				1 (0.00)
MERCKFORMIN			1 (0.00)		1 (0.00)
MERIDIA		1 (0.01)	4 (0.01)		5 (0.01)
MEROPEN		2 (0.01)	2 (0.01)		4 (0.01)
MEROPEN (MEROPENEM)			1 (0.00)		1 (0.00)
MEROPEN (MEROPENEM)			4 (0.01)		4 (0.01)
MEROPEN (MEROPENEM) IN			2 (0.01)		2 (0.00)
MEROPENEM	3 (0.05)	6 (0.04)	7 (0.02)	4 (0.05)	20 (0.03)
MEROPENEM (MEROPENEM)	1 (0.02)	4 (0.02)	1 (0.00)		6 (0.01)
MESALAMINE	2 (0.03)	4 (0.02)	7 (0.02)	2 (0.03)	15 (0.02)
MESALAZINE			1 (0.00)		1 (0.00)
MESALAZINE CONTROLLED		1 (0.01)			1 (0.00)
MESNA		2 (0.01)			2 (0.00)
MESNEX	1 (0.02)				1 (0.00)
MESTACINE	1 (0.02)				1 (0.00)
MESTINON		1 (0.01)	3 (0.01)		4 (0.01)
MESULID (NIMESULIDE)			1 (0.00)		1 (0.00)
METADATE CD	3 (0.05)				3 (0.00)
METAGLIP			5 (0.02)	1 (0.01)	6 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
METAMIZOL		1 (0.01)			1 (0.00)
METAMIZOLE		1 (0.01)	1 (0.00)		2 (0.00)
METAMUCIL				1 (0.01)	1 (0.00)
METAMUCIL SUGAR-FREE T				1 (0.01)	1 (0.00)
METAMUCIL-2		1 (0.01)			1 (0.00)
METFIN			1 (0.00)		1 (0.00)
METFORMAX		3 (0.02)			3 (0.00)
METFORMIN	4 (0.07)	81 (0.47)	304 (1.00)	31 (0.40)	420 (0.69)
METFORMIN (METFORMIN /		1 (0.01)			1 (0.00)
METFORMIN (NGX) (METFO			1 (0.00)	1 (0.01)	2 (0.00)
METFORMIN HCL	3 (0.05)	20 (0.12)	57 (0.19)	6 (0.08)	86 (0.14)
METFORMIN HYDROCHLORID		9 (0.05)	17 (0.06)	2 (0.03)	28 (0.05)
METFORMIN HYDROCHLORID			1 (0.00)		1 (0.00)
METFORMINE (METFORMIN)			1 (0.00)		1 (0.00)
METHADONE	1 (0.02)	10 (0.06)	2 (0.01)		13 (0.02)
METHADONE (METHADONE)	1 (0.02)	2 (0.01)			3 (0.00)
METHADONE DISKETTE		1 (0.01)			1 (0.00)
METHADONE HCL	5 (0.08)	13 (0.08)	4 (0.01)	1 (0.01)	23 (0.04)
METHADONE HYDROCHLORID		3 (0.02)	2 (0.01)		5 (0.01)
METHADONE STREULI		1 (0.01)			1 (0.00)
METHADOSE	2 (0.03)	1 (0.01)			3 (0.00)
METHADOSE			1 (0.00)		1 (0.00)
METHAMPHETAMINE HYDROC	2 (0.03)	1 (0.01)			3 (0.00)
METHAMPHETAMINE HYDROC	1 (0.02)				1 (0.00)
METHANOL (METHANOL)		1 (0.01)			1 (0.00)
METHERGINE	1 (0.02)	8 (0.05)			9 (0.01)
METHIMAZOLE	1 (0.02)	4 (0.02)	3 (0.01)		8 (0.01)
METHIMAZOLE TABLETS, U		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
METHOCARBAMOL			4 (0.01)		4 (0.01)
METHOTREXATE	36 (0.61)	82 (0.48)	146 (0.48)	16 (0.21)	280 (0.46)
METHOTREXATE SODIUM		3 (0.02)	7 (0.02)		10 (0.02)
METHYCELLULOSE SUSPENS			1 (0.00)		1 (0.00)
METHYCOBAL (MECOBALAMI		1 (0.01)			1 (0.00)
METHYCOBAL (MECOBALAMI			1 (0.00)		1 (0.00)
METHYLCELLULOSE	1 (0.02)				1 (0.00)
METHYLCELLULOSE (FORMU		1 (0.01)			1 (0.00)
METHYLCOBAL			1 (0.00)		1 (0.00)
METHYLCOBAL (MECOBALAM		1 (0.01)			1 (0.00)
METHYLDIGOXIN			1 (0.00)		1 (0.00)
METHYLDOPA	1 (0.02)		2 (0.01)	1 (0.01)	4 (0.01)
METHYLPHENIDATE	4 (0.07)	1 (0.01)			5 (0.01)
METHYLPHENIDATE HCL	13 (0.22)	1 (0.01)	2 (0.01)		16 (0.03)
METHYLPHENIDATE HYDROC	1 (0.02)				1 (0.00)
METHYLPHENIDATE SR	1 (0.02)				1 (0.00)
METHYLPHENOBARBITONE		1 (0.01)			1 (0.00)
METHYLPREDNISOLONE	6 (0.10)	15 (0.09)	20 (0.07)		41 (0.07)
METHYLPREDNISOLONE (ME			1 (0.00)		1 (0.00)
METHYLPREDNISOLONE ACE			1 (0.00)		1 (0.00)
METHYLPREDNISOLONE SOD	1 (0.02)	1 (0.01)	4 (0.01)		6 (0.01)
METHYLPREDNISONE		1 (0.01)			1 (0.00)
METHYSERGIDE		1 (0.01)			1 (0.00)
METICILINA (METICILLIN	1 (0.02)				1 (0.00)
METLIGINE		1 (0.01)			1 (0.00)
METOCLOPRAMIDE	4 (0.07)	11 (0.06)	14 (0.05)	4 (0.05)	33 (0.05)
METOCLOPRAMIDE (METOCL			1 (0.00)		1 (0.00)
METOCLOPRAMIDE 10 MG /		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
METOCLOPRAMIDE HYDROCH				1 (0.01)	1 (0.00)
METOHEXAL		2 (0.01)			2 (0.00)
METOLATE		1 (0.01)			1 (0.00)
METOLAZONE			2 (0.01)	1 (0.01)	3 (0.00)
METOPROLANOL			1 (0.00)		1 (0.00)
METOPROLOL	1 (0.02)	13 (0.08)	48 (0.16)	16 (0.21)	78 (0.13)
METOPROLOL			1 (0.00)		1 (0.00)
METOPROLOL (MEROPROLOL			1 (0.00)		1 (0.00)
METOPROLOL (METOPROLOL		2 (0.01)	10 (0.03)	3 (0.04)	15 (0.02)
METOPROLOL SUCCINATE		3 (0.02)	19 (0.06)	3 (0.04)	25 (0.04)
METOPROLOL TARTRATE		1 (0.01)	11 (0.04)	5 (0.06)	17 (0.03)
METOPROLOL XL (METOPRO			1 (0.00)		1 (0.00)
METROCREAM		1 (0.01)			1 (0.00)
METROGEL-VAGINAL	1 (0.02)				1 (0.00)
METRONAZOLE			1 (0.00)		1 (0.00)
METRONIDAZOLE	7 (0.12)	4 (0.02)	7 (0.02)	4 (0.05)	22 (0.04)
METRONIDAZOLE CREAM		5 (0.03)			5 (0.01)
METRONIDAZOLE HCL			1 (0.00)		1 (0.00)
METRONIDAZOLE W/SPIRAM			2 (0.01)		2 (0.00)
METRONIDOZOLE			1 (0.00)		1 (0.00)
METROPROLOL 50MG		1 (0.01)			1 (0.00)
MEVACOR		2 (0.01)	2 (0.01)	3 (0.04)	7 (0.01)
MEVALOTIN			4 (0.01)		4 (0.01)
MEXAZOLAM	1 (0.02)				1 (0.00)
MEXILETINE HYDROCHLORI		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
MEXITIL			2 (0.01)	3 (0.04)	5 (0.01)
MIACALCIN		1 (0.01)	1 (0.00)	5 (0.06)	7 (0.01)
MIANSERIN HYDROCHLORID		1 (0.01)			1 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MICAFUNGIN (MICAFUNGIN			4 (0.01)		4 (0.01)
MICAFUNGIN SODIUM			4 (0.01)		4 (0.01)
MICARDIS		2 (0.01)	17 (0.06)	8 (0.10)	27 (0.04)
MICARDIS HCT		1 (0.01)		1 (0.01)	2 (0.00)
MICARDIS HCT (TELMISAR				1 (0.01)	1 (0.00)
MICARDIS TABLETS (7/14		1 (0.01)			1 (0.00)
MICONAZOLE			1 (0.00)	1 (0.01)	2 (0.00)
MICROGESTIN FE 1/20		1 (0.01)			1 (0.00)
MICROGYNON /GFR/ (ETH	1 (0.02)				1 (0.00)
MICROGYNON (ETHINYLEST		2 (0.01)			2 (0.00)
MICRONASE			11 (0.04)		11 (0.02)
MICRONOR		3 (0.02)			3 (0.00)
MICROPAKINE GRANULE	3 (0.05)				3 (0.00)
MICROPAKINE GRANULES	1 (0.02)				1 (0.00)
MICROVLAR		1 (0.01)			1 (0.00)
MIDAZOLAM		3 (0.02)	3 (0.01)		6 (0.01)
MIDAZOLAM HCL	1 (0.02)	3 (0.02)	1 (0.00)	3 (0.04)	8 (0.01)
MIDAZOLAM HYDROCHLORID	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
MIDODRINE (MIDODRINE)				1 (0.01)	1 (0.00)
MIDODRINE (MIDODRINE)				1 (0.01)	1 (0.00)
MIDODRINE HCL			1 (0.00)		1 (0.00)
MIDODRINE HYDROCHLORID			1 (0.00)		1 (0.00)
MIDOL	4 (0.07)	1 (0.01)			5 (0.01)
MIDRIN		1 (0.01)			1 (0.00)
MIFEPREX	1 (0.02)				1 (0.00)
MIFEPRISTONE	1 (0.02)				1 (0.00)
MIFEPRISTONE TABLETS,	20 (0.34)	19 (0.11)			39 (0.06)
MIFLASONE				1 (0.01)	1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MIFLONIDE		1 (0.01)			1 (0.00)
MIGLITOL TABLET (MIGLI			2 (0.01)		2 (0.00)
MIGRALEVE		1 (0.01)			1 (0.00)
MILK OF MAGNESIA TAB				1 (0.01)	1 (0.00)
MILK OF MAGNESIUM			1 (0.00)		1 (0.00)
MILK THISTLE FRUIT CAP			2 (0.01)		2 (0.00)
MILNACIPRAN			4 (0.01)		4 (0.01)
MILRINONE LACTATE			2 (0.01)		2 (0.00)
MILURIT				1 (0.01)	1 (0.00)
MIMPARA	1 (0.02)		3 (0.01)		4 (0.01)
MINI MED 715 INSULIN P			1 (0.00)		1 (0.00)
MINI MED METRONIC INSU	1 (0.02)				1 (0.00)
MINIMED 508 PUMP		1 (0.01)			1 (0.00)
MINIMED INSULIN PUMP		1 (0.01)			1 (0.00)
MINIMED MEDTRONIC			1 (0.00)		1 (0.00)
MINIMED PARADIGM INSUL		2 (0.01)	1 (0.00)		3 (0.00)
MINIPRESS				1 (0.01)	1 (0.00)
MINIRIN		4 (0.02)		1 (0.01)	5 (0.01)
MINIRIN ^AVENTIS PHARM	1 (0.02)				1 (0.00)
MINOCIN	4 (0.07)				4 (0.01)
MINOCYCLINE 100 MG RAN			1 (0.00)		1 (0.00)
MINOCYCLINE HCL	17 (0.29)	3 (0.02)		1 (0.01)	21 (0.03)
MINOCYCLINE HYDROCHLOR			2 (0.01)		2 (0.00)
MINOXIDIL		6 (0.04)	1 (0.00)		7 (0.01)
MINOXIDIL 2%			1 (0.00)		1 (0.00)
MIO ALDORON			1 (0.00)		1 (0.00)
MIOSTAT			1 (0.00)		1 (0.00)
MIRACLID			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MIRALAX	3 (0.05)	1 (0.01)	1 (0.00)		5 (0.01)
MIRAPEX		3 (0.02)	8 (0.03)	6 (0.08)	17 (0.03)
MIRAPEX HARMACIA + U			1 (0.00)		1 (0.00)
MIRAPEXIN			1 (0.00)		1 (0.00)
MIRCETTE	1 (0.02)				1 (0.00)
MIRENA	49 (0.83)	168 (0.98)	3 (0.01)	1 (0.01)	221 (0.36)
MIRTAZAPINE	2 (0.03)	24 (0.14)	11 (0.04)	8 (0.10)	45 (0.07)
MISOPROSTOL	3 (0.05)	2 (0.01)	1 (0.00)		6 (0.01)
MIST (MORPHINE SULFATE			1 (0.00)		1 (0.00)
MISULBAN		1 (0.01)			1 (0.00)
MITOMYCIN		2 (0.01)	12 (0.04)	1 (0.01)	15 (0.02)
MITOXANTRONE			3 (0.01)	1 (0.01)	4 (0.01)
MIVACRON	1 (0.02)				1 (0.00)
MIXTARD 20			1 (0.00)		1 (0.00)
MIXTARD 20/80			1 (0.00)		1 (0.00)
MIXTARD 30/70 PENFILL			1 (0.00)		1 (0.00)
MIXTARD HUMAN 70/30			2 (0.01)	2 (0.03)	4 (0.01)
MIZORIBINE		1 (0.01)			1 (0.00)
MIZORIBINE (MIZORIBINE			1 (0.00)		1 (0.00)
MIZORIBINE (MIZORIBINE			1 (0.00)		1 (0.00)
MOBAN			1 (0.00)		1 (0.00)
MOBIC		14 (0.08)	14 (0.05)	13 (0.17)	41 (0.07)
MOBICOX 15.0 MG TABLET			3 (0.01)		3 (0.00)
MOCLAMINE			2 (0.01)		2 (0.00)
MOCLOBEMIDE (MOCLOBEMI		1 (0.01)			1 (0.00)
MODACIN			2 (0.01)		2 (0.00)
MODACIN (CEFTAZIDIME)				2 (0.03)	2 (0.00)
MODAFINIL	1 (0.02)		4 (0.01)		5 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MODAFINILO			1 (0.00)		1 (0.00)
MODECATE		1 (0.01)			1 (0.00)
MODOPAR			4 (0.01)	1 (0.01)	5 (0.01)
MODURETIC 5-50			1 (0.00)	3 (0.04)	4 (0.01)
MOGADON				1 (0.01)	1 (0.00)
MOLSIDOMIN				1 (0.01)	1 (0.00)
MOLSIDOMINE			3 (0.01)	1 (0.01)	4 (0.01)
MOLSIDOMINE - SLOW REL				1 (0.01)	1 (0.00)
MOMETASONE		1 (0.01)			1 (0.00)
MOMETASONE FUROATE			1 (0.00)		1 (0.00)
MONISTAT	2 (0.03)				2 (0.00)
MONISTAT 1 COMBINATION	44 (0.74)	80 (0.47)	5 (0.02)	1 (0.01)	130 (0.21)
MONISTAT 7 VAG CREAM W			1 (0.00)		1 (0.00)
MONISTAT-1	3 (0.05)				3 (0.00)
MONISTAT-1 VAG OINT 6.	86 (1.45)	160 (0.94)	10 (0.03)	2 (0.03)	258 (0.42)
MONO-TILDIEM			2 (0.01)	1 (0.01)	3 (0.00)
MONOCOR (BISOPROLOL)			1 (0.00)		1 (0.00)
MONOCOR (BISOPROLOL, U			1 (0.00)		1 (0.00)
MONOCORDIL			1 (0.00)		1 (0.00)
MONOCORDIL (ISOSORBIDE				1 (0.01)	1 (0.00)
MONONESSA	1 (0.02)				1 (0.00)
MONOPRIL		3 (0.02)	19 (0.06)	2 (0.03)	24 (0.04)
MONTELUKAST	1 (0.02)				1 (0.00)
MONURIL		1 (0.01)			1 (0.00)
MOOD MEDICATION			1 (0.00)		1 (0.00)
MOPRAL		8 (0.05)	8 (0.03)	4 (0.05)	20 (0.03)
MOPRAL (OMEPRAZOLE) CA	1 (0.02)				1 (0.00)
MORPHINE	5 (0.08)	29 (0.17)	27 (0.09)	7 (0.09)	68 (0.11)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MORPHINE PUMP			1 (0.00)		1 (0.00)
MORPHINE SULFATE	8 (0.14)	20 (0.12)	28 (0.09)	5 (0.06)	61 (0.10)
MORPHINE SULFATE INJ		2 (0.01)			2 (0.00)
MOSAPRIDE CITRATE			1 (0.00)		1 (0.00)
MOTILIMUM			4 (0.01)		4 (0.01)
MOTILYO			1 (0.00)		1 (0.00)
MOTIVAN			1 (0.00)		1 (0.00)
MOTRIN	5 (0.08)	27 (0.16)	32 (0.11)		64 (0.10)
MOTRIN (CONTIN)		1 (0.01)			1 (0.00)
MOVELAT			1 (0.00)		1 (0.00)
MOVER			1 (0.00)		1 (0.00)
MOVICOLON (SODIUM CHLO			1 (0.00)		1 (0.00)
MOXIFLOXACIN 400 MG			2 (0.01)		2 (0.00)
MOXIFLOXACIN HCL		3 (0.02)	3 (0.01)	2 (0.03)	8 (0.01)
MOXIFLOXACIN HYDROCHLO		1 (0.01)			1 (0.00)
MOXONIDINE		1 (0.01)			1 (0.00)
MOXYPEN	2 (0.03)				2 (0.00)
MS CONTIN	2 (0.03)	13 (0.08)	6 (0.02)	6 (0.08)	27 (0.04)
MS CONTN				1 (0.01)	1 (0.00)
MS04			1 (0.00)		1 (0.00)
MSIR			1 (0.00)		1 (0.00)
MST			3 (0.01)		3 (0.00)
MUCINEX	1 (0.02)			1 (0.01)	2 (0.00)
MUCINEX D		1 (0.01)			1 (0.00)
MUCINEX DM			1 (0.00)		1 (0.00)
MUCODYNE	14 (0.24)	3 (0.02)		1 (0.01)	18 (0.03)
MUCODYNE (CARBOCISTEIN	1 (0.02)				1 (0.00)
MUCOMYST	1 (0.02)		3 (0.01)	3 (0.04)	7 (0.01)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MUCOSOLVAN		1 (0.01)			1 (0.00)
MUCOSOLVAN (AMBROXOL H			1 (0.00)		1 (0.00)
MUCOSTA			4 (0.01)	5 (0.06)	9 (0.01)
MUCOSTA (REBAMIPIDE)			1 (0.00)		1 (0.00)
MUCOSTA (REBAMIPIDE) (1 (0.00)		1 (0.00)
MUCOSTA (REBAMIPIDE) T				1 (0.01)	1 (0.00)
MUCOSTAN (REBAMIPIDE)			1 (0.00)		1 (0.00)
MUCOTRON				2 (0.03)	2 (0.00)
MULTI-VITAMIN	4 (0.07)	16 (0.09)	9 (0.03)	3 (0.04)	32 (0.05)
MULTI-VITAMINS			1 (0.00)		1 (0.00)
MULTIHANCE		1 (0.01)	1 (0.00)		2 (0.00)
MULTIPLE DRUG THERAPY				2 (0.03)	2 (0.00)
MULTIPLE HEART MEDICAT				1 (0.01)	1 (0.00)
MULTIPLE MEDICATIONS		2 (0.01)	1 (0.00)	2 (0.03)	5 (0.01)
MULTIPLE MEDICATIONS (2 (0.01)	1 (0.01)	3 (0.00)
MULTIPLE UNSPECIFIED M		2 (0.01)		2 (0.03)	4 (0.01)
MULTIPLE VITAMINS (ASC			1 (0.00)		1 (0.00)
MULTIVITAMIN		18 (0.11)	21 (0.07)	6 (0.08)	45 (0.07)
MULTIVITAMIN (MULTIVIT			1 (0.00)		1 (0.00)
MULTIVITAMIN AND MINER			1 (0.00)		1 (0.00)
MULTIVITAMIN ^LAPPE^			1 (0.00)		1 (0.00)
MULTIVITAMINS (ASCORBI		1 (0.01)			1 (0.00)
MULTIVITAMINS (ASCORBI		2 (0.01)	1 (0.00)		3 (0.00)
MULTIVITAMINS (ERGOCAL				1 (0.01)	1 (0.00)
MULTIVITAMINS (MULTIVI		1 (0.01)			1 (0.00)
MULTIVITAMINS AND IRON	2 (0.03)				2 (0.00)
MULTIVITAMINS, COMBINA		1 (0.01)			1 (0.00)
MULTIVITAMINS, PLAIN			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MULTIVITAMINS, PLAIN (3 (0.01)		3 (0.00)
MUPIROCIN		2 (0.01)			2 (0.00)
MUSCLE RELAXANT		2 (0.01)			2 (0.00)
MUSCLE RELAXANT (NOS)			1 (0.00)		1 (0.00)
MUSCULAX	1 (0.02)		2 (0.01)		3 (0.00)
MYAMBUTOL	2 (0.03)		1 (0.00)	1 (0.01)	4 (0.01)
MYCOPHENOLATE		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
MYCOPHENOLATE MOFETIL	4 (0.07)	9 (0.05)	18 (0.06)		31 (0.05)
MYCOPHENOLATE MOFETIL	1 (0.02)				1 (0.00)
MYCOPHENOLATE MOFETIL			1 (0.00)		1 (0.00)
MYCOPHENOLATE MOFETIL			1 (0.00)		1 (0.00)
MYCOPHENOLATE MOFETIL			1 (0.00)		1 (0.00)
MYCOPHENOLATE MOFETIL	5 (0.08)	3 (0.02)	9 (0.03)		17 (0.03)
MYCOPHENOLATE SODIUM		1 (0.01)			1 (0.00)
MYCOPHENOLIC ACID		1 (0.01)	1 (0.00)		2 (0.00)
MYFORTIC		1 (0.01)	2 (0.01)		3 (0.00)
MYLANTA		1 (0.01)	1 (0.00)		2 (0.00)
MYLANTA (ALUMINIUM HYD				1 (0.01)	1 (0.00)
MYLOTARG	2 (0.03)	21 (0.12)	37 (0.12)	9 (0.12)	69 (0.11)
MYOBLOC		1 (0.01)			1 (0.00)
MYOBLOC (BOTULINUM TOX		1 (0.01)			1 (0.00)
MYOCET			1 (0.00)		1 (0.00)
MYONAL			1 (0.00)		1 (0.00)
MYONAL (EPERISONE HYDR		1 (0.01)			1 (0.00)
MYOVIEW			1 (0.00)		1 (0.00)
MYSLEE	4 (0.07)	4 (0.02)	2 (0.01)	2 (0.03)	12 (0.02)
MYSOLINE			1 (0.00)		1 (0.00)
MYTELASE			1 (0.00)		1 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
NABUMETONE			1 (0.00)		1 (0.00)
NACOM RETARD			3 (0.01)		3 (0.00)
NADOLOL			5 (0.02)	1 (0.01)	6 (0.01)
NADROPARIN CALCIUM				3 (0.04)	3 (0.00)
NAFAMOSTAT MESILATE			1 (0.00)		1 (0.00)
NAFAMOSTAT MESILATE (N	3 (0.05)				3 (0.00)
NAFCILLIN			1 (0.00)		1 (0.00)
NAFCILLIN INJECTION IN		1 (0.01)			1 (0.00)
NAFTIDROFURYL (NAFTIDR				1 (0.01)	1 (0.00)
NALCROM	2 (0.03)				2 (0.00)
NALOXONE	2 (0.03)				2 (0.00)
NAMENDA		2 (0.01)	5 (0.02)	29 (0.37)	36 (0.06)
NANDROLONE DECANOATE	1 (0.02)				1 (0.00)
NAPA			2 (0.01)		2 (0.00)
NAPHAZOLINE HCL	1 (0.02)				1 (0.00)
NAPRAPAC 375 (COPACKAG				1 (0.01)	1 (0.00)
NAPRELAN			1 (0.00)		1 (0.00)
NAPROSYN	4 (0.07)	6 (0.04)	3 (0.01)		13 (0.02)
NAPROSYN CR				1 (0.01)	1 (0.00)
NAPROXEN	7 (0.12)	18 (0.11)	19 (0.06)	3 (0.04)	47 (0.08)
NAPROXEN SODIUM			2 (0.01)		2 (0.00)
NARAMIG		2 (0.01)			2 (0.00)
NARCAN		1 (0.01)	1 (0.00)		2 (0.00)
NARCOTICS NOS			1 (0.00)		1 (0.00)
NARDIL	1 (0.02)	7 (0.04)	8 (0.03)	1 (0.01)	17 (0.03)
NAROPIN		1 (0.01)	2 (0.01)		3 (0.00)
NASACORT			5 (0.02)		5 (0.01)
NASACORT AQ		1 (0.01)	1 (0.00)		2 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
NASAL SPRAY			2 (0.01)		2 (0.00)
NASAL SPRAY ^IPRATROPI				1 (0.01)	1 (0.00)
NASALCROM	1 (0.02)		1 (0.00)		2 (0.00)
NASAREL				1 (0.01)	1 (0.00)
NASOLIN		1 (0.01)			1 (0.00)
NASONEX	2 (0.03)	8 (0.05)	7 (0.02)		17 (0.03)
NATALIZUMAB		5 (0.03)			5 (0.01)
NATEGLINIDE			2 (0.01)	1 (0.01)	3 (0.00)
NATRECOR				2 (0.03)	2 (0.00)
NATRILIX		1 (0.01)			1 (0.00)
NATRIX		1 (0.01)			1 (0.00)
NATULAN (PROCARBAZINE	1 (0.02)				1 (0.00)
NATURAL CITRUS LISTERI		1 (0.01)	1 (0.00)		2 (0.00)
NATURE-MADE MULTIVITAM		1 (0.01)			1 (0.00)
NATURETI		1 (0.01)			1 (0.00)
NAUZELIN		3 (0.02)	3 (0.01)		6 (0.01)
NAVANE		4 (0.02)			4 (0.01)
NAVELBINE			13 (0.04)	3 (0.04)	16 (0.03)
NAVELBINE (VINORELBINE			3 (0.01)		3 (0.00)
NAVELBINE (VINORELBINE			2 (0.01)	1 (0.01)	3 (0.00)
NAVOBAN		2 (0.01)	2 (0.01)		4 (0.01)
NEBILET		1 (0.01)	2 (0.01)		3 (0.00)
NEBIVOLOL (NEBIVOLOL)			1 (0.00)		1 (0.00)
NEBIVOLOL HCL		1 (0.01)		1 (0.01)	2 (0.00)
NEBULIZER			1 (0.00)		1 (0.00)
NECON		1 (0.01)			1 (0.00)
NEFAZODONE HCL			1 (0.00)		1 (0.00)
NEFOPAM		3 (0.02)			3 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
NELFINAVIR	3 (0.05)	1 (0.01)			4 (0.01)
NELFINAVIR MESILATE (N	1 (0.02)				1 (0.00)
NELFINAVIR TABLETS		1 (0.01)			1 (0.00)
NEO DOPASTON (CARBIDOP				2 (0.03)	2 (0.00)
NEO-MERCAZOLE TAB	1 (0.02)	1 (0.01)		2 (0.03)	4 (0.01)
NEO-MINOPHAGEN C		1 (0.01)	3 (0.01)		4 (0.01)
NEOBLOC		1 (0.01)			1 (0.00)
NEOPAREN (AMINO ACIDS/			2 (0.01)		2 (0.00)
NEOPERIDOL		2 (0.01)			2 (0.00)
NEOPHAGEN			2 (0.01)		2 (0.00)
NEOPHYLLIN			3 (0.01)		3 (0.00)
NEORAL	7 (0.12)	8 (0.05)	14 (0.05)	2 (0.03)	31 (0.05)
NEORECORMON		2 (0.01)	2 (0.01)		4 (0.01)
NEOSPORIN	2 (0.03)	4 (0.02)	1 (0.00)	1 (0.01)	8 (0.01)
NEOSPORIN G.U. IRRIGAN			1 (0.00)		1 (0.00)
NEOSPORIN LIP THERAPY		1 (0.01)			1 (0.00)
NEOZINE		1 (0.01)			1 (0.00)
NEPHROCAPS			1 (0.00)		1 (0.00)
NEULASTA		1 (0.01)	7 (0.02)	3 (0.04)	11 (0.02)
NEUPOGEN	2 (0.03)	6 (0.04)	6 (0.02)		14 (0.02)
NEUROBION			1 (0.00)		1 (0.00)
NEUROMUSCULAR MEDICATI		1 (0.01)			1 (0.00)
NEURONTIN	4 (0.07)	105 (0.62)	121 (0.40)	26 (0.34)	256 (0.42)
NEUROVITAN			1 (0.00)		1 (0.00)
NEUTRA-PHOS (SODIUM PH		1 (0.01)			1 (0.00)
NEUTROGIN	3 (0.05)				3 (0.00)
NEUTROSPEC		3 (0.02)	6 (0.02)		9 (0.01)
NEVANAC		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
NEVIRAPINE	2 (0.03)	12 (0.07)	1 (0.00)		15 (0.02)
NEXAVAR		1 (0.01)	12 (0.04)	5 (0.06)	18 (0.03)
NEXIUM	7 (0.12)	53 (0.31)	96 (0.32)	19 (0.25)	175 (0.29)
NIACIN		1 (0.01)	10 (0.03)		11 (0.02)
NIASPAN		3 (0.02)	11 (0.04)	1 (0.01)	15 (0.02)
NIASPAN ER			1 (0.00)		1 (0.00)
NICABATE CQ 4MG LOZENG		2 (0.01)			2 (0.00)
NICARDIPINE HCL	1 (0.02)		3 (0.01)	1 (0.01)	5 (0.01)
NICARDIPINE HYDROCHLOR	1 (0.02)	5 (0.03)	1 (0.00)	1 (0.01)	8 (0.01)
NICERGOLINE			2 (0.01)		2 (0.00)
NICHOLIN				1 (0.01)	1 (0.00)
NICODERM	1 (0.02)	2 (0.01)		1 (0.01)	4 (0.01)
NICODERM CQ		3 (0.02)	2 (0.01)		5 (0.01)
NICORANDIL			1 (0.00)	1 (0.01)	2 (0.00)
NICORANDIL (NICORANDIL			3 (0.01)		3 (0.00)
NICORETTE	5 (0.08)	42 (0.25)	41 (0.14)	6 (0.08)	94 (0.15)
NICORETTE (MINT)	21 (0.36)	102 (0.60)	72 (0.24)	6 (0.08)	201 (0.33)
NICORETTE (ORANGE)	5 (0.08)	25 (0.15)	11 (0.04)		41 (0.07)
NICORETTE FRESHMINT		2 (0.01)	1 (0.00)		3 (0.00)
NICORETTE OTC GUM, ORI	1 (0.02)				1 (0.00)
NICORETTE OTC, MINT		1 (0.01)	3 (0.01)		4 (0.01)
NICOTINE	1 (0.02)	6 (0.04)	10 (0.03)		17 (0.03)
NICOTINE GUM		1 (0.01)			1 (0.00)
NICOTINE PATCHES		1 (0.01)			1 (0.00)
NICOTINE POLACRILEX				1 (0.01)	1 (0.00)
NICOTINE POLACRILEX GU			1 (0.00)		1 (0.00)
NICOTINIC ACID		1 (0.01)			1 (0.00)
NIDREL				1 (0.01)	1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
NIFATENOL			2 (0.01)		2 (0.00)
NIFEDIPINE	3 (0.05)	12 (0.07)	31 (0.10)	10 (0.13)	56 (0.09)
NIFEDIPINE LONG ACTING			1 (0.00)		1 (0.00)
NIFELANTERN CR			3 (0.01)		3 (0.00)
NIFLAN		2 (0.01)			2 (0.00)
NIMBEX	1 (0.02)		1 (0.00)		2 (0.00)
NIMESULIDE	1 (0.02)		1 (0.00)		2 (0.00)
NIMODIPINE			1 (0.00)		1 (0.00)
NINJIN-TO		2 (0.01)			2 (0.00)
NIOPAM		1 (0.01)			1 (0.00)
NIPENT		1 (0.01)	2 (0.01)		3 (0.00)
NIPHEDIPINE	1 (0.02)				1 (0.00)
NIQUITIN			1 (0.00)		1 (0.00)
NIQUITIN CQ CLEAR 21MG		1 (0.01)			1 (0.00)
NISOLDIPINE			1 (0.00)		1 (0.00)
NITRATES			1 (0.00)		1 (0.00)
NITRENDIPINE			2 (0.01)		2 (0.00)
NITRO				3 (0.04)	3 (0.00)
NITRO-DUR			2 (0.01)	3 (0.04)	5 (0.01)
NITRO-SPRAY				1 (0.01)	1 (0.00)
NITRO-TABL		2 (0.01)			2 (0.00)
NITRODERM	1 (0.02)		2 (0.01)	4 (0.05)	7 (0.01)
NITROFURANTOIN	1 (0.02)	2 (0.01)		1 (0.01)	4 (0.01)
NITROGLYCERIN		5 (0.03)	17 (0.06)	7 (0.09)	29 (0.05)
NITROLINGUAL PUMPSPRAY			1 (0.00)		1 (0.00)
NITROQUICK				1 (0.01)	1 (0.00)
NITROQUICK 0.4 MG TABL		1 (0.01)			1 (0.00)
NITROSTAT		1 (0.01)	3 (0.01)	2 (0.03)	6 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
NITROUS OXIDE W/ OXYGE	1 (0.02)				1 (0.00)
NIVADIL		3 (0.02)	2 (0.01)	5 (0.06)	10 (0.02)
NIVADIL (NILVADIPINE)			1 (0.00)		1 (0.00)
NIVADIL (NILVADIPINE)			1 (0.00)		1 (0.00)
NIX		1 (0.01)			1 (0.00)
NIZORAL	1 (0.02)	2 (0.01)	1 (0.00)	2 (0.03)	6 (0.01)
NO CONCURRENT MEDICATI	81 (1.37)	220 (1.29)	98 (0.32)	11 (0.14)	410 (0.67)
NO CONCURRENT MEDICATI	1 (0.02)	4 (0.02)	1 (0.00)		6 (0.01)
NO THERAPY		1 (0.01)			1 (0.00)
NOCTAMID			1 (0.00)		1 (0.00)
NOCTAMID (LORMETAZEPAM		1 (0.01)			1 (0.00)
NOCTRAN 10				1 (0.01)	1 (0.00)
NOLVADEX	1 (0.02)	7 (0.04)	13 (0.04)	1 (0.01)	22 (0.04)
NON-SPECIFIED URINARY			1 (0.00)		1 (0.00)
NON-STEROIDAL ANTI-INF		1 (0.01)			1 (0.00)
NONE	1 (0.02)				1 (0.00)
NOOTROPYL			1 (0.00)		1 (0.00)
NORCO		6 (0.04)	3 (0.01)		9 (0.01)
NORDITROPIN CARTRIDGES	1 (0.02)				1 (0.00)
NORDITROPIN NORDIFLEX	4 (0.07)	1 (0.01)			5 (0.01)
NORDITROPIN SIMPLEXX	8 (0.14)		1 (0.00)		9 (0.01)
NOREPINEPHRINE	1 (0.02)		2 (0.01)		3 (0.00)
NOREPINEPHRINE HYDROCH		1 (0.01)			1 (0.00)
NORETHINDRONE + ETHINY		1 (0.01)			1 (0.00)
NORETHINDRONE ACETATE			1 (0.00)		1 (0.00)
NORETHISTERONE	1 (0.02)				1 (0.00)
NORFLEX		1 (0.01)	1 (0.00)		2 (0.00)
NORFLOXACIN	1 (0.02)				1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
NORGESTIMATE AND ETHIN		1 (0.01)			1 (0.00)
NORGESTON LEVONORGESTR		1 (0.01)			1 (0.00)
NORGESTON TABLET		1 (0.01)			1 (0.00)
NORGESTREL AND ETHINYL		2 (0.01)			2 (0.00)
NORLUTEN	1 (0.02)				1 (0.00)
NORMAL HUMAN IMMUNOGLO		1 (0.01)			1 (0.00)
NORMAL SALINE	2 (0.03)	1 (0.01)		2 (0.03)	5 (0.01)
NORMISON (TEMAZEPAM)		2 (0.01)			2 (0.00)
NORMITEN			2 (0.01)	1 (0.01)	3 (0.00)
NORMODYNE				1 (0.01)	1 (0.00)
NOROXIN		3 (0.02)	4 (0.01)	2 (0.03)	9 (0.01)
NORPLANT SYSTEM	2 (0.03)				2 (0.00)
NORSET	2 (0.03)	1 (0.01)	3 (0.01)		6 (0.01)
NORTRIPTYLINE		1 (0.01)	4 (0.01)		5 (0.01)
NORTRIPTYLINE 25MG		1 (0.01)			1 (0.00)
NORTRIPTYLINE HCL	3 (0.05)	9 (0.05)	7 (0.02)		19 (0.03)
NORTRIPTYLINE HYDROCHL			1 (0.00)		1 (0.00)
NORVASC	5 (0.08)	49 (0.29)	145 (0.48)	66 (0.85)	265 (0.43)
NORVASC /00972401/				1 (0.01)	1 (0.00)
NORVASC/DEN/ (AMLODIPI			1 (0.00)		1 (0.00)
NORVASK			1 (0.00)	1 (0.01)	2 (0.00)
NORVASTATIN			1 (0.00)		1 (0.00)
NORVIR	1 (0.02)	13 (0.08)	6 (0.02)		20 (0.03)
NOT REPORTED MEDICATIO			1 (0.00)		1 (0.00)
NOTEN (STENOLOL)			1 (0.00)		1 (0.00)
NOVALGIN		1 (0.01)	2 (0.01)		3 (0.00)
NOVALGIN (METAMIZOLE S			1 (0.00)		1 (0.00)
NOVAMIN (PROCHLORPERAZ			1 (0.00)	2 (0.03)	3 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
NOVANTRONE	2 (0.03)	13 (0.08)	11 (0.04)	2 (0.03)	28 (0.05)
NOVAS (ALL OTHER THERA			1 (0.00)		1 (0.00)
NOVATREX		3 (0.02)	2 (0.01)	1 (0.01)	6 (0.01)
NOVATREX (METHOTREXATE		1 (0.01)			1 (0.00)
NOVATREX ^ACHE^			1 (0.00)		1 (0.00)
NOVO NORDISK			1 (0.00)		1 (0.00)
NOVOLIN			6 (0.02)		6 (0.01)
NOVOLIN 30/70			1 (0.00)		1 (0.00)
NOVOLIN 30R			1 (0.00)		1 (0.00)
NOVOLIN 30R CHU		1 (0.01)			1 (0.00)
NOVOLIN 70/30			7 (0.02)		7 (0.01)
NOVOLIN GE NPH PENFILL			3 (0.01)		3 (0.00)
NOVOLIN INSULIN SLIDIN			1 (0.00)		1 (0.00)
NOVOLIN N	1 (0.02)	2 (0.01)	5 (0.02)	1 (0.01)	9 (0.01)
NOVOLIN R		2 (0.01)	1 (0.00)		3 (0.00)
NOVOLOG	9 (0.15)	7 (0.04)	31 (0.10)	1 (0.01)	48 (0.08)
NOVOLOG MIX 70/30		5 (0.03)	3 (0.01)		8 (0.01)
NOVOLOG PEN				1 (0.01)	1 (0.00)
NOVOMIX			1 (0.00)		1 (0.00)
NOVOMIX (INSULIN ASPAR		1 (0.01)			1 (0.00)
NOVONORM		2 (0.01)	6 (0.02)		8 (0.01)
NOVOPLATINUM			1 (0.00)		1 (0.00)
NOVORAPID	8 (0.14)	12 (0.07)	9 (0.03)		29 (0.05)
NOVORAPID /DEN/ (INSUL	1 (0.02)				1 (0.00)
NOVORAPID CHU			1 (0.00)		1 (0.00)
NOVOSEVEN	7 (0.12)	12 (0.07)	6 (0.02)	2 (0.03)	27 (0.04)
NOZINAN			1 (0.00)		1 (0.00)
NOZINAN (LEVOMEPRMAZI		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
NPH INSULIN		1 (0.01)	9 (0.03)	4 (0.05)	14 (0.02)
NSAID'S		2 (0.01)	5 (0.02)		7 (0.01)
NSAIDS			2 (0.01)		2 (0.00)
NSAR		1 (0.01)			1 (0.00)
NU-LOTAN				2 (0.03)	2 (0.00)
NUBAIN		1 (0.01)	1 (0.00)		2 (0.00)
NUFOL				1 (0.01)	1 (0.00)
NUROFEN PLUS (CODEINE)		1 (0.01)			1 (0.00)
NUTRAVIEW			1 (0.00)		1 (0.00)
NUTRIFLEX (AMINO ACIDS			1 (0.00)		1 (0.00)
NUTROPIN	11 (0.19)	1 (0.01)			12 (0.02)
NUTROPIN AQ	15 (0.25)				15 (0.02)
NUVARING	5 (0.08)	23 (0.13)			28 (0.05)
NYASPAN			1 (0.00)		1 (0.00)
NYQUIL COLD/FLU RELIEF	1 (0.02)				1 (0.00)
NYQUIL MULTISYMP TOM		1 (0.01)			1 (0.00)
NYSTATIN	4 (0.07)		2 (0.01)	2 (0.03)	8 (0.01)
OCTAGAM	1 (0.02)				1 (0.00)
OCTAGAM 5% (IMMUNOGLOB			1 (0.00)		1 (0.00)
OCUFLOX				1 (0.01)	1 (0.00)
OCUPRESS				1 (0.01)	1 (0.00)
OCUVITE			1 (0.00)		1 (0.00)
ODRIC			1 (0.00)		1 (0.00)
OESTROGENIC DRUG		1 (0.01)			1 (0.00)
OESTROPROGESTATIVE MED		1 (0.01)			1 (0.00)
OFLOCET		1 (0.01)		2 (0.03)	3 (0.00)
OFLOCET (OFLOXACINE)				1 (0.01)	1 (0.00)
OFLOXACIN		8 (0.05)		2 (0.03)	10 (0.02)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
OGEN		1 (0.01)		1 (0.01)	2 (0.00)
OLANZAPINE	5 (0.08)	24 (0.14)	19 (0.06)	8 (0.10)	56 (0.09)
OLANZAPINE				1 (0.01)	1 (0.00)
OLMESARTAN		1 (0.01)		1 (0.01)	2 (0.00)
OLMETEC			10 (0.03)	6 (0.08)	16 (0.03)
OLMETEC (OLMESARTAN ME			1 (0.00)		1 (0.00)
OLMETEC (OLMESARTAN)				5 (0.06)	5 (0.01)
OMACOR	1 (0.02)	3 (0.02)	4 (0.01)		8 (0.01)
OMALIZUMAB (OMALIZUMAB		1 (0.01)			1 (0.00)
OMEGA 3			1 (0.00)		1 (0.00)
OMEGA 3 (FISH OIL)			1 (0.00)		1 (0.00)
OMEGA 3-6-9 (OMEGA 6 T		1 (0.01)			1 (0.00)
OMEGA-3	1 (0.02)				1 (0.00)
OMEGA-3 MARINE TRIGLYC		1 (0.01)			1 (0.00)
OMEPRAL			4 (0.01)	3 (0.04)	7 (0.01)
OMEPRAL (OMEPRAZOLE0 T			1 (0.00)		1 (0.00)
OMEPRAL SODIUM			1 (0.00)		1 (0.00)
OMEPRAZOLE	6 (0.10)	22 (0.13)	89 (0.29)	39 (0.50)	156 (0.26)
OMEPRAZOLE UNKNOWN	1 (0.02)				1 (0.00)
OMEPRAZOLE MAGNESIUM				1 (0.01)	1 (0.00)
OMEPRAZOLUM			1 (0.00)		1 (0.00)
OMIX			1 (0.00)		1 (0.00)
OMNIC			1 (0.00)	2 (0.03)	3 (0.00)
OMNICEF	9 (0.15)	2 (0.01)	4 (0.01)		15 (0.02)
OMNIPAQUE 140	1 (0.02)	2 (0.01)	2 (0.01)	1 (0.01)	6 (0.01)
OMNIPAQUE 300	1 (0.02)	2 (0.01)	1 (0.00)		4 (0.01)
OMNIPAQUE 350		2 (0.01)			2 (0.00)
OMNISCAN	1 (0.02)		2 (0.01)	1 (0.01)	4 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ONCOVIN	2 (0.03)		5 (0.02)		7 (0.01)
ONDANSETRON	1 (0.02)	4 (0.02)	15 (0.05)	3 (0.04)	23 (0.04)
ONDANSETRON HYDROCHLOR			1 (0.00)		1 (0.00)
ONE-A-DAY ESSENTIAL VI			1 (0.00)		1 (0.00)
ONE-A-DAY WOMEN'S VITA		1 (0.01)			1 (0.00)
ONE-ALPHA (ALFACALCIDO				1 (0.01)	1 (0.00)
ONEALFA		6 (0.04)			6 (0.01)
ONON	1 (0.02)		1 (0.00)		2 (0.00)
ONTAK (DENILEUKIN DIFT			1 (0.00)		1 (0.00)
ONXOL 300 MG MAYNE			1 (0.00)		1 (0.00)
OPALMON				1 (0.01)	1 (0.00)
OPIOIDS			2 (0.01)		2 (0.00)
OPIPRAMOL HYDROCHLORID			1 (0.00)		1 (0.00)
OPIUM TINCTURE (OPIUM	1 (0.02)				1 (0.00)
OPIUM TINCTURE (OPIUM	1 (0.02)				1 (0.00)
OPSO			1 (0.00)		1 (0.00)
OPTIMARK	1 (0.02)		1 (0.00)		2 (0.00)
OPTIRAY (IOVERSOL) SOL		1 (0.01)			1 (0.00)
OPTIRAY 160			1 (0.00)	1 (0.01)	2 (0.00)
OPTIRAY 240			2 (0.01)		2 (0.00)
OPTIRAY 300	1 (0.02)		1 (0.00)		2 (0.00)
OPTIRAY 320		1 (0.01)	7 (0.02)	5 (0.06)	13 (0.02)
OPTIRAY 350		1 (0.01)			1 (0.00)
OPTIRAY(IOVERSOL) SOLU			1 (0.00)		1 (0.00)
OPTIVAR		1 (0.01)			1 (0.00)
ORABET	2 (0.03)				2 (0.00)
ORACEFAL	1 (0.02)				1 (0.00)
ORACILLINE	2 (0.03)				2 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ORAGEL ADVANCED TOOTH		1 (0.01)			1 (0.00)
ORAL (CONTRACEPTIVE NO	1 (0.02)				1 (0.00)
ORAL ANTIDIABETICS			1 (0.00)		1 (0.00)
ORAL B REMBRANT COMPLE			1 (0.00)		1 (0.00)
ORAL CONTRACEPTIVE		1 (0.01)			1 (0.00)
ORAL CONTRACEPTIVE NOS	1 (0.02)	1 (0.01)			2 (0.00)
ORAL CONTRACEPTIVE PIL	3 (0.05)	1 (0.01)			4 (0.01)
ORAL CONTRACEPTIVES	2 (0.03)	1 (0.01)			3 (0.00)
ORAL SOLUTION THER		1 (0.01)			1 (0.00)
ORALOVITE			1 (0.00)		1 (0.00)
ORAMORPH SR	3 (0.05)		1 (0.00)		4 (0.01)
ORAP		2 (0.01)			2 (0.00)
ORAPRED			1 (0.00)		1 (0.00)
ORAPRED (PREDNISOLONE	1 (0.02)				1 (0.00)
ORAPRED (PREDNISOLONE		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
ORAPRED(PREDNISOLONE S				1 (0.01)	1 (0.00)
ORAPRED(PREDNISOLONE S		1 (0.01)			1 (0.00)
ORAPRED(PREDNISOLONE S			1 (0.00)		1 (0.00)
ORBENINE			1 (0.00)		1 (0.00)
ORCIPRENALINE			3 (0.01)		3 (0.00)
ORFIDAL			1 (0.00)		1 (0.00)
ORFINIL		1 (0.01)			1 (0.00)
ORGANIC NITRATES			1 (0.00)		1 (0.00)
ORGANIC NITRATES (ORGA			1 (0.00)		1 (0.00)
ORIGLUCON			1 (0.00)		1 (0.00)
ORLISTAT	3 (0.05)		1 (0.00)		4 (0.01)
OROCAL			3 (0.01)		3 (0.00)
OROCAL D3				1 (0.01)	1 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
OROMORPH			1 (0.00)		1 (0.00)
OROXINE		2 (0.01)			2 (0.00)
ORPHENADRINE		3 (0.02)	2 (0.01)		5 (0.01)
ORTHO CYCLEN-28		4 (0.02)			4 (0.01)
ORTHO DIAPHRAGM	1 (0.02)				1 (0.00)
ORTHO EVRA	76 (1.29)	90 (0.53)	1 (0.00)		167 (0.27)
ORTHO TRI-CYCLEN	23 (0.39)	17 (0.10)			40 (0.07)
ORTHO TRI-CYCLEN LO	3 (0.05)	1 (0.01)			4 (0.01)
ORTHO TRI-CYCLEN LO (E	1 (0.02)				1 (0.00)
ORTHO-NOVUM		1 (0.01)			1 (0.00)
ORTHO-NOVUM 7/7/7-21	2 (0.03)	4 (0.02)			6 (0.01)
ORTHO-PREFEST			1 (0.00)		1 (0.00)
ORTHOCLONE OKT3		1 (0.01)			1 (0.00)
ORTHOSIPHON ARISTATUS		1 (0.01)			1 (0.00)
ORUDIS				1 (0.01)	1 (0.00)
OS-CAL		1 (0.01)	5 (0.02)		6 (0.01)
OS-CAL + D (CALCIUM CA			1 (0.00)		1 (0.00)
OS-CAL 500 + D				1 (0.01)	1 (0.00)
OSCAL (CALCIUM CARBONA				1 (0.01)	1 (0.00)
OSELTAMIVIR			1 (0.00)		1 (0.00)
OSTELUC (ETODOLAC) PER			1 (0.00)		1 (0.00)
OSTEO-BI-FLEX			1 (0.00)		1 (0.00)
OSTRAM-VIT.D3			1 (0.00)		1 (0.00)
OTC COLD MEDICINE			1 (0.00)		1 (0.00)
OTC COLD MEDICINE (OTH			1 (0.00)		1 (0.00)
OTHER COLD COMBINATION	2 (0.03)				2 (0.00)
OTHER MEDICATIONS			1 (0.00)		1 (0.00)
OTHER MEDICATIONS () A				1 (0.01)	1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
OVCON 35 + GENERIC OF		1 (0.01)			1 (0.00)
OVCON-35	1 (0.02)	3 (0.02)			4 (0.01)
OVESTERIN				1 (0.01)	1 (0.00)
OVESTIN			1 (0.00)		1 (0.00)
OVIDE	2 (0.03)				2 (0.00)
OVIDREL		1 (0.01)			1 (0.00)
OVRAL	1 (0.02)	1 (0.01)			2 (0.00)
OVRAL-L (LEVONORGESTRE		1 (0.01)			1 (0.00)
OXACILLIN				1 (0.01)	1 (0.00)
OXALIPLATIN		4 (0.02)	22 (0.07)	1 (0.01)	27 (0.04)
OXALIPLATIN (OXALIPLAT		1 (0.01)	2 (0.01)		3 (0.00)
OXALIPLATIN 130 MG/M2			2 (0.01)		2 (0.00)
OXALIPLATIN 130MG/M2			1 (0.00)		1 (0.00)
OXALIPLATIN(OXALIPLATI			1 (0.00)		1 (0.00)
OXALIPLATINO			1 (0.00)		1 (0.00)
OXANDRIN		1 (0.01)			1 (0.00)
OXANDROLONE			4 (0.01)		4 (0.01)
OXAPAX	1 (0.02)				1 (0.00)
OXAPAX (OXAZEPAM)			1 (0.00)		1 (0.00)
OXAPROZIN		1 (0.01)			1 (0.00)
OXAZEPAM	1 (0.02)	3 (0.02)	7 (0.02)	1 (0.01)	12 (0.02)
OXCARBAZEPINE	3 (0.05)	2 (0.01)	2 (0.01)		7 (0.01)
OXEOL			1 (0.00)		1 (0.00)
OXETORONE FUMARATE (OX		1 (0.01)			1 (0.00)
OXGEN			1 (0.00)		1 (0.00)
OXIS TURBOHALER				1 (0.01)	1 (0.00)
OXPRENOLOL HCL			1 (0.00)		1 (0.00)
OXPRENOLOL HYDROCHLORI			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
OXYBUTYNIN	1 (0.02)	2 (0.01)	3 (0.01)		6 (0.01)
OXYBUTYNIN CHLORIDE	2 (0.03)				2 (0.00)
OXYBUTYNIN CHLORIDE SY	1 (0.02)				1 (0.00)
OXYBUTYNIN CHLORIDE SY	1 (0.02)				1 (0.00)
OXYCODON KAPSELN 5MG(O				1 (0.01)	1 (0.00)
OXYCODONE	2 (0.03)	6 (0.04)	8 (0.03)	2 (0.03)	18 (0.03)
OXYCODONE (OXYCODONE)		1 (0.01)			1 (0.00)
OXYCODONE - EXTENDED R			1 (0.00)		1 (0.00)
OXYCODONE 20 MG			1 (0.00)		1 (0.00)
OXYCODONE 40MG			1 (0.00)		1 (0.00)
OXYCODONE 5/APAP 500	1 (0.02)				1 (0.00)
OXYCODONE AND ACETAMIN		1 (0.01)			1 (0.00)
OXYCODONE ER		1 (0.01)			1 (0.00)
OXYCODONE ER 40 MG DAV		1 (0.01)			1 (0.00)
OXYCODONE ER 80 MG		1 (0.01)			1 (0.00)
OXYCODONE HCI CONTROLL			1 (0.00)		1 (0.00)
OXYCODONE HCL	4 (0.07)	24 (0.14)	30 (0.10)	2 (0.03)	60 (0.10)
OXYCODONE HYDROCHLORID		1 (0.01)			1 (0.00)
OXYCODONE HYDROCHLORID		1 (0.01)			1 (0.00)
OXYCODONE HYDROCHLORID		1 (0.01)			1 (0.00)
OXYCODONE HYDROCHLORID		1 (0.01)			1 (0.00)
OXYCODONE TABLETS, USP			1 (0.00)		1 (0.00)
OXYCODONE-EXTENDED REL			1 (0.00)		1 (0.00)
OXYCODONE/APAP	1 (0.02)				1 (0.00)
OXYCODONE/APAP 5MG/325			1 (0.00)		1 (0.00)
OXYCONTIN	18 (0.30)	74 (0.43)	59 (0.20)	5 (0.06)	156 (0.26)
OXYCONTIN CR				1 (0.01)	1 (0.00)
OXYGEN	3 (0.05)	3 (0.02)	4 (0.01)	4 (0.05)	14 (0.02)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
OXYGEN (OXYGEN)	2 (0.03)	1 (0.01)	2 (0.01)	2 (0.03)	7 (0.01)
OXYIR		2 (0.01)			2 (0.00)
OXYMETAZOLINE HYDROCHL			1 (0.00)		1 (0.00)
OXYNORM		1 (0.01)			1 (0.00)
OXYTETRACYCLINE	1 (0.02)		1 (0.00)		2 (0.00)
OXYTOCIN	3 (0.05)	1 (0.01)			4 (0.01)
OXYTROL				1 (0.01)	1 (0.00)
OYCODONE (OXYCODONE)			1 (0.00)		1 (0.00)
PA		2 (0.01)	1 (0.00)		3 (0.00)
PACERONE			2 (0.01)	1 (0.01)	3 (0.00)
PACIL			1 (0.00)		1 (0.00)
PACKED RED BLOOD CELLS				1 (0.01)	1 (0.00)
PACLITAXEL	1 (0.02)	7 (0.04)	26 (0.09)	4 (0.05)	38 (0.06)
PACLITAXEL 350 MG 100			1 (0.00)		1 (0.00)
PAIN KILLERS			1 (0.00)		1 (0.00)
PAIN MED (NOS)				1 (0.01)	1 (0.00)
PAIN MEDICATION		1 (0.01)	3 (0.01)	1 (0.01)	5 (0.01)
PAMELOR		2 (0.01)			2 (0.00)
PAMIDORNATE (PAMIDRONA			1 (0.00)		1 (0.00)
PAMIDRONATE (PAMIDRONA		1 (0.01)			1 (0.00)
PAMIDRONATE DISODIUM	2 (0.03)	3 (0.02)	15 (0.05)	4 (0.05)	24 (0.04)
PAMIDRONIC ACID	1 (0.02)				1 (0.00)
PANADOL HOT		2 (0.01)			2 (0.00)
PANAFIL (PAPAIN, UREA,		1 (0.01)			1 (0.00)
PANALDINE		2 (0.01)	7 (0.02)	2 (0.03)	11 (0.02)
PANAMAX				1 (0.01)	1 (0.00)
PANCREASE		1 (0.01)			1 (0.00)
PANCREASE (PANCRELIPAS			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PANCREASE/LIPASE/AMYLASE		1 (0.01)			1 (0.00)
PANCREATIN TRIPLE STRENGTH			1 (0.00)		1 (0.00)
PANCREON				1 (0.01)	1 (0.00)
PANCURONIUM BROMIDE			1 (0.00)		1 (0.00)
PANODIL ZAPP		1 (0.01)			1 (0.00)
PANOKASE				1 (0.01)	1 (0.00)
PANSPORIN T			1 (0.00)		1 (0.00)
PANTECTA				1 (0.01)	1 (0.00)
PANTECTA (PANTOPRAZOLE)		1 (0.01)			1 (0.00)
PANTELMIN		1 (0.01)			1 (0.00)
PANTETHINE		1 (0.01)			1 (0.00)
PANTHOL			1 (0.00)		1 (0.00)
PANTOLOC ^SOLVAY ^				2 (0.03)	2 (0.00)
PANTOPRAZOL			2 (0.01)		2 (0.00)
PANTOPRAZOLE		4 (0.02)	11 (0.04)	2 (0.03)	17 (0.03)
PANTOPRAZOLE SODIUM	1 (0.02)	10 (0.06)	24 (0.08)	9 (0.12)	44 (0.07)
PANTOSIN				1 (0.01)	1 (0.00)
PANTOTHENIC ACID (PANTOTHENIC)			1 (0.00)		1 (0.00)
PANTOZOL		3 (0.02)	1 (0.00)	2 (0.03)	6 (0.01)
PANTOZOL (PANTOPRAZOLE)			2 (0.01)	1 (0.01)	3 (0.00)
PANTOZOL (PATNOPRAZOLE)			1 (0.00)		1 (0.00)
PANTPAS (PANTOPRAZOLE,		1 (0.01)			1 (0.00)
PANVITAN	1 (0.02)		2 (0.01)		3 (0.00)
PARACETAMOL	5 (0.08)	6 (0.04)	15 (0.05)	1 (0.01)	27 (0.04)
PARACETAMOL (PARACETAMOL)	1 (0.02)				1 (0.00)
PARACETAMOL+CODEINE (NORCO)		1 (0.01)			1 (0.00)
PARACETAMOL/HYDROCODON			1 (0.00)		1 (0.00)
PARACETAMOL/HYDROCODON			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PARACETAMOL/OXYCODONE		2 (0.01)			2 (0.00)
PARACETAMOLUM				1 (0.01)	1 (0.00)
PARAFON FORTE DSC		2 (0.01)			2 (0.00)
PARALGIN FORTE		3 (0.02)			3 (0.00)
PARAMOL-118			1 (0.00)		1 (0.00)
PARAPLATIN	1 (0.02)	6 (0.04)	26 (0.09)	2 (0.03)	35 (0.06)
PARAPRES (CANDESARTAN			1 (0.00)		1 (0.00)
PARAPSYLLIUM			1 (0.00)		1 (0.00)
PARCOPA			1 (0.00)		1 (0.00)
PAREMYD	2 (0.03)	1 (0.01)			3 (0.00)
PAREMYD, 1%/0.25%, AKO		1 (0.01)			1 (0.00)
PARGEVERINE HYDROCHLOR			2 (0.01)		2 (0.00)
PARIET		1 (0.01)	5 (0.02)	1 (0.01)	7 (0.01)
PARIET (RABEPRAZOLE) (1 (0.02)				1 (0.00)
PARKINANE			1 (0.00)		1 (0.00)
PARLODEL	1 (0.02)	2 (0.01)	3 (0.01)		6 (0.01)
PARNATE		2 (0.01)			2 (0.00)
PAROXETINE		1 (0.01)	5 (0.02)		6 (0.01)
PAROXETINE 20 MG ANDRX		1 (0.01)			1 (0.00)
PAROXETINE HCL	7 (0.12)	38 (0.22)	19 (0.06)	2 (0.03)	66 (0.11)
PAROXETINE HYDROCHLORI	3 (0.05)	5 (0.03)	3 (0.01)		11 (0.02)
PARVOLEX	1 (0.02)				1 (0.00)
PASIL (PAZUFLOXACIN ME		1 (0.01)			1 (0.00)
PATANOL			1 (0.00)		1 (0.00)
PAVALIX		2 (0.01)			2 (0.00)
PAVULON		1 (0.01)			1 (0.00)
PAXAM (2 MG, TABLET) (1 (0.01)			1 (0.00)
PAXIL	54 (0.91)	121 (0.71)	106 (0.35)	16 (0.21)	297 (0.49)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PAXIL (PAROXETINE HYDR		1 (0.01)			1 (0.00)
PAXIL CR	13 (0.22)	29 (0.17)	19 (0.06)		61 (0.10)
PAYNOCIL				1 (0.01)	1 (0.00)
PAZUCROSS INJECTION				1 (0.01)	1 (0.00)
PCA PUMP COUN		1 (0.01)			1 (0.00)
PEDIAPRED (GENERIC)	1 (0.02)				1 (0.00)
PEG-INRON INJECTABLE P		1 (0.01)			1 (0.00)
PEG-INTERFERON A-2A (R		1 (0.01)	5 (0.02)		6 (0.01)
PEG-INTERFERON ALFA 2A	2 (0.03)	9 (0.05)	5 (0.02)		16 (0.03)
PEG-INTERFERON ALFA-2B		3 (0.02)	1 (0.00)		4 (0.01)
PEG-INTERFERON ALFA-2B			1 (0.00)		1 (0.00)
PEG-INTRON	5 (0.08)	52 (0.30)	47 (0.16)		104 (0.17)
PEG-INTRON (PEGINTERFE		1 (0.01)	1 (0.00)		2 (0.00)
PEG-INTRON (PEGINTERFE			1 (0.00)		1 (0.00)
PEG-INTRON (PEGINTERFE				1 (0.01)	1 (0.00)
PEG-INTRON 120 MG SCHE		1 (0.01)			1 (0.00)
PEGASYS	5 (0.08)	57 (0.33)	43 (0.14)	6 (0.08)	111 (0.18)
PEGINTERFERON ALFA 2A			1 (0.00)		1 (0.00)
PEGINTERFERON ALFA-2A			1 (0.00)		1 (0.00)
PEGINTRON (PEGINTERFER		1 (0.01)			1 (0.00)
PEMETREXED DAY 1 OF			1 (0.00)		1 (0.00)
PEMETREXED (PEMETREXED			1 (0.00)	2 (0.03)	3 (0.00)
PEMETREXED (PEMETREXED			1 (0.00)		1 (0.00)
PEMETREXED - ELI LILLY			1 (0.00)		1 (0.00)
PEMETREXED(PEMETREXED)			1 (0.00)		1 (0.00)
PEMETREXED(PEMETREXED)			1 (0.00)		1 (0.00)
PEMOLINE			2 (0.01)		2 (0.00)
PENFILL 30R CHU		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PENFILL N CHU	1 (0.02)	1 (0.01)			2 (0.00)
PENFILL R CHU			1 (0.00)		1 (0.00)
PENICILLIN	2 (0.03)		9 (0.03)		11 (0.02)
PENICILLIN (UNSPECIFIE		2 (0.01)			2 (0.00)
PENICILLIN G		1 (0.01)			1 (0.00)
PENICILLIN G PROCAINE		1 (0.01)			1 (0.00)
PENICILLIN G SODIUM		1 (0.01)			1 (0.00)
PENICILLIN V		2 (0.01)	1 (0.00)		3 (0.00)
PENICILLIN V POTASSIUM	1 (0.02)	2 (0.01)			3 (0.00)
PENTACARINAT		2 (0.01)			2 (0.00)
PENTAMIDINE 300 MG INJ	1 (0.02)				1 (0.00)
PENTASA	5 (0.08)	8 (0.05)	3 (0.01)	2 (0.03)	18 (0.03)
PENTAZOCINE AND NALOXO			1 (0.00)		1 (0.00)
PENTAZOCINE LACTATE			1 (0.00)		1 (0.00)
PENTCILLIN (PIPERACILL				1 (0.01)	1 (0.00)
PENTOSAN POLYSULFATE S		1 (0.01)			1 (0.00)
PENTOTHAL	1 (0.02)				1 (0.00)
PENTOXIFYLLINE		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
PEPCID		7 (0.04)	11 (0.04)	1 (0.01)	19 (0.03)
PEPCID AC		1 (0.01)	4 (0.01)		5 (0.01)
PEPCID RPD		1 (0.01)	2 (0.01)		3 (0.00)
PEPTO BISMOL	1 (0.02)				1 (0.00)
PERAZINE		1 (0.01)			1 (0.00)
PERCOCET	1 (0.02)	24 (0.14)	31 (0.10)	8 (0.10)	64 (0.10)
PERCOCET (OXYCODONE HY		1 (0.01)			1 (0.00)
PERCODAN		1 (0.01)	1 (0.00)		2 (0.00)
PERCOGESIC				2 (0.03)	2 (0.00)
PERDIPINE				2 (0.03)	2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PERFALGAN	2 (0.03)	3 (0.02)	3 (0.01)		8 (0.01)
PERFALGAN (ACETAMINOPH			1 (0.00)		1 (0.00)
PERGOLIDE MESYLATE			1 (0.00)		1 (0.00)
PERIACTIN	10 (0.17)		1 (0.00)		11 (0.02)
PERINDOPRIL		3 (0.02)	4 (0.01)	1 (0.01)	8 (0.01)
PERINDOPRIL (PERINDOPR				1 (0.01)	1 (0.00)
PERINDOPRIL ERBUMINE			3 (0.01)		3 (0.00)
PERINDOPRIL ERUMINE				1 (0.01)	1 (0.00)
PERIOSTAT			2 (0.01)		2 (0.00)
PERMAX	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
PERMIXON				1 (0.01)	1 (0.00)
PEROCT			1 (0.00)		1 (0.00)
PERSANTIN		3 (0.02)	2 (0.01)		5 (0.01)
PERSANTIN DEPOT		1 (0.01)			1 (0.00)
PERSANTINE		1 (0.01)			1 (0.00)
PETHIDINE	1 (0.02)				1 (0.00)
PETIBELLE 30 (21) (DRO		1 (0.01)			1 (0.00)
PETIBELLE 30 (21)(ETHI	1 (0.02)				1 (0.00)
PETROLATUM, WHITE			1 (0.00)		1 (0.00)
PHEN-FEN 30MG W			1 (0.00)		1 (0.00)
PHENAZOPYRIDINE HCL TA				1 (0.01)	1 (0.00)
PHENERGAN		5 (0.03)	2 (0.01)	1 (0.01)	8 (0.01)
PHENERGAN HCL		1 (0.01)	1 (0.00)		2 (0.00)
PHENERGAN TABLETS/SUPP		1 (0.01)			1 (0.00)
PHENERGAN VC W/ CODEIN	1 (0.02)				1 (0.00)
PHENERGAN W/ CODEINE		1 (0.01)			1 (0.00)
PHENIRAMINE			1 (0.00)		1 (0.00)
PHENOBAL (PHENOBARBITA			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PHENOBAL (PHENOBARITAL			1 (0.00)		1 (0.00)
PHENOBARBITAL		1 (0.01)			1 (0.00)
PHENOBARBITAL TAB	5 (0.08)	4 (0.02)	4 (0.01)	2 (0.03)	15 (0.02)
PHENOBARBITAL TABLETS		1 (0.01)			1 (0.00)
PHENOBARBITONE	1 (0.02)	2 (0.01)			3 (0.00)
PHENOL + ZINC OXIDE LI	2 (0.03)				2 (0.00)
PHENORAL (PHENOBARBITA			1 (0.00)		1 (0.00)
PHENOXYMETHYLPENICILLI		1 (0.01)			1 (0.00)
PHENPROCOUMON			7 (0.02)		7 (0.01)
PHEENTERMINE	1 (0.02)	10 (0.06)	1 (0.00)		12 (0.02)
PHEENTERMINE CAPSULES,		1 (0.01)			1 (0.00)
PHEENTERMINE TABLETS, U		1 (0.01)			1 (0.00)
PHENYLBUTAZONE		1 (0.01)	1 (0.00)		2 (0.00)
PHENYLPROPANOLAMINE	1 (0.02)				1 (0.00)
PHENYTEK				1 (0.01)	1 (0.00)
PHENYTOIN	8 (0.14)	14 (0.08)	18 (0.06)	7 (0.09)	47 (0.08)
PHENYTOIN INJECTION (P			1 (0.00)		1 (0.00)
PHENYTOIN SODIUM	2 (0.03)	5 (0.03)	5 (0.02)		12 (0.02)
PHENYTOIN SODIUM CAP	6 (0.10)	2 (0.01)	1 (0.00)		9 (0.01)
PHOSBLOCK 250 MG TABLE			1 (0.00)		1 (0.00)
PHOTOFRIN		1 (0.01)	2 (0.01)		3 (0.00)
PHYSIO 35		3 (0.02)			3 (0.00)
PHYTOMENADIONE			1 (0.00)		1 (0.00)
PHYTONADIONE	1 (0.02)				1 (0.00)
PIAS			1 (0.00)		1 (0.00)
PILOCARPINE				1 (0.01)	1 (0.00)
PIMOZIDE	1 (0.02)	1 (0.01)			2 (0.00)
PINAVERIUM BROMIDE				1 (0.01)	1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PINDOLOL			1 (0.00)		1 (0.00)
PINEX			1 (0.00)		1 (0.00)
PIOGLITAZONE HCL		3 (0.02)	5 (0.02)	1 (0.01)	9 (0.01)
PIPERACILLIN AND TAZOB		1 (0.01)	1 (0.00)		2 (0.00)
PIPERACILLIN SODIUM		1 (0.01)			1 (0.00)
PIPERACILLIN SODIUM W/			1 (0.00)		1 (0.00)
PIPERACILLIN SODIUM/TA			1 (0.00)		1 (0.00)
PIPERACILLIN/TAZOBACTA			1 (0.00)		1 (0.00)
PIPERACILLINE/TAZOBACT			1 (0.00)		1 (0.00)
PIPRAM			1 (0.00)		1 (0.00)
PIRACETAM				1 (0.01)	1 (0.00)
PIRIBEDIL		1 (0.01)			1 (0.00)
PIRITON		2 (0.01)			2 (0.00)
PIRITRAMIDE	1 (0.02)				1 (0.00)
PIROXICAM	3 (0.05)	2 (0.01)	9 (0.03)		14 (0.02)
PITOCIN		1 (0.01)			1 (0.00)
PL	5 (0.08)	5 (0.03)	8 (0.03)		18 (0.03)
PL (PYRIDOXAL)		1 (0.01)		1 (0.01)	2 (0.00)
PL GRAN.		1 (0.01)	1 (0.00)		2 (0.00)
PL-GRANULES				2 (0.03)	2 (0.00)
PLACEBO		1 (0.01)	1 (0.00)		2 (0.00)
PLANTABEN		4 (0.02)			4 (0.01)
PLANTAGO OVATA		1 (0.01)		1 (0.01)	2 (0.00)
PLANUM		1 (0.01)			1 (0.00)
PLAQUENIL	1 (0.02)	18 (0.11)	15 (0.05)	2 (0.03)	36 (0.06)
PLASIL	1 (0.02)				1 (0.00)
PLASMA		1 (0.01)			1 (0.00)
PLASMAPHERESIS	2 (0.03)		2 (0.01)		4 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PLASMAPHERESIS (PLASMA		2 (0.01)			2 (0.00)
PLASMAPHORESIS (ALL OT		1 (0.01)			1 (0.00)
PLATELETS			1 (0.00)	1 (0.01)	2 (0.00)
PLATINOL		1 (0.01)	3 (0.01)		4 (0.01)
PLAVIX	2 (0.03)	25 (0.15)	154 (0.51)	82 (1.06)	263 (0.43)
PLENDIL		6 (0.04)	12 (0.04)	2 (0.03)	20 (0.03)
PLETAL		1 (0.01)	4 (0.01)	1 (0.01)	6 (0.01)
PNEUMOREL		1 (0.01)			1 (0.00)
PNEUMOVAX (PNEUMOCOCCA			1 (0.00)		1 (0.00)
POLARAMINE	2 (0.03)		5 (0.02)	1 (0.01)	8 (0.01)
POLOCAINE				3 (0.04)	3 (0.00)
POLPRAZOL			2 (0.01)		2 (0.00)
POLYGAM			1 (0.00)		1 (0.00)
POLYGAM S/D		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
POLYPHARMACY			1 (0.00)	1 (0.01)	2 (0.00)
PONTAL (MEFENAMIC ACID		1 (0.01)			1 (0.00)
POSACONAZOLE			1 (0.00)		1 (0.00)
POTASSIUM		2 (0.01)	4 (0.01)	3 (0.04)	9 (0.01)
POTASSIUM (POTASSIUM)			1 (0.00)		1 (0.00)
POTASSIUM (UNSPECIFIED			2 (0.01)		2 (0.00)
POTASSIUM CHLORIDE		2 (0.01)	18 (0.06)	9 (0.12)	29 (0.05)
POTASSIUM PERMANGANATE		1 (0.01)			1 (0.00)
POTASSIUM PHOSPHATES		1 (0.01)			1 (0.00)
POVIDONE IODINE				2 (0.03)	2 (0.00)
PPD PARKDALE LOT U			1 (0.00)		1 (0.00)
PPD PARKDALE PPD LO			1 (0.00)		1 (0.00)
PPD AVENTIS PASTEUR LO			1 (0.00)		1 (0.00)
PPD-PARKEDALE PHARMACE			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PPD-TUBERCULIN			1 (0.00)		1 (0.00)
PRAMIPEXOLE DIHYDROCHL			4 (0.01)		4 (0.01)
PRANDIN		2 (0.01)	22 (0.07)	4 (0.05)	28 (0.05)
PRANLUKAST (PRANLUKAST		1 (0.01)			1 (0.00)
PRANOLOL			1 (0.00)		1 (0.00)
PRAVACHOL		2 (0.01)	41 (0.14)	12 (0.15)	55 (0.09)
PRAVASIN			2 (0.01)		2 (0.00)
PRAVASTATIN	1 (0.02)		9 (0.03)	8 (0.10)	18 (0.03)
PRAVASTATIN SODIUM			6 (0.02)	2 (0.03)	8 (0.01)
PRAXILENE				1 (0.01)	1 (0.00)
PRAXILENE (NAFTIDROFUR				1 (0.01)	1 (0.00)
PRAXILENE (NAFTIDROFUR				1 (0.01)	1 (0.00)
PRAZEPAM			3 (0.01)		3 (0.00)
PRAZOSIN			2 (0.01)		2 (0.00)
PRAZOSIN GITS	1 (0.02)				1 (0.00)
PRAZOSIN HYDROCHLORIDE			1 (0.00)		1 (0.00)
PRECEDEX			1 (0.00)		1 (0.00)
PRECIPATED CALCIUM CAR				1 (0.01)	1 (0.00)
PRECIPITATED CALCIUM C		1 (0.01)		2 (0.03)	3 (0.00)
PRECOSE			3 (0.01)		3 (0.00)
PRED FORTE			3 (0.01)	1 (0.01)	4 (0.01)
PRED-G			1 (0.00)		1 (0.00)
PREDFOAM (PREDNISOLONE		1 (0.01)			1 (0.00)
PREDNISOLONE	23 (0.39)	34 (0.20)	77 (0.25)	13 (0.17)	147 (0.24)
PREDNISOLONE ACETATE				1 (0.01)	1 (0.00)
PREDNISOLONE ACETATE O			1 (0.00)		1 (0.00)
PREDNISOLONE SODIUM ME	2 (0.03)				2 (0.00)
PREDNISOLONE SODIUM PH	1 (0.02)	1 (0.01)			2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PREDNISOLONE SODIUM SU			2 (0.01)		2 (0.00)
PREDNISOLONE TAB	4 (0.07)	1 (0.01)	2 (0.01)		7 (0.01)
PREDNISOLUT	1 (0.02)				1 (0.00)
PREDNISON		1 (0.01)			1 (0.00)
PREDNISONE	16 (0.27)	82 (0.48)	113 (0.37)	20 (0.26)	231 (0.38)
PREDNISONE (PREDNISONE		1 (0.01)			1 (0.00)
PREDNISONE (PREDNISONE			1 (0.00)		1 (0.00)
PREDNISONE 50MG TAB	1 (0.02)				1 (0.00)
PREDNISONE TAB	2 (0.03)	15 (0.09)	46 (0.15)	8 (0.10)	71 (0.12)
PREDNISONUM		1 (0.01)			1 (0.00)
PREDNISOONE		1 (0.01)			1 (0.00)
PREDNSIOLIONE		1 (0.01)			1 (0.00)
PREDONINE	3 (0.05)	10 (0.06)	7 (0.02)	1 (0.01)	21 (0.03)
PREGABALIN		1 (0.01)			1 (0.00)
PREGABALIN 75 MG P			1 (0.00)		1 (0.00)
PREGABALIN (PREGABALIN		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
PREGABALIN 50 MG/TID		1 (0.01)			1 (0.00)
PRELONE	3 (0.05)		1 (0.00)		4 (0.01)
PREMARIN		32 (0.19)	159 (0.53)	19 (0.25)	210 (0.34)
PREMARIN(CONJUGATED ES			1 (0.00)		1 (0.00)
PREMPHASE (CONJUGATED			1 (0.00)		1 (0.00)
PREMPHASE (PREMARIN;CY		1 (0.01)	2 (0.01)		3 (0.00)
PREMPHASE 14/14		4 (0.02)	5 (0.02)		9 (0.01)
PREMPRO		44 (0.26)	474 (1.57)	10 (0.13)	528 (0.87)
PREMPRO (CONJUGATED A			1 (0.00)		1 (0.00)
PREMPRO (CONJUGATED AC			1 (0.00)		1 (0.00)
PREMPRO (CONJUGATED ES			1 (0.00)		1 (0.00)
PREMPRO (ESTROGENS CON			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PRENATAL VITAMINS	4 (0.07)	17 (0.10)			21 (0.03)
PRENATAL VITAMINS (ASC		1 (0.01)			1 (0.00)
PRENATAL VITAMINS (ASC		2 (0.01)			2 (0.00)
PRENATE	1 (0.02)				1 (0.00)
PREPARATION H			1 (0.00)		1 (0.00)
PREPIDIL		1 (0.01)			1 (0.00)
PRESTARIUM FORTE			1 (0.00)		1 (0.00)
PRETERAX			1 (0.00)	1 (0.01)	2 (0.00)
PRETERAX (INDAPAMIDE,				1 (0.01)	1 (0.00)
PREVACID	5 (0.08)	30 (0.18)	67 (0.22)	16 (0.21)	118 (0.19)
PREVALITE				2 (0.03)	2 (0.00)
PREVICID			1 (0.00)		1 (0.00)
PREVISCAN		2 (0.01)	2 (0.01)	7 (0.09)	11 (0.02)
PREVISCAN (FLUINDIONE)	1 (0.02)		3 (0.01)	3 (0.04)	7 (0.01)
PREVISCAN 9FLUINDIONE)			1 (0.00)		1 (0.00)
PREZOLON				1 (0.01)	1 (0.00)
PRIADEL		1 (0.01)	1 (0.00)		2 (0.00)
PRIALT		1 (0.01)	1 (0.00)		2 (0.00)
PRIALTZ (ZICONOTIDE IN			1 (0.00)		1 (0.00)
PRILOCAINE CITANEST 4%		1 (0.01)			1 (0.00)
PRILOSEC	3 (0.05)	40 (0.23)	70 (0.23)	10 (0.13)	123 (0.20)
PRILOSEC OTC		2 (0.01)			2 (0.00)
PRIMATENE MIST	3 (0.05)	9 (0.05)	8 (0.03)		20 (0.03)
PRIMATENE NASAL MIST		1 (0.01)			1 (0.00)
PRIMAXIN	1 (0.02)		12 (0.04)	5 (0.06)	18 (0.03)
PRIMIDONE	2 (0.03)	1 (0.01)	4 (0.01)	1 (0.01)	8 (0.01)
PRIMPERAN INJ			4 (0.01)		4 (0.01)
PRIMPERAN TAB	1 (0.02)	2 (0.01)	10 (0.03)	3 (0.04)	16 (0.03)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PRINIVIL	1 (0.02)	5 (0.03)	29 (0.10)	9 (0.12)	44 (0.07)
PRINZIDE			3 (0.01)		3 (0.00)
PRIORIX	2 (0.03)				2 (0.00)
PRIXAR				1 (0.01)	1 (0.00)
PROBENECID			1 (0.00)		1 (0.00)
PROCAINE HCL	3 (0.05)				3 (0.00)
PROCAPTAN				1 (0.01)	1 (0.00)
PROCARBAZINE HYDROCHLO			1 (0.00)		1 (0.00)
PROCARDIA			12 (0.04)	2 (0.03)	14 (0.02)
PROCARDIA XL		1 (0.01)	6 (0.02)	2 (0.03)	9 (0.01)
PROCHLORPERAZINE		2 (0.01)	2 (0.01)	2 (0.03)	6 (0.01)
PROCHLORPERAZINE MALEA				1 (0.01)	1 (0.00)
PROCRIT		8 (0.05)	18 (0.06)	2 (0.03)	28 (0.05)
PROCYCLIDINE HYDROCHLO	1 (0.02)	2 (0.01)			3 (0.00)
PROCYCLINE		1 (0.01)			1 (0.00)
PRODIF (FOSFLUCONAZOLE				1 (0.01)	1 (0.00)
PROFASI HP (CHORIONIC		1 (0.01)			1 (0.00)
PROFEN FORTE		1 (0.01)			1 (0.00)
PROGESTAN		3 (0.02)			3 (0.00)
PROGESTAN (PROGESTERON			1 (0.00)		1 (0.00)
PROGESTERON			2 (0.01)		2 (0.00)
PROGESTERONE		10 (0.06)	3 (0.01)		13 (0.02)
PROGESTERONE VAGINAL S		1 (0.01)			1 (0.00)
PROGLYCEM				1 (0.01)	1 (0.00)
PROGOUT		1 (0.01)			1 (0.00)
PROGRAF	17 (0.29)	22 (0.13)	32 (0.11)		71 (0.12)
PROHANCE	3 (0.05)	10 (0.06)	11 (0.04)	2 (0.03)	26 (0.04)
PROLEUKIN			5 (0.02)		5 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PROLIXIN		2 (0.01)	1 (0.00)		3 (0.00)
PROMAZINE HCL			3 (0.01)		3 (0.00)
PROMAZINE HYDROCHLORID			2 (0.01)		2 (0.00)
PROMETHAZINE	1 (0.02)	9 (0.05)	4 (0.01)	1 (0.01)	15 (0.02)
PROMETHAZINE HCL		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
PROMETRIUM		1 (0.01)	6 (0.02)		7 (0.01)
PROPAFENONE HCL		1 (0.01)	3 (0.01)	3 (0.04)	7 (0.01)
PROPAFENONE HYDROCHLOR	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
PROPAIN		1 (0.01)			1 (0.00)
PROPANOLOL (PROPANOLOL		2 (0.01)			2 (0.00)
PROPANOLOL HYDROCHLORI			1 (0.00)		1 (0.00)
PROPECIA	1 (0.02)	19 (0.11)	5 (0.02)	1 (0.01)	26 (0.04)
PROPIVERINE HYDROCHLOR			2 (0.01)	2 (0.03)	4 (0.01)
PROPOFOL	6 (0.10)	8 (0.05)	5 (0.02)	2 (0.03)	21 (0.03)
PROPOLUS			1 (0.00)		1 (0.00)
PROPOXYPHENE HCL		1 (0.01)			1 (0.00)
PROPOXYPHENE HCL AND A				1 (0.01)	1 (0.00)
PROPOXYPHENE HYDROCHLO			6 (0.02)		6 (0.01)
PROPOXYPHENE NAPSYLATE		1 (0.01)			1 (0.00)
PROPOXYPHENE NAPSYLATE				1 (0.01)	1 (0.00)
PROPRANOLOL		14 (0.08)	11 (0.04)	2 (0.03)	27 (0.04)
PROPRANOLOL HYDROCHLOR	1 (0.02)	1 (0.01)	3 (0.01)	1 (0.01)	6 (0.01)
PROPULSID			2 (0.01)		2 (0.00)
PROPYDERM				1 (0.01)	1 (0.00)
PROPYLENE GLYCOL	2 (0.03)				2 (0.00)
PROPYLTHIOURACIL		1 (0.01)	1 (0.00)		2 (0.00)
PROPYLTHIOURACIL TABLE			1 (0.00)		1 (0.00)
PRORENAL				1 (0.01)	1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PROSCAR		4 (0.02)	9 (0.03)	6 (0.08)	19 (0.03)
PROSCOPE			1 (0.00)		1 (0.00)
PROSCOPE 300(IOPROMIDE			1 (0.00)		1 (0.00)
PROSTACUR (FLUTAMIDE)				1 (0.01)	1 (0.00)
PROSTACYCLIN (1 (0.00)		1 (0.00)
PROSTACYCLIN (EPOPROST			1 (0.00)		1 (0.00)
PROSTAL			4 (0.01)		4 (0.01)
PROSTIN VR PEDIATRIC	1 (0.02)				1 (0.00)
PROSTINE	2 (0.03)				2 (0.00)
PROTAMINE SULFATE			2 (0.01)		2 (0.00)
PROTAPHANE		2 (0.01)	3 (0.01)		5 (0.01)
PROTAPHANE PENFILL			1 (0.00)		1 (0.00)
PROTHIADEN			1 (0.00)		1 (0.00)
PROTON PUMP INHIBITOR		1 (0.01)		1 (0.01)	2 (0.00)
PROTONIX	3 (0.05)	28 (0.16)	48 (0.16)	14 (0.18)	93 (0.15)
PROTONIX ^WYETHY-AYERS		1 (0.01)			1 (0.00)
PROTOPIC	9 (0.15)	6 (0.04)	9 (0.03)		24 (0.04)
PROTOVIT (VITAMINS NOS	1 (0.02)				1 (0.00)
PROVASIN TAB		1 (0.01)	1 (0.00)		2 (0.00)
PROVENTIL	1 (0.02)	6 (0.04)	4 (0.01)		11 (0.02)
PROVENTIL-HFA				2 (0.03)	2 (0.00)
PROVERA		3 (0.02)	93 (0.31)	4 (0.05)	100 (0.16)
PROVETA TABLET (MEDROX			1 (0.00)		1 (0.00)
PROVIGIL	1 (0.02)	17 (0.10)	6 (0.02)	1 (0.01)	25 (0.04)
PROZAC	18 (0.30)	62 (0.36)	75 (0.25)	8 (0.10)	163 (0.27)
PRYLTEC			2 (0.01)		2 (0.00)
PSEUDOEPHEDRINE			4 (0.01)		4 (0.01)
PSEUDOEPHEDRINE HCL	1 (0.02)		2 (0.01)		3 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PSEUDOEPHEDRINE HYDROC	1 (0.02)	1 (0.01)			2 (0.00)
PSYCHOLEPTICS (PSYCHOL	1 (0.02)				1 (0.00)
PSYCHOTROPIC DRUGS		1 (0.01)			1 (0.00)
PSYLLIUM HUSK			1 (0.00)		1 (0.00)
PULMICORT	9 (0.15)	5 (0.03)	3 (0.01)	3 (0.04)	20 (0.03)
PULMICORT RESPULES	1 (0.02)		1 (0.00)		2 (0.00)
PULSMARIN A	2 (0.03)				2 (0.00)
PURAN T4		1 (0.01)	3 (0.01)		4 (0.01)
PURGATIVES AND CLYSTER			1 (0.00)		1 (0.00)
PURIFIED PROTEIN DERIV		1 (0.01)			1 (0.00)
PURINETHOL	3 (0.05)	1 (0.01)			4 (0.01)
PURSENNID	3 (0.05)		1 (0.00)		4 (0.01)
PYOSTACINE				1 (0.01)	1 (0.00)
PYRALGINUM	1 (0.02)				1 (0.00)
PYRIDIUM(PHENAZOPYRIDI			1 (0.00)		1 (0.00)
PYRIDOSTIGMINE BROMIDE			1 (0.00)		1 (0.00)
PYRIDOSTIGMINE BROMIDE			1 (0.00)		1 (0.00)
PYRIDOXINE			1 (0.00)		1 (0.00)
PYRIDOXINE HCL		2 (0.01)	3 (0.01)		5 (0.01)
PYRINAZIN	1 (0.02)			2 (0.03)	3 (0.00)
QUESTRAN			1 (0.00)		1 (0.00)
QUETIAPINE	4 (0.07)	9 (0.05)	3 (0.01)		16 (0.03)
QUETIAPINE FUMARATE	3 (0.05)	6 (0.04)	5 (0.02)		14 (0.02)
QUILONUM RETARD		2 (0.01)	6 (0.02)	1 (0.01)	9 (0.01)
QUINAPRIL		3 (0.02)	10 (0.03)	2 (0.03)	15 (0.02)
QUINAPRIL HCL		1 (0.01)	4 (0.01)	1 (0.01)	6 (0.01)
QUININE			3 (0.01)		3 (0.00)
QUININE SULFATE		2 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
QUININE SULPHATE			1 (0.00)	1 (0.01)	2 (0.00)
QVAR (BECLOMETASONE DI			1 (0.00)		1 (0.00)
QVAR 40			1 (0.00)		1 (0.00)
QVAR 80			1 (0.00)		1 (0.00)
R115777		1 (0.01)			1 (0.00)
RABEPRAZOLE (RABEPRAZO		1 (0.01)			1 (0.00)
RABEPRAZOLE SODIUM		2 (0.01)	11 (0.04)	2 (0.03)	15 (0.02)
RADIATION		2 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)
RADIATION THERAPY	1 (0.02)	3 (0.02)	21 (0.07)		25 (0.04)
RADIATION THERAPY (RAD			1 (0.00)		1 (0.00)
RADIATION THERAPY NO D		1 (0.01)	1 (0.00)		2 (0.00)
RADICUT				2 (0.03)	2 (0.00)
RADIO-ABLATION		1 (0.01)			1 (0.00)
RADIOTHERAPY	1 (0.02)	4 (0.02)	8 (0.03)	1 (0.01)	14 (0.02)
RADIOTHERAPY TO BREAST				1 (0.01)	1 (0.00)
RALOXIFENE HCL			7 (0.02)	2 (0.03)	9 (0.01)
RAMIPRIL		4 (0.02)	26 (0.09)	7 (0.09)	37 (0.06)
RAMOSETRON (RAMOSETRON			1 (0.00)		1 (0.00)
RANAGEL (SEVELAMER HYD		1 (0.01)			1 (0.00)
RANIDITINE (RANIDITINE			1 (0.00)		1 (0.00)
RANITIDINE	7 (0.12)	5 (0.03)	29 (0.10)	5 (0.06)	46 (0.08)
RANITIDINE (RANITIDINE		1 (0.01)			1 (0.00)
RANITIDINE HCL			4 (0.01)	2 (0.03)	6 (0.01)
RANITIDINE HYDROCHLORI	1 (0.02)	3 (0.02)	3 (0.01)	2 (0.03)	9 (0.01)
RAPAMUNE	7 (0.12)	20 (0.12)	36 (0.12)		63 (0.10)
RAPAMUNE		1 (0.01)			1 (0.00)
RAPIFEN			1 (0.00)		1 (0.00)
RAPIMUNE			1 (0.00)		1 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
RAPTIVA		14 (0.08)	13 (0.04)	1 (0.01)	28 (0.05)
RAPTIVA (EFALIZUMAB) P			1 (0.00)		1 (0.00)
RAPTIVA(EFALIZUMAB) PW		1 (0.01)	1 (0.00)		2 (0.00)
RAZADYNE			1 (0.00)	5 (0.06)	6 (0.01)
RAZADYNE ER				3 (0.04)	3 (0.00)
REBETOL	1 (0.02)	7 (0.04)	8 (0.03)		16 (0.03)
REBETRON		1 (0.01)			1 (0.00)
REBETRON SCHERIN		1 (0.01)			1 (0.00)
REBIF	4 (0.07)	48 (0.28)	27 (0.09)		79 (0.13)
REBIF (BETA FERON BETA)			1 (0.00)		1 (0.00)
REBIF (INTERFERON BETA		3 (0.02)	2 (0.01)		5 (0.01)
REBIF (INTREFERON BETA		1 (0.01)			1 (0.00)
RECITAL	1 (0.02)				1 (0.00)
RECLIPSEN (WATSON LABO	1 (0.02)				1 (0.00)
RECLIPSEN (WATSON LABO	1 (0.02)				1 (0.00)
RECOMBINATE	4 (0.07)				4 (0.01)
RED BLOOD CELLS		4 (0.02)	3 (0.01)		7 (0.01)
RED YEAST RICE			1 (0.00)		1 (0.00)
REDUCTIL 10MG		2 (0.01)			2 (0.00)
REFACTO	25 (0.42)	1 (0.01)	2 (0.01)		28 (0.05)
REGLAN		2 (0.01)	2 (0.01)	2 (0.03)	6 (0.01)
REGLAN			1 (0.00)		1 (0.00)
REGRANEX	1 (0.02)				1 (0.00)
REGULAR INSULIN		1 (0.01)	2 (0.01)		3 (0.00)
RELACORE		1 (0.01)			1 (0.00)
RELACORE CARTER REED C		1 (0.01)			1 (0.00)
RELAFEN		5 (0.03)	5 (0.02)	4 (0.05)	14 (0.02)
RELENZA	2 (0.03)	2 (0.01)			4 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
RELPAX	3 (0.05)	4 (0.02)	3 (0.01)		10 (0.02)
REMERGON 30			1 (0.00)		1 (0.00)
REMERON	2 (0.03)	14 (0.08)	10 (0.03)	3 (0.04)	29 (0.05)
REMESTYP			1 (0.00)		1 (0.00)
REMICADE	14 (0.24)	52 (0.30)	58 (0.19)	8 (0.10)	132 (0.22)
REMINARON			1 (0.00)		1 (0.00)
REMINYL			2 (0.01)	10 (0.13)	12 (0.02)
REMODULIN	1 (0.02)	4 (0.02)	1 (0.00)		6 (0.01)
REMODULIN (ALFACALCIDO		1 (0.01)			1 (0.00)
RENAGEL	3 (0.05)	3 (0.02)	7 (0.02)	2 (0.03)	15 (0.02)
RENITEC			3 (0.01)		3 (0.00)
RENITEC /NET/ (ENALA			1 (0.00)		1 (0.00)
RENIVACE		1 (0.01)	2 (0.01)	3 (0.04)	6 (0.01)
RENOVA		1 (0.01)			1 (0.00)
REOPRO			3 (0.01)		3 (0.00)
REPAGLINIDE		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
REPAGLINIDE (REPAGLINI				3 (0.04)	3 (0.00)
REPRODUCTIVE CELLS HUM		1 (0.01)	1 (0.00)		2 (0.00)
REQUIP		17 (0.10)	45 (0.15)	10 (0.13)	72 (0.12)
RESERPINE				2 (0.03)	2 (0.00)
RESPITANN PD CARBETAP	1 (0.02)				1 (0.00)
RESTAMIN			1 (0.00)		1 (0.00)
RESTASIS			1 (0.00)		1 (0.00)
RESTORIL		11 (0.06)	9 (0.03)	4 (0.05)	24 (0.04)
RESTYLANE (HYALURONIC		1 (0.01)			1 (0.00)
RETA FYLLIN			1 (0.00)		1 (0.00)
RETAPLASE (RETAPLASE)			1 (0.00)		1 (0.00)
RETEPLASE			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
RETEPLASE			1 (0.00)		1 (0.00)
RETEPLASE (RETEPLASE)		14 (0.08)	35 (0.12)		49 (0.08)
RETEVASE			4 (0.01)		4 (0.01)
RETIN-A	1 (0.02)	2 (0.01)	1 (0.00)		4 (0.01)
RETROVIR	4 (0.07)	18 (0.11)	2 (0.01)		24 (0.04)
REVATIO	3 (0.05)			2 (0.03)	5 (0.01)
REVIA		1 (0.01)			1 (0.00)
REVLIMID			39 (0.13)	29 (0.37)	68 (0.11)
REVOXYL TABLET				1 (0.01)	1 (0.00)
REXALL TRANSDERMAL NIC		1 (0.01)			1 (0.00)
REYATAC (ATAZANAVIR SU		1 (0.01)			1 (0.00)
REYATAZ	3 (0.05)	17 (0.10)	7 (0.02)		27 (0.04)
RHEUMATREX		1 (0.01)	4 (0.01)		5 (0.01)
RHEUMATREX 9METHOTREXA				1 (0.01)	1 (0.00)
RHINADVIL (IBUPROFEN/P	1 (0.02)	1 (0.01)			2 (0.00)
RHINOCORT	1 (0.02)	2 (0.01)	5 (0.02)		8 (0.01)
RHINOLAST			3 (0.01)		3 (0.00)
RHOPHYLAC (ANTI-D IMMU	1 (0.02)				1 (0.00)
RIBASPHERE		9 (0.05)	4 (0.01)		13 (0.02)
RIBASPHERE/RIBAVIRIN/T		1 (0.01)			1 (0.00)
RIBAVIRIN	1 (0.02)	12 (0.07)	11 (0.04)		24 (0.04)
RIBAVIRIN (NGX) (RIBAV			1 (0.00)		1 (0.00)
RIBOFLAVINE 400		1 (0.01)			1 (0.00)
RID MOUSSE	1 (0.02)				1 (0.00)
RID SHAMPOO + CONDITIO	1 (0.02)				1 (0.00)
RIFABUTIN (RIFABUTIN)			1 (0.00)		1 (0.00)
RIFADIN		2 (0.01)	8 (0.03)	1 (0.01)	11 (0.02)
RIFADIN (RIFAMPICIN) P			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
RIFAMPICIN	3 (0.05)	6 (0.04)	3 (0.01)	2 (0.03)	14 (0.02)
RIFAMPIN			2 (0.01)		2 (0.00)
RIFAMPIN AND ISONIAZID	2 (0.03)	1 (0.01)	1 (0.00)		4 (0.01)
RIFATER		2 (0.01)			2 (0.00)
RIFINAH			2 (0.01)		2 (0.00)
RILMENIDINE PHOSPHATE		2 (0.01)			2 (0.00)
RILUTEK	2 (0.03)		5 (0.02)	1 (0.01)	8 (0.01)
RILUZOLE			1 (0.00)		1 (0.00)
RIMACTANE				2 (0.03)	2 (0.00)
RIMATIL				1 (0.01)	1 (0.00)
RIMIFON		1 (0.01)			1 (0.00)
RINDERON		1 (0.01)	4 (0.01)		5 (0.01)
RINGER SOLUTION			1 (0.00)		1 (0.00)
RINGER'S			2 (0.01)		2 (0.00)
RISEDRONATE (RISEDRONA			1 (0.00)		1 (0.00)
RISEDRONATE MONOSODIQU		2 (0.01)			2 (0.00)
RISEDRONATE SODIUM	1 (0.02)	2 (0.01)	6 (0.02)		9 (0.01)
RISEDRONIC ACID				1 (0.01)	1 (0.00)
RISORDAN			1 (0.00)		1 (0.00)
RISPERDAL	38 (0.64)	50 (0.29)	34 (0.11)	11 (0.14)	133 (0.22)
RISPERDAL		1 (0.01)			1 (0.00)
RISPERDAL /SWE/ (RI		1 (0.01)			1 (0.00)
RISPERDAL /SWE/ (RISP		1 (0.01)			1 (0.00)
RISPERDAL /SWE/ (RISPE			2 (0.01)		2 (0.00)
RISPERDAL /SWE/ (RISPE			1 (0.00)		1 (0.00)
RISPERDAL /SWE/(RISPER		1 (0.01)			1 (0.00)
RISPERDAL /SWE/RISPERI			1 (0.00)		1 (0.00)
RISPERDAL CONSTA	3 (0.05)	23 (0.13)	3 (0.01)	1 (0.01)	30 (0.05)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
RISPERDAL CONSTA (RISP		1 (0.01)			1 (0.00)
RISPERDAL CONSTA (RISP		1 (0.01)			1 (0.00)
RISPERDAL CONSTA 9RISP			1 (0.00)		1 (0.00)
RISPERDAL/SWE/(RISPERI		2 (0.01)	1 (0.00)		3 (0.00)
RISPERIDONE	13 (0.22)	18 (0.11)	14 (0.05)		45 (0.07)
RITALIN	34 (0.58)	9 (0.05)	13 (0.04)		56 (0.09)
RITALIN LA	7 (0.12)	1 (0.01)			8 (0.01)
RITONAVIR	1 (0.02)	14 (0.08)	3 (0.01)	1 (0.01)	19 (0.03)
RITONAVIR SOFT GELATIN			2 (0.01)		2 (0.00)
RITUXAN	4 (0.07)	8 (0.05)	15 (0.05)	7 (0.09)	34 (0.06)
RITUXAN (RITUXIMAB) CO			1 (0.00)		1 (0.00)
RITUXAN (RITUXIMAB) CO		1 (0.01)	1 (0.00)		2 (0.00)
RITUXIMAB		7 (0.04)	10 (0.03)	4 (0.05)	21 (0.03)
RITUXIMAB (RITUXIMAB)		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
RITUXIMAB 375 MG/M2				1 (0.01)	1 (0.00)
RITUXIMAB OR PLACEBO (1 (0.02)				1 (0.00)
RITUXIMAB OR PLACEBO (1 (0.01)			1 (0.00)
RITUXIMIAB			1 (0.00)		1 (0.00)
RIVASTIGMINE			1 (0.00)	1 (0.01)	2 (0.00)
RIVOTRIL	4 (0.07)	2 (0.01)	11 (0.04)	1 (0.01)	18 (0.03)
RIZABEN	1 (0.02)				1 (0.00)
RIZE	1 (0.02)			3 (0.04)	4 (0.01)
RIZEN			2 (0.01)		2 (0.00)
ROACCUTAN	15 (0.25)	2 (0.01)			17 (0.03)
ROACCUTANE	28 (0.47)	12 (0.07)	2 (0.01)		42 (0.07)
ROACCUTANE ROCH		1 (0.01)			1 (0.00)
ROACCUTANE GEL		1 (0.01)			1 (0.00)
ROACUTAN	7 (0.12)	3 (0.02)			10 (0.02)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ROBAXIN	1 (0.02)	1 (0.01)	5 (0.02)		7 (0.01)
ROBITUSSIN			1 (0.00)	1 (0.01)	2 (0.00)
ROBITUSSIN-DM		3 (0.02)			3 (0.00)
ROCEPHIN	10 (0.17)	8 (0.05)	17 (0.06)	9 (0.12)	44 (0.07)
ROCEPHINE (CEFTRIAZONE)	1 (0.02)				1 (0.00)
RODOGYL			1 (0.00)		1 (0.00)
ROFECOXIB		1 (0.01)	3 (0.01)	2 (0.03)	6 (0.01)
ROFERON-A		4 (0.02)	1 (0.00)		5 (0.01)
ROGAINE	3 (0.05)	4 (0.02)	4 (0.01)		11 (0.02)
ROGAINE 5	1 (0.02)				1 (0.00)
ROHYPNOL	1 (0.02)	1 (0.01)		1 (0.01)	3 (0.00)
ROHYPNOL (FLUNITRAZEPAM)		1 (0.01)			1 (0.00)
ROHYPNOL /NET/ (FLUNITRAZEPAM)		2 (0.01)			2 (0.00)
ROLAIDS (MAGNESIUM HYDROXIDE)		1 (0.01)			1 (0.00)
ROLAIDS EXTRA STRENGTH			1 (0.00)		1 (0.00)
ROPINIROLE			4 (0.01)	1 (0.01)	5 (0.01)
ROPINIROLE HYDROCHLORIDE				1 (0.01)	1 (0.00)
ROSAC CREAM 10% / 5% S			1 (0.00)		1 (0.00)
ROSIGLITAZONE		2 (0.01)	2 (0.01)		4 (0.01)
ROSIGLITAZONE MALEATE		1 (0.01)	2 (0.01)	2 (0.03)	5 (0.01)
ROSUVASTATIN		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
ROSUVASTATIN 10MG ASTR			1 (0.00)		1 (0.00)
ROSUVASTATIN CALCIUM		1 (0.01)			1 (0.00)
ROVALCYTE			1 (0.00)		1 (0.00)
ROVAMYCINE			3 (0.01)		3 (0.00)
ROXATIDINE ACETATE HCL			1 (0.00)		1 (0.00)
ROXICET				1 (0.01)	1 (0.00)
ROXICODONE		3 (0.02)			3 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ROZEREM	3 (0.05)	6 (0.04)	16 (0.05)	2 (0.03)	27 (0.04)
RUBINTUSSIN CF?			1 (0.00)		1 (0.00)
RUBOZINC			1 (0.00)		1 (0.00)
RULID		2 (0.01)	1 (0.00)		3 (0.00)
RYTHMODAN				1 (0.01)	1 (0.00)
RYTHMOL	1 (0.02)		8 (0.03)	4 (0.05)	13 (0.02)
RYTMONORM (PROPAFENONE			1 (0.00)		1 (0.00)
SABRILEX	1 (0.02)				1 (0.00)
SAIZEN	2 (0.03)				2 (0.00)
SALAZOPYRIN			3 (0.01)		3 (0.00)
SALBUTAMOL	3 (0.05)	3 (0.02)	7 (0.02)	5 (0.06)	18 (0.03)
SALBUTAMOL	1 (0.02)				1 (0.00)
SALBUTAMOL (SALBUTAMOL	10 (0.17)		1 (0.00)		11 (0.02)
SALBUTAMOL SULFATE			1 (0.00)		1 (0.00)
SALBUTAMOL SULPHATE	1 (0.02)	2 (0.01)			3 (0.00)
SALIGREN			1 (0.00)		1 (0.00)
SALINE MIXTURE (AMMONI	1 (0.02)				1 (0.00)
SALMETEROL			4 (0.01)		4 (0.01)
SALMETEROL DISKUS (GLA			1 (0.00)		1 (0.00)
SALMETEROL XINAFOATE			1 (0.00)		1 (0.00)
SALMETEROL XINAFOATE A			1 (0.00)		1 (0.00)
SALMETEROL/FLUTICASONE				1 (0.01)	1 (0.00)
SALSALATE 500MG			1 (0.00)		1 (0.00)
SAMARIUM [153 SM] LEXI		1 (0.01)			1 (0.00)
SANCTURA	1 (0.02)			6 (0.08)	7 (0.01)
SANCTURA (TROSPIUM CHL				1 (0.01)	1 (0.00)
SANDIMMUNE	4 (0.07)	4 (0.02)	8 (0.03)		16 (0.03)
SANDOGLOBULIN			1 (0.00)		1 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
SANDOGLOBULIN 6G (IMMU	1 (0.02)				1 (0.00)
SANDOSTATIN	1 (0.02)	1 (0.01)	10 (0.03)		12 (0.02)
SANDOSTATIN LAR		2 (0.01)	10 (0.03)	2 (0.03)	14 (0.02)
SANDOSTATIN LAR DEPOT(1 (0.00)		1 (0.00)
SANMIGRAN		1 (0.01)			1 (0.00)
SANSERT		1 (0.01)			1 (0.00)
SAQUINAVIR		1 (0.01)	1 (0.00)		2 (0.00)
SARAFEN INCORRECT PROD			1 (0.00)		1 (0.00)
SARGENTI RC -2B		1 (0.01)			1 (0.00)
SARGRAMOSTIN IV			1 (0.00)		1 (0.00)
SAROTEX			1 (0.00)		1 (0.00)
SAVARINE	1 (0.02)				1 (0.00)
SAW PALMETTO			2 (0.01)		2 (0.00)
SAWACILLIN	9 (0.15)	3 (0.02)	2 (0.01)		14 (0.02)
SAXIZON			1 (0.00)		1 (0.00)
SB-743921 INJECTION			1 (0.00)		1 (0.00)
SCOPOLAMINE AMINOXIDE		1 (0.01)			1 (0.00)
SEASONABLE (LEVONORGES	1 (0.02)				1 (0.00)
SEASONALE		4 (0.02)	1 (0.00)		5 (0.01)
SECOTEX (TAMSULOSIN HY			2 (0.01)		2 (0.00)
SECOTEX CAPSULES				1 (0.01)	1 (0.00)
SECOTEX CAPSULES 0.4MG			6 (0.02)	2 (0.03)	8 (0.01)
SECTRAL			3 (0.01)	1 (0.01)	4 (0.01)
SEDIEL		2 (0.01)			2 (0.00)
SEGURIL				3 (0.04)	3 (0.00)
SEIZURE MEDICATION			1 (0.00)		1 (0.00)
SEIZURE MEDICATIONS	1 (0.02)				1 (0.00)
SELBEX		2 (0.01)	3 (0.01)	7 (0.09)	12 (0.02)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
SELBEX (TEPRENONE)		1 (0.01)	2 (0.01)		3 (0.00)
SELEGILINE HCL			1 (0.00)	2 (0.03)	3 (0.00)
SELENE		1 (0.01)			1 (0.00)
SELENIUM SULFIDE	1 (0.02)		1 (0.00)		2 (0.00)
SELEPARINA			1 (0.00)		1 (0.00)
SELOKEEN			2 (0.01)		2 (0.00)
SELOKEN			7 (0.02)	3 (0.04)	10 (0.02)
SELOKEN ZOC (METOPROLOL)				1 (0.01)	1 (0.00)
SEMISODIUM VALPROATE		1 (0.01)			1 (0.00)
SENNA	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
SENNA FRUIT		2 (0.01)			2 (0.00)
SENNA S			1 (0.00)		1 (0.00)
SENNOSIDE			2 (0.01)		2 (0.00)
SENOKOT		3 (0.02)	2 (0.01)		5 (0.01)
SENOKOT-S TABLETS		1 (0.01)			1 (0.00)
SENSIBIT	1 (0.02)				1 (0.00)
SENSIPAR		1 (0.01)		2 (0.03)	3 (0.00)
SENSODYNE EXTRA WHITEN			1 (0.00)		1 (0.00)
SENSODYNE F TOOTHPASTE			1 (0.00)		1 (0.00)
SEPAZON		1 (0.01)			1 (0.00)
SEPTOCAINE	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
SEPTRA	4 (0.07)	11 (0.06)	2 (0.01)		17 (0.03)
SEPTRA DS	3 (0.05)	1 (0.01)			4 (0.01)
SEPTRIN		1 (0.01)			1 (0.00)
SERAX		2 (0.01)			2 (0.00)
SERENASE			2 (0.01)		2 (0.00)
SERESTA		1 (0.01)	1 (0.00)		2 (0.00)
SERETIDE	7 (0.12)	3 (0.02)	9 (0.03)	2 (0.03)	21 (0.03)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
SERETIDE (FLUTICASONE/		1 (0.01)			1 (0.00)
SERETIDE (SALMETEROL/F		1 (0.01)			1 (0.00)
SERETIDE AEROSOL				1 (0.01)	1 (0.00)
SERETIDE DISKUS	1 (0.02)	3 (0.02)	1 (0.00)		5 (0.01)
SEREVENT	4 (0.07)	2 (0.01)	8 (0.03)	1 (0.01)	15 (0.02)
SERMION			3 (0.01)	4 (0.05)	7 (0.01)
SERMION (NICERGOLINE)				2 (0.03)	2 (0.00)
SEROPHENE		1 (0.01)			1 (0.00)
SEROPLEX (ESCITALOPRAM		3 (0.02)			3 (0.00)
SEROPRAM		1 (0.01)			1 (0.00)
SEROPRAM /SCH/ (CITALO			1 (0.00)		1 (0.00)
SEROPRAM /SCH/(CITALOP		1 (0.01)			1 (0.00)
SEROQUEL	42 (0.71)	96 (0.56)	37 (0.12)	13 (0.17)	188 (0.31)
SEROSTIM	1 (0.02)				1 (0.00)
SEROXAT	4 (0.07)	4 (0.02)	5 (0.02)	2 (0.03)	15 (0.02)
SEROXATE			1 (0.00)		1 (0.00)
SERTRALINE	4 (0.07)	11 (0.06)	14 (0.05)	3 (0.04)	32 (0.05)
SERTRALINE HCL		3 (0.02)	3 (0.01)	2 (0.03)	8 (0.01)
SERTRALINE HYDROCHLORI	1 (0.02)	4 (0.02)	2 (0.01)		7 (0.01)
SERZONE	1 (0.02)	18 (0.11)	27 (0.09)	1 (0.01)	47 (0.08)
SEVEN EP				2 (0.03)	2 (0.00)
SEVEN EP (ENZYMES NOS)			1 (0.00)		1 (0.00)
SEVERAL CARDIAC DRUGS			1 (0.00)		1 (0.00)
SEVOFLURANE	1 (0.02)	2 (0.01)	3 (0.01)		6 (0.01)
SEVREDOL		1 (0.01)			1 (0.00)
SEVREDOL TABLETS 20 MG				1 (0.01)	1 (0.00)
SHA-KU-YA-KU-KANN-ZO-U			1 (0.00)		1 (0.00)
SIBUTRAMINA 15MG BERAN		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
SIFROL		1 (0.01)	3 (0.01)		4 (0.01)
SIGMART			2 (0.01)		2 (0.00)
SILDENAFIL	1 (0.02)	1 (0.01)	4 (0.01)	6 (0.08)	12 (0.02)
SILDENAFIL 50 MG			1 (0.00)		1 (0.00)
SILDENAFIL CITRATE	2 (0.03)	4 (0.02)	12 (0.04)		18 (0.03)
SILECE			2 (0.01)		2 (0.00)
SILVADENE CREAM 1%	1 (0.02)				1 (0.00)
SILVER GENERATOR				1 (0.01)	1 (0.00)
SIMPLY SLEEP TYLENOL		1 (0.01)			1 (0.00)
SIMULECT		1 (0.01)	4 (0.01)		5 (0.01)
SIMVASTATIN	1 (0.02)	13 (0.08)	46 (0.15)	18 (0.23)	78 (0.13)
SIMVASTATIN (SIMVASTAT			1 (0.00)		1 (0.00)
SINEMET		4 (0.02)	36 (0.12)	23 (0.30)	63 (0.10)
SINEMET				1 (0.01)	1 (0.00)
SINEMET 50/200 CARBIDO			1 (0.00)		1 (0.00)
SINEMET CR			2 (0.01)	4 (0.05)	6 (0.01)
SINEQUAN		5 (0.03)	2 (0.01)		7 (0.01)
SINGULAIR	28 (0.47)	23 (0.13)	22 (0.07)	1 (0.01)	74 (0.12)
SINGULAIR (MONTELIKAST		1 (0.01)			1 (0.00)
SINTROM			9 (0.03)	3 (0.04)	12 (0.02)
SINUPRET FORTE			1 (0.00)		1 (0.00)
SINUS MEDICATION		1 (0.01)			1 (0.00)
SINUTAB REGULAR STRENG			1 (0.00)		1 (0.00)
SINUTAB SINUS EXTRA S		1 (0.01)			1 (0.00)
SIRDALUD		1 (0.01)	4 (0.01)		5 (0.01)
SIROLIMUS (SIROLIMUS,		1 (0.01)			1 (0.00)
SKELAXIN		10 (0.06)	12 (0.04)	7 (0.09)	29 (0.05)
SKENAN			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
SLEEP AID	1 (0.02)				1 (0.00)
SLEEPING PILL			1 (0.00)		1 (0.00)
SLEEPING PILL NOS		1 (0.01)			1 (0.00)
SLEEPING PILLS		1 (0.01)			1 (0.00)
SLOW-K			1 (0.00)		1 (0.00)
SLOZEM (DILTIAZEM HYDR				1 (0.01)	1 (0.00)
SOBREROL		1 (0.01)			1 (0.00)
SOBRIL		1 (0.01)			1 (0.00)
SODIUM BICARBONATE	1 (0.02)	2 (0.01)	1 (0.00)	2 (0.03)	6 (0.01)
SODIUM BICARBONATE IN		1 (0.01)		1 (0.01)	2 (0.00)
SODIUM CHLORIDE	1 (0.02)		1 (0.00)	2 (0.03)	4 (0.01)
SODIUM CHLORIDE 0.9%	2 (0.03)		1 (0.00)	1 (0.01)	4 (0.01)
SODIUM CHROMOGLYCAT		1 (0.01)			1 (0.00)
SODIUM FERROUS CITRATE		1 (0.01)			1 (0.00)
SODIUM RISEDRONATE			1 (0.00)		1 (0.00)
SOFRASOLONE (PREDNISOL				1 (0.01)	1 (0.00)
SOL-MEDROL				1 (0.01)	1 (0.00)
SOLANAX		5 (0.03)			5 (0.01)
SOLDACTONE				1 (0.01)	1 (0.00)
SOLDEM 3A		1 (0.01)	1 (0.00)		2 (0.00)
SOLDESAM			1 (0.00)		1 (0.00)
SOLIAN	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
SOLITA-T			1 (0.00)		1 (0.00)
SOLITAR T3	1 (0.02)				1 (0.00)
SOLON				2 (0.03)	2 (0.00)
SOLON (SOFALCONE)				1 (0.01)	1 (0.00)
SOLU-CORTEF	1 (0.02)	3 (0.02)	3 (0.01)	1 (0.01)	8 (0.01)
SOLU-DECORTIN-H (PREDN		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
SOLU-MEDROL	6 (0.10)	12 (0.07)	29 (0.10)	4 (0.05)	51 (0.08)
SOLULACT		2 (0.01)			2 (0.00)
SOLUMEDROL - UPJOHN			1 (0.00)		1 (0.00)
SOLUPRED	2 (0.03)	1 (0.01)	5 (0.02)		8 (0.01)
SOMA		18 (0.11)	10 (0.03)		28 (0.05)
SOMA COMPOUND W/ CODEI			1 (0.00)		1 (0.00)
SOMAC			1 (0.00)		1 (0.00)
SOMATROPIN (SOMATROPIN		3 (0.02)	2 (0.01)		5 (0.01)
SOMATROPIN (SOMATROPIN	10 (0.17)	14 (0.08)	5 (0.02)		29 (0.05)
SOMATROPIN (SOMATROPIN	3 (0.05)				3 (0.00)
SOMATROPIN(SOMATROPIN	1 (0.02)		1 (0.00)		2 (0.00)
SOMATROPIN(SOMATROPIN)	1 (0.02)				1 (0.00)
SOMAVERT		5 (0.03)	2 (0.01)		7 (0.01)
SOMINEX MAXIMUM STRENG		1 (0.01)			1 (0.00)
SONATA	2 (0.03)	2 (0.01)	3 (0.01)		7 (0.01)
SORAFENIB		3 (0.02)	15 (0.05)		18 (0.03)
SORIATANE	2 (0.03)	3 (0.02)	3 (0.01)		8 (0.01)
SORTIS			3 (0.01)		3 (0.00)
SORTIS (ATORVASTATIN)			2 (0.01)		2 (0.00)
SOTALOL HCL	1 (0.02)		14 (0.05)	6 (0.08)	21 (0.03)
SOTALOL HYDROCHLORIDE			1 (0.00)	1 (0.01)	2 (0.00)
SOTOLOL 120 MG			1 (0.00)		1 (0.00)
SOTRET	2 (0.03)				2 (0.00)
SPASFON		2 (0.01)			2 (0.00)
SPECIAFOLDINE	1 (0.02)	6 (0.04)	3 (0.01)		10 (0.02)
SPIRICORT				1 (0.01)	1 (0.00)
SPIRIVA		4 (0.02)	52 (0.17)	18 (0.23)	74 (0.12)
SPIRONOLACTONE	6 (0.10)	9 (0.05)	20 (0.07)	11 (0.14)	46 (0.08)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
SPIRONOLACTONE ALTIZID			1 (0.00)		1 (0.00)
SPIROPENT			2 (0.01)		2 (0.00)
SPORANOX			3 (0.01)	1 (0.01)	4 (0.01)
SPP100 +/- AMLDPINE VS			1 (0.00)		1 (0.00)
SSRI			1 (0.00)		1 (0.00)
ST JOHN'S WORT			1 (0.00)		1 (0.00)
ST JOHNS WORT			1 (0.00)		1 (0.00)
ST. JOSEPH ADULT CHEWA		2 (0.01)	1 (0.00)		3 (0.00)
STACKER 2			1 (0.00)		1 (0.00)
STADOL	3 (0.05)	20 (0.12)	1 (0.00)		24 (0.04)
STALEVO (CARBIDOPA, EN			1 (0.00)		1 (0.00)
STALEVO (CARBIDOPA, EN		1 (0.01)			1 (0.00)
STALEVO 100			9 (0.03)	1 (0.01)	10 (0.02)
STALEVO 150			1 (0.00)		1 (0.00)
STANBACK			1 (0.00)		1 (0.00)
STANGYL				1 (0.01)	1 (0.00)
STARLIX		2 (0.01)	13 (0.04)	3 (0.04)	18 (0.03)
STARSIS			4 (0.01)		4 (0.01)
STATIN (UNSPECIFIED)			1 (0.00)		1 (0.00)
STAVUDINE	4 (0.07)	7 (0.04)	5 (0.02)		16 (0.03)
STELAZINE			1 (0.00)		1 (0.00)
STEROID	1 (0.02)		1 (0.00)		2 (0.00)
STEROID (STEROID NOS)		1 (0.01)			1 (0.00)
STEROID BLOCK CERVICAL			1 (0.00)		1 (0.00)
STEROID NOS (STEROID N			1 (0.00)		1 (0.00)
STEROIDS	3 (0.05)	2 (0.01)	4 (0.01)		9 (0.01)
STEROIDS (CORTICOSTERO		1 (0.01)			1 (0.00)
STEROIDS (STEROID NOS)		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
STEROIDS (UNK INGREDIE		1 (0.01)			1 (0.00)
STEROIDS NOS	6 (0.10)	10 (0.06)	4 (0.01)		20 (0.03)
STI 571 VS IFN-ALPHA +		2 (0.01)	1 (0.00)		3 (0.00)
STILNOCT				1 (0.01)	1 (0.00)
STILNOCT			1 (0.00)		1 (0.00)
STILNOCT (ZOLPIDEM TAR			1 (0.00)		1 (0.00)
STILNOX	1 (0.02)	6 (0.04)	1 (0.00)	3 (0.04)	11 (0.02)
STILNOX (ZOLPIDEM)	1 (0.02)			1 (0.01)	2 (0.00)
STILNOX /FRA/ (ZOLPIDE	1 (0.02)				1 (0.00)
STIMATE		1 (0.01)			1 (0.00)
STOCRIN		1 (0.01)	4 (0.01)		5 (0.01)
STOOL SOFTENER (DOCUSA			1 (0.00)		1 (0.00)
STRATTERA	109 (1.84)	20 (0.12)	7 (0.02)		136 (0.22)
STRATTERA (ATOMOXETINE		1 (0.01)			1 (0.00)
STREPTASE			1 (0.00)		1 (0.00)
STREPTOMYCIN	2 (0.03)		1 (0.00)		3 (0.00)
STREPTOMYCIN (STREPTOM		1 (0.01)			1 (0.00)
STROMECTOL		1 (0.01)	2 (0.01)		3 (0.00)
STUDY MEDICATION NOT G			1 (0.00)		1 (0.00)
SU 11248			1 (0.00)		1 (0.00)
SU-011,248			2 (0.01)		2 (0.00)
SU-011,248 (SUNITINIB		1 (0.01)			1 (0.00)
SUBOXONE	1 (0.02)	2 (0.01)			3 (0.00)
SUBSTITOL RETARD KAPSE	1 (0.02)				1 (0.00)
SUBUTEX		1 (0.01)			1 (0.00)
SUCCINYLCHOLINE CHLORI	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
SUCRALFATE		2 (0.01)	11 (0.04)	1 (0.01)	14 (0.02)
SUDAFED (PSEUDOEPHEDRI		2 (0.01)	1 (0.00)		3 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
SUDAFED (SHOWER SOOTHE			1 (0.00)		1 (0.00)
SUDAFED 12 HOUR	4 (0.07)	4 (0.02)	2 (0.01)		10 (0.02)
SUDAFED COLD + SINUS (1 (0.01)			1 (0.00)
SUDAFED COLD + SINUS (1 (0.02)	1 (0.01)			2 (0.00)
SUDAFED PE (PHENYLEPHR	1 (0.02)	1 (0.01)			2 (0.00)
SUDAFED PE SINUS HEAD	1 (0.02)	2 (0.01)			3 (0.00)
SUDAFED PFIZER	1 (0.02)				1 (0.00)
SUDAFED PLUS (PSEUDOEP		2 (0.01)			2 (0.00)
SUDAFED SEVERE COLD CA		1 (0.01)			1 (0.00)
SUFENTA		2 (0.01)			2 (0.00)
SUFENTANIL CITRATE			1 (0.00)		1 (0.00)
SULFACET-R			2 (0.01)		2 (0.00)
SULFADIAZINE		1 (0.01)			1 (0.00)
SULFAMETHOXAZOLE			1 (0.00)		1 (0.00)
SULFAMETHOXAZOLE + TRI	1 (0.02)	6 (0.04)	4 (0.01)	2 (0.03)	13 (0.02)
SULFAMETHOXAZOLE AND T			1 (0.00)		1 (0.00)
SULFAMETHOXAZOLE W/TRI			1 (0.00)		1 (0.00)
SULFASALAZINE	1 (0.02)	11 (0.06)	12 (0.04)	1 (0.01)	25 (0.04)
SULFASALAZINE (WATSON	1 (0.02)				1 (0.00)
SULFUR (HOMEOPATHIC)		1 (0.01)			1 (0.00)
SULPERAZON (SULBACTAM,	3 (0.05)	1 (0.01)	1 (0.00)	2 (0.03)	7 (0.01)
SULPERAZONE (CEFOPERAZ			1 (0.00)		1 (0.00)
SULPIRIDE			4 (0.01)		4 (0.01)
SULTANOL	1 (0.02)	2 (0.01)			3 (0.00)
SUMATRIPTAN SUCCINATE	2 (0.03)	1 (0.01)			3 (0.00)
SUN BATH PROTECTIVE TA			1 (0.00)		1 (0.00)
SUNRYTHM				3 (0.04)	3 (0.00)
SUPPLEMENTS		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
SUPPOSITORY	2 (0.03)				2 (0.00)
SUPRAX		1 (0.01)			1 (0.00)
SURBRONC			1 (0.00)		1 (0.00)
SURGILUBE DK FOUGE		1 (0.01)			1 (0.00)
SURMONTIL			2 (0.01)	1 (0.01)	3 (0.00)
SUSTIVA	5 (0.08)	16 (0.09)	7 (0.02)		28 (0.05)
SUTENT		6 (0.04)	35 (0.12)	8 (0.10)	49 (0.08)
SUXAMETHONIUM CHLORIDE			1 (0.00)		1 (0.00)
SUXINUTIN	1 (0.02)				1 (0.00)
SYMBICORT	1 (0.02)		7 (0.02)	2 (0.03)	10 (0.02)
SYMBICORT (SYMBICORT)			1 (0.00)		1 (0.00)
SYMBICORT TURBUHALER ^				1 (0.01)	1 (0.00)
SYMBYAX	1 (0.02)	3 (0.02)		2 (0.03)	6 (0.01)
SYMBYAX (OLANZAPINE AN		1 (0.01)			1 (0.00)
SYMLIN		1 (0.01)			1 (0.00)
SYMMETREL	2 (0.03)	1 (0.01)	2 (0.01)	6 (0.08)	11 (0.02)
SYNAGIS	31 (0.52)				31 (0.05)
SYNAGIS (LIQUID) (PALI	1 (0.02)				1 (0.00)
SYNAGIS (PALIVIZUMAB)	3 (0.05)				3 (0.00)
SYNTHROID	18 (0.30)	102 (0.60)	229 (0.76)	56 (0.72)	405 (0.66)
SYNTHROID (LEVOTHYROXI			1 (0.00)		1 (0.00)
SYNTOCINON	1 (0.02)	1 (0.01)			2 (0.00)
TAC 3	1 (0.02)				1 (0.00)
TACHIPIRINA (PARACETAM		1 (0.01)			1 (0.00)
TACLONEX (CALCIPOTRIEN		1 (0.01)			1 (0.00)
TACROLIMUS		4 (0.02)	4 (0.01)		8 (0.01)
TACROLIMUS (TACROLIMUS	1 (0.02)				1 (0.00)
TACROLIMUS, CONTROL FO			3 (0.01)		3 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
TADALAFIL			1 (0.00)		1 (0.00)
TADALAFIL (TADALAFIL)		2 (0.01)			2 (0.00)
TADALAFIL (TADALAFIL)T		1 (0.01)			1 (0.00)
TAGAMET		1 (0.01)	13 (0.04)	1 (0.01)	15 (0.02)
TAGONIS			1 (0.00)		1 (0.00)
TAHOR			5 (0.02)		5 (0.01)
TAHOR (ATORVASTATIN)	2 (0.03)	2 (0.01)	2 (0.01)	1 (0.01)	7 (0.01)
TAKEPRON			1 (0.00)	1 (0.01)	2 (0.00)
TAKEPRON OD TABLETS 15			1 (0.00)		1 (0.00)
TALION				3 (0.04)	3 (0.00)
TALIPEXOLE HYDROCHLORI				1 (0.01)	1 (0.00)
TALWIN		2 (0.01)	1 (0.00)		3 (0.00)
TAMBOCOR			2 (0.01)	1 (0.01)	3 (0.00)
TAMIFLU	88 (1.49)	37 (0.22)	11 (0.04)	6 (0.08)	142 (0.23)
TAMOXIFEN		3 (0.02)	1 (0.00)		4 (0.01)
TAMOXIFEN CITRATE	2 (0.03)	15 (0.09)	29 (0.10)	4 (0.05)	50 (0.08)
TAMOXIFEN TABLETS			1 (0.00)		1 (0.00)
TAMOXIFEN TABLETS BP 1			1 (0.00)		1 (0.00)
TAMOXIFENO				1 (0.01)	1 (0.00)
TAMSULOSIN HCL			6 (0.02)	5 (0.06)	11 (0.02)
TAMSULOSIN HYDROCHLORI			2 (0.01)		2 (0.00)
TANAKAN			1 (0.00)		1 (0.00)
TANATRIL			2 (0.01)	2 (0.03)	4 (0.01)
TARCEVA		9 (0.05)	80 (0.26)	37 (0.48)	126 (0.21)
TARCOLIMUS			1 (0.00)		1 (0.00)
TARDYFERON		1 (0.01)	2 (0.01)	3 (0.04)	6 (0.01)
TARDYFERON B9		1 (0.01)			1 (0.00)
TARDYFERON-FOL (FERROU		1 (0.01)			1 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
TAREG		3 (0.02)	1 (0.00)	4 (0.05)	8 (0.01)
TAREG D			1 (0.00)		1 (0.00)
TARGET NTS 21MG	1 (0.02)				1 (0.00)
TARGET ORIGINAL 2MG		2 (0.01)	1 (0.00)		3 (0.00)
TARGOCID			4 (0.01)	1 (0.01)	5 (0.01)
TARGRETIN		3 (0.02)	4 (0.01)		7 (0.01)
TARIVID OPHTHALMIC			2 (0.01)		2 (0.00)
TARIVID OTIC SOLUTION		1 (0.01)			1 (0.00)
TARKA		1 (0.01)	5 (0.02)	2 (0.03)	8 (0.01)
TATHION (GLUTATHIONE)		1 (0.01)			1 (0.00)
TAVANIC		5 (0.03)	6 (0.02)		11 (0.02)
TAVANIC 500		1 (0.01)			1 (0.00)
TAVEGYL	1 (0.02)				1 (0.00)
TAVIST-D			2 (0.01)		2 (0.00)
TAVONIN				2 (0.03)	2 (0.00)
TAVOR	5 (0.08)	8 (0.05)	3 (0.01)		16 (0.03)
TAVOR /0027		1 (0.01)			1 (0.00)
TAVOR /00273201/		1 (0.01)	1 (0.00)		2 (0.00)
TAXILAN (PERAZINE)			2 (0.01)		2 (0.00)
TAXOL		28 (0.16)	62 (0.20)	16 (0.21)	106 (0.17)
TAXOTERE	1 (0.02)	8 (0.05)	42 (0.14)	3 (0.04)	54 (0.09)
TAXUS (TAMOXIFEN CITRA			2 (0.01)		2 (0.00)
TAZOCILLINE	2 (0.03)		1 (0.00)		3 (0.00)
TAZOCILLINE (PIPERACIL		1 (0.01)			1 (0.00)
TAZOCILLINE (PIPERACIL		2 (0.01)	1 (0.00)		3 (0.00)
TAZOCIN	1 (0.02)		1 (0.00)		2 (0.00)
TAZOCIN (PIPERACILLIN				2 (0.03)	2 (0.00)
TAZOCIN (PIPERACILLIN/	2 (0.03)		2 (0.01)		4 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
TAZONAM (PIPERACILLIN/			1 (0.00)		1 (0.00)
TAZTIA XT			1 (0.00)		1 (0.00)
TECHNETIUM TC-99M PENT			1 (0.00)		1 (0.00)
TECIPUL		1 (0.01)			1 (0.00)
TEDIVAX			1 (0.00)		1 (0.00)
TEETING TABLETS NONE H	1 (0.02)				1 (0.00)
TEGAFUR/GIMERACIL/OTER			1 (0.00)		1 (0.00)
TEGASEROD		2 (0.01)			2 (0.00)
TEGRETOL	37 (0.63)	47 (0.28)	20 (0.07)	12 (0.15)	116 (0.19)
TEGRETOL - LOW RELEASE			1 (0.00)		1 (0.00)
TEGRETOL-XR	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
TEICOPLANIN (TEICOPLAN		1 (0.01)			1 (0.00)
TELGIN G	1 (0.02)				1 (0.00)
TELITHROMYCIN		1 (0.01)	1 (0.00)		2 (0.00)
TELITHROMYCIN 400 MG T				1 (0.01)	1 (0.00)
TELMISARTAN			3 (0.01)		3 (0.00)
TELMISARTAN (TELMISART			2 (0.01)		2 (0.00)
TELZIR		4 (0.02)			4 (0.01)
TEMAZEPAM		9 (0.05)	14 (0.05)	6 (0.08)	29 (0.05)
TEMERIT		1 (0.01)			1 (0.00)
TEMESTA	4 (0.07)	3 (0.02)	3 (0.01)	2 (0.03)	12 (0.02)
TEMGESIC			1 (0.00)		1 (0.00)
TEMODAL	3 (0.05)		7 (0.02)		10 (0.02)
TEMODAR		3 (0.02)	4 (0.01)	1 (0.01)	8 (0.01)
TEMOZOLOMIDE CAPSULE		1 (0.01)			1 (0.00)
TEMOZOLOMIDE CAPSULES		2 (0.01)			2 (0.00)
TENECTEPLASE - UNKNOWN			1 (0.00)		1 (0.00)
TENEX	1 (0.02)				1 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
TENOFOVIR		6 (0.04)	2 (0.01)		8 (0.01)
TENOFOVIR DISOPROXIL F		1 (0.01)			1 (0.00)
TENORDATE			1 (0.00)		1 (0.00)
TENORETIC 100		2 (0.01)	1 (0.00)		3 (0.00)
TENORMIN	1 (0.02)	11 (0.06)	36 (0.12)	11 (0.14)	59 (0.10)
TENOX				1 (0.01)	1 (0.00)
TEPRENONE		1 (0.01)	3 (0.01)		4 (0.01)
TEQUIN	1 (0.02)	11 (0.06)	6 (0.02)	9 (0.12)	27 (0.04)
TERALITHE		1 (0.01)	1 (0.00)		2 (0.00)
TERAZOSIN			4 (0.01)	4 (0.05)	8 (0.01)
TERAZOSIN (TERAZOSIN)			1 (0.00)	1 (0.01)	2 (0.00)
TERAZOSIN 2 MG (SANDOZ			1 (0.00)		1 (0.00)
TERAZOSIN 5 MG			1 (0.00)		1 (0.00)
TERAZOSIN 5 MG CAPSULE			1 (0.00)		1 (0.00)
TERAZOSIN CAPS 5 MG AP			1 (0.00)		1 (0.00)
TERAZOSIN HCL			4 (0.01)	1 (0.01)	5 (0.01)
TERAZOSIN HYDROCHLORID				2 (0.03)	2 (0.00)
TERBINAFINE			1 (0.00)		1 (0.00)
TERBINAFINE HCL	2 (0.03)	1 (0.01)	3 (0.01)	1 (0.01)	7 (0.01)
TERBUTALINE		1 (0.01)			1 (0.00)
TERBUTALINE SULFATE		1 (0.01)	1 (0.00)		2 (0.00)
TERCIAN	1 (0.02)				1 (0.00)
TERCIAN (CYAMEMAZINE)		1 (0.01)			1 (0.00)
TERCIAN CYAMEMAZINE			1 (0.00)		1 (0.00)
TERIPARATIDE (TERIPARA				1 (0.01)	1 (0.00)
TERLIPRESSIN			1 (0.00)		1 (0.00)
TERMALGIN				2 (0.03)	2 (0.00)
TERNELIN		1 (0.01)	1 (0.00)		2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
TERRA-CORTRIL POLYMYXI			1 (0.00)		1 (0.00)
TERSIGAN			1 (0.00)		1 (0.00)
TESSALON	1 (0.02)		3 (0.01)		4 (0.01)
TESTOGEL 25 MG			2 (0.01)		2 (0.00)
TESTOSTERONE		4 (0.02)	2 (0.01)		6 (0.01)
TETRACYCLINE	3 (0.05)	2 (0.01)	2 (0.01)	3 (0.04)	10 (0.02)
TETRAMIDE				3 (0.04)	3 (0.00)
TEVETEN		1 (0.01)	3 (0.01)		4 (0.01)
TEVETEN HCT			1 (0.00)		1 (0.00)
TEVILOR RETARD (VENLAF			1 (0.00)		1 (0.00)
THALIDOMID			1 (0.00)		1 (0.00)
THALIDOMIDE	2 (0.03)	1 (0.01)	22 (0.07)	1 (0.01)	26 (0.04)
THALIDOMIDE (THALIDOM		1 (0.01)			1 (0.00)
THALIDOMIDE 100MG				1 (0.01)	1 (0.00)
THALIDOMIDE (THALIDOMI			2 (0.01)		2 (0.00)
THALIDOMIDE - PHARMION			2 (0.01)		2 (0.00)
THALIDOMIDE - PHARMION			1 (0.00)		1 (0.00)
THALIDOMIDE - PHARMION			1 (0.00)		1 (0.00)
THALIDOMIDE 200 MG			1 (0.00)		1 (0.00)
THALOMID		10 (0.06)	56 (0.19)	29 (0.37)	95 (0.16)
THALOMID 300MG + 50M	1 (0.02)				1 (0.00)
THEO-24			1 (0.00)		1 (0.00)
THEO-DUR	1 (0.02)	3 (0.02)	4 (0.01)	2 (0.03)	10 (0.02)
THEOCHRON			1 (0.00)		1 (0.00)
THEOPHYLLINE	10 (0.17)	11 (0.06)	10 (0.03)	7 (0.09)	38 (0.06)
THERACYS			1 (0.00)		1 (0.00)
THERAGESIC			1 (0.00)		1 (0.00)
THERAPEUTIC RADIOPHARM			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
THERAPY UNSPECIFIED		1 (0.01)	1 (0.00)		2 (0.00)
THIAMINE		4 (0.02)	2 (0.01)		6 (0.01)
THIAMINE HCL		1 (0.01)	1 (0.00)		2 (0.00)
THIETHYLPERAZINE MALEA	1 (0.02)				1 (0.00)
THIOGUANINE			1 (0.00)		1 (0.00)
THIOLA (TIOPRONIN) (TI		1 (0.01)			1 (0.00)
THIOPENTAL SODIUM	1 (0.02)	4 (0.02)	2 (0.01)		7 (0.01)
THIOPETA	2 (0.03)				2 (0.00)
THIORIDAZINE HCL			3 (0.01)		3 (0.00)
THIOTEPA	2 (0.03)				2 (0.00)
THORAZINE		2 (0.01)	3 (0.01)		5 (0.01)
THROMBO ASS			2 (0.01)		2 (0.00)
THYM-UVOCAL	1 (0.02)				1 (0.00)
THYMOGLOBULIN	1 (0.02)	2 (0.01)	4 (0.01)		7 (0.01)
THYRADIN		1 (0.01)	3 (0.01)		4 (0.01)
THYRADIN S				1 (0.01)	1 (0.00)
THYRADIN S TABLETS			1 (0.00)		1 (0.00)
THYRAX		1 (0.01)	1 (0.00)		2 (0.00)
THYROGEN		2 (0.01)	2 (0.01)		4 (0.01)
THYROID			1 (0.00)		1 (0.00)
THYROID PILLS			1 (0.00)		1 (0.00)
THYROID TAB		10 (0.06)	18 (0.06)	3 (0.04)	31 (0.05)
THYROID TABLETS USP				2 (0.03)	2 (0.00)
THYROXIN			3 (0.01)		3 (0.00)
THYROXINE		3 (0.02)	5 (0.02)		8 (0.01)
THYROXINE SODIUM		1 (0.01)	1 (0.00)		2 (0.00)
TIAGABINE HCL	1 (0.02)				1 (0.00)
TIANEPTINE SODIUM				1 (0.01)	1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
TIAPRIDAL			1 (0.00)		1 (0.00)
TIAPROFENIC ACID		2 (0.01)			2 (0.00)
TIATRAL			2 (0.01)		2 (0.00)
TIAZAC		4 (0.02)	6 (0.02)	1 (0.01)	11 (0.02)
TIBIALIS TENDON #05005		1 (0.01)			1 (0.00)
TICARCILLIN (TICARCILL			2 (0.01)		2 (0.00)
TICE BCG			1 (0.00)		1 (0.00)
TICLID			1 (0.00)	2 (0.03)	3 (0.00)
TICLOPIDINE HCL			9 (0.03)	4 (0.05)	13 (0.02)
TICLOPIDINE HYDROCHLOR			1 (0.00)		1 (0.00)
TICLOPIDINE HYDROCHLOR			1 (0.00)		1 (0.00)
TICLOPIODINE			1 (0.00)		1 (0.00)
TIENAM			1 (0.00)		1 (0.00)
TIGECYCLINE		1 (0.01)			1 (0.00)
TIGECYCLINE 50MG WYE			1 (0.00)		1 (0.00)
TIGECYCLINE (TIGECYCLI		1 (0.01)	2 (0.01)		3 (0.00)
TIGECYCLINE (TYGECYCLI		1 (0.01)			1 (0.00)
TIKOSYN		1 (0.01)	11 (0.04)	1 (0.01)	13 (0.02)
TILDIEM 200 R			1 (0.00)		1 (0.00)
TILIDIN COMP ^ALIUD PH			4 (0.01)		4 (0.01)
TIMENTIN			1 (0.00)	2 (0.03)	3 (0.00)
TIMOLOL MALEATE			2 (0.01)	4 (0.05)	6 (0.01)
TIMOPTIC			3 (0.01)	4 (0.05)	7 (0.01)
TIMOPTIC-XE				1 (0.01)	1 (0.00)
TIMOPTOL-XE		1 (0.01)			1 (0.00)
TIMOPTOL-XE (TIMOLOL M		1 (0.01)			1 (0.00)
TINACTIN	1 (0.02)				1 (0.00)
TINENTIN			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
TINZAPARIN			2 (0.01)		2 (0.00)
TIOTROPIUM			1 (0.00)		1 (0.00)
TIOTROPIUM BROMIDE			3 (0.01)		3 (0.00)
TIPRANAVIR		1 (0.01)			1 (0.00)
TISSEEL VH KIT			1 (0.00)		1 (0.00)
TISSUCOL		2 (0.01)			2 (0.00)
TISSUCOL/TISSEL KIT ST			1 (0.00)		1 (0.00)
TISSUE (SR CORTICAL BL			1 (0.00)		1 (0.00)
TIZANIDINE HCL	1 (0.02)	2 (0.01)	1 (0.00)		4 (0.01)
TNKASE			1 (0.00)		1 (0.00)
TOBI	3 (0.05)				3 (0.00)
TOBRAMYCIN	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)
TOBRAMYCINE			1 (0.00)		1 (0.00)
TOBREX	1 (0.02)	1 (0.01)			2 (0.00)
TOCOPHEROL CONCENTRATE			1 (0.00)		1 (0.00)
TOCOPHERYL NICOTINATE				1 (0.01)	1 (0.00)
TOFRANIL	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)
TOFRANIL-PM 75MG CAPSU			1 (0.00)		1 (0.00)
TOLBUTAMIDE				3 (0.04)	3 (0.00)
TOLEXINE		1 (0.01)			1 (0.00)
TOLPERISONE HYDROCHLOR			1 (0.00)		1 (0.00)
TOLTERODINE TARTRATE		2 (0.01)		1 (0.01)	3 (0.00)
TOMIRON	3 (0.05)	2 (0.01)	1 (0.00)		6 (0.01)
TOPALGIC		3 (0.02)	5 (0.02)	1 (0.01)	9 (0.01)
TOPAMAX	21 (0.36)	44 (0.26)	18 (0.06)		83 (0.14)
TOPAMAX /AUS/ (TOPIRAM	1 (0.02)				1 (0.00)
TOPICAL ACYCLOVIR		1 (0.01)			1 (0.00)
TOPICAL STEROID			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
TOPIRAMATE	2 (0.03)	7 (0.04)	1 (0.00)		10 (0.02)
TOPLEXIL		1 (0.01)			1 (0.00)
TOPOTECAN		1 (0.01)	6 (0.02)	2 (0.03)	9 (0.01)
TOPOTECAN HYDROCHLORID			1 (0.00)	2 (0.03)	3 (0.00)
TOPRAL			1 (0.00)		1 (0.00)
TOPROL		3 (0.02)	4 (0.01)	5 (0.06)	12 (0.02)
TOPROL-XL	2 (0.03)	22 (0.13)	122 (0.40)	34 (0.44)	180 (0.30)
TORADOL		3 (0.02)	3 (0.01)		6 (0.01)
TORECAN	1 (0.02)				1 (0.00)
TOREM			1 (0.00)		1 (0.00)
TOREM (TORASEMIDE)				1 (0.01)	1 (0.00)
TORSEMIDE			3 (0.01)	3 (0.04)	6 (0.01)
TOSITUMOMAB			1 (0.00)		1 (0.00)
TOSUFLOXACIN TOSILATE			2 (0.01)		2 (0.00)
TOTAL PARENTERAL		1 (0.01)			1 (0.00)
TOWAMIN				1 (0.01)	1 (0.00)
TPN			2 (0.01)		2 (0.00)
TPN (H			1 (0.00)		1 (0.00)
TPN COMPOUNDED IN PHAR			1 (0.00)		1 (0.00)
TRACLEER	7 (0.12)	10 (0.06)	21 (0.07)	1 (0.01)	39 (0.06)
TRACLEER (BOSENTAN TAB		1 (0.01)			1 (0.00)
TRACRIUM		1 (0.01)			1 (0.00)
TRALI RED BLOOD CELLS			1 (0.00)		1 (0.00)
TRAMACET			3 (0.01)		3 (0.00)
TRAMADOL		1 (0.01)	2 (0.01)		3 (0.00)
TRAMADOL (TRAMADOL)			2 (0.01)		2 (0.00)
TRAMADOL 30 MG		1 (0.01)			1 (0.00)
TRAMADOL 50 MG				1 (0.01)	1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
TRAMADOL HCL	5 (0.08)	19 (0.11)	18 (0.06)	8 (0.10)	50 (0.08)
TRAMADOL HYDROCHLORIDE		3 (0.02)	10 (0.03)		13 (0.02)
TRAMADOLOR			3 (0.01)		3 (0.00)
TRAMAL		2 (0.01)	1 (0.00)		3 (0.00)
TRAMSDOL HCL			1 (0.00)		1 (0.00)
TRANDOLAPRIL		2 (0.01)	3 (0.01)		5 (0.01)
TRANEXAMIC ACID			1 (0.00)		1 (0.00)
TRANGOREX (AMIODARONE,				1 (0.01)	1 (0.00)
TRANQUINAL		1 (0.01)			1 (0.00)
TRANSAMIN	2 (0.03)	2 (0.01)			4 (0.01)
TRANSAMIN (TRANEXAMIC		3 (0.02)			3 (0.00)
TRANSDERM SCOP		1 (0.01)			1 (0.00)
TRANSENE (CLORAZEPATE			1 (0.00)		1 (0.00)
TRANSFUSION NOS (TRANS			1 (0.00)		1 (0.00)
TRANSIDERM-NITRO				1 (0.01)	1 (0.00)
TRANSIPEG		2 (0.01)			2 (0.00)
TRANSIPEG				1 (0.01)	1 (0.00)
TRANXENE	1 (0.02)		2 (0.01)		3 (0.00)
TRANXILIUM	1 (0.02)		2 (0.01)		3 (0.00)
TRANXILIUM (CLORAZEPAT			1 (0.00)		1 (0.00)
TRANYLCYPROMINE			1 (0.00)		1 (0.00)
TRASTUZUMAB		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
TRASYLOL	1 (0.02)		9 (0.03)		10 (0.02)
TRAVATAN		1 (0.01)	4 (0.01)	3 (0.04)	8 (0.01)
TRAVOPROST			1 (0.00)		1 (0.00)
TRAZODONE	1 (0.02)	16 (0.09)	7 (0.02)		24 (0.04)
TRAZODONE (NGX) (TRAZO		1 (0.01)			1 (0.00)
TRAZODONE (TRAZODONE)		1 (0.01)	1 (0.00)		2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
TRAZODONE 50 MG PO			1 (0.00)		1 (0.00)
TRAZODONE HCL	1 (0.02)	12 (0.07)	6 (0.02)	2 (0.03)	21 (0.03)
TRAZODONE HYDROCHLORID			5 (0.02)		5 (0.01)
TRAZODONE HYDROCHLORID			1 (0.00)		1 (0.00)
TRELSTAR	1 (0.02)	1 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
TRELSTAR DEPOT	1 (0.02)	4 (0.02)			5 (0.01)
TRENANTONE			1 (0.00)	1 (0.01)	2 (0.00)
TRENTAL			6 (0.02)	1 (0.01)	7 (0.01)
TRENTAL ^BORG^ (PENTOX			1 (0.00)		1 (0.00)
TREO COMP			1 (0.00)		1 (0.00)
TREVILOR (VENLAFAXINE			1 (0.00)		1 (0.00)
TRI-SPRINTEC		1 (0.01)			1 (0.00)
TRIAMCINOLONE			3 (0.01)		3 (0.00)
TRIAMCINOLONE ACETONID		1 (0.01)	3 (0.01)		4 (0.01)
TRIAMCORT		1 (0.01)			1 (0.00)
TRIAMCORT		1 (0.01)			1 (0.00)
TRIAMETRINE			1 (0.00)		1 (0.00)
TRIAMINIC SRT	1 (0.02)				1 (0.00)
TRIAMINIC VAPOR PATCH	1 (0.02)				1 (0.00)
TRIAMPTERENE			1 (0.00)		1 (0.00)
TRIAMTERENE			2 (0.01)		2 (0.00)
TRIAMTERENE AND HYDROC		1 (0.01)	4 (0.01)	4 (0.05)	9 (0.01)
TRIAMTERENE/CYCLOTHIAZ			1 (0.00)		1 (0.00)
TRIA TEC			6 (0.02)	1 (0.01)	7 (0.01)
TRIAZOLAM	1 (0.02)	1 (0.01)		1 (0.01)	3 (0.00)
TRICOR		15 (0.09)	18 (0.06)	2 (0.03)	35 (0.06)
TRIFLUCAN			1 (0.00)		1 (0.00)
TRIFLUOPERAZINE HCL		1 (0.01)			1 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
TRIHENYDROPHENIDYL HCL			1 (0.00)		1 (0.00)
TRIKOZOL			4 (0.01)		4 (0.01)
TRILAFON	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
TRILEPTAL	40 (0.68)	24 (0.14)	23 (0.08)	3 (0.04)	90 (0.15)
TRIMEBUTINE			2 (0.01)		2 (0.00)
TRIMETAZIDINE DIHYDROCHLORIDE				1 (0.01)	1 (0.00)
TRIMETHOPRIM	1 (0.02)		1 (0.00)	3 (0.04)	5 (0.01)
TRIMETHOPRIM + SULFAMETHOXAZOLE			1 (0.00)		1 (0.00)
TRIMOX		1 (0.01)			1 (0.00)
TRINIPATCH			1 (0.00)		1 (0.00)
TRIOFAN (CARBOCISTEINE)		1 (0.01)			1 (0.00)
TRIOMUNE		1 (0.01)			1 (0.00)
TRIOMUNE TABLETS		1 (0.01)			1 (0.00)
TRIOPTAL			1 (0.00)		1 (0.00)
TRIQUILAR	1 (0.02)				1 (0.00)
TRIQUILAR-21		1 (0.01)			1 (0.00)
TRIQUILAR-21 (LEVONORGESTREL)		1 (0.01)			1 (0.00)
TRISENOX		1 (0.01)			1 (0.00)
TRITACE			2 (0.01)		2 (0.00)
TRITTICO	1 (0.02)				1 (0.00)
TRIVASTAL				1 (0.01)	1 (0.00)
TRIVASTAL LP			1 (0.00)		1 (0.00)
TRIVORA-21	1 (0.02)	1 (0.01)			2 (0.00)
TRIZIVIR		6 (0.04)			6 (0.01)
TROMBYL			1 (0.00)	2 (0.03)	3 (0.00)
TROPICAMIDE		1 (0.01)			1 (0.00)
TROPISETRON			2 (0.01)		2 (0.00)
TROXERUTIN			1 (0.00)	1 (0.01)	2 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
TROXIDONE			1 (0.00)		1 (0.00)
TRUSOPT			3 (0.01)		3 (0.00)
TRUVADA	1 (0.02)	7 (0.04)	2 (0.01)		10 (0.02)
TRUXAL (CHLORPROTHIXEN		2 (0.01)			2 (0.00)
TS 1 /JPN/ TEGAFUR, GI			1 (0.00)		1 (0.00)
TS-1			1 (0.00)		1 (0.00)
TSUMARA DAIKENCHUTO EX				1 (0.01)	1 (0.00)
TUBERCULIN PURIFIED PR		1 (0.01)			1 (0.00)
TUBERSOL	2 (0.03)	1 (0.01)	1 (0.00)		4 (0.01)
TUBERSOL 5 TU	1 (0.02)				1 (0.00)
TUBERTEST	1 (0.02)	1 (0.01)			2 (0.00)
TUMS		2 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)
TUMS E-X TABLETS, TROP	1 (0.02)				1 (0.00)
TUSSI-ORANIDIN NR10-10	1 (0.02)				1 (0.00)
TUSSIN DM WALGREENS	1 (0.02)				1 (0.00)
TUSSIONEX		2 (0.01)			2 (0.00)
TWINLAB RIPPED FUEL WI		1 (0.01)			1 (0.00)
TYGACIL			3 (0.01)		3 (0.00)
TYLENOL	6 (0.10)	40 (0.23)	104 (0.34)	26 (0.34)	176 (0.29)
TYLENOL (CAPLET)	14 (0.24)	88 (0.52)	269 (0.89)	53 (0.68)	424 (0.70)
TYLENOL 8 HOUR EXTENDE			1 (0.00)		1 (0.00)
TYLENOL ARTHRITIS EXTE			5 (0.02)		5 (0.01)
TYLENOL CHILDRENS ELIX	1 (0.02)				1 (0.00)
TYLENOL SINUS			1 (0.00)		1 (0.00)
TYLENOL W/ CODEINE		3 (0.02)	3 (0.01)	1 (0.01)	7 (0.01)
TYLENOL W/ CODEINE NO.		7 (0.04)	10 (0.03)	3 (0.04)	20 (0.03)
TYLENOL W/ CODEINE NO.		1 (0.01)	2 (0.01)		3 (0.00)
TYLENOL-500		3 (0.02)	6 (0.02)		9 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
UFT			2 (0.01)		2 (0.00)
ULCER MEDICATION			1 (0.00)		1 (0.00)
ULCERLMIN			1 (0.00)		1 (0.00)
ULTANE		1 (0.01)			1 (0.00)
ULTRACET		6 (0.04)	8 (0.03)	4 (0.05)	18 (0.03)
ULTRAM		24 (0.14)	26 (0.09)	2 (0.03)	52 (0.09)
ULTRASE MT20		1 (0.01)			1 (0.00)
ULTRAVATE		1 (0.01)		2 (0.03)	3 (0.00)
ULTRAVIST (PHARMACY BU		1 (0.01)	2 (0.01)		3 (0.00)
ULTRAVIST 150			1 (0.00)		1 (0.00)
ULTRAVIST 300		4 (0.02)	8 (0.03)		12 (0.02)
ULTRAVIST 370		2 (0.01)	6 (0.02)	2 (0.03)	10 (0.02)
UMATROPE	1 (0.02)				1 (0.00)
UMULINE (INSULIN HUMAN			1 (0.00)		1 (0.00)
UMULINE PROTAMINE ISOP			2 (0.01)		2 (0.00)
UN ALPHA			2 (0.01)		2 (0.00)
UNACID INJECTION (SULB		1 (0.01)			1 (0.00)
UNASYN		5 (0.03)	4 (0.01)	1 (0.01)	10 (0.02)
UNASYN (AMPICILLIN SOD			1 (0.00)		1 (0.00)
UNIBENESTAN			1 (0.00)		1 (0.00)
UNIPHYL		1 (0.01)	1 (0.00)		2 (0.00)
UNIRETIC		1 (0.01)	1 (0.00)		2 (0.00)
UNISOM	9 (0.15)	6 (0.04)	1 (0.00)	1 (0.01)	17 (0.03)
UNISOM SLEEPLESS (DIPH	1 (0.02)				1 (0.00)
UNITHROID			1 (0.00)		1 (0.00)
UNIVASC			2 (0.01)		2 (0.00)
UNKNOWN	2 (0.03)	9 (0.05)	9 (0.03)	2 (0.03)	22 (0.04)
UNKNOWN ANTIBIOTIC			1 (0.00)		1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
UNKNOWN ANTIDEPRESSANT		1 (0.01)			1 (0.00)
UNKNOWN DRUG		3 (0.02)	6 (0.02)		9 (0.01)
UNKNOWN MEDICATION		2 (0.01)	5 (0.02)	1 (0.01)	8 (0.01)
UNSPECIFIED ANTIBIOTIC	2 (0.03)				2 (0.00)
UNSPECIFIED ANTICANCER			1 (0.00)		1 (0.00)
UNSPECIFIED ANTIEPILEP	2 (0.03)				2 (0.00)
UNSPECIFIED DRUG	1 (0.02)	1 (0.01)	4 (0.01)		6 (0.01)
UNSPECIFIED DRUGS		1 (0.01)	6 (0.02)		7 (0.01)
UNSPECIFIED MEDICATION	1 (0.02)	3 (0.02)	3 (0.01)	1 (0.01)	8 (0.01)
UNSPECIFIED MEDICATION		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)
UNSPECIFIED NON-STEROI		1 (0.01)			1 (0.00)
UNSPECIFIED OTHER MEDI				1 (0.01)	1 (0.00)
UNSPECIFIED PAIN MEDIC			1 (0.00)		1 (0.00)
UNSPECIFIED THYROID ME			1 (0.00)		1 (0.00)
UNSPECIFIED THYROID ME		1 (0.01)			1 (0.00)
UNSPECIFIED VITAMINS (2 (0.01)		2 (0.00)
URALYT			1 (0.00)		1 (0.00)
URAPIDIL			3 (0.01)		3 (0.00)
URBADAN	2 (0.03)				2 (0.00)
URBANYL	1 (0.02)		1 (0.00)		2 (0.00)
URBASON		1 (0.01)	1 (0.00)		2 (0.00)
UREA PEROXIDE		1 (0.01)			1 (0.00)
URICONT			1 (0.00)		1 (0.00)
URINORM			2 (0.01)		2 (0.00)
URION			1 (0.00)		1 (0.00)
URION ^BYK GULDEN^			1 (0.00)		1 (0.00)
UROMITEXAN		3 (0.02)	3 (0.01)		6 (0.01)
UROXATRAL			4 (0.01)	2 (0.03)	6 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
URSO		2 (0.01)	4 (0.01)	2 (0.03)	8 (0.01)
URSO			1 (0.00)		1 (0.00)
URSO (URSODEOXYCHOLIC			1 (0.00)		1 (0.00)
URSO 250			1 (0.00)	1 (0.01)	2 (0.00)
URSODEOXYCHOLIC ACID				1 (0.01)	1 (0.00)
URSODIOL		1 (0.01)			1 (0.00)
URSOLVAN		1 (0.01)		1 (0.01)	2 (0.00)
UTROGESTAN		3 (0.02)			3 (0.00)
VACCINATION	2 (0.03)				2 (0.00)
VACCINES (VACCINES)				1 (0.01)	1 (0.00)
VAGIFEM	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)
VAGINEX	3 (0.05)				3 (0.00)
VAGISIL		3 (0.02)			3 (0.00)
VAGISTAT-1	57 (0.96)	94 (0.55)	12 (0.04)		163 (0.27)
VALACYCLOVIR HCL		3 (0.02)	1 (0.00)		4 (0.01)
VALCOTE			1 (0.00)		1 (0.00)
VALCYTE	3 (0.05)		1 (0.00)		4 (0.01)
VALDECOXIB			3 (0.01)		3 (0.00)
VALETTE		1 (0.01)			1 (0.00)
VALIUM		27 (0.16)	42 (0.14)	4 (0.05)	73 (0.12)
VALPROATE CHRONO	1 (0.02)	2 (0.01)			3 (0.00)
VALPROATE SODIUM	21 (0.36)	22 (0.13)	19 (0.06)	3 (0.04)	65 (0.11)
VALPROIC ACID	12 (0.20)	21 (0.12)	11 (0.04)		44 (0.07)
VALPROIC ACID TABLETS		1 (0.01)			1 (0.00)
VALPROICUM		1 (0.01)			1 (0.00)
VALSARTAN		3 (0.02)	23 (0.08)	14 (0.18)	40 (0.07)
VALTRAN		1 (0.01)			1 (0.00)
VALTREX	16 (0.27)	27 (0.16)	27 (0.09)	12 (0.15)	82 (0.13)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
VALVERDE (VALERAN EXTR	1 (0.02)				1 (0.00)
VANCOCIN (VANCOMYCIN H			1 (0.00)		1 (0.00)
VANCOMYCIN	9 (0.15)	11 (0.06)	39 (0.13)	14 (0.18)	73 (0.12)
VANCOMYCIN HCL		1 (0.01)			1 (0.00)
VANCOMYCIN HYDROCHLORI	2 (0.03)	1 (0.01)	3 (0.01)		6 (0.01)
VANEX-LA (GUAIFENESIN,		1 (0.01)			1 (0.00)
VANIQA	1 (0.02)	1 (0.01)			2 (0.00)
VANQUISH			1 (0.00)		1 (0.00)
VANTAS				1 (0.01)	1 (0.00)
VAPO STEAM (CAMPHOR 6.	1 (0.02)				1 (0.00)
VAPORUB	1 (0.02)				1 (0.00)
VAPOSTEAM	1 (0.02)				1 (0.00)
VARDENAFIL		1 (0.01)	1 (0.00)		2 (0.00)
VASERETIC		2 (0.01)	1 (0.00)		3 (0.00)
VASOCARDOL CD			1 (0.00)		1 (0.00)
VASOPRESSIN INJECTION				1 (0.01)	1 (0.00)
VASOTEC		3 (0.02)	14 (0.05)	7 (0.09)	24 (0.04)
VASOTEC RPD		1 (0.01)	22 (0.07)	1 (0.01)	24 (0.04)
VASTAREL			1 (0.00)	2 (0.03)	3 (0.00)
VASTAREL ^BIOPHARMA^				2 (0.03)	2 (0.00)
VASTEN		1 (0.01)	1 (0.00)	4 (0.05)	6 (0.01)
VASTEN 20			1 (0.00)		1 (0.00)
VASTEN TABS			2 (0.01)		2 (0.00)
VASTEN TABS 40 MG				1 (0.01)	1 (0.00)
VECURONIUM BROMIDE	4 (0.07)	1 (0.01)	3 (0.01)		8 (0.01)
VEEN 3G	1 (0.02)				1 (0.00)
VEGETAMIN (CHLORPROMAZ				1 (0.01)	1 (0.00)
VEGETAMIN B (CHLORPROM			5 (0.02)		5 (0.01)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
VEINAMITOL				1 (0.01)	1 (0.00)
VELCADE		13 (0.08)	73 (0.24)	13 (0.17)	99 (0.16)
VELCADE (BORTEZPMIB) I			6 (0.02)	1 (0.01)	7 (0.01)
VELOSEF			1 (0.00)		1 (0.00)
VELOSULIN	1 (0.02)	1 (0.01)			2 (0.00)
VELOX (RIMEXOLONE)				1 (0.01)	1 (0.00)
VENDAL	1 (0.02)				1 (0.00)
VENLAFAXINE HCL	3 (0.05)	26 (0.15)	4 (0.01)	2 (0.03)	35 (0.06)
VENLAFAXINE HYDROCHLOR			1 (0.00)		1 (0.00)
VENOFER		2 (0.01)			2 (0.00)
VENOGLOBULIN-I	1 (0.02)				1 (0.00)
VENTAVIS	1 (0.02)	1 (0.01)	3 (0.01)		5 (0.01)
VENTOLIN	7 (0.12)	6 (0.04)	6 (0.02)	3 (0.04)	22 (0.04)
VENTOLIN HFA	1 (0.02)				1 (0.00)
VEPESID			1 (0.00)		1 (0.00)
VERAPAMIL	3 (0.05)	4 (0.02)	61 (0.20)	19 (0.25)	87 (0.14)
VERAPAMIL (CONTIN)				1 (0.01)	1 (0.00)
VERAPAMIL EXTENDED-REL		8 (0.05)	3 (0.01)	1 (0.01)	12 (0.02)
VERAPAMIL HCL			1 (0.00)		1 (0.00)
VERAPAMIL HYDROCHLORID		2 (0.01)	3 (0.01)	2 (0.03)	7 (0.01)
VERAPAMIL MSD LP			1 (0.00)		1 (0.00)
VERCYTE				1 (0.01)	1 (0.00)
VERELAN			4 (0.01)		4 (0.01)
VERSED	2 (0.03)	2 (0.01)	1 (0.00)		5 (0.01)
VERTEPROFIN				1 (0.01)	1 (0.00)
VESANOID	1 (0.02)	3 (0.02)	3 (0.01)		7 (0.01)
VESICARE	1 (0.02)	8 (0.05)	11 (0.04)	8 (0.10)	28 (0.05)
VESIKUR(SOLIFENACIN) T				1 (0.01)	1 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
VFEND		4 (0.02)	7 (0.02)	7 (0.09)	18 (0.03)
VIADUR			1 (0.00)		1 (0.00)
VIAGRA	2 (0.03)	21 (0.12)	76 (0.25)	3 (0.04)	102 (0.17)
VIANI	1 (0.02)				1 (0.00)
VIBRAMYCIN	2 (0.03)			1 (0.01)	3 (0.00)
VIC ES GENERIC		1 (0.01)			1 (0.00)
VICKS VAPOSTEAM LIQUID	1 (0.02)				1 (0.00)
VICODEN		1 (0.01)			1 (0.00)
VICODIN		69 (0.40)	61 (0.20)	11 (0.14)	141 (0.23)
VICODIN ES		4 (0.02)	4 (0.01)		8 (0.01)
VICOPROFEN		3 (0.02)	4 (0.01)		7 (0.01)
VIDEX		13 (0.08)	3 (0.01)		16 (0.03)
VIDEX EC		1 (0.01)	1 (0.00)		2 (0.00)
VIDISIC EYE GEL				2 (0.03)	2 (0.00)
VIGABATRIN	1 (0.02)				1 (0.00)
VIGAMOX	4 (0.07)	4 (0.02)	2 (0.01)	2 (0.03)	12 (0.02)
VIGAMOX SOLUTIONS				1 (0.01)	1 (0.00)
VIGIL			2 (0.01)		2 (0.00)
VINBLASTINE		5 (0.03)	1 (0.00)	1 (0.01)	7 (0.01)
VINBLASTINE (NGX) (VIN	1 (0.02)				1 (0.00)
VINCRISTINE	11 (0.19)		6 (0.02)	1 (0.01)	18 (0.03)
VINCRISTINE SULFATE	1 (0.02)				1 (0.00)
VINFLUNINE			1 (0.00)		1 (0.00)
VINORELBINE			3 (0.01)		3 (0.00)
VINORELBINE TARTRATE		2 (0.01)	4 (0.01)		6 (0.01)
VIOXX	25 (0.42)	1251 (7.33)	3346 (11.06)	543 (7.00)	5165 (8.47)
VIRACEPT	2 (0.03)	7 (0.04)	1 (0.00)		10 (0.02)
VIRAFERON (INTEFERON A		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
VIRAFERONPEG	1 (0.02)	1 (0.01)	7 (0.02)	1 (0.01)	10 (0.02)
VIRAFERONPEG REDIPEN (1 (0.00)		1 (0.00)
VIRAMUNE	5 (0.08)	9 (0.05)	1 (0.00)		15 (0.02)
VIREAD	1 (0.02)	20 (0.12)	3 (0.01)		24 (0.04)
VIRUS INFECTION MEDICA			1 (0.00)		1 (0.00)
VISINE II EYE DROPS	2 (0.03)	1 (0.01)			3 (0.00)
VISINE-A		1 (0.01)			1 (0.00)
VISIPAQUE			4 (0.01)	1 (0.01)	5 (0.01)
VISIPAQUE 320				1 (0.01)	1 (0.00)
VISKEN			1 (0.00)		1 (0.00)
VISTAGAN		1 (0.01)			1 (0.00)
VISTARIL	4 (0.07)	2 (0.01)	2 (0.01)		8 (0.01)
VISUDYNE	1 (0.02)	1 (0.01)	10 (0.03)	3 (0.04)	15 (0.02)
VIT C			1 (0.00)		1 (0.00)
VITA C				1 (0.01)	1 (0.00)
VITAMEDIN		3 (0.02)			3 (0.00)
VITAMIN		2 (0.01)			2 (0.00)
VITAMIN A			1 (0.00)		1 (0.00)
VITAMIN A (NATURAL) CA			1 (0.00)	1 (0.01)	2 (0.00)
VITAMIN AND MINERAL PR	2 (0.03)	1 (0.01)			3 (0.00)
VITAMIN B (UNSPECIFIED		1 (0.01)		1 (0.01)	2 (0.00)
VITAMIN B COMPLEX CAP	2 (0.03)	1 (0.01)	3 (0.01)		6 (0.01)
VITAMIN B-12	1 (0.02)		5 (0.02)		6 (0.01)
VITAMIN B12		3 (0.02)	11 (0.04)	2 (0.03)	16 (0.03)
VITAMIN D		2 (0.01)	5 (0.02)	5 (0.06)	12 (0.02)
VITAMIN D (UNSPECIFIED		1 (0.01)			1 (0.00)
VITAMIN E		4 (0.02)	2 (0.01)	5 (0.06)	11 (0.02)
VITAMIN E (VEGETABLE O				2 (0.03)	2 (0.00)

Drug Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
VITAMIN K	1 (0.02)		2 (0.01)		3 (0.00)
VITAMIN NOS (VITAMIN N	1 (0.02)				1 (0.00)
VITAMIN SOURCE GLUCOSA			1 (0.00)		1 (0.00)
VITAMINS	7 (0.12)	11 (0.06)	9 (0.03)	4 (0.05)	31 (0.05)
VITAMINS (UNSPECIFIED)	4 (0.07)	5 (0.03)	21 (0.07)	2 (0.03)	32 (0.05)
VITAMINS + HERBS			3 (0.01)		3 (0.00)
VITAMINS NOS		3 (0.02)	1 (0.00)		4 (0.01)
VITAMINS NOS (VITAMINS			1 (0.00)		1 (0.00)
VITAMINS/MINERALS/DIET	1 (0.02)				1 (0.00)
VITANEURIN (PO)				1 (0.01)	1 (0.00)
VITARUBIN			2 (0.01)		2 (0.00)
VITORIN			2 (0.01)		2 (0.00)
VIVACTIL		2 (0.01)			2 (0.00)
VIVELLE			1 (0.00)		1 (0.00)
VIVELLE-DOT		6 (0.04)	5 (0.02)		11 (0.02)
VOCODIN ES (HYDROCODON		1 (0.01)			1 (0.00)
VOGLIBOSE			2 (0.01)		2 (0.00)
VOLMAC			1 (0.00)		1 (0.00)
VOLON			1 (0.00)		1 (0.00)
VOLTAREN	8 (0.14)	13 (0.08)	27 (0.09)	4 (0.05)	52 (0.09)
VOLTAREN-XR			2 (0.01)		2 (0.00)
VOLTARENE L.P.		1 (0.01)			1 (0.00)
VOLTARENE LP		3 (0.02)			3 (0.00)
VORICONAZOLE	2 (0.03)	5 (0.03)			7 (0.01)
VORICONAZOLE (VORICONA		1 (0.01)	1 (0.00)		2 (0.00)
VOTUM 20			1 (0.00)		1 (0.00)
VP-16	1 (0.02)	1 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
VYTORIN		4 (0.02)	39 (0.13)	5 (0.06)	48 (0.08)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
WAL-OPHEN EXTRA STRENG	1 (0.02)				1 (0.00)
WARAN			1 (0.00)		1 (0.00)
WARFARIN		3 (0.02)	41 (0.14)	22 (0.28)	66 (0.11)
WARFARIN 2.5				1 (0.01)	1 (0.00)
WARFARIN 4MG				1 (0.01)	1 (0.00)
WARFARIN 7.5MG			1 (0.00)		1 (0.00)
WARFARIN 10MG-02/06/			1 (0.00)		1 (0.00)
WARFARIN 2MG				1 (0.01)	1 (0.00)
WARFARIN 5MG			1 (0.00)		1 (0.00)
WARFARIN 10 MG Q DAY				1 (0.01)	1 (0.00)
WARFARIN 10 MG			1 (0.00)		1 (0.00)
WARFARIN 2 MG				2 (0.03)	2 (0.00)
WARFARIN 2 MG AND 3 MG				1 (0.01)	1 (0.00)
WARFARIN 2MG AND 3 MG				1 (0.01)	1 (0.00)
WARFARIN 6 MG BRISTOL-			1 (0.00)		1 (0.00)
WARFARIN DOSE NOT SPEC				1 (0.01)	1 (0.00)
WARFARIN SODIUM	6 (0.10)	12 (0.07)	63 (0.21)	28 (0.36)	109 (0.18)
WARFARIN TABS 5; 5 MG			1 (0.00)		1 (0.00)
WATER PILL NOS			1 (0.00)		1 (0.00)
WELCHOL		1 (0.01)			1 (0.00)
WELLBUTRIBN SR 100 MG		1 (0.01)			1 (0.00)
WELLBUTRIN	22 (0.37)	74 (0.43)	48 (0.16)	6 (0.08)	150 (0.25)
WELLBUTRIN (BUPROPION			2 (0.01)		2 (0.00)
WELLBUTRIN SR	1 (0.02)	14 (0.08)	6 (0.02)		21 (0.03)
WELLBUTRIN XL	18 (0.30)	41 (0.24)	17 (0.06)	2 (0.03)	78 (0.13)
WINRHO D BAXTER		1 (0.01)			1 (0.00)
WINRHO SDF		2 (0.01)	1 (0.00)		3 (0.00)
WOMEN'S LAXITIVE WALGR		1 (0.01)			1 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
WYTENS /SPA/			1 (0.00)		1 (0.00)
XALACOM			1 (0.00)		1 (0.00)
XALATAN		5 (0.03)	18 (0.06)	8 (0.10)	31 (0.05)
XALCOM (LATANOPROST, T				1 (0.01)	1 (0.00)
XANAX	13 (0.22)	73 (0.43)	53 (0.18)	7 (0.09)	146 (0.24)
XANAX /USA/ (ALPRAZO		1 (0.01)			1 (0.00)
XANAX XR			1 (0.00)		1 (0.00)
XANOR		1 (0.01)			1 (0.00)
XATRAL			6 (0.02)	3 (0.04)	9 (0.01)
XATRAL OD				1 (0.01)	1 (0.00)
XATRAL XL				1 (0.01)	1 (0.00)
XELODA		3 (0.02)	30 (0.10)	12 (0.15)	45 (0.07)
XENADERM (BALSALM OF P				2 (0.03)	2 (0.00)
XENICAL	1 (0.02)	11 (0.06)	10 (0.03)		22 (0.04)
XIFAXAN		1 (0.01)			1 (0.00)
XIGRIS	5 (0.08)	9 (0.05)	15 (0.05)	3 (0.04)	32 (0.05)
XIGRIS (DROTRECOGIN AL		1 (0.01)	3 (0.01)	1 (0.01)	5 (0.01)
XIGRIS (DROTRECOGIN AL			1 (0.00)		1 (0.00)
XIPAMIDE				1 (0.01)	1 (0.00)
XOLAIR	2 (0.03)	11 (0.06)	7 (0.02)		20 (0.03)
XOLAIR (OMALIZUMAB)PWD			1 (0.00)		1 (0.00)
XOLAIR (OMALIZUMAB)PWD		1 (0.01)	1 (0.00)		2 (0.00)
XOPENEX	7 (0.12)		3 (0.01)	2 (0.03)	12 (0.02)
XOPONEX	1 (0.02)				1 (0.00)
XTRA CARE BODY LOTION			1 (0.00)		1 (0.00)
XYLOCAINE		6 (0.04)	15 (0.05)	3 (0.04)	24 (0.04)
XYLOCAINE INJECTION WI			1 (0.00)		1 (0.00)
XYLOCAINE VISCOUS			1 (0.00)		1 (0.00)

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
XYLOCAINE W/ EPINEPHRI	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
XYREM	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
YASMIN	23 (0.39)	27 (0.16)			50 (0.08)
YENTREVE (DULOXETINE H			1 (0.00)		1 (0.00)
YENTREVE (DULOXETINE H			3 (0.01)		3 (0.00)
YENTREVE (DULOXETINE H			1 (0.00)		1 (0.00)
YENTREVE(DULOXETINE HY		1 (0.01)			1 (0.00)
YENTREVE(DULOXETINE HY			1 (0.00)		1 (0.00)
YENTREVE(DULOXETINE HY		1 (0.01)			1 (0.00)
Z-PACK			1 (0.00)		1 (0.00)
ZADITEN	3 (0.05)	2 (0.01)			5 (0.01)
ZALDIAR	1 (0.02)				1 (0.00)
ZALEPLON	1 (0.02)				1 (0.00)
ZANAFLEX		5 (0.03)	11 (0.04)	1 (0.01)	17 (0.03)
ZAND CLEANSING FIBER Z			1 (0.00)		1 (0.00)
ZANIDIP			2 (0.01)		2 (0.00)
ZANTAC	12 (0.20)	13 (0.08)	29 (0.10)	8 (0.10)	62 (0.10)
ZARONTIN	1 (0.02)				1 (0.00)
ZAROXOLYN		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)
ZAVESCA			2 (0.01)		2 (0.00)
ZD2171			1 (0.00)		1 (0.00)
ZEBETA		2 (0.01)	7 (0.02)	2 (0.03)	11 (0.02)
ZECLAR				2 (0.03)	2 (0.00)
ZECLAR TABLETS		1 (0.01)			1 (0.00)
ZEFFIX			1 (0.00)		1 (0.00)
ZEFIX		3 (0.02)	11 (0.04)		14 (0.02)
ZEGERID			1 (0.00)		1 (0.00)
ZELDOX		1 (0.01)			1 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ZELDOX (CAPSULES) (ZI		1 (0.01)	1 (0.00)		2 (0.00)
ZELDOX (CAPSULES) (ZIP		2 (0.01)			2 (0.00)
ZELITREX	1 (0.02)	1 (0.01)			2 (0.00)
ZELMAC		1 (0.01)	2 (0.01)		3 (0.00)
ZELMAC / HTF 919A		2 (0.01)	5 (0.02)	1 (0.01)	8 (0.01)
ZELNORM	2 (0.03)	18 (0.11)	12 (0.04)	2 (0.03)	34 (0.06)
ZELNORM /USA/		1 (0.01)			1 (0.00)
ZENAPAX		7 (0.04)	5 (0.02)		12 (0.02)
ZENTEL	1 (0.02)				1 (0.00)
ZENTEL 400		1 (0.01)			1 (0.00)
ZERIT	2 (0.03)	9 (0.05)	8 (0.03)		19 (0.03)
ZESTORETIC		2 (0.01)	7 (0.02)	1 (0.01)	10 (0.02)
ZESTRIL		10 (0.06)	50 (0.17)	12 (0.15)	72 (0.12)
ZETIA		3 (0.02)	35 (0.12)	6 (0.08)	44 (0.07)
ZEVALIN		2 (0.01)	1 (0.00)		3 (0.00)
ZIAC	1 (0.02)	9 (0.05)	12 (0.04)	3 (0.04)	25 (0.04)
ZIAGEN	2 (0.03)	4 (0.02)	2 (0.01)		8 (0.01)
ZIAGEN (FORMULATION UN		1 (0.01)			1 (0.00)
ZICAM	1 (0.02)	5 (0.03)	3 (0.01)		9 (0.01)
ZICAM ZICUM GLUCO			1 (0.00)		1 (0.00)
ZICAM 3X			1 (0.00)		1 (0.00)
ZICAM NA ZICA			1 (0.00)		1 (0.00)
ZICAM UNKNOWN -OVER T		1 (0.01)			1 (0.00)
ZICAM COLD NAZAL SPRAY		1 (0.01)			1 (0.00)
ZICAM COLD REMEDY			1 (0.00)	1 (0.01)	2 (0.00)
ZICAM COLD REMEDY M		1 (0.01)			1 (0.00)
ZICAM COLD REMEDY SWAB		1 (0.01)			1 (0.00)
ZICAM COLD REMEDY ZICA		1 (0.01)			1 (0.00)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ZICAM EXTREME CONGESTI		1 (0.01)			1 (0.00)
ZICAM INHALER OVER THE			1 (0.00)		1 (0.00)
ZICAM LIQUID NASAL GEL			1 (0.00)		1 (0.00)
ZICAM MATRIX INITIATI		1 (0.01)			1 (0.00)
ZICAM NASAL SPRAY			1 (0.00)		1 (0.00)
ZICAM NASAL SPRAY GEL			1 (0.00)		1 (0.00)
ZICAM NASAL SWABS MATR			1 (0.00)		1 (0.00)
ZICAM NO-DRIP LIQUID N		1 (0.01)			1 (0.00)
ZICAM SEVERE CONGESTIO		1 (0.01)			1 (0.00)
ZICAM ZICAM LLC/MATRIX			1 (0.00)		1 (0.00)
ZIDOVUDINE	4 (0.07)	28 (0.16)	3 (0.01)		35 (0.06)
ZINACEF	1 (0.02)	1 (0.01)			2 (0.00)
ZINC GLUCONATE (ZINC G	1 (0.02)				1 (0.00)
ZINC SULFATE	2 (0.03)				2 (0.00)
ZINNAT		4 (0.02)	2 (0.01)		6 (0.01)
ZINNAT INJECTABLE			1 (0.00)		1 (0.00)
ZIPRASIDONE (CAPS) (ZI	1 (0.02)		1 (0.00)		2 (0.00)
ZIPRASIDONE (ZIPRASIDO	1 (0.02)				1 (0.00)
ZIPRASIDONE HCL	8 (0.14)	5 (0.03)	2 (0.01)		15 (0.02)
ZIPRASIDONE HYDROCHLOR	1 (0.02)				1 (0.00)
ZITHROMAC		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
ZITHROMAX	16 (0.27)	16 (0.09)	13 (0.04)	7 (0.09)	52 (0.09)
ZMAX	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
ZOCOR	1 (0.02)	29 (0.17)	179 (0.59)	42 (0.54)	251 (0.41)
ZOFRAN	4 (0.07)	6 (0.04)	23 (0.08)	3 (0.04)	36 (0.06)
ZOLADEX		11 (0.06)	6 (0.02)	9 (0.12)	26 (0.04)
ZOLEDRONATE			1 (0.00)	1 (0.01)	2 (0.00)
ZOLEDRONIC ACID			9 (0.03)	2 (0.03)	11 (0.02)

Drug Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ZOLENDRONIC ACID 4 MG			1 (0.00)		1 (0.00)
ZOLMITRIPTAN		1 (0.01)			1 (0.00)
ZOLOFT	42 (0.71)	114 (0.67)	76 (0.25)	14 (0.18)	246 (0.40)
ZOLPIDEM		1 (0.01)			1 (0.00)
ZOLPIDEM 10			1 (0.00)		1 (0.00)
ZOLPIDEM TARTRATE		11 (0.06)	9 (0.03)	1 (0.01)	21 (0.03)
ZOMETA		13 (0.08)	108 (0.36)	24 (0.31)	145 (0.24)
ZOMIG		13 (0.08)	4 (0.01)		17 (0.03)
ZOMIGORO			1 (0.00)		1 (0.00)
ZOMORPH			2 (0.01)		2 (0.00)
ZONDAR			1 (0.00)		1 (0.00)
ZONEGRAN	7 (0.12)	7 (0.04)	3 (0.01)		17 (0.03)
ZONISAMIDE	3 (0.05)	3 (0.02)	1 (0.00)		7 (0.01)
ZOPENEX (LEVALBUTEROL				1 (0.01)	1 (0.00)
ZOPHREN	3 (0.05)	1 (0.01)	3 (0.01)		7 (0.01)
ZOPICLONE	1 (0.02)	1 (0.01)	4 (0.01)		6 (0.01)
ZOPICLONE (ZOPICLONE)		1 (0.01)	1 (0.00)		2 (0.00)
ZOPICOL			2 (0.01)		2 (0.00)
ZOSYN		5 (0.03)	4 (0.01)	4 (0.05)	13 (0.02)
ZOTEPINE		1 (0.01)	1 (0.00)		2 (0.00)
ZOTEPINE (ZOTEPINE)			1 (0.00)		1 (0.00)
ZOVIA 1/35E-21		1 (0.01)			1 (0.00)
ZOVIRAX	4 (0.07)	7 (0.04)	3 (0.01)	1 (0.01)	15 (0.02)
ZOXAN			2 (0.01)		2 (0.00)
ZOXAN LP (DOXAZOSIN)			2 (0.01)		2 (0.00)
ZUCLOPENTHIXOL DECANOA		1 (0.01)			1 (0.00)
ZYBAN	5 (0.08)	16 (0.09)	4 (0.01)		25 (0.04)
ZYCAM NASAL SPRAY		1 (0.01)			1 (0.00)

Drug Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ZYDOL			1 (0.00)		1 (0.00)
ZYDONE			2 (0.01)		2 (0.00)
ZYLOPRIM			3 (0.01)		3 (0.00)
ZYLOPRIUM			1 (0.00)		1 (0.00)
ZYLORIC		1 (0.01)	1 (0.00)	8 (0.10)	10 (0.02)
ZYLORIC 100				1 (0.01)	1 (0.00)
ZYMAR	1 (0.02)	10 (0.06)	1 (0.00)		12 (0.02)
ZYNTABAC		2 (0.01)	3 (0.01)		5 (0.01)
ZYPREXA	25 (0.42)	89 (0.52)	42 (0.14)	15 (0.19)	171 (0.28)
ZYPREXA ZYDIS	2 (0.03)	1 (0.01)	1 (0.00)		4 (0.01)
ZYRTEC	25 (0.42)	28 (0.16)	12 (0.04)	4 (0.05)	69 (0.11)
ZYRTEC-D 12 HOUR		2 (0.01)			2 (0.00)
ZYVOX	4 (0.07)	7 (0.04)	8 (0.03)	2 (0.03)	21 (0.03)
[COMPOSITION UNSPECIFI		2 (0.01)	4 (0.01)	2 (0.03)	8 (0.01)
[THERAPY UNSPECIFIED]	1 (0.02)	33 (0.19)	134 (0.44)	23 (0.30)	191 (0.31)
Derived Drug MISSING	5912 (100.00)	17058 (100.00)	30251 (100.00)	7755 (100.00)	60976 (100.00)

Reaction Summary Table Derived Age Group

		<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
Preferred Term	5'NUCLEOTIDASE INCREASED		1 (0.01)			1 (0.00)
	ABASIA	13 (0.22)	88 (0.52)	134 (0.44)	54 (0.70)	289 (0.47)
	ABDOMINAL ABSCESS	12 (0.20)	4 (0.02)	14 (0.05)	2 (0.03)	32 (0.05)
	ABDOMINAL ADHESIONS	2 (0.03)	13 (0.08)	14 (0.05)	2 (0.03)	31 (0.05)
	ABDOMINAL BRUIT		2 (0.01)	4 (0.01)		6 (0.01)
	ABDOMINAL CAVITY DRAINAGE				1 (0.01)	1 (0.00)
	ABDOMINAL DISCOMFORT	23 (0.39)	48 (0.28)	107 (0.35)	14 (0.18)	192 (0.31)
	ABDOMINAL DISTENSION	32 (0.54)	96 (0.56)	243 (0.80)	43 (0.55)	414 (0.68)
	ABDOMINAL HAEMATOMA	1 (0.02)	4 (0.02)	14 (0.05)	4 (0.05)	23 (0.04)
	ABDOMINAL HERNIA		3 (0.02)	31 (0.10)	3 (0.04)	37 (0.06)
	ABDOMINAL HERNIA REPAIR		1 (0.01)			1 (0.00)
	ABDOMINAL INFECTION		1 (0.01)	8 (0.03)	1 (0.01)	10 (0.02)
	ABDOMINAL INJURY	3 (0.05)	1 (0.01)			4 (0.01)
	ABDOMINAL MASS	4 (0.07)	2 (0.01)	18 (0.06)	3 (0.04)	27 (0.04)
	ABDOMINAL NEOPLASM		4 (0.02)	3 (0.01)	3 (0.04)	10 (0.02)
	ABDOMINAL OPERATION		1 (0.01)	1 (0.00)		2 (0.00)
	ABDOMINAL PAIN	190 (3.21)	419 (2.46)	528 (1.75)	118 (1.52)	1255 (2.06)
	ABDOMINAL PAIN LOWER	9 (0.15)	29 (0.17)	65 (0.21)	8 (0.10)	111 (0.18)
	ABDOMINAL PAIN UPPER	53 (0.90)	194 (1.14)	386 (1.28)	71 (0.92)	704 (1.15)
	ABDOMINAL RIGIDITY	1 (0.02)	3 (0.02)	1 (0.00)		5 (0.01)
	ABDOMINAL SEPSIS			5 (0.02)		5 (0.01)
	ABDOMINAL STRANGULATED HERNIA			3 (0.01)	1 (0.01)	4 (0.01)
	ABDOMINAL SYMPTOM		1 (0.01)	1 (0.00)		2 (0.00)
	ABDOMINAL TENDERNESS	1 (0.02)	5 (0.03)	4 (0.01)	3 (0.04)	13 (0.02)
	ABDOMINAL WALL ABSCESS		5 (0.03)	1 (0.00)		6 (0.01)
	ABDOMINAL WALL CYST		1 (0.01)			1 (0.00)
	ABDOMINAL WALL DISORDER				1 (0.01)	1 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ABDOMINAL WALL INFECTION				1 (0.01)	1 (0.00)
ABDOMINAL WALL MASS			2 (0.01)		2 (0.00)
ABNORMAL BEHAVIOUR	166 (2.81)	91 (0.53)	76 (0.25)	40 (0.52)	373 (0.61)
ABNORMAL DREAMS	5 (0.08)	43 (0.25)	41 (0.14)	6 (0.08)	95 (0.16)
ABNORMAL FAECES	2 (0.03)	2 (0.01)	10 (0.03)	5 (0.06)	19 (0.03)
ABNORMAL PALMAR/PLANTAR CREASES		4 (0.02)			4 (0.01)
ABNORMAL SENSATION IN EYE		5 (0.03)	6 (0.02)	1 (0.01)	12 (0.02)
ABNORMAL SLEEP-RELATED EVENT		9 (0.05)	3 (0.01)	1 (0.01)	13 (0.02)
ABORTION	3 (0.05)	11 (0.06)			14 (0.02)
ABORTION COMPLETE	1 (0.02)				1 (0.00)
ABORTION INCOMPLETE	7 (0.12)	6 (0.04)			13 (0.02)
ABORTION INDUCED	34 (0.58)	71 (0.42)			105 (0.17)
ABORTION INDUCED COMPLICATED	1 (0.02)				1 (0.00)
ABORTION MISSED	6 (0.10)	10 (0.06)			16 (0.03)
ABORTION SPONTANEOUS	37 (0.63)	152 (0.89)	1 (0.00)		190 (0.31)
ABORTION THREATENED	1 (0.02)	1 (0.01)			2 (0.00)
ABSCESS	7 (0.12)	28 (0.16)	33 (0.11)	5 (0.06)	73 (0.12)
ABSCESS DRAINAGE		3 (0.02)	1 (0.00)		4 (0.01)
ABSCESS INTESTINAL	6 (0.10)	3 (0.02)	3 (0.01)		12 (0.02)
ABSCESS JAW		1 (0.01)	4 (0.01)	3 (0.04)	8 (0.01)
ABSCESS LIMB	1 (0.02)	12 (0.07)	14 (0.05)	3 (0.04)	30 (0.05)
ABSCESS NECK		1 (0.01)	7 (0.02)		8 (0.01)
ABSCESS ORAL		1 (0.01)	3 (0.01)	3 (0.04)	7 (0.01)
ABSCESS RUPTURE		1 (0.01)			1 (0.00)
ABSCESS SOFT TISSUE			2 (0.01)		2 (0.00)
ABULIA			2 (0.01)		2 (0.00)
ACALCULIA			2 (0.01)		2 (0.00)
ACANTHAMOEBA INFECTION	2 (0.03)				2 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
ACANTHOLYSIS			1 (0.00)		1 (0.00)
ACANTHOSIS		2 (0.01)		1 (0.01)	3 (0.00)
ACARODERMATITIS		1 (0.01)	4 (0.01)	2 (0.03)	7 (0.01)
ACCELERATED HYPERTENSION		1 (0.01)	20 (0.07)	1 (0.01)	22 (0.04)
ACCELERATED IDIOVENTRICULAR RHYTHM		2 (0.01)			2 (0.00)
ACCESSORY BREAST		2 (0.01)			2 (0.00)
ACCIDENT	4 (0.07)	7 (0.04)	28 (0.09)	6 (0.08)	45 (0.07)
ACCIDENT AT HOME		1 (0.01)	1 (0.00)		2 (0.00)
ACCIDENT AT WORK	1 (0.02)	11 (0.06)	5 (0.02)		17 (0.03)
ACCIDENTAL DEATH	4 (0.07)	13 (0.08)	5 (0.02)	2 (0.03)	24 (0.04)
ACCIDENTAL DRUG INTAKE BY CHILD	51 (0.86)				51 (0.08)
ACCIDENTAL EXPOSURE	20 (0.34)	14 (0.08)	9 (0.03)	5 (0.06)	48 (0.08)
ACCIDENTAL NEEDLE STICK	1 (0.02)		7 (0.02)	1 (0.01)	9 (0.01)
ACCIDENTAL OVERDOSE	15 (0.25)	36 (0.21)	46 (0.15)	13 (0.17)	110 (0.18)
ACCOMMODATION DISORDER		8 (0.05)	2 (0.01)		10 (0.02)
ACETABULUM FRACTURE			5 (0.02)	1 (0.01)	6 (0.01)
ACHOLIA			1 (0.00)		1 (0.00)
ACID-BASE BALANCE DISORDER MIXED			1 (0.00)		1 (0.00)
ACIDOSIS	11 (0.19)	13 (0.08)	24 (0.08)	7 (0.09)	55 (0.09)
ACIDOSIS HYPERCHLORAEMIC	2 (0.03)				2 (0.00)
ACINETOBACTER BACTERAEemia		1 (0.01)			1 (0.00)
ACINETOBACTER INFECTION	1 (0.02)		3 (0.01)	2 (0.03)	6 (0.01)
ACNE	24 (0.41)	26 (0.15)	19 (0.06)	8 (0.10)	77 (0.13)
ACNE CYSTIC		1 (0.01)	1 (0.00)		2 (0.00)
ACNE FULMINANS	1 (0.02)				1 (0.00)
ACOUSTIC NEUROMA	1 (0.02)		2 (0.01)		3 (0.00)
ACQUIRED CLAW TOE		1 (0.01)			1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
ACQUIRED DIAPHRAGMATIC EVENTRATION			3 (0.01)	1 (0.01)	4 (0.01)
ACQUIRED HAEMOPHILIA			1 (0.00)	1 (0.01)	2 (0.00)
ACQUIRED IMMUNODEFICIENCY SYNDROME		4 (0.02)			4 (0.01)
ACQUIRED OESOPHAGEAL WEB			5 (0.02)	1 (0.01)	6 (0.01)
ACROCHORDON	1 (0.02)	3 (0.02)	6 (0.02)		10 (0.02)
ACRODERMATITIS ENTEROPATHICA	1 (0.02)				1 (0.00)
ACTINIC KERATOSIS			17 (0.06)	2 (0.03)	19 (0.03)
ACTINOMYCOSIS		2 (0.01)	12 (0.04)	4 (0.05)	18 (0.03)
ACTINOMYCOTIC PULMONARY INFECTION			1 (0.00)		1 (0.00)
ACTIVATED PARTIAL THROMBOPLASTIN TIME ABNORMAL			2 (0.01)		2 (0.00)
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED	6 (0.10)	24 (0.14)	41 (0.14)	16 (0.21)	87 (0.14)
ACTIVATED PARTIAL THROMBOPLASTIN TIME SHORTENED	1 (0.02)	1 (0.01)	7 (0.02)		9 (0.01)
ACTIVATED PROTEIN C RESISTANCE	1 (0.02)		1 (0.00)		2 (0.00)
ACTIVITIES OF DAILY LIVING IMPAIRED	8 (0.14)	27 (0.16)	43 (0.14)	26 (0.34)	104 (0.17)
ACUTE ABDOMEN	2 (0.03)	4 (0.02)	8 (0.03)	1 (0.01)	15 (0.02)
ACUTE CHEST SYNDROME		1 (0.01)			1 (0.00)
ACUTE CORONARY SYNDROME		43 (0.25)	136 (0.45)	20 (0.26)	199 (0.33)
ACUTE FEBRILE NEUTROPHILIC DERMATOSIS		2 (0.01)	6 (0.02)		8 (0.01)
ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS	6 (0.10)	7 (0.04)	14 (0.05)	12 (0.15)	39 (0.06)
ACUTE LEFT VENTRICULAR FAILURE		1 (0.01)	2 (0.01)		3 (0.00)
ACUTE LEUKAEMIA			1 (0.00)	4 (0.05)	5 (0.01)
ACUTE LYMPHOCYTIC LEUKAEMIA	12 (0.20)	2 (0.01)	1 (0.00)		15 (0.02)
ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT	5 (0.08)		1 (0.00)		6 (0.01)
ACUTE MYELOID LEUKAEMIA	2 (0.03)	14 (0.08)	52 (0.17)	13 (0.17)	81 (0.13)
ACUTE MYELOID LEUKAEMIA RECURRENT		2 (0.01)	1 (0.00)		3 (0.00)
ACUTE MYOCARDIAL INFARCTION	5 (0.08)	220 (1.29)	727 (2.40)	98 (1.26)	1050 (1.72)
ACUTE PRERENAL FAILURE		3 (0.02)	15 (0.05)	17 (0.22)	35 (0.06)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
ACUTE PROMYELOCYTIC LEUKAEMIA	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
ACUTE PSYCHOSIS	3 (0.05)	3 (0.02)	2 (0.01)	2 (0.03)	10 (0.02)
ACUTE PULMONARY HISTOPLASMOSIS			1 (0.00)		1 (0.00)
ACUTE PULMONARY OEDEMA	2 (0.03)	20 (0.12)	41 (0.14)	16 (0.21)	79 (0.13)
ACUTE RESPIRATORY DISTRESS SYNDROME	23 (0.39)	35 (0.21)	78 (0.26)	21 (0.27)	157 (0.26)
ACUTE RESPIRATORY FAILURE	4 (0.07)	8 (0.05)	39 (0.13)	25 (0.32)	76 (0.12)
ACUTE RIGHT VENTRICULAR FAILURE		1 (0.01)			1 (0.00)
ACUTE SINUSITIS		4 (0.02)	30 (0.10)	2 (0.03)	36 (0.06)
ACUTE TONSILLITIS	2 (0.03)	2 (0.01)		1 (0.01)	5 (0.01)
ADAMS-STOKES SYNDROME		2 (0.01)	1 (0.00)		3 (0.00)
ADENOCARCINOMA		2 (0.01)	11 (0.04)	1 (0.01)	14 (0.02)
ADENOCARCINOMA PANCREAS			4 (0.01)	1 (0.01)	5 (0.01)
ADENOID CYSTIC CARCINOMA		1 (0.01)			1 (0.00)
ADENOIDAL DISORDER	1 (0.02)		1 (0.00)		2 (0.00)
ADENOIDAL HYPERTROPHY	4 (0.07)				4 (0.01)
ADENOIDECTOMY		1 (0.01)			1 (0.00)
ADENOMA BENIGN		2 (0.01)	5 (0.02)		7 (0.01)
ADENOMATOUS POLYPOSIS COLI				1 (0.01)	1 (0.00)
ADENOMYOSIS		3 (0.02)		1 (0.01)	4 (0.01)
ADENOPATHY SYPHILITIC		1 (0.01)			1 (0.00)
ADENOSQUAMOUS CELL LUNG CANCER			1 (0.00)		1 (0.00)
ADENOVIRAL HAEMORRHAGIC CYSTITIS		2 (0.01)			2 (0.00)
ADENOVIRUS INFECTION	3 (0.05)				3 (0.00)
ADHESION	1 (0.02)	9 (0.05)	7 (0.02)	2 (0.03)	19 (0.03)
ADIPOSIS DOLOROSA		4 (0.02)			4 (0.01)
ADJUSTMENT DISORDER	3 (0.05)	8 (0.05)	3 (0.01)	1 (0.01)	15 (0.02)
ADJUSTMENT DISORDER WITH ANXIETY			1 (0.00)		1 (0.00)
ADJUSTMENT DISORDER WITH DEPRESSED MOOD			5 (0.02)		5 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
ADNEXA UTERI MASS	2 (0.03)	4 (0.02)			6 (0.01)
ADNEXA UTERI PAIN		2 (0.01)			2 (0.00)
ADRENAL ADENOMA		3 (0.02)	5 (0.02)		8 (0.01)
ADRENAL CARCINOMA	2 (0.03)				2 (0.00)
ADRENAL CORTEX DYSPLASIA	1 (0.02)				1 (0.00)
ADRENAL CORTICAL INSUFFICIENCY	1 (0.02)		1 (0.00)		2 (0.00)
ADRENAL DISORDER	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)
ADRENAL GLAND CANCER METASTATIC			1 (0.00)		1 (0.00)
ADRENAL HAEMORRHAGE			1 (0.00)	2 (0.03)	3 (0.00)
ADRENAL INSUFFICIENCY	3 (0.05)	10 (0.06)	9 (0.03)		22 (0.04)
ADRENAL INSUFFICIENCY NEONATAL	1 (0.02)				1 (0.00)
ADRENAL MASS		2 (0.01)	4 (0.01)	1 (0.01)	7 (0.01)
ADRENAL NEOPLASM		2 (0.01)	3 (0.01)		5 (0.01)
ADRENAL SUPPRESSION	1 (0.02)		2 (0.01)		3 (0.00)
ADRENALECTOMY			1 (0.00)		1 (0.00)
ADRENALITIS				1 (0.01)	1 (0.00)
ADRENOCORTICAL INSUFFICIENCY ACUTE		1 (0.01)	6 (0.02)	1 (0.01)	8 (0.01)
ADRENOCORTICAL INSUFFICIENCY CHRONIC			3 (0.01)		3 (0.00)
ADRENOMEGALY	1 (0.02)				1 (0.00)
ADULT T-CELL LYMPHOMA/LEUKAEMIA				1 (0.01)	1 (0.00)
ADVERSE DRUG REACTION	6 (0.10)	13 (0.08)	29 (0.10)	4 (0.05)	52 (0.09)
ADVERSE EVENT	5 (0.08)	93 (0.55)	224 (0.74)	35 (0.45)	357 (0.59)
AEROMONA INFECTION		4 (0.02)			4 (0.01)
AFFECT LABILITY	5 (0.08)	11 (0.06)	7 (0.02)	4 (0.05)	27 (0.04)
AFFECTIVE DISORDER	7 (0.12)	10 (0.06)	5 (0.02)	1 (0.01)	23 (0.04)
AFFERENT LOOP SYNDROME				1 (0.01)	1 (0.00)
AGEUSIA		28 (0.16)	41 (0.14)	15 (0.19)	84 (0.14)
AGGRESSION	79 (1.34)	80 (0.47)	50 (0.17)	16 (0.21)	225 (0.37)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
AGITATION	44 (0.74)	129 (0.76)	127 (0.42)	39 (0.50)	339 (0.56)
AGITATION NEONATAL	4 (0.07)				4 (0.01)
AGNOSIA			1 (0.00)		1 (0.00)
AGONAL RHYTHM	1 (0.02)				1 (0.00)
AGORAPHOBIA	1 (0.02)	5 (0.03)	5 (0.02)		11 (0.02)
AGRANULOCYTOSIS	22 (0.37)	42 (0.25)	82 (0.27)	16 (0.21)	162 (0.27)
AIDS DEMENTIA COMPLEX		1 (0.01)			1 (0.00)
AIDS ENCEPHALOPATHY		1 (0.01)			1 (0.00)
AIR EMBOLISM			1 (0.00)		1 (0.00)
AKATHISIA	6 (0.10)	11 (0.06)	4 (0.01)	2 (0.03)	23 (0.04)
AKINESIA		4 (0.02)	5 (0.02)	7 (0.09)	16 (0.03)
ALANINE AMINOTRANSFERASE ABNORMAL			4 (0.01)		4 (0.01)
ALANINE AMINOTRANSFERASE DECREASED	2 (0.03)		1 (0.00)	1 (0.01)	4 (0.01)
ALANINE AMINOTRANSFERASE INCREASED	86 (1.45)	258 (1.51)	369 (1.22)	106 (1.37)	819 (1.34)
ALBUMIN URINE PRESENT				1 (0.01)	1 (0.00)
ALBUMINURIA		1 (0.01)			1 (0.00)
ALCOHOL DETOXIFICATION			1 (0.00)	2 (0.03)	3 (0.00)
ALCOHOL INTERACTION	1 (0.02)	3 (0.02)			4 (0.01)
ALCOHOL INTOLERANCE		2 (0.01)		1 (0.01)	3 (0.00)
ALCOHOL POISONING	4 (0.07)	16 (0.09)	6 (0.02)	1 (0.01)	27 (0.04)
ALCOHOL PROBLEM		1 (0.01)	1 (0.00)		2 (0.00)
ALCOHOL USE	25 (0.42)	25 (0.15)	21 (0.07)	1 (0.01)	72 (0.12)
ALCOHOL WITHDRAWAL SYNDROME		5 (0.03)	4 (0.01)		9 (0.01)
ALCOHOLIC	2 (0.03)		1 (0.00)		3 (0.00)
ALCOHOLIC LIVER DISEASE		3 (0.02)	1 (0.00)		4 (0.01)
ALCOHOLIC PANCREATITIS			1 (0.00)		1 (0.00)
ALCOHOLISM		12 (0.07)	21 (0.07)		33 (0.05)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
ALDOLASE INCREASED		1 (0.01)	2 (0.01)		3 (0.00)
ALKALOSIS			4 (0.01)		4 (0.01)
ALLERGENIC DESENSITISATION PROCEDURE		1 (0.01)			1 (0.00)
ALLERGIC GRANULOMATOUS ANGIITIS		4 (0.02)	20 (0.07)	6 (0.08)	30 (0.05)
ALLERGIC KERATITIS		1 (0.01)			1 (0.00)
ALLERGIC RESPIRATORY DISEASE			1 (0.00)		1 (0.00)
ALLERGIC SINUSITIS			1 (0.00)		1 (0.00)
ALLERGY TEST POSITIVE		3 (0.02)	1 (0.00)		4 (0.01)
ALLERGY TO ANIMAL			2 (0.01)		2 (0.00)
ALLERGY TO ARTHROPOD STING			2 (0.01)		2 (0.00)
ALLERGY TO CHEMICALS		1 (0.01)			1 (0.00)
ALLODYNIA		3 (0.02)	1 (0.00)		4 (0.01)
ALLOGENIC BONE MARROW TRANSPLANTATION THERAPY	1 (0.02)				1 (0.00)
ALOPECIA	27 (0.46)	99 (0.58)	124 (0.41)	23 (0.30)	273 (0.45)
ALOPECIA AREATA		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
ALOPECIA EFFLUVIUM			1 (0.00)		1 (0.00)
ALOPECIA TOTALIS			1 (0.00)		1 (0.00)
ALOPECIA UNIVERSALIS		2 (0.01)			2 (0.00)
ALPHA 1 FOETOPROTEIN ABNORMAL	2 (0.03)				2 (0.00)
ALPHA 1 FOETOPROTEIN INCREASED		1 (0.01)	1 (0.00)		2 (0.00)
ALPHA 1 GLOBULIN ABNORMAL		1 (0.01)			1 (0.00)
ALPHA 2 GLOBULIN DECREASED			1 (0.00)		1 (0.00)
ALPHA 2 GLOBULIN INCREASED			1 (0.00)	1 (0.01)	2 (0.00)
ALPHA HAEMOLYTIC STREPTOCOCCAL INFECTION		4 (0.02)	6 (0.02)	1 (0.01)	11 (0.02)
ALPHA TUMOUR NECROSIS FACTOR INCREASED			1 (0.00)		1 (0.00)
ALPHA-1 ACID GLYCOPROTEIN INCREASED		1 (0.01)			1 (0.00)
ALTERED VISUAL DEPTH PERCEPTION			2 (0.01)	1 (0.01)	3 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ALTERNARIA INFECTION		1 (0.01)			1 (0.00)
ALVEOLITIS		3 (0.02)	8 (0.03)	1 (0.01)	12 (0.02)
ALVEOLITIS ALLERGIC		9 (0.05)	4 (0.01)		13 (0.02)
ALVEOLITIS FIBROSING			5 (0.02)	1 (0.01)	6 (0.01)
ALVEOLOPLASTY			2 (0.01)		2 (0.00)
AMAUROSIS		1 (0.01)			1 (0.00)
AMAUROSIS FUGAX		1 (0.01)	19 (0.06)	3 (0.04)	23 (0.04)
AMBLYOPIA	1 (0.02)		8 (0.03)		9 (0.01)
AMBLYOPIA STRABISMIC		2 (0.01)			2 (0.00)
AMENORRHOEA	12 (0.20)	37 (0.22)	2 (0.01)		51 (0.08)
AMERICAN TRYPAOSOMIASIS				1 (0.01)	1 (0.00)
AMMONIA INCREASED	3 (0.05)	16 (0.09)	6 (0.02)	5 (0.06)	30 (0.05)
AMNESIA	16 (0.27)	133 (0.78)	175 (0.58)	32 (0.41)	356 (0.58)
AMNIOTIC FLUID VOLUME DECREASED	1 (0.02)				1 (0.00)
AMNIOTIC FLUID VOLUME INCREASED		1 (0.01)			1 (0.00)
AMOEBIASIS			1 (0.00)		1 (0.00)
AMPHETAMINES POSITIVE			1 (0.00)		1 (0.00)
AMPUTATION		3 (0.02)	2 (0.01)		5 (0.01)
AMYLOIDOSIS			2 (0.01)		2 (0.00)
AMYOTROPHIC LATERAL SCLEROSIS		3 (0.02)	9 (0.03)		12 (0.02)
AMYOTROPHY			5 (0.02)		5 (0.01)
ANAEMIA	80 (1.35)	226 (1.32)	545 (1.80)	186 (2.40)	1037 (1.70)
ANAEMIA FOLATE DEFICIENCY			2 (0.01)		2 (0.00)
ANAEMIA HAEMOLYTIC AUTOIMMUNE	1 (0.02)	5 (0.03)	17 (0.06)	3 (0.04)	26 (0.04)
ANAEMIA MACROCYTIC		8 (0.05)	13 (0.04)	4 (0.05)	25 (0.04)
ANAEMIA NEONATAL	3 (0.05)	1 (0.01)			4 (0.01)
ANAEMIA OF CHRONIC DISEASE	1 (0.02)	3 (0.02)	5 (0.02)	1 (0.01)	10 (0.02)
ANAEMIA OF MALIGNANT DISEASE			5 (0.02)	2 (0.03)	7 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
ANAEMIA POSTOPERATIVE			12 (0.04)	4 (0.05)	16 (0.03)
ANAEMIA VITAMIN B12 DEFICIENCY			1 (0.00)		1 (0.00)
ANAEMIC HYPOXIA			1 (0.00)		1 (0.00)
ANAESTHETIC COMPLICATION	3 (0.05)	7 (0.04)	12 (0.04)	2 (0.03)	24 (0.04)
ANAESTHETIC COMPLICATION CARDIAC			1 (0.00)		1 (0.00)
ANAESTHETIC COMPLICATION NEONATAL	1 (0.02)				1 (0.00)
ANAESTHETIC COMPLICATION PULMONARY			1 (0.00)		1 (0.00)
ANAL ABSCESS		1 (0.01)	1 (0.00)		2 (0.00)
ANAL CANCER		2 (0.01)	1 (0.00)		3 (0.00)
ANAL DISCOMFORT		5 (0.03)	3 (0.01)		8 (0.01)
ANAL FISSURE	9 (0.15)	6 (0.04)	9 (0.03)		24 (0.04)
ANAL FISSURE EXCISION		1 (0.01)			1 (0.00)
ANAL FISTULA	3 (0.05)		9 (0.03)	2 (0.03)	14 (0.02)
ANAL HAEMORRHAGE	1 (0.02)	1 (0.01)	3 (0.01)		5 (0.01)
ANAL INFLAMMATION				1 (0.01)	1 (0.00)
ANAL SPHINCTER ATONY		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
ANAL ULCER	2 (0.03)		1 (0.00)		3 (0.00)
ANALGESIC ASTHMA SYNDROME		1 (0.01)			1 (0.00)
ANALGESIC DRUG LEVEL INCREASED		2 (0.01)	1 (0.00)		3 (0.00)
ANALGESIC EFFECT		1 (0.01)	1 (0.00)		2 (0.00)
ANAPHYLACTIC REACTION	36 (0.61)	65 (0.38)	85 (0.28)	10 (0.13)	196 (0.32)
ANAPHYLACTIC SHOCK	20 (0.34)	49 (0.29)	74 (0.24)	10 (0.13)	153 (0.25)
ANAPHYLACTOID REACTION	10 (0.17)	11 (0.06)	15 (0.05)		36 (0.06)
ANAPHYLACTOID SHOCK	3 (0.05)	1 (0.01)	1 (0.00)	1 (0.01)	6 (0.01)
ANAPLASTIC ASTROCYTOMA	1 (0.02)				1 (0.00)
ANASTOMOTIC COMPLICATION		1 (0.01)	2 (0.01)		3 (0.00)
ANASTOMOTIC HAEMORRHAGE			1 (0.00)		1 (0.00)
ANASTOMOTIC ULCER			1 (0.00)		1 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
ANDROGENS DECREASED			1 (0.00)		1 (0.00)
ANDROGENS INCREASED	2 (0.03)				2 (0.00)
ANENCEPHALY		1 (0.01)			1 (0.00)
ANEURYSM		19 (0.11)	52 (0.17)	7 (0.09)	78 (0.13)
ANEURYSM RUPTURED		1 (0.01)	5 (0.02)	1 (0.01)	7 (0.01)
ANGER	10 (0.17)	31 (0.18)	22 (0.07)	2 (0.03)	65 (0.11)
ANGINA BULLOSA HAEMORRHAGICA			1 (0.00)		1 (0.00)
ANGINA PECTORIS	10 (0.17)	179 (1.05)	527 (1.74)	60 (0.77)	776 (1.27)
ANGINA UNSTABLE		74 (0.43)	210 (0.69)	10 (0.13)	294 (0.48)
ANGIOCENTRIC LYMPHOMA			1 (0.00)		1 (0.00)
ANGIODYSPLASIA			1 (0.00)	1 (0.01)	2 (0.00)
ANGIOGRAM ABNORMAL		1 (0.01)	2 (0.01)		3 (0.00)
ANGIOMYOLIPOMA			1 (0.00)		1 (0.00)
ANGIONEUROTIC OEDEMA	16 (0.27)	59 (0.35)	104 (0.34)	22 (0.28)	201 (0.33)
ANGIOPATHY	5 (0.08)	12 (0.07)	63 (0.21)	8 (0.10)	88 (0.14)
ANGIOPLASTY			3 (0.01)	1 (0.01)	4 (0.01)
ANGIOTENSIN CONVERTING ENZYME INCREASED		3 (0.02)			3 (0.00)
ANGLE CLOSURE GLAUCOMA		4 (0.02)	5 (0.02)	2 (0.03)	11 (0.02)
ANHEDONIA	16 (0.27)	13 (0.08)	24 (0.08)	6 (0.08)	59 (0.10)
ANHIDROSIS			2 (0.01)		2 (0.00)
ANIMAL BITE		1 (0.01)	7 (0.02)		8 (0.01)
ANIMAL SCRATCH		2 (0.01)	1 (0.00)		3 (0.00)
ANION GAP ABNORMAL				1 (0.01)	1 (0.00)
ANION GAP DECREASED				1 (0.01)	1 (0.00)
ANION GAP INCREASED	2 (0.03)	4 (0.02)			6 (0.01)
ANISOCYTOSIS	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
ANKLE FRACTURE	1 (0.02)	17 (0.10)	33 (0.11)	5 (0.06)	56 (0.09)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
ANKLE OPERATION			2 (0.01)		2 (0.00)
ANKYLOSING SPONDYLITIS		2 (0.01)	5 (0.02)		7 (0.01)
ANOMALY OF EXTERNAL EAR CONGENITAL	2 (0.03)				2 (0.00)
ANORECTAL DISORDER	2 (0.03)	3 (0.02)	8 (0.03)	2 (0.03)	15 (0.02)
ANOREXIA	36 (0.61)	82 (0.48)	217 (0.72)	70 (0.90)	405 (0.66)
ANOREXIA NERVOSA			1 (0.00)	1 (0.01)	2 (0.00)
ANORGASMIA	1 (0.02)	8 (0.05)	7 (0.02)		16 (0.03)
ANOSMIA		6 (0.04)	16 (0.05)	2 (0.03)	24 (0.04)
ANOXIA			3 (0.01)		3 (0.00)
ANOXIC ENCEPHALOPATHY		8 (0.05)	13 (0.04)	6 (0.08)	27 (0.04)
ANTEPARTUM HAEMORRHAGE	1 (0.02)	2 (0.01)			3 (0.00)
ANTEROGRADE AMNESIA	1 (0.02)	1 (0.01)		4 (0.05)	6 (0.01)
ANTI FACTOR VII ANTIBODY POSITIVE		1 (0.01)			1 (0.00)
ANTI FACTOR VIII ANTIBODY POSITIVE	7 (0.12)	2 (0.01)	2 (0.01)		11 (0.02)
ANTI-ERYTHROCYTE ANTIBODY POSITIVE	2 (0.03)				2 (0.00)
ANTI-ERYTHROPOIETIN ANTIBODY POSITIVE			1 (0.00)		1 (0.00)
ANTI-GAD ANTIBODY POSITIVE		1 (0.01)			1 (0.00)
ANTI-HBC ANTIBODY POSITIVE			1 (0.00)		1 (0.00)
ANTI-HBS ANTIBODY POSITIVE	1 (0.02)				1 (0.00)
ANTI-INSULIN ANTIBODY			2 (0.01)		2 (0.00)
ANTI-INSULIN ANTIBODY POSITIVE	1 (0.02)		5 (0.02)		6 (0.01)
ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE VASC		1 (0.01)	1 (0.00)		2 (0.00)
ANTI-PLATELET ANTIBODY POSITIVE		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)
ANTI-SS-A ANTIBODY POSITIVE				1 (0.01)	1 (0.00)
ANTI-THYROID ANTIBODY POSITIVE	1 (0.02)	3 (0.02)			4 (0.01)
ANTIBIOTIC LEVEL ABOVE THERAPEUTIC	1 (0.02)		3 (0.01)	1 (0.01)	5 (0.01)
ANTIBODY TEST ABNORMAL	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
ANTIBODY TEST POSITIVE	2 (0.03)		2 (0.01)	4 (0.05)	8 (0.01)
ANTICHOLINERGIC SYNDROME	2 (0.03)	1 (0.01)	1 (0.00)		4 (0.01)
ANTICOAGULATION DRUG LEVEL			1 (0.00)		1 (0.00)
ANTICONVULSANT DRUG LEVEL ABNORMAL	1 (0.02)	1 (0.01)		1 (0.01)	3 (0.00)
ANTICONVULSANT DRUG LEVEL ABOVE THERAPEUTIC		3 (0.02)	2 (0.01)		5 (0.01)
ANTICONVULSANT DRUG LEVEL BELOW THERAPEUTIC	1 (0.02)	2 (0.01)	7 (0.02)	1 (0.01)	11 (0.02)
ANTICONVULSANT DRUG LEVEL DECREASED	3 (0.05)	1 (0.01)	6 (0.02)	2 (0.03)	12 (0.02)
ANTICONVULSANT DRUG LEVEL INCREASED	2 (0.03)		5 (0.02)	3 (0.04)	10 (0.02)
ANTICONVULSANT TOXICITY			2 (0.01)		2 (0.00)
ANTIDEPRESSANT DRUG LEVEL	1 (0.02)				1 (0.00)
ANTIDEPRESSANT DRUG LEVEL INCREASED			1 (0.00)	1 (0.01)	2 (0.00)
ANTIDIURETIC HORMONE ABNORMALITY		1 (0.01)			1 (0.00)
ANTIMICROBIAL SUSCEPTIBILITY TEST RESISTANT				1 (0.01)	1 (0.00)
ANTIMITOCHONDRIAL ANTIBODY POSITIVE		1 (0.01)			1 (0.00)
ANTINEUTROPHIL CYTOPLASMIC ANTIBODY INCREASED			1 (0.00)		1 (0.00)
ANTINEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE		1 (0.01)	2 (0.01)		3 (0.00)
ANTINUCLEAR ANTIBODY		1 (0.01)		1 (0.01)	2 (0.00)
ANTINUCLEAR ANTIBODY INCREASED		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
ANTINUCLEAR ANTIBODY POSITIVE	6 (0.10)	7 (0.04)	19 (0.06)	6 (0.08)	38 (0.06)
ANTIPHOSPHOLIPID ANTIBODIES			2 (0.01)		2 (0.00)
ANTIPHOSPHOLIPID ANTIBODIES POSITIVE		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
ANTIPHOSPHOLIPID SYNDROME	3 (0.05)	7 (0.04)	1 (0.00)		11 (0.02)
ANTIPSYCHOTIC DRUG LEVEL ABOVE THERAPEUTIC		2 (0.01)		1 (0.01)	3 (0.00)
ANTIPSYCHOTIC DRUG LEVEL BELOW THERAPEUTIC			2 (0.01)		2 (0.00)
ANTIPSYCHOTIC DRUG LEVEL INCREASED		1 (0.01)	3 (0.01)		4 (0.01)
ANTISOCIAL BEHAVIOUR	1 (0.02)				1 (0.00)
ANTISOCIAL PERSONALITY DISORDER		1 (0.01)	1 (0.00)		2 (0.00)

Reaction Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ANTITHROMBIN III DECREASED			3 (0.01)	1 (0.01)	4 (0.01)
ANTITHROMBIN III DEFICIENCY		1 (0.01)	2 (0.01)		3 (0.00)
ANURIA	3 (0.05)	11 (0.06)	23 (0.08)	7 (0.09)	44 (0.07)
ANXIETY	50 (0.85)	373 (2.19)	513 (1.70)	70 (0.90)	1006 (1.65)
ANXIETY DISORDER	2 (0.03)	14 (0.08)	14 (0.05)	1 (0.01)	31 (0.05)
AORTIC ANEURYSM		5 (0.03)	44 (0.15)	16 (0.21)	65 (0.11)
AORTIC ANEURYSM REPAIR			1 (0.00)	2 (0.03)	3 (0.00)
AORTIC ANEURYSM RUPTURE			5 (0.02)	2 (0.03)	7 (0.01)
AORTIC ARTERIOSCLEROSIS		4 (0.02)	25 (0.08)	11 (0.14)	40 (0.07)
AORTIC BYPASS			1 (0.00)		1 (0.00)
AORTIC CALCIFICATION			5 (0.02)	1 (0.01)	6 (0.01)
AORTIC DILATATION		1 (0.01)	3 (0.01)		4 (0.01)
AORTIC DISORDER		1 (0.01)	3 (0.01)	1 (0.01)	5 (0.01)
AORTIC DISSECTION	2 (0.03)	6 (0.04)	13 (0.04)		21 (0.03)
AORTIC EMBOLUS		1 (0.01)	1 (0.00)		2 (0.00)
AORTIC OCCLUSION			3 (0.01)		3 (0.00)
AORTIC RUPTURE			1 (0.00)		1 (0.00)
AORTIC SURGERY			1 (0.00)		1 (0.00)
AORTIC THROMBOSIS			5 (0.02)	1 (0.01)	6 (0.01)
AORTIC VALVE CALCIFICATION			5 (0.02)		5 (0.01)
AORTIC VALVE DISEASE		1 (0.01)	10 (0.03)	3 (0.04)	14 (0.02)
AORTIC VALVE DISEASE MIXED			2 (0.01)		2 (0.00)
AORTIC VALVE INCOMPETENCE	1 (0.02)	19 (0.11)	46 (0.15)	9 (0.12)	75 (0.12)
AORTIC VALVE REPLACEMENT		1 (0.01)	2 (0.01)	3 (0.04)	6 (0.01)
AORTIC VALVE SCLEROSIS			6 (0.02)	2 (0.03)	8 (0.01)
AORTIC VALVE STENOSIS			18 (0.06)	14 (0.18)	32 (0.05)
APALLIC SYNDROME	1 (0.02)	2 (0.01)	3 (0.01)	2 (0.03)	8 (0.01)
APATHY	6 (0.10)	3 (0.02)	18 (0.06)	6 (0.08)	33 (0.05)

Reaction Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
APGAR SCORE ABNORMAL	1 (0.02)				1 (0.00)
APGAR SCORE LOW	14 (0.24)	1 (0.01)			15 (0.02)
APHAGIA	2 (0.03)	3 (0.02)	5 (0.02)	2 (0.03)	12 (0.02)
APHASIA	13 (0.22)	31 (0.18)	61 (0.20)	11 (0.14)	116 (0.19)
APHONIA	1 (0.02)	4 (0.02)	5 (0.02)	3 (0.04)	13 (0.02)
APHTHOUS STOMATITIS	7 (0.12)	8 (0.05)	14 (0.05)	2 (0.03)	31 (0.05)
APICECTOMY		2 (0.01)			2 (0.00)
APLASIA	2 (0.03)	3 (0.02)	4 (0.01)	2 (0.03)	11 (0.02)
APLASIA PURE RED CELL	5 (0.08)	12 (0.07)	12 (0.04)	4 (0.05)	33 (0.05)
APLASTIC ANAEMIA	3 (0.05)	1 (0.01)	7 (0.02)	7 (0.09)	18 (0.03)
APNOEA	21 (0.36)	15 (0.09)	19 (0.06)	5 (0.06)	60 (0.10)
APNOEIC ATTACK	5 (0.08)				5 (0.01)
APPENDICECTOMY	3 (0.05)	5 (0.03)	8 (0.03)		16 (0.03)
APPENDICITIS	4 (0.07)	12 (0.07)	10 (0.03)	3 (0.04)	29 (0.05)
APPENDICITIS PERFORATED		2 (0.01)	9 (0.03)		11 (0.02)
APPENDIX DISORDER	1 (0.02)	2 (0.01)	6 (0.02)	4 (0.05)	13 (0.02)
APPETITE DISORDER	1 (0.02)	2 (0.01)	4 (0.01)		7 (0.01)
APPLICATION SITE ABSCESS		2 (0.01)			2 (0.00)
APPLICATION SITE BLEEDING		1 (0.01)	1 (0.00)		2 (0.00)
APPLICATION SITE BURN	1 (0.02)	4 (0.02)	3 (0.01)		8 (0.01)
APPLICATION SITE DERMATITIS		3 (0.02)	2 (0.01)		5 (0.01)
APPLICATION SITE DISCOLOURATION		1 (0.01)			1 (0.00)
APPLICATION SITE ERYTHEMA	1 (0.02)	12 (0.07)	7 (0.02)		20 (0.03)
APPLICATION SITE HYPERSENSITIVITY			1 (0.00)		1 (0.00)
APPLICATION SITE INFECTION	2 (0.03)			1 (0.01)	3 (0.00)
APPLICATION SITE IRRITATION		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
APPLICATION SITE NECROSIS				1 (0.01)	1 (0.00)
APPLICATION SITE PAIN	1 (0.02)	1 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)

Reaction Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
APPLICATION SITE PRURITUS		1 (0.01)			1 (0.00)
APPLICATION SITE REACTION			1 (0.00)		1 (0.00)
APPLICATION SITE URTICARIA		1 (0.01)			1 (0.00)
APRAXIA			2 (0.01)	2 (0.03)	4 (0.01)
APTYALISM		3 (0.02)		1 (0.01)	4 (0.01)
ARACHNOIDITIS		2 (0.01)	2 (0.01)		4 (0.01)
AREFLEXIA	8 (0.14)	2 (0.01)	11 (0.04)	3 (0.04)	24 (0.04)
ARM AMPUTATION	2 (0.03)	1 (0.01)	1 (0.00)		4 (0.01)
ARNOLD-CHIARI MALFORMATION	1 (0.02)		1 (0.00)		2 (0.00)
ARRESTED LABOUR		1 (0.01)			1 (0.00)
ARRHYTHMIA	16 (0.27)	83 (0.49)	201 (0.66)	45 (0.58)	345 (0.57)
ARRHYTHMIA SUPRAVENTRICULAR	2 (0.03)		6 (0.02)	7 (0.09)	15 (0.02)
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA	1 (0.02)				1 (0.00)
ARTERIAL BRUIT			1 (0.00)		1 (0.00)
ARTERIAL BYPASS OPERATION			3 (0.01)		3 (0.00)
ARTERIAL DISORDER		1 (0.01)	20 (0.07)	6 (0.08)	27 (0.04)
ARTERIAL GRAFT			1 (0.00)		1 (0.00)
ARTERIAL HAEMORRHAGE			3 (0.01)		3 (0.00)
ARTERIAL INJURY		5 (0.03)	4 (0.01)		9 (0.01)
ARTERIAL INSUFFICIENCY			1 (0.00)	1 (0.01)	2 (0.00)
ARTERIAL OCCLUSIVE DISEASE	3 (0.05)	23 (0.13)	116 (0.38)	15 (0.19)	157 (0.26)
ARTERIAL REPAIR		2 (0.01)	1 (0.00)	3 (0.04)	6 (0.01)
ARTERIAL RESTENOSIS			2 (0.01)		2 (0.00)
ARTERIAL RUPTURE		1 (0.01)	3 (0.01)	1 (0.01)	5 (0.01)
ARTERIAL SPASM			3 (0.01)		3 (0.00)
ARTERIAL STENOSIS		2 (0.01)	5 (0.02)	4 (0.05)	11 (0.02)
ARTERIAL STENOSIS LIMB		1 (0.01)	2 (0.01)		3 (0.00)
ARTERIAL STENT INSERTION			3 (0.01)	1 (0.01)	4 (0.01)

Reaction Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ARTERIAL THERAPEUTIC PROCEDURE			2 (0.01)	1 (0.01)	3 (0.00)
ARTERIAL THROMBOSIS		12 (0.07)	17 (0.06)	1 (0.01)	30 (0.05)
ARTERIAL THROMBOSIS LIMB	1 (0.02)	3 (0.02)	6 (0.02)	1 (0.01)	11 (0.02)
ARTERIOGRAM CORONARY ABNORMAL			1 (0.00)		1 (0.00)
ARTERIOGRAM CORONARY NORMAL			1 (0.00)		1 (0.00)
ARTERIOPATHIC DISEASE		1 (0.01)		1 (0.01)	2 (0.00)
ARTERIOSCLEROSIS		35 (0.21)	120 (0.40)	32 (0.41)	187 (0.31)
ARTERIOSCLEROSIS CORONARY ARTERY		23 (0.13)	89 (0.29)	19 (0.25)	131 (0.21)
ARTERIOSPASM CORONARY		9 (0.05)	5 (0.02)	1 (0.01)	15 (0.02)
ARTERIOVENOUS FISTULA		1 (0.01)	4 (0.01)		5 (0.01)
ARTERIOVENOUS FISTULA SITE COMPLICATION		1 (0.01)	1 (0.00)		2 (0.00)
ARTERIOVENOUS FISTULA THROMBOSIS		2 (0.01)	2 (0.01)		4 (0.01)
ARTERIOVENOUS MALFORMATION		3 (0.02)	3 (0.01)	2 (0.03)	8 (0.01)
ARTERITIS				1 (0.01)	1 (0.00)
ARTERY DISSECTION		3 (0.02)	3 (0.01)		6 (0.01)
ARTHRALGIA	56 (0.95)	150 (0.88)	321 (1.06)	62 (0.80)	589 (0.97)
ARTHRITIS	6 (0.10)	52 (0.30)	81 (0.27)	15 (0.19)	154 (0.25)
ARTHRITIS BACTERIAL	2 (0.03)	2 (0.01)	11 (0.04)		15 (0.02)
ARTHRITIS ENTEROPATHIC		1 (0.01)			1 (0.00)
ARTHRITIS INFECTIVE		3 (0.02)	7 (0.02)		10 (0.02)
ARTHRITIS REACTIVE			2 (0.01)		2 (0.00)
ARTHRODESIS		2 (0.01)	4 (0.01)		6 (0.01)
ARTHROPATHY	8 (0.14)	78 (0.46)	255 (0.84)	38 (0.49)	379 (0.62)
ARTHROPOD BITE	4 (0.07)	2 (0.01)	7 (0.02)		13 (0.02)
ARTHROPOD STING		1 (0.01)	1 (0.00)		2 (0.00)
ARTHROSCOPIC SURGERY			2 (0.01)	1 (0.01)	3 (0.00)
ARTHROSCOPY		1 (0.01)			1 (0.00)
ARTIFICIAL CROWN PROCEDURE		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
ARTIFICIAL RUPTURE OF MEMBRANES	2 (0.03)				2 (0.00)
ASBESTOSIS				1 (0.01)	1 (0.00)
ASCITES	12 (0.20)	25 (0.15)	50 (0.17)	15 (0.19)	102 (0.17)
ASPARTATE AMINOTRANSFERASE ABNORMAL		1 (0.01)	1 (0.00)		2 (0.00)
ASPARTATE AMINOTRANSFERASE DECREASED			2 (0.01)		2 (0.00)
ASPARTATE AMINOTRANSFERASE INCREASED	8 (0.14)	16 (0.09)	32 (0.11)	5 (0.06)	61 (0.10)
ASPERGILLOSIS	5 (0.08)	3 (0.02)	10 (0.03)	2 (0.03)	20 (0.03)
ASPHYXIA	4 (0.07)	4 (0.02)	3 (0.01)		11 (0.02)
ASPIRATION	9 (0.15)	9 (0.05)	23 (0.08)	12 (0.15)	53 (0.09)
ASPIRATION BONE MARROW ABNORMAL		1 (0.01)		1 (0.01)	2 (0.00)
ASPIRATION BRONCHIAL	1 (0.02)		1 (0.00)		2 (0.00)
ASPIRATION JOINT			1 (0.00)		1 (0.00)
ASTERIXIS	1 (0.02)		2 (0.01)	3 (0.04)	6 (0.01)
ASTHENIA	51 (0.86)	250 (1.47)	518 (1.71)	191 (2.46)	1010 (1.66)
ASTHENOPIA	1 (0.02)	5 (0.03)	7 (0.02)	6 (0.08)	19 (0.03)
ASTHMA	30 (0.51)	62 (0.36)	101 (0.33)	21 (0.27)	214 (0.35)
ASTHMATIC CRISIS				2 (0.03)	2 (0.00)
ASTIGMATISM		3 (0.02)	1 (0.00)	1 (0.01)	5 (0.01)
ASTROCYTOMA	1 (0.02)	1 (0.01)			2 (0.00)
ASTROCYTOMA, LOW GRADE	1 (0.02)				1 (0.00)
ATELECTASIS	6 (0.10)	4 (0.02)	33 (0.11)	4 (0.05)	47 (0.08)
ATHETOSIS			1 (0.00)		1 (0.00)
ATONIC SEIZURES	1 (0.02)				1 (0.00)
ATONIC URINARY BLADDER			2 (0.01)		2 (0.00)
ATRIAL CONDUCTION TIME PROLONGATION			1 (0.00)		1 (0.00)
ATRIAL FIBRILLATION	3 (0.05)	32 (0.19)	242 (0.80)	103 (1.33)	380 (0.62)
ATRIAL FLUTTER	1 (0.02)	2 (0.01)	23 (0.08)	6 (0.08)	32 (0.05)
ATRIAL HYPERTROPHY		2 (0.01)			2 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
ATRIAL PRESSURE INCREASED			1 (0.00)		1 (0.00)
ATRIAL SEPTAL DEFECT	5 (0.08)	2 (0.01)	5 (0.02)		12 (0.02)
ATRIAL SEPTAL DEFECT REPAIR			1 (0.00)		1 (0.00)
ATRIAL TACHYCARDIA		1 (0.01)		1 (0.01)	2 (0.00)
ATRIAL THROMBOSIS			5 (0.02)	1 (0.01)	6 (0.01)
ATRIOVENTRICULAR BLOCK		4 (0.02)	27 (0.09)	6 (0.08)	37 (0.06)
ATRIOVENTRICULAR BLOCK COMPLETE	5 (0.08)	6 (0.04)	37 (0.12)	12 (0.15)	60 (0.10)
ATRIOVENTRICULAR BLOCK FIRST DEGREE	2 (0.03)	5 (0.03)	12 (0.04)	7 (0.09)	26 (0.04)
ATRIOVENTRICULAR BLOCK SECOND DEGREE		3 (0.02)	8 (0.03)	8 (0.10)	19 (0.03)
ATROPHIC VULVOVAGINITIS			3 (0.01)		3 (0.00)
ATROPHY	1 (0.02)	4 (0.02)	8 (0.03)		13 (0.02)
ATROPHY OF TONGUE PAPILLAE		2 (0.01)	1 (0.00)		3 (0.00)
ATTENTION DEFICIT/HYPERACTIVITY DISORDER	2 (0.03)	2 (0.01)	3 (0.01)		7 (0.01)
ATYPICAL MYCOBACTERIAL INFECTION	3 (0.05)				3 (0.00)
AUDIOGRAM ABNORMAL		1 (0.01)			1 (0.00)
AURA	1 (0.02)	1 (0.01)			2 (0.00)
AURICULAR SWELLING		2 (0.01)	4 (0.01)		6 (0.01)
AUTISM	1 (0.02)				1 (0.00)
AUTOANTIBODY POSITIVE		1 (0.01)			1 (0.00)
AUTOIMMUNE DISORDER	1 (0.02)	4 (0.02)	4 (0.01)		9 (0.01)
AUTOIMMUNE HEPATITIS	4 (0.07)	10 (0.06)	9 (0.03)	1 (0.01)	24 (0.04)
AUTOIMMUNE NEUTROPENIA	1 (0.02)	1 (0.01)			2 (0.00)
AUTOIMMUNE THROMBOCYTOPENIA		1 (0.01)	1 (0.00)		2 (0.00)
AUTOIMMUNE THYROIDITIS	2 (0.03)	1 (0.01)	1 (0.00)		4 (0.01)
AUTOMATISM			1 (0.00)		1 (0.00)
AUTONOMIC FAILURE SYNDROME			1 (0.00)	1 (0.01)	2 (0.00)
AUTONOMIC NERVOUS SYSTEM IMBALANCE	1 (0.02)	3 (0.02)	2 (0.01)		6 (0.01)
AUTONOMIC NEUROPATHY			1 (0.00)		1 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
AV DISSOCIATION		1 (0.01)			1 (0.00)
AXILLARY MASS			1 (0.00)	1 (0.01)	2 (0.00)
AXILLARY PAIN		1 (0.01)	1 (0.00)		2 (0.00)
AXILLARY VEIN THROMBOSIS		1 (0.01)	2 (0.01)		3 (0.00)
AZOOSPERMIA		6 (0.04)	5 (0.02)		11 (0.02)
AZOTAEMIA		1 (0.01)	10 (0.03)	4 (0.05)	15 (0.02)
B-CELL LYMPHOMA		6 (0.04)	7 (0.02)	1 (0.01)	14 (0.02)
B-CELL LYMPHOMA STAGE I			1 (0.00)		1 (0.00)
B-CELL SMALL LYMPHOCYTIC LYMPHOMA			1 (0.00)		1 (0.00)
B-CELL UNCLASSIFIABLE LYMPHOMA LOW GRADE			1 (0.00)		1 (0.00)
B-LYMPHOCYTE COUNT DECREASED	1 (0.02)		1 (0.00)		2 (0.00)
BACK DISORDER		36 (0.21)	68 (0.22)	11 (0.14)	115 (0.19)
BACK INJURY		34 (0.20)	28 (0.09)	3 (0.04)	65 (0.11)
BACK PAIN	9 (0.15)	117 (0.69)	203 (0.67)	55 (0.71)	384 (0.63)
BACTERAEMIA		4 (0.02)	16 (0.05)	6 (0.08)	26 (0.04)
BACTERIA BLOOD IDENTIFIED		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
BACTERIA SPUTUM IDENTIFIED			2 (0.01)		2 (0.00)
BACTERIA STOOL IDENTIFIED		2 (0.01)	1 (0.00)		3 (0.00)
BACTERIA URINE IDENTIFIED	2 (0.03)	1 (0.01)	4 (0.01)	1 (0.01)	8 (0.01)
BACTERIAL CULTURE POSITIVE	1 (0.02)				1 (0.00)
BACTERIAL DISEASE CARRIER	1 (0.02)				1 (0.00)
BACTERIAL INFECTION	5 (0.08)	22 (0.13)	30 (0.10)	1 (0.01)	58 (0.10)
BACTERIAL PYELONEPHRITIS	1 (0.02)		1 (0.00)		2 (0.00)
BACTERIAL SEPSIS	2 (0.03)	4 (0.02)	6 (0.02)	1 (0.01)	13 (0.02)
BACTERIAL TEST POSITIVE			1 (0.00)		1 (0.00)
BACTERIURIA			2 (0.01)		2 (0.00)
BAKER'S CYST EXCISION			2 (0.01)		2 (0.00)
BALANCE DISORDER	12 (0.20)	36 (0.21)	78 (0.26)	26 (0.34)	152 (0.25)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
BALANITIS	1 (0.02)	2 (0.01)	1 (0.00)		4 (0.01)
BAND NEUTROPHIL COUNT INCREASED		1 (0.01)	1 (0.00)		2 (0.00)
BANKRUPTCY			1 (0.00)		1 (0.00)
BARRETT'S OESOPHAGUS		3 (0.02)	5 (0.02)	1 (0.01)	9 (0.01)
BASAL CELL CARCINOMA		3 (0.02)	16 (0.05)	3 (0.04)	22 (0.04)
BASE EXCESS DECREASED				1 (0.01)	1 (0.00)
BASEDOW'S DISEASE	1 (0.02)	1 (0.01)	6 (0.02)		8 (0.01)
BASILAR ARTERY THROMBOSIS		1 (0.01)			1 (0.00)
BASILAR MIGRAINE		2 (0.01)	1 (0.00)		3 (0.00)
BASOPHIL COUNT INCREASED		2 (0.01)	1 (0.00)		3 (0.00)
BASOSQUAMOUS CARCINOMA		1 (0.01)			1 (0.00)
BECKER'S MUSCULAR DYSTROPHY			1 (0.00)		1 (0.00)
BED REST			3 (0.01)		3 (0.00)
BEDRIDDEN	1 (0.02)	5 (0.03)	7 (0.02)	1 (0.01)	14 (0.02)
BEHCET'S SYNDROME			1 (0.00)		1 (0.00)
BELLIGERENCE			1 (0.00)		1 (0.00)
BENCE JONES PROTEIN URINE PRESENT			2 (0.01)		2 (0.00)
BENCE JONES PROTEINURIA			1 (0.00)		1 (0.00)
BENIGN BILIARY NEOPLASM			1 (0.00)		1 (0.00)
BENIGN BREAST NEOPLASM			3 (0.01)	1 (0.01)	4 (0.01)
BENIGN COLONIC NEOPLASM			1 (0.00)	1 (0.01)	2 (0.00)
BENIGN FEMALE REPRODUCTIVE TRACT NEOPLASM		1 (0.01)			1 (0.00)
BENIGN GASTRIC NEOPLASM		1 (0.01)			1 (0.00)
BENIGN HEPATIC NEOPLASM			1 (0.00)		1 (0.00)
BENIGN HYDATIDIFORM MOLE		1 (0.01)			1 (0.00)
BENIGN INTRACRANIAL HYPERTENSION	9 (0.15)	6 (0.04)	2 (0.01)		17 (0.03)
BENIGN LUNG NEOPLASM			1 (0.00)		1 (0.00)
BENIGN MUSCLE NEOPLASM		1 (0.01)			1 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
BENIGN NEOPLASM		2 (0.01)	1 (0.00)		3 (0.00)
BENIGN NEOPLASM OF SPINAL CORD	1 (0.02)				1 (0.00)
BENIGN PANCREATIC NEOPLASM			1 (0.00)		1 (0.00)
BENIGN PROSTATIC HYPERPLASIA	1 (0.02)	5 (0.03)	21 (0.07)	5 (0.06)	32 (0.05)
BEREAVEMENT REACTION				1 (0.01)	1 (0.00)
BETA 2 MICROGLOBULIN INCREASED				1 (0.01)	1 (0.00)
BETA HAEMOLYTIC STREPTOCOCCAL INFECTION	1 (0.02)		1 (0.00)	1 (0.01)	3 (0.00)
BEZOAR		1 (0.01)			1 (0.00)
BICUSPID AORTIC VALVE			1 (0.00)		1 (0.00)
BICYTOPENIA				1 (0.01)	1 (0.00)
BIFASCICULAR BLOCK		2 (0.01)	1 (0.00)		3 (0.00)
BILE DUCT CANCER	1 (0.02)	2 (0.01)	2 (0.01)	1 (0.01)	6 (0.01)
BILE DUCT NECROSIS		1 (0.01)	1 (0.00)		2 (0.00)
BILE DUCT OBSTRUCTION	1 (0.02)		14 (0.05)	1 (0.01)	16 (0.03)
BILE DUCT STENOSIS		3 (0.02)	1 (0.00)		4 (0.01)
BILE DUCT STENT INSERTION				1 (0.01)	1 (0.00)
BILE DUCT STONE		3 (0.02)	4 (0.01)	3 (0.04)	10 (0.02)
BILIARY ANASTOMOSIS COMPLICATION			1 (0.00)		1 (0.00)
BILIARY CANCER METASTATIC				1 (0.01)	1 (0.00)
BILIARY CIRRHOSIS		1 (0.01)			1 (0.00)
BILIARY CIRRHOSIS PRIMARY				2 (0.03)	2 (0.00)
BILIARY COLIC			2 (0.01)	1 (0.01)	3 (0.00)
BILIARY CYST			1 (0.00)		1 (0.00)
BILIARY DILATATION			5 (0.02)	1 (0.01)	6 (0.01)
BILIARY DYSKINESIA		3 (0.02)	1 (0.00)		4 (0.01)
BILIARY TRACT DISORDER			2 (0.01)		2 (0.00)
BILIARY TRACT INFECTION			1 (0.00)		1 (0.00)
BILIRUBIN CONJUGATED INCREASED			2 (0.01)		2 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
BINGE EATING		1 (0.01)			1 (0.00)
BIOPSY	1 (0.02)		1 (0.00)		2 (0.00)
BIOPSY BLOOD VESSEL ABNORMAL			1 (0.00)		1 (0.00)
BIOPSY BONE MARROW			2 (0.01)		2 (0.00)
BIOPSY BONE MARROW ABNORMAL			1 (0.00)	1 (0.01)	2 (0.00)
BIOPSY KIDNEY	2 (0.03)	2 (0.01)			4 (0.01)
BIOPSY KIDNEY ABNORMAL		3 (0.02)	1 (0.00)	1 (0.01)	5 (0.01)
BIOPSY LIVER ABNORMAL		1 (0.01)			1 (0.00)
BIOPSY LYMPH GLAND ABNORMAL		1 (0.01)			1 (0.00)
BIOPSY MUCOSA ABNORMAL		1 (0.01)			1 (0.00)
BIOPSY MUSCLE ABNORMAL				1 (0.01)	1 (0.00)
BIOPSY PROSTATE ABNORMAL			1 (0.00)		1 (0.00)
BIOPSY SITE UNSPECIFIED ABNORMAL			1 (0.00)		1 (0.00)
BIOPSY SKIN ABNORMAL	1 (0.02)	3 (0.02)	3 (0.01)		7 (0.01)
BIOPSY VOCAL CORD			2 (0.01)		2 (0.00)
BIPOLAR DISORDER	4 (0.07)	12 (0.07)	11 (0.04)		27 (0.04)
BIPOLAR I DISORDER	1 (0.02)	3 (0.02)			4 (0.01)
BITE			1 (0.00)		1 (0.00)
BLADDER ADENOCARCINOMA STAGE III				1 (0.01)	1 (0.00)
BLADDER CANCER		1 (0.01)	11 (0.04)		12 (0.02)
BLADDER CANCER RECURRENT			2 (0.01)		2 (0.00)
BLADDER CANCER STAGE II			1 (0.00)		1 (0.00)
BLADDER CANCER STAGE III				2 (0.03)	2 (0.00)
BLADDER CANCER STAGE IV			1 (0.00)		1 (0.00)
BLADDER CATHETER PERMANENT				1 (0.01)	1 (0.00)
BLADDER CATHETERISATION		1 (0.01)		1 (0.01)	2 (0.00)
BLADDER CYST		1 (0.01)			1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
BLADDER DISORDER		13 (0.08)	12 (0.04)	2 (0.03)	27 (0.04)
BLADDER DISTENSION	2 (0.03)		2 (0.01)	1 (0.01)	5 (0.01)
BLADDER DIVERTICULUM		1 (0.01)			1 (0.00)
BLADDER INJURY		1 (0.01)			1 (0.00)
BLADDER NECK OBSTRUCTION			1 (0.00)		1 (0.00)
BLADDER NECROSIS			2 (0.01)		2 (0.00)
BLADDER NEOPLASM		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
BLADDER NEOPLASM SURGERY				1 (0.01)	1 (0.00)
BLADDER OBSTRUCTION		1 (0.01)	3 (0.01)		4 (0.01)
BLADDER OPERATION		1 (0.01)	3 (0.01)		4 (0.01)
BLADDER PAIN		4 (0.02)	2 (0.01)	1 (0.01)	7 (0.01)
BLADDER PERFORATION			1 (0.00)		1 (0.00)
BLADDER PROLAPSE			1 (0.00)		1 (0.00)
BLADDER SPASM		1 (0.01)	4 (0.01)		5 (0.01)
BLADDER SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED				4 (0.05)	4 (0.01)
BLADDER TAMPONADE			2 (0.01)		2 (0.00)
BLAST CELL COUNT INCREASED	1 (0.02)		3 (0.01)	1 (0.01)	5 (0.01)
BLAST CELL PROLIFERATION			1 (0.00)		1 (0.00)
BLAST CELLS PRESENT			1 (0.00)		1 (0.00)
BLAST CRISIS IN MYELOGENOUS LEUKAEMIA			2 (0.01)		2 (0.00)
BLASTOCYSTIS INFECTION		1 (0.01)			1 (0.00)
BLEEDING TIME	2 (0.03)				2 (0.00)
BLEEDING TIME ABNORMAL			1 (0.00)		1 (0.00)
BLEEDING TIME PROLONGED		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)
BLEPHARAL PIGMENTATION			2 (0.01)		2 (0.00)
BLEPHARITIS		3 (0.02)	5 (0.02)	2 (0.03)	10 (0.02)
BLEPHAROPLASTY			1 (0.00)		1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
BLEPHAROSPASM		1 (0.01)			1 (0.00)
BLIGHTED OVUM	1 (0.02)	2 (0.01)			3 (0.00)
BLINDNESS	7 (0.12)	27 (0.16)	56 (0.19)	19 (0.25)	109 (0.18)
BLINDNESS CORTICAL		3 (0.02)	2 (0.01)		5 (0.01)
BLINDNESS TRANSIENT	2 (0.03)	14 (0.08)	23 (0.08)	4 (0.05)	43 (0.07)
BLINDNESS UNILATERAL	4 (0.07)	20 (0.12)	52 (0.17)	12 (0.15)	88 (0.14)
BLISTER	15 (0.25)	36 (0.21)	36 (0.12)	13 (0.17)	100 (0.16)
BLISTER INFECTED		1 (0.01)	1 (0.00)		2 (0.00)
BLOOD ALBUMIN DECREASED		6 (0.04)	16 (0.05)	2 (0.03)	24 (0.04)
BLOOD ALBUMIN INCREASED	1 (0.02)	1 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
BLOOD ALCOHOL INCREASED	3 (0.05)	3 (0.02)			6 (0.01)
BLOOD ALDOSTERONE DECREASED				1 (0.01)	1 (0.00)
BLOOD ALDOSTERONE INCREASED			1 (0.00)		1 (0.00)
BLOOD ALKALINE PHOSPHATASE ABNORMAL			1 (0.00)		1 (0.00)
BLOOD ALKALINE PHOSPHATASE INCREASED	11 (0.19)	12 (0.07)	36 (0.12)	12 (0.15)	71 (0.12)
BLOOD AMYLASE INCREASED	2 (0.03)	3 (0.02)	9 (0.03)	1 (0.01)	15 (0.02)
BLOOD ANDROSTENEDIONE INCREASED		1 (0.01)			1 (0.00)
BLOOD ANTIDIURETIC HORMONE INCREASED	1 (0.02)	1 (0.01)			2 (0.00)
BLOOD BETA-D-GLUCAN INCREASED			3 (0.01)		3 (0.00)
BLOOD BICARBONATE DECREASED	1 (0.02)	5 (0.03)	12 (0.04)	3 (0.04)	21 (0.03)
BLOOD BICARBONATE INCREASED	2 (0.03)		1 (0.00)	2 (0.03)	5 (0.01)
BLOOD BILIRUBIN ABNORMAL			1 (0.00)		1 (0.00)
BLOOD BILIRUBIN INCREASED	9 (0.15)	15 (0.09)	38 (0.13)	7 (0.09)	69 (0.11)
BLOOD BILIRUBIN UNCONJUGATED INCREASED		2 (0.01)	1 (0.00)		3 (0.00)
BLOOD BLISTER	2 (0.03)		2 (0.01)		4 (0.01)
BLOOD CALCITONIN INCREASED	1 (0.02)				1 (0.00)
BLOOD CALCIUM ABNORMAL			2 (0.01)	1 (0.01)	3 (0.00)
BLOOD CALCIUM DECREASED	1 (0.02)	4 (0.02)	9 (0.03)	2 (0.03)	16 (0.03)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
BLOOD CALCIUM INCREASED		1 (0.01)	11 (0.04)	3 (0.04)	15 (0.02)
BLOOD CARBON MONOXIDE INCREASED			1 (0.00)		1 (0.00)
BLOOD CHLORIDE DECREASED		3 (0.02)	2 (0.01)	7 (0.09)	12 (0.02)
BLOOD CHLORIDE INCREASED	1 (0.02)	2 (0.01)		1 (0.01)	4 (0.01)
BLOOD CHOLESTEROL			2 (0.01)		2 (0.00)
BLOOD CHOLESTEROL ABNORMAL	2 (0.03)	6 (0.04)	2 (0.01)		10 (0.02)
BLOOD CHOLESTEROL DECREASED		1 (0.01)	1 (0.00)		2 (0.00)
BLOOD CHOLESTEROL INCREASED	6 (0.10)	75 (0.44)	144 (0.48)	11 (0.14)	236 (0.39)
BLOOD CHOLINESTERASE DECREASED		1 (0.01)		3 (0.04)	4 (0.01)
BLOOD CORTISOL DECREASED	4 (0.07)	2 (0.01)	1 (0.00)		7 (0.01)
BLOOD CORTISOL INCREASED				3 (0.04)	3 (0.00)
BLOOD COUNT ABNORMAL		1 (0.01)	4 (0.01)	3 (0.04)	8 (0.01)
BLOOD CREATINE INCREASED	3 (0.05)	6 (0.04)	7 (0.02)	3 (0.04)	19 (0.03)
BLOOD CREATINE PHOSPHOKINASE			1 (0.00)		1 (0.00)
BLOOD CREATINE PHOSPHOKINASE ABNORMAL			2 (0.01)		2 (0.00)
BLOOD CREATINE PHOSPHOKINASE INCREASED	26 (0.44)	57 (0.33)	80 (0.26)	38 (0.49)	201 (0.33)
BLOOD CREATINE PHOSPHOKINASE MB INCREASED		4 (0.02)	3 (0.01)	1 (0.01)	8 (0.01)
BLOOD CREATININE				1 (0.01)	1 (0.00)
BLOOD CREATININE ABNORMAL			4 (0.01)		4 (0.01)
BLOOD CREATININE DECREASED		1 (0.01)	5 (0.02)		6 (0.01)
BLOOD CREATININE INCREASED	14 (0.24)	49 (0.29)	160 (0.53)	41 (0.53)	264 (0.43)
BLOOD CULTURE POSITIVE		5 (0.03)	7 (0.02)		12 (0.02)
BLOOD DISORDER		7 (0.04)	12 (0.04)	2 (0.03)	21 (0.03)
BLOOD ELECTROLYTES ABNORMAL	2 (0.03)	1 (0.01)		1 (0.01)	4 (0.01)
BLOOD ELECTROLYTES DECREASED			1 (0.00)		1 (0.00)
BLOOD FIBRINOGEN ABNORMAL			1 (0.00)		1 (0.00)
BLOOD FIBRINOGEN DECREASED	1 (0.02)				1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
BLOOD FIBRINOGEN INCREASED			1 (0.00)	2 (0.03)	3 (0.00)
BLOOD FOLATE DECREASED		1 (0.01)	1 (0.00)		2 (0.00)
BLOOD FOLLICLE STIMULATING HORMONE INCREASED		1 (0.01)	1 (0.00)		2 (0.00)
BLOOD GASES ABNORMAL	1 (0.02)		1 (0.00)		2 (0.00)
BLOOD GLUCOSE			3 (0.01)		3 (0.00)
BLOOD GLUCOSE ABNORMAL	1 (0.02)	1 (0.01)	9 (0.03)	1 (0.01)	12 (0.02)
BLOOD GLUCOSE DECREASED	9 (0.15)	37 (0.22)	198 (0.65)	30 (0.39)	274 (0.45)
BLOOD GLUCOSE FLUCTUATION	2 (0.03)	5 (0.03)	21 (0.07)	4 (0.05)	32 (0.05)
BLOOD GLUCOSE INCREASED	24 (0.41)	128 (0.75)	478 (1.58)	61 (0.79)	691 (1.13)
BLOOD GLUCOSE NORMAL		1 (0.01)			1 (0.00)
BLOOD GROWTH HORMONE INCREASED		1 (0.01)			1 (0.00)
BLOOD HIV RNA INCREASED		2 (0.01)			2 (0.00)
BLOOD HOMOCYSTEINE INCREASED	1 (0.02)	1 (0.01)	3 (0.01)		5 (0.01)
BLOOD HUMAN CHORIONIC GONADOTROPIN ABNORMAL		1 (0.01)			1 (0.00)
BLOOD HUMAN CHORIONIC GONADOTROPIN INCREASED		5 (0.03)	2 (0.01)		7 (0.01)
BLOOD HUMAN CHORIONIC GONADOTROPIN POSITIVE		3 (0.02)			3 (0.00)
BLOOD IMMUNOGLOBULIN A	2 (0.03)				2 (0.00)
BLOOD IMMUNOGLOBULIN A DECREASED			1 (0.00)		1 (0.00)
BLOOD IMMUNOGLOBULIN A INCREASED		1 (0.01)		1 (0.01)	2 (0.00)
BLOOD IMMUNOGLOBULIN E INCREASED	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
BLOOD IMMUNOGLOBULIN G DECREASED	1 (0.02)		2 (0.01)		3 (0.00)
BLOOD IMMUNOGLOBULIN G INCREASED			1 (0.00)		1 (0.00)
BLOOD IMMUNOGLOBULIN M INCREASED	1 (0.02)				1 (0.00)
BLOOD INSULIN DECREASED			1 (0.00)		1 (0.00)
BLOOD IRON DECREASED	1 (0.02)	3 (0.02)	5 (0.02)		9 (0.01)
BLOOD IRON INCREASED			2 (0.01)		2 (0.00)
BLOOD LACTATE DEHYDROGENASE ABNORMAL		1 (0.01)			1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
BLOOD LACTATE DEHYDROGENASE INCREASED	6 (0.10)	3 (0.02)	30 (0.10)	3 (0.04)	42 (0.07)
BLOOD LACTIC ACID DECREASED			1 (0.00)		1 (0.00)
BLOOD LACTIC ACID INCREASED			6 (0.02)		6 (0.01)
BLOOD MAGNESIUM ABNORMAL				1 (0.01)	1 (0.00)
BLOOD MAGNESIUM DECREASED		3 (0.02)	8 (0.03)	5 (0.06)	16 (0.03)
BLOOD MAGNESIUM INCREASED	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
BLOOD METHAEMOGLOBIN PRESENT	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)
BLOOD METHANOL INCREASED		1 (0.01)			1 (0.00)
BLOOD OESTROGEN ABNORMAL		1 (0.01)			1 (0.00)
BLOOD OESTROGEN DECREASED		2 (0.01)			2 (0.00)
BLOOD OESTROGEN INCREASED		2 (0.01)			2 (0.00)
BLOOD OSMOLARITY DECREASED				2 (0.03)	2 (0.00)
BLOOD OSMOLARITY INCREASED	1 (0.02)				1 (0.00)
BLOOD PARATHYROID HORMONE DECREASED			1 (0.00)		1 (0.00)
BLOOD PARATHYROID HORMONE INCREASED	1 (0.02)		2 (0.01)		3 (0.00)
BLOOD PH DECREASED	1 (0.02)	4 (0.02)	3 (0.01)	1 (0.01)	9 (0.01)
BLOOD PH INCREASED		3 (0.02)	2 (0.01)		5 (0.01)
BLOOD PHOSPHORUS DECREASED			1 (0.00)		1 (0.00)
BLOOD POTASSIUM ABNORMAL		1 (0.01)	1 (0.00)		2 (0.00)
BLOOD POTASSIUM DECREASED	4 (0.07)	9 (0.05)	27 (0.09)	10 (0.13)	50 (0.08)
BLOOD POTASSIUM INCREASED	4 (0.07)	5 (0.03)	18 (0.06)	11 (0.14)	38 (0.06)
BLOOD PRESSURE		3 (0.02)	2 (0.01)	1 (0.01)	6 (0.01)
BLOOD PRESSURE ABNORMAL		7 (0.04)	7 (0.02)	2 (0.03)	16 (0.03)
BLOOD PRESSURE DECREASED	14 (0.24)	39 (0.23)	93 (0.31)	32 (0.41)	178 (0.29)
BLOOD PRESSURE DIASTOLIC ABNORMAL	1 (0.02)				1 (0.00)
BLOOD PRESSURE DIASTOLIC DECREASED	4 (0.07)	2 (0.01)	9 (0.03)	4 (0.05)	19 (0.03)
BLOOD PRESSURE DIASTOLIC INCREASED		6 (0.04)	3 (0.01)		9 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
BLOOD PRESSURE FLUCTUATION	1 (0.02)	2 (0.01)	7 (0.02)	7 (0.09)	17 (0.03)
BLOOD PRESSURE IMMEASURABLE		1 (0.01)	10 (0.03)	3 (0.04)	14 (0.02)
BLOOD PRESSURE INADEQUATELY CONTROLLED		5 (0.03)	25 (0.08)	4 (0.05)	34 (0.06)
BLOOD PRESSURE INCREASED	14 (0.24)	80 (0.47)	210 (0.69)	44 (0.57)	348 (0.57)
BLOOD PRESSURE ORTHOSTATIC ABNORMAL			2 (0.01)		2 (0.00)
BLOOD PRESSURE ORTHOSTATIC DECREASED				2 (0.03)	2 (0.00)
BLOOD PRESSURE SYSTOLIC DECREASED	3 (0.05)	2 (0.01)	5 (0.02)		10 (0.02)
BLOOD PRESSURE SYSTOLIC INCREASED	1 (0.02)	6 (0.04)	24 (0.08)	10 (0.13)	41 (0.07)
BLOOD PROLACTIN INCREASED	2 (0.03)	4 (0.02)	2 (0.01)		8 (0.01)
BLOOD SODIUM			3 (0.01)		3 (0.00)
BLOOD SODIUM DECREASED	1 (0.02)	10 (0.06)	19 (0.06)	13 (0.17)	43 (0.07)
BLOOD SODIUM INCREASED	2 (0.03)	1 (0.01)			3 (0.00)
BLOOD STEM CELL TRANSPLANT FAILURE		1 (0.01)			1 (0.00)
BLOOD TEST ABNORMAL		1 (0.01)	4 (0.01)		5 (0.01)
BLOOD TESTOSTERONE DECREASED		3 (0.02)	5 (0.02)		8 (0.01)
BLOOD TESTOSTERONE INCREASED			1 (0.00)	1 (0.01)	2 (0.00)
BLOOD THYROID STIMULATING HORMONE DECREASED	1 (0.02)	2 (0.01)	3 (0.01)		6 (0.01)
BLOOD THYROID STIMULATING HORMONE INCREASED		9 (0.05)	7 (0.02)		16 (0.03)
BLOOD TRIGLYCERIDES			1 (0.00)		1 (0.00)
BLOOD TRIGLYCERIDES INCREASED	5 (0.08)	19 (0.11)	13 (0.04)	5 (0.06)	42 (0.07)
BLOOD UREA INCREASED	1 (0.02)	1 (0.01)	9 (0.03)	5 (0.06)	16 (0.03)
BLOOD URIC ACID INCREASED	1 (0.02)	1 (0.01)	3 (0.01)	1 (0.01)	6 (0.01)
BLOOD URINE		1 (0.01)	1 (0.00)		2 (0.00)
BLOOD URINE PRESENT	1 (0.02)	7 (0.04)	19 (0.06)	6 (0.08)	33 (0.05)
BLOOD VISCOSITY INCREASED		1 (0.01)	4 (0.01)		5 (0.01)
BLOOD ZINC ABNORMAL	1 (0.02)				1 (0.00)
BLOOD ZINC DECREASED			1 (0.00)		1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
BLOODY DISCHARGE	2 (0.03)			1 (0.01)	3 (0.00)
BLUE TOE SYNDROME		1 (0.01)			1 (0.00)
BLUNTED AFFECT		1 (0.01)	1 (0.00)		2 (0.00)
BODY DYSMORPHIC DISORDER		1 (0.01)	1 (0.00)		2 (0.00)
BODY FAT DISORDER			1 (0.00)		1 (0.00)
BODY HEIGHT DECREASED	1 (0.02)		5 (0.02)	3 (0.04)	9 (0.01)
BODY MASS INDEX DECREASED			1 (0.00)		1 (0.00)
BODY MASS INDEX INCREASED		3 (0.02)			3 (0.00)
BODY TEMPERATURE	1 (0.02)				1 (0.00)
BODY TEMPERATURE DECREASED	2 (0.03)	3 (0.02)	7 (0.02)	1 (0.01)	13 (0.02)
BODY TEMPERATURE FLUCTUATION			1 (0.00)		1 (0.00)
BODY TEMPERATURE INCREASED	13 (0.22)	17 (0.10)	26 (0.09)	1 (0.01)	57 (0.09)
BONE CALLUS EXCESSIVE			1 (0.00)		1 (0.00)
BONE DEBRIDEMENT		5 (0.03)	23 (0.08)	10 (0.13)	38 (0.06)
BONE DENSITY DECREASED	3 (0.05)	3 (0.02)	12 (0.04)	4 (0.05)	22 (0.04)
BONE DENSITY INCREASED			1 (0.00)		1 (0.00)
BONE DEVELOPMENT ABNORMAL	1 (0.02)				1 (0.00)
BONE DISORDER		10 (0.06)	71 (0.23)	15 (0.19)	96 (0.16)
BONE EROSION		2 (0.01)	1 (0.00)		3 (0.00)
BONE FISSURE		3 (0.02)	1 (0.00)		4 (0.01)
BONE FORMATION INCREASED			4 (0.01)		4 (0.01)
BONE FRAGMENTATION			1 (0.00)		1 (0.00)
BONE GRAFT		3 (0.02)	1 (0.00)	1 (0.01)	5 (0.01)
BONE LESION			1 (0.00)		1 (0.00)
BONE MARROW DISORDER	2 (0.03)	3 (0.02)	2 (0.01)	3 (0.04)	10 (0.02)
BONE MARROW FAILURE	7 (0.12)	21 (0.12)	32 (0.11)	7 (0.09)	67 (0.11)
BONE MARROW MYELOGRAM ABNORMAL		1 (0.01)			1 (0.00)
BONE MARROW NECROSIS		1 (0.01)			1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
BONE MARROW TRANSPLANT	3 (0.05)	1 (0.01)			4 (0.01)
BONE NEOPLASM MALIGNANT			2 (0.01)	3 (0.04)	5 (0.01)
BONE OPERATION			4 (0.01)		4 (0.01)
BONE PAIN	4 (0.07)	12 (0.07)	24 (0.08)	6 (0.08)	46 (0.08)
BONE SARCOMA	1 (0.02)		3 (0.01)	1 (0.01)	5 (0.01)
BONE SCAN ABNORMAL				1 (0.01)	1 (0.00)
BONE SWELLING			3 (0.01)		3 (0.00)
BONE TRIMMING			6 (0.02)	2 (0.03)	8 (0.01)
BONE TUBERCULOSIS			1 (0.00)		1 (0.00)
BORDERLINE GLAUCOMA				1 (0.01)	1 (0.00)
BORDERLINE PERSONALITY DISORDER		2 (0.01)	1 (0.00)		3 (0.00)
BORRELIA INFECTION			2 (0.01)		2 (0.00)
BOTULISM	1 (0.02)				1 (0.00)
BOVINE TUBERCULOSIS			9 (0.03)	3 (0.04)	12 (0.02)
BOWEL MOVEMENT IRREGULARITY			1 (0.00)		1 (0.00)
BOWEL SOUNDS ABNORMAL			1 (0.00)		1 (0.00)
BRADYARRHYTHMIA	1 (0.02)	2 (0.01)	8 (0.03)	6 (0.08)	17 (0.03)
BRADYCARDIA	12 (0.20)	29 (0.17)	109 (0.36)	60 (0.77)	210 (0.34)
BRADYCARDIA FOETAL	2 (0.03)				2 (0.00)
BRADYCARDIA NEONATAL	4 (0.07)				4 (0.01)
BRADYKINESIA			2 (0.01)	1 (0.01)	3 (0.00)
BRADYPHRENIA	1 (0.02)	2 (0.01)	3 (0.01)		6 (0.01)
BRADYPNOEA		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
BRAIN ABSCESS		1 (0.01)		1 (0.01)	2 (0.00)
BRAIN CANCER METASTATIC				1 (0.01)	1 (0.00)
BRAIN COMPRESSION	1 (0.02)	2 (0.01)	4 (0.01)		7 (0.01)
BRAIN CONTUSION		1 (0.01)			1 (0.00)
BRAIN DAMAGE	1 (0.02)	7 (0.04)	14 (0.05)	2 (0.03)	24 (0.04)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
BRAIN DEATH	1 (0.02)	5 (0.03)	3 (0.01)	2 (0.03)	11 (0.02)
BRAIN HERNIATION		3 (0.02)	4 (0.01)	3 (0.04)	10 (0.02)
BRAIN HYPOXIA			1 (0.00)		1 (0.00)
BRAIN MALFORMATION		1 (0.01)			1 (0.00)
BRAIN MASS			2 (0.01)	1 (0.01)	3 (0.00)
BRAIN NATRIURETIC PEPTIDE DECREASED		1 (0.01)			1 (0.00)
BRAIN NATRIURETIC PEPTIDE INCREASED				2 (0.03)	2 (0.00)
BRAIN NEOPLASM	3 (0.05)	6 (0.04)	7 (0.02)	1 (0.01)	17 (0.03)
BRAIN NEOPLASM MALIGNANT			2 (0.01)		2 (0.00)
BRAIN OEDEMA	16 (0.27)	11 (0.06)	21 (0.07)	5 (0.06)	53 (0.09)
BRAIN OPERATION		5 (0.03)	1 (0.00)		6 (0.01)
BRAIN SCAN ABNORMAL	3 (0.05)				3 (0.00)
BRAIN STEM GLIOMA	1 (0.02)				1 (0.00)
BRAIN STEM HAEMORRHAGE			4 (0.01)	1 (0.01)	5 (0.01)
BRAIN STEM INFARCTION		1 (0.01)	8 (0.03)	1 (0.01)	10 (0.02)
BRAIN STEM ISCHAEMIA			3 (0.01)		3 (0.00)
BRAIN STEM SYNDROME			3 (0.01)		3 (0.00)
BRAIN STEM THROMBOSIS			4 (0.01)		4 (0.01)
BREAKTHROUGH PAIN		1 (0.01)			1 (0.00)
BREAST CANCER		70 (0.41)	563 (1.86)	19 (0.25)	652 (1.07)
BREAST CANCER FEMALE		38 (0.22)	118 (0.39)	9 (0.12)	165 (0.27)
BREAST CANCER IN SITU		7 (0.04)	31 (0.10)	2 (0.03)	40 (0.07)
BREAST CANCER MALE			1 (0.00)	1 (0.01)	2 (0.00)
BREAST CANCER METASTATIC		1 (0.01)	32 (0.11)	1 (0.01)	34 (0.06)
BREAST CANCER RECURRENT		3 (0.02)	6 (0.02)	1 (0.01)	10 (0.02)
BREAST CANCER STAGE I		1 (0.01)	1 (0.00)		2 (0.00)
BREAST CANCER STAGE II		1 (0.01)	2 (0.01)		3 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
BREAST CANCER STAGE III			2 (0.01)		2 (0.00)
BREAST CANCER STAGE IV		1 (0.01)	1 (0.00)		2 (0.00)
BREAST CELLULITIS			1 (0.00)		1 (0.00)
BREAST COSMETIC SURGERY	1 (0.02)	4 (0.02)			5 (0.01)
BREAST CYST		6 (0.04)	4 (0.01)		10 (0.02)
BREAST DISCHARGE		3 (0.02)			3 (0.00)
BREAST DISCOMFORT		1 (0.01)			1 (0.00)
BREAST DISORDER		2 (0.01)	3 (0.01)		5 (0.01)
BREAST ENGORGEMENT	2 (0.03)		1 (0.00)		3 (0.00)
BREAST FIBROMA			1 (0.00)		1 (0.00)
BREAST HAEMATOMA				1 (0.01)	1 (0.00)
BREAST HAEMORRHAGE			1 (0.00)		1 (0.00)
BREAST MASS	1 (0.02)	11 (0.06)	7 (0.02)	1 (0.01)	20 (0.03)
BREAST MICROCALCIFICATION		2 (0.01)			2 (0.00)
BREAST NEOPLASM	1 (0.02)	2 (0.01)			3 (0.00)
BREAST OEDEMA	1 (0.02)				1 (0.00)
BREAST PAIN	1 (0.02)	7 (0.04)	14 (0.05)		22 (0.04)
BREAST PROSTHESIS REMOVAL		1 (0.01)			1 (0.00)
BREAST SWELLING		3 (0.02)	3 (0.01)	2 (0.03)	8 (0.01)
BREAST TENDERNESS	1 (0.02)	3 (0.02)	2 (0.01)	3 (0.04)	9 (0.01)
BREATH HOLDING		1 (0.01)			1 (0.00)
BREATH ODOUR	1 (0.02)	2 (0.01)	4 (0.01)		7 (0.01)
BREATH SOUNDS ABNORMAL		1 (0.01)	3 (0.01)	1 (0.01)	5 (0.01)
BREECH PRESENTATION	2 (0.03)	3 (0.02)			5 (0.01)
BRIEF PSYCHOTIC DISORDER WITH MARKED STRESSORS	1 (0.02)				1 (0.00)
BRIEF PSYCHOTIC DISORDER, WITH POSTPARTUM ONSET	2 (0.03)				2 (0.00)
BRONCHIAL CARCINOMA			3 (0.01)		3 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
BRONCHIAL DISORDER			1 (0.00)		1 (0.00)
BRONCHIAL FISTULA			5 (0.02)	1 (0.01)	6 (0.01)
BRONCHIAL HYPERACTIVITY	3 (0.05)	1 (0.01)	2 (0.01)		6 (0.01)
BRONCHIAL OBSTRUCTION	2 (0.03)	1 (0.01)	4 (0.01)		7 (0.01)
BRONCHIECTASIS			5 (0.02)	4 (0.05)	9 (0.01)
BRONCHIOLITIS	7 (0.12)				7 (0.01)
BRONCHIOLOALVEOLAR CARCINOMA			2 (0.01)	1 (0.01)	3 (0.00)
BRONCHITIS	4 (0.07)	19 (0.11)	47 (0.16)	18 (0.23)	88 (0.14)
BRONCHITIS ACUTE	1 (0.02)	1 (0.01)	9 (0.03)	2 (0.03)	13 (0.02)
BRONCHITIS BACTERIAL		1 (0.01)		1 (0.01)	2 (0.00)
BRONCHITIS CHRONIC		1 (0.01)	1 (0.00)		2 (0.00)
BRONCHOALVEOLAR LAVAGE ABNORMAL			1 (0.00)		1 (0.00)
BRONCHOMALACIA	1 (0.02)				1 (0.00)
BRONCHOPLEURAL FISTULA		1 (0.01)			1 (0.00)
BRONCHOPNEUMONIA	1 (0.02)	4 (0.02)	17 (0.06)	4 (0.05)	26 (0.04)
BRONCHOPNEUMOPATHY				1 (0.01)	1 (0.00)
BRONCHOPULMONARY ASPERGILLOSIS	1 (0.02)	4 (0.02)	4 (0.01)	1 (0.01)	10 (0.02)
BRONCHOSPASM	6 (0.10)	9 (0.05)	25 (0.08)	3 (0.04)	43 (0.07)
BRONCHOSPASM PARADOXICAL	1 (0.02)		1 (0.00)	4 (0.05)	6 (0.01)
BRONCHOSTENOSIS			2 (0.01)	2 (0.03)	4 (0.01)
BRUXISM		1 (0.01)	7 (0.02)	5 (0.06)	13 (0.02)
BUDD-CHIARI SYNDROME	1 (0.02)		1 (0.00)		2 (0.00)
BULBAR PALSY				1 (0.01)	1 (0.00)
BUNDLE BRANCH BLOCK			4 (0.01)	1 (0.01)	5 (0.01)
BUNDLE BRANCH BLOCK LEFT	1 (0.02)	5 (0.03)	17 (0.06)	3 (0.04)	26 (0.04)
BUNDLE BRANCH BLOCK RIGHT	2 (0.03)	7 (0.04)	4 (0.01)		13 (0.02)
BUNION			4 (0.01)		4 (0.01)
BUNION OPERATION		1 (0.01)	1 (0.00)		2 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
BURN OESOPHAGEAL			1 (0.00)		1 (0.00)
BURNING SENSATION	9 (0.15)	47 (0.28)	49 (0.16)	12 (0.15)	117 (0.19)
BURNING SENSATION MUCOSAL	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)
BURNS FIRST DEGREE			3 (0.01)		3 (0.00)
BURNS SECOND DEGREE		1 (0.01)		1 (0.01)	2 (0.00)
BURNS THIRD DEGREE	2 (0.03)				2 (0.00)
BURSITIS		4 (0.02)	9 (0.03)		13 (0.02)
BURSITIS INFECTIVE			1 (0.00)		1 (0.00)
BUTTOCK PAIN		1 (0.01)			1 (0.00)
C-REACTIVE PROTEIN INCREASED	5 (0.08)	19 (0.11)	12 (0.04)	4 (0.05)	40 (0.07)
CACHEXIA		2 (0.01)	6 (0.02)	1 (0.01)	9 (0.01)
CAECITIS	5 (0.08)		4 (0.01)	1 (0.01)	10 (0.02)
CAESAREAN SECTION	24 (0.41)	50 (0.29)			74 (0.12)
CAFFEINE CONSUMPTION		2 (0.01)			2 (0.00)
CALCINOSIS		1 (0.01)	4 (0.01)		5 (0.01)
CALCIPHYLAXIS		1 (0.01)			1 (0.00)
CALCULUS BLADDER		1 (0.01)			1 (0.00)
CALCULUS URETERIC		2 (0.01)	2 (0.01)	2 (0.03)	6 (0.01)
CALCULUS URETHRAL		4 (0.02)			4 (0.01)
CALCULUS URINARY	2 (0.03)				2 (0.00)
CAMPYLOBACTER INFECTION			1 (0.00)		1 (0.00)
CANCER PAIN		2 (0.01)	2 (0.01)		4 (0.01)
CANDIDA PNEUMONIA			2 (0.01)		2 (0.00)
CANDIDIASIS	1 (0.02)	6 (0.04)	18 (0.06)	7 (0.09)	32 (0.05)
CAPILLARY DISORDER	3 (0.05)	1 (0.01)	2 (0.01)		6 (0.01)
CAPILLARY FRAGILITY			1 (0.00)		1 (0.00)
CAPILLARY LEAK SYNDROME	3 (0.05)	1 (0.01)	1 (0.00)		5 (0.01)
CARBOHYDRATE ANTIGEN 15-3 INCREASED			1 (0.00)		1 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CARBOHYDRATE ANTIGEN 19-9 INCREASED			2 (0.01)		2 (0.00)
CARBON DIOXIDE INCREASED			4 (0.01)		4 (0.01)
CARBON MONOXIDE POISONING	1 (0.02)	5 (0.03)	1 (0.00)		7 (0.01)
CARBOXYHAEMOGLOBIN INCREASED			1 (0.00)		1 (0.00)
CARCINOEMBRYONIC ANTIGEN INCREASED		3 (0.02)	1 (0.00)		4 (0.01)
CARCINOID SYNDROME			1 (0.00)		1 (0.00)
CARCINOID TUMOUR	1 (0.02)		1 (0.00)		2 (0.00)
CARCINOID TUMOUR OF THE STOMACH			1 (0.00)		1 (0.00)
CARCINOID TUMOUR PULMONARY		2 (0.01)			2 (0.00)
CARCINOMA IN SITU				1 (0.01)	1 (0.00)
CARCINOMA IN SITU OF SKIN		1 (0.01)			1 (0.00)
CARDIAC ABLATION		1 (0.01)	1 (0.00)		2 (0.00)
CARDIAC ANEURYSM			6 (0.02)		6 (0.01)
CARDIAC ARREST	19 (0.32)	69 (0.40)	167 (0.55)	48 (0.62)	303 (0.50)
CARDIAC DEATH			2 (0.01)	2 (0.03)	4 (0.01)
CARDIAC DISCOMFORT			1 (0.00)		1 (0.00)
CARDIAC DISORDER	12 (0.20)	140 (0.82)	381 (1.26)	64 (0.83)	597 (0.98)
CARDIAC ENZYMES INCREASED		4 (0.02)	2 (0.01)	6 (0.08)	12 (0.02)
CARDIAC FAILURE	7 (0.12)	45 (0.26)	131 (0.43)	68 (0.88)	251 (0.41)
CARDIAC FAILURE ACUTE		7 (0.04)	7 (0.02)	6 (0.08)	20 (0.03)
CARDIAC FAILURE CHRONIC			3 (0.01)		3 (0.00)
CARDIAC FAILURE CONGESTIVE	3 (0.05)	27 (0.16)	152 (0.50)	73 (0.94)	255 (0.42)
CARDIAC FIBRILLATION		3 (0.02)	2 (0.01)	4 (0.05)	9 (0.01)
CARDIAC FLUTTER		4 (0.02)	6 (0.02)		10 (0.02)
CARDIAC FUNCTION DISTURBANCE POSTOPERATIVE		1 (0.01)			1 (0.00)
CARDIAC INFECTION		1 (0.01)			1 (0.00)
CARDIAC MURMUR	4 (0.07)	6 (0.04)	11 (0.04)		21 (0.03)
CARDIAC OPERATION	2 (0.03)	2 (0.01)	3 (0.01)	1 (0.01)	8 (0.01)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CARDIAC PACEMAKER INSERTION			4 (0.01)	6 (0.08)	10 (0.02)
CARDIAC PACEMAKER REPLACEMENT				1 (0.01)	1 (0.00)
CARDIAC PROCEDURE COMPLICATION	1 (0.02)		7 (0.02)	1 (0.01)	9 (0.01)
CARDIAC REHABILITATION THERAPY			1 (0.00)		1 (0.00)
CARDIAC SEPTAL DEFECT			1 (0.00)		1 (0.00)
CARDIAC STRESS TEST ABNORMAL		1 (0.01)	6 (0.02)		7 (0.01)
CARDIAC TAMPONADE		2 (0.01)	7 (0.02)	3 (0.04)	12 (0.02)
CARDIAC VALVE DISEASE		9 (0.05)	12 (0.04)		21 (0.03)
CARDIAC VALVE REPLACEMENT COMPLICATION			1 (0.00)		1 (0.00)
CARDIO-RESPIRATORY ARREST	20 (0.34)	47 (0.28)	68 (0.22)	22 (0.28)	157 (0.26)
CARDIOACTIVE DRUG LEVEL INCREASED			1 (0.00)		1 (0.00)
CARDIOGENIC SHOCK	2 (0.03)	9 (0.05)	15 (0.05)	4 (0.05)	30 (0.05)
CARDIOMEGALY	1 (0.02)	11 (0.06)	28 (0.09)	7 (0.09)	47 (0.08)
CARDIOMYOPATHY	1 (0.02)	11 (0.06)	13 (0.04)	4 (0.05)	29 (0.05)
CARDIOMYOPATHY ACUTE			1 (0.00)		1 (0.00)
CARDIOPULMONARY FAILURE		1 (0.01)	11 (0.04)	3 (0.04)	15 (0.02)
CARDIOTOXICITY			2 (0.01)	1 (0.01)	3 (0.00)
CARDIOVASCULAR DECONDITIONING		1 (0.01)			1 (0.00)
CARDIOVASCULAR DISORDER	2 (0.03)	59 (0.35)	163 (0.54)	30 (0.39)	254 (0.42)
CARDIOVASCULAR INSUFFICIENCY			1 (0.00)		1 (0.00)
CARDIOVERSION			1 (0.00)		1 (0.00)
CARDITIS	2 (0.03)				2 (0.00)
CAREGIVER		1 (0.01)			1 (0.00)
CAROTID ARTERY ANEURYSM		1 (0.01)	1 (0.00)		2 (0.00)
CAROTID ARTERY ATHEROMA			3 (0.01)	1 (0.01)	4 (0.01)
CAROTID ARTERY DISEASE			10 (0.03)	2 (0.03)	12 (0.02)
CAROTID ARTERY DISSECTION			4 (0.01)	1 (0.01)	5 (0.01)
CAROTID ARTERY OCCLUSION			26 (0.09)	5 (0.06)	31 (0.05)

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
CAROTID ARTERY STENOSIS	2 (0.03)	3 (0.02)	22 (0.07)	11 (0.14)	38 (0.06)
CAROTID BRUIT			1 (0.00)		1 (0.00)
CARPAL TUNNEL DECOMPRESSION			2 (0.01)	2 (0.03)	4 (0.01)
CARPAL TUNNEL SYNDROME	1 (0.02)	10 (0.06)	22 (0.07)	5 (0.06)	38 (0.06)
CARPUS CURVUS			1 (0.00)		1 (0.00)
CARTILAGE INJURY			2 (0.01)		2 (0.00)
CASTLEMAN'S DISEASE			3 (0.01)		3 (0.00)
CAT SCRATCH DISEASE		1 (0.01)			1 (0.00)
CATAPLEXY			1 (0.00)		1 (0.00)
CATARACT	3 (0.05)	10 (0.06)	41 (0.14)	19 (0.25)	73 (0.12)
CATARACT CONGENITAL	1 (0.02)				1 (0.00)
CATARACT CORTICAL				1 (0.01)	1 (0.00)
CATARACT NUCLEAR			2 (0.01)		2 (0.00)
CATARACT OPERATION		1 (0.01)	6 (0.02)	6 (0.08)	13 (0.02)
CATARACT OPERATION COMPLICATION			4 (0.01)	4 (0.05)	8 (0.01)
CATARACT SUBCAPSULAR	1 (0.02)	2 (0.01)			3 (0.00)
CATATONIA	3 (0.05)	4 (0.02)	3 (0.01)	1 (0.01)	11 (0.02)
CATHETER PLACEMENT			1 (0.00)		1 (0.00)
CATHETER RELATED COMPLICATION	1 (0.02)	10 (0.06)	27 (0.09)	6 (0.08)	44 (0.07)
CATHETER RELATED INFECTION	4 (0.07)	10 (0.06)	14 (0.05)		28 (0.05)
CATHETER SEPSIS		1 (0.01)	2 (0.01)		3 (0.00)
CATHETER SITE CELLULITIS	1 (0.02)				1 (0.00)
CATHETER SITE DISCHARGE		2 (0.01)			2 (0.00)
CATHETER SITE ERYTHEMA		2 (0.01)			2 (0.00)
CATHETER SITE HAEMATOMA			3 (0.01)		3 (0.00)
CATHETER SITE INFECTION		2 (0.01)	1 (0.00)		3 (0.00)
CATHETER SITE RELATED REACTION		1 (0.01)	1 (0.00)		2 (0.00)
CATHETERISATION CARDIAC		2 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CAUDA EQUINA SYNDROME		1 (0.01)			1 (0.00)
CAUDAL REGRESSION SYNDROME		2 (0.01)			2 (0.00)
CAUSTIC INJURY	2 (0.03)	3 (0.02)			5 (0.01)
CAVERNOUS SINUS THROMBOSIS		4 (0.02)			4 (0.01)
CD4 LYMPHOCYTES ABNORMAL	1 (0.02)				1 (0.00)
CD4 LYMPHOCYTES DECREASED	1 (0.02)	3 (0.02)	2 (0.01)		6 (0.01)
CD4/CD8 RATIO INCREASED			1 (0.00)		1 (0.00)
CELL MARKER INCREASED			2 (0.01)		2 (0.00)
CELLULITIS	3 (0.05)	20 (0.12)	43 (0.14)	6 (0.08)	72 (0.12)
CELLULITIS GANGRENOUS	1 (0.02)				1 (0.00)
CELLULITIS OF MALE EXTERNAL GENITAL ORGAN				1 (0.01)	1 (0.00)
CENTRAL LINE INFECTION	3 (0.05)	6 (0.04)	3 (0.01)		12 (0.02)
CENTRAL NERVOUS SYSTEM ABSCESS		1 (0.01)			1 (0.00)
CENTRAL NERVOUS SYSTEM LESION	2 (0.03)				2 (0.00)
CENTRAL NERVOUS SYSTEM LYMPHOMA	1 (0.02)				1 (0.00)
CENTRAL NERVOUS SYSTEM STIMULATION		2 (0.01)			2 (0.00)
CENTRAL OBESITY			2 (0.01)		2 (0.00)
CENTRAL PAIN SYNDROME			1 (0.00)		1 (0.00)
CENTRAL PONTINE MYELINOLYSIS		1 (0.01)			1 (0.00)
CENTRAL VENOUS PRESSURE INCREASED		1 (0.01)	1 (0.00)		2 (0.00)
CEREBELLAR ARTERY THROMBOSIS		1 (0.01)			1 (0.00)
CEREBELLAR ATAXIA		2 (0.01)	5 (0.02)		7 (0.01)
CEREBELLAR ATROPHY	2 (0.03)		4 (0.01)		6 (0.01)
CEREBELLAR HAEMORRHAGE			2 (0.01)	1 (0.01)	3 (0.00)
CEREBELLAR INFARCTION		3 (0.02)	9 (0.03)	1 (0.01)	13 (0.02)
CEREBELLAR SYNDROME		4 (0.02)	5 (0.02)	1 (0.01)	10 (0.02)
CEREBELLAR TUMOUR	2 (0.03)				2 (0.00)
CEREBRAL ARTERIOSCLEROSIS			1 (0.00)		1 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CEREBRAL ARTERITIS	1 (0.02)				1 (0.00)
CEREBRAL ARTERY EMBOLISM		2 (0.01)	1 (0.00)		3 (0.00)
CEREBRAL ARTERY OCCLUSION			6 (0.02)	1 (0.01)	7 (0.01)
CEREBRAL ARTERY STENOSIS		2 (0.01)	2 (0.01)		4 (0.01)
CEREBRAL ARTERY THROMBOSIS		1 (0.01)	1 (0.00)		2 (0.00)
CEREBRAL ASPERGILLOSIS		2 (0.01)			2 (0.00)
CEREBRAL ATROPHY	1 (0.02)	2 (0.01)	13 (0.04)	7 (0.09)	23 (0.04)
CEREBRAL CIRCULATORY FAILURE			1 (0.00)		1 (0.00)
CEREBRAL DISORDER			4 (0.01)	1 (0.01)	5 (0.01)
CEREBRAL HAEMATOMA		4 (0.02)	4 (0.01)	5 (0.06)	13 (0.02)
CEREBRAL HAEMORRHAGE	8 (0.14)	20 (0.12)	69 (0.23)	23 (0.30)	120 (0.20)
CEREBRAL INFARCTION	6 (0.10)	19 (0.11)	78 (0.26)	22 (0.28)	125 (0.20)
CEREBRAL ISCHAEMIA	1 (0.02)	3 (0.02)	13 (0.04)	4 (0.05)	21 (0.03)
CEREBRAL THROMBOSIS	1 (0.02)	3 (0.02)	5 (0.02)		9 (0.01)
CEREBRAL TOXOPLASMOSIS			1 (0.00)		1 (0.00)
CEREBRAL VENOUS THROMBOSIS			2 (0.01)		2 (0.00)
CEREBRAL VENTRICLE DILATATION	1 (0.02)	1 (0.01)	4 (0.01)		6 (0.01)
CEREBROVASCULAR ACCIDENT	12 (0.20)	252 (1.48)	789 (2.61)	208 (2.68)	1261 (2.07)
CEREBROVASCULAR DISORDER		5 (0.03)	16 (0.05)	5 (0.06)	26 (0.04)
CEREBROVASCULAR INSUFFICIENCY			1 (0.00)		1 (0.00)
CEREBROVASCULAR SPASM		2 (0.01)			2 (0.00)
CERUMEN IMPACTION			2 (0.01)		2 (0.00)
CERVICAL DYSPLASIA	2 (0.03)	3 (0.02)			5 (0.01)
CERVICAL GLAND TUBERCULOSIS			3 (0.01)		3 (0.00)
CERVICAL INCOMPETENCE		3 (0.02)			3 (0.00)
CERVICAL MYELOPATHY	1 (0.02)				1 (0.00)
CERVICAL POLYP		3 (0.02)	4 (0.01)		7 (0.01)
CERVICAL ROOT PAIN			1 (0.00)		1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
CERVICAL SPINAL STENOSIS			3 (0.01)		3 (0.00)
CERVICAL VERTEBRAL FRACTURE			3 (0.01)		3 (0.00)
CERVICOBRACHIAL SYNDROME			4 (0.01)		4 (0.01)
CERVICOGENIC HEADACHE		1 (0.01)			1 (0.00)
CERVIX CARCINOMA	1 (0.02)	4 (0.02)	4 (0.01)		9 (0.01)
CERVIX DISORDER	1 (0.02)				1 (0.00)
CHANGE OF BOWEL HABIT		2 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)
CHAPPED LIPS	4 (0.07)	4 (0.02)	5 (0.02)	1 (0.01)	14 (0.02)
CHEILITIS	3 (0.05)	5 (0.03)	9 (0.03)	2 (0.03)	19 (0.03)
CHEMICAL BURNS OF EYE		2 (0.01)			2 (0.00)
CHEMICAL INJURY		1 (0.01)			1 (0.00)
CHEMICAL POISONING	1 (0.02)				1 (0.00)
CHEMOTHERAPEUTIC DRUG LEVEL INCREASED			1 (0.00)		1 (0.00)
CHEST DISCOMFORT	5 (0.08)	47 (0.28)	67 (0.22)	7 (0.09)	126 (0.21)
CHEST INJURY		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
CHEST PAIN	31 (0.52)	188 (1.10)	277 (0.92)	46 (0.59)	542 (0.89)
CHEST TUBE INSERTION				1 (0.01)	1 (0.00)
CHEST WALL MASS	1 (0.02)				1 (0.00)
CHEST X-RAY ABNORMAL		2 (0.01)	7 (0.02)	7 (0.09)	16 (0.03)
CHEST X-RAY NORMAL			1 (0.00)		1 (0.00)
CHEYNE-STOKES RESPIRATION			1 (0.00)	1 (0.01)	2 (0.00)
CHILD NEGLECT		1 (0.01)			1 (0.00)
CHILLBLAINS			1 (0.00)		1 (0.00)
CHILLS	8 (0.14)	55 (0.32)	88 (0.29)	14 (0.18)	165 (0.27)
CHLOROMA		2 (0.01)			2 (0.00)
CHOKING	3 (0.05)	10 (0.06)	11 (0.04)	4 (0.05)	28 (0.05)
CHOKING SENSATION	1 (0.02)	3 (0.02)	1 (0.00)		5 (0.01)

Reaction Summary Table

Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
CHOLANGIOLITIS		1 (0.01)			1 (0.00)
CHOLANGITIS	1 (0.02)	6 (0.04)	7 (0.02)	1 (0.01)	15 (0.02)
CHOLANGITIS SCLEROSING	1 (0.02)	2 (0.01)			3 (0.00)
CHOLECYSTECTOMY	1 (0.02)	8 (0.05)	12 (0.04)	2 (0.03)	23 (0.04)
CHOLECYSTITIS	3 (0.05)	4 (0.02)	12 (0.04)	2 (0.03)	21 (0.03)
CHOLECYSTITIS ACUTE	1 (0.02)	4 (0.02)	5 (0.02)		10 (0.02)
CHOLECYSTITIS CHRONIC		4 (0.02)			4 (0.01)
CHOLECYSTITIS INFECTIVE		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
CHOLECYSTOSTOMY			1 (0.00)		1 (0.00)
CHOLELITHIASIS	4 (0.07)	20 (0.12)	25 (0.08)	10 (0.13)	59 (0.10)
CHOLESTASIS	3 (0.05)	19 (0.11)	27 (0.09)	8 (0.10)	57 (0.09)
CHOLESTEROL GRANULOMA		1 (0.01)			1 (0.00)
CHOLINERGIC SYNDROME		3 (0.02)			3 (0.00)
CHOLURIA	1 (0.02)				1 (0.00)
CHONDROCALCINOSIS				1 (0.01)	1 (0.00)
CHONDROMA	1 (0.02)				1 (0.00)
CHONDROMALACIA		2 (0.01)	1 (0.00)		3 (0.00)
CHONDROMATOSIS	1 (0.02)				1 (0.00)
CHONDROPATHY			5 (0.02)		5 (0.01)
CHONDROSARCOMA	2 (0.03)	1 (0.01)			3 (0.00)
CHOREA	4 (0.07)	1 (0.01)	2 (0.01)		7 (0.01)
CHOREOATHETOSIS	1 (0.02)				1 (0.00)
CHORIOAMNIONITIS		1 (0.01)			1 (0.00)
CHORIORETINITIS		1 (0.01)			1 (0.00)
CHORIORETINOPATHY		1 (0.01)	2 (0.01)		3 (0.00)
CHOROIDAL DETACHMENT			1 (0.00)		1 (0.00)
CHOROIDAL DYSTROPHY				1 (0.01)	1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
CHOROIDAL HAEMORRHAGE			4 (0.01)		4 (0.01)
CHOROIDAL NEOVASCULARISATION			1 (0.00)		1 (0.00)
CHOROIDITIS	1 (0.02)				1 (0.00)
CHROMATOPSIA		1 (0.01)	1 (0.00)		2 (0.00)
CHROMATURIA	9 (0.15)	11 (0.06)	16 (0.05)	4 (0.05)	40 (0.07)
CHROMOSOMAL DELETION	1 (0.02)				1 (0.00)
CHROMOSOME ABNORMALITY	1 (0.02)				1 (0.00)
CHRONIC FATIGUE SYNDROME	1 (0.02)				1 (0.00)
CHRONIC HEPATITIS		2 (0.01)	2 (0.01)		4 (0.01)
CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEU			4 (0.01)		4 (0.01)
CHRONIC LYMPHOCYTIC LEUKAEMIA		3 (0.02)	10 (0.03)	4 (0.05)	17 (0.03)
CHRONIC LYMPHOCYTIC LEUKAEMIA TRANSFORMATION			2 (0.01)		2 (0.00)
CHRONIC MYELOID LEUKAEMIA		1 (0.01)		1 (0.01)	2 (0.00)
CHRONIC OBSTRUCTIVE PULMONARY DISEASE		3 (0.02)	43 (0.14)	12 (0.15)	58 (0.10)
CHRONIC RESPIRATORY FAILURE			1 (0.00)		1 (0.00)
CHRONIC SINUSITIS		1 (0.01)	2 (0.01)		3 (0.00)
CIRCULATORY COLLAPSE	5 (0.08)	11 (0.06)	15 (0.05)	6 (0.08)	37 (0.06)
CIRCUMORAL OEDEMA			1 (0.00)		1 (0.00)
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO	1 (0.02)	5 (0.03)	4 (0.01)	2 (0.03)	12 (0.02)
CIRRHOSIS ALCOHOLIC		4 (0.02)			4 (0.01)
CLAUSTROPHOBIA			1 (0.00)		1 (0.00)
CLAVICLE FRACTURE			1 (0.00)	2 (0.03)	3 (0.00)
CLEAR CELL CARCINOMA OF THE KIDNEY			2 (0.01)		2 (0.00)
CLEFT LIP	2 (0.03)				2 (0.00)
CLEFT LIP AND PALATE	1 (0.02)				1 (0.00)
CLEFT PALATE	3 (0.05)				3 (0.00)
CLONIC CONVULSION		2 (0.01)		1 (0.01)	3 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
CLONUS		1 (0.01)	2 (0.01)		3 (0.00)
CLOSTRIDIAL INFECTION	1 (0.02)	5 (0.03)	6 (0.02)	7 (0.09)	19 (0.03)
CLOSTRIDIUM COLITIS	5 (0.08)	4 (0.02)	23 (0.08)	19 (0.25)	51 (0.08)
CLOSTRIDIUM DIFFICILE COLITIS			1 (0.00)	2 (0.03)	3 (0.00)
CLOSTRIDIUM DIFFICILE TOXIN TEST POSITIVE			1 (0.00)		1 (0.00)
CLUMSINESS	1 (0.02)	4 (0.02)	4 (0.01)	1 (0.01)	10 (0.02)
CLUSTER HEADACHE		1 (0.01)			1 (0.00)
CNS VENTRICULITIS	1 (0.02)				1 (0.00)
COAGULATION FACTOR DECREASED			1 (0.00)		1 (0.00)
COAGULATION FACTOR IX LEVEL DECREASED		1 (0.01)			1 (0.00)
COAGULATION FACTOR V LEVEL DECREASED		1 (0.01)	2 (0.01)		3 (0.00)
COAGULATION FACTOR VIII LEVEL DECREASED	4 (0.07)				4 (0.01)
COAGULATION FACTOR VIII LEVEL INCREASED		1 (0.01)			1 (0.00)
COAGULATION TEST ABNORMAL		1 (0.01)			1 (0.00)
COAGULATION TIME ABNORMAL		1 (0.01)	1 (0.00)		2 (0.00)
COAGULATION TIME PROLONGED			1 (0.00)	1 (0.01)	2 (0.00)
COAGULATION TIME SHORTENED			1 (0.00)		1 (0.00)
COAGULOPATHY		7 (0.04)	16 (0.05)	8 (0.10)	31 (0.05)
COELIAC DISEASE			4 (0.01)	1 (0.01)	5 (0.01)
COGNITIVE DETERIORATION			5 (0.02)	2 (0.03)	7 (0.01)
COGNITIVE DISORDER	3 (0.05)	1 (0.01)	12 (0.04)	4 (0.05)	20 (0.03)
COGWHEEL RIGIDITY	1 (0.02)	4 (0.02)		1 (0.01)	6 (0.01)
COITAL BLEEDING		1 (0.01)			1 (0.00)
COLD SWEAT		7 (0.04)	6 (0.02)	2 (0.03)	15 (0.02)
COLECTOMY			7 (0.02)		7 (0.01)
COLITIS	15 (0.25)	11 (0.06)	16 (0.05)	5 (0.06)	47 (0.08)
COLITIS COLLAGENOUS			1 (0.00)	1 (0.01)	2 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
COLITIS ISCHAEMIC		14 (0.08)	17 (0.06)		31 (0.05)
COLITIS MICROSCOPIC			1 (0.00)		1 (0.00)
COLITIS ULCERATIVE	3 (0.05)	5 (0.03)	3 (0.01)	3 (0.04)	14 (0.02)
COLLAGEN DISORDER			1 (0.00)		1 (0.00)
COLLAPSE OF LUNG	1 (0.02)	2 (0.01)	6 (0.02)	3 (0.04)	12 (0.02)
COLON ADENOMA		1 (0.01)	2 (0.01)		3 (0.00)
COLON CANCER	1 (0.02)	2 (0.01)	20 (0.07)	7 (0.09)	30 (0.05)
COLON CANCER METASTATIC		2 (0.01)	5 (0.02)	2 (0.03)	9 (0.01)
COLON CANCER RECURRENT			1 (0.00)		1 (0.00)
COLON NEOPLASM			1 (0.00)		1 (0.00)
COLON OPERATION			4 (0.01)		4 (0.01)
COLONIC POLYP			6 (0.02)	2 (0.03)	8 (0.01)
COLONIC PSEUDO-OBSTRUCTION			1 (0.00)		1 (0.00)
COLONOSCOPY			1 (0.00)		1 (0.00)
COLORECTAL CANCER			2 (0.01)		2 (0.00)
COLOSTOMY	1 (0.02)		3 (0.01)	1 (0.01)	5 (0.01)
COLOUR BLINDNESS	2 (0.03)	2 (0.01)	1 (0.00)	1 (0.01)	6 (0.01)
COLOUR VISION TESTS ABNORMAL	1 (0.02)				1 (0.00)
COLPOCELE			2 (0.01)		2 (0.00)
COMA	21 (0.36)	32 (0.19)	46 (0.15)	18 (0.23)	117 (0.19)
COMA HEPATIC	1 (0.02)	2 (0.01)	5 (0.02)	1 (0.01)	9 (0.01)
COMMUNICATION DISORDER	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
COMPARTMENT SYNDROME	2 (0.03)		1 (0.00)		3 (0.00)
COMPLEMENT FACTOR C3 INCREASED			1 (0.00)		1 (0.00)
COMPLEMENT FACTOR C4 DECREASED		1 (0.01)			1 (0.00)
COMPLETED SUICIDE	59 (1.00)	116 (0.68)	47 (0.16)	9 (0.12)	231 (0.38)
COMPLEX PARTIAL SEIZURES	7 (0.12)	8 (0.05)	1 (0.00)		16 (0.03)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
COMPLEX REGIONAL PAIN SYNDROME		3 (0.02)	1 (0.00)		4 (0.01)
COMPLICATION OF DEVICE INSERTION	7 (0.12)	11 (0.06)	2 (0.01)		20 (0.03)
COMPLICATION OF DEVICE REMOVAL	2 (0.03)	9 (0.05)			11 (0.02)
COMPLICATION OF PREGNANCY		2 (0.01)			2 (0.00)
COMPLICATIONS OF MATERNAL EXPOSURE TO THERAPEUTIC	1 (0.02)	2 (0.01)			3 (0.00)
COMPLICATIONS OF TRANSPLANT SURGERY	3 (0.05)	4 (0.02)	4 (0.01)	2 (0.03)	13 (0.02)
COMPLICATIONS OF TRANSPLANTED HEART			2 (0.01)		2 (0.00)
COMPLICATIONS OF TRANSPLANTED KIDNEY	1 (0.02)	7 (0.04)	13 (0.04)		21 (0.03)
COMPLICATIONS OF TRANSPLANTED LIVER		1 (0.01)	1 (0.00)		2 (0.00)
COMPLICATIONS OF TRANSPLANTED LUNG	1 (0.02)		1 (0.00)		2 (0.00)
COMPRESSION FRACTURE			7 (0.02)	3 (0.04)	10 (0.02)
COMPULSIONS		1 (0.01)			1 (0.00)
COMPUTERISED TOMOGRAM ABNORMAL			5 (0.02)	2 (0.03)	7 (0.01)
COMPUTERISED TOMOGRAM NORMAL		2 (0.01)			2 (0.00)
COMPUTERISED TOMOGRAM THORAX				1 (0.01)	1 (0.00)
COMPUTERISED TOMOGRAM THORAX ABNORMAL		1 (0.01)			1 (0.00)
CONCOMITANT DISEASE AGGRAVATED		1 (0.01)	3 (0.01)		4 (0.01)
CONCOMITANT DISEASE PROGRESSION	3 (0.05)	2 (0.01)	4 (0.01)	2 (0.03)	11 (0.02)
CONCUSSION	1 (0.02)	1 (0.01)	3 (0.01)		5 (0.01)
CONDITION AGGRAVATED	55 (0.93)	112 (0.66)	202 (0.67)	70 (0.90)	439 (0.72)
CONDUCTION DISORDER	1 (0.02)		1 (0.00)		2 (0.00)
CONDUCTIVE DEAFNESS		1 (0.01)			1 (0.00)
CONDYLOMA ACUMINATUM		1 (0.01)			1 (0.00)
CONFABULATION				1 (0.01)	1 (0.00)
CONFUSIONAL STATE	15 (0.25)	60 (0.35)	109 (0.36)	75 (0.97)	259 (0.42)
CONGENITAL ANOMALY	4 (0.07)	1 (0.01)			5 (0.01)
CONGENITAL CEREBROVASCULAR ANOMALY	1 (0.02)				1 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
CONGENITAL CYSTIC KIDNEY DISEASE	1 (0.02)	3 (0.02)	1 (0.00)		5 (0.01)
CONGENITAL HAND MALFORMATION	1 (0.02)				1 (0.00)
CONGENITAL HEART VALVE DISORDER		1 (0.01)			1 (0.00)
CONGENITAL JAW MALFORMATION	1 (0.02)				1 (0.00)
CONGENITAL MEGACOLON		1 (0.01)			1 (0.00)
CONGESTIVE CARDIOMYOPATHY		5 (0.03)	7 (0.02)		12 (0.02)
CONJUNCTIVAL HAEMORRHAGE		4 (0.02)	2 (0.01)		6 (0.01)
CONJUNCTIVAL HYPERAEMIA	1 (0.02)	1 (0.01)			2 (0.00)
CONJUNCTIVAL OEDEMA	1 (0.02)	1 (0.01)	5 (0.02)	1 (0.01)	8 (0.01)
CONJUNCTIVAL ULCER			4 (0.01)		4 (0.01)
CONJUNCTIVITIS	1 (0.02)	5 (0.03)	16 (0.05)	6 (0.08)	28 (0.05)
CONJUNCTIVITIS ALLERGIC			2 (0.01)		2 (0.00)
CONJUNCTIVITIS INFECTIVE			1 (0.00)		1 (0.00)
CONNECTIVE TISSUE DISORDER		1 (0.01)			1 (0.00)
CONNECTIVE TISSUE INFLAMMATION			1 (0.00)		1 (0.00)
CONSCIOUSNESS FLUCTUATING				2 (0.03)	2 (0.00)
CONSTIPATION	8 (0.14)	30 (0.18)	108 (0.36)	47 (0.61)	193 (0.32)
CONTRAINDICATION TO MEDICAL TREATMENT	1 (0.02)				1 (0.00)
CONTRALATERAL BREAST CANCER				1 (0.01)	1 (0.00)
CONTRAST MEDIA REACTION	1 (0.02)	5 (0.03)	2 (0.01)		8 (0.01)
CONTUSION	7 (0.12)	32 (0.19)	38 (0.13)	18 (0.23)	95 (0.16)
CONVERSION DISORDER	3 (0.05)	6 (0.04)	1 (0.00)		10 (0.02)
CONVULSION	140 (2.37)	189 (1.11)	117 (0.39)	31 (0.40)	477 (0.78)
CONVULSION NEONATAL	2 (0.03)				2 (0.00)
COOMBS NEGATIVE HAEMOLYTIC ANAEMIA			2 (0.01)		2 (0.00)
COORDINATION ABNORMAL	4 (0.07)	16 (0.09)	27 (0.09)	11 (0.14)	58 (0.10)
COPROPORPHYRINOGEN INCREASED		2 (0.01)			2 (0.00)
CORNEAL ABRASION			1 (0.00)	1 (0.01)	2 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CORNEAL DECOMPENSATION	1 (0.02)				1 (0.00)
CORNEAL DEFECT			1 (0.00)		1 (0.00)
CORNEAL DEPOSITS		3 (0.02)	1 (0.00)		4 (0.01)
CORNEAL DISORDER			1 (0.00)	1 (0.01)	2 (0.00)
CORNEAL EPITHELIUM DEFECT	1 (0.02)	5 (0.03)	2 (0.01)		8 (0.01)
CORNEAL EPITHELIUM DISORDER		2 (0.01)	2 (0.01)		4 (0.01)
CORNEAL EXFOLIATION			3 (0.01)		3 (0.00)
CORNEAL GRAFT REJECTION			1 (0.00)		1 (0.00)
CORNEAL HYPERTROPHY	1 (0.02)				1 (0.00)
CORNEAL INFILTRATES		2 (0.01)			2 (0.00)
CORNEAL LESION			1 (0.00)		1 (0.00)
CORNEAL OEDEMA			1 (0.00)	1 (0.01)	2 (0.00)
CORNEAL OPACITY		1 (0.01)	1 (0.00)		2 (0.00)
CORNEAL REFLEX DECREASED	1 (0.02)		1 (0.00)		2 (0.00)
CORNEAL TRANSPLANT			4 (0.01)		4 (0.01)
CORONARY ANGIOPLASTY			1 (0.00)		1 (0.00)
CORONARY ARTERIAL STENT INSERTION		1 (0.01)	5 (0.02)		6 (0.01)
CORONARY ARTERY ANEURYSM		1 (0.01)			1 (0.00)
CORONARY ARTERY DISEASE	1 (0.02)	40 (0.23)	123 (0.41)	15 (0.19)	179 (0.29)
CORONARY ARTERY DISSECTION			1 (0.00)		1 (0.00)
CORONARY ARTERY INSUFFICIENCY			1 (0.00)		1 (0.00)
CORONARY ARTERY OCCLUSION		15 (0.09)	57 (0.19)	9 (0.12)	81 (0.13)
CORONARY ARTERY PERFORATION			1 (0.00)		1 (0.00)
CORONARY ARTERY RESTENOSIS		1 (0.01)	4 (0.01)		5 (0.01)
CORONARY ARTERY STENOSIS		8 (0.05)	25 (0.08)	5 (0.06)	38 (0.06)
CORONARY ARTERY SURGERY		2 (0.01)	4 (0.01)	1 (0.01)	7 (0.01)
CORONARY ARTERY THROMBOSIS		1 (0.01)	11 (0.04)	3 (0.04)	15 (0.02)
CORONARY OSTIAL STENOSIS			2 (0.01)		2 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CORRECTIVE LENS USER			1 (0.00)		1 (0.00)
CORTISOL FREE URINE DECREASED			1 (0.00)		1 (0.00)
COSTOCHONDRITIS		1 (0.01)			1 (0.00)
COUGH	13 (0.22)	32 (0.19)	78 (0.26)	23 (0.30)	146 (0.24)
CRANIAL NERVE PARALYSIS			1 (0.00)		1 (0.00)
CRANIOPHARYNGIOMA	3 (0.05)	7 (0.04)	2 (0.01)		12 (0.02)
CRANIOTOMY			2 (0.01)		2 (0.00)
CREATINE PHOSPHOKINASE DECREASED			1 (0.00)		1 (0.00)
CREATININE RENAL CLEARANCE DECREASED		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
CREATININE URINE INCREASED			1 (0.00)		1 (0.00)
CREPITATIONS	1 (0.02)		1 (0.00)	1 (0.01)	3 (0.00)
CROHN'S DISEASE	5 (0.08)	6 (0.04)	7 (0.02)	1 (0.01)	19 (0.03)
CROSS SENSITIVITY REACTION				1 (0.01)	1 (0.00)
CROUP INFECTIOUS	1 (0.02)		2 (0.01)		3 (0.00)
CRUSH INJURY		1 (0.01)			1 (0.00)
CRUSH SYNDROME		2 (0.01)			2 (0.00)
CRYING	13 (0.22)	20 (0.12)	18 (0.06)	4 (0.05)	55 (0.09)
CRYPTOCOCCOSIS	1 (0.02)	1 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
CRYPTOGENIC CIRRHOSIS			2 (0.01)		2 (0.00)
CRYPTOGENIC ORGANIZING PNEUMONIA	1 (0.02)	2 (0.01)	10 (0.03)	3 (0.04)	16 (0.03)
CRYSTAL URINE		1 (0.01)			1 (0.00)
CSF LYMPHOCYTE COUNT ABNORMAL	2 (0.03)				2 (0.00)
CSF PRESSURE INCREASED	4 (0.07)				4 (0.01)
CSF PROTEIN INCREASED				1 (0.01)	1 (0.00)
CSF TEST ABNORMAL		3 (0.02)	2 (0.01)		5 (0.01)
CUBITAL TUNNEL SYNDROME		1 (0.01)			1 (0.00)
CULTURE POSITIVE		1 (0.01)	6 (0.02)		7 (0.01)
CULTURE THROAT POSITIVE	3 (0.05)				3 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CULTURE URINE POSITIVE		1 (0.01)			1 (0.00)
CULTURE WOUND POSITIVE		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
CUSHING'S SYNDROME	4 (0.07)	3 (0.02)	2 (0.01)		9 (0.01)
CUSHINGOID	1 (0.02)		2 (0.01)		3 (0.00)
CUTANEOUS LUPUS ERYTHEMATOSUS	1 (0.02)	3 (0.02)	6 (0.02)	1 (0.01)	11 (0.02)
CUTANEOUS SARCOIDOSIS		1 (0.01)			1 (0.00)
CUTANEOUS TUBERCULOSIS			2 (0.01)		2 (0.00)
CUTANEOUS VASCULITIS		2 (0.01)	7 (0.02)	2 (0.03)	11 (0.02)
CYANOSIS	17 (0.29)	13 (0.08)	6 (0.02)	5 (0.06)	41 (0.07)
CYANOSIS NEONATAL	2 (0.03)				2 (0.00)
CYCLOPLEGIC REFRACTION	1 (0.02)				1 (0.00)
CYCLOTHYMIC DISORDER		1 (0.01)			1 (0.00)
CYST	1 (0.02)	3 (0.02)	3 (0.01)	3 (0.04)	10 (0.02)
CYST REMOVAL	1 (0.02)				1 (0.00)
CYSTIC FIBROSIS	1 (0.02)				1 (0.00)
CYSTITIS	2 (0.03)	4 (0.02)	5 (0.02)	3 (0.04)	14 (0.02)
CYSTITIS ESCHERICHIA			1 (0.00)		1 (0.00)
CYSTITIS HAEMORRHAGIC	2 (0.03)	2 (0.01)	3 (0.01)	3 (0.04)	10 (0.02)
CYSTITIS INTERSTITIAL		1 (0.01)			1 (0.00)
CYSTITIS NONINFECTIVE			4 (0.01)		4 (0.01)
CYSTOCELE			3 (0.01)		3 (0.00)
CYSTOCELE REPAIR		1 (0.01)			1 (0.00)
CYSTOSCOPY			1 (0.00)		1 (0.00)
CYTOKINE RELEASE SYNDROME			1 (0.00)		1 (0.00)
CYTOLYTIC HEPATITIS	2 (0.03)	11 (0.06)	16 (0.05)	6 (0.08)	35 (0.06)
CYTOMEGALOVIRUS ANTIBODY POSITIVE			1 (0.00)		1 (0.00)
CYTOMEGALOVIRUS ANTIGEN POSITIVE	1 (0.02)				1 (0.00)
CYTOMEGALOVIRUS CHORIORETINITIS	1 (0.02)		1 (0.00)		2 (0.00)

Reaction Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
CYTOMEGALOVIRUS COLITIS			1 (0.00)		1 (0.00)
CYTOMEGALOVIRUS ENTERITIS			2 (0.01)		2 (0.00)
CYTOMEGALOVIRUS ENTEROCOLITIS	1 (0.02)	1 (0.01)			2 (0.00)
CYTOMEGALOVIRUS GASTROENTERITIS		1 (0.01)			1 (0.00)
CYTOMEGALOVIRUS HEPATITIS		1 (0.01)			1 (0.00)
CYTOMEGALOVIRUS INFECTION	7 (0.12)	8 (0.05)	11 (0.04)		26 (0.04)
CYTOMEGALOVIRUS TEST POSITIVE		1 (0.01)			1 (0.00)
CYTOMEGALOVIRUS VIRAEMIA	3 (0.05)	4 (0.02)			7 (0.01)
DACRYOSTENOSIS ACQUIRED			1 (0.00)		1 (0.00)
DAYDREAMING		1 (0.01)			1 (0.00)
DEAFNESS	7 (0.12)	16 (0.09)	30 (0.10)	8 (0.10)	61 (0.10)
DEAFNESS BILATERAL		2 (0.01)	2 (0.01)		4 (0.01)
DEAFNESS NEUROSENSORY	1 (0.02)	5 (0.03)	2 (0.01)	1 (0.01)	9 (0.01)
DEAFNESS UNILATERAL	1 (0.02)	4 (0.02)	8 (0.03)	2 (0.03)	15 (0.02)
DEATH	29 (0.49)	94 (0.55)	229 (0.76)	135 (1.74)	487 (0.80)
DEATH NEONATAL	2 (0.03)				2 (0.00)
DEATH OF RELATIVE			1 (0.00)		1 (0.00)
DEATH OF SIBLING				1 (0.01)	1 (0.00)
DECREASED ACTIVITY		2 (0.01)	5 (0.02)		7 (0.01)
DECREASED APPETITE	3 (0.05)	28 (0.16)	131 (0.43)	22 (0.28)	184 (0.30)
DECREASED IMMUNE RESPONSIVENESS			1 (0.00)		1 (0.00)
DECUBITUS ULCER		7 (0.04)	9 (0.03)	1 (0.01)	17 (0.03)
DEEP VEIN THROMBOSIS	19 (0.32)	70 (0.41)	78 (0.26)	16 (0.21)	183 (0.30)
DEFAECATION URGENCY			1 (0.00)		1 (0.00)
DEHYDRATION	12 (0.20)	54 (0.32)	131 (0.43)	40 (0.52)	237 (0.39)
DELAYED RECOVERY FROM ANAESTHESIA	1 (0.02)	1 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
DELAYED SLEEP PHASE	1 (0.02)				1 (0.00)
DELIRIUM	13 (0.22)	6 (0.04)	29 (0.10)	14 (0.18)	62 (0.10)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DELIRIUM FEBRILE	1 (0.02)				1 (0.00)
DELUSION	4 (0.07)	13 (0.08)	7 (0.02)	2 (0.03)	26 (0.04)
DELUSION OF GRANDEUR		1 (0.01)			1 (0.00)
DELUSIONAL DISORDER, PERSECUTORY TYPE		1 (0.01)	1 (0.00)		2 (0.00)
DELUSIONAL DISORDER, UNSPECIFIED TYPE			2 (0.01)		2 (0.00)
DEMENTIA	1 (0.02)	1 (0.01)	15 (0.05)	11 (0.14)	28 (0.05)
DEMENTIA ALZHEIMER'S TYPE			2 (0.01)	7 (0.09)	9 (0.01)
DEMYELINATING POLYNEUROPATHY		1 (0.01)	1 (0.00)		2 (0.00)
DEMYELINATION	5 (0.08)	1 (0.01)	1 (0.00)		7 (0.01)
DENERVATION ATROPHY	2 (0.03)				2 (0.00)
DENGUE FEVER	1 (0.02)				1 (0.00)
DENTAL CARE		1 (0.01)	4 (0.01)		5 (0.01)
DENTAL CARIES	1 (0.02)	3 (0.02)	3 (0.01)	1 (0.01)	8 (0.01)
DENTAL DISCOMFORT		1 (0.01)		1 (0.01)	2 (0.00)
DENTAL IMPLANTATION			2 (0.01)		2 (0.00)
DENTAL NECROSIS	1 (0.02)		1 (0.00)		2 (0.00)
DENTAL OPERATION	1 (0.02)		3 (0.01)		4 (0.01)
DENTAL PROSTHESIS PLACEMENT			2 (0.01)		2 (0.00)
DENTAL TREATMENT			4 (0.01)	3 (0.04)	7 (0.01)
DEPENDENCE	4 (0.07)	63 (0.37)	9 (0.03)		76 (0.12)
DEPERSONALISATION	1 (0.02)	4 (0.02)			5 (0.01)
DEPRESSED LEVEL OF CONSCIOUSNESS	22 (0.37)	28 (0.16)	46 (0.15)	19 (0.25)	115 (0.19)
DEPRESSED MOOD	2 (0.03)	17 (0.10)	7 (0.02)	1 (0.01)	27 (0.04)
DEPRESSION	36 (0.61)	116 (0.68)	86 (0.28)	7 (0.09)	245 (0.40)
DEPRESSION SUICIDAL	1 (0.02)				1 (0.00)
DEPRESSIVE SYMPTOM		3 (0.02)			3 (0.00)
DEREALISATION		1 (0.01)			1 (0.00)
DERMATITIS	1 (0.02)	10 (0.06)	2 (0.01)	2 (0.03)	15 (0.02)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
DERMATITIS ACNEIFORM	4 (0.07)	7 (0.04)	4 (0.01)	2 (0.03)	17 (0.03)
DERMATITIS ALLERGIC	2 (0.03)	3 (0.02)	5 (0.02)	1 (0.01)	11 (0.02)
DERMATITIS ATOPIC			1 (0.00)		1 (0.00)
DERMATITIS BULLOUS	3 (0.05)	8 (0.05)	11 (0.04)		22 (0.04)
DERMATITIS CONTACT		3 (0.02)	8 (0.03)	4 (0.05)	15 (0.02)
DERMATITIS EXFOLIATIVE	2 (0.03)	8 (0.05)	18 (0.06)	11 (0.14)	39 (0.06)
DERMATITIS EXFOLIATIVE GENERALISED				1 (0.01)	1 (0.00)
DERMATITIS PSORIASIFORM		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)
DERMATOMYOSITIS		1 (0.01)	6 (0.02)	1 (0.01)	8 (0.01)
DERMATOSIS		1 (0.01)			1 (0.00)
DERMOID CYST		1 (0.01)			1 (0.00)
DERMOID CYST OF OVARY		2 (0.01)			2 (0.00)
DETACHMENT OF RETINAL PIGMENT EPITHELIUM		3 (0.02)	1 (0.00)		4 (0.01)
DETOXIFICATION			2 (0.01)		2 (0.00)
DEVELOPMENTAL DELAY	10 (0.17)				10 (0.02)
DEVICE FAILURE	5 (0.08)	8 (0.05)	13 (0.04)	2 (0.03)	28 (0.05)
DEVICE INEFFECTIVE			1 (0.00)		1 (0.00)
DEVICE INTERACTION		1 (0.01)	2 (0.01)		3 (0.00)
DEVICE MALFUNCTION	4 (0.07)				4 (0.01)
DEVICE MIGRATION			1 (0.00)	1 (0.01)	2 (0.00)
DEVICE OCCLUSION	1 (0.02)			1 (0.01)	2 (0.00)
DEVICE RELATED INFECTION	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
DIABETES INSIPIDUS		3 (0.02)	1 (0.00)		4 (0.01)
DIABETES MELLITUS	9 (0.15)	46 (0.27)	51 (0.17)	9 (0.12)	115 (0.19)
DIABETES MELLITUS INADEQUATE CONTROL	5 (0.08)	7 (0.04)	22 (0.07)	5 (0.06)	39 (0.06)
DIABETES MELLITUS INSULIN-DEPENDENT	9 (0.15)	9 (0.05)	1 (0.00)	1 (0.01)	20 (0.03)
DIABETES MELLITUS NON-INSULIN-DEPENDENT	1 (0.02)	16 (0.09)	7 (0.02)	2 (0.03)	26 (0.04)
DIABETES WITH HYPEROSMOLARITY			1 (0.00)		1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
DIABETIC BULLOSIS			1 (0.00)		1 (0.00)
DIABETIC COMA		1 (0.01)	2 (0.01)	2 (0.03)	5 (0.01)
DIABETIC COMPLICATION		2 (0.01)	1 (0.00)		3 (0.00)
DIABETIC EYE DISEASE				1 (0.01)	1 (0.00)
DIABETIC FOOT			3 (0.01)	1 (0.01)	4 (0.01)
DIABETIC HYPERGLYCAEMIC COMA			3 (0.01)		3 (0.00)
DIABETIC KETOACIDOSIS	3 (0.05)	8 (0.05)	2 (0.01)		13 (0.02)
DIABETIC NEPHROPATHY			4 (0.01)		4 (0.01)
DIABETIC NEUROPATHY				1 (0.01)	1 (0.00)
DIABETIC RETINOPATHY			5 (0.02)	1 (0.01)	6 (0.01)
DIABETIC VASCULAR DISORDER		1 (0.01)			1 (0.00)
DIAGNOSTIC PROCEDURE			1 (0.00)		1 (0.00)
DIALYSIS	3 (0.05)	8 (0.05)	29 (0.10)	4 (0.05)	44 (0.07)
DIAPHRAGM MUSCLE WEAKNESS			1 (0.00)		1 (0.00)
DIAPHRAGMATIC DISORDER			3 (0.01)	1 (0.01)	4 (0.01)
DIAPHRAGMATIC HERNIA		1 (0.01)	1 (0.00)		2 (0.00)
DIAPHRAGMATIC PARALYSIS		1 (0.01)	1 (0.00)		2 (0.00)
DIARRHOEA	36 (0.61)	111 (0.65)	209 (0.69)	63 (0.81)	419 (0.69)
DIARRHOEA HAEMORRHAGIC	3 (0.05)	3 (0.02)	4 (0.01)	3 (0.04)	13 (0.02)
DIARRHOEA INFECTIOUS			2 (0.01)		2 (0.00)
DIASTOLIC DYSFUNCTION			1 (0.00)		1 (0.00)
DIET REFUSAL				1 (0.01)	1 (0.00)
DIFFICULTY IN WALKING	8 (0.14)	11 (0.06)	41 (0.14)	17 (0.22)	77 (0.13)
DIFFUSE ALVEOLAR DAMAGE			1 (0.00)		1 (0.00)
DIFFUSE LARGE B-CELL LYMPHOMA		2 (0.01)	4 (0.01)		6 (0.01)
DILATATION VENTRICULAR	2 (0.03)	1 (0.01)			3 (0.00)
DIPLEGIA	2 (0.03)		3 (0.01)		5 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
DIPLOPIA	2 (0.03)	15 (0.09)	19 (0.06)	1 (0.01)	37 (0.06)
DISABILITY		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
DISCOMFORT		3 (0.02)	10 (0.03)	1 (0.01)	14 (0.02)
DISEASE PROGRESSION	2 (0.03)	15 (0.09)	67 (0.22)	12 (0.15)	96 (0.16)
DISEASE RECURRENCE	5 (0.08)	18 (0.11)	18 (0.06)	6 (0.08)	47 (0.08)
DISINHIBITION		2 (0.01)			2 (0.00)
DISLOCATION OF JOINT PROSTHESIS		3 (0.02)			3 (0.00)
DISORIENTATION	4 (0.07)	8 (0.05)	20 (0.07)	8 (0.10)	40 (0.07)
DISSEMINATED INTRAVASCULAR COAGULATION	7 (0.12)	7 (0.04)	26 (0.09)	6 (0.08)	46 (0.08)
DISSEMINATED TUBERCULOSIS	1 (0.02)	6 (0.04)	5 (0.02)	3 (0.04)	15 (0.02)
DISSOCIATION		1 (0.01)			1 (0.00)
DISTRACTIBILITY	1 (0.02)				1 (0.00)
DISTURBANCE IN ATTENTION	10 (0.17)	11 (0.06)	14 (0.05)	3 (0.04)	38 (0.06)
DISTURBANCE IN SEXUAL AROUSAL	2 (0.03)				2 (0.00)
DIVERTICULAR PERFORATION		6 (0.04)	3 (0.01)	6 (0.08)	15 (0.02)
DIVERTICULITIS		3 (0.02)	23 (0.08)	1 (0.01)	27 (0.04)
DIVERTICULITIS INTESTINAL HAEMORRHAGIC			3 (0.01)		3 (0.00)
DIVERTICULUM		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
DIVERTICULUM DUODENAL			1 (0.00)		1 (0.00)
DIVERTICULUM INTESTINAL			2 (0.01)	2 (0.03)	4 (0.01)
DIZZINESS	44 (0.74)	147 (0.86)	251 (0.83)	82 (1.06)	524 (0.86)
DIZZINESS EXERTIONAL	1 (0.02)				1 (0.00)
DIZZINESS POSTURAL	2 (0.03)	1 (0.01)	1 (0.00)		4 (0.01)
DOCUMENTED HYPERSENSITIVITY TO ADMINISTERED DRUG			2 (0.01)		2 (0.00)
DOLICHOCOLON ACQUIRED		3 (0.02)			3 (0.00)
DROOLING	3 (0.05)	1 (0.01)	2 (0.01)		6 (0.01)
DROP ATTACKS	1 (0.02)				1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
DROWNING		1 (0.01)	1 (0.00)		2 (0.00)
DRUG ABUSER	21 (0.36)	35 (0.21)	40 (0.13)	1 (0.01)	97 (0.16)
DRUG ADMINISTRATION ERROR	8 (0.14)	10 (0.06)	21 (0.07)	10 (0.13)	49 (0.08)
DRUG CLEARANCE DECREASED			2 (0.01)		2 (0.00)
DRUG DEPENDENCE	2 (0.03)	15 (0.09)	13 (0.04)	2 (0.03)	32 (0.05)
DRUG DETOXIFICATION		1 (0.01)			1 (0.00)
DRUG DISPENSING ERROR	10 (0.17)	12 (0.07)	19 (0.06)	2 (0.03)	43 (0.07)
DRUG DOSE OMISSION	8 (0.14)	4 (0.02)	5 (0.02)	4 (0.05)	21 (0.03)
DRUG EFFECT DECREASED	9 (0.15)	28 (0.16)	39 (0.13)	5 (0.06)	81 (0.13)
DRUG EFFECT INCREASED	1 (0.02)	1 (0.01)			2 (0.00)
DRUG EFFECT PROLONGED	1 (0.02)	4 (0.02)	1 (0.00)		6 (0.01)
DRUG ERUPTION	6 (0.10)	7 (0.04)	31 (0.10)	9 (0.12)	53 (0.09)
DRUG EXPOSURE BEFORE PREGNANCY	6 (0.10)	9 (0.05)			15 (0.02)
DRUG EXPOSURE DURING PREGNANCY	126 (2.13)	160 (0.94)			286 (0.47)
DRUG EXPOSURE VIA BREAST MILK	7 (0.12)				7 (0.01)
DRUG HYPERSENSITIVITY	18 (0.30)	24 (0.14)	27 (0.09)	6 (0.08)	75 (0.12)
DRUG INEFFECTIVE	127 (2.15)	545 (3.19)	654 (2.16)	239 (3.08)	1565 (2.57)
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION	2 (0.03)	10 (0.06)	4 (0.01)		16 (0.03)
DRUG INTERACTION	35 (0.59)	77 (0.45)	120 (0.40)	51 (0.66)	283 (0.46)
DRUG INTERACTION INHIBITION			1 (0.00)		1 (0.00)
DRUG INTERACTION POTENTIATION				2 (0.03)	2 (0.00)
DRUG INTOLERANCE		5 (0.03)	5 (0.02)	2 (0.03)	12 (0.02)
DRUG LEVEL CHANGED		1 (0.01)			1 (0.00)
DRUG LEVEL DECREASED	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)
DRUG LEVEL INCREASED	7 (0.12)	4 (0.02)	5 (0.02)	5 (0.06)	21 (0.03)
DRUG PRESCRIBING ERROR	3 (0.05)	3 (0.02)	5 (0.02)	1 (0.01)	12 (0.02)
DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS	1 (0.02)	1 (0.01)	2 (0.01)	5 (0.06)	9 (0.01)

Reaction Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DRUG RESISTANCE		2 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)
DRUG SCREEN FALSE POSITIVE		2 (0.01)	1 (0.00)		3 (0.00)
DRUG SCREEN POSITIVE	7 (0.12)	5 (0.03)	1 (0.00)		13 (0.02)
DRUG SPECIFIC ANTIBODY PRESENT			1 (0.00)		1 (0.00)
DRUG THERAPY CHANGED		1 (0.01)			1 (0.00)
DRUG TOLERANCE			2 (0.01)		2 (0.00)
DRUG TOXICITY	18 (0.30)	30 (0.18)	27 (0.09)	7 (0.09)	82 (0.13)
DRUG WITHDRAWAL CONVULSIONS		2 (0.01)			2 (0.00)
DRUG WITHDRAWAL HEADACHE			2 (0.01)		2 (0.00)
DRUG WITHDRAWAL SYNDROME	6 (0.10)	34 (0.20)	20 (0.07)	3 (0.04)	63 (0.10)
DRUG WITHDRAWAL SYNDROME NEONATAL	4 (0.07)				4 (0.01)
DRY EYE	1 (0.02)	3 (0.02)	9 (0.03)	3 (0.04)	16 (0.03)
DRY MOUTH	5 (0.08)	23 (0.13)	32 (0.11)	18 (0.23)	78 (0.13)
DRY SKIN	4 (0.07)	5 (0.03)	16 (0.05)	2 (0.03)	27 (0.04)
DRY SOCKET			1 (0.00)	1 (0.01)	2 (0.00)
DRY THROAT	1 (0.02)	2 (0.01)	1 (0.00)		4 (0.01)
DUODENAL OBSTRUCTION	1 (0.02)				1 (0.00)
DUODENAL OPERATION			1 (0.00)		1 (0.00)
DUODENAL PERFORATION			1 (0.00)	4 (0.05)	5 (0.01)
DUODENAL ULCER		3 (0.02)	5 (0.02)	6 (0.08)	14 (0.02)
DUODENAL ULCER HAEMORRHAGE		1 (0.01)	5 (0.02)	2 (0.03)	8 (0.01)
DUODENAL ULCER PERFORATION	1 (0.02)	1 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
DUODENITIS			8 (0.03)	3 (0.04)	11 (0.02)
DURAL TEAR			1 (0.00)		1 (0.00)
DYSAESTHESIA	3 (0.05)		2 (0.01)	1 (0.01)	6 (0.01)
DYSAESTHESIA PHARYNX		1 (0.01)			1 (0.00)
DYSARTHRIA	2 (0.03)	12 (0.07)	8 (0.03)	6 (0.08)	28 (0.05)
DYSFUNCTIONAL UTERINE BLEEDING			1 (0.00)		1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
DYSGEUSIA	8 (0.14)	145 (0.85)	181 (0.60)	20 (0.26)	354 (0.58)
DYSGRAPHIA	1 (0.02)			1 (0.01)	2 (0.00)
DYSKINESIA	10 (0.17)	9 (0.05)	8 (0.03)	5 (0.06)	32 (0.05)
DYSLALIA	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
DYSLEXIA	1 (0.02)				1 (0.00)
DYSLIPIDAEMIA	2 (0.03)	4 (0.02)	1 (0.00)		7 (0.01)
DYSMENORRHOEA		2 (0.01)			2 (0.00)
DYSPAREUNIA		1 (0.01)	1 (0.00)		2 (0.00)
DYSPEPSIA	1 (0.02)	25 (0.15)	40 (0.13)	10 (0.13)	76 (0.12)
DYSPHAGIA	7 (0.12)	19 (0.11)	27 (0.09)	17 (0.22)	70 (0.11)
DYSPHASIA	1 (0.02)		4 (0.01)		5 (0.01)
DYSPHEMIA			1 (0.00)		1 (0.00)
DYSPHONIA		4 (0.02)	9 (0.03)	7 (0.09)	20 (0.03)
DYSPHORIA		1 (0.01)			1 (0.00)
DYSPLASIA				1 (0.01)	1 (0.00)
DYSPNOEA	32 (0.54)	114 (0.67)	164 (0.54)	71 (0.92)	381 (0.62)
DYSPNOEA AT REST			1 (0.00)		1 (0.00)
DYSPNOEA EXACERBATED	1 (0.02)		3 (0.01)	2 (0.03)	6 (0.01)
DYSPNOEA EXERTIONAL		2 (0.01)	8 (0.03)	3 (0.04)	13 (0.02)
DYSSTASIA		4 (0.02)	6 (0.02)	2 (0.03)	12 (0.02)
DYSTONIA	8 (0.14)	6 (0.04)	4 (0.01)	1 (0.01)	19 (0.03)
DYSURIA	5 (0.08)	5 (0.03)	18 (0.06)	10 (0.13)	38 (0.06)
EAR CANAL ERYTHEMA		1 (0.01)			1 (0.00)
EAR DISCOMFORT		2 (0.01)	1 (0.00)		3 (0.00)
EAR DISORDER		1 (0.01)	3 (0.01)	1 (0.01)	5 (0.01)
EAR HAEMORRHAGE		1 (0.01)			1 (0.00)
EAR INFECTION	3 (0.05)	1 (0.01)			4 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
EAR NEOPLASM		1 (0.01)			1 (0.00)
EAR PAIN	1 (0.02)	4 (0.02)	2 (0.01)		7 (0.01)
EARLY SATIETY			3 (0.01)		3 (0.00)
EATING DISORDER			3 (0.01)	1 (0.01)	4 (0.01)
EATING DISORDER SYMPTOM			1 (0.00)		1 (0.00)
ECCHYMOSIS		8 (0.05)	5 (0.02)	1 (0.01)	14 (0.02)
ECHOCARDIOGRAM ABNORMAL	1 (0.02)	4 (0.02)			5 (0.01)
ECONOMIC PROBLEM			1 (0.00)		1 (0.00)
ECTOPIC PREGNANCY	5 (0.08)	10 (0.06)			15 (0.02)
ECTROPION OF CERVIX			1 (0.00)		1 (0.00)
ECZEMA	1 (0.02)	5 (0.03)	7 (0.02)	6 (0.08)	19 (0.03)
ECZEMA NUMMULAR				4 (0.05)	4 (0.01)
EDUCATIONAL PROBLEM	1 (0.02)				1 (0.00)
EFFUSION		1 (0.01)	2 (0.01)		3 (0.00)
EJACULATION DELAYED				1 (0.01)	1 (0.00)
EJACULATION DISORDER	1 (0.02)		3 (0.01)		4 (0.01)
EJACULATION FAILURE	1 (0.02)	2 (0.01)	4 (0.01)	1 (0.01)	8 (0.01)
EJECTION FRACTION DECREASED		3 (0.02)	10 (0.03)	1 (0.01)	14 (0.02)
ELECTRIC SHOCK		1 (0.01)	1 (0.00)		2 (0.00)
ELECTROCARDIOGRAM ABNORMAL	4 (0.07)	1 (0.01)	2 (0.01)	1 (0.01)	8 (0.01)
ELECTROCARDIOGRAM AMBULATORY ABNORMAL			1 (0.00)		1 (0.00)
ELECTROCARDIOGRAM CHANGE		1 (0.01)		1 (0.01)	2 (0.00)
ELECTROCARDIOGRAM Q WAVES			1 (0.00)		1 (0.00)
ELECTROCARDIOGRAM QRS COMPLEX PROLONGED				1 (0.01)	1 (0.00)
ELECTROCARDIOGRAM QT CORRECTED INTERVAL PROLONGED	4 (0.07)	2 (0.01)	4 (0.01)	1 (0.01)	11 (0.02)
ELECTROCARDIOGRAM QT PROLONGED		6 (0.04)	11 (0.04)	5 (0.06)	22 (0.04)
ELECTROCARDIOGRAM REPOLARISATION ABNORMALITY			3 (0.01)		3 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
ELECTROCARDIOGRAM ST SEGMENT ABNORMAL			2 (0.01)		2 (0.00)
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION			2 (0.01)		2 (0.00)
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	2 (0.03)	3 (0.02)			5 (0.01)
ELECTROCARDIOGRAM ST-T SEGMENT ABNORMAL			1 (0.00)		1 (0.00)
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED				1 (0.01)	1 (0.00)
ELECTROCARDIOGRAM T WAVE INVERSION		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
ELECTROCONVULSIVE THERAPY			1 (0.00)		1 (0.00)
ELECTROENCEPHALOGRAM ABNORMAL	1 (0.02)	2 (0.01)	1 (0.00)		4 (0.01)
ELECTROLYTE IMBALANCE		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
ELECTROMECHANICAL DISSOCIATION			4 (0.01)		4 (0.01)
EMBOLIC STROKE		1 (0.01)	3 (0.01)		4 (0.01)
EMBOLISM		1 (0.01)	5 (0.02)	1 (0.01)	7 (0.01)
EMBOLISM VENOUS		1 (0.01)		3 (0.04)	4 (0.01)
EMOTIONAL DISORDER	2 (0.03)	4 (0.02)	8 (0.03)		14 (0.02)
EMOTIONAL DISTRESS		11 (0.06)	14 (0.05)	2 (0.03)	27 (0.04)
EMPHYSEMA		1 (0.01)	8 (0.03)		9 (0.01)
EMPYEMA			7 (0.02)		7 (0.01)
ENAMEL ANOMALY	2 (0.03)		1 (0.00)		3 (0.00)
ENANTHEMA			2 (0.01)		2 (0.00)
ENCEPHALITIS	3 (0.05)	4 (0.02)	2 (0.01)		9 (0.01)
ENCEPHALITIS HERPES	1 (0.02)	1 (0.01)	3 (0.01)		5 (0.01)
ENCEPHALITIS VIRAL			1 (0.00)		1 (0.00)
ENCEPHALOMALACIA		1 (0.01)			1 (0.00)
ENCEPHALOPATHY	8 (0.14)	8 (0.05)	16 (0.05)	7 (0.09)	39 (0.06)
ENDOCARDITIS			4 (0.01)		4 (0.01)
ENDOCARDITIS BACTERIAL	1 (0.02)				1 (0.00)
ENDOCARDITIS ENTEROCOCCAL		1 (0.01)		1 (0.01)	2 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
ENDOCARDITIS STAPHYLOCOCCAL		1 (0.01)	2 (0.01)		3 (0.00)
ENDOCRINE DISORDER		1 (0.01)			1 (0.00)
ENDODONTIC PROCEDURE				1 (0.01)	1 (0.00)
ENDOMETRIAL ATROPHY				1 (0.01)	1 (0.00)
ENDOMETRIAL CANCER		2 (0.01)	7 (0.02)	1 (0.01)	10 (0.02)
ENDOMETRIAL CANCER STAGE I			1 (0.00)	1 (0.01)	2 (0.00)
ENDOMETRIAL DISORDER		3 (0.02)			3 (0.00)
ENDOMETRIAL HYPERPLASIA	1 (0.02)	1 (0.01)		2 (0.03)	4 (0.01)
ENDOMETRIAL METAPLASIA			1 (0.00)		1 (0.00)
ENDOMETRIOSIS		8 (0.05)			8 (0.01)
ENDOMETRITIS		1 (0.01)			1 (0.00)
ENDOPHTHALMITIS			8 (0.03)	3 (0.04)	11 (0.02)
ENERGY INCREASED		3 (0.02)	4 (0.01)		7 (0.01)
ENTERITIS			7 (0.02)	1 (0.01)	8 (0.01)
ENTEROBACTER INFECTION		1 (0.01)	1 (0.00)		2 (0.00)
ENTEROBACTER SEPSIS	1 (0.02)				1 (0.00)
ENTEROCOCCAL INFECTION			3 (0.01)	1 (0.01)	4 (0.01)
ENTEROCOCCAL SEPSIS				1 (0.01)	1 (0.00)
ENTEROCOLITIS	1 (0.02)		7 (0.02)		8 (0.01)
ENTEROCOLITIS HAEMORRHAGIC	4 (0.07)	4 (0.02)	2 (0.01)		10 (0.02)
ENTEROCOLITIS INFECTIOUS	1 (0.02)				1 (0.00)
ENTEROVESICAL FISTULA			2 (0.01)		2 (0.00)
ENURESIS		4 (0.02)	2 (0.01)		6 (0.01)
EOSINOPHIL COUNT INCREASED	2 (0.03)	2 (0.01)	6 (0.02)	4 (0.05)	14 (0.02)
EOSINOPHIL PERCENTAGE INCREASED		1 (0.01)			1 (0.00)
EOSINOPHILIA	4 (0.07)	10 (0.06)	14 (0.05)	5 (0.06)	33 (0.05)
EOSINOPHILIC MYOCARDITIS	1 (0.02)				1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
EOSINOPHILIC PNEUMONIA		1 (0.01)	2 (0.01)		3 (0.00)
EOSINOPHILS URINE PRESENT	1 (0.02)			1 (0.01)	2 (0.00)
EPIDERMAL NECROSIS		1 (0.01)			1 (0.00)
EPIDERMOLYSIS BULLOSA	1 (0.02)				1 (0.00)
EPIDIDYMAL DISORDER		2 (0.01)			2 (0.00)
EPIDIDYMITIS		2 (0.01)	5 (0.02)	6 (0.08)	13 (0.02)
EPIDIDYMITIS TUBERCULOUS			2 (0.01)		2 (0.00)
EPIGLOTTITIS	1 (0.02)	1 (0.01)			2 (0.00)
EPILEPSY	12 (0.20)	17 (0.10)	9 (0.03)	5 (0.06)	43 (0.07)
EPIPHYSIOLYSIS	3 (0.05)				3 (0.00)
EPISCLERITIS			2 (0.01)		2 (0.00)
EPISTAXIS	13 (0.22)	10 (0.06)	34 (0.11)	16 (0.21)	73 (0.12)
EPSTEIN-BARR VIRUS ANTIBODY POSITIVE		1 (0.01)	1 (0.00)		2 (0.00)
EPSTEIN-BARR VIRUS INFECTION	1 (0.02)		5 (0.02)		6 (0.01)
EPULIS			2 (0.01)		2 (0.00)
ERECTILE DYSFUNCTION		24 (0.14)	66 (0.22)	19 (0.25)	109 (0.18)
ERECTION INCREASED		9 (0.05)	3 (0.01)		12 (0.02)
EROSIVE DUODENITIS			2 (0.01)		2 (0.00)
EROSIVE OESOPHAGITIS	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
ERUCTATION	1 (0.02)	1 (0.01)	13 (0.04)	3 (0.04)	18 (0.03)
ERYSIPELAS			2 (0.01)	2 (0.03)	4 (0.01)
ERYTHEMA	19 (0.32)	46 (0.27)	75 (0.25)	21 (0.27)	161 (0.26)
ERYTHEMA ANNULARE			1 (0.00)		1 (0.00)
ERYTHEMA INFECTIOSUM			2 (0.01)		2 (0.00)
ERYTHEMA MULTIFORME	13 (0.22)	23 (0.13)	10 (0.03)	3 (0.04)	49 (0.08)
ERYTHEMA NODOSUM	2 (0.03)	2 (0.01)	4 (0.01)		8 (0.01)
ERYTHEMA OF EYELID		1 (0.01)			1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
ERYTHRODERMIC PSORIASIS		1 (0.01)			1 (0.00)
ESCHERICHIA BACTERAEemia	1 (0.02)	1 (0.01)			2 (0.00)
ESCHERICHIA INFECTION		2 (0.01)	2 (0.01)		4 (0.01)
ESCHERICHIA SEPSIS			1 (0.00)		1 (0.00)
ESCHERICHIA URINARY TRACT INFECTION		1 (0.01)	3 (0.01)		4 (0.01)
ESSENTIAL HYPERTENSION		1 (0.01)			1 (0.00)
ESSENTIAL TREMOR			1 (0.00)		1 (0.00)
EUPHORIC MOOD	1 (0.02)	2 (0.01)	4 (0.01)	1 (0.01)	8 (0.01)
EVACUATION OF RETAINED PRODUCTS OF CONCEPTION		1 (0.01)			1 (0.00)
EVAN'S SYNDROME	1 (0.02)		2 (0.01)		3 (0.00)
EX-SMOKER		1 (0.01)			1 (0.00)
EXCESSIVE GRANULATION TISSUE			2 (0.01)		2 (0.00)
EXCESSIVE OCULAR CONVERGENCE		1 (0.01)			1 (0.00)
EXCITABILITY	3 (0.05)	3 (0.02)			6 (0.01)
EXCORIATION		6 (0.04)			6 (0.01)
EXERCISE LACK OF				1 (0.01)	1 (0.00)
EXERCISE TOLERANCE DECREASED			1 (0.00)		1 (0.00)
EXFOLIATIVE RASH		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
EXOPHTHALMOS		1 (0.01)	1 (0.00)		2 (0.00)
EXOSTOSIS			10 (0.03)		10 (0.02)
EXTRADURAL ABSCESS		1 (0.01)			1 (0.00)
EXTRADURAL HAEMATOMA		2 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)
EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYP				1 (0.01)	1 (0.00)
EXTRAPYRAMIDAL DISORDER	2 (0.03)	3 (0.02)	2 (0.01)	2 (0.03)	9 (0.01)
EXTRASYSTOLES	2 (0.03)	2 (0.01)	2 (0.01)	1 (0.01)	7 (0.01)
EXTRAVASATION	1 (0.02)	3 (0.02)	6 (0.02)	1 (0.01)	11 (0.02)
EXTREMITY NECROSIS		4 (0.02)	1 (0.00)		5 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
EYE DISCHARGE			3 (0.01)		3 (0.00)
EYE DISORDER	1 (0.02)	5 (0.03)	10 (0.03)	3 (0.04)	19 (0.03)
EYE HAEMORRHAGE		1 (0.01)	9 (0.03)	2 (0.03)	12 (0.02)
EYE INFECTION	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
EYE INFECTION BACTERIAL			2 (0.01)		2 (0.00)
EYE INFLAMMATION		1 (0.01)	2 (0.01)	3 (0.04)	6 (0.01)
EYE INJURY		1 (0.01)			1 (0.00)
EYE IRRITATION		5 (0.03)	7 (0.02)	4 (0.05)	16 (0.03)
EYE MOVEMENT DISORDER	3 (0.05)	1 (0.01)		1 (0.01)	5 (0.01)
EYE OEDEMA		3 (0.02)	1 (0.00)	1 (0.01)	5 (0.01)
EYE PAIN	2 (0.03)	12 (0.07)	13 (0.04)	3 (0.04)	30 (0.05)
EYE PRURITUS		1 (0.01)	5 (0.02)	1 (0.01)	7 (0.01)
EYE SWELLING	8 (0.14)	11 (0.06)	4 (0.01)		23 (0.04)
EYEBALL AVULSION			1 (0.00)		1 (0.00)
EYELID FUNCTION DISORDER			1 (0.00)		1 (0.00)
EYELID OEDEMA	3 (0.05)	1 (0.01)	5 (0.02)		9 (0.01)
EYELID PTOSIS	1 (0.02)	1 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
FACE INJURY				1 (0.01)	1 (0.00)
FACE OEDEMA	3 (0.05)	13 (0.08)	6 (0.02)	3 (0.04)	25 (0.04)
FACIAL BONES FRACTURE		1 (0.01)	2 (0.01)		3 (0.00)
FACIAL PAIN	2 (0.03)	2 (0.01)	2 (0.01)		6 (0.01)
FACIAL PALSY	1 (0.02)	7 (0.04)	9 (0.03)	1 (0.01)	18 (0.03)
FACIAL PARESIS		1 (0.01)			1 (0.00)
FACTOR II MUTATION	2 (0.03)				2 (0.00)
FACTOR IX INHIBITION	1 (0.02)				1 (0.00)
FACTOR VIII INHIBITION	6 (0.10)		1 (0.00)		7 (0.01)
FAECAL INCONTINENCE	3 (0.05)		4 (0.01)	2 (0.03)	9 (0.01)

Reaction Summary Table

Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
FAECAL VOMITING		1 (0.01)			1 (0.00)
FAECALOMA			2 (0.01)		2 (0.00)
FAECES DISCOLOURED	1 (0.02)		6 (0.02)	4 (0.05)	11 (0.02)
FAECES HARD	1 (0.02)			2 (0.03)	3 (0.00)
FAECES PALE		1 (0.01)	1 (0.00)		2 (0.00)
FAILURE OF IMPLANT			2 (0.01)	1 (0.01)	3 (0.00)
FAILURE TO THRIVE			1 (0.00)		1 (0.00)
FALL	8 (0.14)	32 (0.19)	125 (0.41)	73 (0.94)	238 (0.39)
FALLOPIAN TUBE CANCER STAGE III		1 (0.01)			1 (0.00)
FALSE POSITIVE LABORATORY RESULT	1 (0.02)				1 (0.00)
FALSE POSITIVE TUBERCULOSIS TEST		1 (0.01)			1 (0.00)
FAMILIAL POLYCYTHAEMIA	1 (0.02)				1 (0.00)
FAMILY STRESS		2 (0.01)			2 (0.00)
FANCONI SYNDROME		2 (0.01)	1 (0.00)		3 (0.00)
FANCONI SYNDROME ACQUIRED			1 (0.00)		1 (0.00)
FAT ATROPHY			1 (0.00)		1 (0.00)
FAT EMBOLISM		1 (0.01)			1 (0.00)
FAT REDISTRIBUTION		2 (0.01)			2 (0.00)
FAT TISSUE INCREASED	1 (0.02)		1 (0.00)		2 (0.00)
FATIGUE	9 (0.15)	44 (0.26)	69 (0.23)	14 (0.18)	136 (0.22)
FEAR	2 (0.03)	1 (0.01)	2 (0.01)		5 (0.01)
FEAR OF FALLING				1 (0.01)	1 (0.00)
FEBRILE BONE MARROW APLASIA			6 (0.02)		6 (0.01)
FEBRILE CONVULSION	3 (0.05)				3 (0.00)
FEBRILE INFECTION			1 (0.00)		1 (0.00)
FEBRILE NEUTROPENIA	1 (0.02)	14 (0.08)	43 (0.14)	14 (0.18)	72 (0.12)
FEEDING DISORDER OF INFANCY OR EARLY CHILDHOOD	1 (0.02)				1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
FEELING ABNORMAL	4 (0.07)	20 (0.12)	35 (0.12)	9 (0.12)	68 (0.11)
FEELING COLD		1 (0.01)	8 (0.03)		9 (0.01)
FEELING DRUNK			2 (0.01)	2 (0.03)	4 (0.01)
FEELING HOT	3 (0.05)	8 (0.05)	7 (0.02)	2 (0.03)	20 (0.03)
FEELING HOT AND COLD		3 (0.02)			3 (0.00)
FEELING JITTERY	1 (0.02)	3 (0.02)	12 (0.04)	2 (0.03)	18 (0.03)
FEELING OF RELAXATION		1 (0.01)			1 (0.00)
FEELINGS OF WORTHLESSNESS	1 (0.02)				1 (0.00)
FEMALE GENITAL TRACT FISTULA			1 (0.00)		1 (0.00)
FEMALE ORGASMIC DISORDER		1 (0.01)			1 (0.00)
FEMORAL ARTERIAL STENOSIS			1 (0.00)		1 (0.00)
FEMORAL ARTERY DISSECTION			1 (0.00)		1 (0.00)
FEMORAL ARTERY OCCLUSION			1 (0.00)	1 (0.01)	2 (0.00)
FEMORAL NECK FRACTURE			1 (0.00)	2 (0.03)	3 (0.00)
FEMUR FRACTURE	1 (0.02)		7 (0.02)	1 (0.01)	9 (0.01)
FEVER NEONATAL	1 (0.02)				1 (0.00)
FIBROCYSTIC BREAST DISEASE			1 (0.00)		1 (0.00)
FIBROMA			2 (0.01)		2 (0.00)
FIBROMYALGIA		5 (0.03)	5 (0.02)		10 (0.02)
FIBROSIS		1 (0.01)	2 (0.01)		3 (0.00)
FIBULA FRACTURE			1 (0.00)		1 (0.00)
FISTULA			5 (0.02)		5 (0.01)
FLANK PAIN	1 (0.02)	1 (0.01)	4 (0.01)		6 (0.01)
FLASHBACK		1 (0.01)			1 (0.00)
FLAT AFFECT		1 (0.01)	1 (0.00)		2 (0.00)
FLAT ANTERIOR CHAMBER OF EYE				1 (0.01)	1 (0.00)
FLATULENCE		5 (0.03)	14 (0.05)	3 (0.04)	22 (0.04)
FLIGHT OF IDEAS	1 (0.02)				1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
FLUID INTAKE REDUCED		1 (0.01)			1 (0.00)
FLUID OVERLOAD			1 (0.00)	4 (0.05)	5 (0.01)
FLUID RETENTION		6 (0.04)	9 (0.03)	1 (0.01)	16 (0.03)
FLUSHING	1 (0.02)	11 (0.06)	16 (0.05)	1 (0.01)	29 (0.05)
FOAMING AT MOUTH			1 (0.00)		1 (0.00)
FOCAL GLOMERULOSCLEROSIS	1 (0.02)	4 (0.02)			5 (0.01)
FOCAL NODULAR HYPERPLASIA		6 (0.04)			6 (0.01)
FOETAL MOVEMENTS DECREASED	1 (0.02)				1 (0.00)
FOLATE DEFICIENCY			1 (0.00)		1 (0.00)
FOLLICULITIS		3 (0.02)	1 (0.00)		4 (0.01)
FOOD ALLERGY	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
FOOD AVERSION			1 (0.00)		1 (0.00)
FOOD CRAVING	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)
FOOD POISONING		2 (0.01)	1 (0.00)		3 (0.00)
FOOT AMPUTATION			1 (0.00)		1 (0.00)
FOOT FRACTURE		6 (0.04)	1 (0.00)	1 (0.01)	8 (0.01)
FOOT OPERATION		3 (0.02)	2 (0.01)		5 (0.01)
FORCED EXPIRATORY VOLUME DECREASED		1 (0.01)			1 (0.00)
FOREIGN BODY TRAUMA			7 (0.02)		7 (0.01)
FOREIGN TRAVEL		1 (0.01)			1 (0.00)
FORMICATION	1 (0.02)	3 (0.02)	3 (0.01)		7 (0.01)
FRACTURE		1 (0.01)	2 (0.01)	2 (0.03)	5 (0.01)
FRACTURE TREATMENT			1 (0.00)		1 (0.00)
FRACTURED COCCYX				2 (0.03)	2 (0.00)
FREQUENT BOWEL MOVEMENTS			3 (0.01)	1 (0.01)	4 (0.01)
FULL BLOOD COUNT DECREASED		1 (0.01)	5 (0.02)		6 (0.01)
FULL BLOOD COUNT INCREASED	2 (0.03)				2 (0.00)
FUNGAL INFECTION	1 (0.02)	1 (0.01)	6 (0.02)		8 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
FUNGAL SEPSIS		2 (0.01)	1 (0.00)		3 (0.00)
FURUNCLE			3 (0.01)	2 (0.03)	5 (0.01)
GAIT DISTURBANCE	2 (0.03)	2 (0.01)	7 (0.02)	2 (0.03)	13 (0.02)
GALACTORRHOEA	1 (0.02)	4 (0.02)	1 (0.00)		6 (0.01)
GALLBLADDER DISORDER	1 (0.02)	6 (0.04)	14 (0.05)	1 (0.01)	22 (0.04)
GALLBLADDER NON-FUNCTIONING			1 (0.00)		1 (0.00)
GALLBLADDER OPERATION	1 (0.02)		5 (0.02)		6 (0.01)
GALLBLADDER PAIN			1 (0.00)		1 (0.00)
GALLBLADDER POLYP		1 (0.01)			1 (0.00)
GAMBLING		1 (0.01)	3 (0.01)		4 (0.01)
GAMMA-GLUTAMYLTRANSFERASE ABNORMAL		1 (0.01)			1 (0.00)
GAMMA-GLUTAMYLTRANSFERASE INCREASED		5 (0.03)	8 (0.03)	5 (0.06)	18 (0.03)
GAMMOPATHY				1 (0.01)	1 (0.00)
GANGLIONEUROMA		2 (0.01)			2 (0.00)
GANGRENE			5 (0.02)		5 (0.01)
GAS GANGRENE			1 (0.00)		1 (0.00)
GASTRECTOMY			1 (0.00)		1 (0.00)
GASTRIC BYPASS		1 (0.01)			1 (0.00)
GASTRIC CANCER			12 (0.04)	1 (0.01)	13 (0.02)
GASTRIC CANCER STAGE IV			1 (0.00)		1 (0.00)
GASTRIC DISORDER		5 (0.03)	6 (0.02)		11 (0.02)
GASTRIC HAEMORRHAGE	2 (0.03)	2 (0.01)	4 (0.01)	4 (0.05)	12 (0.02)
GASTRIC HYPOMOTILITY			1 (0.00)		1 (0.00)
GASTRIC MUCOSAL HYPERTROPHY			1 (0.00)		1 (0.00)
GASTRIC MUCOSAL LESION			1 (0.00)	1 (0.01)	2 (0.00)
GASTRIC NEOPLASM			1 (0.00)		1 (0.00)
GASTRIC PERFORATION		1 (0.01)	4 (0.01)		5 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
GASTRIC POLYPS			1 (0.00)	1 (0.01)	2 (0.00)
GASTRIC ULCER	1 (0.02)	8 (0.05)	16 (0.05)	3 (0.04)	28 (0.05)
GASTRIC ULCER HAEMORRHAGE		3 (0.02)	7 (0.02)	3 (0.04)	13 (0.02)
GASTRIC ULCER PERFORATION			2 (0.01)	1 (0.01)	3 (0.00)
GASTRIC VARICES		1 (0.01)	1 (0.00)		2 (0.00)
GASTRIC VARICES HAEMORRHAGE			4 (0.01)		4 (0.01)
GASTRITIS	1 (0.02)	8 (0.05)	14 (0.05)		23 (0.04)
GASTRITIS EROSION		3 (0.02)	3 (0.01)	2 (0.03)	8 (0.01)
GASTRITIS HAEMORRHAGIC		3 (0.02)		2 (0.03)	5 (0.01)
GASTROENTERITIS		6 (0.04)	2 (0.01)		8 (0.01)
GASTROENTERITIS ESCHERICHIA COLI		1 (0.01)			1 (0.00)
GASTROENTERITIS RADIATION				1 (0.01)	1 (0.00)
GASTROENTERITIS ROTAVIRUS	1 (0.02)				1 (0.00)
GASTROENTERITIS VIRAL		1 (0.01)	1 (0.00)		2 (0.00)
GASTROINTESTINAL ANGIODYSPLASIA HAEMORRHAGIC			1 (0.00)		1 (0.00)
GASTROINTESTINAL CARCINOMA			4 (0.01)	1 (0.01)	5 (0.01)
GASTROINTESTINAL DISORDER	3 (0.05)	9 (0.05)	10 (0.03)	7 (0.09)	29 (0.05)
GASTROINTESTINAL EROSION			1 (0.00)	2 (0.03)	3 (0.00)
GASTROINTESTINAL FISTULA		1 (0.01)	1 (0.00)		2 (0.00)
GASTROINTESTINAL HAEMORRHAGE	1 (0.02)	10 (0.06)	40 (0.13)	31 (0.40)	82 (0.13)
GASTROINTESTINAL HYPOMOTILITY		1 (0.01)			1 (0.00)
GASTROINTESTINAL INFECTION		1 (0.01)	3 (0.01)		4 (0.01)
GASTROINTESTINAL INFLAMMATION		1 (0.01)	1 (0.00)		2 (0.00)
GASTROINTESTINAL MOTILITY DISORDER			1 (0.00)		1 (0.00)
GASTROINTESTINAL NECROSIS			4 (0.01)	1 (0.01)	5 (0.01)
GASTROINTESTINAL OBSTRUCTION			2 (0.01)		2 (0.00)
GASTROINTESTINAL OEDEMA		1 (0.01)			1 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
GASTROINTESTINAL PAIN		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)
GASTROINTESTINAL PERFORATION		3 (0.02)	12 (0.04)		15 (0.02)
GASTROINTESTINAL TRACT ADENOMA			1 (0.00)		1 (0.00)
GASTROINTESTINAL ULCER		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
GASTROINTESTINAL ULCER HAEMORRHAGE			1 (0.00)	1 (0.01)	2 (0.00)
GASTROOESOPHAGEAL REFLUX DISEASE	1 (0.02)	3 (0.02)	23 (0.08)	3 (0.04)	30 (0.05)
GAZE PALSY	1 (0.02)	1 (0.01)			2 (0.00)
GENE MUTATION	1 (0.02)				1 (0.00)
GENERAL PHYSICAL CONDITION ABNORMAL		1 (0.01)	1 (0.00)		2 (0.00)
GENERAL PHYSICAL HEALTH DETERIORATION	5 (0.08)	6 (0.04)	23 (0.08)	7 (0.09)	41 (0.07)
GENERAL SYMPTOM	1 (0.02)				1 (0.00)
GENERALISED ERYTHEMA	1 (0.02)	3 (0.02)	6 (0.02)		10 (0.02)
GENERALISED OEDEMA		3 (0.02)	4 (0.01)	2 (0.03)	9 (0.01)
GENITAL BURNING SENSATION	3 (0.05)	6 (0.04)			9 (0.01)
GENITAL CYST			1 (0.00)		1 (0.00)
GENITAL DISORDER FEMALE				1 (0.01)	1 (0.00)
GENITAL HAEMORRHAGE		1 (0.01)	4 (0.01)		5 (0.01)
GENITAL NEOPLASM MALIGNANT FEMALE			1 (0.00)		1 (0.00)
GENITAL PAIN		1 (0.01)	1 (0.00)		2 (0.00)
GENITAL PAIN FEMALE	1 (0.02)				1 (0.00)
GENITAL PRURITUS FEMALE	24 (0.41)	81 (0.47)	10 (0.03)	1 (0.01)	116 (0.19)
GENITAL RASH		1 (0.01)	1 (0.00)		2 (0.00)
GERM CELL CANCER	1 (0.02)	2 (0.01)	1 (0.00)		4 (0.01)
GERSTMANN'S SYNDROME			2 (0.01)		2 (0.00)
GESTATIONAL DIABETES		2 (0.01)			2 (0.00)
GINGIVAL BLEEDING		3 (0.02)	9 (0.03)	2 (0.03)	14 (0.02)
GINGIVAL DISCOLOURATION		1 (0.01)			1 (0.00)
GINGIVAL DISORDER		2 (0.01)	1 (0.00)		3 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
GINGIVAL EROSION			2 (0.01)		2 (0.00)
GINGIVAL HYPERPLASIA			3 (0.01)		3 (0.00)
GINGIVAL HYPERTROPHY			1 (0.00)		1 (0.00)
GINGIVAL INFECTION			2 (0.01)		2 (0.00)
GINGIVAL PAIN	1 (0.02)	2 (0.01)	7 (0.02)		10 (0.02)
GINGIVAL PRURITUS		1 (0.01)			1 (0.00)
GINGIVAL RECESSON		3 (0.02)			3 (0.00)
GINGIVAL SWELLING	3 (0.05)		1 (0.00)		4 (0.01)
GINGIVAL ULCERATION			1 (0.00)	1 (0.01)	2 (0.00)
GINGIVITIS		2 (0.01)	5 (0.02)		7 (0.01)
GLASGOW COMA SCALE ABNORMAL		1 (0.01)			1 (0.00)
GLAUCOMA	2 (0.03)	9 (0.05)	4 (0.01)	1 (0.01)	16 (0.03)
GLIOBLASTOMA MULTIFORME		1 (0.01)	2 (0.01)		3 (0.00)
GLIOMA	1 (0.02)				1 (0.00)
GLOBAL AMNESIA		1 (0.01)	9 (0.03)	1 (0.01)	11 (0.02)
GLOMERULAR FILTRATION RATE DECREASED			1 (0.00)		1 (0.00)
GLOMERULAR FILTRATION RATE INCREASED			1 (0.00)		1 (0.00)
GLOMERULONEPHRITIS			4 (0.01)		4 (0.01)
GLOMERULONEPHRITIS MEMBRANOUS	1 (0.02)		1 (0.00)		2 (0.00)
GLOMERULONEPHRITIS MINIMAL LESION			1 (0.00)		1 (0.00)
GLOMERULONEPHRITIS PROLIFERATIVE	2 (0.03)				2 (0.00)
GLOMERULOSCLEROSIS			1 (0.00)		1 (0.00)
GLOSSITIS		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
GLOSSODYNIA		3 (0.02)	12 (0.04)	1 (0.01)	16 (0.03)
GLOSSOPHARYNGEAL NERVE PARALYSIS		1 (0.01)			1 (0.00)
GLOSSOPTOSIS			1 (0.00)		1 (0.00)
GLUCOSE TOLERANCE IMPAIRED		3 (0.02)			3 (0.00)
GLYCOSURIA	4 (0.07)	2 (0.01)			6 (0.01)

Reaction Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
GLYCOSYLATED HAEMOGLOBIN INCREASED			5 (0.02)	3 (0.04)	8 (0.01)
GOITRE		1 (0.01)	6 (0.02)		7 (0.01)
GOUT		1 (0.01)	5 (0.02)	2 (0.03)	8 (0.01)
GOUTY ARTHRITIS				1 (0.01)	1 (0.00)
GRAFT COMPLICATION		1 (0.01)	2 (0.01)		3 (0.00)
GRAFT DELAMINATION		1 (0.01)			1 (0.00)
GRAFT DYSFUNCTION			1 (0.00)		1 (0.00)
GRAFT INFECTION		1 (0.01)			1 (0.00)
GRAFT VERSUS HOST DISEASE	3 (0.05)	3 (0.02)	3 (0.01)		9 (0.01)
GRAND MAL CONVULSION	13 (0.22)	22 (0.13)	19 (0.06)	5 (0.06)	59 (0.10)
GRANULOCYTE COUNT DECREASED	1 (0.02)		1 (0.00)		2 (0.00)
GRANULOCYTES ABNORMAL			1 (0.00)		1 (0.00)
GRANULOCYTES MATURATION ARREST				1 (0.01)	1 (0.00)
GRANULOCYTOPENIA	8 (0.14)	23 (0.13)	16 (0.05)		47 (0.08)
GRANULOCYTOSIS		1 (0.01)			1 (0.00)
GRANULOMA	1 (0.02)	1 (0.01)	3 (0.01)		5 (0.01)
GRANULOMATOUS LIVER DISEASE		1 (0.01)	3 (0.01)		4 (0.01)
GRAVITATIONAL OEDEMA		2 (0.01)			2 (0.00)
GROIN PAIN			1 (0.00)	1 (0.01)	2 (0.00)
GROWTH HORMONE DEFICIENCY	1 (0.02)				1 (0.00)
GROWTH RETARDATION	1 (0.02)				1 (0.00)
GUILLAIN-BARRE SYNDROME	2 (0.03)	2 (0.01)	2 (0.01)		6 (0.01)
GUN SHOT WOUND		2 (0.01)	1 (0.00)		3 (0.00)
GUTTATE PSORIASIS		2 (0.01)			2 (0.00)
GYNAECOLOGICAL EXAMINATION ABNORMAL		1 (0.01)			1 (0.00)
GYNAECOMASTIA	2 (0.03)	1 (0.01)	3 (0.01)	6 (0.08)	12 (0.02)
HAEMANGIOMA		2 (0.01)	1 (0.00)		3 (0.00)
HAEMANGIOMA OF LIVER		1 (0.01)	1 (0.00)		2 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
HAEMARTHROSIS		1 (0.01)			1 (0.00)
HAEMATEMESIS	3 (0.05)	6 (0.04)	8 (0.03)	6 (0.08)	23 (0.04)
HAEMATOCHYZIA	2 (0.03)	5 (0.03)	5 (0.02)	5 (0.06)	17 (0.03)
HAEMATOCRIT DECREASED	2 (0.03)	4 (0.02)	13 (0.04)	4 (0.05)	23 (0.04)
HAEMATOCRIT INCREASED			1 (0.00)		1 (0.00)
HAEMATOLOGY TEST ABNORMAL			1 (0.00)		1 (0.00)
HAEMATOMA		5 (0.03)	15 (0.05)	8 (0.10)	28 (0.05)
HAEMATOMA INFECTION		1 (0.01)			1 (0.00)
HAEMATOSPERMIA			2 (0.01)		2 (0.00)
HAEMATURIA	6 (0.10)	6 (0.04)	17 (0.06)	13 (0.17)	42 (0.07)
HAEMATURIA TRAUMATIC				1 (0.01)	1 (0.00)
HAEMOCHROMATOSIS		1 (0.01)	1 (0.00)		2 (0.00)
HAEMODIALYSIS	2 (0.03)	7 (0.04)	17 (0.06)		26 (0.04)
HAEMODIALYSIS-INDUCED SYMPTOM			1 (0.00)		1 (0.00)
HAEMODYNAMIC INSTABILITY			1 (0.00)		1 (0.00)
HAEMOGLOBIN		1 (0.01)			1 (0.00)
HAEMOGLOBIN DECREASED	3 (0.05)	10 (0.06)	24 (0.08)	9 (0.12)	46 (0.08)
HAEMOGLOBIN INCREASED		1 (0.01)			1 (0.00)
HAEMOLYSIS	2 (0.03)		1 (0.00)		3 (0.00)
HAEMOLYTIC ANAEMIA	1 (0.02)	3 (0.02)	11 (0.04)	6 (0.08)	21 (0.03)
HAEMOLYTIC URAEMIC SYNDROME	1 (0.02)	3 (0.02)	3 (0.01)		7 (0.01)
HAEMOPTYSIS	3 (0.05)	8 (0.05)	16 (0.05)	1 (0.01)	28 (0.05)
HAEMORRHAGE	2 (0.03)	14 (0.08)	25 (0.08)	12 (0.15)	53 (0.09)
HAEMORRHAGE CORONARY ARTERY			2 (0.01)		2 (0.00)
HAEMORRHAGE INTRACRANIAL		2 (0.01)	6 (0.02)	3 (0.04)	11 (0.02)
HAEMORRHAGE SUBCUTANEOUS	1 (0.02)		2 (0.01)	1 (0.01)	4 (0.01)
HAEMORRHAGE URINARY TRACT			1 (0.00)		1 (0.00)
HAEMORRHAGIC INFARCTION			1 (0.00)	1 (0.01)	2 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
HAEMORRHAGIC OVARIAN CYST		1 (0.01)			1 (0.00)
HAEMORRHAGIC STROKE	2 (0.03)	2 (0.01)	4 (0.01)	1 (0.01)	9 (0.01)
HAEMORRHOID OPERATION		1 (0.01)			1 (0.00)
HAEMORRHOIDS			1 (0.00)		1 (0.00)
HAEMOTHORAX		1 (0.01)	2 (0.01)		3 (0.00)
HAIR COLOUR CHANGES	1 (0.02)				1 (0.00)
HAIR DISORDER				1 (0.01)	1 (0.00)
HAIR GROWTH ABNORMAL			2 (0.01)	2 (0.03)	4 (0.01)
HAIR TEXTURE ABNORMAL			1 (0.00)		1 (0.00)
HALLUCINATION	19 (0.32)	19 (0.11)	21 (0.07)	14 (0.18)	73 (0.12)
HALLUCINATION, AUDITORY	4 (0.07)	13 (0.08)	5 (0.02)	1 (0.01)	23 (0.04)
HALLUCINATION, VISUAL	5 (0.08)	6 (0.04)	9 (0.03)	4 (0.05)	24 (0.04)
HALLUCINATIONS, MIXED			1 (0.00)	2 (0.03)	3 (0.00)
HALO VISION				1 (0.01)	1 (0.00)
HAND FRACTURE			3 (0.01)		3 (0.00)
HANGOVER		1 (0.01)	3 (0.01)	1 (0.01)	5 (0.01)
HEAD BANGING	2 (0.03)				2 (0.00)
HEAD DISCOMFORT		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
HEAD INJURY		1 (0.01)	1 (0.00)		2 (0.00)
HEAD TITUBATION			1 (0.00)		1 (0.00)
HEADACHE	22 (0.37)	86 (0.50)	113 (0.37)	15 (0.19)	236 (0.39)
HEARING IMPAIRED	1 (0.02)	2 (0.01)			3 (0.00)
HEART INJURY		5 (0.03)	1 (0.00)	1 (0.01)	7 (0.01)
HEART RATE ABNORMAL		1 (0.01)	1 (0.00)		2 (0.00)
HEART RATE DECREASED		1 (0.01)	4 (0.01)		5 (0.01)
HEART RATE INCREASED	3 (0.05)	16 (0.09)	21 (0.07)	4 (0.05)	44 (0.07)
HEART RATE IRREGULAR	3 (0.05)	3 (0.02)	10 (0.03)	5 (0.06)	21 (0.03)
HEART TRANSPLANT REJECTION			1 (0.00)		1 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
HEART VALVE OPERATION				1 (0.01)	1 (0.00)
HEAT RASH	1 (0.02)				1 (0.00)
HELICOBACTER GASTRITIS			2 (0.01)		2 (0.00)
HELICOBACTER INFECTION				1 (0.01)	1 (0.00)
HEMIANOPIA			1 (0.00)		1 (0.00)
HEMIPARESIS	1 (0.02)	1 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)
HEMIPLEGIA		2 (0.01)	10 (0.03)		12 (0.02)
HENOCH-SCHONLEIN PURPURA	3 (0.05)	1 (0.01)	6 (0.02)		10 (0.02)
HEPARIN-INDUCED THROMBOCYTOPENIA		6 (0.04)	7 (0.02)	2 (0.03)	15 (0.02)
HEPATIC ADENOMA		2 (0.01)			2 (0.00)
HEPATIC CANCER METASTATIC		1 (0.01)		1 (0.01)	2 (0.00)
HEPATIC CIRRHOSIS	1 (0.02)	7 (0.04)	11 (0.04)	2 (0.03)	21 (0.03)
HEPATIC CONGESTION		1 (0.01)	1 (0.00)		2 (0.00)
HEPATIC CYST		1 (0.01)	3 (0.01)		4 (0.01)
HEPATIC ENCEPHALOPATHY		4 (0.02)	6 (0.02)	2 (0.03)	12 (0.02)
HEPATIC ENZYME ABNORMAL		1 (0.01)	3 (0.01)		4 (0.01)
HEPATIC ENZYME INCREASED	8 (0.14)	37 (0.22)	29 (0.10)	5 (0.06)	79 (0.13)
HEPATIC FAILURE	12 (0.20)	17 (0.10)	30 (0.10)	6 (0.08)	65 (0.11)
HEPATIC FIBROSIS	1 (0.02)	2 (0.01)	1 (0.00)		4 (0.01)
HEPATIC FUNCTION ABNORMAL	2 (0.03)	9 (0.05)	24 (0.08)	13 (0.17)	48 (0.08)
HEPATIC ISCHAEMIA			1 (0.00)		1 (0.00)
HEPATIC LESION		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
HEPATIC NECROSIS			2 (0.01)	1 (0.01)	3 (0.00)
HEPATIC NEOPLASM		2 (0.01)	5 (0.02)	1 (0.01)	8 (0.01)
HEPATIC NEOPLASM MALIGNANT		1 (0.01)	11 (0.04)	1 (0.01)	13 (0.02)
HEPATIC STEATOSIS	2 (0.03)	12 (0.07)	6 (0.02)		20 (0.03)
HEPATIC TRAUMA			1 (0.00)		1 (0.00)
HEPATIC VEIN OCCLUSION	1 (0.02)				1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
HEPATITIS	10 (0.17)	10 (0.06)	30 (0.10)	7 (0.09)	57 (0.09)
HEPATITIS A		1 (0.01)	2 (0.01)		3 (0.00)
HEPATITIS ACUTE		4 (0.02)	5 (0.02)	3 (0.04)	12 (0.02)
HEPATITIS B	2 (0.03)	3 (0.02)	4 (0.01)	1 (0.01)	10 (0.02)
HEPATITIS C	1 (0.02)	9 (0.05)	3 (0.01)	1 (0.01)	14 (0.02)
HEPATITIS C ANTIBODY POSITIVE		2 (0.01)			2 (0.00)
HEPATITIS C POSITIVE		1 (0.01)	2 (0.01)		3 (0.00)
HEPATITIS C VIRUS			1 (0.00)		1 (0.00)
HEPATITIS CHOLESTATIC	3 (0.05)	4 (0.02)	13 (0.04)	3 (0.04)	23 (0.04)
HEPATITIS CHRONIC ACTIVE			1 (0.00)		1 (0.00)
HEPATITIS E		1 (0.01)	2 (0.01)		3 (0.00)
HEPATITIS FULMINANT	1 (0.02)	3 (0.02)	5 (0.02)	2 (0.03)	11 (0.02)
HEPATITIS TOXIC		5 (0.03)	3 (0.01)	1 (0.01)	9 (0.01)
HEPATITIS VIRAL			2 (0.01)		2 (0.00)
HEPATOCELLULAR DAMAGE		5 (0.03)	3 (0.01)		8 (0.01)
HEPATOMEGALY	3 (0.05)	2 (0.01)	5 (0.02)		10 (0.02)
HEPATORENAL FAILURE	2 (0.03)				2 (0.00)
HEPATORENAL SYNDROME			1 (0.00)	1 (0.01)	2 (0.00)
HEPATOSPLENOMEGALY		1 (0.01)			1 (0.00)
HEPATOTOXICITY	2 (0.03)	2 (0.01)	3 (0.01)	3 (0.04)	10 (0.02)
HERNIA		4 (0.02)	5 (0.02)	1 (0.01)	10 (0.02)
HERNIA REPAIR			1 (0.00)		1 (0.00)
HERPES OPHTHALMIC			1 (0.00)		1 (0.00)
HERPES SIMPLEX		4 (0.02)	3 (0.01)	1 (0.01)	8 (0.01)
HERPES SIMPLEX OPHTHALMIC		3 (0.02)			3 (0.00)
HERPES VIRUS INFECTION		3 (0.02)			3 (0.00)
HERPES ZOSTER	3 (0.05)	5 (0.03)	6 (0.02)	3 (0.04)	17 (0.03)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
HERPES ZOSTER OPHTHALMIC		1 (0.01)			1 (0.00)
HIATUS HERNIA			1 (0.00)	1 (0.01)	2 (0.00)
HICCUPS	1 (0.02)	5 (0.03)	11 (0.04)	2 (0.03)	19 (0.03)
HIGH DENSITY LIPOPROTEIN DECREASED		1 (0.01)	2 (0.01)		3 (0.00)
HIP ARTHROPLASTY	1 (0.02)	2 (0.01)	9 (0.03)	1 (0.01)	13 (0.02)
HIP DEFORMITY	1 (0.02)				1 (0.00)
HIP DISARTICULATION			1 (0.00)		1 (0.00)
HIP DYSPLASIA		3 (0.02)			3 (0.00)
HIP FRACTURE		1 (0.01)	31 (0.10)	35 (0.45)	67 (0.11)
HIP SURGERY		1 (0.01)	2 (0.01)		3 (0.00)
HIRSUTISM		1 (0.01)			1 (0.00)
HISTAMINE LEVEL INCREASED			1 (0.00)		1 (0.00)
HISTIOCYTOSIS HAEMATOPHAGIC	2 (0.03)				2 (0.00)
HISTOPLASMOSIS			1 (0.00)		1 (0.00)
HISTOPLASMOSIS DISSEMINATED		1 (0.01)	1 (0.00)		2 (0.00)
HIV TEST FALSE POSITIVE	2 (0.03)				2 (0.00)
HIV TEST POSITIVE		1 (0.01)			1 (0.00)
HODGKIN'S DISEASE	3 (0.05)	5 (0.03)	1 (0.00)		9 (0.01)
HODGKIN'S DISEASE MIXED CELLULARITY STAGE UNSPECIF		1 (0.01)			1 (0.00)
HOMICIDAL IDEATION	3 (0.05)	1 (0.01)	1 (0.00)		5 (0.01)
HOMICIDE	1 (0.02)	2 (0.01)			3 (0.00)
HORNER'S SYNDROME		1 (0.01)			1 (0.00)
HOSPITALISATION		5 (0.03)	7 (0.02)	1 (0.01)	13 (0.02)
HOT FLUSH	2 (0.03)	4 (0.02)	8 (0.03)	1 (0.01)	15 (0.02)
HUNGER		1 (0.01)	2 (0.01)		3 (0.00)
HYDROCELE			2 (0.01)		2 (0.00)
HYDROCEPHALUS		1 (0.01)			1 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
HYDROMETRA		1 (0.01)			1 (0.00)
HYDRONEPHROSIS		6 (0.04)	2 (0.01)		8 (0.01)
HYDROPNEUMOTHORAX			2 (0.01)		2 (0.00)
HYDROTHORAX		1 (0.01)			1 (0.00)
HYPERACUSIS			1 (0.00)		1 (0.00)
HYPERAEMIA	1 (0.02)				1 (0.00)
HYPERAESTHESIA		1 (0.01)			1 (0.00)
HYPERALDOSTERONISM			1 (0.00)		1 (0.00)
HYPERAMMONAEMIA	1 (0.02)		1 (0.00)	1 (0.01)	3 (0.00)
HYPERBARIC OXYGEN THERAPY			3 (0.01)		3 (0.00)
HYPERBILIRUBINAEMIA			1 (0.00)	1 (0.01)	2 (0.00)
HYPERCALCAEMIA	2 (0.03)	2 (0.01)	6 (0.02)		10 (0.02)
HYPERCAPNIA			2 (0.01)	2 (0.03)	4 (0.01)
HYPERCHOLESTEROLAEMIA		2 (0.01)	5 (0.02)		7 (0.01)
HYPERCOAGULATION				1 (0.01)	1 (0.00)
HYPERCREATININAEMIA			1 (0.00)		1 (0.00)
HYPEREOSINOPHILIC SYNDROME			1 (0.00)		1 (0.00)
HYPERGLYCAEMIA	7 (0.12)	9 (0.05)	18 (0.06)	8 (0.10)	42 (0.07)
HYPERHIDROSIS	2 (0.03)	13 (0.08)	15 (0.05)	1 (0.01)	31 (0.05)
HYPERINSULINAEMIA				1 (0.01)	1 (0.00)
HYPERKALAEMIA	1 (0.02)	3 (0.02)	28 (0.09)	6 (0.08)	38 (0.06)
HYPERKERATOSIS			2 (0.01)		2 (0.00)
HYPERKINESIA				1 (0.01)	1 (0.00)
HYPERLACTACIDAEMIA		3 (0.02)			3 (0.00)
HYPERLIPIDAEMIA		2 (0.01)	4 (0.01)		6 (0.01)
HYPERNATRAEMIA			1 (0.00)		1 (0.00)
HYPEROXALURIA			1 (0.00)		1 (0.00)
HYPERPARATHYROIDISM		3 (0.02)			3 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
HYPERPHAGIA		1 (0.01)			1 (0.00)
HYPERPHOSPHATAEMIA		1 (0.01)			1 (0.00)
HYPERPLASIA	2 (0.03)				2 (0.00)
HYPERPYREXIA			1 (0.00)		1 (0.00)
HYPERREFLEXIA		2 (0.01)			2 (0.00)
HYPERSENSITIVITY	18 (0.30)	36 (0.21)	45 (0.15)	4 (0.05)	103 (0.17)
HYPERSONNIA	1 (0.02)	3 (0.02)	1 (0.00)	3 (0.04)	8 (0.01)
HYPERTENSION	11 (0.19)	32 (0.19)	44 (0.15)	10 (0.13)	97 (0.16)
HYPERTENSIVE CARDIOMYOPATHY		1 (0.01)			1 (0.00)
HYPERTENSIVE CRISIS		3 (0.02)	5 (0.02)	5 (0.06)	13 (0.02)
HYPERTENSIVE EMERGENCY			1 (0.00)		1 (0.00)
HYPERTENSIVE HEART DISEASE		1 (0.01)	3 (0.01)	1 (0.01)	5 (0.01)
HYPERTHERMIA			1 (0.00)	1 (0.01)	2 (0.00)
HYPERTHERMIA MALIGNANT	2 (0.03)	1 (0.01)	1 (0.00)		4 (0.01)
HYPERTHYROIDISM	1 (0.02)	3 (0.02)	4 (0.01)	1 (0.01)	9 (0.01)
HYPERTONIA	1 (0.02)			1 (0.01)	2 (0.00)
HYPERTONIC BLADDER			3 (0.01)		3 (0.00)
HYPERTRICHOSIS				1 (0.01)	1 (0.00)
HYPERTRIGLYCERIDAEMIA	1 (0.02)	7 (0.04)	1 (0.00)		9 (0.01)
HYPERTROPHIC CARDIOMYOPATHY	1 (0.02)		1 (0.00)		2 (0.00)
HYPERTROPHY BREAST	1 (0.02)				1 (0.00)
HYPERURICAEMIA			1 (0.00)		1 (0.00)
HYPERVENTILATION		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
HYPERVIGILANCE			1 (0.00)		1 (0.00)
HYPHAEMA				1 (0.01)	1 (0.00)
HYPOACUSIS	1 (0.02)		4 (0.01)	2 (0.03)	7 (0.01)
HYPOAESTHESIA	2 (0.03)	32 (0.19)	24 (0.08)	2 (0.03)	60 (0.10)
HYPOAESTHESIA ORAL	2 (0.03)	4 (0.02)	3 (0.01)		9 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
HYPOALBUMINAEMIA		2 (0.01)	1 (0.00)		3 (0.00)
HYPOCALCAEMIA		1 (0.01)	6 (0.02)	5 (0.06)	12 (0.02)
HYPOCHLORAEMIA			1 (0.00)	1 (0.01)	2 (0.00)
HYPOGAMMAGLOBULINAEMIA	1 (0.02)	1 (0.01)			2 (0.00)
HYPOGEUSIA			1 (0.00)		1 (0.00)
HYPOGLYCAEMIA	2 (0.03)	18 (0.11)	39 (0.13)	31 (0.40)	90 (0.15)
HYPOGLYCAEMIA UNAWARENESS	1 (0.02)				1 (0.00)
HYPOGLYCAEMIC COMA	2 (0.03)	5 (0.03)	17 (0.06)	13 (0.17)	37 (0.06)
HYPOGLYCAEMIC SEIZURE	1 (0.02)	1 (0.01)		1 (0.01)	3 (0.00)
HYPOHIDROSIS	1 (0.02)				1 (0.00)
HYPOKALAEMIA		1 (0.01)	7 (0.02)	5 (0.06)	13 (0.02)
HYPOKINESIA				1 (0.01)	1 (0.00)
HYPOMANIA		4 (0.02)	1 (0.00)		5 (0.01)
HYPOMENORRHOEA		1 (0.01)			1 (0.00)
HYPONATRAEMIA	1 (0.02)	9 (0.05)	26 (0.09)	17 (0.22)	53 (0.09)
HYPOPERFUSION			1 (0.00)		1 (0.00)
HYPOPROTEINAEMIA			1 (0.00)		1 (0.00)
HYPOTENSION	3 (0.05)	14 (0.08)	46 (0.15)	17 (0.22)	80 (0.13)
HYPOTHERMIA	12 (0.20)	4 (0.02)	4 (0.01)	1 (0.01)	21 (0.03)
HYPOTHYROIDISM	1 (0.02)	3 (0.02)	4 (0.01)	5 (0.06)	13 (0.02)
HYPOTONIA			1 (0.00)		1 (0.00)
HYPOTRICHOSIS		2 (0.01)	1 (0.00)		3 (0.00)
HYPOVENTILATION	1 (0.02)		1 (0.00)		2 (0.00)
HYPOVOLAEMIA		2 (0.01)	3 (0.01)		5 (0.01)
HYPOVOLAEMIC SHOCK			4 (0.01)		4 (0.01)
HYPOXIA	1 (0.02)	4 (0.02)	10 (0.03)	1 (0.01)	16 (0.03)
HYPOXIC ENCEPHALOPATHY			2 (0.01)		2 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
HYSTERECTOMY		12 (0.07)	9 (0.03)		21 (0.03)
IATROGENIC INJURY	1 (0.02)	1 (0.01)			2 (0.00)
ICHTHYOSIS			1 (0.00)		1 (0.00)
IDIOPATHIC PULMONARY FIBROSIS			1 (0.00)		1 (0.00)
IDIOPATHIC THROMBOCYTOPENIC PURPURA	2 (0.03)	4 (0.02)	9 (0.03)	3 (0.04)	18 (0.03)
IIIRD NERVE DISORDER	1 (0.02)				1 (0.00)
ILEAL PERFORATION		1 (0.01)	1 (0.00)		2 (0.00)
ILEAL STENOSIS			1 (0.00)		1 (0.00)
ILEUS	1 (0.02)	4 (0.02)	16 (0.05)		21 (0.03)
ILEUS PARALYTIC		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
ILL-DEFINED DISORDER	1 (0.02)	3 (0.02)	3 (0.01)		7 (0.01)
IMMOBILE				1 (0.01)	1 (0.00)
IMMUNE RECONSTITUTION SYNDROME		10 (0.06)	4 (0.01)		14 (0.02)
IMMUNE SYSTEM DISORDER		1 (0.01)	3 (0.01)		4 (0.01)
IMMUNODEFICIENCY		1 (0.01)			1 (0.00)
IMMUNOSUPPRESSANT DRUG LEVEL DECREASED			1 (0.00)		1 (0.00)
IMMUNOSUPPRESSION			2 (0.01)	2 (0.03)	4 (0.01)
IMPAIRED DRIVING ABILITY		1 (0.01)			1 (0.00)
IMPAIRED HEALING	3 (0.05)	5 (0.03)	12 (0.04)	2 (0.03)	22 (0.04)
IMPAIRED WORK ABILITY		2 (0.01)			2 (0.00)
IMPETIGO	1 (0.02)	1 (0.01)			2 (0.00)
IMPLANT SITE ERYTHEMA		1 (0.01)			1 (0.00)
IMPLANT SITE REACTION		1 (0.01)	1 (0.00)		2 (0.00)
IMPLANTABLE DEFIBRILLATOR INSERTION			1 (0.00)		1 (0.00)
IMPULSIVE BEHAVIOUR		1 (0.01)			1 (0.00)
INADEQUATE ANALGESIA		6 (0.04)	3 (0.01)		9 (0.01)
INADEQUATE DIET			2 (0.01)		2 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION		2 (0.01)	5 (0.02)	3 (0.04)	10 (0.02)
INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION		1 (0.01)	2 (0.01)	2 (0.03)	5 (0.01)
INCISION SITE COMPLICATION			2 (0.01)		2 (0.00)
INCISION SITE HAEMORRHAGE			1 (0.00)	2 (0.03)	3 (0.00)
INCOHERENT	1 (0.02)				1 (0.00)
INCONTINENCE		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
INCORRECT DOSE ADMINISTERED	8 (0.14)	5 (0.03)	12 (0.04)	2 (0.03)	27 (0.04)
INCORRECT DRUG ADMINISTRATION RATE			1 (0.00)		1 (0.00)
INCORRECT ROUTE OF DRUG ADMINISTRATION	3 (0.05)	2 (0.01)	3 (0.01)	1 (0.01)	9 (0.01)
INCREASED APPETITE	1 (0.02)		11 (0.04)	1 (0.01)	13 (0.02)
INCREASED BRONCHIAL SECRETION				1 (0.01)	1 (0.00)
INCREASED TENDENCY TO BRUISE			4 (0.01)	1 (0.01)	5 (0.01)
INDURATION			2 (0.01)		2 (0.00)
INFANTILE APNOEIC ATTACK	1 (0.02)				1 (0.00)
INFARCTION		1 (0.01)	3 (0.01)		4 (0.01)
INFECTED BUNION			1 (0.00)		1 (0.00)
INFECTED CYST	1 (0.02)				1 (0.00)
INFECTION	6 (0.10)	7 (0.04)	31 (0.10)		44 (0.07)
INFECTION IN AN IMMUNOCOMPROMISED HOST			4 (0.01)	1 (0.01)	5 (0.01)
INFECTIOUS MONONUCLEOSIS	1 (0.02)	1 (0.01)			2 (0.00)
INFECTIVE SPONDYLITIS			1 (0.00)		1 (0.00)
INFECTIVE TENOSYNOVITIS			1 (0.00)		1 (0.00)
INFERTILITY		1 (0.01)			1 (0.00)
INFERTILITY FEMALE		1 (0.01)			1 (0.00)
INFERTILITY MALE		1 (0.01)	1 (0.00)		2 (0.00)
INFLAMMATION	1 (0.02)	5 (0.03)	10 (0.03)		16 (0.03)
INFLAMMATION OF WOUND			2 (0.01)		2 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
INFLAMMATORY BOWEL DISEASE	1 (0.02)				1 (0.00)
INFLUENZA	4 (0.07)	10 (0.06)	3 (0.01)	1 (0.01)	18 (0.03)
INFLUENZA LIKE ILLNESS	4 (0.07)	16 (0.09)	13 (0.04)	1 (0.01)	34 (0.06)
INFLUENZA SEROLOGY POSITIVE			1 (0.00)		1 (0.00)
INFUSION RELATED REACTION	2 (0.03)	15 (0.09)	17 (0.06)	5 (0.06)	39 (0.06)
INFUSION SITE ABSCESS		1 (0.01)			1 (0.00)
INFUSION SITE ERYTHEMA	1 (0.02)	1 (0.01)			2 (0.00)
INFUSION SITE EXTRAVASATION			1 (0.00)		1 (0.00)
INFUSION SITE PAIN	1 (0.02)				1 (0.00)
INFUSION SITE REACTION		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
INGROWING NAIL			2 (0.01)		2 (0.00)
INGUINAL HERNIA			2 (0.01)	2 (0.03)	4 (0.01)
INGUINAL HERNIA REPAIR		2 (0.01)	1 (0.00)		3 (0.00)
INGUINAL MASS		1 (0.01)			1 (0.00)
INITIAL INSOMNIA	1 (0.02)	2 (0.01)	8 (0.03)	2 (0.03)	13 (0.02)
INJECTED LIMB MOBILITY DECREASED		1 (0.01)			1 (0.00)
INJECTION				1 (0.01)	1 (0.00)
INJECTION SITE ABSCESS		2 (0.01)	9 (0.03)		11 (0.02)
INJECTION SITE ANAESTHESIA	1 (0.02)		1 (0.00)		2 (0.00)
INJECTION SITE ATROPHY		2 (0.01)			2 (0.00)
INJECTION SITE BRUISING	1 (0.02)	30 (0.18)	61 (0.20)	4 (0.05)	96 (0.16)
INJECTION SITE CELLULITIS	1 (0.02)	2 (0.01)			3 (0.00)
INJECTION SITE DESQUAMATION			1 (0.00)		1 (0.00)
INJECTION SITE DISCOLOURATION		2 (0.01)			2 (0.00)
INJECTION SITE DISCOMFORT			1 (0.00)		1 (0.00)
INJECTION SITE ERYTHEMA	1 (0.02)	11 (0.06)	18 (0.06)	2 (0.03)	32 (0.05)
INJECTION SITE EXTRAVASATION			3 (0.01)		3 (0.00)
INJECTION SITE HAEMATOMA		1 (0.01)			1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
INJECTION SITE HAEMORRHAGE	2 (0.03)	13 (0.08)	35 (0.12)	4 (0.05)	54 (0.09)
INJECTION SITE INDURATION		1 (0.01)			1 (0.00)
INJECTION SITE INFECTION			2 (0.01)		2 (0.00)
INJECTION SITE IRRITATION		1 (0.01)	9 (0.03)		10 (0.02)
INJECTION SITE MASS	1 (0.02)				1 (0.00)
INJECTION SITE NECROSIS			1 (0.00)	1 (0.01)	2 (0.00)
INJECTION SITE NODULE		2 (0.01)	1 (0.00)		3 (0.00)
INJECTION SITE PAIN		10 (0.06)	20 (0.07)	1 (0.01)	31 (0.05)
INJECTION SITE PHLEBITIS			1 (0.00)	1 (0.01)	2 (0.00)
INJECTION SITE PRURITUS		4 (0.02)	3 (0.01)		7 (0.01)
INJECTION SITE RASH		3 (0.02)	1 (0.00)		4 (0.01)
INJECTION SITE REACTION		4 (0.02)	2 (0.01)	1 (0.01)	7 (0.01)
INJECTION SITE SWELLING		1 (0.01)			1 (0.00)
INJECTION SITE ULCER			1 (0.00)		1 (0.00)
INJECTION SITE URTICARIA		6 (0.04)	7 (0.02)	1 (0.01)	14 (0.02)
INJECTION SITE WARMTH			1 (0.00)		1 (0.00)
INJURY		8 (0.05)	14 (0.05)	4 (0.05)	26 (0.04)
INJURY ASPHYXIATION	4 (0.07)			1 (0.01)	5 (0.01)
INNER EAR DISORDER		1 (0.01)			1 (0.00)
INSOMNIA	14 (0.24)	28 (0.16)	52 (0.17)	9 (0.12)	103 (0.17)
INSULIN-REQUIRING TYPE II DIABETES MELLITUS				1 (0.01)	1 (0.00)
INTENTIONAL DRUG MISUSE	8 (0.14)	17 (0.10)	4 (0.01)		29 (0.05)
INTENTIONAL OVERDOSE	14 (0.24)	13 (0.08)	6 (0.02)	1 (0.01)	34 (0.06)
INTENTIONAL SELF-INJURY	4 (0.07)	2 (0.01)	1 (0.00)		7 (0.01)
INTERCEPTED MEDICATION ERROR	1 (0.02)		2 (0.01)		3 (0.00)
INTERMITTENT CLAUDICATION	1 (0.02)				1 (0.00)
INTERNATIONAL NORMALISED RATIO ABNORMAL			2 (0.01)		2 (0.00)
INTERNATIONAL NORMALISED RATIO DECREASED		1 (0.01)		1 (0.01)	2 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
INTERNATIONAL NORMALISED RATIO INCREASED	5 (0.08)	7 (0.04)	34 (0.11)	17 (0.22)	63 (0.10)
INTERSTITIAL LUNG DISEASE	3 (0.05)	13 (0.08)	58 (0.19)	26 (0.34)	100 (0.16)
INTERTRIGO		1 (0.01)	1 (0.00)		2 (0.00)
INTERVERTEBRAL DISC DEGENERATION		1 (0.01)	2 (0.01)		3 (0.00)
INTERVERTEBRAL DISC DISORDER		3 (0.02)	3 (0.01)	1 (0.01)	7 (0.01)
INTERVERTEBRAL DISC INJURY			1 (0.00)		1 (0.00)
INTERVERTEBRAL DISC PROTRUSION	1 (0.02)	9 (0.05)	15 (0.05)	2 (0.03)	27 (0.04)
INTESTINAL FUNCTIONAL DISORDER		1 (0.01)	2 (0.01)		3 (0.00)
INTESTINAL HAEMORRHAGE		2 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)
INTESTINAL INFARCTION				1 (0.01)	1 (0.00)
INTESTINAL ISCHAEMIA	2 (0.03)			2 (0.03)	4 (0.01)
INTESTINAL OBSTRUCTION		9 (0.05)	16 (0.05)	1 (0.01)	26 (0.04)
INTESTINAL OPERATION			1 (0.00)		1 (0.00)
INTESTINAL PERFORATION	2 (0.03)	4 (0.02)	3 (0.01)		9 (0.01)
INTRA-ABDOMINAL HAEMORRHAGE		2 (0.01)		1 (0.01)	3 (0.00)
INTRA-UTERINE CONTRACEPTIVE DEVICE EXPELLED		1 (0.01)			1 (0.00)
INTRA-UTERINE DEATH		1 (0.01)			1 (0.00)
INTRACARDIAC THROMBUS		1 (0.01)	3 (0.01)		4 (0.01)
INTRACRANIAL ANEURYSM		3 (0.02)	4 (0.01)		7 (0.01)
INTRACRANIAL HYPOTENSION			1 (0.00)		1 (0.00)
INTRACRANIAL INJURY			1 (0.00)		1 (0.00)
INTRACRANIAL PRESSURE INCREASED	3 (0.05)	1 (0.01)	1 (0.00)		5 (0.01)
INTRACRANIAL TUMOUR HAEMORRHAGE			1 (0.00)		1 (0.00)
INTRACRANIAL VENOUS SINUS THROMBOSIS	1 (0.02)	1 (0.01)	3 (0.01)		5 (0.01)
INTRAOCULAR PRESSURE DECREASED				4 (0.05)	4 (0.01)
INTRAOCULAR PRESSURE INCREASED	2 (0.03)		15 (0.05)	6 (0.08)	23 (0.04)
INTRAOCULAR PRESSURE TEST ABNORMAL			1 (0.00)		1 (0.00)
INTRASPINAL ABSCESS			1 (0.00)		1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
INTRAVENTRICULAR HAEMORRHAGE		2 (0.01)			2 (0.00)
INTUSSUSCEPTION	1 (0.02)				1 (0.00)
IRIDOCYCLITIS			1 (0.00)		1 (0.00)
IRIS DISORDER				2 (0.03)	2 (0.00)
IRITIS	1 (0.02)			1 (0.01)	2 (0.00)
IRON DEFICIENCY ANAEMIA		1 (0.01)	3 (0.01)	1 (0.01)	5 (0.01)
IRRITABILITY	2 (0.03)	6 (0.04)	8 (0.03)		16 (0.03)
IRRITABLE BOWEL SYNDROME	1 (0.02)	1 (0.01)			2 (0.00)
ISCHAEMIA			1 (0.00)	1 (0.01)	2 (0.00)
ISCHAEMIC CEREBRAL INFARCTION		1 (0.01)	1 (0.00)		2 (0.00)
ISCHAEMIC STROKE		12 (0.07)	26 (0.09)	6 (0.08)	44 (0.07)
IUCD COMPLICATION	4 (0.07)	8 (0.05)			12 (0.02)
IUD MIGRATION	7 (0.12)	16 (0.09)			23 (0.04)
JARISCH-HERXHEIMER REACTION	1 (0.02)				1 (0.00)
JAUNDICE	3 (0.05)	2 (0.01)	18 (0.06)	1 (0.01)	24 (0.04)
JAUNDICE CHOLESTATIC		3 (0.02)	5 (0.02)	4 (0.05)	12 (0.02)
JAW DISORDER		3 (0.02)	3 (0.01)	1 (0.01)	7 (0.01)
JAW FRACTURE			2 (0.01)		2 (0.00)
JAW OPERATION			2 (0.01)		2 (0.00)
JOINT ANKYLOSIS		1 (0.01)			1 (0.00)
JOINT ARTHROPLASTY			4 (0.01)		4 (0.01)
JOINT DISLOCATION	1 (0.02)	1 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
JOINT EFFUSION		1 (0.01)	1 (0.00)		2 (0.00)
JOINT INJURY		1 (0.01)	16 (0.05)		17 (0.03)
JOINT STIFFNESS		1 (0.01)			1 (0.00)
JOINT SWELLING	3 (0.05)	7 (0.04)	7 (0.02)	2 (0.03)	19 (0.03)
JOINT TUBERCULOSIS			1 (0.00)		1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
KAPOSIS SARCOMA		1 (0.01)			1 (0.00)
KAWASAKI'S DISEASE	3 (0.05)				3 (0.00)
KELOID SCAR		1 (0.01)			1 (0.00)
KERATITIS		7 (0.04)	3 (0.01)		10 (0.02)
KERATOPATHY		1 (0.01)	1 (0.00)		2 (0.00)
KETOACIDOSIS	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
KIDNEY ENLARGEMENT	2 (0.03)				2 (0.00)
KIDNEY FIBROSIS			2 (0.01)		2 (0.00)
KIDNEY INFECTION	1 (0.02)	3 (0.02)	3 (0.01)		7 (0.01)
KIDNEY RUPTURE			1 (0.00)		1 (0.00)
KIDNEY SMALL				1 (0.01)	1 (0.00)
KIDNEY TRANSPLANT REJECTION	6 (0.10)	12 (0.07)	2 (0.01)		20 (0.03)
KLEBSIELLA INFECTION				1 (0.01)	1 (0.00)
KLEBSIELLA SEPSIS			2 (0.01)		2 (0.00)
KLEPTOMANIA		3 (0.02)			3 (0.00)
KNEE ARTHROPLASTY		2 (0.01)	19 (0.06)	4 (0.05)	25 (0.04)
KNEE OPERATION		1 (0.01)			1 (0.00)
LABORATORY TEST			1 (0.00)		1 (0.00)
LABORATORY TEST ABNORMAL	1 (0.02)	2 (0.01)	4 (0.01)	1 (0.01)	8 (0.01)
LABORATORY TEST INTERFERENCE	1 (0.02)				1 (0.00)
LABYRINTHITIS		3 (0.02)			3 (0.00)
LACRIMAL DISORDER			1 (0.00)		1 (0.00)
LACRIMATION DECREASED	1 (0.02)				1 (0.00)
LACRIMATION INCREASED		4 (0.02)	7 (0.02)	3 (0.04)	14 (0.02)
LACTATION DISORDER		1 (0.01)			1 (0.00)
LACTIC ACIDOSIS	3 (0.05)	9 (0.05)	4 (0.01)	1 (0.01)	17 (0.03)
LACUNAR INFARCTION			2 (0.01)		2 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
LARGE CELL CARCINOMA OF THE RESPIRATORY TRACT STAG			1 (0.00)		1 (0.00)
LARGE INTESTINAL HAEMORRHAGE			1 (0.00)		1 (0.00)
LARGE INTESTINAL OBSTRUCTION		1 (0.01)			1 (0.00)
LARGE INTESTINE CARCINOMA			1 (0.00)		1 (0.00)
LARGE INTESTINE PERFORATION		2 (0.01)	3 (0.01)		5 (0.01)
LARYNGEAL CANCER			3 (0.01)		3 (0.00)
LARYNGEAL OEDEMA		1 (0.01)	1 (0.00)		2 (0.00)
LARYNGITIS			2 (0.01)	3 (0.04)	5 (0.01)
LARYNGOCELE		1 (0.01)			1 (0.00)
LARYNGOSPASM		1 (0.01)	2 (0.01)		3 (0.00)
LEARNING DISABILITY	2 (0.03)				2 (0.00)
LEFT VENTRICULAR FAILURE				1 (0.01)	1 (0.00)
LEG AMPUTATION		1 (0.01)	2 (0.01)		3 (0.00)
LEGIONELLA INFECTION			1 (0.00)		1 (0.00)
LEIOMYOMA		1 (0.01)			1 (0.00)
LEIOMYOSARCOMA		2 (0.01)			2 (0.00)
LEIOMYOSARCOMA METASTATIC		1 (0.01)			1 (0.00)
LENS DISORDER		2 (0.01)			2 (0.00)
LENTIGO MALIGNA STAGE UNSPECIFIED			2 (0.01)		2 (0.00)
LEPROSY		1 (0.01)			1 (0.00)
LETHARGY	3 (0.05)	3 (0.02)	8 (0.03)	3 (0.04)	17 (0.03)
LEUKAEMIA	1 (0.02)	3 (0.02)	7 (0.02)		11 (0.02)
LEUKOCYTOCLASTIC VASCULITIS	1 (0.02)	4 (0.02)	9 (0.03)	2 (0.03)	16 (0.03)
LEUKOCYTOSIS		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
LEUKOENCEPHALOMYELITIS		1 (0.01)	1 (0.00)		2 (0.00)
LEUKOENCEPHALOPATHY		2 (0.01)	2 (0.01)		4 (0.01)
LEUKOPENIA	6 (0.10)	10 (0.06)	39 (0.13)	3 (0.04)	58 (0.10)

Reaction Summary Table

Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
LEUKOPLAKIA ORAL		1 (0.01)			1 (0.00)
LIBIDO DECREASED			4 (0.01)		4 (0.01)
LIBIDO INCREASED			1 (0.00)		1 (0.00)
LICHEN PLANUS		2 (0.01)	1 (0.00)		3 (0.00)
LICHENOID KERATOSIS			3 (0.01)		3 (0.00)
LIGAMENT INJURY	1 (0.02)	1 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)
LIMB CRUSHING INJURY			2 (0.01)		2 (0.00)
LIMB DISCOMFORT			1 (0.00)		1 (0.00)
LIMB INJURY		1 (0.01)	5 (0.02)	1 (0.01)	7 (0.01)
LIMB OPERATION		1 (0.01)			1 (0.00)
LINEAR IGA DISEASE			1 (0.00)	1 (0.01)	2 (0.00)
LIP AND/OR ORAL CAVITY CANCER		1 (0.01)			1 (0.00)
LIP BLISTER	1 (0.02)	1 (0.01)	2 (0.01)	3 (0.04)	7 (0.01)
LIP HAEMORRHAGE	1 (0.02)			1 (0.01)	2 (0.00)
LIP LESION EXCISION				1 (0.01)	1 (0.00)
LIPASE INCREASED		1 (0.01)	1 (0.00)		2 (0.00)
LIPIDS INCREASED		1 (0.01)			1 (0.00)
LIPOATROPHY		2 (0.01)			2 (0.00)
LIPOHYPERTROPHY		1 (0.01)			1 (0.00)
LIPOMA			1 (0.00)		1 (0.00)
LIPOMATOSIS			1 (0.00)		1 (0.00)
LIPOSARCOMA		1 (0.01)			1 (0.00)
LISTERIA SEPSIS			2 (0.01)		2 (0.00)
LISTERIOSIS			2 (0.01)		2 (0.00)
LISTLESS	1 (0.02)				1 (0.00)
LIVEDO RETICULARIS				1 (0.01)	1 (0.00)
LIVER DISORDER	3 (0.05)	9 (0.05)	25 (0.08)	5 (0.06)	42 (0.07)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
LIVER FUNCTION TEST ABNORMAL	2 (0.03)	16 (0.09)	11 (0.04)	3 (0.04)	32 (0.05)
LIVER SCAN ABNORMAL		1 (0.01)			1 (0.00)
LIVER TRANSPLANT		2 (0.01)			2 (0.00)
LOBAR PNEUMONIA		1 (0.01)	3 (0.01)		4 (0.01)
LOCAL SWELLING	3 (0.05)	1 (0.01)	3 (0.01)	1 (0.01)	8 (0.01)
LOCALISED INFECTION			4 (0.01)		4 (0.01)
LOCALISED OEDEMA	3 (0.05)	2 (0.01)		1 (0.01)	6 (0.01)
LOGORRHOEA			1 (0.00)		1 (0.00)
LONG QT SYNDROME		1 (0.01)			1 (0.00)
LOSS OF CONSCIOUSNESS	15 (0.25)	27 (0.16)	81 (0.27)	11 (0.14)	134 (0.22)
LOSS OF LIBIDO			1 (0.00)		1 (0.00)
LOWER EXTREMITY MASS			1 (0.00)		1 (0.00)
LOWER GASTROINTESTINAL HAEMORRHAGE			3 (0.01)	1 (0.01)	4 (0.01)
LOWER LIMB FRACTURE		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
LOWER RESPIRATORY TRACT INFECTION	1 (0.02)	2 (0.01)	5 (0.02)	3 (0.04)	11 (0.02)
LUMBAR SPINAL STENOSIS			1 (0.00)		1 (0.00)
LUMBAR VERTEBRAL FRACTURE				1 (0.01)	1 (0.00)
LUNG ABSCESS		1 (0.01)			1 (0.00)
LUNG ADENOCARCINOMA			1 (0.00)		1 (0.00)
LUNG ADENOCARCINOMA METASTATIC			1 (0.00)		1 (0.00)
LUNG ADENOCARCINOMA STAGE IV			1 (0.00)		1 (0.00)
LUNG CANCER METASTATIC		1 (0.01)	4 (0.01)	4 (0.05)	9 (0.01)
LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE III			1 (0.00)		1 (0.00)
LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV			1 (0.00)		1 (0.00)
LUNG DISORDER		3 (0.02)	16 (0.05)	7 (0.09)	26 (0.04)
LUNG INFECTION	1 (0.02)		5 (0.02)	1 (0.01)	7 (0.01)
LUNG INFECTION PSEUDOMONAL			1 (0.00)		1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
LUNG INFILTRATION			8 (0.03)	1 (0.01)	9 (0.01)
LUNG NEOPLASM	1 (0.02)		3 (0.01)		4 (0.01)
LUNG NEOPLASM MALIGNANT		5 (0.03)	29 (0.10)	9 (0.12)	43 (0.07)
LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED			5 (0.02)		5 (0.01)
LUPUS-LIKE SYNDROME	3 (0.05)		5 (0.02)	1 (0.01)	9 (0.01)
LYMPH NODE PAIN			1 (0.00)		1 (0.00)
LYMPHADENECTOMY			1 (0.00)		1 (0.00)
LYMPHADENOPATHY	8 (0.14)	12 (0.07)	9 (0.03)	1 (0.01)	30 (0.05)
LYMPHADENOPATHY MEDIASTINAL			1 (0.00)		1 (0.00)
LYMPHOCELE		1 (0.01)			1 (0.00)
LYMPHOCYTE COUNT DECREASED	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
LYMPHOCYTE COUNT INCREASED				1 (0.01)	1 (0.00)
LYMPHOCYTE STIMULATION TEST POSITIVE	1 (0.02)	2 (0.01)	2 (0.01)	1 (0.01)	6 (0.01)
LYMPHOCYTIC LEUKAEMIA			1 (0.00)		1 (0.00)
LYMPHOCYTOSIS		1 (0.01)	1 (0.00)		2 (0.00)
LYMPHOEDEMA			2 (0.01)		2 (0.00)
LYMPHOMA	4 (0.07)	5 (0.03)	11 (0.04)	3 (0.04)	23 (0.04)
LYMPHOMATOID PAPULOSIS		2 (0.01)			2 (0.00)
LYMPHOPENIA	1 (0.02)		3 (0.01)		4 (0.01)
LYMPHOPROLIFERATIVE DISORDER	1 (0.02)		2 (0.01)		3 (0.00)
MACROGLOSSIA	1 (0.02)				1 (0.00)
MACULAR DEGENERATION		2 (0.01)	9 (0.03)	3 (0.04)	14 (0.02)
MACULAR HOLE		1 (0.01)			1 (0.00)
MACULAR OEDEMA		1 (0.01)	16 (0.05)	2 (0.03)	19 (0.03)
MACULOPATHY	1 (0.02)		6 (0.02)		7 (0.01)
MAJOR DEPRESSION		1 (0.01)			1 (0.00)
MALABSORPTION				1 (0.01)	1 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
MALAISE	7 (0.12)	22 (0.13)	25 (0.08)	7 (0.09)	61 (0.10)
MALARIA			1 (0.00)		1 (0.00)
MALE ORGASMIC DISORDER			1 (0.00)		1 (0.00)
MALIGNANT FIBROUS HISTIOCYTOMA				1 (0.01)	1 (0.00)
MALIGNANT HYPERTENSION		2 (0.01)	1 (0.00)		3 (0.00)
MALIGNANT MELANOMA		4 (0.02)	13 (0.04)		17 (0.03)
MALIGNANT NEOPLASM OF CHOROID			1 (0.00)		1 (0.00)
MALIGNANT NEOPLASM PROGRESSION		11 (0.06)	46 (0.15)	12 (0.15)	69 (0.11)
MALLORY-WEISS SYNDROME	2 (0.03)	1 (0.01)			3 (0.00)
MALNUTRITION		1 (0.01)			1 (0.00)
MAMMOGRAM ABNORMAL		1 (0.01)			1 (0.00)
MANIA	4 (0.07)	3 (0.02)	5 (0.02)		12 (0.02)
MANTLE CELL LYMPHOMA			1 (0.00)		1 (0.00)
MASS	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
MASTECTOMY		2 (0.01)			2 (0.00)
MASTICATION DISORDER		1 (0.01)			1 (0.00)
MASTITIS		2 (0.01)			2 (0.00)
MASTOIDITIS			2 (0.01)		2 (0.00)
MECHANICAL COMPLICATION OF IMPLANT			1 (0.00)		1 (0.00)
MEDIASTINAL FIBROSIS		1 (0.01)			1 (0.00)
MEDICAL DEVICE COMPLICATION		2 (0.01)	1 (0.00)		3 (0.00)
MEDICAL DEVICE IMPLANTATION			1 (0.00)		1 (0.00)
MEDICATION ERROR	14 (0.24)	12 (0.07)	14 (0.05)	6 (0.08)	46 (0.08)
MEDICATION RESIDUE		2 (0.01)	1 (0.00)		3 (0.00)
MEDICATION TAMPERING			1 (0.00)		1 (0.00)
MEDULLOBLASTOMA	5 (0.08)				5 (0.01)
MELAENA			4 (0.01)	1 (0.01)	5 (0.01)
MELANOCYTIC NAEVUS	2 (0.03)	1 (0.01)		1 (0.01)	4 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
MELANOSIS COLI			1 (0.00)		1 (0.00)
MEMORY IMPAIRMENT		4 (0.02)	8 (0.03)	1 (0.01)	13 (0.02)
MENIERE'S DISEASE				1 (0.01)	1 (0.00)
MENINGIOMA		1 (0.01)	5 (0.02)		6 (0.01)
MENINGIOMA BENIGN		1 (0.01)		1 (0.01)	2 (0.00)
MENINGITIS	2 (0.03)		2 (0.01)		4 (0.01)
MENINGITIS ASEPTIC	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
MENINGITIS CRYPTOCOCCAL			2 (0.01)		2 (0.00)
MENINGITIS LISTERIA	2 (0.03)	1 (0.01)			3 (0.00)
MENINGITIS MENINGOCOCCAL	2 (0.03)				2 (0.00)
MENINGITIS TUBERCULOUS		1 (0.01)			1 (0.00)
MENINGITIS VIRAL		1 (0.01)			1 (0.00)
MENINGORRHAGIA			1 (0.00)		1 (0.00)
MENISCUS LESION		1 (0.01)	1 (0.00)		2 (0.00)
MENORRHAGIA	2 (0.03)	17 (0.10)	1 (0.00)		20 (0.03)
MENSTRUAL DISORDER	1 (0.02)	2 (0.01)			3 (0.00)
MENSTRUATION IRREGULAR	1 (0.02)	2 (0.01)			3 (0.00)
MENTAL DISORDER	3 (0.05)	3 (0.02)	5 (0.02)	1 (0.01)	12 (0.02)
MENTAL IMPAIRMENT		3 (0.02)			3 (0.00)
MENTAL STATUS CHANGES	1 (0.02)	2 (0.01)	10 (0.03)	3 (0.04)	16 (0.03)
MESENTERIC ARTERY THROMBOSIS	1 (0.02)			1 (0.01)	2 (0.00)
MESENTERIC FIBROSIS				1 (0.01)	1 (0.00)
MESOTHELIOMA				1 (0.01)	1 (0.00)
METABOLIC ACIDOSIS	1 (0.02)		2 (0.01)	3 (0.04)	6 (0.01)
METABOLIC DISORDER			1 (0.00)		1 (0.00)
METASTASES TO ADRENALS			1 (0.00)		1 (0.00)
METASTASES TO BONE			1 (0.00)		1 (0.00)
METASTASES TO CENTRAL NERVOUS SYSTEM			1 (0.00)		1 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
METASTASES TO CHEST WALL			1 (0.00)		1 (0.00)
METASTASES TO LIVER			8 (0.03)	1 (0.01)	9 (0.01)
METASTASES TO LUNG	1 (0.02)				1 (0.00)
METASTASES TO LYMPH NODES				1 (0.01)	1 (0.00)
METASTASES TO PERITONEUM			1 (0.00)		1 (0.00)
METASTASIS			1 (0.00)		1 (0.00)
METASTATIC BRONCHIAL CARCINOMA			2 (0.01)		2 (0.00)
METASTATIC MALIGNANT MELANOMA			1 (0.00)		1 (0.00)
METASTATIC NEOPLASM	2 (0.03)				2 (0.00)
METASTATIC RENAL CELL CARCINOMA			1 (0.00)		1 (0.00)
METHAEMOGLOBINAEMIA		3 (0.02)	11 (0.04)		14 (0.02)
METRORRHAGIA	3 (0.05)	6 (0.04)	4 (0.01)		13 (0.02)
MICROANGIOPATHY			1 (0.00)		1 (0.00)
MICROCYTIC ANAEMIA		1 (0.01)		1 (0.01)	2 (0.00)
MICTURITION URGENCY	1 (0.02)		1 (0.00)	2 (0.03)	4 (0.01)
MIDDLE INSOMNIA	1 (0.02)	1 (0.01)	4 (0.01)	4 (0.05)	10 (0.02)
MIGRAINE	2 (0.03)	17 (0.10)	8 (0.03)		27 (0.04)
MILIA			1 (0.00)		1 (0.00)
MILK-ALKALI SYNDROME			1 (0.00)		1 (0.00)
MITOCHONDRIAL MYOPATHY			1 (0.00)		1 (0.00)
MITRAL VALVE INCOMPETENCE		1 (0.01)	1 (0.00)		2 (0.00)
MOBILITY DECREASED		5 (0.03)	2 (0.01)	1 (0.01)	8 (0.01)
MONOCLONAL IMMUNOGLOBULIN PRESENT			1 (0.00)		1 (0.00)
MONONEURITIS		1 (0.01)			1 (0.00)
MONOPARESIS				1 (0.01)	1 (0.00)
MONOPLEGIA		2 (0.01)	2 (0.01)	2 (0.03)	6 (0.01)
MOOD ALTERED	2 (0.03)	2 (0.01)			4 (0.01)
MOOD SWINGS	3 (0.05)	1 (0.01)			4 (0.01)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MORBID THOUGHTS		1 (0.01)	1 (0.00)		2 (0.00)
MORPHOEIA	1 (0.02)				1 (0.00)
MOTOR DYSFUNCTION			1 (0.00)	1 (0.01)	2 (0.00)
MOUTH HAEMORRHAGE		2 (0.01)			2 (0.00)
MOUTH ULCERATION	4 (0.07)	15 (0.09)	7 (0.02)		26 (0.04)
MOVEMENT DISORDER	1 (0.02)		4 (0.01)	1 (0.01)	6 (0.01)
MUCOSAL INFLAMMATION	3 (0.05)	5 (0.03)	11 (0.04)	2 (0.03)	21 (0.03)
MUCOUS MEMBRANE DISORDER		1 (0.01)			1 (0.00)
MULTI-ORGAN FAILURE	1 (0.02)	3 (0.02)	12 (0.04)	6 (0.08)	22 (0.04)
MULTIPLE CHEMICAL SENSITIVITY			1 (0.00)		1 (0.00)
MULTIPLE DRUG OVERDOSE	1 (0.02)	5 (0.03)	1 (0.00)		7 (0.01)
MULTIPLE DRUG OVERDOSE ACCIDENTAL	1 (0.02)				1 (0.00)
MULTIPLE DRUG OVERDOSE INTENTIONAL	2 (0.03)	5 (0.03)	1 (0.00)		8 (0.01)
MULTIPLE FRACTURES		1 (0.01)			1 (0.00)
MULTIPLE MYELOMA		1 (0.01)	6 (0.02)	2 (0.03)	9 (0.01)
MULTIPLE SCLEROSIS	2 (0.03)	8 (0.05)	1 (0.00)		11 (0.02)
MULTIPLE SCLEROSIS RELAPSE	1 (0.02)	7 (0.04)	2 (0.01)		10 (0.02)
MUSCLE ATROPHY		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
MUSCLE CONTRACTIONS INVOLUNTARY	1 (0.02)				1 (0.00)
MUSCLE DISORDER			3 (0.01)		3 (0.00)
MUSCLE FATIGUE		1 (0.01)	2 (0.01)		3 (0.00)
MUSCLE HAEMORRHAGE			1 (0.00)	2 (0.03)	3 (0.00)
MUSCLE HYPERTROPHY	1 (0.02)				1 (0.00)
MUSCLE INJURY			2 (0.01)		2 (0.00)
MUSCLE NECROSIS			3 (0.01)		3 (0.00)
MUSCLE RIGIDITY			1 (0.00)	1 (0.01)	2 (0.00)
MUSCLE RUPTURE		2 (0.01)	3 (0.01)		5 (0.01)
MUSCLE SPASMS	6 (0.10)	21 (0.12)	25 (0.08)	6 (0.08)	58 (0.10)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MUSCLE STRAIN			1 (0.00)		1 (0.00)
MUSCLE TIGHTNESS		1 (0.01)		3 (0.04)	4 (0.01)
MUSCLE TWITCHING	2 (0.03)	4 (0.02)			6 (0.01)
MUSCULAR WEAKNESS	1 (0.02)	2 (0.01)	16 (0.05)	5 (0.06)	24 (0.04)
MUSCULOSKELETAL CHEST PAIN		1 (0.01)	2 (0.01)	4 (0.05)	7 (0.01)
MUSCULOSKELETAL DISCOMFORT			2 (0.01)		2 (0.00)
MUSCULOSKELETAL PAIN			1 (0.00)		1 (0.00)
MUSCULOSKELETAL STIFFNESS		1 (0.01)	3 (0.01)		4 (0.01)
MUTISM				2 (0.03)	2 (0.00)
MYALGIA	6 (0.10)	17 (0.10)	38 (0.13)	8 (0.10)	69 (0.11)
MYASTHENIA GRAVIS	1 (0.02)	1 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)
MYASTHENIA GRAVIS CRISIS			1 (0.00)	1 (0.01)	2 (0.00)
MYASTHENIC SYNDROME			1 (0.00)		1 (0.00)
MYCOBACTERIAL INFECTION			1 (0.00)		1 (0.00)
MYCOBACTERIUM AVIUM COMPLEX INFECTION		1 (0.01)	3 (0.01)		4 (0.01)
MYCOSIS FUNGOIDES		1 (0.01)	3 (0.01)		4 (0.01)
MYDRIASIS	1 (0.02)	1 (0.01)			2 (0.00)
MYELITIS TRANSVERSE		2 (0.01)			2 (0.00)
MYELOCYTE PRESENT			1 (0.00)		1 (0.00)
MYELOYDYSPLASTIC SYNDROME	1 (0.02)	6 (0.04)	9 (0.03)	3 (0.04)	19 (0.03)
MYELOFIBROSIS			2 (0.01)		2 (0.00)
MYELOID LEUKAEMIA	1 (0.02)				1 (0.00)
MYELOPROLIFERATIVE DISORDER				1 (0.01)	1 (0.00)
MYOCARDIAL INFARCTION	8 (0.14)	162 (0.95)	404 (1.34)	66 (0.85)	640 (1.05)
MYOCARDIAL ISCHAEMIA		2 (0.01)	3 (0.01)		5 (0.01)
MYOCARDIAL OEDEMA				1 (0.01)	1 (0.00)
MYOCARDIAL RUPTURE			1 (0.00)		1 (0.00)
MYOCARDITIS		1 (0.01)			1 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MYOCLONIC EPILEPSY			1 (0.00)		1 (0.00)
MYOCLONUS	2 (0.03)	1 (0.01)	8 (0.03)	3 (0.04)	14 (0.02)
MYOPATHY		1 (0.01)	4 (0.01)	1 (0.01)	6 (0.01)
MYOPATHY STEROID			1 (0.00)		1 (0.00)
MYOPERICARDITIS	1 (0.02)				1 (0.00)
MYOPIA	1 (0.02)	3 (0.02)			4 (0.01)
MYOSITIS		2 (0.01)	4 (0.01)	2 (0.03)	8 (0.01)
NAIL BED INFLAMMATION			1 (0.00)		1 (0.00)
NAIL DISCOLOURATION				1 (0.01)	1 (0.00)
NAIL DISORDER			2 (0.01)		2 (0.00)
NAIL GROWTH ABNORMAL			1 (0.00)		1 (0.00)
NASAL CAVITY CANCER			1 (0.00)		1 (0.00)
NASAL CONGESTION		1 (0.01)	3 (0.01)		4 (0.01)
NASAL MUCOSAL DISORDER	1 (0.02)				1 (0.00)
NASAL NEOPLASM			1 (0.00)		1 (0.00)
NASAL POLYPS	1 (0.02)				1 (0.00)
NASAL SEPTUM PERFORATION			2 (0.01)	1 (0.01)	3 (0.00)
NASAL TURBINATE HYPERTROPHY			1 (0.00)		1 (0.00)
NASOPHARYNGITIS	2 (0.03)	2 (0.01)	7 (0.02)	3 (0.04)	14 (0.02)
NAUSEA	16 (0.27)	70 (0.41)	78 (0.26)	22 (0.28)	186 (0.31)
NECK MASS			1 (0.00)		1 (0.00)
NECK PAIN		1 (0.01)	2 (0.01)		3 (0.00)
NECROSIS	1 (0.02)	5 (0.03)			6 (0.01)
NECROSIS ISCHAEMIC		1 (0.01)			1 (0.00)
NECROTISING COLITIS				1 (0.01)	1 (0.00)
NECROTISING ENTEROCOLITIS NEONATAL	1 (0.02)				1 (0.00)
NECROTISING FASCIITIS	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)
NEONATAL ASPHYXIA	1 (0.02)				1 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
NEONATAL DISORDER	1 (0.02)				1 (0.00)
NEONATAL TACHYPNOEA	1 (0.02)				1 (0.00)
NEOPLASM		4 (0.02)	1 (0.00)		5 (0.01)
NEOPLASM MALIGNANT	5 (0.08)	3 (0.02)	9 (0.03)	2 (0.03)	19 (0.03)
NEOPLASM OF APPENDIX		1 (0.01)			1 (0.00)
NEOPLASM PROGRESSION	1 (0.02)	1 (0.01)	5 (0.02)	1 (0.01)	8 (0.01)
NEOPLASM PROSTATE			2 (0.01)		2 (0.00)
NEOPLASM RECURRENCE	2 (0.03)	2 (0.01)	1 (0.00)		5 (0.01)
NEOPLASM SKIN		1 (0.01)	1 (0.00)		2 (0.00)
NEPHRECTOMY		1 (0.01)			1 (0.00)
NEPHRITIS INTERSTITIAL	2 (0.03)	3 (0.02)	7 (0.02)		12 (0.02)
NEPHROCALCINOSIS			1 (0.00)		1 (0.00)
NEPHROGENIC ANAEMIA			1 (0.00)		1 (0.00)
NEPHROGENIC DIABETES INSIPIDUS		1 (0.01)			1 (0.00)
NEPHROLITHIASIS	3 (0.05)	12 (0.07)	13 (0.04)	3 (0.04)	31 (0.05)
NEPHROPATHY		1 (0.01)		1 (0.01)	2 (0.00)
NEPHROPATHY TOXIC			2 (0.01)		2 (0.00)
NEPHROTIC SYNDROME	3 (0.05)	6 (0.04)	4 (0.01)		13 (0.02)
NERVE COMPRESSION			1 (0.00)		1 (0.00)
NERVE INJURY		2 (0.01)		1 (0.01)	3 (0.00)
NERVE ROOT LESION		1 (0.01)			1 (0.00)
NERVOUS SYSTEM DISORDER	1 (0.02)	1 (0.01)	4 (0.01)		6 (0.01)
NERVOUSNESS	1 (0.02)	3 (0.02)	3 (0.01)		7 (0.01)
NEURALGIA		2 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)
NEUROECTODERMAL NEOPLASM	1 (0.02)				1 (0.00)
NEUROENDOCRINE CARCINOMA OF THE SKIN			2 (0.01)	1 (0.01)	3 (0.00)
NEUROFIBROMA	1 (0.02)				1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
NEUROGENIC BLADDER			1 (0.00)	1 (0.01)	2 (0.00)
NEUROLEPTIC MALIGNANT SYNDROME	4 (0.07)	4 (0.02)	10 (0.03)	3 (0.04)	21 (0.03)
NEUROLOGICAL EXAMINATION			1 (0.00)		1 (0.00)
NEUROLOGICAL SYMPTOM		1 (0.01)	1 (0.00)		2 (0.00)
NEUROMUSCULAR BLOCK PROLONGED		3 (0.02)	1 (0.00)		4 (0.01)
NEUROMYOPATHY			1 (0.00)		1 (0.00)
NEUROPATHY		3 (0.02)	12 (0.04)	2 (0.03)	17 (0.03)
NEUROPATHY PERIPHERAL		2 (0.01)	11 (0.04)	4 (0.05)	17 (0.03)
NEUTROPENIA	19 (0.32)	36 (0.21)	66 (0.22)	8 (0.10)	129 (0.21)
NEUTROPENIC SEPSIS		1 (0.01)	12 (0.04)		13 (0.02)
NEUTROPHIL COUNT DECREASED	4 (0.07)	8 (0.05)	14 (0.05)	1 (0.01)	27 (0.04)
NEUTROPHIL COUNT INCREASED		2 (0.01)		1 (0.01)	3 (0.00)
NEUTROPHILIA		1 (0.01)			1 (0.00)
NICOTINE DEPENDENCE		4 (0.02)	4 (0.01)		8 (0.01)
NIGHT BLINDNESS		1 (0.01)			1 (0.00)
NIGHT SWEATS		6 (0.04)	1 (0.00)		7 (0.01)
NIGHTMARE	1 (0.02)	5 (0.03)	4 (0.01)	1 (0.01)	11 (0.02)
NO ADVERSE DRUG EFFECT	1 (0.02)	8 (0.05)	9 (0.03)	6 (0.08)	24 (0.04)
NO ADVERSE EFFECT	7 (0.12)	13 (0.08)	9 (0.03)	3 (0.04)	32 (0.05)
NO REACTION ON PREVIOUS EXPOSURE TO DRUG		1 (0.01)			1 (0.00)
NO THERAPEUTIC RESPONSE			1 (0.00)	1 (0.01)	2 (0.00)
NOCTURIA			2 (0.01)	1 (0.01)	3 (0.00)
NODAL ARRHYTHMIA				2 (0.03)	2 (0.00)
NODULE		1 (0.01)	2 (0.01)		3 (0.00)
NON-CARDIAC CHEST PAIN			2 (0.01)		2 (0.00)
NON-CARDIOGENIC PULMONARY OEDEMA	2 (0.03)	1 (0.01)			3 (0.00)
NON-HODGKIN'S LYMPHOMA	1 (0.02)	2 (0.01)	2 (0.01)		5 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
NON-HODGKIN'S LYMPHOMA STAGE III		1 (0.01)			1 (0.00)
NON-HODGKIN'S LYMPHOMA STAGE IV			2 (0.01)		2 (0.00)
NON-SMALL CELL LUNG CANCER			1 (0.00)		1 (0.00)
NON-SMALL CELL LUNG CANCER METASTATIC		1 (0.01)			1 (0.00)
NONSPECIFIC REACTION			2 (0.01)	1 (0.01)	3 (0.00)
NOREPINEPHRINE INCREASED			2 (0.01)		2 (0.00)
NORMAL NEWBORN		1 (0.01)			1 (0.00)
NORMOCHROMIC NORMOCYTIC ANAEMIA			1 (0.00)		1 (0.00)
NUCLEAR MAGNETIC RESONANCE IMAGING ABNORMAL			1 (0.00)		1 (0.00)
NYSTAGMUS	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
OBESITY	1 (0.02)				1 (0.00)
OBSESSIVE THOUGHTS			1 (0.00)		1 (0.00)
OBSESSIVE-COMPULSIVE DISORDER	1 (0.02)	2 (0.01)			3 (0.00)
OBSTRUCTION		1 (0.01)			1 (0.00)
OBSTRUCTION GASTRIC			1 (0.00)	1 (0.01)	2 (0.00)
OBSTRUCTIVE AIRWAYS DISORDER				1 (0.01)	1 (0.00)
OCULAR DISCOMFORT				1 (0.01)	1 (0.00)
OCULAR HYPERTENSION			1 (0.00)		1 (0.00)
OCULAR TOXICITY		1 (0.01)			1 (0.00)
OCULAR VASCULAR DISORDER			1 (0.00)	1 (0.01)	2 (0.00)
OCULOMUCOCUTANEOUS SYNDROME	3 (0.05)	1 (0.01)	1 (0.00)		5 (0.01)
OEDEMA	1 (0.02)	3 (0.02)	18 (0.06)	12 (0.15)	34 (0.06)
OEDEMA GENITAL	3 (0.05)	3 (0.02)	3 (0.01)		9 (0.01)
OEDEMA MOUTH		1 (0.01)	4 (0.01)		5 (0.01)
OEDEMA PERIPHERAL	6 (0.10)	30 (0.18)	26 (0.09)	20 (0.26)	82 (0.13)
OESOPHAGEAL ADENOCARCINOMA			2 (0.01)		2 (0.00)
OESOPHAGEAL CANDIDIASIS			1 (0.00)		1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
OESOPHAGEAL CARCINOMA		1 (0.01)	6 (0.02)		7 (0.01)
OESOPHAGEAL DILATATION				1 (0.01)	1 (0.00)
OESOPHAGEAL HAEMORRHAGE				2 (0.03)	2 (0.00)
OESOPHAGEAL INJURY			1 (0.00)		1 (0.00)
OESOPHAGEAL RUPTURE			1 (0.00)		1 (0.00)
OESOPHAGEAL SPASM			1 (0.00)		1 (0.00)
OESOPHAGEAL SQUAMOUS CELL CARCINOMA			1 (0.00)		1 (0.00)
OESOPHAGEAL STENOSIS			2 (0.01)		2 (0.00)
OESOPHAGEAL ULCER				1 (0.01)	1 (0.00)
OESOPHAGEAL VARICES HAEMORRHAGE		1 (0.01)	1 (0.00)		2 (0.00)
OESOPHAGITIS			1 (0.00)		1 (0.00)
OESOPHAGITIS HAEMORRHAGIC				1 (0.01)	1 (0.00)
OFF LABEL USE	4 (0.07)	1 (0.01)		1 (0.01)	6 (0.01)
OLIGOMENORRHOEA		2 (0.01)			2 (0.00)
ONYCHOCLASIS				1 (0.01)	1 (0.00)
ONYCHOMADESIS			1 (0.00)		1 (0.00)
OOPHORECTOMY			1 (0.00)		1 (0.00)
OPEN WOUND			3 (0.01)		3 (0.00)
OPPORTUNISTIC INFECTION			1 (0.00)		1 (0.00)
OPTIC ATROPHY	1 (0.02)	1 (0.01)		1 (0.01)	3 (0.00)
OPTIC ISCHAEMIC NEUROPATHY			7 (0.02)	1 (0.01)	8 (0.01)
OPTIC NERVE DISORDER	1 (0.02)		2 (0.01)		3 (0.00)
OPTIC NERVE SHEATH HAEMORRHAGE				2 (0.03)	2 (0.00)
OPTIC NEURITIS	2 (0.03)	4 (0.02)	4 (0.01)		10 (0.02)
OPTIC NEURITIS RETROBULBAR		2 (0.01)			2 (0.00)
OPTIC NEUROPATHY			1 (0.00)		1 (0.00)
ORAL CANDIDIASIS			1 (0.00)		1 (0.00)
ORAL DISCOMFORT	1 (0.02)	3 (0.02)	1 (0.00)		5 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25) (N=4591)</i>	<i>Group2 (26-50) (N=14283)</i>	<i>Group3 (51-75) (N=25653)</i>	<i>Group4 (75+) (N=6415)</i>	<i>Total (N=50942)</i>
ORAL INTAKE REDUCED		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)
ORAL MUCOSA EROSION			1 (0.00)		1 (0.00)
ORAL MUCOSAL BLISTERING	1 (0.02)	3 (0.02)	3 (0.01)		7 (0.01)
ORAL MUCOSAL DISCOLOURATION		2 (0.01)			2 (0.00)
ORAL MUCOSAL ERUPTION	1 (0.02)				1 (0.00)
ORAL MUCOSAL EXFOLIATION			1 (0.00)	1 (0.01)	2 (0.00)
ORAL NEOPLASM			1 (0.00)		1 (0.00)
ORAL PAIN		1 (0.01)	4 (0.01)	1 (0.01)	6 (0.01)
ORAL PRURITUS			1 (0.00)		1 (0.00)
ORAL SURGERY				1 (0.01)	1 (0.00)
ORBITAL OEDEMA			1 (0.00)		1 (0.00)
ORCHITIS			2 (0.01)		2 (0.00)
ORGAN FAILURE			1 (0.00)		1 (0.00)
ORGASM ABNORMAL		1 (0.01)		1 (0.01)	2 (0.00)
OROPHARYNGEAL SWELLING			2 (0.01)		2 (0.00)
ORTHOPEDIC PROCEDURE		3 (0.02)	1 (0.00)		4 (0.01)
ORTHOSTATIC HYPOTENSION	1 (0.02)	2 (0.01)	4 (0.01)	3 (0.04)	10 (0.02)
OSTEITIS DEFORMANS				1 (0.01)	1 (0.00)
OSTEOARTHRITIS		1 (0.01)	4 (0.01)	1 (0.01)	6 (0.01)
OSTEOLYSIS			3 (0.01)		3 (0.00)
OSTEOMALACIA			1 (0.00)		1 (0.00)
OSTEOMYELITIS	1 (0.02)	1 (0.01)	10 (0.03)	3 (0.04)	15 (0.02)
OSTEOMYELITIS CHRONIC				1 (0.01)	1 (0.00)
OSTEONECROSIS	2 (0.03)	13 (0.08)	89 (0.29)	8 (0.10)	112 (0.18)
OSTEOPENIA			1 (0.00)		1 (0.00)
OSTEOPOROSIS	1 (0.02)	3 (0.02)	1 (0.00)	1 (0.01)	6 (0.01)
OSTEOPOROTIC FRACTURE		1 (0.01)			1 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
OSTEOTOMY		1 (0.01)			1 (0.00)
OVARIAN CANCER	2 (0.03)	5 (0.03)	15 (0.05)		22 (0.04)
OVARIAN CANCER METASTATIC			2 (0.01)		2 (0.00)
OVARIAN CYST	4 (0.07)	5 (0.03)			9 (0.01)
OVARIAN CYST TORSION		1 (0.01)			1 (0.00)
OVARIAN DISORDER	1 (0.02)	1 (0.01)			2 (0.00)
OVARIAN DYSGERMINOMA STAGE UNSPECIFIED		1 (0.01)			1 (0.00)
OVARIAN FIBROMA		1 (0.01)			1 (0.00)
OVARIAN GRANULOSA-THECA CELL TUMOUR			1 (0.00)		1 (0.00)
OVARIAN NEOPLASM		1 (0.01)		1 (0.01)	2 (0.00)
OVARIAN TORSION		1 (0.01)			1 (0.00)
OVERDOSE	16 (0.27)	28 (0.16)	14 (0.05)	1 (0.01)	59 (0.10)
OXYGEN SATURATION DECREASED		2 (0.01)	4 (0.01)		6 (0.01)
PACEMAKER COMPLICATION				1 (0.01)	1 (0.00)
PAIN	4 (0.07)	14 (0.08)	10 (0.03)	4 (0.05)	32 (0.05)
PAIN IN EXTREMITY	3 (0.05)	7 (0.04)	19 (0.06)	2 (0.03)	31 (0.05)
PAIN IN JAW		8 (0.05)			8 (0.01)
PAIN OF SKIN			1 (0.00)		1 (0.00)
PAINFUL ERECTION		2 (0.01)			2 (0.00)
PALLOR			1 (0.00)		1 (0.00)
PALMAR ERYTHEMA			1 (0.00)		1 (0.00)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME		9 (0.05)	8 (0.03)	2 (0.03)	19 (0.03)
PALPITATIONS	1 (0.02)	10 (0.06)	19 (0.06)		30 (0.05)
PANCREATIC CARCINOMA			7 (0.02)	2 (0.03)	9 (0.01)
PANCREATIC CYST			1 (0.00)		1 (0.00)
PANCREATIC PSEUDOCYST	1 (0.02)				1 (0.00)
PANCREATITIS	7 (0.12)	21 (0.12)	23 (0.08)		51 (0.08)

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
PANCREATITIS ACUTE	9 (0.15)	6 (0.04)	16 (0.05)	2 (0.03)	33 (0.05)
PANCREATITIS CHRONIC			1 (0.00)		1 (0.00)
PANCREATITIS HAEMORRHAGIC		3 (0.02)	1 (0.00)		4 (0.01)
PANCREATITIS NECROTISING		1 (0.01)			1 (0.00)
PANCYTOPENIA	1 (0.02)	3 (0.02)	23 (0.08)	11 (0.14)	38 (0.06)
PANIC ATTACK		5 (0.03)	4 (0.01)		9 (0.01)
PANIC DISORDER	1 (0.02)				1 (0.00)
PAPILLARY THYROID CANCER	3 (0.05)	4 (0.02)			7 (0.01)
PAPILLITIS			1 (0.00)		1 (0.00)
PAPILLOEDEMA		4 (0.02)	3 (0.01)	3 (0.04)	10 (0.02)
PARADOXICAL DRUG REACTION	1 (0.02)	2 (0.01)	5 (0.02)	6 (0.08)	14 (0.02)
PARAESTHESIA	1 (0.02)	15 (0.09)	13 (0.04)	2 (0.03)	31 (0.05)
PARAESTHESIA ORAL	2 (0.03)	2 (0.01)	1 (0.00)	1 (0.01)	6 (0.01)
PARALYSIS	1 (0.02)			4 (0.05)	5 (0.01)
PARANOIA		4 (0.02)	4 (0.01)		8 (0.01)
PARAPARESIS			1 (0.00)		1 (0.00)
PARAPLEGIA	1 (0.02)	1 (0.01)			2 (0.00)
PARATHYROID GLAND ENLARGEMENT			1 (0.00)		1 (0.00)
PARATHYROID TUMOUR MALIGNANT			1 (0.00)		1 (0.00)
PARESIS		2 (0.01)			2 (0.00)
PARESIS CRANIAL NERVE			1 (0.00)		1 (0.00)
PARKINSON'S DISEASE		1 (0.01)	2 (0.01)	4 (0.05)	7 (0.01)
PARKINSONISM		1 (0.01)	4 (0.01)		5 (0.01)
PARONYCHIA			1 (0.00)		1 (0.00)
PAROSMIA	1 (0.02)	3 (0.02)	3 (0.01)		7 (0.01)
PAROTITIS			1 (0.00)		1 (0.00)
PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	1 (0.02)				1 (0.00)
PARTIAL SEIZURES	2 (0.03)		3 (0.01)		5 (0.01)

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
PATELLA FRACTURE		1 (0.01)	2 (0.01)	2 (0.03)	5 (0.01)
PATENT DUCTUS ARTERIOSUS	2 (0.03)				2 (0.00)
PATHOGEN RESISTANCE	1 (0.02)				1 (0.00)
PATHOLOGICAL FRACTURE			2 (0.01)	1 (0.01)	3 (0.00)
PATHOLOGICAL GAMBLING		2 (0.01)	2 (0.01)		4 (0.01)
PELVIC FRACTURE			2 (0.01)	6 (0.08)	8 (0.01)
PELVIC INFLAMMATORY DISEASE		4 (0.02)			4 (0.01)
PELVIC MASS		1 (0.01)	2 (0.01)		3 (0.00)
PELVIC VENOUS THROMBOSIS		5 (0.03)			5 (0.01)
PEMPHIGOID			4 (0.01)	6 (0.08)	10 (0.02)
PEMPHIGUS	1 (0.02)		1 (0.00)		2 (0.00)
PENILE PAIN			1 (0.00)	1 (0.01)	2 (0.00)
PEPTIC ULCER PERFORATION			1 (0.00)		1 (0.00)
PERFORATED ULCER				1 (0.01)	1 (0.00)
PERFORMANCE STATUS DECREASED		1 (0.01)	4 (0.01)		5 (0.01)
PERIANAL ABSCESS			1 (0.00)		1 (0.00)
PERIARTHRITIS			1 (0.00)		1 (0.00)
PERICARDIAL EFFUSION	2 (0.03)	6 (0.04)	4 (0.01)		12 (0.02)
PERICARDITIS			3 (0.01)		3 (0.00)
PERICARDITIS TUBERCULOUS			1 (0.00)		1 (0.00)
PERIODONTITIS		1 (0.01)			1 (0.00)
PERIORBITAL OEDEMA		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE				1 (0.01)	1 (0.00)
PERIPHERAL COLDNESS	3 (0.05)	1 (0.01)			4 (0.01)
PERIPHERAL EMBOLISM			1 (0.00)	1 (0.01)	2 (0.00)
PERIPHERAL ISCHAEMIA	1 (0.02)	1 (0.01)	4 (0.01)		6 (0.01)
PERIPHERAL MOTOR NEUROPATHY			3 (0.01)		3 (0.00)
PERIPHERAL SENSORY NEUROPATHY		1 (0.01)	2 (0.01)	1 (0.01)	4 (0.01)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED			1 (0.00)		1 (0.00)
PERIPHERAL VASCULAR DISORDER		1 (0.01)		1 (0.01)	2 (0.00)
PERIRECTAL ABSCESS			1 (0.00)		1 (0.00)
PERITONEAL HAEMORRHAGE			1 (0.00)		1 (0.00)
PERITONEAL TUBERCULOSIS		1 (0.01)	4 (0.01)		5 (0.01)
PERITONITIS			1 (0.00)		1 (0.00)
PERITONITIS BACTERIAL			3 (0.01)		3 (0.00)
PERNICIOUS ANAEMIA	1 (0.02)		1 (0.00)		2 (0.00)
PERONEAL NERVE PALSY		1 (0.01)			1 (0.00)
PERSECUTORY DELUSION			1 (0.00)		1 (0.00)
PERSONALITY CHANGE			3 (0.01)		3 (0.00)
PERSONALITY DISORDER			1 (0.00)		1 (0.00)
PETECHIAE	2 (0.03)	4 (0.02)	1 (0.00)	2 (0.03)	9 (0.01)
PETIT MAL EPILEPSY	2 (0.03)	4 (0.02)	1 (0.00)		7 (0.01)
PEYRONIE'S DISEASE			1 (0.00)		1 (0.00)
PH URINE INCREASED			1 (0.00)		1 (0.00)
PHARMACEUTICAL PRODUCT COMPLAINT	6 (0.10)	11 (0.06)	19 (0.06)	9 (0.12)	45 (0.07)
PHARYNGEAL HAEMORRHAGE			1 (0.00)		1 (0.00)
PHARYNGEAL OEDEMA	1 (0.02)	6 (0.04)	5 (0.02)	2 (0.03)	14 (0.02)
PHARYNGEAL ULCERATION	1 (0.02)				1 (0.00)
PHARYNGITIS	2 (0.03)				2 (0.00)
PHARYNGOLARYNGEAL PAIN	2 (0.03)	6 (0.04)	5 (0.02)		13 (0.02)
PHARYNX DISCOMFORT		1 (0.01)			1 (0.00)
PHIMOSIS				3 (0.04)	3 (0.00)
PHLEBITIS		6 (0.04)	4 (0.01)	3 (0.04)	13 (0.02)
PHLEBITIS SUPERFICIAL			1 (0.00)		1 (0.00)
PHOTODERMATOSIS			1 (0.00)		1 (0.00)
PHOTOPSIA	1 (0.02)				1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
PHOTOSENSITIVITY REACTION	2 (0.03)	4 (0.02)	2 (0.01)	1 (0.01)	9 (0.01)
PHYSICAL ASSAULT	2 (0.03)				2 (0.00)
PIGMENTATION DISORDER	2 (0.03)	2 (0.01)	1 (0.00)		5 (0.01)
PITUITARY CYST		3 (0.02)			3 (0.00)
PITUITARY TUMOUR		1 (0.01)	1 (0.00)		2 (0.00)
PITUITARY TUMOUR BENIGN	4 (0.07)	1 (0.01)			5 (0.01)
PITUITARY TUMOUR RECURRENT		1 (0.01)	1 (0.00)		2 (0.00)
PITYRIASIS ROSEA			3 (0.01)	2 (0.03)	5 (0.01)
PITYRIASIS RUBRA PILARIS		1 (0.01)			1 (0.00)
PLACENTAL DISORDER	1 (0.02)				1 (0.00)
PLASMIN INHIBITOR INCREASED	2 (0.03)				2 (0.00)
PLATELET COUNT ABNORMAL		1 (0.01)		1 (0.01)	2 (0.00)
PLATELET COUNT DECREASED	1 (0.02)	8 (0.05)	28 (0.09)	7 (0.09)	44 (0.07)
PLATELET COUNT INCREASED	1 (0.02)	2 (0.01)	4 (0.01)		7 (0.01)
PLEURAL EFFUSION		4 (0.02)	10 (0.03)	3 (0.04)	17 (0.03)
PLEURAL FIBROSIS				1 (0.01)	1 (0.00)
PLEURISY	1 (0.02)	1 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
PLEUROTHOTONUS			2 (0.01)		2 (0.00)
PNEUMATOSIS INTESTINALIS				2 (0.03)	2 (0.00)
PNEUMOCOCCAL SEPSIS	1 (0.02)				1 (0.00)
PNEUMOCYSTIS JIROVECI INFECTION		2 (0.01)	1 (0.00)		3 (0.00)
PNEUMOCYSTIS JIROVECI PNEUMONIA		1 (0.01)	6 (0.02)	1 (0.01)	8 (0.01)
PNEUMONIA	5 (0.08)	33 (0.19)	89 (0.29)	21 (0.27)	148 (0.24)
PNEUMONIA ASPIRATION	1 (0.02)	1 (0.01)	4 (0.01)	2 (0.03)	8 (0.01)
PNEUMONIA BACTERIAL			3 (0.01)		3 (0.00)
PNEUMONIA CYTOMEGALOVIRAL		1 (0.01)			1 (0.00)
PNEUMONIA KLEBSIELLA		1 (0.01)			1 (0.00)
PNEUMONIA LEGIONELLA			2 (0.01)		2 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
PNEUMONIA MORAXELLA			1 (0.00)		1 (0.00)
PNEUMONIA MYCOPLASMAL	1 (0.02)		1 (0.00)		2 (0.00)
PNEUMONIA PRIMARY ATYPICAL				1 (0.01)	1 (0.00)
PNEUMONIA STAPHYLOCOCCAL			1 (0.00)		1 (0.00)
PNEUMONIA STREPTOCOCCAL			1 (0.00)		1 (0.00)
PNEUMONIA VIRAL			1 (0.00)		1 (0.00)
PNEUMONITIS	1 (0.02)	2 (0.01)	19 (0.06)	3 (0.04)	25 (0.04)
PNEUMONITIS CRYPTOCOCCAL			1 (0.00)		1 (0.00)
PNEUMOTHORAX		2 (0.01)	2 (0.01)	2 (0.03)	6 (0.01)
POLLAKIURIA		1 (0.01)	1 (0.00)		2 (0.00)
POLYARTHRITIS		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
POLYCYTHAEMIA		3 (0.02)	1 (0.00)		4 (0.01)
POLYCYTHAEMIA VERA			1 (0.00)		1 (0.00)
POLYDACTYLY		1 (0.01)			1 (0.00)
POLYMENORRHOEA		1 (0.01)			1 (0.00)
POLYMYALGIA			1 (0.00)		1 (0.00)
POLYMYALGIA RHEUMATICA			3 (0.01)	1 (0.01)	4 (0.01)
POLYMYOSITIS		1 (0.01)	5 (0.02)		6 (0.01)
POLYNEUROPATHY		1 (0.01)	6 (0.02)	1 (0.01)	8 (0.01)
POLYSUBSTANCE ABUSE		1 (0.01)			1 (0.00)
POLYURIA	1 (0.02)		2 (0.01)		3 (0.00)
POOR PERIPHERAL CIRCULATION		1 (0.01)			1 (0.00)
POOR QUALITY DRUG ADMINISTERED			2 (0.01)		2 (0.00)
POOR VENOUS ACCESS			1 (0.00)		1 (0.00)
PORPHYRIA NON-ACUTE			2 (0.01)		2 (0.00)
PORTAL HYPERTENSION		1 (0.01)			1 (0.00)
PORTAL VEIN THROMBOSIS		4 (0.02)	2 (0.01)		6 (0.01)
POST GASTRIC SURGERY SYNDROME			1 (0.00)		1 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
POST PROCEDURAL COMPLICATION		4 (0.02)	8 (0.03)	2 (0.03)	14 (0.02)
POST PROCEDURAL DIARRHOEA			1 (0.00)		1 (0.00)
POST PROCEDURAL HAEMORRHAGE	1 (0.02)	2 (0.01)	3 (0.01)		6 (0.01)
POST PROCEDURAL NAUSEA			1 (0.00)		1 (0.00)
POST THROMBOTIC SYNDROME			2 (0.01)		2 (0.00)
POST-TRAUMATIC STRESS DISORDER		1 (0.01)			1 (0.00)
POSTMENOPAUSAL HAEMORRHAGE			3 (0.01)	1 (0.01)	4 (0.01)
POSTOPERATIVE FEVER			1 (0.00)		1 (0.00)
POSTOPERATIVE INFECTION		1 (0.01)	1 (0.00)		2 (0.00)
POSTOPERATIVE RENAL FAILURE	1 (0.02)				1 (0.00)
POSTOPERATIVE WOUND COMPLICATION			1 (0.00)		1 (0.00)
POSTOPERATIVE WOUND INFECTION		1 (0.01)	1 (0.00)		2 (0.00)
PRE-EXISTING DISEASE		18 (0.11)	36 (0.12)	21 (0.27)	75 (0.12)
PRECOCIOUS PUBERTY	3 (0.05)				3 (0.00)
PRECURSOR B-LYMPHOBLASTIC LYMPHOMA	1 (0.02)				1 (0.00)
PREGNANCY	6 (0.10)	8 (0.05)			14 (0.02)
PREGNANCY OF PARTNER		1 (0.01)			1 (0.00)
PREGNANCY ON ORAL CONTRACEPTIVE		1 (0.01)			1 (0.00)
PREGNANCY TEST POSITIVE	1 (0.02)				1 (0.00)
PREGNANCY WITH CONTRACEPTIVE DEVICE		1 (0.01)			1 (0.00)
PREGNANCY WITH INJECTABLE CONTRACEPTIVE	1 (0.02)				1 (0.00)
PREMATURE BABY	1 (0.02)				1 (0.00)
PREMATURE LABOUR		2 (0.01)			2 (0.00)
PRESCRIBED OVERDOSE			3 (0.01)	4 (0.05)	7 (0.01)
PRIAPISM	2 (0.03)	6 (0.04)			8 (0.01)
PROCEDURAL COMPLICATION	2 (0.03)		1 (0.00)		3 (0.00)
PROCEDURAL PAIN	1 (0.02)	2 (0.01)			3 (0.00)
PROCTITIS ULCERATIVE			2 (0.01)	1 (0.01)	3 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
PRODUCTIVE COUGH		1 (0.01)			1 (0.00)
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY		1 (0.01)			1 (0.00)
PROGRESSIVE MULTIPLE SCLEROSIS			1 (0.00)		1 (0.00)
PROPOFOL INFUSION SYNDROME	1 (0.02)				1 (0.00)
PROSTATE CANCER		1 (0.01)	14 (0.05)	8 (0.10)	23 (0.04)
PROSTATE CANCER METASTATIC			3 (0.01)		3 (0.00)
PROSTATE CANCER STAGE IV			1 (0.00)		1 (0.00)
PROSTATE EXAMINATION ABNORMAL				1 (0.01)	1 (0.00)
PROSTATECTOMY			1 (0.00)		1 (0.00)
PROSTATIC ADENOMA			2 (0.01)		2 (0.00)
PROSTATIC DISORDER		1 (0.01)			1 (0.00)
PROSTATIC OPERATION			2 (0.01)		2 (0.00)
PROSTATIC SPECIFIC ANTIGEN INCREASED			1 (0.00)	1 (0.01)	2 (0.00)
PROSTHESIS IMPLANTATION				1 (0.01)	1 (0.00)
PROTEIN S DECREASED	1 (0.02)				1 (0.00)
PROTEIN URINE PRESENT		1 (0.01)			1 (0.00)
PROTEINURIA	1 (0.02)	3 (0.02)	4 (0.01)		8 (0.01)
PROTHROMBIN TIME PROLONGED		1 (0.01)			1 (0.00)
PRURIGO	1 (0.02)		1 (0.00)		2 (0.00)
PRURITUS	18 (0.30)	56 (0.33)	40 (0.13)	8 (0.10)	122 (0.20)
PRURITUS GENERALISED	1 (0.02)	4 (0.02)	7 (0.02)		12 (0.02)
PSEUDO LYMPHOMA		1 (0.01)	5 (0.02)		6 (0.01)
PSEUDOBULBAR PALSY	1 (0.02)				1 (0.00)
PSEUDOMONAS INFECTION	2 (0.03)		1 (0.00)		3 (0.00)
PSORIASIS		7 (0.04)	9 (0.03)		16 (0.03)
PSYCHIATRIC EVALUATION		9 (0.05)	5 (0.02)		14 (0.02)
PSYCHIATRIC SYMPTOM	5 (0.08)	22 (0.13)	9 (0.03)	1 (0.01)	37 (0.06)
PSYCHOMOTOR HYPERACTIVITY	1 (0.02)	1 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
PSYCHOMOTOR SEIZURES				1 (0.01)	1 (0.00)
PSYCHOTIC DISORDER	4 (0.07)	33 (0.19)	13 (0.04)	1 (0.01)	51 (0.08)
PUBIC RAMI FRACTURE			2 (0.01)		2 (0.00)
PULMONARY ALVEOLAR HAEMORRHAGE	1 (0.02)		4 (0.01)		5 (0.01)
PULMONARY ARTERIAL PRESSURE INCREASED		1 (0.01)			1 (0.00)
PULMONARY ARTERY STENOSIS	1 (0.02)				1 (0.00)
PULMONARY ARTERY THROMBOSIS	1 (0.02)		2 (0.01)		3 (0.00)
PULMONARY EMBOLISM	16 (0.27)	38 (0.22)	48 (0.16)	12 (0.15)	114 (0.19)
PULMONARY EOSINOPHILIA	1 (0.02)	3 (0.02)	2 (0.01)		6 (0.01)
PULMONARY FIBROSIS			10 (0.03)	4 (0.05)	14 (0.02)
PULMONARY FUNCTION TEST DECREASED	1 (0.02)				1 (0.00)
PULMONARY HAEMORRHAGE	8 (0.14)		2 (0.01)		10 (0.02)
PULMONARY HYPERTENSION	2 (0.03)	2 (0.01)	3 (0.01)		7 (0.01)
PULMONARY INFARCTION		2 (0.01)	3 (0.01)		5 (0.01)
PULMONARY OEDEMA		1 (0.01)	5 (0.02)	3 (0.04)	9 (0.01)
PULMONARY PNEUMATOCELE		2 (0.01)			2 (0.00)
PULMONARY THROMBOSIS		4 (0.02)	1 (0.00)	1 (0.01)	6 (0.01)
PULMONARY TOXICITY			3 (0.01)	1 (0.01)	4 (0.01)
PULMONARY TUBERCULOSIS	1 (0.02)	4 (0.02)	18 (0.06)	1 (0.01)	24 (0.04)
PULSE ABSENT				2 (0.03)	2 (0.00)
PUNCTATE KERATITIS		1 (0.01)			1 (0.00)
PUNCTURE SITE HAEMORRHAGE				1 (0.01)	1 (0.00)
PUNCTURE SITE REACTION		1 (0.01)			1 (0.00)
PUPILS UNEQUAL		1 (0.01)			1 (0.00)
PURPURA	1 (0.02)	3 (0.02)	3 (0.01)	3 (0.04)	10 (0.02)
PURPURA NON-THROMBOCYTOPENIC				1 (0.01)	1 (0.00)
PUSTULAR PSORIASIS		2 (0.01)	4 (0.01)		6 (0.01)
PUTAMEN HAEMORRHAGE		2 (0.01)			2 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
PYELONEPHRITIS		3 (0.02)	3 (0.01)		6 (0.01)
PYELONEPHRITIS ACUTE		1 (0.01)	1 (0.00)		2 (0.00)
PYREXIA	10 (0.17)	22 (0.13)	32 (0.11)	7 (0.09)	71 (0.12)
PYURIA			1 (0.00)		1 (0.00)
RADIAL NERVE PALSY		1 (0.01)			1 (0.00)
RADIATION MYELOPATHY			3 (0.01)		3 (0.00)
RADIATION PNEUMONITIS		2 (0.01)	1 (0.00)		3 (0.00)
RADICAL PROSTATECTOMY			1 (0.00)		1 (0.00)
RADIUS FRACTURE				1 (0.01)	1 (0.00)
RASH	65 (1.10)	133 (0.78)	108 (0.36)	27 (0.35)	333 (0.55)
RASH ERYTHEMATOUS	2 (0.03)	6 (0.04)	5 (0.02)	4 (0.05)	17 (0.03)
RASH GENERALISED	7 (0.12)	23 (0.13)	21 (0.07)	4 (0.05)	55 (0.09)
RASH MACULAR	1 (0.02)	2 (0.01)	5 (0.02)	1 (0.01)	9 (0.01)
RASH MACULO-PAPULAR	1 (0.02)	8 (0.05)	3 (0.01)	3 (0.04)	15 (0.02)
RASH MORBILLIFORM			1 (0.00)		1 (0.00)
RASH PAPULAR	2 (0.03)	6 (0.04)	2 (0.01)	1 (0.01)	11 (0.02)
RASH PRURITIC	5 (0.08)	6 (0.04)	7 (0.02)	4 (0.05)	22 (0.04)
RASH PUSTULAR		2 (0.01)	1 (0.00)		3 (0.00)
RASH VESICULAR		1 (0.01)	1 (0.00)	1 (0.01)	3 (0.00)
RAYNAUD'S PHENOMENON	1 (0.02)		2 (0.01)	1 (0.01)	4 (0.01)
REBOUND EFFECT			1 (0.00)		1 (0.00)
RECALL PHENOMENON			1 (0.00)		1 (0.00)
RECTAL CANCER		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
RECTAL DISCHARGE		1 (0.01)			1 (0.00)
RECTAL HAEMORRHAGE	2 (0.03)	3 (0.02)	6 (0.02)	8 (0.10)	19 (0.03)
RECTAL NEOPLASM			1 (0.00)		1 (0.00)
RECTOCELE		1 (0.01)			1 (0.00)
RECURRENT CANCER	1 (0.02)		1 (0.00)		2 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
RED BLOOD CELL COUNT ABNORMAL			1 (0.00)		1 (0.00)
RED BLOOD CELL COUNT DECREASED			3 (0.01)		3 (0.00)
RED BLOOD CELL MORPHOLOGY ABNORMAL	1 (0.02)				1 (0.00)
REFRACTORY ANAEMIA	1 (0.02)				1 (0.00)
REGRESSIVE BEHAVIOUR			1 (0.00)		1 (0.00)
REHABILITATION THERAPY		1 (0.01)			1 (0.00)
REITER'S SYNDROME		1 (0.01)			1 (0.00)
RENAL ABSCESS		2 (0.01)			2 (0.00)
RENAL ADENOMA			1 (0.00)		1 (0.00)
RENAL ARTERY THROMBOSIS		1 (0.01)			1 (0.00)
RENAL ATROPHY				1 (0.01)	1 (0.00)
RENAL CELL CARCINOMA STAGE UNSPECIFIED	1 (0.02)	2 (0.01)	7 (0.02)		10 (0.02)
RENAL COLIC		1 (0.01)	1 (0.00)		2 (0.00)
RENAL CYST	1 (0.02)		1 (0.00)		2 (0.00)
RENAL DISORDER	1 (0.02)	1 (0.01)	5 (0.02)	1 (0.01)	8 (0.01)
RENAL FAILURE	2 (0.03)	7 (0.04)	28 (0.09)	19 (0.25)	56 (0.09)
RENAL FAILURE ACUTE	8 (0.14)	7 (0.04)	38 (0.13)	15 (0.19)	68 (0.11)
RENAL FAILURE CHRONIC		2 (0.01)	4 (0.01)	2 (0.03)	8 (0.01)
RENAL IMPAIRMENT			7 (0.02)	4 (0.05)	11 (0.02)
RENAL INFARCT		1 (0.01)	1 (0.00)		2 (0.00)
RENAL INJURY		1 (0.01)			1 (0.00)
RENAL MASS			1 (0.00)		1 (0.00)
RENAL NEOPLASM			1 (0.00)		1 (0.00)
RENAL PAIN		1 (0.01)	2 (0.01)		3 (0.00)
RENAL SURGERY		1 (0.01)			1 (0.00)
RENAL TRANSPLANT		1 (0.01)			1 (0.00)
RENAL TUBULAR DISORDER		1 (0.01)			1 (0.00)
RENAL TUBULAR NECROSIS	1 (0.02)	1 (0.01)	6 (0.02)		8 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
RENAL VEIN THROMBOSIS			1 (0.00)		1 (0.00)
RESPIRATION ABNORMAL		1 (0.01)		1 (0.01)	2 (0.00)
RESPIRATORY ARREST	5 (0.08)	2 (0.01)	4 (0.01)	1 (0.01)	12 (0.02)
RESPIRATORY DEPRESSION	1 (0.02)	2 (0.01)			3 (0.00)
RESPIRATORY DISORDER	1 (0.02)	1 (0.01)	3 (0.01)		5 (0.01)
RESPIRATORY DISTRESS	3 (0.05)	2 (0.01)	6 (0.02)	2 (0.03)	13 (0.02)
RESPIRATORY FAILURE		2 (0.01)	16 (0.05)	5 (0.06)	23 (0.04)
RESPIRATORY PARALYSIS			1 (0.00)		1 (0.00)
RESPIRATORY SYNCYTIAL VIRUS INFECTION	3 (0.05)				3 (0.00)
RESPIRATORY TRACT CONGESTION			1 (0.00)		1 (0.00)
RESPIRATORY TRACT HAEMORRHAGE		1 (0.01)			1 (0.00)
RESPIRATORY TRACT INFECTION		1 (0.01)		1 (0.01)	2 (0.00)
RESPIRATORY TRACT INFECTION VIRAL			1 (0.00)		1 (0.00)
RESPIRATORY TRACT IRRITATION		1 (0.01)			1 (0.00)
RESPIRE CARE		1 (0.01)	1 (0.00)		2 (0.00)
RESTLESS LEGS SYNDROME		3 (0.02)	5 (0.02)	2 (0.03)	10 (0.02)
RESTLESSNESS		2 (0.01)			2 (0.00)
RESUSCITATION	1 (0.02)				1 (0.00)
RETCHING		1 (0.01)			1 (0.00)
RETINAL ANEURYSM			1 (0.00)		1 (0.00)
RETINAL ARTERY OCCLUSION		2 (0.01)	2 (0.01)		4 (0.01)
RETINAL ARTERY THROMBOSIS			1 (0.00)		1 (0.00)
RETINAL DEGENERATION			1 (0.00)		1 (0.00)
RETINAL DETACHMENT	1 (0.02)	4 (0.02)	4 (0.01)	1 (0.01)	10 (0.02)
RETINAL DISORDER		1 (0.01)		1 (0.01)	2 (0.00)
RETINAL EXUDATES			2 (0.01)		2 (0.00)
RETINAL HAEMORRHAGE	1 (0.02)	1 (0.01)	12 (0.04)	5 (0.06)	19 (0.03)

Reaction Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
RETINAL INFARCTION			1 (0.00)		1 (0.00)
RETINAL ISCHAEMIA		3 (0.02)			3 (0.00)
RETINAL OEDEMA		1 (0.01)			1 (0.00)
RETINAL PIGMENT EPITHELIOPATHY		3 (0.02)			3 (0.00)
RETINAL PIGMENTATION			1 (0.00)		1 (0.00)
RETINAL TEAR		2 (0.01)	3 (0.01)		5 (0.01)
RETINAL VASCULAR THROMBOSIS		3 (0.02)			3 (0.00)
RETINAL VEIN OCCLUSION		1 (0.01)	7 (0.02)		8 (0.01)
RETINAL VEIN THROMBOSIS		2 (0.01)	4 (0.01)		6 (0.01)
RETINITIS			2 (0.01)		2 (0.00)
RETINOIC ACID SYNDROME			1 (0.00)		1 (0.00)
RETINOPATHY		2 (0.01)	1 (0.00)		3 (0.00)
RETROGRADE EJACULATION			1 (0.00)		1 (0.00)
RETROPERITONEAL FIBROSIS			1 (0.00)		1 (0.00)
RETROPERITONEAL HAEMORRHAGE				1 (0.01)	1 (0.00)
REVERSIBLE POSTERIOR LEUKOENCEPHALOPATHY SYNDROME	1 (0.02)				1 (0.00)
RHABDOMYOLYSIS	3 (0.05)	18 (0.11)	23 (0.08)	22 (0.28)	66 (0.11)
RHEUMATOID ARTHRITIS		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
RHEUMATOID NODULE REMOVAL			1 (0.00)		1 (0.00)
RHINITIS ALLERGIC		1 (0.01)			1 (0.00)
RIB FRACTURE			1 (0.00)		1 (0.00)
RIGHT VENTRICULAR FAILURE		1 (0.01)		1 (0.01)	2 (0.00)
ROAD TRAFFIC ACCIDENT		7 (0.04)	10 (0.03)		17 (0.03)
ROSEOLA			1 (0.00)		1 (0.00)
ROTATOR CUFF SYNDROME		1 (0.01)	2 (0.01)		3 (0.00)
RUPTURED CEREBRAL ANEURYSM			1 (0.00)		1 (0.00)
RUPTURED ECTOPIC PREGNANCY		1 (0.01)			1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
SALIVARY GLAND ADENOMA		1 (0.01)			1 (0.00)
SALPINGITIS		1 (0.01)			1 (0.00)
SARCOIDOSIS			3 (0.01)		3 (0.00)
SARCOMA			2 (0.01)		2 (0.00)
SARCOMA UTERUS			2 (0.01)		2 (0.00)
SCAR		2 (0.01)			2 (0.00)
SCHIZOPHRENIA	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
SCIATICA				1 (0.01)	1 (0.00)
SCLERAL HAEMORRHAGE	1 (0.02)				1 (0.00)
SCLERODERMA	1 (0.02)	1 (0.01)			2 (0.00)
SCOTOMA	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
SCREAMING			1 (0.00)		1 (0.00)
SCROTAL SWELLING		1 (0.01)			1 (0.00)
SEBACEOUS HYPERPLASIA		2 (0.01)			2 (0.00)
SEBACEOUS NAEVUS			1 (0.00)		1 (0.00)
SECONDARY HYPERTENSION			1 (0.00)		1 (0.00)
SEDATION	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
SELF-INJURIOUS IDEATION	1 (0.02)	2 (0.01)			3 (0.00)
SELF-MEDICATION	1 (0.02)		1 (0.00)		2 (0.00)
SEMEN DISCOLOURATION		1 (0.01)	1 (0.00)		2 (0.00)
SEMEN VOLUME DECREASED		1 (0.01)	1 (0.00)		2 (0.00)
SENSATION OF FOREIGN BODY		1 (0.01)			1 (0.00)
SENSATION OF PRESSURE		2 (0.01)			2 (0.00)
SENSITIVITY OF TEETH			2 (0.01)		2 (0.00)
SENSORY LOSS			1 (0.00)		1 (0.00)
SEPSIS	3 (0.05)	4 (0.02)	10 (0.03)	1 (0.01)	18 (0.03)
SEPTIC SHOCK	1 (0.02)	4 (0.02)	9 (0.03)		14 (0.02)
SEPTOPLASTY				1 (0.01)	1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
SEROMA		2 (0.01)			2 (0.00)
SEROTONIN SYNDROME	1 (0.02)	2 (0.01)	3 (0.01)		6 (0.01)
SERUM SICKNESS	2 (0.03)	3 (0.02)	1 (0.00)		6 (0.01)
SEXUAL DYSFUNCTION		1 (0.01)	1 (0.00)		2 (0.00)
SHOCK		4 (0.02)	7 (0.02)	1 (0.01)	12 (0.02)
SHOCK HAEMORRHAGIC		1 (0.01)	1 (0.00)		2 (0.00)
SHOULDER ARTHROPLASTY				1 (0.01)	1 (0.00)
SHOULDER OPERATION			1 (0.00)		1 (0.00)
SHOULDER PAIN			3 (0.01)	2 (0.03)	5 (0.01)
SHUNT THROMBOSIS		1 (0.01)			1 (0.00)
SIALOADENITIS			3 (0.01)		3 (0.00)
SICK SINUS SYNDROME			1 (0.00)	2 (0.03)	3 (0.00)
SICKLE CELL ANAEMIA WITH CRISIS			1 (0.00)		1 (0.00)
SILENT MYOCARDIAL INFARCTION			2 (0.01)		2 (0.00)
SIMPLE PARTIAL SEIZURES			1 (0.00)		1 (0.00)
SINUS ARRHYTHMIA	1 (0.02)				1 (0.00)
SINUS BRADYCARDIA				2 (0.03)	2 (0.00)
SINUS TACHYCARDIA			2 (0.01)		2 (0.00)
SINUSITIS			1 (0.00)		1 (0.00)
SKIN BURNING SENSATION	1 (0.02)				1 (0.00)
SKIN CANCER		1 (0.01)	6 (0.02)	4 (0.05)	11 (0.02)
SKIN DISCOLOURATION		6 (0.04)	1 (0.00)	1 (0.01)	8 (0.01)
SKIN DISORDER			2 (0.01)	3 (0.04)	5 (0.01)
SKIN EXFOLIATION	1 (0.02)	2 (0.01)	2 (0.01)	3 (0.04)	8 (0.01)
SKIN HAEMORRHAGE				1 (0.01)	1 (0.00)
SKIN LACERATION	1 (0.02)		3 (0.01)		4 (0.01)
SKIN LESION	2 (0.03)				2 (0.00)
SKIN NECROSIS	3 (0.05)		3 (0.01)		6 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
SKIN ODOUR ABNORMAL	2 (0.03)		5 (0.02)		7 (0.01)
SKIN PAPILLOMA	3 (0.05)				3 (0.00)
SKIN REACTION			1 (0.00)	1 (0.01)	2 (0.00)
SKIN STRIAE	1 (0.02)				1 (0.00)
SKIN ULCER		2 (0.01)		1 (0.01)	3 (0.00)
SLE ARTHRITIS		1 (0.01)			1 (0.00)
SLEEP APNOEA SYNDROME	1 (0.02)	3 (0.02)	5 (0.02)		9 (0.01)
SLEEP ATTACKS				1 (0.01)	1 (0.00)
SLEEP DISORDER	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.00)
SLEEP TERROR			1 (0.00)		1 (0.00)
SLEEP WALKING		2 (0.01)			2 (0.00)
SMALL CELL LUNG CANCER STAGE UNSPECIFIED			4 (0.01)	2 (0.03)	6 (0.01)
SMALL INTESTINAL HAEMORRHAGE			1 (0.00)		1 (0.00)
SMALL INTESTINAL OBSTRUCTION		2 (0.01)	7 (0.02)		9 (0.01)
SMALL INTESTINAL PERFORATION			2 (0.01)		2 (0.00)
SMALL INTESTINE CARCINOMA METASTATIC			1 (0.00)		1 (0.00)
SMEAR CERVIX ABNORMAL			1 (0.00)		1 (0.00)
SMOKER	1 (0.02)	1 (0.01)			2 (0.00)
SNEEZING		1 (0.01)			1 (0.00)
SOCIAL PROBLEM		3 (0.02)			3 (0.00)
SODIUM RETENTION			1 (0.00)		1 (0.00)
SOMNOLENCE	5 (0.08)	11 (0.06)	16 (0.05)	11 (0.14)	43 (0.07)
SPEECH DISORDER		1 (0.01)	3 (0.01)		4 (0.01)
SPERM COUNT DECREASED		1 (0.01)			1 (0.00)
SPERMATOGENESIS ABNORMAL		1 (0.01)			1 (0.00)
SPERMATOZOA ABNORMAL		1 (0.01)			1 (0.00)
SPINAL COLUMN STENOSIS		1 (0.01)	4 (0.01)	1 (0.01)	6 (0.01)
SPINAL COMPRESSION FRACTURE			1 (0.00)	1 (0.01)	2 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
SPINAL CORD DISORDER	1 (0.02)				1 (0.00)
SPINAL CORD ISCHAEMIA	1 (0.02)				1 (0.00)
SPINAL CORD OPERATION		1 (0.01)			1 (0.00)
SPINAL DISORDER		1 (0.01)	2 (0.01)		3 (0.00)
SPINAL FRACTURE			4 (0.01)	6 (0.08)	10 (0.02)
SPINAL FUSION SURGERY		2 (0.01)	3 (0.01)		5 (0.01)
SPINAL HAEMATOMA			1 (0.00)		1 (0.00)
SPINAL OPERATION			3 (0.01)		3 (0.00)
SPLENIC INFARCTION			1 (0.00)		1 (0.00)
SPLENIC RUPTURE		1 (0.01)			1 (0.00)
SPLENOMEGALY		1 (0.01)			1 (0.00)
SPONTANEOUS PENILE ERECTION			2 (0.01)		2 (0.00)
SPUTUM DISCOLOURED				1 (0.01)	1 (0.00)
SQUAMOUS CELL CARCINOMA			4 (0.01)		4 (0.01)
SQUAMOUS CELL CARCINOMA OF SKIN			5 (0.02)		5 (0.01)
STAPHYLOCOCCAL INFECTION		2 (0.01)			2 (0.00)
STAPHYLOCOCCAL SEPSIS		1 (0.01)	2 (0.01)		3 (0.00)
STARING	1 (0.02)				1 (0.00)
STATUS EPILEPTICUS	1 (0.02)	2 (0.01)	1 (0.00)	2 (0.03)	6 (0.01)
STENT OCCLUSION		1 (0.01)	6 (0.02)	1 (0.01)	8 (0.01)
STENT PLACEMENT			2 (0.01)		2 (0.00)
STEREOTYPIC MOVEMENT DISORDER				2 (0.03)	2 (0.00)
STEVENS-JOHNSON SYNDROME	14 (0.24)	19 (0.11)	24 (0.08)	11 (0.14)	68 (0.11)
STOMACH DISCOMFORT	3 (0.05)	1 (0.01)	9 (0.03)	4 (0.05)	17 (0.03)
STOMATITIS		1 (0.01)	4 (0.01)		5 (0.01)
STOMATITIS NECROTISING			1 (0.00)		1 (0.00)
STREPTOCOCCAL SEPSIS				1 (0.01)	1 (0.00)
STRESS		2 (0.01)	1 (0.00)		3 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
STRESS AT WORK			1 (0.00)		1 (0.00)
STRESS FRACTURE		1 (0.01)	2 (0.01)		3 (0.00)
STRIDOR			1 (0.00)		1 (0.00)
SUBARACHNOID HAEMORRHAGE		4 (0.02)	3 (0.01)	6 (0.08)	13 (0.02)
SUBCLAVIAN VEIN THROMBOSIS	1 (0.02)				1 (0.00)
SUBCUTANEOUS ABSCESS	1 (0.02)				1 (0.00)
SUBDURAL HAEMATOMA	3 (0.05)	2 (0.01)			5 (0.01)
SUBILEUS		2 (0.01)	1 (0.00)		3 (0.00)
SUDDEN CARDIAC DEATH		5 (0.03)	4 (0.01)		9 (0.01)
SUDDEN DEATH	5 (0.08)	6 (0.04)	26 (0.09)	8 (0.10)	45 (0.07)
SUDDEN HEARING LOSS	1 (0.02)		2 (0.01)		3 (0.00)
SUDDEN INFANT DEATH SYNDROME	1 (0.02)				1 (0.00)
SUDDEN ONSET OF SLEEP			3 (0.01)		3 (0.00)
SUDDEN UNEXPLAINED DEATH IN EPILEPSY				3 (0.04)	3 (0.00)
SUICIDAL IDEATION	7 (0.12)	21 (0.12)	11 (0.04)		39 (0.06)
SUICIDE ATTEMPT	8 (0.14)	6 (0.04)	4 (0.01)	1 (0.01)	19 (0.03)
SULPHAEMOGLOBINAEMIA			1 (0.00)		1 (0.00)
SUPERIOR SAGITTAL SINUS THROMBOSIS	3 (0.05)	1 (0.01)			4 (0.01)
SUPRAVENTRICULAR EXTRASYSTOLES			1 (0.00)	2 (0.03)	3 (0.00)
SUPRAVENTRICULAR TACHYCARDIA	6 (0.10)		1 (0.00)	1 (0.01)	8 (0.01)
SURGERY	1 (0.02)	12 (0.07)	5 (0.02)		18 (0.03)
SWELLING			1 (0.00)		1 (0.00)
SWELLING FACE	4 (0.07)	6 (0.04)	8 (0.03)	1 (0.01)	19 (0.03)
SWOLLEN TONGUE	1 (0.02)	1 (0.01)	8 (0.03)	2 (0.03)	12 (0.02)
SYNCOPE	6 (0.10)	8 (0.05)	12 (0.04)	9 (0.12)	35 (0.06)
SYNCOPE VASOVAGAL			2 (0.01)		2 (0.00)
SYNOVECTOMY		1 (0.01)			1 (0.00)
SYNOVIAL CYST			1 (0.00)		1 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
SYPHILIS TEST POSITIVE			1 (0.00)		1 (0.00)
SYSTEMIC LUPUS ERYTHEMATOSUS		2 (0.01)	2 (0.01)	2 (0.03)	6 (0.01)
SYSTEMIC LUPUS ERYTHEMATOSUS RASH			1 (0.00)		1 (0.00)
T-CELL LYMPHOMA	1 (0.02)	1 (0.01)	3 (0.01)	1 (0.01)	6 (0.01)
T-CELL LYMPHOMA STAGE IV			2 (0.01)		2 (0.00)
TACHYARRHYTHMIA		2 (0.01)	1 (0.00)		3 (0.00)
TACHYCARDIA	3 (0.05)	3 (0.02)	3 (0.01)		9 (0.01)
TARDIVE DYSKINESIA	1 (0.02)		1 (0.00)	1 (0.01)	3 (0.00)
TEETH BRITTLE		1 (0.01)			1 (0.00)
TEMPERATURE REGULATION DISORDER	1 (0.02)				1 (0.00)
TENDON DISORDER		1 (0.01)	1 (0.00)		2 (0.00)
TENDON INJURY			1 (0.00)		1 (0.00)
TENDON RUPTURE		2 (0.01)	7 (0.02)	1 (0.01)	10 (0.02)
TENDONITIS	1 (0.02)		4 (0.01)		5 (0.01)
TENOSYNOVITIS STENOSANS			1 (0.00)		1 (0.00)
TENSION HEADACHE				1 (0.01)	1 (0.00)
TERMINAL STATE			1 (0.00)		1 (0.00)
TESTICULAR PAIN			2 (0.01)		2 (0.00)
TESTIS CANCER		1 (0.01)			1 (0.00)
THERAPEUTIC AGENT TOXICITY				1 (0.01)	1 (0.00)
THERAPEUTIC PROCEDURE			1 (0.00)	1 (0.01)	2 (0.00)
THERAPEUTIC PRODUCT INEFFECTIVE			1 (0.00)		1 (0.00)
THERAPEUTIC RESPONSE DECREASED		6 (0.04)	6 (0.02)	2 (0.03)	14 (0.02)
THERAPEUTIC RESPONSE DELAYED			1 (0.00)		1 (0.00)
THERAPEUTIC RESPONSE UNEXPECTED		2 (0.01)	5 (0.02)		7 (0.01)
THERAPY NON-RESPONDER	1 (0.02)	3 (0.02)	3 (0.01)	1 (0.01)	8 (0.01)
THERMAL BURN	1 (0.02)	1 (0.01)			2 (0.00)
THINKING ABNORMAL		3 (0.02)	2 (0.01)		5 (0.01)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
THIRST		2 (0.01)	2 (0.01)	1 (0.01)	5 (0.01)
THIRST DECREASED			1 (0.00)		1 (0.00)
THORACIC VERTEBRAL FRACTURE				1 (0.01)	1 (0.00)
THROAT CANCER		1 (0.01)			1 (0.00)
THROAT IRRITATION	2 (0.03)	5 (0.03)	1 (0.00)		8 (0.01)
THROAT TIGHTNESS	1 (0.02)		3 (0.01)		4 (0.01)
THROMBOCYTHAEMIA	1 (0.02)		7 (0.02)		8 (0.01)
THROMBOCYTOPENIA	8 (0.14)	20 (0.12)	22 (0.07)	8 (0.10)	58 (0.10)
THROMBOCYTOPENIA NEONATAL				1 (0.01)	1 (0.00)
THROMBOCYTOPENIC PURPURA			3 (0.01)	2 (0.03)	5 (0.01)
THROMBOEMBOLIC STROKE			1 (0.00)		1 (0.00)
THROMBOPHLEBITIS			2 (0.01)		2 (0.00)
THROMBOPHLEBITIS SUPERFICIAL		1 (0.01)			1 (0.00)
THROMBOSIS	6 (0.10)	15 (0.09)	18 (0.06)	4 (0.05)	43 (0.07)
THROMBOSIS IN DEVICE	1 (0.02)		1 (0.00)		2 (0.00)
THROMBOTIC STROKE	1 (0.02)		2 (0.01)		3 (0.00)
THROMBOTIC THROMBOCYTOPENIC PURPURA		3 (0.02)	2 (0.01)		5 (0.01)
THYROID DISORDER	1 (0.02)				1 (0.00)
THYROID GLAND CANCER		1 (0.01)	1 (0.00)		2 (0.00)
THYROID NEOPLASM		1 (0.01)			1 (0.00)
THYROID OPERATION			1 (0.00)		1 (0.00)
TIBIA FRACTURE				2 (0.03)	2 (0.00)
TIC	2 (0.03)	3 (0.02)			5 (0.01)
TINNITUS	2 (0.03)	10 (0.06)	3 (0.01)	2 (0.03)	17 (0.03)
TOE DEFORMITY			1 (0.00)		1 (0.00)
TONGUE BLACK HAIRY	1 (0.02)			1 (0.01)	2 (0.00)
TONGUE CANCER METASTATIC		1 (0.01)			1 (0.00)
TONGUE DISCOLOURATION			1 (0.00)		1 (0.00)

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED		2 (0.01)	1 (0.00)		3 (0.00)
TONGUE OEDEMA	1 (0.02)		2 (0.01)		3 (0.00)
TONGUE SPASM	1 (0.02)				1 (0.00)
TONIC CLONIC MOVEMENTS		1 (0.01)			1 (0.00)
TOOTH ABSCESS		1 (0.01)	2 (0.01)		3 (0.00)
TOOTH DISCOLOURATION	2 (0.03)	1 (0.01)			3 (0.00)
TOOTH DISORDER			6 (0.02)	1 (0.01)	7 (0.01)
TOOTH EROSION			1 (0.00)		1 (0.00)
TOOTH FRACTURE		1 (0.01)	2 (0.01)		3 (0.00)
TOOTH INJURY		1 (0.01)	1 (0.00)		2 (0.00)
TOOTHACHE			1 (0.00)		1 (0.00)
TORSADE DE POINTES	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
TOXIC EPIDERMAL NECROLYSIS	3 (0.05)	2 (0.01)	17 (0.06)	4 (0.05)	26 (0.04)
TOXIC SKIN ERUPTION	1 (0.02)	2 (0.01)	3 (0.01)	1 (0.01)	7 (0.01)
TRANSAMINASES INCREASED	1 (0.02)	3 (0.02)	2 (0.01)	2 (0.03)	8 (0.01)
TRANSFUSION-RELATED ACUTE LUNG INJURY			1 (0.00)		1 (0.00)
TRANSIENT ISCHAEMIC ATTACK		6 (0.04)	19 (0.06)	10 (0.13)	35 (0.06)
TRANSPLANT FAILURE		1 (0.01)			1 (0.00)
TRANSPLANT REJECTION		2 (0.01)	1 (0.00)		3 (0.00)
TRANSVERSE SINUS THROMBOSIS	1 (0.02)		1 (0.00)		2 (0.00)
TRAUMATIC HAEMATOMA				1 (0.01)	1 (0.00)
TRAUMATIC HAEMORRHAGE			1 (0.00)		1 (0.00)
TRAUMATIC INTRACRANIAL HAEMORRHAGE				1 (0.01)	1 (0.00)
TREATMENT NONCOMPLIANCE	7 (0.12)	69 (0.40)	16 (0.05)		92 (0.15)
TREATMENT RELATED SECONDARY MALIGNANCY			1 (0.00)		1 (0.00)
TREMOR	2 (0.03)	5 (0.03)	10 (0.03)	4 (0.05)	21 (0.03)
TRIGEMINAL NEURALGIA			3 (0.01)		3 (0.00)
TRIGEMINAL PALSYP			1 (0.00)		1 (0.00)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
TRIPLE VESSEL BYPASS GRAFT			1 (0.00)		1 (0.00)
TUBAL LIGATION		1 (0.01)			1 (0.00)
TUBERCULOSIS	1 (0.02)	14 (0.08)	7 (0.02)	1 (0.01)	23 (0.04)
TUBERCULOSIS GASTROINTESTINAL		1 (0.01)		1 (0.01)	2 (0.00)
TUBO-OVARIAN ABSCESS	1 (0.02)				1 (0.00)
TUMOUR LYSIS SYNDROME			6 (0.02)		6 (0.01)
TYPE I HYPERSENSITIVITY			2 (0.01)		2 (0.00)
TYPE IV HYPERSENSITIVITY REACTION		1 (0.01)			1 (0.00)
ULCER			3 (0.01)		3 (0.00)
ULCER HAEMORRHAGE			2 (0.01)	1 (0.01)	3 (0.00)
ULCERATIVE KERATITIS			3 (0.01)		3 (0.00)
UMBILICAL HERNIA			1 (0.00)		1 (0.00)
UNEVALUABLE EVENT	2 (0.03)	40 (0.23)	49 (0.16)	21 (0.27)	112 (0.18)
UNINTENDED PREGNANCY		1 (0.01)			1 (0.00)
UNRESPONSIVE TO VERBAL STIMULI	1 (0.02)				1 (0.00)
UPPER GASTROINTESTINAL HAEMORRHAGE		4 (0.02)		3 (0.04)	7 (0.01)
UPPER LIMB FRACTURE			3 (0.01)	3 (0.04)	6 (0.01)
UPPER RESPIRATORY TRACT INFECTION	2 (0.03)		2 (0.01)		4 (0.01)
URETERIC STENOSIS		1 (0.01)			1 (0.00)
URETHRAL CANCER		1 (0.01)			1 (0.00)
URETHRAL DISCHARGE			1 (0.00)		1 (0.00)
URETHRAL FISTULA			1 (0.00)		1 (0.00)
URETHRAL ULCER			2 (0.01)	1 (0.01)	3 (0.00)
URINARY INCONTINENCE	2 (0.03)	2 (0.01)	3 (0.01)	1 (0.01)	8 (0.01)
URINARY RETENTION		2 (0.01)	6 (0.02)	3 (0.04)	11 (0.02)
URINARY TRACT INFECTION	1 (0.02)	1 (0.01)	6 (0.02)	3 (0.04)	11 (0.02)
URINE COLOUR ABNORMAL		1 (0.01)			1 (0.00)
URINE FLOW DECREASED		1 (0.01)	1 (0.00)		2 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
URINE ODOUR ABNORMAL		1 (0.01)			1 (0.00)
UROSEPSIS		1 (0.01)	1 (0.00)		2 (0.00)
URTICARIA	6 (0.10)	25 (0.15)	31 (0.10)	4 (0.05)	66 (0.11)
URTICARIA GENERALISED	1 (0.02)		1 (0.00)		2 (0.00)
UTERINE CANCER		1 (0.01)		1 (0.01)	2 (0.00)
UTERINE LEIOMYOMA		1 (0.01)		2 (0.03)	3 (0.00)
UTERINE LEIOMYOSARCOMA			2 (0.01)		2 (0.00)
UTERINE PERFORATION	10 (0.17)	27 (0.16)			37 (0.06)
UTERINE POLYP			1 (0.00)		1 (0.00)
UTERINE PROLAPSE			2 (0.01)		2 (0.00)
UVEITIS		1 (0.01)	4 (0.01)	1 (0.01)	6 (0.01)
VACCINATION COMPLICATION		1 (0.01)			1 (0.00)
VAGINAL BURNING SENSATION	45 (0.76)	124 (0.73)	6 (0.02)	4 (0.05)	179 (0.29)
VAGINAL DISCHARGE	9 (0.15)	16 (0.09)	3 (0.01)		28 (0.05)
VAGINAL DISORDER		1 (0.01)			1 (0.00)
VAGINAL HAEMORRHAGE	8 (0.14)	8 (0.05)	3 (0.01)		19 (0.03)
VAGINAL INFECTION	1 (0.02)				1 (0.00)
VAGINAL INFLAMMATION		3 (0.02)			3 (0.00)
VAGINAL MUCOSAL BLISTERING	3 (0.05)				3 (0.00)
VAGINAL OEDEMA		9 (0.05)			9 (0.01)
VAGINAL OPERATION		1 (0.01)			1 (0.00)
VAGINAL PAIN	6 (0.10)	18 (0.11)	2 (0.01)	3 (0.04)	29 (0.05)
VAGINAL PROLAPSE			1 (0.00)		1 (0.00)
VAGINAL SWELLING	69 (1.17)	54 (0.32)	9 (0.03)		132 (0.22)
VAGINITIS BACTERIAL		3 (0.02)			3 (0.00)
VARICOSE ULCERATION				1 (0.01)	1 (0.00)
VARICOSE VEIN		1 (0.01)			1 (0.00)
VASCULAR BYPASS GRAFT			1 (0.00)		1 (0.00)

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
VASCULAR PSEUDOANEURYSM		1 (0.01)			1 (0.00)
VASCULAR PURPURA	2 (0.03)				2 (0.00)
VASCULAR STENT INSERTION			1 (0.00)		1 (0.00)
VASCULITIS		2 (0.01)	1 (0.00)	1 (0.01)	4 (0.01)
VEIN DISORDER		1 (0.01)			1 (0.00)
VENA CAVA THROMBOSIS			2 (0.01)		2 (0.00)
VENOOCCLUSIVE DISEASE	1 (0.02)		2 (0.01)		3 (0.00)
VENOOCCLUSIVE LIVER DISEASE				1 (0.01)	1 (0.00)
VENOUS THROMBOSIS		1 (0.01)	1 (0.00)		2 (0.00)
VENOUS THROMBOSIS LIMB		2 (0.01)	3 (0.01)		5 (0.01)
VENTRICULAR ARRHYTHMIA			1 (0.00)		1 (0.00)
VENTRICULAR ASYSTOLE				1 (0.01)	1 (0.00)
VENTRICULAR EXTRASYSTOLES	1 (0.02)		3 (0.01)		4 (0.01)
VENTRICULAR FAILURE			1 (0.00)		1 (0.00)
VENTRICULAR FIBRILLATION		1 (0.01)	5 (0.02)	3 (0.04)	9 (0.01)
VENTRICULAR SEPTAL DEFECT	1 (0.02)				1 (0.00)
VENTRICULAR TACHYCARDIA	1 (0.02)	1 (0.01)	5 (0.02)		7 (0.01)
VERTIGO		1 (0.01)	5 (0.02)		6 (0.01)
VERTIGO POSITIONAL			1 (0.00)		1 (0.00)
VESSEL PUNCTURE SITE HAEMORRHAGE			1 (0.00)		1 (0.00)
VICTIM OF ABUSE		1 (0.01)			1 (0.00)
VIRAL INFECTION	1 (0.02)		1 (0.00)		2 (0.00)
VIRAL LOAD INCREASED		1 (0.01)			1 (0.00)
VISCERAL LEISHMANIASIS			1 (0.00)		1 (0.00)
VISION BLURRED	3 (0.05)	14 (0.08)	14 (0.05)	7 (0.09)	38 (0.06)
VISUAL ACUITY REDUCED	3 (0.05)		10 (0.03)	2 (0.03)	15 (0.02)
VISUAL ACUITY TESTS ABNORMAL		1 (0.01)			1 (0.00)
VISUAL DISTURBANCE		5 (0.03)	5 (0.02)	2 (0.03)	12 (0.02)

Reaction Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
VISUAL FIELD DEFECT	1 (0.02)	1 (0.01)	3 (0.01)		5 (0.01)
VITREOUS DETACHMENT			4 (0.01)		4 (0.01)
VITREOUS FLOATERS			1 (0.00)		1 (0.00)
VITREOUS HAEMORRHAGE			3 (0.01)	3 (0.04)	6 (0.01)
VOCAL CORD PARALYSIS		1 (0.01)			1 (0.00)
VOCAL CORD PARESIS		1 (0.01)			1 (0.00)
VOGT-KOYANAGI-HARADA SYNDROME		4 (0.02)			4 (0.01)
VOMITING	4 (0.07)	5 (0.03)	8 (0.03)	1 (0.01)	18 (0.03)
VULVAL OEDEMA	51 (0.86)	33 (0.19)	3 (0.01)		87 (0.14)
VULVAL ULCERATION	1 (0.02)				1 (0.00)
VULVOVAGINAL DISCOMFORT	3 (0.05)	3 (0.02)			6 (0.01)
WATER INTOXICATION		2 (0.01)			2 (0.00)
WEIGHT DECREASED	2 (0.03)	17 (0.10)	41 (0.14)	3 (0.04)	63 (0.10)
WEIGHT INCREASED	3 (0.05)	10 (0.06)	12 (0.04)	2 (0.03)	27 (0.04)
WERNICKE'S ENCEPHALOPATHY			1 (0.00)		1 (0.00)
WHEEZING				1 (0.01)	1 (0.00)
WHITE BLOOD CELL COUNT DECREASED	7 (0.12)	3 (0.02)	5 (0.02)	3 (0.04)	18 (0.03)
WHITE BLOOD CELL COUNT INCREASED		2 (0.01)	1 (0.00)	2 (0.03)	5 (0.01)
WOUND DEHISCENCE		1 (0.01)			1 (0.00)
WOUND INFECTION			3 (0.01)	1 (0.01)	4 (0.01)
WOUND INFECTION STAPHYLOCOCCAL			1 (0.00)		1 (0.00)
WOUND NECROSIS				1 (0.01)	1 (0.00)
WRIST FRACTURE			1 (0.00)		1 (0.00)
WRONG DRUG ADMINISTERED	1 (0.02)		1 (0.00)		2 (0.00)
WRONG TECHNIQUE IN DRUG USAGE PROCESS				2 (0.03)	2 (0.00)
XANTHOPSIA			1 (0.00)		1 (0.00)
YAWNING	1 (0.02)	2 (0.01)			3 (0.00)

Outcome Summary Table Derived Age Group

		<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
Outcome Code	Congenital Anomaly	82 (1.65)	32 (0.23)	9 (0.03)		123 (0.24)
	Death	542 (10.89)	1445 (10.41)	3677 (14.14)	1496 (21.94)	7160 (13.86)
	Disability	475 (9.54)	1570 (11.31)	2741 (10.54)	358 (5.25)	5144 (9.95)
	Hospitalization - Initial or Prolonged	1812 (36.39)	5931 (42.73)	12620 (48.54)	3239 (47.49)	23602 (45.67)
	Life-Threatening	163 (3.27)	347 (2.50)	480 (1.85)	177 (2.60)	1167 (2.26)
	Other	1826 (36.67)	4390 (31.63)	6278 (24.15)	1513 (22.18)	14007 (27.10)
	Required Intervention to Prevent Permanent Impairment/Damage	79 (1.59)	164 (1.18)	194 (0.75)	37 (0.54)	474 (0.92)

Report Source Summary Table

Derived Age Group

		<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
Report Source	Foreign	912 (35.23)	1640 (22.36)	3162 (23.70)	970 (26.44)	6684 (24.82)
	Study	16 (0.62)	122 (1.66)	202 (1.51)	33 (0.90)	373 (1.38)
	Literature	38 (1.47)	26 (0.35)	30 (0.22)	10 (0.27)	104 (0.39)
	Consumer	504 (19.47)	3014 (41.09)	6185 (46.37)	1575 (42.93)	11278 (41.87)
	Health Professional	694 (26.81)	1715 (23.38)	2534 (19.00)	727 (19.81)	5670 (21.05)
	User Facility		2 (0.03)	1 (0.01)		3 (0.01)
	Company Representative	312 (12.05)	748 (10.20)	1114 (8.35)	332 (9.05)	2506 (9.30)
	Distributor	25 (0.97)	19 (0.26)	47 (0.35)	9 (0.25)	100 (0.37)
	Other	88 (3.40)	50 (0.68)	64 (0.48)	13 (0.35)	215 (0.80)

Therapy Summary Table
Derived Age Group

		<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
Derived Duration (Years)	N	4992	15536	27993	7117	55638
	MEAN	0.25	0.64	0.90	0.63	0.74
	MEDIAN	0.00	0.00	0.00	0.00	0.00
	GEOMETRIC MEAN	0.25	0.64	0.90	0.63	0.74
	MIN	0.00	0.00	0.00	0.00	0.00
	MAX	42.00	104.0	103.0	101.0	104.0
	STD	1.17	2.30	3.01	2.61	2.66
	RANGE	0-42	0-104	0-103	0-101	0-104

Indication Summary Table Derived Age Group

		<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
Preferred Terms	ABDOMEN SCAN			9 (0.03)	1 (0.02)	10 (0.02)
	ABDOMINAL ABSCESS		1 (0.01)	6 (0.02)		7 (0.01)
	ABDOMINAL DISCOMFORT		1 (0.01)	9 (0.03)	3 (0.05)	13 (0.02)
	ABDOMINAL DISTENSION		1 (0.01)	1 (0.00)		2 (0.00)
	ABDOMINAL HERNIA		2 (0.01)			2 (0.00)
	ABDOMINAL INFECTION		3 (0.02)	3 (0.01)	3 (0.05)	9 (0.02)
	ABDOMINAL OPERATION			1 (0.00)		1 (0.00)
	ABDOMINAL PAIN	1 (0.02)	20 (0.14)	26 (0.10)	1 (0.02)	48 (0.09)
	ABDOMINAL PAIN UPPER	2 (0.04)	11 (0.08)	18 (0.07)	3 (0.05)	34 (0.06)
	ABDOMINAL SEPSIS			2 (0.01)		2 (0.00)
	ABNORMAL BEHAVIOUR	2 (0.04)	10 (0.07)	4 (0.02)	10 (0.15)	26 (0.05)
	ABORTION	4 (0.08)	1 (0.01)			5 (0.01)
	ABORTION INDUCED	20 (0.41)	21 (0.14)			41 (0.08)
	ABORTION SPONTANEOUS		1 (0.01)			1 (0.00)
	ABSCESS	3 (0.06)		4 (0.02)		7 (0.01)
	ABSCESS INTESTINAL	1 (0.02)		1 (0.00)	1 (0.02)	3 (0.01)
	ABSCESS LIMB		1 (0.01)	1 (0.00)		2 (0.00)
	ABSCESS NECK	1 (0.02)				1 (0.00)
	ACARODERMATITIS			4 (0.02)	9 (0.14)	13 (0.02)
	ACCIDENT			1 (0.00)		1 (0.00)
	ACCIDENT AT WORK		1 (0.01)	2 (0.01)		3 (0.01)
	ACCIDENTAL DRUG INTAKE BY CHILD	3 (0.06)				3 (0.01)
	ACCIDENTAL EXPOSURE	19 (0.39)	3 (0.02)	1 (0.00)	1 (0.02)	24 (0.05)
	ACCIDENTAL OVERDOSE	5 (0.10)	2 (0.01)			7 (0.01)
	ACIDOSIS	1 (0.02)		1 (0.00)	1 (0.02)	3 (0.01)
	ACINETOBACTER BACTERAEMIA			2 (0.01)		2 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
ACINETOBACTER INFECTION			4 (0.02)	2 (0.03)	6 (0.01)
ACNE	345 (7.14)	81 (0.55)	8 (0.03)		434 (0.82)
ACNE CONGLOBATA	2 (0.04)				2 (0.00)
ACNE CYSTIC	18 (0.37)	8 (0.05)	1 (0.00)		27 (0.05)
ACQUIRED HAEMOPHILIA			5 (0.02)	3 (0.05)	8 (0.02)
ACQUIRED HAEMOPHILIA WITH ANTI FVIII, XI, OR			1 (0.00)	2 (0.03)	3 (0.01)
ACQUIRED IMMUNODEFICIENCY SYNDROME	8 (0.17)	20 (0.14)	18 (0.07)		46 (0.09)
ACROMEGALY	1 (0.02)	13 (0.09)	10 (0.04)		24 (0.05)
ACTINIC KERATOSIS			5 (0.02)	1 (0.02)	6 (0.01)
ACUTE CORONARY SYNDROME		4 (0.03)	39 (0.15)	10 (0.15)	53 (0.10)
ACUTE ENDOCARDITIS				1 (0.02)	1 (0.00)
ACUTE LEUKAEMIA	2 (0.04)	1 (0.01)			3 (0.01)
ACUTE LYMPHOCYTIC LEUKAEMIA	54 (1.12)	18 (0.12)	3 (0.01)	1 (0.02)	76 (0.14)
ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT	3 (0.06)				3 (0.01)
ACUTE MYELOID LEUKAEMIA	8 (0.17)	69 (0.47)	195 (0.73)	54 (0.82)	326 (0.62)
ACUTE MYELOID LEUKAEMIA RECURRENT	1 (0.02)	7 (0.05)	14 (0.05)	1 (0.02)	23 (0.04)
ACUTE MYELOMONOCYTIC LEUKAEMIA		1 (0.01)	2 (0.01)		3 (0.01)
ACUTE MYOCARDIAL INFARCTION		27 (0.18)	146 (0.55)	43 (0.65)	216 (0.41)
ACUTE PROMYELOCYTIC LEUKAEMIA	4 (0.08)	13 (0.09)	18 (0.07)		35 (0.07)
ACUTE PSYCHOSIS	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.01)
ACUTE RESPIRATORY DISTRESS SYNDROME	5 (0.10)				5 (0.01)
ACUTE RESPIRATORY FAILURE				1 (0.02)	1 (0.00)
ACUTE SINUSITIS	5 (0.10)	5 (0.03)	1 (0.00)		11 (0.02)
ACUTE TONSILLITIS		10 (0.07)	2 (0.01)		12 (0.02)
ADENOCARCINOMA			12 (0.05)	2 (0.03)	14 (0.03)
ADENOCARCINOMA PANCREAS			13 (0.05)		13 (0.02)
ADENOIDAL HYPERTROPHY	1 (0.02)				1 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
ADENOMYOSIS		2 (0.01)			2 (0.00)
ADHERENT LEUKOMA				1 (0.02)	1 (0.00)
ADHESION		1 (0.01)			1 (0.00)
ADJUSTMENT DISORDER		1 (0.01)		1 (0.02)	2 (0.00)
ADNEXA UTERI PAIN		1 (0.01)			1 (0.00)
ADRENAL CARCINOMA	2 (0.04)		1 (0.00)		3 (0.01)
ADRENAL CORTICAL INSUFFICIENCY		1 (0.01)			1 (0.00)
ADRENAL GLAND CANCER METASTATIC		1 (0.01)			1 (0.00)
ADRENAL INSUFFICIENCY			3 (0.01)		3 (0.01)
ADRENOCORTICAL INSUFFICIENCY CHRONIC			2 (0.01)		2 (0.00)
ADRENOGENITAL SYNDROME	2 (0.04)	3 (0.02)			5 (0.01)
ADULT T-CELL LYMPHOMA/LEUKAEMIA		2 (0.01)	1 (0.00)		3 (0.01)
ADULT T-CELL LYMPHOMA/LEUKAEMIA REFRACTORY		2 (0.01)			2 (0.00)
ADVERSE DRUG REACTION	1 (0.02)	1 (0.01)	4 (0.02)		6 (0.01)
ADVERSE EVENT			1 (0.00)		1 (0.00)
AFFECT LABILITY	2 (0.04)				2 (0.00)
AFFECTIVE DISORDER	20 (0.41)	25 (0.17)	14 (0.05)	2 (0.03)	61 (0.12)
AGGRESSION	10 (0.21)	6 (0.04)	5 (0.02)		21 (0.04)
AGITATION	11 (0.23)	12 (0.08)	19 (0.07)	10 (0.15)	52 (0.10)
AGORAPHOBIA		2 (0.01)	1 (0.00)		3 (0.01)
AGRANULOCYTOSIS		1 (0.01)	2 (0.01)	1 (0.02)	4 (0.01)
AIDS RELATED COMPLICATION		1 (0.01)			1 (0.00)
AKATHISIA	2 (0.04)	1 (0.01)	1 (0.00)		4 (0.01)
ALCOHOL DETOXIFICATION		1 (0.01)			1 (0.00)
ALCOHOL POISONING		1 (0.01)			1 (0.00)
ALCOHOL USE		2 (0.01)	1 (0.00)		3 (0.01)
ALCOHOL WITHDRAWAL SYNDROME		5 (0.03)	6 (0.02)		11 (0.02)

Indication Summary Table

Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
ALCOHOLIC LIVER DISEASE			3 (0.01)		3 (0.01)
ALCOHOLISM	2 (0.04)	20 (0.14)	10 (0.04)	1 (0.02)	33 (0.06)
ALLERGENIC DESENSITISATION PROCEDURE		1 (0.01)			1 (0.00)
ALLERGIC SINUSITIS		1 (0.01)	3 (0.01)		4 (0.01)
ALLERGY TEST	1 (0.02)	1 (0.01)			2 (0.00)
ALLOGENIC BONE MARROW TRANSPLANTATION THERAPY	3 (0.06)	1 (0.01)	2 (0.01)		6 (0.01)
ALLOIMMUNISATION	1 (0.02)				1 (0.00)
ALOPECIA	8 (0.17)	19 (0.13)	12 (0.05)	4 (0.06)	43 (0.08)
ALPHA-1 ANTI-TRYPSIN DEFICIENCY		2 (0.01)			2 (0.00)
ALVEOLITIS		4 (0.03)			4 (0.01)
AMAUROSIS FUGAX			1 (0.00)		1 (0.00)
AMENORRHOEA		2 (0.01)			2 (0.00)
AMNESIA		2 (0.01)	9 (0.03)	20 (0.30)	31 (0.06)
AMPUTATION			1 (0.00)		1 (0.00)
AMYLOIDOSIS			2 (0.01)	2 (0.03)	4 (0.01)
AMYOTROPHIC LATERAL SCLEROSIS			7 (0.03)	1 (0.02)	8 (0.02)
ANAEMIA	3 (0.06)	14 (0.10)	48 (0.18)	13 (0.20)	78 (0.15)
ANAEMIA HAEMOLYTIC AUTOIMMUNE	3 (0.06)	1 (0.01)	3 (0.01)		7 (0.01)
ANAEMIA OF MALIGNANT DISEASE	1 (0.02)	6 (0.04)	4 (0.02)		11 (0.02)
ANAEMIA POSTOPERATIVE				1 (0.02)	1 (0.00)
ANAEMIA PROPHYLAXIS		1 (0.01)			1 (0.00)
ANAEMIA VITAMIN B12 DEFICIENCY			4 (0.02)		4 (0.01)
ANAESTHESIA	15 (0.31)	31 (0.21)	36 (0.14)	3 (0.05)	85 (0.16)
ANAESTHESIA REVERSAL			1 (0.00)		1 (0.00)
ANAESTHETIC PREMEDICATION		3 (0.02)	1 (0.00)		4 (0.01)
ANAL CANCER		2 (0.01)			2 (0.00)
ANAL CANCER METASTATIC		2 (0.01)	1 (0.00)		3 (0.01)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ANAL FISSURE		3 (0.02)			3 (0.01)
ANAL FISTULA	1 (0.02)				1 (0.00)
ANALGESIC EFFECT	6 (0.12)	39 (0.27)	76 (0.29)	13 (0.20)	134 (0.25)
ANALGESIC INTERVENTION SUPPORTIVE THERAPY			3 (0.01)		3 (0.01)
ANALGESIC THERAPY		2 (0.01)	4 (0.02)		6 (0.01)
ANAPHYLACTIC REACTION		2 (0.01)	1 (0.00)		3 (0.01)
ANAPLASTIC ASTROCYTOMA			4 (0.02)		4 (0.01)
ANDROGEN DEFICIENCY			1 (0.00)		1 (0.00)
ANEURYSM			1 (0.00)		1 (0.00)
ANGELMAN'S SYNDROME	1 (0.02)				1 (0.00)
ANGER	1 (0.02)	2 (0.01)	1 (0.00)		4 (0.01)
ANGINA PECTORIS		13 (0.09)	84 (0.32)	46 (0.70)	143 (0.27)
ANGINA UNSTABLE			11 (0.04)	11 (0.17)	22 (0.04)
ANGIODYSPLASIA			2 (0.01)		2 (0.00)
ANGIOGRAM		2 (0.01)	6 (0.02)	3 (0.05)	11 (0.02)
ANGIOGRAM CEREBRAL			3 (0.01)		3 (0.01)
ANGIOGRAM RETINA	1 (0.02)				1 (0.00)
ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA			3 (0.01)		3 (0.01)
ANGIONEUROTIC OEDEMA		1 (0.01)	2 (0.01)		3 (0.01)
ANGIOPATHY			9 (0.03)	1 (0.02)	10 (0.02)
ANGIOPLASTY		1 (0.01)	10 (0.04)	5 (0.08)	16 (0.03)
ANGIOSARCOMA		1 (0.01)			1 (0.00)
ANKLE OPERATION		1 (0.01)	2 (0.01)		3 (0.01)
ANKYLOSING SPONDYLITIS	2 (0.04)	41 (0.28)	39 (0.15)	4 (0.06)	86 (0.16)
ANORECTAL INFECTION		1 (0.01)			1 (0.00)
ANOREXIA	1 (0.02)	3 (0.02)	4 (0.02)	3 (0.05)	11 (0.02)
ANORGASMIA				2 (0.03)	2 (0.00)
ANOVULATORY CYCLE		2 (0.01)			2 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
ANTACID THERAPY		4 (0.03)	4 (0.02)		8 (0.02)
ANTI-INFECTIVE THERAPY			1 (0.00)		1 (0.00)
ANTIALLERGIC THERAPY			4 (0.02)		4 (0.01)
ANTIANDROGEN THERAPY			1 (0.00)		1 (0.00)
ANTIBIOTIC LEVEL THERAPEUTIC		2 (0.01)	1 (0.00)		3 (0.01)
ANTIBIOTIC PROPHYLAXIS	5 (0.10)	17 (0.12)	26 (0.10)	2 (0.03)	50 (0.09)
ANTICOAGULANT THERAPY	2 (0.04)	13 (0.09)	66 (0.25)	18 (0.27)	99 (0.19)
ANTICOAGULATION DRUG LEVEL			1 (0.00)	2 (0.03)	3 (0.01)
ANTIDEPRESSANT THERAPY		7 (0.05)	9 (0.03)		16 (0.03)
ANTIEMETIC SUPPORTIVE CARE		4 (0.03)	7 (0.03)	7 (0.11)	18 (0.03)
ANTIFUNGAL PROPHYLAXIS		7 (0.05)	5 (0.02)		12 (0.02)
ANTIINFLAMMATORY THERAPY		7 (0.05)	4 (0.02)		11 (0.02)
ANTINEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE				1 (0.02)	1 (0.00)
ANTIPHOSPHOLIPID ANTIBODIES POSITIVE			2 (0.01)		2 (0.00)
ANTIPHOSPHOLIPID SYNDROME		5 (0.03)			5 (0.01)
ANTIPLATELET THERAPY			13 (0.05)	6 (0.09)	19 (0.04)
ANTIPSYCHOTIC DRUG LEVEL INCREASED			1 (0.00)		1 (0.00)
ANTIPYRESIS	6 (0.12)				6 (0.01)
ANTITUSSIVE THERAPY			2 (0.01)		2 (0.00)
ANTIVIRAL PROPHYLAXIS	65 (1.34)	10 (0.07)	2 (0.01)		77 (0.15)
ANXIETY	40 (0.83)	241 (1.65)	228 (0.86)	51 (0.78)	560 (1.06)
ANXIETY DISORDER	3 (0.06)	14 (0.10)	29 (0.11)	3 (0.05)	49 (0.09)
AORTIC ANEURYSM			2 (0.01)		2 (0.00)
AORTIC ANEURYSM REPAIR			2 (0.01)		2 (0.00)
AORTIC DISSECTION			6 (0.02)		6 (0.01)
AORTIC THROMBOSIS			1 (0.00)		1 (0.00)
AORTIC VALVE INCOMPETENCE		1 (0.01)	1 (0.00)		2 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
AORTIC VALVE REPLACEMENT		1 (0.01)	5 (0.02)	2 (0.03)	8 (0.02)
AORTIC VALVE STENOSIS		1 (0.01)	1 (0.00)		2 (0.00)
APHTHOUS STOMATITIS	1 (0.02)				1 (0.00)
APLASIA PURE RED CELL	1 (0.02)			1 (0.02)	2 (0.00)
APLASTIC ANAEMIA	2 (0.04)	3 (0.02)	2 (0.01)	2 (0.03)	9 (0.02)
APPENDICITIS	1 (0.02)				1 (0.00)
APPETITE DISORDER				1 (0.02)	1 (0.00)
APPLICATION SITE ANAESTHESIA	1 (0.02)				1 (0.00)
ARACHNOIDITIS		1 (0.01)	2 (0.01)		3 (0.01)
ARRHYTHMIA	2 (0.04)	2 (0.01)	35 (0.13)	25 (0.38)	64 (0.12)
ARRHYTHMIA PROPHYLAXIS			2 (0.01)	1 (0.02)	3 (0.01)
ARRHYTHMIA SUPRAVENTRICULAR				2 (0.03)	2 (0.00)
ARTERIAL BYPASS OPERATION			1 (0.00)		1 (0.00)
ARTERIAL DISORDER			4 (0.02)	3 (0.05)	7 (0.01)
ARTERIAL OCCLUSIVE DISEASE			3 (0.01)	1 (0.02)	4 (0.01)
ARTERIAL STENOSIS			5 (0.02)		5 (0.01)
ARTERIAL STENT INSERTION			1 (0.00)		1 (0.00)
ARTERIAL THROMBOSIS			1 (0.00)		1 (0.00)
ARTERIAL THROMBOSIS LIMB			1 (0.00)		1 (0.00)
ARTERIOGRAM		1 (0.01)			1 (0.00)
ARTERIOGRAM CAROTID			2 (0.01)	1 (0.02)	3 (0.01)
ARTERIOGRAM CORONARY		2 (0.01)	7 (0.03)	1 (0.02)	10 (0.02)
ARTERIOSCLEROSIS		3 (0.02)	9 (0.03)	3 (0.05)	15 (0.03)
ARTERIOSCLEROSIS CORONARY ARTERY				1 (0.02)	1 (0.00)
ARTERIOSCLEROSIS OBLITERANS			7 (0.03)	9 (0.14)	16 (0.03)
ARTERIOVENOUS GRAFT SITE INFECTION		1 (0.01)			1 (0.00)
ARTERITIS			5 (0.02)	1 (0.02)	6 (0.01)
ARTHRALGIA	8 (0.17)	347 (2.38)	1156 (4.34)	191 (2.90)	1702 (3.23)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
ARTHRITIS	9 (0.19)	679 (4.65)	3063 (11.50)	570 (8.66)	4321 (8.21)
ARTHRITIS BACTERIAL		4 (0.03)	8 (0.03)		12 (0.02)
ARTHRITIS INFECTIVE		2 (0.01)	3 (0.01)	1 (0.02)	6 (0.01)
ARTHRITIS REACTIVE				1 (0.02)	1 (0.00)
ARTHRODESIS		2 (0.01)			2 (0.00)
ARTHROGRAM			1 (0.00)		1 (0.00)
ARTHROPATHY		9 (0.06)	33 (0.12)	10 (0.15)	52 (0.10)
ARTHROPOD BITE		2 (0.01)	3 (0.01)		5 (0.01)
ARTHROPOD STING		2 (0.01)	4 (0.02)	1 (0.02)	7 (0.01)
ARTIFICIAL MENOPAUSE		1 (0.01)			1 (0.00)
ASBESTOSIS			2 (0.01)	1 (0.02)	3 (0.01)
ASCITES		4 (0.03)	10 (0.04)		14 (0.03)
ASCITES INFECTION	1 (0.02)				1 (0.00)
ASPERGER'S DISORDER	2 (0.04)				2 (0.00)
ASPERGILLOMA				3 (0.05)	3 (0.01)
ASPERGILLOSIS	2 (0.04)	3 (0.02)	16 (0.06)	4 (0.06)	25 (0.05)
ASSISTED FERTILISATION	3 (0.06)	1 (0.01)			4 (0.01)
ASTHENIA	2 (0.04)	4 (0.03)	7 (0.03)	2 (0.03)	15 (0.03)
ASTHMA	145 (3.00)	159 (1.09)	209 (0.78)	53 (0.81)	566 (1.08)
ASTROCYTOMA	1 (0.02)	2 (0.01)	5 (0.02)		8 (0.02)
ATELECTASIS			1 (0.00)		1 (0.00)
ATRIAL FIBRILLATION	1 (0.02)	25 (0.17)	183 (0.69)	133 (2.02)	342 (0.65)
ATRIAL FLUTTER		2 (0.01)	25 (0.09)	17 (0.26)	44 (0.08)
ATRIAL SEPTAL DEFECT			2 (0.01)		2 (0.00)
ATRIAL SEPTAL DEFECT REPAIR	1 (0.02)				1 (0.00)
ATRIAL TACHYCARDIA		1 (0.01)	1 (0.00)	1 (0.02)	3 (0.01)
ATRIAL THROMBOSIS	1 (0.02)				1 (0.00)
ATRIOVENTRICULAR BLOCK				1 (0.02)	1 (0.00)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
ATROPHIC VULVOVAGINITIS			1 (0.00)		1 (0.00)
ATTENTION DEFICIT/HYPERACTIVITY DISORDER	230 (4.76)	36 (0.25)	26 (0.10)		292 (0.55)
ATYPICAL MYCOBACTERIAL INFECTION			3 (0.01)	1 (0.02)	4 (0.01)
ATYPICAL MYCOBACTERIAL LYMPHADENITIS			2 (0.01)		2 (0.00)
AUTISM	6 (0.12)				6 (0.01)
AUTOIMMUNE DISORDER		1 (0.01)	3 (0.01)		4 (0.01)
AUTOIMMUNE HEPATITIS		2 (0.01)	1 (0.00)		3 (0.01)
AUTOIMMUNE THYROIDITIS		2 (0.01)	6 (0.02)		8 (0.02)
AUTOMATISM		1 (0.01)			1 (0.00)
AUTONOMIC NERVOUS SYSTEM IMBALANCE		1 (0.01)	3 (0.01)	2 (0.03)	6 (0.01)
AUTONOMIC NEUROPATHY		2 (0.01)			2 (0.00)
B PRECURSOR TYPE ACUTE LEUKAEMIA		2 (0.01)			2 (0.00)
B-CELL LYMPHOMA	1 (0.02)	7 (0.05)	23 (0.09)	4 (0.06)	35 (0.07)
B-CELL SMALL LYMPHOCYTIC LYMPHOMA			1 (0.00)		1 (0.00)
BACILLUS INFECTION			1 (0.00)		1 (0.00)
BACK DISORDER		17 (0.12)	40 (0.15)	2 (0.03)	59 (0.11)
BACK INJURY	1 (0.02)	41 (0.28)	34 (0.13)		76 (0.14)
BACK PAIN	6 (0.12)	486 (3.33)	872 (3.27)	117 (1.78)	1481 (2.81)
BACTERAEMIA		3 (0.02)	8 (0.03)	1 (0.02)	12 (0.02)
BACTERIA BLOOD IDENTIFIED				1 (0.02)	1 (0.00)
BACTERIAL CULTURE POSITIVE	1 (0.02)				1 (0.00)
BACTERIAL INFECTION	3 (0.06)	14 (0.10)	28 (0.11)	6 (0.09)	51 (0.10)
BARIUM ENEMA			1 (0.00)		1 (0.00)
BARRETT'S OESOPHAGUS		2 (0.01)	5 (0.02)		7 (0.01)
BARTHOLINITIS			1 (0.00)		1 (0.00)
BARTTER'S SYNDROME		1 (0.01)			1 (0.00)
BASAL CELL CARCINOMA		2 (0.01)	3 (0.01)	1 (0.02)	6 (0.01)
BASEDOW'S DISEASE		10 (0.07)	2 (0.01)		12 (0.02)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
BENIGN NEOPLASM			1 (0.00)		1 (0.00)
BENIGN NEOPLASM OF PROSTATE			3 (0.01)		3 (0.01)
BENIGN PROSTATIC HYPERPLASIA			131 (0.49)	71 (1.08)	202 (0.38)
BEREAVEMENT REACTION				1 (0.02)	1 (0.00)
BETA HAEMOLYTIC STREPTOCOCCAL INFECTION		1 (0.01)			1 (0.00)
BILE DUCT CANCER		1 (0.01)	5 (0.02)	2 (0.03)	8 (0.02)
BILE DUCT OBSTRUCTION		3 (0.02)			3 (0.01)
BILIARY CANCER METASTATIC			1 (0.00)		1 (0.00)
BILIARY CIRRHOSIS			1 (0.00)		1 (0.00)
BILIARY CIRRHOSIS PRIMARY			5 (0.02)	1 (0.02)	6 (0.01)
BILIARY NEOPLASM			2 (0.01)		2 (0.00)
BILOMA			1 (0.00)		1 (0.00)
BIOPSY			2 (0.01)		2 (0.00)
BIPOLAR DISORDER	164 (3.39)	504 (3.45)	233 (0.87)	20 (0.30)	921 (1.75)
BIPOLAR I DISORDER	14 (0.29)	34 (0.23)	18 (0.07)	4 (0.06)	70 (0.13)
BIPOLAR II DISORDER	6 (0.12)	9 (0.06)	2 (0.01)		17 (0.03)
BLADDER ADENOCARCINOMA STAGE UNSPECIFIED			1 (0.00)		1 (0.00)
BLADDER CANCER		1 (0.01)	72 (0.27)	24 (0.36)	97 (0.18)
BLADDER CANCER RECURRENT			6 (0.02)		6 (0.01)
BLADDER DISORDER		2 (0.01)	7 (0.03)	7 (0.11)	16 (0.03)
BLADDER DISTENSION				1 (0.02)	1 (0.00)
BLADDER IRRIGATION			1 (0.00)		1 (0.00)
BLADDER NEOPLASM		1 (0.01)	1 (0.00)	1 (0.02)	3 (0.01)
BLADDER SPASM	1 (0.02)	3 (0.02)	3 (0.01)	1 (0.02)	8 (0.02)
BLAST CRISIS IN MYELOGENOUS LEUKAEMIA			3 (0.01)		3 (0.01)
BLASTOMYCOSIS	1 (0.02)		1 (0.00)		2 (0.00)
BLEPHARITIS			1 (0.00)		1 (0.00)
BLIGHTED OVUM		1 (0.01)			1 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
BLISTER	1 (0.02)		2 (0.01)	1 (0.02)	4 (0.01)
BLOOD BETA-D-GLUCAN INCREASED			5 (0.02)	2 (0.03)	7 (0.01)
BLOOD CALCIUM	1 (0.02)				1 (0.00)
BLOOD CALCIUM DECREASED			2 (0.01)		2 (0.00)
BLOOD CHOLESTEROL		26 (0.18)	87 (0.33)	15 (0.23)	128 (0.24)
BLOOD CHOLESTEROL ABNORMAL		3 (0.02)	8 (0.03)	3 (0.05)	14 (0.03)
BLOOD CHOLESTEROL DECREASED			1 (0.00)		1 (0.00)
BLOOD CHOLESTEROL INCREASED		96 (0.66)	454 (1.70)	120 (1.82)	670 (1.27)
BLOOD CORTISOL DECREASED		1 (0.01)			1 (0.00)
BLOOD DISORDER		1 (0.01)	1 (0.00)		2 (0.00)
BLOOD GLUCOSE			4 (0.02)	1 (0.02)	5 (0.01)
BLOOD GLUCOSE ABNORMAL		3 (0.02)	2 (0.01)		5 (0.01)
BLOOD GLUCOSE DECREASED			1 (0.00)		1 (0.00)
BLOOD GLUCOSE INCREASED	1 (0.02)	2 (0.01)	3 (0.01)	3 (0.05)	9 (0.02)
BLOOD GROWTH HORMONE	3 (0.06)				3 (0.01)
BLOOD GROWTH HORMONE DECREASED		1 (0.01)			1 (0.00)
BLOOD GROWTH HORMONE INCREASED		1 (0.01)			1 (0.00)
BLOOD HOMOCYSTEINE INCREASED		1 (0.01)	3 (0.01)		4 (0.01)
BLOOD HUMAN CHORIONIC GONADOTROPIN INCREASED		1 (0.01)			1 (0.00)
BLOOD IMMUNOGLOBULIN G DECREASED		1 (0.01)	1 (0.00)		2 (0.00)
BLOOD IRON		1 (0.01)	1 (0.00)		2 (0.00)
BLOOD IRON DECREASED		2 (0.01)			2 (0.00)
BLOOD IRON INCREASED	7 (0.14)	2 (0.01)	7 (0.03)	10 (0.15)	26 (0.05)
BLOOD MAGNESIUM DECREASED			6 (0.02)		6 (0.01)
BLOOD OESTROGEN			2 (0.01)		2 (0.00)
BLOOD PHOSPHORUS INCREASED		1 (0.01)	2 (0.01)	2 (0.03)	5 (0.01)
BLOOD POTASSIUM			3 (0.01)		3 (0.01)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
BLOOD POTASSIUM ABNORMAL		1 (0.01)			1 (0.00)
BLOOD POTASSIUM DECREASED		4 (0.03)	7 (0.03)	7 (0.11)	18 (0.03)
BLOOD PRESSURE		14 (0.10)	83 (0.31)	18 (0.27)	115 (0.22)
BLOOD PRESSURE ABNORMAL		2 (0.01)	15 (0.06)	3 (0.05)	20 (0.04)
BLOOD PRESSURE DIASTOLIC INCREASED		2 (0.01)			2 (0.00)
BLOOD PRESSURE FLUCTUATION		1 (0.01)		3 (0.05)	4 (0.01)
BLOOD PRESSURE INCREASED		10 (0.07)	16 (0.06)	11 (0.17)	37 (0.07)
BLOOD PRESSURE MANAGEMENT		1 (0.01)		4 (0.06)	5 (0.01)
BLOOD PRODUCT TRANSFUSION			1 (0.00)		1 (0.00)
BLOOD PROLACTIN DECREASED		1 (0.01)			1 (0.00)
BLOOD PROLACTIN INCREASED		2 (0.01)			2 (0.00)
BLOOD TESTOSTERONE		1 (0.01)			1 (0.00)
BLOOD TESTOSTERONE DECREASED		6 (0.04)	12 (0.05)	1 (0.02)	19 (0.04)
BLOOD TRIGLYCERIDES		1 (0.01)	6 (0.02)		7 (0.01)
BLOOD TRIGLYCERIDES ABNORMAL				1 (0.02)	1 (0.00)
BLOOD TRIGLYCERIDES INCREASED		9 (0.06)	16 (0.06)	1 (0.02)	26 (0.05)
BLOOD URIC ACID INCREASED			1 (0.00)		1 (0.00)
BODY DYSMORPHIC DISORDER			1 (0.00)		1 (0.00)
BODY HEIGHT BELOW NORMAL	20 (0.41)				20 (0.04)
BODY TEMPERATURE			1 (0.00)		1 (0.00)
BODY TEMPERATURE INCREASED	1 (0.02)				1 (0.00)
BONE DENSITY DECREASED	2 (0.04)	1 (0.01)	8 (0.03)	3 (0.05)	14 (0.03)
BONE DISORDER		5 (0.03)	11 (0.04)	7 (0.11)	23 (0.04)
BONE MARROW CONDITIONING REGIMEN		6 (0.04)	6 (0.02)		12 (0.02)
BONE MARROW FAILURE	1 (0.02)				1 (0.00)
BONE MARROW TRANSPLANT	31 (0.64)	30 (0.21)	24 (0.09)		85 (0.16)
BONE MARROW TUMOUR CELL INFILTRATION				1 (0.02)	1 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
BONE NEOPLASM		1 (0.01)	2 (0.01)		3 (0.01)
BONE NEOPLASM MALIGNANT	1 (0.02)		4 (0.02)	2 (0.03)	7 (0.01)
BONE OPERATION		1 (0.01)			1 (0.00)
BONE PAIN		7 (0.05)	20 (0.08)	6 (0.09)	33 (0.06)
BONE SARCOMA	4 (0.08)	1 (0.01)	2 (0.01)	1 (0.02)	8 (0.02)
BORDERLINE MENTAL IMPAIRMENT	1 (0.02)				1 (0.00)
BORDERLINE PERSONALITY DISORDER	2 (0.04)	4 (0.03)			6 (0.01)
BORRELIA INFECTION	1 (0.02)		1 (0.00)		2 (0.00)
BOTULISM			1 (0.00)		1 (0.00)
BOVINE TUBERCULOSIS	2 (0.04)				2 (0.00)
BOWEL MOVEMENT IRREGULARITY		1 (0.01)			1 (0.00)
BOWEN'S DISEASE		2 (0.01)	1 (0.00)		3 (0.01)
BRACHIAL PLEXOPATHY			1 (0.00)		1 (0.00)
BRACHIAL PLEXUS INJURY			1 (0.00)		1 (0.00)
BRACHYTHERAPY			2 (0.01)		2 (0.00)
BRADYCARDIA				1 (0.02)	1 (0.00)
BRAIN ABSCESS	1 (0.02)		5 (0.02)		6 (0.01)
BRAIN CONTUSION			2 (0.01)		2 (0.00)
BRAIN DAMAGE		1 (0.01)			1 (0.00)
BRAIN NEOPLASM		3 (0.02)	3 (0.01)		6 (0.01)
BRAIN NEOPLASM MALIGNANT	1 (0.02)		2 (0.01)		3 (0.01)
BRAIN OEDEMA		1 (0.01)	6 (0.02)		7 (0.01)
BRAIN STEM GLIOMA	1 (0.02)				1 (0.00)
BREAKTHROUGH PAIN		1 (0.01)	4 (0.02)		5 (0.01)
BREAST CANCER	1 (0.02)	114 (0.78)	370 (1.39)	43 (0.65)	528 (1.00)
BREAST CANCER FEMALE		7 (0.05)	22 (0.08)	6 (0.09)	35 (0.07)
BREAST CANCER IN SITU		1 (0.01)	3 (0.01)		4 (0.01)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
BREAST CANCER MALE				2 (0.03)	2 (0.00)
BREAST CANCER METASTATIC		48 (0.33)	118 (0.44)	20 (0.30)	186 (0.35)
BREAST CANCER RECURRENT			10 (0.04)		10 (0.02)
BREAST CANCER STAGE I		1 (0.01)	1 (0.00)		2 (0.00)
BREAST CANCER STAGE IV		2 (0.01)	6 (0.02)		8 (0.02)
BREAST COSMETIC SURGERY		1 (0.01)			1 (0.00)
BREAST FIBROSIS		2 (0.01)			2 (0.00)
BREAST NEOPLASM				1 (0.02)	1 (0.00)
BRIEF PSYCHOTIC DISORDER WITH MARKED STRESSOR	2 (0.04)				2 (0.00)
BRONCHIAL CARCINOMA			5 (0.02)	1 (0.02)	6 (0.01)
BRONCHIAL DISORDER		1 (0.01)	2 (0.01)	1 (0.02)	4 (0.01)
BRONCHIAL HYPERACTIVITY	1 (0.02)				1 (0.00)
BRONCHIECTASIS		2 (0.01)	13 (0.05)		15 (0.03)
BRONCHIOLITIS	1 (0.02)				1 (0.00)
BRONCHIOLOALVEOLAR CARCINOMA			1 (0.00)		1 (0.00)
BRONCHITIS	16 (0.33)	38 (0.26)	63 (0.24)	33 (0.50)	150 (0.28)
BRONCHITIS ACUTE	2 (0.04)	10 (0.07)	12 (0.05)	15 (0.23)	39 (0.07)
BRONCHITIS BACTERIAL		1 (0.01)	1 (0.00)		2 (0.00)
BRONCHITIS CHRONIC		3 (0.02)	4 (0.02)	4 (0.06)	11 (0.02)
BRONCHITIS VIRAL	1 (0.02)				1 (0.00)
BRONCHOPNEUMONIA		2 (0.01)	6 (0.02)	6 (0.09)	14 (0.03)
BRONCHOPNEUMOPATHY			3 (0.01)	1 (0.02)	4 (0.01)
BRONCHOPULMONARY ASPERGILLOSIS	1 (0.02)	2 (0.01)	21 (0.08)	7 (0.11)	31 (0.06)
BRONCHOPULMONARY ASPERGILLOSIS ALLERGIC	1 (0.02)				1 (0.00)
BRONCHOSCOPY		1 (0.01)	4 (0.02)		5 (0.01)
BRONCHOSPASM		3 (0.02)	5 (0.02)	1 (0.02)	9 (0.02)
BUBONIC PLAGUE	1 (0.02)				1 (0.00)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
BULIMIA NERVOSA	1 (0.02)	1 (0.01)			2 (0.00)
BURKITT'S LYMPHOMA		1 (0.01)	4 (0.02)		5 (0.01)
BURNING SENSATION	1 (0.02)			2 (0.03)	3 (0.01)
BURSA DISORDER			1 (0.00)		1 (0.00)
BURSITIS		12 (0.08)	35 (0.13)	3 (0.05)	50 (0.09)
C-REACTIVE PROTEIN INCREASED	3 (0.06)				3 (0.01)
CACHEXIA		1 (0.01)			1 (0.00)
CAECITIS			1 (0.00)		1 (0.00)
CAESAREAN SECTION	3 (0.06)	6 (0.04)			9 (0.02)
CALCIUM METABOLISM DISORDER				4 (0.06)	4 (0.01)
CANCER PAIN	1 (0.02)	8 (0.05)	53 (0.20)	7 (0.11)	69 (0.13)
CANDIDA SEPSIS		2 (0.01)			2 (0.00)
CANDIDIASIS	6 (0.12)	12 (0.08)	14 (0.05)	3 (0.05)	35 (0.07)
CARCINOID SYNDROME		1 (0.01)	9 (0.03)		10 (0.02)
CARCINOID TUMOUR		1 (0.01)	2 (0.01)	2 (0.03)	5 (0.01)
CARCINOMA IN SITU OF BLADDER		3 (0.02)	3 (0.01)	8 (0.12)	14 (0.03)
CARCINOMA IN SITU OF SKIN			1 (0.00)		1 (0.00)
CARDIAC ANEURYSM				1 (0.02)	1 (0.00)
CARDIAC ARREST	1 (0.02)				1 (0.00)
CARDIAC DISORDER	1 (0.02)	21 (0.14)	134 (0.50)	34 (0.52)	190 (0.36)
CARDIAC FAILURE	1 (0.02)	5 (0.03)	26 (0.10)	43 (0.65)	75 (0.14)
CARDIAC FAILURE ACUTE				2 (0.03)	2 (0.00)
CARDIAC FAILURE CHRONIC			2 (0.01)	7 (0.11)	9 (0.02)
CARDIAC FAILURE CONGESTIVE		7 (0.05)	49 (0.18)	46 (0.70)	102 (0.19)
CARDIAC FIBRILLATION			2 (0.01)	2 (0.03)	4 (0.01)
CARDIAC FLUTTER			1 (0.00)	2 (0.03)	3 (0.01)
CARDIAC GRANULOMA	1 (0.02)				1 (0.00)
CARDIAC IMAGING PROCEDURE ABNORMAL			1 (0.00)		1 (0.00)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
CARDIAC MURMUR			1 (0.00)		1 (0.00)
CARDIAC OPERATION		2 (0.01)	4 (0.02)		6 (0.01)
CARDIAC PACEMAKER INSERTION				2 (0.03)	2 (0.00)
CARDIAC PHARMACOLOGIC STRESS TEST		1 (0.01)	1 (0.00)		2 (0.00)
CARDIAC STRESS TEST		6 (0.04)	1 (0.00)	4 (0.06)	11 (0.02)
CARDIAC VALVE DISEASE			4 (0.02)	1 (0.02)	5 (0.01)
CARDIAC VALVE PROSTHESIS USER				1 (0.02)	1 (0.00)
CARDIOGENIC SHOCK		1 (0.01)			1 (0.00)
CARDIOMYOPATHY	2 (0.04)	7 (0.05)	5 (0.02)		14 (0.03)
CARDIOSPASM				1 (0.02)	1 (0.00)
CARDIOVASCULAR DISORDER		2 (0.01)	28 (0.11)	6 (0.09)	36 (0.07)
CARDIOVASCULAR EVALUATION			1 (0.00)		1 (0.00)
CARDIOVASCULAR EVENT PROPHYLAXIS		3 (0.02)	6 (0.02)	3 (0.05)	12 (0.02)
CARDIOVERSION			1 (0.00)		1 (0.00)
CAROTID ARTERY ATHEROMA		1 (0.01)			1 (0.00)
CAROTID ARTERY DISEASE			1 (0.00)		1 (0.00)
CAROTID ARTERY INSUFFICIENCY			1 (0.00)		1 (0.00)
CAROTID ARTERY OCCLUSION		1 (0.01)	1 (0.00)		2 (0.00)
CAROTID ARTERY STENOSIS			2 (0.01)		2 (0.00)
CAROTID BRUIT			1 (0.00)		1 (0.00)
CARPAL TUNNEL SYNDROME		13 (0.09)	35 (0.13)		48 (0.09)
CARTILAGE INJURY			1 (0.00)		1 (0.00)
CASTLEMAN'S DISEASE		1 (0.01)			1 (0.00)
CATAPLEXY	1 (0.02)	1 (0.01)			2 (0.00)
CATARACT				1 (0.02)	1 (0.00)
CATARACT OPERATION				2 (0.03)	2 (0.00)
CATATONIA	1 (0.02)	1 (0.01)			2 (0.00)
CATHETER PLACEMENT			2 (0.01)		2 (0.00)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
CATHETER RELATED COMPLICATION		1 (0.01)	1 (0.00)		2 (0.00)
CATHETER RELATED INFECTION			1 (0.00)		1 (0.00)
CATHETERISATION CARDIAC		1 (0.01)	5 (0.02)	4 (0.06)	10 (0.02)
CAUDA EQUINA SYNDROME			4 (0.02)		4 (0.01)
CELLULITIS	8 (0.17)	8 (0.05)	30 (0.11)	6 (0.09)	52 (0.10)
CELLULITIS ENTEROCOCCAL			1 (0.00)		1 (0.00)
CELLULITIS STAPHYLOCOCCAL		1 (0.01)			1 (0.00)
CELLULITIS STREPTOCOCCAL		1 (0.01)			1 (0.00)
CENTRAL NERVOUS SYSTEM INFECTION	2 (0.04)				2 (0.00)
CENTRAL NERVOUS SYSTEM INFLAMMATION	1 (0.02)				1 (0.00)
CENTRAL NERVOUS SYSTEM LYMPHOMA			3 (0.01)		3 (0.01)
CENTRAL NERVOUS SYSTEM NEOPLASM	2 (0.04)				2 (0.00)
CENTRAL NERVOUS SYSTEM STIMULATION			1 (0.00)		1 (0.00)
CEREBELLAR INFARCTION				3 (0.05)	3 (0.01)
CEREBRAL ARTERY EMBOLISM			3 (0.01)	3 (0.05)	6 (0.01)
CEREBRAL ARTERY THROMBOSIS				1 (0.02)	1 (0.00)
CEREBRAL CIRCULATORY FAILURE			2 (0.01)		2 (0.00)
CEREBRAL DISORDER	2 (0.04)	1 (0.01)	1 (0.00)		4 (0.01)
CEREBRAL HAEMATOMA	1 (0.02)				1 (0.00)
CEREBRAL HAEMORRHAGE			13 (0.05)	4 (0.06)	17 (0.03)
CEREBRAL INFARCTION			29 (0.11)	26 (0.40)	55 (0.10)
CEREBRAL ISCHAEMIA			2 (0.01)	1 (0.02)	3 (0.01)
CEREBRAL THROMBOSIS			2 (0.01)		2 (0.00)
CEREBRAL TOXOPLASMOSIS		1 (0.01)			1 (0.00)
CEREBROVASCULAR ACCIDENT		8 (0.05)	22 (0.08)	13 (0.20)	43 (0.08)
CEREBROVASCULAR ACCIDENT PROPHYLAXIS		7 (0.05)	17 (0.06)	11 (0.17)	35 (0.07)
CEREBROVASCULAR DISORDER			5 (0.02)	3 (0.05)	8 (0.02)
CEREBROVASCULAR INSUFFICIENCY			1 (0.00)		1 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
CERUMEN IMPACTION				2 (0.03)	2 (0.00)
CERVICAL DYSPLASIA		1 (0.01)			1 (0.00)
CERVICAL MYELOPATHY		1 (0.01)			1 (0.00)
CERVICAL ROOT PAIN			2 (0.01)	1 (0.02)	3 (0.01)
CERVICAL SPINAL STENOSIS			1 (0.00)	1 (0.02)	2 (0.00)
CERVICOBRACHIAL SYNDROME		9 (0.06)	6 (0.02)	2 (0.03)	17 (0.03)
CERVIX CARCINOMA		3 (0.02)	12 (0.05)		15 (0.03)
CERVIX CARCINOMA RECURRENT		2 (0.01)			2 (0.00)
CHALAZION	1 (0.02)				1 (0.00)
CHANGE OF BOWEL HABIT		1 (0.01)			1 (0.00)
CHAPPED LIPS		2 (0.01)	1 (0.00)		3 (0.01)
CHEILITIS		1 (0.01)	1 (0.00)		2 (0.00)
CHELATION THERAPY	1 (0.02)		1 (0.00)	1 (0.02)	3 (0.01)
CHEMICAL POISONING	1 (0.02)				1 (0.00)
CHEMOTHERAPY	5 (0.10)	16 (0.11)	47 (0.18)	9 (0.14)	77 (0.15)
CHEMOTHERAPY MULTIPLE AGENTS SYSTEMIC		1 (0.01)	2 (0.01)		3 (0.01)
CHEST DISCOMFORT	4 (0.08)		5 (0.02)		9 (0.02)
CHEST INJURY				1 (0.02)	1 (0.00)
CHEST PAIN	1 (0.02)	17 (0.12)	56 (0.21)	15 (0.23)	89 (0.17)
CHEST X-RAY ABNORMAL			2 (0.01)		2 (0.00)
CHILLS	1 (0.02)		1 (0.00)		2 (0.00)
CHLAMYDIAL INFECTION	2 (0.04)	3 (0.02)			5 (0.01)
CHLOASMA		1 (0.01)			1 (0.00)
CHLOROMA	1 (0.02)		1 (0.00)		2 (0.00)
CHOLANGIOGRAM			1 (0.00)		1 (0.00)
CHOLANGITIS			3 (0.01)	1 (0.02)	4 (0.01)
CHOLANGITIS SCLEROSING		1 (0.01)			1 (0.00)

Indication Summary Table

Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
CHOLECYSTECTOMY		1 (0.01)			1 (0.00)
CHOLECYSTITIS		1 (0.01)	1 (0.00)	4 (0.06)	6 (0.01)
CHOLELITHIASIS		1 (0.01)	2 (0.01)	2 (0.03)	5 (0.01)
CHONDROMALACIA		1 (0.01)			1 (0.00)
CHORIORETINOPATHY			1 (0.00)		1 (0.00)
CHOROIDAL NEOVASCULARISATION			1 (0.00)	2 (0.03)	3 (0.01)
CHOROIDITIS	2 (0.04)	1 (0.01)			3 (0.01)
CHRONIC FATIGUE SYNDROME		2 (0.01)	2 (0.01)		4 (0.01)
CHRONIC GRANULOMATOUS DISEASE	3 (0.06)				3 (0.01)
CHRONIC HEPATITIS		5 (0.03)	4 (0.02)	2 (0.03)	11 (0.02)
CHRONIC INFLAMMATORY DEMYELINATING POLYRADICU		2 (0.01)	3 (0.01)	1 (0.02)	6 (0.01)
CHRONIC LYMPHOCYTIC LEUKAEMIA		5 (0.03)	49 (0.18)	10 (0.15)	64 (0.12)
CHRONIC LYMPHOCYTIC LEUKAEMIA RECURRENT			1 (0.00)		1 (0.00)
CHRONIC LYMPHOCYTIC LEUKAEMIA REFRACTORY			3 (0.01)		3 (0.01)
CHRONIC MYELOID LEUKAEMIA	10 (0.21)	25 (0.17)	59 (0.22)	21 (0.32)	115 (0.22)
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	1 (0.02)	10 (0.07)	206 (0.77)	86 (1.31)	303 (0.58)
CHRONIC RESPIRATORY FAILURE			1 (0.00)		1 (0.00)
CHRONIC SINUSITIS		4 (0.03)	9 (0.03)		13 (0.02)
CHYLOTHORAX	2 (0.04)				2 (0.00)
CIRCADIAN RHYTHM SLEEP DISORDER			1 (0.00)		1 (0.00)
CLEAR CELL CARCINOMA OF THE KIDNEY			1 (0.00)		1 (0.00)
CLOSTRIDIAL INFECTION		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)
CLOSTRIDIUM COLITIS	1 (0.02)	2 (0.01)	1 (0.00)	4 (0.06)	8 (0.02)
CLUSTER HEADACHE		8 (0.05)			8 (0.02)
COAGULOPATHY	1 (0.02)	2 (0.01)	8 (0.03)	6 (0.09)	17 (0.03)
COCCIDIOIDOMYCOSIS	1 (0.02)	1 (0.01)			2 (0.00)
COELIAC DISEASE	1 (0.02)				1 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
COGNITIVE DETERIORATION			1 (0.00)		1 (0.00)
COGNITIVE DISORDER		1 (0.01)	4 (0.02)	2 (0.03)	7 (0.01)
COLD SWEAT		2 (0.01)			2 (0.00)
COLECTOMY			1 (0.00)		1 (0.00)
COLITIS	1 (0.02)	5 (0.03)	6 (0.02)		12 (0.02)
COLITIS ULCERATIVE	12 (0.25)	26 (0.18)	12 (0.05)	1 (0.02)	51 (0.10)
COLLAGEN DISORDER			1 (0.00)		1 (0.00)
COLON CANCER	2 (0.04)	13 (0.09)	123 (0.46)	9 (0.14)	147 (0.28)
COLON CANCER METASTATIC		10 (0.07)	37 (0.14)	11 (0.17)	58 (0.11)
COLON CANCER STAGE II		1 (0.01)	1 (0.00)		2 (0.00)
COLON CANCER STAGE III			3 (0.01)		3 (0.01)
COLON CANCER STAGE IV			3 (0.01)		3 (0.01)
COLON NEOPLASM			1 (0.00)		1 (0.00)
COLONIC ATONY			1 (0.00)		1 (0.00)
COLONOSCOPY		6 (0.04)	11 (0.04)	2 (0.03)	19 (0.04)
COLONY STIMULATING FACTOR THERAPY		2 (0.01)			2 (0.00)
COLORECTAL CANCER		20 (0.14)	62 (0.23)	17 (0.26)	99 (0.19)
COLORECTAL CANCER METASTATIC		30 (0.21)	133 (0.50)	17 (0.26)	180 (0.34)
COLORECTAL CANCER RECURRENT			1 (0.00)		1 (0.00)
COLORECTAL CANCER STAGE III			1 (0.00)		1 (0.00)
COLORECTAL CANCER STAGE IV			1 (0.00)		1 (0.00)
COLOSTOMY		1 (0.01)			1 (0.00)
COMA		1 (0.01)			1 (0.00)
COMA HEPATIC			3 (0.01)		3 (0.01)
COMBINED IMMUNODEFICIENCY	2 (0.04)		1 (0.00)		3 (0.01)
COMPLETED SUICIDE		2 (0.01)			2 (0.00)
COMPLEX PARTIAL SEIZURES	6 (0.12)	4 (0.03)	7 (0.03)		17 (0.03)
COMPLEX REGIONAL PAIN SYNDROME	2 (0.04)	9 (0.06)	2 (0.01)		13 (0.02)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
COMPLICATIONS OF TRANSPLANT SURGERY		2 (0.01)			2 (0.00)
COMPRESSION FRACTURE				2 (0.03)	2 (0.00)
COMPULSIONS		2 (0.01)			2 (0.00)
COMPUTERISED TOMOGRAM	3 (0.06)	13 (0.09)	29 (0.11)	8 (0.12)	53 (0.10)
COMPUTERISED TOMOGRAM ABDOMEN	2 (0.04)	5 (0.03)	6 (0.02)	1 (0.02)	14 (0.03)
COMPUTERISED TOMOGRAM THORAX		2 (0.01)	4 (0.02)	2 (0.03)	8 (0.02)
CONDITION AGGRAVATED	1 (0.02)	3 (0.02)	4 (0.02)	1 (0.02)	9 (0.02)
CONDUCT DISORDER	1 (0.02)	2 (0.01)			3 (0.01)
CONDUCTION DISORDER				1 (0.02)	1 (0.00)
CONFUSIONAL STATE			2 (0.01)	4 (0.06)	6 (0.01)
CONGENITAL APLASTIC ANAEMIA	1 (0.02)				1 (0.00)
CONGENITAL AURAL FISTULA		1 (0.01)			1 (0.00)
CONGENITAL CYSTIC KIDNEY DISEASE	1 (0.02)				1 (0.00)
CONGENITAL DYSKERATOSIS	1 (0.02)				1 (0.00)
CONGENITAL HYPOTHYROIDISM	1 (0.02)		1 (0.00)		2 (0.00)
CONGESTIVE CARDIOMYOPATHY		2 (0.01)			2 (0.00)
CONJUNCTIVITIS		4 (0.03)	2 (0.01)	1 (0.02)	7 (0.01)
CONJUNCTIVITIS ALLERGIC	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
CONNECTIVE TISSUE DISORDER		2 (0.01)	4 (0.02)		6 (0.01)
CONSTIPATION	6 (0.12)	22 (0.15)	93 (0.35)	54 (0.82)	175 (0.33)
CONSTIPATION PROPHYLAXIS		1 (0.01)	1 (0.00)		2 (0.00)
CONTRACEPTION	197 (4.07)	351 (2.40)	6 (0.02)		554 (1.05)
CONTUSION	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
CONVULSION	70 (1.45)	68 (0.47)	87 (0.33)	17 (0.26)	242 (0.46)
CONVULSION IN CHILDHOOD		1 (0.01)			1 (0.00)
CONVULSION PROPHYLAXIS	2 (0.04)	5 (0.03)	6 (0.02)	3 (0.05)	16 (0.03)
CORD BLOOD TRANSPLANT THERAPY	10 (0.21)	3 (0.02)			13 (0.02)
CORNEAL DEGENERATION				1 (0.02)	1 (0.00)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
CORNEAL DISORDER				1 (0.02)	1 (0.00)
CORNEAL DYSTROPHY			2 (0.01)		2 (0.00)
CORNEAL OEDEMA				1 (0.02)	1 (0.00)
CORNEAL SCAR				1 (0.02)	1 (0.00)
CORONARY ANGIOPLASTY		2 (0.01)	7 (0.03)	4 (0.06)	13 (0.02)
CORONARY ARTERIAL STENT INSERTION		1 (0.01)	20 (0.08)	12 (0.18)	33 (0.06)
CORONARY ARTERY DISEASE		6 (0.04)	52 (0.20)	28 (0.43)	86 (0.16)
CORONARY ARTERY INSUFFICIENCY			1 (0.00)	2 (0.03)	3 (0.01)
CORONARY ARTERY OCCLUSION			6 (0.02)	3 (0.05)	9 (0.02)
CORONARY ARTERY RESTENOSIS			2 (0.01)		2 (0.00)
CORONARY ARTERY STENOSIS				2 (0.03)	2 (0.00)
CORONARY ARTERY SURGERY		2 (0.01)	17 (0.06)	3 (0.05)	22 (0.04)
CORONARY ARTERY THROMBOSIS			1 (0.00)		1 (0.00)
CORRECTIVE LENS USER			1 (0.00)		1 (0.00)
COSTOCHONDRITIS		7 (0.05)	7 (0.03)		14 (0.03)
COUGH	18 (0.37)	14 (0.10)	51 (0.19)	11 (0.17)	94 (0.18)
CRANIAL NEUROPATHY		1 (0.01)			1 (0.00)
CRANIOPHARYNGIOMA	1 (0.02)		2 (0.01)		3 (0.01)
CRANIOTOMY			2 (0.01)		2 (0.00)
CREUTZFELDT-JAKOB DISEASE		1 (0.01)			1 (0.00)
CROHN'S DISEASE	39 (0.81)	90 (0.62)	59 (0.22)	2 (0.03)	190 (0.36)
CRYING			1 (0.00)		1 (0.00)
CRYPTOCOCCOSIS		1 (0.01)			1 (0.00)
CULTURE URINE POSITIVE				1 (0.02)	1 (0.00)
CUTANEOUS LUPUS ERYTHEMATOSUS	1 (0.02)	3 (0.02)			4 (0.01)
CUTANEOUS VASCULITIS		1 (0.01)			1 (0.00)
CYCLOTHYMIC DISORDER		1 (0.01)			1 (0.00)
CYST			2 (0.01)		2 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
CYSTIC FIBROSIS	3 (0.06)	1 (0.01)	1 (0.00)		5 (0.01)
CYSTIC FIBROSIS PANCREATIC	1 (0.02)				1 (0.00)
CYSTINOSIS	3 (0.06)				3 (0.01)
CYSTINURIA	2 (0.04)				2 (0.00)
CYSTITIS		3 (0.02)	16 (0.06)	5 (0.08)	24 (0.05)
CYSTITIS HAEMORRHAGIC	1 (0.02)				1 (0.00)
CYSTITIS INTERSTITIAL		4 (0.03)	1 (0.00)	1 (0.02)	6 (0.01)
CYTOMEGALOVIRUS CHORIORETINITIS	2 (0.04)	1 (0.01)			3 (0.01)
CYTOMEGALOVIRUS COLITIS		1 (0.01)			1 (0.00)
CYTOMEGALOVIRUS GASTROINTESTINAL INFECTION		1 (0.01)			1 (0.00)
CYTOMEGALOVIRUS INFECTION	1 (0.02)	6 (0.04)	3 (0.01)		10 (0.02)
CYTOMEGALOVIRUS VIRAEMIA			1 (0.00)		1 (0.00)
DANDRUFF				2 (0.03)	2 (0.00)
DEAFNESS		1 (0.01)	1 (0.00)		2 (0.00)
DEATH OF PARENT			1 (0.00)		1 (0.00)
DECREASED APPETITE		1 (0.01)	3 (0.01)	5 (0.08)	9 (0.02)
DECUBITUS ULCER		1 (0.01)			1 (0.00)
DEEP VEIN THROMBOSIS	1 (0.02)	10 (0.07)	46 (0.17)	20 (0.30)	77 (0.15)
DEHYDRATION	2 (0.04)		6 (0.02)		8 (0.02)
DELIRIUM		2 (0.01)	12 (0.05)	4 (0.06)	18 (0.03)
DELUSION	1 (0.02)	2 (0.01)	21 (0.08)	1 (0.02)	25 (0.05)
DELUSIONAL DISORDER, PERSECUTORY TYPE		3 (0.02)			3 (0.01)
DELUSIONAL DISORDER, UNSPECIFIED TYPE		1 (0.01)	5 (0.02)	2 (0.03)	8 (0.02)
DEMENTIA		1 (0.01)	26 (0.10)	81 (1.23)	108 (0.21)
DEMENTIA ALZHEIMER'S TYPE		1 (0.01)	48 (0.18)	159 (2.42)	208 (0.40)
DEMYELINATING POLYNEUROPATHY		5 (0.03)	2 (0.01)	3 (0.05)	10 (0.02)
DENTAL CARE	1 (0.02)	3 (0.02)	2 (0.01)		6 (0.01)
DENTAL CLEANING		2 (0.01)	2 (0.01)		4 (0.01)

Indication Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
DENTAL DISCOMFORT			2 (0.01)		2 (0.00)
DENTAL DISORDER PROPHYLAXIS		4 (0.03)	5 (0.02)		9 (0.02)
DENTAL IMPLANTATION			1 (0.00)		1 (0.00)
DENTAL OPERATION		1 (0.01)	2 (0.01)		3 (0.01)
DENTAL PROSTHESIS PLACEMENT		1 (0.01)			1 (0.00)
DENTAL TREATMENT		5 (0.03)	3 (0.01)		8 (0.02)
DEPENDENCE	1 (0.02)	2 (0.01)			3 (0.01)
DEPENDENT PERSONALITY DISORDER		1 (0.01)			1 (0.00)
DEPRESSED LEVEL OF CONSCIOUSNESS		1 (0.01)			1 (0.00)
DEPRESSED MOOD	1 (0.02)		2 (0.01)		3 (0.01)
DEPRESSION	218 (4.51)	927 (6.35)	782 (2.94)	215 (3.27)	2142 (4.07)
DEPRESSIVE DELUSION			1 (0.00)	3 (0.05)	4 (0.01)
DEPRESSIVE SYMPTOM	3 (0.06)	1 (0.01)	2 (0.01)	1 (0.02)	7 (0.01)
DERMAL CYST		1 (0.01)	1 (0.00)		2 (0.00)
DERMATITIS	3 (0.06)	1 (0.01)	9 (0.03)		13 (0.02)
DERMATITIS ACNEIFORM			1 (0.00)		1 (0.00)
DERMATITIS ALLERGIC			4 (0.02)		4 (0.01)
DERMATITIS ATOPIC	21 (0.43)	5 (0.03)	5 (0.02)		31 (0.06)
DERMATITIS CONTACT		1 (0.01)			1 (0.00)
DERMATITIS EXFOLIATIVE				1 (0.02)	1 (0.00)
DERMATITIS PSORIASIFORM			1 (0.00)		1 (0.00)
DERMATOFIBROSARCOMA		1 (0.01)			1 (0.00)
DERMATOMYOSITIS		2 (0.01)	5 (0.02)	3 (0.05)	10 (0.02)
DESMOID TUMOUR		1 (0.01)			1 (0.00)
DETOXIFICATION		3 (0.02)			3 (0.01)
DEVELOPMENTAL GLAUCOMA		1 (0.01)			1 (0.00)
DEVICE RELATED INFECTION		1 (0.01)	8 (0.03)	5 (0.08)	14 (0.03)
DIABETES INSIPIDUS		4 (0.03)	2 (0.01)		6 (0.01)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
DIABETES MELLITUS	20 (0.41)	163 (1.12)	678 (2.55)	173 (2.63)	1034 (1.96)
DIABETES MELLITUS INADEQUATE CONTROL			3 (0.01)	1 (0.02)	4 (0.01)
DIABETES MELLITUS INSULIN-DEPENDENT	33 (0.68)	54 (0.37)	66 (0.25)	4 (0.06)	157 (0.30)
DIABETES MELLITUS MALNUTRITION-RELATED			2 (0.01)		2 (0.00)
DIABETES MELLITUS MANAGEMENT				1 (0.02)	1 (0.00)
DIABETES MELLITUS NON-INSULIN-DEPENDENT	9 (0.19)	373 (2.55)	1570 (5.89)	169 (2.57)	2121 (4.03)
DIABETIC FOOT			2 (0.01)	1 (0.02)	3 (0.01)
DIABETIC FOOT INFECTION			1 (0.00)	1 (0.02)	2 (0.00)
DIABETIC GANGRENE			2 (0.01)		2 (0.00)
DIABETIC GASTROPARESIS		1 (0.01)			1 (0.00)
DIABETIC KETOACIDOSIS		1 (0.01)			1 (0.00)
DIABETIC MICROANGIOPATHY			1 (0.00)		1 (0.00)
DIABETIC NEPHROPATHY		2 (0.01)	12 (0.05)		14 (0.03)
DIABETIC NEUROPATHY	1 (0.02)	12 (0.08)	49 (0.18)	13 (0.20)	75 (0.14)
DIABETIC RETINAL OEDEMA			1 (0.00)		1 (0.00)
DIABETIC RETINOPATHY		1 (0.01)	8 (0.03)		9 (0.02)
DIABETIC ULCER			1 (0.00)		1 (0.00)
DIAGNOSTIC PROCEDURE		5 (0.03)	7 (0.03)		12 (0.02)
DIALYSIS	2 (0.04)	1 (0.01)	2 (0.01)	5 (0.08)	10 (0.02)
DIAPHRAGM MUSCLE WEAKNESS				1 (0.02)	1 (0.00)
DIARRHOEA	1 (0.02)	5 (0.03)	43 (0.16)	7 (0.11)	56 (0.11)
DIARRHOEA INFECTIOUS			1 (0.00)		1 (0.00)
DIFFICULTY IN WALKING			1 (0.00)		1 (0.00)
DIFFUSE LARGE B-CELL LYMPHOMA		7 (0.05)	20 (0.08)	5 (0.08)	32 (0.06)
DISCOMFORT	1 (0.02)	2 (0.01)	1 (0.00)		4 (0.01)
DISEASE PROGRESSION			1 (0.00)		1 (0.00)
DISEASE RECURRENCE	2 (0.04)	1 (0.01)	3 (0.01)	2 (0.03)	8 (0.02)
DISORIENTATION				1 (0.02)	1 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
DISSEMINATED INTRAVASCULAR COAGULATION	2 (0.04)	3 (0.02)	7 (0.03)	2 (0.03)	14 (0.03)
DISSEMINATED TUBERCULOSIS		1 (0.01)	2 (0.01)		3 (0.01)
DISSOCIATIVE DISORDER	2 (0.04)				2 (0.00)
DISTURBANCE IN ATTENTION	2 (0.04)	1 (0.01)			3 (0.01)
DIURETIC EFFECT			4 (0.02)	1 (0.02)	5 (0.01)
DIURETIC THERAPY		4 (0.03)	9 (0.03)	1 (0.02)	14 (0.03)
DIVERTICULAR PERFORATION			2 (0.01)		2 (0.00)
DIVERTICULITIS		1 (0.01)	3 (0.01)		4 (0.01)
DIVERTICULUM			1 (0.00)		1 (0.00)
DIVERTICULUM INTESTINAL			1 (0.00)		1 (0.00)
DIZZINESS		8 (0.05)	7 (0.03)	4 (0.06)	19 (0.04)
DRESSLER'S SYNDROME			1 (0.00)		1 (0.00)
DRUG ABUSER	7 (0.14)	6 (0.04)			13 (0.02)
DRUG ADMINISTRATION ERROR				1 (0.02)	1 (0.00)
DRUG DEPENDENCE	15 (0.31)	27 (0.18)	3 (0.01)		45 (0.09)
DRUG DETOXIFICATION			1 (0.00)		1 (0.00)
DRUG DISPENSING ERROR	1 (0.02)	1 (0.01)		1 (0.02)	3 (0.01)
DRUG ERUPTION		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)
DRUG EXPOSURE DURING PREGNANCY	18 (0.37)	1 (0.01)			19 (0.04)
DRUG EXPOSURE VIA BREAST MILK	1 (0.02)				1 (0.00)
DRUG HYPERSENSITIVITY		1 (0.01)	2 (0.01)		3 (0.01)
DRUG LEVEL			2 (0.01)		2 (0.00)
DRUG LEVEL CHANGED		1 (0.01)			1 (0.00)
DRUG RESISTANCE		1 (0.01)	1 (0.00)		2 (0.00)
DRUG THERAPY	1 (0.02)	2 (0.01)	6 (0.02)		9 (0.02)
DRUG TOXICITY	2 (0.04)	2 (0.01)	1 (0.00)		5 (0.01)
DRUG USE FOR UNKNOWN INDICATION	378 (7.82)	669 (4.58)	688 (2.58)	250 (3.80)	1985 (3.77)
DRUG WITHDRAWAL CONVULSIONS		3 (0.02)			3 (0.01)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
DRUG WITHDRAWAL MAINTENANCE THERAPY		3 (0.02)	2 (0.01)		5 (0.01)
DRUG WITHDRAWAL SYNDROME		8 (0.05)	1 (0.00)		9 (0.02)
DRY EYE		2 (0.01)	5 (0.02)	3 (0.05)	10 (0.02)
DRY MOUTH		4 (0.03)	3 (0.01)		7 (0.01)
DRY SKIN		3 (0.02)	8 (0.03)	1 (0.02)	12 (0.02)
DUODENAL ULCER	1 (0.02)	4 (0.03)	10 (0.04)	5 (0.08)	20 (0.04)
DUODENAL ULCER HAEMORRHAGE				1 (0.02)	1 (0.00)
DUODENITIS		2 (0.01)	4 (0.02)		6 (0.01)
DYSAESTHESIA			1 (0.00)	1 (0.02)	2 (0.00)
DYSFUNCTIONAL UTERINE BLEEDING	1 (0.02)	2 (0.01)	1 (0.00)		4 (0.01)
DYSGLOBULINAEMIA			1 (0.00)		1 (0.00)
DYSKINESIA		1 (0.01)	1 (0.00)		2 (0.00)
DYSLIPIDAEMIA	1 (0.02)	11 (0.08)	63 (0.24)	24 (0.36)	99 (0.19)
DYSMENORRHOEA	16 (0.33)	17 (0.12)			33 (0.06)
DYSPAREUNIA			1 (0.00)		1 (0.00)
DYSPEPSIA	7 (0.14)	25 (0.17)	61 (0.23)	15 (0.23)	108 (0.21)
DYSPHAGIA		3 (0.02)	4 (0.02)	2 (0.03)	9 (0.02)
DYSPHASIA			1 (0.00)		1 (0.00)
DYSPHONIA			2 (0.01)		2 (0.00)
DYSPNOEA	4 (0.08)	7 (0.05)	28 (0.11)	5 (0.08)	44 (0.08)
DYSPNOEA EXERTIONAL			1 (0.00)	1 (0.02)	2 (0.00)
DYSSOMNIA			2 (0.01)		2 (0.00)
DYSTHYMIC DISORDER	1 (0.02)	7 (0.05)	11 (0.04)	17 (0.26)	36 (0.07)
DYSTONIA	1 (0.02)	2 (0.01)	3 (0.01)		6 (0.01)
DYSURIA		2 (0.01)	10 (0.04)	3 (0.05)	15 (0.03)
EAR DISORDER		3 (0.02)	2 (0.01)		5 (0.01)
EAR INFECTION	12 (0.25)	10 (0.07)	9 (0.03)		31 (0.06)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
EAR PAIN	2 (0.04)	4 (0.03)	1 (0.00)	1 (0.02)	8 (0.02)
EATING DISORDER	3 (0.06)				3 (0.01)
ECHINOCOCCIASIS		3 (0.02)			3 (0.01)
ECHOCARDIOGRAM		2 (0.01)	3 (0.01)		5 (0.01)
ECZEMA	25 (0.52)	9 (0.06)	7 (0.03)	4 (0.06)	45 (0.09)
ECZEMA NUMMULAR			2 (0.01)		2 (0.00)
EHLERS-DANLOS SYNDROME	1 (0.02)				1 (0.00)
EJACULATION DISORDER			1 (0.00)		1 (0.00)
EJECTION FRACTION DECREASED	1 (0.02)		1 (0.00)		2 (0.00)
ELECTROCARDIOGRAM ABNORMAL			1 (0.00)		1 (0.00)
ELECTROCONVULSIVE THERAPY	1 (0.02)				1 (0.00)
ELECTROENCEPHALOGRAPH ABNORMAL	1 (0.02)				1 (0.00)
ELECTROLYTE IMBALANCE				3 (0.05)	3 (0.01)
ELECTROLYTE SUBSTITUTION THERAPY		7 (0.05)	11 (0.04)	2 (0.03)	20 (0.04)
EMBOLIC CEREBRAL INFARCTION			1 (0.00)		1 (0.00)
EMBOLISM			4 (0.02)	1 (0.02)	5 (0.01)
EMOTIONAL DISORDER		2 (0.01)	2 (0.01)		4 (0.01)
EMOTIONAL DISTRESS	1 (0.02)	1 (0.01)			2 (0.00)
EMPHYSEMA		4 (0.03)	25 (0.09)	12 (0.18)	41 (0.08)
EMPYEMA			1 (0.00)	1 (0.02)	2 (0.00)
ENCEPHALITIS			1 (0.00)		1 (0.00)
ENCEPHALITIS HERPES	2 (0.04)		2 (0.01)		4 (0.01)
ENCEPHALITIS PERIAXIALIS DIFFUSA				1 (0.02)	1 (0.00)
ENCEPHALOPATHY			1 (0.00)		1 (0.00)
ENDARTERECTOMY			1 (0.00)		1 (0.00)
ENDOCARDIAL DISEASE			1 (0.00)		1 (0.00)
ENDOCARDITIS		5 (0.03)	6 (0.02)	3 (0.05)	14 (0.03)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
ENDOCARDITIS BACTERIAL			2 (0.01)		2 (0.00)
ENDOCARDITIS ENTEROCOCCAL			1 (0.00)	1 (0.02)	2 (0.00)
ENDOCARDITIS STAPHYLOCOCCAL		2 (0.01)	2 (0.01)		4 (0.01)
ENDODONTIC PROCEDURE		4 (0.03)	2 (0.01)		6 (0.01)
ENDOMETRIAL CANCER			10 (0.04)	1 (0.02)	11 (0.02)
ENDOMETRIAL DYSPLASIA			1 (0.00)		1 (0.00)
ENDOMETRIOSIS	9 (0.19)	28 (0.19)			37 (0.07)
ENDOMETRITIS	1 (0.02)				1 (0.00)
ENDOPHTHALMITIS			4 (0.02)		4 (0.01)
ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPH			1 (0.00)		1 (0.00)
ENDOSCOPY		2 (0.01)	3 (0.01)		5 (0.01)
ENDOSCOPY UPPER GASTROINTESTINAL TRACT			1 (0.00)	1 (0.02)	2 (0.00)
ENDOTHELIAL DYSFUNCTION			1 (0.00)		1 (0.00)
ENTERITIS	1 (0.02)				1 (0.00)
ENTERITIS INFECTIOUS		1 (0.01)			1 (0.00)
ENTEROBACTER BACTERAEemia				1 (0.02)	1 (0.00)
ENTEROBACTER SEPSIS	1 (0.02)				1 (0.00)
ENTEROCOCCAL BACTERAEemia		3 (0.02)	3 (0.01)	2 (0.03)	8 (0.02)
ENTEROCOCCAL INFECTION	1 (0.02)	2 (0.01)	6 (0.02)		9 (0.02)
ENTEROCOCCAL SEPSIS				1 (0.02)	1 (0.00)
ENTEROCOLITIS	1 (0.02)	4 (0.03)	1 (0.00)		6 (0.01)
ENURESIS	6 (0.12)		1 (0.00)		7 (0.01)
ENZYME ABNORMALITY	4 (0.08)				4 (0.01)
EOSINOPHILIA			1 (0.00)		1 (0.00)
EOSINOPHILIC CYSTITIS		1 (0.01)			1 (0.00)
EOSINOPHILIC LEUKAEMIA		1 (0.01)			1 (0.00)
EOSINOPHILIC PNEUMONIA	1 (0.02)				1 (0.00)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
EPHELIDES		1 (0.01)			1 (0.00)
EPICONDYLITIS		6 (0.04)	13 (0.05)	1 (0.02)	20 (0.04)
EPIDIDYMITIS	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
EPIDURAL ANAESTHESIA	2 (0.04)	10 (0.07)	4 (0.02)	7 (0.11)	23 (0.04)
EPIGASTRIC DISCOMFORT			1 (0.00)		1 (0.00)
EPILEPSY	178 (3.68)	171 (1.17)	108 (0.41)	37 (0.56)	494 (0.94)
EPISCLERITIS	1 (0.02)				1 (0.00)
EPISTAXIS		1 (0.01)	1 (0.00)		2 (0.00)
EPSTEIN-BARR VIRUS INFECTION		1 (0.01)	1 (0.00)		2 (0.00)
ERECTILE DYSFUNCTION	1 (0.02)	100 (0.68)	325 (1.22)	46 (0.70)	472 (0.90)
ERYSIPELAS			5 (0.02)	5 (0.08)	10 (0.02)
ERYSIPELOID				1 (0.02)	1 (0.00)
ERYTHEMA	1 (0.02)		4 (0.02)		5 (0.01)
ERYTHEMA INFECTIOSUM	1 (0.02)				1 (0.00)
ERYTHEMA NODOSUM		1 (0.01)			1 (0.00)
ERYTHEMA OF EYELID		2 (0.01)			2 (0.00)
ERYTHRODERMIC PSORIASIS	1 (0.02)	1 (0.01)	2 (0.01)	1 (0.02)	5 (0.01)
ERYTHROPENIA			1 (0.00)		1 (0.00)
ESCHERICHIA INFECTION		2 (0.01)		1 (0.02)	3 (0.01)
ESCHERICHIA SEPSIS	1 (0.02)		2 (0.01)	1 (0.02)	4 (0.01)
ESCHERICHIA URINARY TRACT INFECTION			1 (0.00)		1 (0.00)
ESSENTIAL HYPERTENSION	3 (0.06)	6 (0.04)	65 (0.24)	59 (0.90)	133 (0.25)
ESSENTIAL THROMBOCYTHAEMIA		1 (0.01)	3 (0.01)	1 (0.02)	5 (0.01)
ESSENTIAL TREMOR	3 (0.06)		1 (0.00)		4 (0.01)
EUPHORIC MOOD	3 (0.06)	1 (0.01)			4 (0.01)
EWING'S SARCOMA		1 (0.01)			1 (0.00)
EWING'S SARCOMA METASTATIC	1 (0.02)				1 (0.00)
EX-SMOKER	1 (0.02)	9 (0.06)	10 (0.04)		20 (0.04)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
EXCITABILITY	1 (0.02)			2 (0.03)	3 (0.01)
EXERCISE TEST			2 (0.01)		2 (0.00)
EXOSTOSIS		8 (0.05)	13 (0.05)		21 (0.04)
EXPOSURE TO COMMUNICABLE DISEASE			5 (0.02)		5 (0.01)
EXTRADURAL ABSCESS			1 (0.00)		1 (0.00)
EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MAL		1 (0.01)			1 (0.00)
EXTRAPYRAMIDAL DISORDER	3 (0.06)	3 (0.02)	2 (0.01)		8 (0.02)
EYE DEGENERATIVE DISORDER		1 (0.01)			1 (0.00)
EYE DISORDER			4 (0.02)	1 (0.02)	5 (0.01)
EYE INFECTION		3 (0.02)	3 (0.01)	2 (0.03)	8 (0.02)
EYE INFECTION TOXOPLASMAL			1 (0.00)		1 (0.00)
EYE INFLAMMATION				1 (0.02)	1 (0.00)
EYE IRRIGATION			2 (0.01)		2 (0.00)
EYE IRRITATION			3 (0.01)		3 (0.01)
EYE LASER SURGERY		3 (0.02)			3 (0.01)
EYE OPERATION			1 (0.00)		1 (0.00)
EYE PAIN				2 (0.03)	2 (0.00)
EYE PRURITUS			2 (0.01)		2 (0.00)
EYE SWELLING		1 (0.01)	3 (0.01)		4 (0.01)
EYELID OEDEMA		2 (0.01)			2 (0.00)
EYELID OPERATION		2 (0.01)			2 (0.00)
EYELIDS PRURITUS		1 (0.01)			1 (0.00)
FABRY'S DISEASE	10 (0.21)	26 (0.18)	26 (0.10)		62 (0.12)
FACET JOINT SYNDROME			1 (0.00)		1 (0.00)
FACIAL NEURALGIA		4 (0.03)	2 (0.01)	3 (0.05)	9 (0.02)
FACIAL PAIN		3 (0.02)	4 (0.02)		7 (0.01)
FACIAL PALSY			4 (0.02)		4 (0.01)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
FACIAL SPASM			1 (0.00)		1 (0.00)
FACTOR IX DEFICIENCY	3 (0.06)	3 (0.02)	1 (0.00)		7 (0.01)
FACTOR V LEIDEN MUTATION		1 (0.01)	1 (0.00)		2 (0.00)
FACTOR VII DEFICIENCY	3 (0.06)	1 (0.01)			4 (0.01)
FACTOR VIII DEFICIENCY	22 (0.46)	2 (0.01)	8 (0.03)		32 (0.06)
FAECES DISCOLOURED			1 (0.00)		1 (0.00)
FAECES HARD				1 (0.02)	1 (0.00)
FALL		2 (0.01)		1 (0.02)	3 (0.01)
FALLOPIAN TUBE CANCER			1 (0.00)		1 (0.00)
FALLOT'S TETRALOGY	1 (0.02)	1 (0.01)			2 (0.00)
FALSE POSITIVE LABORATORY RESULT		1 (0.01)			1 (0.00)
FAMILIAL RISK FACTOR			1 (0.00)		1 (0.00)
FAMILIAL TREMOR				1 (0.02)	1 (0.00)
FASCIITIS			1 (0.00)		1 (0.00)
FAT EMBOLISM			1 (0.00)		1 (0.00)
FATIGUE	2 (0.04)	10 (0.07)	6 (0.02)	2 (0.03)	20 (0.04)
FEBRILE BONE MARROW APLASIA		2 (0.01)			2 (0.00)
FEBRILE NEUTROPENIA		5 (0.03)	3 (0.01)	5 (0.08)	13 (0.02)
FEELING ABNORMAL	2 (0.04)		1 (0.00)		3 (0.01)
FEELING OF RELAXATION		1 (0.01)	5 (0.02)		6 (0.01)
FELTY'S SYNDROME			1 (0.00)		1 (0.00)
FEMALE PATTERN BALDNESS	1 (0.02)				1 (0.00)
FEMUR FRACTURE				1 (0.02)	1 (0.00)
FIBROMUSCULAR DYSPLASIA		1 (0.01)			1 (0.00)
FIBROMYALGIA	1 (0.02)	83 (0.57)	125 (0.47)	3 (0.05)	212 (0.40)
FIBROSIS			2 (0.01)		2 (0.00)
FIBROUS DYSPLASIA OF BONE	1 (0.02)		2 (0.01)		3 (0.01)
FIBULA FRACTURE		2 (0.01)			2 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
FILARIASIS LYMPHATIC	2 (0.04)				2 (0.00)
FISTULA				2 (0.03)	2 (0.00)
FLANK PAIN		1 (0.01)			1 (0.00)
FLATULENCE		1 (0.01)	1 (0.00)		2 (0.00)
FLUID OVERLOAD			6 (0.02)	1 (0.02)	7 (0.01)
FLUID REPLACEMENT	3 (0.06)		6 (0.02)	1 (0.02)	10 (0.02)
FLUID RETENTION	1 (0.02)	6 (0.04)	33 (0.12)	5 (0.08)	45 (0.09)
FOETAL GROWTH RETARDATION	3 (0.06)				3 (0.01)
FOLATE DEFICIENCY		2 (0.01)	1 (0.00)		3 (0.01)
FOLLICLE CENTRE LYMPHOMA, FOLLICULAR GRADE I,				1 (0.02)	1 (0.00)
FOLLICULITIS	1 (0.02)	1 (0.01)			2 (0.00)
FOOD ALLERGY	2 (0.04)	1 (0.01)			3 (0.01)
FOOD AVERSION	1 (0.02)				1 (0.00)
FOOT DEFORMITY				1 (0.02)	1 (0.00)
FOOT FRACTURE			1 (0.00)		1 (0.00)
FOOT OPERATION		1 (0.01)		1 (0.02)	2 (0.00)
FOREIGN TRAVEL	1 (0.02)		1 (0.00)		2 (0.00)
FRACTURE		1 (0.01)	6 (0.02)	2 (0.03)	9 (0.02)
FRACTURE MALUNION		2 (0.01)			2 (0.00)
FREQUENT BOWEL MOVEMENTS			1 (0.00)		1 (0.00)
FUNDOSCOPY	2 (0.04)				2 (0.00)
FUNGAEMIA	2 (0.04)			2 (0.03)	4 (0.01)
FUNGAL INFECTION	9 (0.19)	18 (0.12)	30 (0.11)	8 (0.12)	65 (0.12)
FUNGAL OESOPHAGITIS				1 (0.02)	1 (0.00)
FUNGAL PERITONITIS			1 (0.00)		1 (0.00)
FUNGAL SKIN INFECTION		3 (0.02)	1 (0.00)	2 (0.03)	6 (0.01)
FURUNCLE	1 (0.02)		2 (0.01)		3 (0.01)
FUSARIUM INFECTION	1 (0.02)				1 (0.00)

Indication Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
GAIT DISTURBANCE			1 (0.00)		1 (0.00)
GALLBLADDER CANCER		3 (0.02)	3 (0.01)	3 (0.05)	9 (0.02)
GALLBLADDER CANCER STAGE IV				1 (0.02)	1 (0.00)
GALLBLADDER DISORDER			1 (0.00)		1 (0.00)
GALLBLADDER PAIN		1 (0.01)	1 (0.00)		2 (0.00)
GAMMOPATHY			2 (0.01)		2 (0.00)
GANGRENE			2 (0.01)	1 (0.02)	3 (0.01)
GASTRIC BYPASS		1 (0.01)			1 (0.00)
GASTRIC CANCER		27 (0.18)	63 (0.24)	14 (0.21)	104 (0.20)
GASTRIC CANCER RECURRENT				1 (0.02)	1 (0.00)
GASTRIC CANCER STAGE IV		2 (0.01)	4 (0.02)	1 (0.02)	7 (0.01)
GASTRIC DISORDER		6 (0.04)	32 (0.12)	10 (0.15)	48 (0.09)
GASTRIC HAEMORRHAGE	1 (0.02)			1 (0.02)	2 (0.00)
GASTRIC PERFORATION			1 (0.00)		1 (0.00)
GASTRIC PH DECREASED		1 (0.01)			1 (0.00)
GASTRIC ULCER	1 (0.02)	12 (0.08)	67 (0.25)	27 (0.41)	107 (0.20)
GASTRIC ULCER HAEMORRHAGE			1 (0.00)	4 (0.06)	5 (0.01)
GASTRIC ULCER HELICOBACTER		1 (0.01)		1 (0.02)	2 (0.00)
GASTRINOMA			1 (0.00)		1 (0.00)
GASTRITIS	1 (0.02)	17 (0.12)	85 (0.32)	48 (0.73)	151 (0.29)
GASTRITIS EROSION	1 (0.02)		3 (0.01)		4 (0.01)
GASTRODUODENAL ULCER			2 (0.01)	1 (0.02)	3 (0.01)
GASTRODUODENITIS		1 (0.01)			1 (0.00)
GASTROENTERITIS	2 (0.04)	3 (0.02)	5 (0.02)	1 (0.02)	11 (0.02)
GASTROINTESTINAL CANDIDIASIS				2 (0.03)	2 (0.00)
GASTROINTESTINAL CARCINOMA			1 (0.00)		1 (0.00)
GASTROINTESTINAL DISORDER	2 (0.04)	7 (0.05)	23 (0.09)	6 (0.09)	38 (0.07)
GASTROINTESTINAL DISORDER THERAPY		1 (0.01)	1 (0.00)		2 (0.00)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
GASTROINTESTINAL HAEMORRHAGE	1 (0.02)	3 (0.02)	1 (0.00)	2 (0.03)	7 (0.01)
GASTROINTESTINAL INFECTION		2 (0.01)			2 (0.00)
GASTROINTESTINAL INFLAMMATION	1 (0.02)				1 (0.00)
GASTROINTESTINAL MALFORMATION			1 (0.00)		1 (0.00)
GASTROINTESTINAL MOTILITY DISORDER			1 (0.00)		1 (0.00)
GASTROINTESTINAL MUCOSAL NECROSIS			1 (0.00)		1 (0.00)
GASTROINTESTINAL PAIN		2 (0.01)			2 (0.00)
GASTROINTESTINAL STROMAL TUMOUR		19 (0.13)	39 (0.15)	10 (0.15)	68 (0.13)
GASTROINTESTINAL ULCER		3 (0.02)			3 (0.01)
GASTROINTESTINAL ULCER HAEMORRHAGE				1 (0.02)	1 (0.00)
GASTROOESOPHAGEAL CANCER		6 (0.04)	2 (0.01)	1 (0.02)	9 (0.02)
GASTROOESOPHAGEAL REFLUX DISEASE	8 (0.17)	57 (0.39)	189 (0.71)	25 (0.38)	279 (0.53)
GASTROOESOPHAGITIS			1 (0.00)		1 (0.00)
GAUCHER'S DISEASE	16 (0.33)	9 (0.06)	20 (0.08)	8 (0.12)	53 (0.10)
GENERAL ANAESTHESIA	9 (0.19)	13 (0.09)	17 (0.06)	3 (0.05)	42 (0.08)
GENERAL NUTRITION DISORDER	1 (0.02)				1 (0.00)
GENERAL PHYSICAL HEALTH DETERIORATION		1 (0.01)		1 (0.02)	2 (0.00)
GENERAL SYMPTOM		1 (0.01)			1 (0.00)
GENERALISED ANXIETY DISORDER	9 (0.19)	13 (0.09)	5 (0.02)	2 (0.03)	29 (0.06)
GENERALISED OEDEMA				1 (0.02)	1 (0.00)
GENITAL PRURITUS FEMALE	3 (0.06)	12 (0.08)	3 (0.01)		18 (0.03)
GERM CELL CANCER	4 (0.08)	2 (0.01)			6 (0.01)
GESTATIONAL DIABETES	1 (0.02)	2 (0.01)			3 (0.01)
GINGIVAL INFECTION		1 (0.01)			1 (0.00)
GINGIVAL PAIN				1 (0.02)	1 (0.00)
GINGIVITIS		1 (0.01)	3 (0.01)	1 (0.02)	5 (0.01)
GLAUCOMA		11 (0.08)	82 (0.31)	35 (0.53)	128 (0.24)
GLIOBLASTOMA	2 (0.04)	9 (0.06)	18 (0.07)		29 (0.06)

Indication Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
GLIOBLASTOMA MULTIFORME		3 (0.02)	21 (0.08)		24 (0.05)
GLIOMA	2 (0.04)		8 (0.03)		10 (0.02)
GLOMERULONEPHRITIS		1 (0.01)		1 (0.02)	2 (0.00)
GLOMERULONEPHRITIS CHRONIC		3 (0.02)	5 (0.02)		8 (0.02)
GLOMERULONEPHRITIS MEMBRANOUS			1 (0.00)		1 (0.00)
GLOMERULONEPHRITIS RAPIDLY PROGRESSIVE	1 (0.02)		1 (0.00)		2 (0.00)
GLOMERULOSCLEROSIS		1 (0.01)			1 (0.00)
GLUCOSE TOLERANCE IMPAIRED		1 (0.01)	11 (0.04)	4 (0.06)	16 (0.03)
GOUT		27 (0.18)	94 (0.35)	13 (0.20)	134 (0.25)
GOUTY ARTHRITIS			7 (0.03)	2 (0.03)	9 (0.02)
GOUTY TOPHUS		1 (0.01)		1 (0.02)	2 (0.00)
GRAFT INFECTION			3 (0.01)	1 (0.02)	4 (0.01)
GRAFT VERSUS HOST DISEASE	5 (0.10)	6 (0.04)	5 (0.02)		16 (0.03)
GRAM STAIN POSITIVE			1 (0.00)		1 (0.00)
GRAND MAL CONVULSION	5 (0.10)	12 (0.08)	5 (0.02)		22 (0.04)
GRANULOCYTE COUNT DECREASED			1 (0.00)		1 (0.00)
GROIN PAIN		3 (0.02)		1 (0.02)	4 (0.01)
GROWING PAINS	1 (0.02)				1 (0.00)
GROWTH HORMONE DEFICIENCY	60 (1.24)	16 (0.11)	20 (0.08)	1 (0.02)	97 (0.18)
GROWTH RETARDATION	6 (0.12)				6 (0.01)
GUILLAIN-BARRE SYNDROME		4 (0.03)	9 (0.03)		13 (0.02)
GYNAECOLOGICAL CHLAMYDIA INFECTION	3 (0.06)				3 (0.01)
GYNAECOLOGICAL EXAMINATION		1 (0.01)			1 (0.00)
HAEMANGIOBLASTOMA			1 (0.00)		1 (0.00)
HAEMANGIOMA OF LIVER		1 (0.01)			1 (0.00)
HAEMANGIOMA OF RETINA	1 (0.02)				1 (0.00)
HAEMARTHROSIS		2 (0.01)			2 (0.00)
HAEMATEMESIS				1 (0.02)	1 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
HAEMATOCRIT DECREASED				1 (0.02)	1 (0.00)
HAEMATOMA			2 (0.01)		2 (0.00)
HAEMATOPHOIETIC NEOPLASM			1 (0.00)		1 (0.00)
HAEMATURIA				1 (0.02)	1 (0.00)
HAEMOCHROMATOSIS		1 (0.01)	3 (0.01)		4 (0.01)
HAEMODIALYSIS			2 (0.01)		2 (0.00)
HAEMODILUTION			1 (0.00)		1 (0.00)
HAEMOGLOBIN DECREASED			2 (0.01)	2 (0.03)	4 (0.01)
HAEMOPHILIA	5 (0.10)	1 (0.01)			6 (0.01)
HAEMOPHILIA A WITH ANTI FACTOR VIII		1 (0.01)	1 (0.00)		2 (0.00)
HAEMOPHILIC ARTHROPATHY			1 (0.00)		1 (0.00)
HAEMOPTYSIS		1 (0.01)			1 (0.00)
HAEMORRHAGE	6 (0.12)	6 (0.04)	3 (0.01)	1 (0.02)	16 (0.03)
HAEMORRHAGE CONTROL		2 (0.01)	3 (0.01)		5 (0.01)
HAEMORRHAGE INTRACRANIAL	1 (0.02)		1 (0.00)		2 (0.00)
HAEMORRHOIDS		1 (0.01)	1 (0.00)		2 (0.00)
HAEMOSIDEROSES	5 (0.10)	3 (0.02)		1 (0.02)	9 (0.02)
HAIRY CELL LEUKAEMIA		1 (0.01)			1 (0.00)
HALLUCINATION		4 (0.03)	5 (0.02)	4 (0.06)	13 (0.02)
HALLUCINATION, AUDITORY	1 (0.02)	2 (0.01)	4 (0.02)		7 (0.01)
HALLUCINATION, VISUAL	1 (0.02)				1 (0.00)
HEAD INJURY	1 (0.02)	1 (0.01)	8 (0.03)		10 (0.02)
HEADACHE	24 (0.50)	105 (0.72)	104 (0.39)	8 (0.12)	241 (0.46)
HEART AND LUNG TRANSPLANT		5 (0.03)			5 (0.01)
HEART DISEASE CONGENITAL	5 (0.10)	2 (0.01)			7 (0.01)
HEART INJURY			1 (0.00)		1 (0.00)
HEART RATE	1 (0.02)		2 (0.01)		3 (0.01)
HEART RATE ABNORMAL				1 (0.02)	1 (0.00)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
HEART RATE DECREASED			5 (0.02)	1 (0.02)	6 (0.01)
HEART RATE INCREASED			2 (0.01)	2 (0.03)	4 (0.01)
HEART RATE IRREGULAR		2 (0.01)	4 (0.02)	4 (0.06)	10 (0.02)
HEART TRANSPLANT	2 (0.04)	3 (0.02)	12 (0.05)		17 (0.03)
HEART VALVE REPLACEMENT			3 (0.01)	4 (0.06)	7 (0.01)
HELICOBACTER GASTRITIS		1 (0.01)	2 (0.01)	1 (0.02)	4 (0.01)
HELICOBACTER INFECTION	2 (0.04)	15 (0.10)	18 (0.07)	7 (0.11)	42 (0.08)
HELICOBACTER PYLORI IDENTIFICATION TEST POSIT			2 (0.01)		2 (0.00)
HEMIPLEGIA	1 (0.02)	1 (0.01)			2 (0.00)
HEPARIN NEUTRALISATION THERAPY			1 (0.00)		1 (0.00)
HEPARIN-INDUCED THROMBOCYTOPENIA		2 (0.01)	5 (0.02)		7 (0.01)
HEPATIC CANCER METASTATIC		1 (0.01)		1 (0.02)	2 (0.00)
HEPATIC CIRRHOSIS		7 (0.05)	8 (0.03)		15 (0.03)
HEPATIC ENCEPHALOPATHY				1 (0.02)	1 (0.00)
HEPATIC FUNCTION ABNORMAL			11 (0.04)	3 (0.05)	14 (0.03)
HEPATIC NEOPLASM			1 (0.00)		1 (0.00)
HEPATIC NEOPLASM MALIGNANT	1 (0.02)	1 (0.01)	15 (0.06)	3 (0.05)	20 (0.04)
HEPATIC PAIN			1 (0.00)		1 (0.00)
HEPATIC STEATOSIS				1 (0.02)	1 (0.00)
HEPATITIS	2 (0.04)	2 (0.01)	10 (0.04)		14 (0.03)
HEPATITIS B	3 (0.06)	20 (0.14)	32 (0.12)	1 (0.02)	56 (0.11)
HEPATITIS B SURFACE ANTIGEN POSITIVE	1 (0.02)				1 (0.00)
HEPATITIS B VIRUS		1 (0.01)			1 (0.00)
HEPATITIS C	14 (0.29)	232 (1.59)	246 (0.92)	2 (0.03)	494 (0.94)
HEPATITIS C VIRUS		4 (0.03)	4 (0.02)		8 (0.02)
HEPATITIS CHOLESTATIC				2 (0.03)	2 (0.00)
HEPATITIS INFECTIOUS		1 (0.01)			1 (0.00)
HEPATO-LENTICULAR DEGENERATION		1 (0.01)			1 (0.00)

Indication Summary Table Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
HEPATOBLASTOMA	1 (0.02)				1 (0.00)
HEPATOMEGALY				1 (0.02)	1 (0.00)
HEPATORENAL SYNDROME			1 (0.00)		1 (0.00)
HEREDITARY ANGIOEDEMA		1 (0.01)			1 (0.00)
HERNIA		1 (0.01)			1 (0.00)
HERNIA PAIN		2 (0.01)			2 (0.00)
HERNIA REPAIR		2 (0.01)	1 (0.00)		3 (0.01)
HERPES GESTATIONIS		1 (0.01)			1 (0.00)
HERPES OPHTHALMIC			1 (0.00)	1 (0.02)	2 (0.00)
HERPES SIMPLEX	3 (0.06)	7 (0.05)	18 (0.07)	4 (0.06)	32 (0.06)
HERPES VIRUS INFECTION	2 (0.04)	3 (0.02)			5 (0.01)
HERPES ZOSTER	4 (0.08)	18 (0.12)	69 (0.26)	35 (0.53)	126 (0.24)
HERPES ZOSTER INFECTION NEUROLOGICAL			1 (0.00)		1 (0.00)
HERPES ZOSTER OPHTHALMIC			1 (0.00)		1 (0.00)
HERPETIC STOMATITIS			2 (0.01)		2 (0.00)
HIATUS HERNIA		1 (0.01)	11 (0.04)	2 (0.03)	14 (0.03)
HICCUPS		5 (0.03)	1 (0.00)	2 (0.03)	8 (0.02)
HIDRADENITIS		2 (0.01)			2 (0.00)
HIGH DENSITY LIPOPROTEIN			1 (0.00)		1 (0.00)
HIGH DENSITY LIPOPROTEIN DECREASED		1 (0.01)	1 (0.00)		2 (0.00)
HIGH DENSITY LIPOPROTEIN INCREASED			1 (0.00)	2 (0.03)	3 (0.01)
HIP ARTHROPLASTY			8 (0.03)	1 (0.02)	9 (0.02)
HIP DYSPLASIA		1 (0.01)			1 (0.00)
HIP FRACTURE			1 (0.00)	1 (0.02)	2 (0.00)
HIP SURGERY		2 (0.01)			2 (0.00)
HIRSUTISM				1 (0.02)	1 (0.00)
HISTIOCYTOSIS HAEMATOPHAGIC			1 (0.00)		1 (0.00)
HISTOPLASMOSIS	2 (0.04)				2 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
HIV INFECTION	63 (1.30)	446 (3.05)	110 (0.41)	2 (0.03)	621 (1.18)
HIV INFECTION CDC CATEGORY A2		1 (0.01)			1 (0.00)
HIV INFECTION CDC CATEGORY B2		2 (0.01)			2 (0.00)
HIV TEST POSITIVE	2 (0.04)	9 (0.06)	1 (0.00)		12 (0.02)
HODGKIN'S DISEASE	4 (0.08)	7 (0.05)	10 (0.04)		21 (0.04)
HODGKIN'S DISEASE STAGE III			2 (0.01)		2 (0.00)
HORMONE LEVEL ABNORMAL		9 (0.06)	11 (0.04)		20 (0.04)
HORMONE REPLACEMENT THERAPY		70 (0.48)	436 (1.64)	17 (0.26)	523 (0.99)
HORMONE THERAPY			1 (0.00)		1 (0.00)
HOT FLUSH		4 (0.03)	59 (0.22)	1 (0.02)	64 (0.12)
HUMAN HERPESVIRUS 6 INFECTION	2 (0.04)				2 (0.00)
HUMERUS FRACTURE			1 (0.00)		1 (0.00)
HUNGER			2 (0.01)		2 (0.00)
HUNTINGTON'S CHOREA			1 (0.00)		1 (0.00)
HYDRONEPHROSIS		1 (0.01)			1 (0.00)
HYPERCALCAEMIA			3 (0.01)		3 (0.01)
HYPERCALCAEMIA OF MALIGNANCY			5 (0.02)	1 (0.02)	6 (0.01)
HYPERCHLORHYDRIA	1 (0.02)	2 (0.01)	5 (0.02)	1 (0.02)	9 (0.02)
HYPERCHOLESTEROLAEMIA	2 (0.04)	48 (0.33)	233 (0.87)	83 (1.26)	366 (0.70)
HYPERCOAGULATION	1 (0.02)				1 (0.00)
HYPEREMESIS GRAVIDARUM	1 (0.02)	3 (0.02)			4 (0.01)
HYPEREOSINOPHILIC SYNDROME	1 (0.02)				1 (0.00)
HYPERGLYCAEMIA	1 (0.02)		15 (0.06)		16 (0.03)
HYPERHIDROSIS	4 (0.08)	2 (0.01)	2 (0.01)		8 (0.02)
HYPERHOMOCYSTEINAEMIA	1 (0.02)	1 (0.01)			2 (0.00)
HYPERINSULINISM	2 (0.04)				2 (0.00)
HYPERKALAEMIA			4 (0.02)	1 (0.02)	5 (0.01)
HYPERKERATOSIS		2 (0.01)	5 (0.02)		7 (0.01)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
HYPERLIPIDAEMIA	1 (0.02)	40 (0.27)	250 (0.94)	46 (0.70)	337 (0.64)
HYPERPARATHYROIDISM			2 (0.01)	1 (0.02)	3 (0.01)
HYPERPARATHYROIDISM SECONDARY	1 (0.02)	4 (0.03)	10 (0.04)	2 (0.03)	17 (0.03)
HYPERPHOSPHATAEMIA	3 (0.06)	13 (0.09)	33 (0.12)	8 (0.12)	57 (0.11)
HYPERPLASIA			1 (0.00)		1 (0.00)
HYPERPROLACTINAEMIA	3 (0.06)	4 (0.03)			7 (0.01)
HYPERPYREXIA		1 (0.01)			1 (0.00)
HYPERSENSITIVITY	13 (0.27)	37 (0.25)	100 (0.38)	12 (0.18)	162 (0.31)
HYPERSONMIA	1 (0.02)	1 (0.01)	3 (0.01)		5 (0.01)
HYPERTENSION	21 (0.43)	310 (2.12)	1393 (5.23)	550 (8.36)	2274 (4.32)
HYPERTENSIVE CARDIOMYOPATHY				8 (0.12)	8 (0.02)
HYPERTENSIVE HEART DISEASE			6 (0.02)	12 (0.18)	18 (0.03)
HYPERTHERMIA	4 (0.08)		3 (0.01)		7 (0.01)
HYPERTHYROIDISM	2 (0.04)	6 (0.04)	5 (0.02)	1 (0.02)	14 (0.03)
HYPERTONIA		1 (0.01)	2 (0.01)	1 (0.02)	4 (0.01)
HYPERTONIC BLADDER	1 (0.02)	20 (0.14)	74 (0.28)	60 (0.91)	155 (0.29)
HYPERTRICHOSIS		1 (0.01)			1 (0.00)
HYPERTRIGLYCERIDAEMIA		6 (0.04)	21 (0.08)		27 (0.05)
HYPERTROPHIC CARDIOMYOPATHY		1 (0.01)	2 (0.01)		3 (0.01)
HYPERTROPHIC SCAR	1 (0.02)				1 (0.00)
HYPERURICAEMIA		6 (0.04)	31 (0.12)	20 (0.30)	57 (0.11)
HYPERVENTILATION	3 (0.06)				3 (0.01)
HYPOAESTHESIA		4 (0.03)	10 (0.04)	4 (0.06)	18 (0.03)
HYPOALBUMINAEMIA				2 (0.03)	2 (0.00)
HYPOCALCAEMIA			3 (0.01)		3 (0.01)
HYPOGAMMAGLOBULINAEMIA	3 (0.06)	1 (0.01)	3 (0.01)		7 (0.01)
HYPOGLYCAEMIA		1 (0.01)	2 (0.01)	2 (0.03)	5 (0.01)
HYPOGONADISM		1 (0.01)	3 (0.01)	1 (0.02)	5 (0.01)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
HYPOGONADISM MALE			2 (0.01)		2 (0.00)
HYPOKALAEMIA		4 (0.03)	18 (0.07)	6 (0.09)	28 (0.05)
HYPOMAGNESAEMIA			3 (0.01)		3 (0.01)
HYPOMANIA	1 (0.02)	3 (0.02)			4 (0.01)
HYPONATRAEMIA				2 (0.03)	2 (0.00)
HYPOPARATHYROIDISM		3 (0.02)	1 (0.00)		4 (0.01)
HYPOPHARYNGEAL CANCER		2 (0.01)			2 (0.00)
HYPOPHARYNGEAL CANCER RECURRENT			1 (0.00)		1 (0.00)
HYPOPHARYNGEAL CANCER STAGE IV		1 (0.01)			1 (0.00)
HYPOPHOSPHATAEMIA		1 (0.01)			1 (0.00)
HYPOPITUITARISM	26 (0.54)	13 (0.09)	23 (0.09)	5 (0.08)	67 (0.13)
HYPOPNOEA			1 (0.00)		1 (0.00)
HYPOPROTEINAEMIA			2 (0.01)		2 (0.00)
HYPOTENSION	1 (0.02)	4 (0.03)	6 (0.02)	2 (0.03)	13 (0.02)
HYPOTHALAMO-PITUITARY DISORDERS		2 (0.01)		1 (0.02)	3 (0.01)
HYPOTHERMIA				1 (0.02)	1 (0.00)
HYPOTHYROIDISM	7 (0.14)	35 (0.24)	124 (0.47)	43 (0.65)	209 (0.40)
HYPOTONIA	1 (0.02)	7 (0.05)	14 (0.05)		22 (0.04)
HYPOTONIC URINARY BLADDER				1 (0.02)	1 (0.00)
HYPOTRICHOSIS			5 (0.02)		5 (0.01)
HYPOVITAMINOSIS		5 (0.03)	2 (0.01)		7 (0.01)
HYSTERECTOMY			3 (0.01)	2 (0.03)	5 (0.01)
HYSTEROSALPINGOGRAM		1 (0.01)			1 (0.00)
IDIOPATHIC PNEUMONIA SYNDROME	1 (0.02)				1 (0.00)
IDIOPATHIC PULMONARY FIBROSIS			43 (0.16)	11 (0.17)	54 (0.10)
IDIOPATHIC THROMBOCYTOPENIC PURPURA	8 (0.17)	5 (0.03)	7 (0.03)	9 (0.14)	29 (0.06)
IDIOPATHIC URTICARIA		1 (0.01)			1 (0.00)
ILEUS		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
ILEUS PARALYTIC	1 (0.02)				1 (0.00)
ILIAC ARTERY THROMBOSIS			1 (0.00)		1 (0.00)
ILL-DEFINED DISORDER	79 (1.63)	242 (1.66)	518 (1.94)	216 (3.28)	1055 (2.00)
IMMUNE ENHANCEMENT THERAPY		1 (0.01)			1 (0.00)
IMMUNE SYSTEM DISORDER			1 (0.00)	1 (0.02)	2 (0.00)
IMMUNISATION	3 (0.06)	5 (0.03)	1 (0.00)		9 (0.02)
IMMUNODEFICIENCY	1 (0.02)	3 (0.02)	1 (0.00)		5 (0.01)
IMMUNODEFICIENCY COMMON VARIABLE	2 (0.04)	2 (0.01)	5 (0.02)	3 (0.05)	12 (0.02)
IMMUNODEFICIENCY CONGENITAL	2 (0.04)				2 (0.00)
IMMUNOSUPPRESSANT DRUG THERAPY	8 (0.17)	4 (0.03)	6 (0.02)		18 (0.03)
IMMUNOSUPPRESSION	3 (0.06)	8 (0.05)	10 (0.04)		21 (0.04)
IMPAIRED GASTRIC EMPTYING		2 (0.01)	5 (0.02)	1 (0.02)	8 (0.02)
IMPAIRED HEALING		1 (0.01)	1 (0.00)		2 (0.00)
IMPETIGO	2 (0.04)		3 (0.01)	1 (0.02)	6 (0.01)
IMPINGEMENT SYNDROME		2 (0.01)		2 (0.03)	4 (0.01)
IMPLANTABLE DEFIBRILLATOR INSERTION			1 (0.00)	2 (0.03)	3 (0.01)
IMPULSE-CONTROL DISORDER	3 (0.06)				3 (0.01)
IMPULSIVE BEHAVIOUR	1 (0.02)				1 (0.00)
IN VITRO FERTILISATION		21 (0.14)			21 (0.04)
INCISION SITE COMPLICATION			1 (0.00)		1 (0.00)
INCONTINENCE		1 (0.01)	20 (0.08)	8 (0.12)	29 (0.06)
INCORRECT DOSE ADMINISTERED	1 (0.02)	3 (0.02)			4 (0.01)
INCREASED APPETITE			2 (0.01)		2 (0.00)
INCREASED BRONCHIAL SECRETION			1 (0.00)		1 (0.00)
INCREASED UPPER AIRWAY SECRETION		1 (0.01)			1 (0.00)
INDUCED ABORTION HAEMORRHAGE		1 (0.01)			1 (0.00)
INDUCED LABOUR	2 (0.04)				2 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
INDUCTION AND MAINTENANCE OF ANAESTHESIA	1 (0.02)	2 (0.01)	7 (0.03)		10 (0.02)
INDUCTION OF ANAESTHESIA	5 (0.10)	8 (0.05)	10 (0.04)	2 (0.03)	25 (0.05)
INDWELLING CATHETER MANAGEMENT				1 (0.02)	1 (0.00)
INFANTILE SPASMS	1 (0.02)				1 (0.00)
INFARCTION		2 (0.01)			2 (0.00)
INFECTION	11 (0.23)	26 (0.18)	75 (0.28)	23 (0.35)	135 (0.26)
INFECTION PARASITIC	2 (0.04)	1 (0.01)			3 (0.01)
INFECTION PROPHYLAXIS	7 (0.14)	12 (0.08)	37 (0.14)	4 (0.06)	60 (0.11)
INFECTION PROTOZOAL			1 (0.00)		1 (0.00)
INFECTIOUS MONONUCLEOSIS	1 (0.02)				1 (0.00)
INFECTIVE SPONDYLITIS		2 (0.01)			2 (0.00)
INFERTILITY		8 (0.05)			8 (0.02)
INFERTILITY FEMALE		3 (0.02)			3 (0.01)
INFESTATION			1 (0.00)		1 (0.00)
INFILTRATION ANAESTHESIA		6 (0.04)	10 (0.04)		16 (0.03)
INFLAMMATION		66 (0.45)	83 (0.31)	15 (0.23)	164 (0.31)
INFLAMMATORY BOWEL DISEASE	4 (0.08)		1 (0.00)	1 (0.02)	6 (0.01)
INFLAMMATORY CARCINOMA OF THE BREAST			3 (0.01)		3 (0.01)
INFLUENZA	68 (1.41)	39 (0.27)	37 (0.14)	15 (0.23)	159 (0.30)
INFLUENZA IMMUNISATION		2 (0.01)	3 (0.01)	2 (0.03)	7 (0.01)
INFLUENZA LIKE ILLNESS	1 (0.02)	1 (0.01)	5 (0.02)		7 (0.01)
INITIAL INSOMNIA		24 (0.16)	34 (0.13)	21 (0.32)	79 (0.15)
INJURY	1 (0.02)	4 (0.03)	3 (0.01)		8 (0.02)
INSOMNIA	50 (1.03)	334 (2.29)	506 (1.90)	155 (2.36)	1045 (1.98)
INSOMNIA RELATED TO ANOTHER MENTAL CONDITION				1 (0.02)	1 (0.00)
INSULIN RESISTANCE	1 (0.02)	7 (0.05)	3 (0.01)		11 (0.02)
INSULIN RESISTANT DIABETES				1 (0.02)	1 (0.00)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
INSULIN-REQUIRING TYPE II DIABETES MELLITUS		12 (0.08)	71 (0.27)	7 (0.11)	90 (0.17)
INSULINOMA			2 (0.01)		2 (0.00)
INTENTIONAL DRUG MISUSE	11 (0.23)	6 (0.04)	1 (0.00)		18 (0.03)
INTENTIONAL OVERDOSE	8 (0.17)	10 (0.07)	1 (0.00)		19 (0.04)
INTERCOSTAL NEURALGIA				2 (0.03)	2 (0.00)
INTERMITTENT CLAUDICATION		2 (0.01)	2 (0.01)	1 (0.02)	5 (0.01)
INTERMITTENT EXPLOSIVE DISORDER		2 (0.01)	1 (0.00)		3 (0.01)
INTERNATIONAL NORMALISED RATIO INCREASED			1 (0.00)		1 (0.00)
INTERSTITIAL LUNG DISEASE		1 (0.01)	16 (0.06)	2 (0.03)	19 (0.04)
INTERTRIGO CANDIDA			1 (0.00)		1 (0.00)
INTERVERTEBRAL DISC DEGENERATION		20 (0.14)	33 (0.12)		53 (0.10)
INTERVERTEBRAL DISC DISORDER		4 (0.03)	4 (0.02)		8 (0.02)
INTERVERTEBRAL DISC DISPLACEMENT		1 (0.01)			1 (0.00)
INTERVERTEBRAL DISC OPERATION		1 (0.01)	1 (0.00)		2 (0.00)
INTERVERTEBRAL DISC PROTRUSION		29 (0.20)	31 (0.12)		60 (0.11)
INTERVERTEBRAL DISCITIS			4 (0.02)	1 (0.02)	5 (0.01)
INTESTINAL FUNCTIONAL DISORDER			1 (0.00)		1 (0.00)
INTRA-THORACIC AORTIC ANEURYSM REPAIR			1 (0.00)		1 (0.00)
INTRA-UTERINE CONTRACEPTIVE DEVICE		1 (0.01)			1 (0.00)
INTRACARDIAC THROMBUS		1 (0.01)	1 (0.00)		2 (0.00)
INTRACRANIAL ANEURYSM			1 (0.00)		1 (0.00)
INTRACRANIAL INJURY			5 (0.02)		5 (0.01)
INTRACRANIAL PRESSURE INCREASED	2 (0.04)	2 (0.01)	2 (0.01)	1 (0.02)	7 (0.01)
INTRAOCULAR PRESSURE DECREASED			1 (0.00)		1 (0.00)
INTRAOCULAR PRESSURE INCREASED		1 (0.01)	3 (0.01)	1 (0.02)	5 (0.01)
INTRAOCULAR PRESSURE TEST			3 (0.01)		3 (0.01)
INTRAVENOUS CATHETER MANAGEMENT			3 (0.01)		3 (0.01)
INTRAVENTRICULAR HAEMORRHAGE NEONATAL	5 (0.10)				5 (0.01)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
INTUBATION		2 (0.01)	2 (0.01)	1 (0.02)	5 (0.01)
INTUBATION COMPLICATION		1 (0.01)			1 (0.00)
INULIN RENAL CLEARANCE	2 (0.04)				2 (0.00)
IRITIS			1 (0.00)	1 (0.02)	2 (0.00)
IRON DEFICIENCY		3 (0.02)	4 (0.02)		7 (0.01)
IRON DEFICIENCY ANAEMIA	1 (0.02)	9 (0.06)	11 (0.04)	4 (0.06)	25 (0.05)
IRON METABOLISM DISORDER	2 (0.04)				2 (0.00)
IRRITABILITY	1 (0.02)	1 (0.01)	1 (0.00)	3 (0.05)	6 (0.01)
IRRITABLE BOWEL SYNDROME	5 (0.10)	36 (0.25)	23 (0.09)	4 (0.06)	68 (0.13)
ISCHAEMIA		1 (0.01)	3 (0.01)	2 (0.03)	6 (0.01)
ISCHAEMIC CARDIOMYOPATHY			4 (0.02)	8 (0.12)	12 (0.02)
ISCHAEMIC HEART DISEASE PROPHYLAXIS		1 (0.01)	11 (0.04)		12 (0.02)
ISCHAEMIC STROKE		2 (0.01)	1 (0.00)	4 (0.06)	7 (0.01)
IUCD COMPLICATION	1 (0.02)				1 (0.00)
JAW DISORDER		1 (0.01)			1 (0.00)
JAW FRACTURE	3 (0.06)				3 (0.01)
JESSNER'S LYMPHOCYTIC INFILTRATION		2 (0.01)			2 (0.00)
JOINT ABSCESS		1 (0.01)			1 (0.00)
JOINT DISLOCATION			5 (0.02)		5 (0.01)
JOINT INJURY	1 (0.02)	30 (0.21)	29 (0.11)		60 (0.11)
JOINT INSTABILITY	1 (0.02)				1 (0.00)
JOINT PROSTHESIS USER			1 (0.00)		1 (0.00)
JOINT SPRAIN	2 (0.04)	9 (0.06)	6 (0.02)		17 (0.03)
JOINT STIFFNESS		4 (0.03)	8 (0.03)	1 (0.02)	13 (0.02)
JOINT SURGERY		1 (0.01)			1 (0.00)
JOINT SWELLING		18 (0.12)	12 (0.05)	1 (0.02)	31 (0.06)
JUVENILE ARTHRITIS	25 (0.52)	6 (0.04)	2 (0.01)		33 (0.06)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
KAPOSI'S SARCOMA		2 (0.01)	2 (0.01)	1 (0.02)	5 (0.01)
KAWASAKI'S DISEASE	10 (0.21)				10 (0.02)
KERATITIS	4 (0.08)	5 (0.03)	1 (0.00)		10 (0.02)
KERATITIS FUNGAL			2 (0.01)	2 (0.03)	4 (0.01)
KERATOCONUS		1 (0.01)			1 (0.00)
KERATOPATHY				1 (0.02)	1 (0.00)
KETOACIDOSIS		1 (0.01)			1 (0.00)
KIDNEY INFECTION		1 (0.01)	4 (0.02)		5 (0.01)
KIDNEY TRANSPLANT REJECTION		5 (0.03)	1 (0.00)		6 (0.01)
KLEBSIELLA BACTERAEemia	1 (0.02)				1 (0.00)
KLEBSIELLA INFECTION	1 (0.02)		1 (0.00)		2 (0.00)
KNEE ARTHROPLASTY		2 (0.01)	15 (0.06)	2 (0.03)	19 (0.04)
KNEE OPERATION		4 (0.03)	18 (0.07)		22 (0.04)
LABORATORY TEST ABNORMAL			1 (0.00)		1 (0.00)
LABOUR INDUCTION	5 (0.10)	5 (0.03)			10 (0.02)
LABYRINTHITIS		1 (0.01)			1 (0.00)
LACERATION	1 (0.02)	3 (0.02)			4 (0.01)
LACRIMATION INCREASED	1 (0.02)				1 (0.00)
LACTATION DISORDER	1 (0.02)				1 (0.00)
LACUNAR INFARCTION			6 (0.02)	3 (0.05)	9 (0.02)
LARGE CELL CARCINOMA OF THE RESPIRATORY TRACT				1 (0.02)	1 (0.00)
LARGE CELL LUNG CANCER STAGE IV		1 (0.01)	2 (0.01)		3 (0.01)
LARYNGEAL CANCER		1 (0.01)	4 (0.02)		5 (0.01)
LARYNGEAL CANCER RECURRENT			1 (0.00)		1 (0.00)
LARYNGECTOMY			1 (0.00)		1 (0.00)
LARYNGITIS ALLERGIC	1 (0.02)				1 (0.00)
LARYNGITIS VIRAL	1 (0.02)				1 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
LARYNGOMALACIA	2 (0.04)				2 (0.00)
LARYNGOPHARYNGITIS		2 (0.01)	2 (0.01)		4 (0.01)
LATENT TETANY		2 (0.01)	1 (0.00)		3 (0.01)
LAXATIVE SUPPORTIVE CARE		2 (0.01)			2 (0.00)
LDL/HDL RATIO			1 (0.00)		1 (0.00)
LEARNING DISABILITY			2 (0.01)		2 (0.00)
LEARNING DISORDER		1 (0.01)			1 (0.00)
LEFT VENTRICULAR FAILURE		1 (0.01)		2 (0.03)	3 (0.01)
LEGIONELLA INFECTION			1 (0.00)		1 (0.00)
LEIOMYOSARCOMA			1 (0.00)		1 (0.00)
LEIOMYOSARCOMA METASTATIC		1 (0.01)	5 (0.02)		6 (0.01)
LENNOX-GASTAUT SYNDROME	1 (0.02)				1 (0.00)
LEPROMATOUS LEPROSY		1 (0.01)			1 (0.00)
LEPROSY	1 (0.02)				1 (0.00)
LETHARGY	1 (0.02)	1 (0.01)	3 (0.01)		5 (0.01)
LEUKAEMIA	3 (0.06)		8 (0.03)		11 (0.02)
LEUKAEMIA PLASMACYTIC			4 (0.02)		4 (0.01)
LEUKAEMIA RECURRENT	2 (0.04)		1 (0.00)		3 (0.01)
LIBIDO DECREASED		1 (0.01)			1 (0.00)
LIBIDO DISORDER			1 (0.00)		1 (0.00)
LICE INFESTATION	4 (0.08)	1 (0.01)	1 (0.00)		6 (0.01)
LICHEN PLANUS		4 (0.03)			4 (0.01)
LICHENIFICATION			1 (0.00)		1 (0.00)
LIFE SUPPORT		1 (0.01)		1 (0.02)	2 (0.00)
LIGAMENT INJURY		3 (0.02)	3 (0.01)		6 (0.01)
LIGAMENT OPERATION		3 (0.02)			3 (0.01)
LIGAMENT SPRAIN		2 (0.01)			2 (0.00)
LIGHT CHAIN DISEASE			1 (0.00)		1 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
LIMB DISCOMFORT			6 (0.02)	1 (0.02)	7 (0.01)
LIMB INJURY		25 (0.17)	5 (0.02)	1 (0.02)	31 (0.06)
LIMB OPERATION			4 (0.02)		4 (0.01)
LIMB TRAUMATIC AMPUTATION			1 (0.00)		1 (0.00)
LIP AND/OR ORAL CAVITY CANCER			3 (0.01)		3 (0.01)
LIP AND/OR ORAL CAVITY CANCER RECURRENT		1 (0.01)			1 (0.00)
LIPID METABOLISM DISORDER		4 (0.03)	7 (0.03)	3 (0.05)	14 (0.03)
LIPIDS			1 (0.00)	1 (0.02)	2 (0.00)
LIPIDS INCREASED		3 (0.02)	6 (0.02)	1 (0.02)	10 (0.02)
LIPOSARCOMA METASTATIC			1 (0.00)		1 (0.00)
LISTERIOSIS	1 (0.02)				1 (0.00)
LIVER ABSCESS	1 (0.02)				1 (0.00)
LIVER DISORDER	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.01)
LIVER SCAN			1 (0.00)		1 (0.00)
LIVER TRANSPLANT	8 (0.17)	15 (0.10)	45 (0.17)		68 (0.13)
LIVER TRANSPLANT REJECTION			1 (0.00)		1 (0.00)
LOBAR PNEUMONIA	1 (0.02)		1 (0.00)	1 (0.02)	3 (0.01)
LOCAL ANAESTHESIA	6 (0.12)	17 (0.12)	19 (0.07)	1 (0.02)	43 (0.08)
LOCAL SWELLING		1 (0.01)			1 (0.00)
LOCALISED INFECTION			5 (0.02)		5 (0.01)
LONG QT SYNDROME CONGENITAL	1 (0.02)				1 (0.00)
LOSS OF CONSCIOUSNESS				1 (0.02)	1 (0.00)
LOSS OF LIBIDO				1 (0.02)	1 (0.00)
LOW DENSITY LIPOPROTEIN			1 (0.00)		1 (0.00)
LOW DENSITY LIPOPROTEIN INCREASED		3 (0.02)	8 (0.03)		11 (0.02)
LOWER LIMB FRACTURE		1 (0.01)	2 (0.01)	2 (0.03)	5 (0.01)
LOWER RESPIRATORY TRACT INFECTION	5 (0.10)	2 (0.01)	27 (0.10)	13 (0.20)	47 (0.09)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
LUMBAR HERNIA			4 (0.02)		4 (0.01)
LUMBAR RADICULOPATHY		7 (0.05)	3 (0.01)	1 (0.02)	11 (0.02)
LUMBAR SPINAL STENOSIS			4 (0.02)	2 (0.03)	6 (0.01)
LUMBAR SPINE FLATTENING			1 (0.00)		1 (0.00)
LUMBAR VERTEBRAL FRACTURE		2 (0.01)			2 (0.00)
LUNG ABSCESS			1 (0.00)		1 (0.00)
LUNG ADENOCARCINOMA		8 (0.05)	29 (0.11)	11 (0.17)	48 (0.09)
LUNG ADENOCARCINOMA METASTATIC			1 (0.00)		1 (0.00)
LUNG ADENOCARCINOMA STAGE III			1 (0.00)		1 (0.00)
LUNG ADENOCARCINOMA STAGE IV			5 (0.02)		5 (0.01)
LUNG CANCER METASTATIC			14 (0.05)	2 (0.03)	16 (0.03)
LUNG CARCINOMA CELL TYPE UNSPECIFIED RECURREN		2 (0.01)			2 (0.00)
LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE II			3 (0.01)		3 (0.01)
LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV			3 (0.01)		3 (0.01)
LUNG DISORDER	17 (0.35)	2 (0.01)	11 (0.04)	6 (0.09)	36 (0.07)
LUNG INFECTION	7 (0.14)	1 (0.01)	7 (0.03)	4 (0.06)	19 (0.04)
LUNG INFECTION PSEUDOMONAL	1 (0.02)	1 (0.01)	4 (0.02)		6 (0.01)
LUNG INJURY	1 (0.02)				1 (0.00)
LUNG NEOPLASM			2 (0.01)		2 (0.00)
LUNG NEOPLASM MALIGNANT		20 (0.14)	122 (0.46)	33 (0.50)	175 (0.33)
LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIE			1 (0.00)	2 (0.03)	3 (0.01)
LUNG TRANSPLANT	4 (0.08)	7 (0.05)	12 (0.05)		23 (0.04)
LUPUS NEPHRITIS	1 (0.02)	3 (0.02)			4 (0.01)
LUTEAL PHASE DEFICIENCY		2 (0.01)			2 (0.00)
LYME DISEASE		11 (0.08)	4 (0.02)		15 (0.03)
LYMPH NODE PAIN			1 (0.00)		1 (0.00)
LYMPH NODE TUBERCULOSIS		3 (0.02)			3 (0.01)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
LYMPHADENITIS		1 (0.01)	2 (0.01)		3 (0.01)
LYMPHADENOPATHY	1 (0.02)	1 (0.01)	2 (0.01)		4 (0.01)
LYMPHOCYTE COUNT ABNORMAL				1 (0.02)	1 (0.00)
LYMPHOCYTIC LEUKAEMIA	2 (0.04)			2 (0.03)	4 (0.01)
LYMPHOMA	2 (0.04)	13 (0.09)	29 (0.11)	8 (0.12)	52 (0.10)
LYMPHOPENIA			1 (0.00)		1 (0.00)
LYMPHOPROLIFERATIVE DISORDER			1 (0.00)		1 (0.00)
MACULAR DEGENERATION	1 (0.02)		20 (0.08)	37 (0.56)	58 (0.11)
MACULAR OEDEMA			6 (0.02)		6 (0.01)
MACULOPATHY			1 (0.00)		1 (0.00)
MAINTENANCE OF ANAESTHESIA	4 (0.08)	7 (0.05)	4 (0.02)	2 (0.03)	17 (0.03)
MAJOR DEPRESSION	7 (0.14)	64 (0.44)	46 (0.17)	3 (0.05)	120 (0.23)
MALABSORPTION			6 (0.02)		6 (0.01)
MALAISE	3 (0.06)	1 (0.01)			4 (0.01)
MALARIA	3 (0.06)	2 (0.01)	2 (0.01)		7 (0.01)
MALARIA PROPHYLAXIS	11 (0.23)	26 (0.18)	16 (0.06)	1 (0.02)	54 (0.10)
MALE PATTERN BALDNESS		7 (0.05)	2 (0.01)	1 (0.02)	10 (0.02)
MALIGNANT ATROPHIC PAPULOSIS		1 (0.01)			1 (0.00)
MALIGNANT FIBROUS HISTIOCYTOMA			1 (0.00)		1 (0.00)
MALIGNANT HISTIOCYTOSIS	1 (0.02)				1 (0.00)
MALIGNANT HYPERTENSION				1 (0.02)	1 (0.00)
MALIGNANT LYMPHOID NEOPLASM				2 (0.03)	2 (0.00)
MALIGNANT LYMPHOMA UNCLASSIFIABLE HIGH GRADE	1 (0.02)				1 (0.00)
MALIGNANT MELANOMA	1 (0.02)	7 (0.05)	18 (0.07)		26 (0.05)
MALIGNANT MELANOMA STAGE III		1 (0.01)	1 (0.00)		2 (0.00)
MALIGNANT MELANOMA STAGE IV			1 (0.00)	4 (0.06)	5 (0.01)
MALIGNANT NEOPLASM OF RENAL PELVIS			5 (0.02)		5 (0.01)
MALIGNANT NEOPLASM PROGRESSION	1 (0.02)				1 (0.00)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MALIGNANT NIPPLE NEOPLASM FEMALE			1 (0.00)		1 (0.00)
MALIGNANT PALATE NEOPLASM			1 (0.00)		1 (0.00)
MALIGNANT TUMOUR EXCISION		1 (0.01)			1 (0.00)
MALNUTRITION			3 (0.01)	2 (0.03)	5 (0.01)
MAMMOGRAM ABNORMAL			1 (0.00)		1 (0.00)
MANIA	6 (0.12)	10 (0.07)	9 (0.03)	3 (0.05)	28 (0.05)
MANTLE CELL LYMPHOMA			19 (0.07)	3 (0.05)	22 (0.04)
MARITAL PROBLEM		1 (0.01)			1 (0.00)
MASTECTOMY		1 (0.01)			1 (0.00)
MASTITIS		3 (0.02)			3 (0.01)
MASTOIDITIS				1 (0.02)	1 (0.00)
MEDIASTINAL MASS	1 (0.02)				1 (0.00)
MEDIASTITIS			1 (0.00)		1 (0.00)
MEDICAL DEVICE IMPLANTATION			3 (0.01)		3 (0.01)
MEDICAL DIET		1 (0.01)	10 (0.04)	6 (0.09)	17 (0.03)
MEDICAL OBSERVATION		1 (0.01)			1 (0.00)
MEDICATION ERROR		2 (0.01)			2 (0.00)
MEDULLOBLASTOMA	1 (0.02)				1 (0.00)
MEMORY IMPAIRMENT		1 (0.01)	5 (0.02)	9 (0.14)	15 (0.03)
MENIERE'S DISEASE		1 (0.01)	5 (0.02)		6 (0.01)
MENINGEAL DISORDER	1 (0.02)				1 (0.00)
MENINGIOMA MALIGNANT			1 (0.00)		1 (0.00)
MENINGITIS	9 (0.19)	3 (0.02)	4 (0.02)	1 (0.02)	17 (0.03)
MENINGITIS BACTERIAL	2 (0.04)		1 (0.00)		3 (0.01)
MENINGITIS CRYPTOCOCCAL		2 (0.01)			2 (0.00)
MENINGITIS ENTEROVIRAL	1 (0.02)				1 (0.00)
MENINGITIS LISTERIA		1 (0.01)			1 (0.00)
MENINGITIS PNEUMOCOCCAL		2 (0.01)			2 (0.00)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MENINGITIS STREPTOCOCCAL				1 (0.02)	1 (0.00)
MENINGOCOCCAL SEPSIS	1 (0.02)				1 (0.00)
MENINGOENCEPHALITIS HERPETIC		1 (0.01)			1 (0.00)
MENISCUS LESION		3 (0.02)	8 (0.03)		11 (0.02)
MENISCUS OPERATION			2 (0.01)		2 (0.00)
MENOMETRORRHAGIA		1 (0.01)	1 (0.00)		2 (0.00)
MENOPAUSAL SYMPTOMS		17 (0.12)	165 (0.62)	1 (0.02)	183 (0.35)
MENOPAUSAL SYMPTOMS PROPHYLAXIS			1 (0.00)		1 (0.00)
MENOPAUSE	1 (0.02)	13 (0.09)	66 (0.25)	2 (0.03)	82 (0.16)
MENORRHAGIA	5 (0.10)	24 (0.16)	3 (0.01)		32 (0.06)
MENSTRUAL DISCOMFORT	1 (0.02)	2 (0.01)			3 (0.01)
MENSTRUAL DISORDER	1 (0.02)	9 (0.06)	3 (0.01)		13 (0.02)
MENSTRUATION IRREGULAR	8 (0.17)	11 (0.08)	6 (0.02)	1 (0.02)	26 (0.05)
MENTAL DISORDER	2 (0.04)	14 (0.10)	13 (0.05)	1 (0.02)	30 (0.06)
MENTAL IMPAIRMENT		1 (0.01)			1 (0.00)
MENTAL RETARDATION SEVERITY UNSPECIFIED		4 (0.03)	1 (0.00)		5 (0.01)
MENTAL STATUS CHANGES		1 (0.01)		3 (0.05)	4 (0.01)
MESOTHELIOMA			10 (0.04)	2 (0.03)	12 (0.02)
MESOTHELIOMA MALIGNANT			2 (0.01)		2 (0.00)
METABOLIC ACIDOSIS	1 (0.02)				1 (0.00)
METABOLIC DISORDER		2 (0.01)	8 (0.03)	1 (0.02)	11 (0.02)
METABOLIC SYNDROME		1 (0.01)	1 (0.00)		2 (0.00)
METAL POISONING			1 (0.00)		1 (0.00)
METASTASES TO ADRENALS			2 (0.01)		2 (0.00)
METASTASES TO BONE		22 (0.15)	167 (0.63)	30 (0.46)	219 (0.42)
METASTASES TO CENTRAL NERVOUS SYSTEM		3 (0.02)	11 (0.04)	2 (0.03)	16 (0.03)
METASTASES TO KIDNEY			2 (0.01)		2 (0.00)
METASTASES TO LIVER		3 (0.02)	14 (0.05)		17 (0.03)

Indication Summary Table

Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
METASTASES TO LUNG		1 (0.01)	7 (0.03)	1 (0.02)	9 (0.02)
METASTASES TO LYMPH NODES			1 (0.00)		1 (0.00)
METASTASES TO MENINGES			1 (0.00)		1 (0.00)
METASTASES TO PERITONEUM			1 (0.00)		1 (0.00)
METASTASES TO PLEURA			2 (0.01)		2 (0.00)
METASTASES TO SMALL INTESTINE			1 (0.00)		1 (0.00)
METASTASIS		2 (0.01)	11 (0.04)		13 (0.02)
METASTATIC BRONCHIAL CARCINOMA			1 (0.00)		1 (0.00)
METASTATIC CARCINOMA OF THE BLADDER		3 (0.02)			3 (0.01)
METASTATIC GASTRIC CANCER		4 (0.03)	5 (0.02)		9 (0.02)
METASTATIC MALIGNANT MELANOMA		9 (0.06)	39 (0.15)	3 (0.05)	51 (0.10)
METASTATIC NEOPLASM		1 (0.01)	7 (0.03)	1 (0.02)	9 (0.02)
METASTATIC PAIN			1 (0.00)		1 (0.00)
METASTATIC RENAL CELL CARCINOMA		18 (0.12)	130 (0.49)	20 (0.30)	168 (0.32)
METRORRHAGIA	1 (0.02)	2 (0.01)	5 (0.02)		8 (0.02)
MICROSPORIDIA INFECTION		1 (0.01)			1 (0.00)
MICTURITION DISORDER		1 (0.01)	6 (0.02)		7 (0.01)
MICTURITION URGENCY		1 (0.01)	6 (0.02)	7 (0.11)	14 (0.03)
MIDDLE INSOMNIA		8 (0.05)	21 (0.08)	9 (0.14)	38 (0.07)
MIGRAINE	28 (0.58)	205 (1.40)	116 (0.44)	3 (0.05)	352 (0.67)
MIGRAINE PROPHYLAXIS	2 (0.04)	6 (0.04)	11 (0.04)		19 (0.04)
MIGRAINE WITH AURA		4 (0.03)	1 (0.00)		5 (0.01)
MIGRAINE WITHOUT AURA		1 (0.01)	2 (0.01)		3 (0.01)
MILLER FISHER SYNDROME			4 (0.02)		4 (0.01)
MINERAL SUPPLEMENTATION		2 (0.01)	22 (0.08)	9 (0.14)	33 (0.06)
MIOSIS			1 (0.00)	2 (0.03)	3 (0.01)
MITOCHONDRIAL CYTOPATHY		1 (0.01)			1 (0.00)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MITOCHONDRIAL ENCEPHALOMYOPATHY	3 (0.06)				3 (0.01)
MITRAL VALVE DISEASE			1 (0.00)	1 (0.02)	2 (0.00)
MITRAL VALVE INCOMPETENCE			1 (0.00)	1 (0.02)	2 (0.00)
MITRAL VALVE PROLAPSE		3 (0.02)	4 (0.02)	1 (0.02)	8 (0.02)
MITRAL VALVE REPAIR	3 (0.06)		3 (0.01)		6 (0.01)
MITRAL VALVE REPLACEMENT		1 (0.01)	8 (0.03)	5 (0.08)	14 (0.03)
MIXED CONNECTIVE TISSUE DISEASE		2 (0.01)			2 (0.00)
MIXED HYPERLIPIDAEMIA		1 (0.01)	3 (0.01)		4 (0.01)
MOANING			1 (0.00)		1 (0.00)
MONARTHRITIS		42 (0.29)	108 (0.41)	17 (0.26)	167 (0.32)
MOOD ALTERED	3 (0.06)	1 (0.01)	3 (0.01)		7 (0.01)
MOOD DISORDER DUE TO A GENERAL MEDICAL CONDIT			3 (0.01)		3 (0.01)
MOOD SWINGS	3 (0.06)	5 (0.03)	5 (0.02)		13 (0.02)
MORGANELLA INFECTION			2 (0.01)		2 (0.00)
MORPHOEA			2 (0.01)		2 (0.00)
MOTION SICKNESS		1 (0.01)	1 (0.00)		2 (0.00)
MOTOR DYSFUNCTION		1 (0.01)			1 (0.00)
MOTOR NEURONE DISEASE				1 (0.02)	1 (0.00)
MOUNTAIN SICKNESS ACUTE		1 (0.01)			1 (0.00)
MOUTH PLAQUE			1 (0.00)		1 (0.00)
MOUTH ULCERATION			4 (0.02)		4 (0.01)
MOVEMENT DISORDER		1 (0.01)			1 (0.00)
MUCOPOLYSACCHARIDOSIS I	6 (0.12)				6 (0.01)
MUCOPOLYSACCHARIDOSIS IH	2 (0.04)				2 (0.00)
MUCORMYCOSIS	1 (0.02)		2 (0.01)		3 (0.01)
MUCOSAL INFLAMMATION		3 (0.02)	7 (0.03)		10 (0.02)
MUCOUS MEMBRANE DISORDER		3 (0.02)			3 (0.01)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
MULTI-ORGAN FAILURE			1 (0.00)		1 (0.00)
MULTIPLE ALLERGIES	5 (0.10)	12 (0.08)	8 (0.03)	1 (0.02)	26 (0.05)
MULTIPLE FRACTURES		1 (0.01)			1 (0.00)
MULTIPLE MYELOMA		68 (0.47)	386 (1.45)	107 (1.63)	561 (1.07)
MULTIPLE PREGNANCY		1 (0.01)			1 (0.00)
MULTIPLE SCLEROSIS	42 (0.87)	906 (6.21)	960 (3.60)	16 (0.24)	1924 (3.65)
MULTIPLE SCLEROSIS RELAPSE		1 (0.01)			1 (0.00)
MULTIPLE-DRUG RESISTANCE			2 (0.01)		2 (0.00)
MUSCLE DISORDER		2 (0.01)	3 (0.01)		5 (0.01)
MUSCLE INJURY		6 (0.04)	4 (0.02)		10 (0.02)
MUSCLE MASS		1 (0.01)			1 (0.00)
MUSCLE RELAXANT THERAPY		12 (0.08)	20 (0.08)	2 (0.03)	34 (0.06)
MUSCLE SPASMS	4 (0.08)	43 (0.29)	67 (0.25)	5 (0.08)	119 (0.23)
MUSCLE SPASTICITY	3 (0.06)	5 (0.03)	9 (0.03)		17 (0.03)
MUSCLE STRAIN	1 (0.02)	5 (0.03)	5 (0.02)	1 (0.02)	12 (0.02)
MUSCLE TIGHTNESS		1 (0.01)			1 (0.00)
MUSCLE TWITCHING		1 (0.01)			1 (0.00)
MUSCULOSKELETAL CHEST PAIN	1 (0.02)	4 (0.03)	8 (0.03)	1 (0.02)	14 (0.03)
MUSCULOSKELETAL DISCOMFORT		4 (0.03)	8 (0.03)		12 (0.02)
MUSCULOSKELETAL DISORDER		6 (0.04)	3 (0.01)		9 (0.02)
MUSCULOSKELETAL PAIN		7 (0.05)	36 (0.14)	4 (0.06)	47 (0.09)
MUSCULOSKELETAL STIFFNESS	1 (0.02)	3 (0.02)	12 (0.05)		16 (0.03)
MYALGIA	2 (0.04)	60 (0.41)	104 (0.39)	9 (0.14)	175 (0.33)
MYASTHENIA GRAVIS		7 (0.05)	14 (0.05)	2 (0.03)	23 (0.04)
MYASTHENIC SYNDROME		3 (0.02)			3 (0.01)
MYCOBACTERIAL INFECTION	1 (0.02)		3 (0.01)	1 (0.02)	5 (0.01)
MYCOBACTERIUM ABSCESSUS INFECTION	1 (0.02)				1 (0.00)
MYCOBACTERIUM AVIUM COMPLEX INFECTION	6 (0.12)	4 (0.03)	2 (0.01)		12 (0.02)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
MYCOSIS FUNGOIDES		5 (0.03)	5 (0.02)	1 (0.02)	11 (0.02)
MYCOTIC CORNEAL ULCER			1 (0.00)		1 (0.00)
MYDRIASIS	1 (0.02)	1 (0.01)			2 (0.00)
MYELITIS		2 (0.01)	2 (0.01)		4 (0.01)
MYELITIS TRANSVERSE		1 (0.01)			1 (0.00)
MYELOYDYSPLASTIC SYNDROME		1 (0.01)	67 (0.25)	64 (0.97)	132 (0.25)
MYELOFIBROSIS			2 (0.01)	1 (0.02)	3 (0.01)
MYELOID LEUKAEMIA			1 (0.00)		1 (0.00)
MYELOMA RECURRENCE			1 (0.00)		1 (0.00)
MYELOPATHY		1 (0.01)	3 (0.01)		4 (0.01)
MYELOPROLIFERATIVE DISORDER			2 (0.01)		2 (0.00)
MYOCARDIAL INFARCTION		15 (0.10)	78 (0.29)	33 (0.50)	126 (0.24)
MYOCARDIAL ISCHAEMIA	1 (0.02)	1 (0.01)	36 (0.14)	19 (0.29)	57 (0.11)
MYOCARDITIS	1 (0.02)				1 (0.00)
MYOCLONIC EPILEPSY	3 (0.06)				3 (0.01)
MYOCLONUS	2 (0.04)		5 (0.02)		7 (0.01)
MYOFASCIAL PAIN SYNDROME		1 (0.01)	1 (0.00)		2 (0.00)
MYOFASCITIS			1 (0.00)		1 (0.00)
MYOPATHY		2 (0.01)	1 (0.00)		3 (0.01)
MYOPIA		1 (0.01)			1 (0.00)
MYOSCLEROSIS		1 (0.01)			1 (0.00)
MYOSITIS		6 (0.04)	5 (0.02)		11 (0.02)
MYRINGITIS			3 (0.01)		3 (0.01)
MYRINGOTOMY	1 (0.02)				1 (0.00)
NAIL INFECTION				1 (0.02)	1 (0.00)
NAIL TINEA	3 (0.06)	25 (0.17)	38 (0.14)	11 (0.17)	77 (0.15)
NARCOLEPSY	1 (0.02)	7 (0.05)	5 (0.02)		13 (0.02)
NASAL CONGESTION	3 (0.06)	13 (0.09)	12 (0.05)		28 (0.05)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
NASAL DECONGESTION THERAPY			2 (0.01)		2 (0.00)
NASAL DISCOMFORT	1 (0.02)				1 (0.00)
NASAL DISORDER		1 (0.01)	1 (0.00)		2 (0.00)
NASAL POLYPS		2 (0.01)			2 (0.00)
NASAL SEPTUM DEVIATION			1 (0.00)		1 (0.00)
NASOPHARYNGEAL CANCER		2 (0.01)	3 (0.01)		5 (0.01)
NASOPHARYNGITIS	33 (0.68)	42 (0.29)	51 (0.19)	14 (0.21)	140 (0.27)
NATURAL KILLER-CELL LYMPHOBLASTIC LYMPHOMA			2 (0.01)		2 (0.00)
NAUSEA	13 (0.27)	34 (0.23)	94 (0.35)	11 (0.17)	152 (0.29)
NECK INJURY		6 (0.04)	7 (0.03)	1 (0.02)	14 (0.03)
NECK MASS	2 (0.04)				2 (0.00)
NECK PAIN	1 (0.02)	81 (0.55)	94 (0.35)	9 (0.14)	185 (0.35)
NECROSIS		1 (0.01)			1 (0.00)
NECROTISING FASCIITIS	2 (0.04)				2 (0.00)
NEONATAL ASPIRATION	1 (0.02)				1 (0.00)
NEONATAL RESPIRATORY DISTRESS SYNDROME	1 (0.02)				1 (0.00)
NEOPLASM	3 (0.06)	1 (0.01)	7 (0.03)	2 (0.03)	13 (0.02)
NEOPLASM MALIGNANT		14 (0.10)	54 (0.20)	10 (0.15)	78 (0.15)
NEOPLASM PROPHYLAXIS			12 (0.05)		12 (0.02)
NEOPLASM PROSTATE			1 (0.00)	1 (0.02)	2 (0.00)
NEOPLASM RECURRENCE	1 (0.02)				1 (0.00)
NEPHROBLASTOMA	3 (0.06)				3 (0.01)
NEPHROGENIC ANAEMIA	1 (0.02)	1 (0.01)	3 (0.01)	3 (0.05)	8 (0.02)
NEPHROLITHIASIS		2 (0.01)	5 (0.02)		7 (0.01)
NEPHROSTOMY TUBE PLACEMENT			1 (0.00)		1 (0.00)
NEPHROTIC SYNDROME	6 (0.12)	11 (0.08)	9 (0.03)	1 (0.02)	27 (0.05)
NERVE BLOCK		1 (0.01)	5 (0.02)	2 (0.03)	8 (0.02)
NERVE COMPRESSION		4 (0.03)	4 (0.02)	3 (0.05)	11 (0.02)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
NERVE INJURY		12 (0.08)	10 (0.04)	6 (0.09)	28 (0.05)
NERVE ROOT COMPRESSION			1 (0.00)		1 (0.00)
NERVOUS SYSTEM DISORDER	1 (0.02)	1 (0.01)	4 (0.02)		6 (0.01)
NERVOUSNESS		7 (0.05)	5 (0.02)	2 (0.03)	14 (0.03)
NEURALGIA	2 (0.04)	63 (0.43)	102 (0.38)	33 (0.50)	200 (0.38)
NEURITIS		2 (0.01)	1 (0.00)		3 (0.01)
NEUROBLASTOMA	6 (0.12)				6 (0.01)
NEUROBORRELIOSIS	1 (0.02)				1 (0.00)
NEUROENDOCRINE CARCINOMA				1 (0.02)	1 (0.00)
NEUROENDOCRINE TUMOUR		2 (0.01)	4 (0.02)		6 (0.01)
NEUROFIBROMATOSIS		1 (0.01)			1 (0.00)
NEUROGENIC BLADDER	1 (0.02)		3 (0.01)	3 (0.05)	7 (0.01)
NEUROLEPTIC MALIGNANT SYNDROME			1 (0.00)		1 (0.00)
NEUROMA			2 (0.01)		2 (0.00)
NEUROMUSCULAR BLOCKADE		3 (0.02)			3 (0.01)
NEUROMUSCULAR BLOCKADE REVERSAL	1 (0.02)				1 (0.00)
NEUROMUSCULAR BLOCKING THERAPY	1 (0.02)				1 (0.00)
NEUROMYELITIS OPTICA			2 (0.01)		2 (0.00)
NEUROMYOPATHY		2 (0.01)			2 (0.00)
NEUROPATHY		19 (0.13)	68 (0.26)	15 (0.23)	102 (0.19)
NEUROPATHY PERIPHERAL		13 (0.09)	53 (0.20)	31 (0.47)	97 (0.18)
NEUROSIS	1 (0.02)	1 (0.01)	2 (0.01)	3 (0.05)	7 (0.01)
NEUTROPENIA			8 (0.03)	2 (0.03)	10 (0.02)
NICOTINE DEPENDENCE		1 (0.01)			1 (0.00)
NIGHT SWEATS			3 (0.01)		3 (0.01)
NIGHTMARE	1 (0.02)		1 (0.00)		2 (0.00)
NOCARDIOSIS	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.01)
NOCTURIA			3 (0.01)	4 (0.06)	7 (0.01)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
NON-CARDIAC CHEST PAIN			1 (0.00)		1 (0.00)
NON-HODGKIN'S LYMPHOMA	4 (0.08)	23 (0.16)	91 (0.34)	24 (0.36)	142 (0.27)
NON-HODGKIN'S LYMPHOMA RECURRENT			1 (0.00)		1 (0.00)
NON-HODGKIN'S LYMPHOMA STAGE II			2 (0.01)		2 (0.00)
NON-HODGKIN'S LYMPHOMA STAGE IV			1 (0.00)		1 (0.00)
NON-SMALL CELL LUNG CANCER		53 (0.36)	448 (1.68)	91 (1.38)	592 (1.12)
NON-SMALL CELL LUNG CANCER METASTATIC		4 (0.03)	9 (0.03)	4 (0.06)	17 (0.03)
NON-SMALL CELL LUNG CANCER RECURRENT			4 (0.02)	1 (0.02)	5 (0.01)
NON-SMALL CELL LUNG CANCER STAGE II			1 (0.00)		1 (0.00)
NON-SMALL CELL LUNG CANCER STAGE IIIB		1 (0.01)	10 (0.04)		11 (0.02)
NON-SMALL CELL LUNG CANCER STAGE IV			11 (0.04)	2 (0.03)	13 (0.02)
NOSOCOMIAL INFECTION			2 (0.01)	1 (0.02)	3 (0.01)
NUCLEAR MAGNETIC RESONANCE IMAGING	3 (0.06)	12 (0.08)	10 (0.04)	4 (0.06)	29 (0.06)
NUCLEAR MAGNETIC RESONANCE IMAGING BRAIN	7 (0.14)	10 (0.07)	8 (0.03)	2 (0.03)	27 (0.05)
NUTRITIONAL SUPPORT	1 (0.02)	1 (0.01)	2 (0.01)	5 (0.08)	9 (0.02)
OBESITY	2 (0.04)	26 (0.18)	20 (0.08)		48 (0.09)
OBSESSIVE THOUGHTS	1 (0.02)				1 (0.00)
OBSESSIVE-COMPULSIVE DISORDER	17 (0.35)	37 (0.25)	12 (0.05)		66 (0.13)
OBSESSIVE-COMPULSIVE PERSONALITY DISORDER	3 (0.06)				3 (0.01)
OBSTRUCTIVE AIRWAYS DISORDER		1 (0.01)	1 (0.00)		2 (0.00)
OCULAR HYPERAEMIA				1 (0.02)	1 (0.00)
OCULAR HYPERTENSION			4 (0.02)		4 (0.01)
OEDEMA	1 (0.02)	5 (0.03)	31 (0.12)	16 (0.24)	53 (0.10)
OEDEMA PERIPHERAL		14 (0.10)	28 (0.11)	10 (0.15)	52 (0.10)
OESOPHAGEAL ADENOCARCINOMA			1 (0.00)		1 (0.00)
OESOPHAGEAL ADENOCARCINOMA METASTATIC			1 (0.00)		1 (0.00)
OESOPHAGEAL CANCER METASTATIC			4 (0.02)		4 (0.01)
OESOPHAGEAL CANDIDIASIS			1 (0.00)	1 (0.02)	2 (0.00)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
OESOPHAGEAL CARCINOMA		5 (0.03)	10 (0.04)	4 (0.06)	19 (0.04)
OESOPHAGEAL DISORDER		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)
OESOPHAGEAL INJURY			1 (0.00)		1 (0.00)
OESOPHAGEAL SPASM		1 (0.01)			1 (0.00)
OESOPHAGEAL SQUAMOUS CELL CARCINOMA		4 (0.03)	1 (0.00)		5 (0.01)
OESOPHAGEAL STENOSIS			1 (0.00)		1 (0.00)
OESOPHAGEAL ULCER			2 (0.01)		2 (0.00)
OESOPHAGITIS		4 (0.03)	20 (0.08)	3 (0.05)	27 (0.05)
OESOPHAGOGASTRODUODENOSCOPY		1 (0.01)			1 (0.00)
OESTROGEN RECEPTOR ASSAY POSITIVE			1 (0.00)		1 (0.00)
OESTROGEN REPLACEMENT THERAPY		8 (0.05)	22 (0.08)	1 (0.02)	31 (0.06)
OFF LABEL USE		3 (0.02)	3 (0.01)		6 (0.01)
OLIGODENDROGLIOMA	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.01)
OLIGOMENORRHOEA	1 (0.02)				1 (0.00)
OLIGURIA			2 (0.01)	2 (0.03)	4 (0.01)
ONYCHOMYCOSIS	1 (0.02)	10 (0.07)	8 (0.03)	2 (0.03)	21 (0.04)
OOPHORECTOMY		2 (0.01)			2 (0.00)
OPEN ANGLE GLAUCOMA				2 (0.03)	2 (0.00)
OPEN FRACTURE			3 (0.01)		3 (0.01)
OPEN WOUND		1 (0.01)			1 (0.00)
OPERATIVE HAEMORRHAGE		1 (0.01)	3 (0.01)		4 (0.01)
OPHTHALMIC FLUID DRAINAGE			1 (0.00)		1 (0.00)
OPHTHALMOLOGICAL EXAMINATION		1 (0.01)			1 (0.00)
OPPORTUNISTIC INFECTION		1 (0.01)			1 (0.00)
OPPOSITIONAL DEFIANT DISORDER	1 (0.02)				1 (0.00)
OPTIC ISCHAEMIC NEUROPATHY			1 (0.00)		1 (0.00)
ORAL CANDIDIASIS	2 (0.04)	5 (0.03)	6 (0.02)	1 (0.02)	14 (0.03)
ORAL CONTRACEPTION	28 (0.58)	23 (0.16)			51 (0.10)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
ORAL DISCOMFORT		1 (0.01)			1 (0.00)
ORAL FUNGAL INFECTION			1 (0.00)	1 (0.02)	2 (0.00)
ORAL INFECTION				1 (0.02)	1 (0.00)
ORAL INTAKE REDUCED				2 (0.03)	2 (0.00)
ORAL LICHEN PLANUS			1 (0.00)		1 (0.00)
ORAL PAIN		1 (0.01)	2 (0.01)		3 (0.01)
ORAL SURGERY			1 (0.00)		1 (0.00)
ORBITAL INFECTION		1 (0.01)			1 (0.00)
ORGAN TRANSPLANT			2 (0.01)		2 (0.00)
OROPHARYNGEAL CANCER RECURRENT			1 (0.00)		1 (0.00)
OROPHARYNGEAL CANCER STAGE UNSPECIFIED			6 (0.02)		6 (0.01)
ORTHOSTATIC HYPOTENSION	2 (0.04)		5 (0.02)	1 (0.02)	8 (0.02)
ORTHOSTATIC INTOLERANCE			1 (0.00)		1 (0.00)
OSTEITIS		2 (0.01)	5 (0.02)		7 (0.01)
OSTEITIS DEFORMANS			2 (0.01)	1 (0.02)	3 (0.01)
OSTEOARTHRITIS		176 (1.21)	875 (3.29)	203 (3.09)	1254 (2.38)
OSTEOARTHROPATHY			1 (0.00)		1 (0.00)
OSTEOCHONDROSIS			3 (0.01)		3 (0.01)
OSTEOLYSIS		1 (0.01)	3 (0.01)		4 (0.01)
OSTEOMYELITIS	8 (0.17)	13 (0.09)	12 (0.05)	5 (0.08)	38 (0.07)
OSTEONECROSIS			3 (0.01)		3 (0.01)
OSTEOPENIA		10 (0.07)	36 (0.14)	5 (0.08)	51 (0.10)
OSTEOPOROSIS	5 (0.10)	70 (0.48)	621 (2.33)	510 (7.75)	1206 (2.29)
OSTEOPOROSIS POSTMENOPAUSAL			36 (0.14)	17 (0.26)	53 (0.10)
OSTEOPOROSIS PROPHYLAXIS		4 (0.03)	20 (0.08)	3 (0.05)	27 (0.05)
OSTEOPOROTIC FRACTURE			4 (0.02)		4 (0.01)
OTITIS EXTERNA			1 (0.00)		1 (0.00)
OTITIS MEDIA	9 (0.19)	3 (0.02)	6 (0.02)		18 (0.03)

Indication Summary Table

Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
OTITIS MEDIA ACUTE	1 (0.02)	2 (0.01)			3 (0.01)
OTITIS MEDIA CHRONIC	1 (0.02)		1 (0.00)		2 (0.00)
OTORRHOEA	1 (0.02)				1 (0.00)
OVARIAN CANCER		28 (0.19)	108 (0.41)	7 (0.11)	143 (0.27)
OVARIAN CANCER METASTATIC		1 (0.01)	2 (0.01)	1 (0.02)	4 (0.01)
OVARIAN CYST		5 (0.03)			5 (0.01)
OVARIAN DISORDER		2 (0.01)			2 (0.00)
OVARIAN EPITHELIAL CANCER		1 (0.01)	3 (0.01)		4 (0.01)
OVARIAN EPITHELIAL CANCER RECURRENT			4 (0.02)	3 (0.05)	7 (0.01)
OVARIAN FAILURE		2 (0.01)			2 (0.00)
OVARIAN GERM CELL CANCER		3 (0.02)			3 (0.01)
OVARIAN HYPERSTIMULATION SYNDROME		2 (0.01)			2 (0.00)
OVERDOSE	13 (0.27)	5 (0.03)			18 (0.03)
OVERGROWTH BACTERIAL		1 (0.01)			1 (0.00)
OVERWEIGHT		3 (0.02)	1 (0.00)		4 (0.01)
OVULATION INDUCTION	3 (0.06)	12 (0.08)			15 (0.03)
OVULATION PAIN		1 (0.01)			1 (0.00)
OXYGEN SATURATION DECREASED		2 (0.01)			2 (0.00)
OXYGEN SUPPLEMENTATION		1 (0.01)			1 (0.00)
PACEMAKER COMPLICATION			1 (0.00)		1 (0.00)
PAIN	39 (0.81)	533 (3.65)	1114 (4.18)	221 (3.36)	1907 (3.62)
PAIN IN EXTREMITY	5 (0.10)	114 (0.78)	242 (0.91)	42 (0.64)	403 (0.77)
PAIN IN JAW		4 (0.03)	2 (0.01)		6 (0.01)
PAIN MANAGEMENT	4 (0.08)	62 (0.42)	109 (0.41)	16 (0.24)	191 (0.36)
PAIN PROPHYLAXIS		1 (0.01)	3 (0.01)		4 (0.01)
PALLIATIVE CARE			6 (0.02)		6 (0.01)
PALPITATIONS		1 (0.01)	6 (0.02)		7 (0.01)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
PANCREATIC CARCINOMA	1 (0.02)	10 (0.07)	81 (0.30)	17 (0.26)	109 (0.21)
PANCREATIC CARCINOMA METASTATIC		5 (0.03)	17 (0.06)	1 (0.02)	23 (0.04)
PANCREATIC CARCINOMA RECURRENT			1 (0.00)		1 (0.00)
PANCREATIC CARCINOMA STAGE IV			11 (0.04)	1 (0.02)	12 (0.02)
PANCREATIC DISORDER			2 (0.01)	1 (0.02)	3 (0.01)
PANCREATIC ENZYMES			1 (0.00)		1 (0.00)
PANCREATIC INSUFFICIENCY		5 (0.03)			5 (0.01)
PANCREATIC NEOPLASM			1 (0.00)		1 (0.00)
PANCREATIC PSEUDOCYST				1 (0.02)	1 (0.00)
PANCREATITIS	1 (0.02)	1 (0.01)	9 (0.03)		11 (0.02)
PANCREATITIS ACUTE		1 (0.01)	1 (0.00)		2 (0.00)
PANCREATITIS CHRONIC		1 (0.01)	1 (0.00)		2 (0.00)
PANCYTOPENIA			5 (0.02)		5 (0.01)
PANIC ATTACK	3 (0.06)	21 (0.14)	16 (0.06)		40 (0.08)
PANIC DISORDER	10 (0.21)	52 (0.36)	27 (0.10)	5 (0.08)	94 (0.18)
PANIC DISORDER WITH AGORAPHOBIA		1 (0.01)			1 (0.00)
PANIC REACTION		6 (0.04)	6 (0.02)		12 (0.02)
PANNICULITIS			1 (0.00)		1 (0.00)
PAPILLARY THYROID CANCER			1 (0.00)		1 (0.00)
PAPILLOMA			1 (0.00)		1 (0.00)
PARAESTHESIA	1 (0.02)	1 (0.01)	6 (0.02)	2 (0.03)	10 (0.02)
PARAGANGLION NEOPLASM			1 (0.00)		1 (0.00)
PARAINFLUENZAE VIRUS INFECTION		1 (0.01)			1 (0.00)
PARALYSIS			1 (0.00)		1 (0.00)
PARANEOPLASTIC SYNDROME			4 (0.02)		4 (0.01)
PARANOIA	1 (0.02)	8 (0.05)	6 (0.02)	2 (0.03)	17 (0.03)
PARAPLEGIA		2 (0.01)			2 (0.00)
PARAPROTEINAEMIA				1 (0.02)	1 (0.00)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
PARENTERAL NUTRITION			1 (0.00)		1 (0.00)
PARESIS	2 (0.04)				2 (0.00)
PARKINSON'S DISEASE		18 (0.12)	191 (0.72)	67 (1.02)	276 (0.52)
PARKINSONISM	1 (0.02)	4 (0.03)	4 (0.02)	13 (0.20)	22 (0.04)
PARONYCHIA			3 (0.01)		3 (0.01)
PAROPHTHALMIA			1 (0.00)		1 (0.00)
PAROTITIS			1 (0.00)		1 (0.00)
PAROXYSMAL ARRHYTHMIA				1 (0.02)	1 (0.00)
PARTIAL SEIZURES	13 (0.27)	7 (0.05)	5 (0.02)		25 (0.05)
PARTIAL SEIZURES WITH SECONDARY GENERALISATIO		2 (0.01)			2 (0.00)
PATELLA FRACTURE			1 (0.00)		1 (0.00)
PATELLOFEMORAL PAIN SYNDROME				2 (0.03)	2 (0.00)
PATENT DUCTUS ARTERIOSUS	1 (0.02)				1 (0.00)
PATHOGEN RESISTANCE			3 (0.01)		3 (0.01)
PELVIC ABSCESS		1 (0.01)			1 (0.00)
PELVIC FRACTURE		1 (0.01)		1 (0.02)	2 (0.00)
PELVIC HAEMORRHAGE			2 (0.01)		2 (0.00)
PELVIC INFECTION		3 (0.02)			3 (0.01)
PELVIC INFLAMMATORY DISEASE		1 (0.01)			1 (0.00)
PELVIC PAIN	2 (0.04)	5 (0.03)	2 (0.01)	1 (0.02)	10 (0.02)
PEMPHIGOID			2 (0.01)	4 (0.06)	6 (0.01)
PEMPHIGUS		6 (0.04)	3 (0.01)		9 (0.02)
PEPTIC ULCER		1 (0.01)	10 (0.04)	6 (0.09)	17 (0.03)
PERCUTANEOUS CORONARY INTERVENTION		1 (0.01)	4 (0.02)	4 (0.06)	9 (0.02)
PERIARTHRITIS		5 (0.03)	11 (0.04)	1 (0.02)	17 (0.03)
PERICARDITIS	1 (0.02)	2 (0.01)	1 (0.00)		4 (0.01)
PERICARDITIS TUBERCULOUS		1 (0.01)			1 (0.00)
PERICHONDritis		1 (0.01)			1 (0.00)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
PERIODIC LIMB MOVEMENT DISORDER			3 (0.01)		3 (0.01)
PERIODONTAL DISEASE		1 (0.01)		1 (0.02)	2 (0.00)
PERIODONTITIS		3 (0.02)		1 (0.02)	4 (0.01)
PERIOPERATIVE ANALGESIA	2 (0.04)				2 (0.00)
PERIORBITAL CELLULITIS	1 (0.02)				1 (0.00)
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE			3 (0.01)	4 (0.06)	7 (0.01)
PERIPHERAL BLOOD STEM CELL APHERESIS			1 (0.00)		1 (0.00)
PERIPHERAL CIRCULATORY FAILURE		1 (0.01)			1 (0.00)
PERIPHERAL EMBOLISM		3 (0.02)			3 (0.01)
PERIPHERAL ISCHAEMIA		1 (0.01)	3 (0.01)		4 (0.01)
PERIPHERAL NERVE INJURY				1 (0.02)	1 (0.00)
PERIPHERAL SENSORY NEUROPATHY			1 (0.00)		1 (0.00)
PERIPHERAL VASCULAR DISORDER			8 (0.03)	5 (0.08)	13 (0.02)
PERITONEAL CARCINOMA			4 (0.02)		4 (0.01)
PERITONEAL DIALYSIS			4 (0.02)	1 (0.02)	5 (0.01)
PERITONEAL HAEMORRHAGE	2 (0.04)				2 (0.00)
PERITONEAL MESOTHELIOMA MALIGNANT			5 (0.02)		5 (0.01)
PERITONITIS	2 (0.04)	1 (0.01)	1 (0.00)	2 (0.03)	6 (0.01)
PERNICIOUS ANAEMIA			1 (0.00)	3 (0.05)	4 (0.01)
PERONEAL NERVE PALSY			1 (0.00)		1 (0.00)
PERSECUTORY DELUSION		2 (0.01)	1 (0.00)		3 (0.01)
PERSONALITY DISORDER	2 (0.04)	8 (0.05)	1 (0.00)		11 (0.02)
PERTUSSIS			1 (0.00)		1 (0.00)
PETECHIAE			2 (0.01)		2 (0.00)
PETIT MAL EPILEPSY	3 (0.06)	8 (0.05)			11 (0.02)
PHAEOCHROMOCYTOMA			1 (0.00)		1 (0.00)
PHANTOM PAIN			2 (0.01)		2 (0.00)
PHARYNGEAL POLYP			1 (0.00)		1 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
PHARYNGITIS	7 (0.14)	16 (0.11)	5 (0.02)	4 (0.06)	32 (0.06)
PHARYNGITIS STREPTOCOCCAL	4 (0.08)	3 (0.02)	1 (0.00)		8 (0.02)
PHARYNGOLARYNGEAL PAIN	9 (0.19)	14 (0.10)	3 (0.01)	1 (0.02)	27 (0.05)
PHLEBITIS		1 (0.01)	4 (0.02)	4 (0.06)	9 (0.02)
PHOTOSENSITIVITY ALLERGIC REACTION		2 (0.01)			2 (0.00)
PHOTOSENSITIVITY REACTION			2 (0.01)		2 (0.00)
PHYSICAL EXAMINATION		1 (0.01)			1 (0.00)
PHYSIOTHERAPY		1 (0.01)			1 (0.00)
PITUITARY CYST		1 (0.01)			1 (0.00)
PITUITARY TUMOUR	1 (0.02)		1 (0.00)		2 (0.00)
PITUITARY TUMOUR BENIGN		4 (0.03)	1 (0.00)		5 (0.01)
PITUITARY-DEPENDENT CUSHING'S SYNDROME		1 (0.01)			1 (0.00)
PITYRIASIS ALBA	1 (0.02)				1 (0.00)
PITYRIASIS RUBRA PILARIS		1 (0.01)		1 (0.02)	2 (0.00)
PLANTAR FASCIITIS		10 (0.07)	10 (0.04)		20 (0.04)
PLASMACYTOMA			2 (0.01)	1 (0.02)	3 (0.01)
PLASMACYTOSIS			1 (0.00)		1 (0.00)
PLASMAPHERESIS		1 (0.01)			1 (0.00)
PLASMODIUM FALCIPARUM INFECTION	4 (0.08)				4 (0.01)
PLASTIC SURGERY			1 (0.00)		1 (0.00)
PLATELET AGGREGATION			1 (0.00)		1 (0.00)
PLATELET AGGREGATION INHIBITION			2 (0.01)	1 (0.02)	3 (0.01)
PLATELET COUNT DECREASED		1 (0.01)			1 (0.00)
PLATELET COUNT INCREASED			2 (0.01)		2 (0.00)
PLATELET DISORDER		1 (0.01)	1 (0.00)		2 (0.00)
PLEURAL EFFUSION			2 (0.01)	2 (0.03)	4 (0.01)
PLEURAL INFECTION			1 (0.00)		1 (0.00)
PLEURAL MESOTHELIOMA			4 (0.02)	1 (0.02)	5 (0.01)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
PLEURAL MESOTHELIOMA MALIGNANT			6 (0.02)	1 (0.02)	7 (0.01)
PLEURAL MESOTHELIOMA MALIGNANT ADVANCED			1 (0.00)		1 (0.00)
PLEURISY		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)
PNEUMOCYSTIS JIROVECI INFECTION	1 (0.02)	1 (0.01)	2 (0.01)	1 (0.02)	5 (0.01)
PNEUMOCYSTIS JIROVECI PNEUMONIA	5 (0.10)	3 (0.02)	2 (0.01)		10 (0.02)
PNEUMONIA	21 (0.43)	42 (0.29)	86 (0.32)	81 (1.23)	230 (0.44)
PNEUMONIA ASPERGILLUS	1 (0.02)		1 (0.00)	2 (0.03)	4 (0.01)
PNEUMONIA ASPIRATION			5 (0.02)	1 (0.02)	6 (0.01)
PNEUMONIA BACTERIAL			6 (0.02)		6 (0.01)
PNEUMONIA CHLAMYDIAL				1 (0.02)	1 (0.00)
PNEUMONIA CYTOMEGALOVIRAL	1 (0.02)				1 (0.00)
PNEUMONIA FUNGAL		2 (0.01)		1 (0.02)	3 (0.01)
PNEUMONIA HAEMOPHILUS			2 (0.01)		2 (0.00)
PNEUMONIA LEGIONELLA		1 (0.01)			1 (0.00)
PNEUMONIA MYCOPLASMAL		2 (0.01)		1 (0.02)	3 (0.01)
PNEUMONIA PNEUMOCOCCAL		1 (0.01)			1 (0.00)
PNEUMONIA PRIMARY ATYPICAL	2 (0.04)				2 (0.00)
PNEUMONIA STAPHYLOCOCCAL			2 (0.01)	2 (0.03)	4 (0.01)
PNEUMONIA STREPTOCOCCAL		1 (0.01)		2 (0.03)	3 (0.01)
PNEUMONITIS			1 (0.00)	3 (0.05)	4 (0.01)
PNEUMONITIS CRYPTOCCAL			1 (0.00)		1 (0.00)
POISONING	2 (0.04)				2 (0.00)
POISONING DELIBERATE	2 (0.04)				2 (0.00)
POLAKIURIA		2 (0.01)	22 (0.08)	21 (0.32)	45 (0.09)
POLYARTERITIS NODOSA		3 (0.02)			3 (0.01)
POLYARTHRITIS	2 (0.04)	13 (0.09)	29 (0.11)	4 (0.06)	48 (0.09)
POLYCYSTIC OVARIES	1 (0.02)	5 (0.03)			6 (0.01)
POLYCYTHAEMIA VERA			1 (0.00)	1 (0.02)	2 (0.00)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
POLYDIPSIA		1 (0.01)			1 (0.00)
POLYMORPHIC LIGHT ERUPTION				1 (0.02)	1 (0.00)
POLYMYALGIA			3 (0.01)		3 (0.01)
POLYMYALGIA RHEUMATICA			12 (0.05)	5 (0.08)	17 (0.03)
POLYMYOSITIS		1 (0.01)	5 (0.02)		6 (0.01)
POLYNEUROPATHY		2 (0.01)	8 (0.03)	9 (0.14)	19 (0.04)
POLYSUBSTANCE ABUSE		1 (0.01)			1 (0.00)
POLYURIA		1 (0.01)	11 (0.04)	6 (0.09)	18 (0.03)
POOR PERIPHERAL CIRCULATION			4 (0.02)	1 (0.02)	5 (0.01)
PORIOMANIA				1 (0.02)	1 (0.00)
PORTAL HYPERTENSION			1 (0.00)		1 (0.00)
PORTAL VEIN THROMBOSIS			1 (0.00)		1 (0.00)
POST ABORTION HAEMORRHAGE		1 (0.01)			1 (0.00)
POST CHOLECYSTECTOMY SYNDROME		1 (0.01)			1 (0.00)
POST COITAL CONTRACEPTION		3 (0.02)			3 (0.01)
POST GASTRIC SURGERY SYNDROME			1 (0.00)		1 (0.00)
POST HERPETIC NEURALGIA		5 (0.03)	24 (0.09)	24 (0.36)	53 (0.10)
POST POLIO SYNDROME			4 (0.02)		4 (0.01)
POST PROCEDURAL CELLULITIS		2 (0.01)			2 (0.00)
POST PROCEDURAL COMPLICATION			4 (0.02)	1 (0.02)	5 (0.01)
POST PROCEDURAL HAEMORRHAGE	3 (0.06)	2 (0.01)	3 (0.01)	2 (0.03)	10 (0.02)
POST PROCEDURAL HEADACHE			1 (0.00)		1 (0.00)
POST PROCEDURAL HYPOTHYROIDISM		1 (0.01)	2 (0.01)		3 (0.01)
POST PROCEDURAL NAUSEA	1 (0.02)	2 (0.01)	3 (0.01)	1 (0.02)	7 (0.01)
POST PROCEDURAL URINE LEAK			1 (0.00)		1 (0.00)
POST PROCEDURAL VOMITING		2 (0.01)		1 (0.02)	3 (0.01)
POST-TRAUMATIC EPILEPSY		1 (0.01)	3 (0.01)		4 (0.01)
POST-TRAUMATIC HEADACHE		1 (0.01)			1 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
POST-TRAUMATIC PAIN		3 (0.02)			3 (0.01)
POST-TRAUMATIC STRESS DISORDER	3 (0.06)	20 (0.14)	9 (0.03)	2 (0.03)	34 (0.06)
POSTMENOPAUSE			7 (0.03)		7 (0.01)
POSTNASAL DRIP			2 (0.01)	1 (0.02)	3 (0.01)
POSTOPERATIVE ANALGESIA	3 (0.06)	7 (0.05)	8 (0.03)	1 (0.02)	19 (0.04)
POSTOPERATIVE CARE		3 (0.02)	9 (0.03)	1 (0.02)	13 (0.02)
POSTOPERATIVE INFECTION		1 (0.01)	3 (0.01)	1 (0.02)	5 (0.01)
POSTOPERATIVE WOUND INFECTION		1 (0.01)	3 (0.01)	1 (0.02)	5 (0.01)
POSTPARTUM DEPRESSION	1 (0.02)	11 (0.08)			12 (0.02)
POSTPARTUM HAEMORRHAGE	3 (0.06)				3 (0.01)
POSTPARTUM HYPOPIUITARISM		1 (0.01)			1 (0.00)
POSTPERICARDIOTOMY SYNDROME		1 (0.01)			1 (0.00)
PRADER-WILLI SYNDROME	5 (0.10)				5 (0.01)
PRE-ECLAMPSIA	2 (0.04)	5 (0.03)			7 (0.01)
PRE-EXISTING DISEASE	2 (0.04)	2 (0.01)	2 (0.01)		6 (0.01)
PRECANCEROUS CELLS PRESENT			1 (0.00)		1 (0.00)
PRECOCIOUS PUBERTY	6 (0.12)				6 (0.01)
PREGNANCY	4 (0.08)	3 (0.02)	1 (0.00)		8 (0.02)
PREGNANCY INDUCED HYPERTENSION	1 (0.02)				1 (0.00)
PREMATURE LABOUR	4 (0.08)	1 (0.01)			5 (0.01)
PREMEDICATION	6 (0.12)	46 (0.32)	117 (0.44)	15 (0.23)	184 (0.35)
PREMENSTRUAL SYNDROME	1 (0.02)	5 (0.03)			6 (0.01)
PREOPERATIVE CARE	3 (0.06)	6 (0.04)	15 (0.06)		24 (0.05)
PRIMARY AMYLOIDOSIS			1 (0.00)		1 (0.00)
PRIMARY IMMUNODEFICIENCY SYNDROME			1 (0.00)		1 (0.00)
PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS		3 (0.02)	3 (0.01)		6 (0.01)
PRINZMETAL ANGINA		1 (0.01)			1 (0.00)
PROCEDURAL HYPERTENSION		2 (0.01)		1 (0.02)	3 (0.01)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
PROCEDURAL PAIN	4 (0.08)	16 (0.11)	38 (0.14)	2 (0.03)	60 (0.11)
PROCTALGIA				3 (0.05)	3 (0.01)
PROCTITIS			1 (0.00)		1 (0.00)
PROCTITIS ULCERATIVE			1 (0.00)		1 (0.00)
PRODUCTIVE COUGH	1 (0.02)	2 (0.01)	7 (0.03)		10 (0.02)
PROFOUND MENTAL RETARDATION		1 (0.01)			1 (0.00)
PROGRESSIVE MULTIPLE SCLEROSIS		1 (0.01)	4 (0.02)		5 (0.01)
PROGRESSIVE SUPRANUCLEAR PALSY			1 (0.00)		1 (0.00)
PROLACTIN-PRODUCING PITUITARY TUMOUR		1 (0.01)	1 (0.00)		2 (0.00)
PROLACTINOMA		1 (0.01)	1 (0.00)		2 (0.00)
PROMOTION OF PERIPHERAL CIRCULATION			1 (0.00)		1 (0.00)
PROMOTION OF WOUND HEALING			1 (0.00)		1 (0.00)
PROPHYLACTIC CHEMOTHERAPY			4 (0.02)	2 (0.03)	6 (0.01)
PROPHYLAXIS	67 (1.39)	121 (0.83)	316 (1.19)	78 (1.19)	582 (1.11)
PROPHYLAXIS AGAINST GASTROINTESTINAL ULCER		5 (0.03)	44 (0.17)	15 (0.23)	64 (0.12)
PROPHYLAXIS AGAINST HIV INFECTION	1 (0.02)	2 (0.01)			3 (0.01)
PROPHYLAXIS AGAINST TRANSPLANT REJECTION	34 (0.70)	101 (0.69)	129 (0.48)		264 (0.50)
PROPHYLAXIS OF NAUSEA AND VOMITING	3 (0.06)	11 (0.08)	33 (0.12)	2 (0.03)	49 (0.09)
PROSTATE CANCER			111 (0.42)	76 (1.16)	187 (0.36)
PROSTATE CANCER METASTATIC			19 (0.07)	12 (0.18)	31 (0.06)
PROSTATE CANCER STAGE 0			2 (0.01)		2 (0.00)
PROSTATE CANCER STAGE I				2 (0.03)	2 (0.00)
PROSTATE CANCER STAGE II			2 (0.01)	1 (0.02)	3 (0.01)
PROSTATE CANCER STAGE III				1 (0.02)	1 (0.00)
PROSTATE CANCER STAGE IV			1 (0.00)		1 (0.00)
PROSTATE EXAMINATION		1 (0.01)			1 (0.00)
PROSTATE EXAMINATION ABNORMAL			4 (0.02)	1 (0.02)	5 (0.01)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
PROSTATE INFECTION		1 (0.01)	1 (0.00)		2 (0.00)
PROSTATECTOMY				1 (0.02)	1 (0.00)
PROSTATIC ADENOMA			1 (0.00)	2 (0.03)	3 (0.01)
PROSTATIC DISORDER		2 (0.01)	14 (0.05)	1 (0.02)	17 (0.03)
PROSTATIC OPERATION			1 (0.00)		1 (0.00)
PROSTATIC SPECIFIC ANTIGEN INCREASED			3 (0.01)		3 (0.01)
PROSTATISM		1 (0.01)	5 (0.02)	5 (0.08)	11 (0.02)
PROSTATITIS	1 (0.02)	5 (0.03)	12 (0.05)	3 (0.05)	21 (0.04)
PROTEIN C DEFICIENCY	1 (0.02)				1 (0.00)
PROTEIN S DEFICIENCY			1 (0.00)		1 (0.00)
PROTEIN URINE PRESENT			1 (0.00)		1 (0.00)
PROTEINURIA		1 (0.01)	1 (0.00)		2 (0.00)
PROTHROMBIN TIME PROLONGED			1 (0.00)		1 (0.00)
PRURITUS	7 (0.14)	11 (0.08)	19 (0.07)	26 (0.40)	63 (0.12)
PRURITUS ANI		1 (0.01)			1 (0.00)
PRURITUS GENERALISED			2 (0.01)	2 (0.03)	4 (0.01)
PSEUDALLESCHERIA INFECTION	1 (0.02)				1 (0.00)
PSEUDODEMENTIA				2 (0.03)	2 (0.00)
PSEUDOMONAL SEPSIS		1 (0.01)		1 (0.02)	2 (0.00)
PSEUDOMONAS INFECTION	9 (0.19)	2 (0.01)	5 (0.02)	11 (0.17)	27 (0.05)
PSORIASIS	4 (0.08)	60 (0.41)	93 (0.35)	12 (0.18)	169 (0.32)
PSORIATIC ARTHROPATHY	3 (0.06)	22 (0.15)	21 (0.08)		46 (0.09)
PSYCHIATRIC SYMPTOM	2 (0.04)	1 (0.01)	3 (0.01)	3 (0.05)	9 (0.02)
PSYCHOMOTOR HYPERACTIVITY	8 (0.17)	1 (0.01)	3 (0.01)		12 (0.02)
PSYCHOMOTOR RETARDATION			3 (0.01)		3 (0.01)
PSYCHOMOTOR SEIZURES			1 (0.00)		1 (0.00)
PSYCHOTIC DISORDER	27 (0.56)	84 (0.58)	64 (0.24)	17 (0.26)	192 (0.36)

Indication Summary Table Derived Age Group

	<i>Group1</i> (0-25) (N=4591)	<i>Group2</i> (26-50) (N=14283)	<i>Group3</i> (51-75) (N=25653)	<i>Group4</i> (75+) (N=6415)	<i>Total</i> (N=50942)
PSYCHOTIC DISORDER DUE TO A GENERAL MEDICAL C		1 (0.01)	1 (0.00)		2 (0.00)
PULMONARY ARTERIAL PRESSURE			1 (0.00)		1 (0.00)
PULMONARY ARTERIAL PRESSURE INCREASED	2 (0.04)				2 (0.00)
PULMONARY CONGESTION			2 (0.01)	1 (0.02)	3 (0.01)
PULMONARY EMBOLISM		7 (0.05)	25 (0.09)	9 (0.14)	41 (0.08)
PULMONARY FIBROSIS		1 (0.01)	5 (0.02)		6 (0.01)
PULMONARY HAEMORRHAGE	1 (0.02)	1 (0.01)			2 (0.00)
PULMONARY HYPERTENSION	49 (1.01)	70 (0.48)	124 (0.47)	20 (0.30)	263 (0.50)
PULMONARY MASS			1 (0.00)		1 (0.00)
PULMONARY MYCOSIS				2 (0.03)	2 (0.00)
PULMONARY OEDEMA			1 (0.00)		1 (0.00)
PULMONARY TUBERCULOSIS	1 (0.02)	5 (0.03)	4 (0.02)	5 (0.08)	15 (0.03)
PUSTULAR PSORIASIS		2 (0.01)	3 (0.01)	1 (0.02)	6 (0.01)
PYELONEPHRITIS	2 (0.04)	5 (0.03)	7 (0.03)	5 (0.08)	19 (0.04)
PYELONEPHRITIS ACUTE			2 (0.01)		2 (0.00)
PYLORIC STENOSIS		1 (0.01)			1 (0.00)
PYODERMA		1 (0.01)			1 (0.00)
PYODERMA GANGRENOSUM			7 (0.03)		7 (0.01)
PYREXIA	34 (0.70)	31 (0.21)	37 (0.14)	14 (0.21)	116 (0.22)
PYURIA		1 (0.01)			1 (0.00)
QUADRIPLEGIA				1 (0.02)	1 (0.00)
QUADRUPLE VESSEL BYPASS GRAFT			1 (0.00)		1 (0.00)
RABIES	1 (0.02)				1 (0.00)
RADIATION EXPOSURE			1 (0.00)		1 (0.00)
RADIATION INJURY			1 (0.00)		1 (0.00)
RADIATION OESOPHAGITIS			1 (0.00)		1 (0.00)
RADICULAR PAIN		3 (0.02)	1 (0.00)	1 (0.02)	5 (0.01)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
RADICULAR SYNDROME		2 (0.01)	4 (0.02)		6 (0.01)
RADICULITIS		1 (0.01)	2 (0.01)		3 (0.01)
RADICULITIS LUMBOSACRAL		2 (0.01)			2 (0.00)
RADICULOPATHY		4 (0.03)	1 (0.00)		5 (0.01)
RADIOISOTOPE SCAN			1 (0.00)		1 (0.00)
RADIOTHERAPY	3 (0.06)	6 (0.04)	22 (0.08)	2 (0.03)	33 (0.06)
RADIOTHERAPY TO BONE			1 (0.00)		1 (0.00)
RADIUS FRACTURE			1 (0.00)		1 (0.00)
RALES				1 (0.02)	1 (0.00)
RASH	8 (0.17)	20 (0.14)	20 (0.08)	11 (0.17)	59 (0.11)
RASH ERYTHEMATOUS		1 (0.01)			1 (0.00)
RASH MACULAR		1 (0.01)			1 (0.00)
RASH PAPULAR			1 (0.00)		1 (0.00)
RASH PRURITIC		2 (0.01)	6 (0.02)		8 (0.02)
RASH VESICULAR	1 (0.02)				1 (0.00)
RAYNAUD'S PHENOMENON		1 (0.01)	1 (0.00)		2 (0.00)
REACTIVE PSYCHOSIS		1 (0.01)			1 (0.00)
REBOUND EFFECT	1 (0.02)				1 (0.00)
RECTAL CANCER	2 (0.04)	7 (0.05)	35 (0.13)	2 (0.03)	46 (0.09)
RECTAL CANCER METASTATIC		1 (0.01)	7 (0.03)		8 (0.02)
RECTAL CANCER STAGE III			3 (0.01)		3 (0.01)
RECTAL CANCER STAGE IV				1 (0.02)	1 (0.00)
RECTAL ULCER			2 (0.01)		2 (0.00)
RECURRENT CANCER	1 (0.02)		1 (0.00)		2 (0.00)
RED BLOOD CELL ABNORMALITY			1 (0.00)		1 (0.00)
RED BLOOD CELL COUNT			1 (0.00)		1 (0.00)
RED BLOOD CELL COUNT DECREASED	1 (0.02)				1 (0.00)
REDUCTION OF INCREASED INTRACRANIAL PRESSURE	1 (0.02)		3 (0.01)		4 (0.01)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
REFLUX GASTRITIS			2 (0.01)		2 (0.00)
REFLUX OESOPHAGITIS		5 (0.03)	34 (0.13)	28 (0.43)	67 (0.13)
REFRACTORY ANAEMIA	1 (0.02)			1 (0.02)	2 (0.00)
REFUSAL OF TREATMENT BY PATIENT			1 (0.00)		1 (0.00)
REGURGITATION OF FOOD		1 (0.01)			1 (0.00)
RELAPSING-REMITTING MULTIPLE SCLEROSIS	5 (0.10)	72 (0.49)	43 (0.16)		120 (0.23)
RENAL AMYLOIDOSIS			1 (0.00)		1 (0.00)
RENAL AND PANCREAS TRANSPLANT		1 (0.01)			1 (0.00)
RENAL ARTERY STENOSIS				2 (0.03)	2 (0.00)
RENAL CANCER METASTATIC		2 (0.01)	5 (0.02)	2 (0.03)	9 (0.02)
RENAL CELL CARCINOMA STAGE IV			1 (0.00)		1 (0.00)
RENAL CELL CARCINOMA STAGE UNSPECIFIED		21 (0.14)	125 (0.47)	20 (0.30)	166 (0.32)
RENAL COLIC		4 (0.03)			4 (0.01)
RENAL DISORDER	1 (0.02)	4 (0.03)	7 (0.03)	1 (0.02)	13 (0.02)
RENAL DYSPLASIA	2 (0.04)				2 (0.00)
RENAL FAILURE	3 (0.06)	2 (0.01)	12 (0.05)	5 (0.08)	22 (0.04)
RENAL FAILURE CHRONIC	8 (0.17)	9 (0.06)	25 (0.09)	9 (0.14)	51 (0.10)
RENAL GLYCOSURIA				2 (0.03)	2 (0.00)
RENAL HYPERTENSION	2 (0.04)				2 (0.00)
RENAL IMPAIRMENT		4 (0.03)			4 (0.01)
RENAL NEOPLASM			1 (0.00)		1 (0.00)
RENAL PAIN		2 (0.01)			2 (0.00)
RENAL TRANSPLANT	18 (0.37)	47 (0.32)	62 (0.23)	1 (0.02)	128 (0.24)
RENAL TUBULAR DISORDER		1 (0.01)			1 (0.00)
REPETITIVE STRAIN INJURY		1 (0.01)			1 (0.00)
RESIDUAL URINE VOLUME				1 (0.02)	1 (0.00)
RESPIRATORY ARREST			1 (0.00)		1 (0.00)
RESPIRATORY DISORDER	4 (0.08)	3 (0.02)	11 (0.04)	2 (0.03)	20 (0.04)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
RESPIRATORY DISTRESS			1 (0.00)		1 (0.00)
RESPIRATORY FAILURE			2 (0.01)	3 (0.05)	5 (0.01)
RESPIRATORY MONILIASIS		2 (0.01)		1 (0.02)	3 (0.01)
RESPIRATORY SYNCYTIAL VIRUS INFECTION	1 (0.02)	1 (0.01)			2 (0.00)
RESPIRATORY THERAPY		1 (0.01)			1 (0.00)
RESPIRATORY TRACT CONGESTION	1 (0.02)	1 (0.01)			2 (0.00)
RESPIRATORY TRACT INFECTION	4 (0.08)	10 (0.07)	14 (0.05)	7 (0.11)	35 (0.07)
RESPIRATORY TRACT INFECTION BACTERIAL	9 (0.19)	48 (0.33)	27 (0.10)	5 (0.08)	89 (0.17)
RESPIRATORY TRACT INFECTION FUNGAL			1 (0.00)		1 (0.00)
RESTLESS LEGS SYNDROME	2 (0.04)	101 (0.69)	166 (0.62)	43 (0.65)	312 (0.59)
RESTLESSNESS		1 (0.01)	3 (0.01)	6 (0.09)	10 (0.02)
RETCHING			1 (0.00)		1 (0.00)
RETINAL ARTERY THROMBOSIS			1 (0.00)		1 (0.00)
RETINAL DETACHMENT			1 (0.00)		1 (0.00)
RETINAL DISORDER			2 (0.01)		2 (0.00)
RETINAL HAEMORRHAGE				2 (0.03)	2 (0.00)
RETINAL VEIN OCCLUSION		3 (0.02)	1 (0.00)		4 (0.01)
RETINOPATHY			1 (0.00)		1 (0.00)
RETROPERITONEAL ABSCESS			1 (0.00)		1 (0.00)
RETROVIRAL INFECTION		1 (0.01)	1 (0.00)		2 (0.00)
REVERSAL OF SEDATION			1 (0.00)		1 (0.00)
REVERSIBLE AIRWAYS OBSTRUCTION	1 (0.02)				1 (0.00)
RHABDOMYOLYSIS	1 (0.02)				1 (0.00)
RHABDOMYOSARCOMA	8 (0.17)				8 (0.02)
RHESUS INCOMPATIBILITY	3 (0.06)				3 (0.01)
RHEUMATOID ARTHRITIS	12 (0.25)	229 (1.57)	728 (2.73)	99 (1.50)	1068 (2.03)
RHEUMATOID FACTOR NEGATIVE	1 (0.02)				1 (0.00)
RHINITIS	6 (0.12)	8 (0.05)	8 (0.03)		22 (0.04)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
RHINITIS ALLERGIC	9 (0.19)	17 (0.12)	17 (0.06)	2 (0.03)	45 (0.09)
RHINITIS PERENNIAL	1 (0.02)	1 (0.01)			2 (0.00)
RHINITIS SEASONAL		1 (0.01)			1 (0.00)
RHINORRHOEA	4 (0.08)	3 (0.02)	3 (0.01)	2 (0.03)	12 (0.02)
RHINOTRACHEITIS	1 (0.02)				1 (0.00)
RIB FRACTURE		1 (0.01)	2 (0.01)		3 (0.01)
ROAD TRAFFIC ACCIDENT			6 (0.02)		6 (0.01)
ROSACEA		6 (0.04)	4 (0.02)	4 (0.06)	14 (0.03)
ROTATOR CUFF REPAIR		3 (0.02)	2 (0.01)		5 (0.01)
ROTATOR CUFF SYNDROME		13 (0.09)	18 (0.07)		31 (0.06)
ROUTINE HEALTH MAINTENANCE			10 (0.04)	1 (0.02)	11 (0.02)
SACROILIITIS		3 (0.02)			3 (0.01)
SALIVARY GLAND CANCER			2 (0.01)		2 (0.00)
SALIVARY HYPERSECRETION		1 (0.01)	3 (0.01)		4 (0.01)
SARCOIDOSIS	1 (0.02)	3 (0.02)			4 (0.01)
SARCOMA	1 (0.02)	7 (0.05)	4 (0.02)	1 (0.02)	13 (0.02)
SARCOMATOSIS			1 (0.00)		1 (0.00)
SCAN		1 (0.01)	2 (0.01)		3 (0.01)
SCAN MYOCARDIAL PERFUSION			4 (0.02)	2 (0.03)	6 (0.01)
SCAN WITH CONTRAST		4 (0.03)			4 (0.01)
SCAR	1 (0.02)	3 (0.02)			4 (0.01)
SCHISTOSOMIASIS		1 (0.01)			1 (0.00)
SCHIZOAFFECTIVE DISORDER	16 (0.33)	143 (0.98)	75 (0.28)	1 (0.02)	235 (0.45)
SCHIZOID PERSONALITY DISORDER		1 (0.01)			1 (0.00)
SCHIZOPHRENIA	73 (1.51)	390 (2.67)	262 (0.98)	29 (0.44)	754 (1.43)
SCHIZOPHRENIA, CATATONIC TYPE	1 (0.02)			2 (0.03)	3 (0.01)
SCHIZOPHRENIA, DISORGANISED TYPE	1 (0.02)	4 (0.03)	1 (0.00)		6 (0.01)
SCHIZOPHRENIA, PARANOID TYPE	17 (0.35)	87 (0.60)	43 (0.16)		147 (0.28)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
SCHIZOPHRENIA, RESIDUAL TYPE			2 (0.01)		2 (0.00)
SCHIZOPHRENIA, UNDIFFERENTIATED TYPE	1 (0.02)	7 (0.05)	1 (0.00)		9 (0.02)
SCHIZOPHRENIFORM DISORDER	3 (0.06)		1 (0.00)		4 (0.01)
SCHIZOTYPAL PERSONALITY DISORDER		4 (0.03)			4 (0.01)
SCIATICA		14 (0.10)	31 (0.12)	11 (0.17)	56 (0.11)
SCINTIGRAPHY		1 (0.01)			1 (0.00)
SCLERITIS				2 (0.03)	2 (0.00)
SCLERODERMA		4 (0.03)	3 (0.01)		7 (0.01)
SCLEROSING ENCAPSULATING PERITONITIS			1 (0.00)		1 (0.00)
SCOLIOSIS		3 (0.02)	1 (0.00)	1 (0.02)	5 (0.01)
SCRATCH		1 (0.01)			1 (0.00)
SEASONAL AFFECTIVE DISORDER				1 (0.02)	1 (0.00)
SEASONAL ALLERGY	10 (0.21)	16 (0.11)	14 (0.05)	2 (0.03)	42 (0.08)
SEBORRHOEIC DERMATITIS			3 (0.01)		3 (0.01)
SECONDARY HYPERTENSION		3 (0.02)	2 (0.01)	2 (0.03)	7 (0.01)
SECONDARY IMMUNODEFICIENCY	2 (0.04)			1 (0.02)	3 (0.01)
SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS		7 (0.05)	17 (0.06)	1 (0.02)	25 (0.05)
SEDATION	19 (0.39)	14 (0.10)	29 (0.11)	9 (0.14)	71 (0.13)
SEDATIVE THERAPY	2 (0.04)	5 (0.03)	5 (0.02)	4 (0.06)	16 (0.03)
SELECTIVE IGA IMMUNODEFICIENCY			2 (0.01)		2 (0.00)
SELECTIVE IGG SUBCLASS DEFICIENCY			4 (0.02)		4 (0.01)
SELF ESTEEM DECREASED	1 (0.02)				1 (0.00)
SELF MUTILATION	1 (0.02)				1 (0.00)
SELF-MEDICATION			3 (0.01)		3 (0.01)
SENILE DEMENTIA			1 (0.00)	3 (0.05)	4 (0.01)
SENILE PSYCHOSIS			1 (0.00)		1 (0.00)
SENSITIVITY OF TEETH		1 (0.01)		1 (0.02)	2 (0.00)
SENSORY DISTURBANCE	2 (0.04)	4 (0.03)			6 (0.01)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
SEPSIS	12 (0.25)	19 (0.13)	48 (0.18)	13 (0.20)	92 (0.17)
SEPSIS SYNDROME		2 (0.01)			2 (0.00)
SEPTIC ARTHRITIS STAPHYLOCOCCAL		1 (0.01)	2 (0.01)		3 (0.01)
SEPTIC SHOCK	2 (0.04)	1 (0.01)	1 (0.00)	1 (0.02)	5 (0.01)
SERONEGATIVE ARTHRITIS			1 (0.00)		1 (0.00)
SERRATIA INFECTION		1 (0.01)			1 (0.00)
SERUM FERRITIN INCREASED			1 (0.00)		1 (0.00)
SERUM SEROTONIN DECREASED			1 (0.00)		1 (0.00)
SERUM SICKNESS		1 (0.01)			1 (0.00)
SEXUAL DYSFUNCTION		4 (0.03)	5 (0.02)	1 (0.02)	10 (0.02)
SHOCK				1 (0.02)	1 (0.00)
SHOCK HAEMORRHAGIC		1 (0.01)	1 (0.00)		2 (0.00)
SHOULDER OPERATION		1 (0.01)	1 (0.00)		2 (0.00)
SHOULDER PAIN	2 (0.04)	85 (0.58)	125 (0.47)	7 (0.11)	219 (0.42)
SHUNT MALFUNCTION	1 (0.02)		1 (0.00)		2 (0.00)
SICK SINUS SYNDROME			1 (0.00)		1 (0.00)
SICKLE CELL ANAEMIA	7 (0.14)	1 (0.01)	1 (0.00)		9 (0.02)
SICKLE CELL ANAEMIA WITH CRISIS		1 (0.01)			1 (0.00)
SIMPLE PARTIAL SEIZURES	3 (0.06)	4 (0.03)	1 (0.00)		8 (0.02)
SINOBRONCHITIS			2 (0.01)	1 (0.02)	3 (0.01)
SINUS ARRHYTHMIA			2 (0.01)		2 (0.00)
SINUS CONGESTION	1 (0.02)	3 (0.02)	8 (0.03)	1 (0.02)	13 (0.02)
SINUS DISORDER	1 (0.02)	5 (0.03)	11 (0.04)	3 (0.05)	20 (0.04)
SINUS HEADACHE	1 (0.02)	7 (0.05)	1 (0.00)		9 (0.02)
SINUS OPERATION		1 (0.01)			1 (0.00)
SINUS TACHYCARDIA	1 (0.02)		1 (0.00)	3 (0.05)	5 (0.01)
SINUSITIS	29 (0.60)	85 (0.58)	51 (0.19)	5 (0.08)	170 (0.32)
SINUSITIS ASPERGILLUS			1 (0.00)		1 (0.00)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
SJOGREN'S SYNDROME		6 (0.04)	8 (0.03)		14 (0.03)
SKELETAL INJURY	1 (0.02)	1 (0.01)			2 (0.00)
SKIN BURNING SENSATION				1 (0.02)	1 (0.00)
SKIN CANCER				2 (0.03)	2 (0.00)
SKIN CANDIDA		2 (0.01)			2 (0.00)
SKIN CHAPPED	1 (0.02)				1 (0.00)
SKIN COSMETIC PROCEDURE		2 (0.01)			2 (0.00)
SKIN DISCOLOURATION				1 (0.02)	1 (0.00)
SKIN DISORDER	1 (0.02)	1 (0.01)	10 (0.04)		12 (0.02)
SKIN EXFOLIATION			2 (0.01)		2 (0.00)
SKIN GRAFT			1 (0.00)		1 (0.00)
SKIN INFECTION	2 (0.04)	5 (0.03)	3 (0.01)	3 (0.05)	13 (0.02)
SKIN IRRITATION	1 (0.02)		5 (0.02)		6 (0.01)
SKIN LESION		1 (0.01)	4 (0.02)		5 (0.01)
SKIN LESION EXCISION			2 (0.01)		2 (0.00)
SKIN PAPILLOMA	1 (0.02)		1 (0.00)		2 (0.00)
SKIN TEST		1 (0.01)	1 (0.00)		2 (0.00)
SKIN ULCER		3 (0.02)	4 (0.02)	4 (0.06)	11 (0.02)
SKIN WRINKLING		8 (0.05)	4 (0.02)		12 (0.02)
SLEEP APNOEA SYNDROME		2 (0.01)	15 (0.06)	2 (0.03)	19 (0.04)
SLEEP DISORDER	12 (0.25)	56 (0.38)	71 (0.27)	25 (0.38)	164 (0.31)
SLEEP DISORDER DUE TO GENERAL MEDICAL CONDITI			1 (0.00)		1 (0.00)
SLEEP DISORDER THERAPY		3 (0.02)	11 (0.04)	1 (0.02)	15 (0.03)
SLEEP PARALYSIS		1 (0.01)			1 (0.00)
SLUGGISHNESS		1 (0.01)			1 (0.00)
SMALL CELL CARCINOMA		1 (0.01)			1 (0.00)
SMALL CELL LUNG CANCER METASTATIC		1 (0.01)	1 (0.00)		2 (0.00)
SMALL CELL LUNG CANCER STAGE UNSPECIFIED		3 (0.02)	29 (0.11)	6 (0.09)	38 (0.07)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
SMALL FOR DATES BABY	1 (0.02)				1 (0.00)
SMALL INTESTINE CARCINOMA METASTATIC			2 (0.01)		2 (0.00)
SMEAR CERVIX		1 (0.01)			1 (0.00)
SMOKER	1 (0.02)		1 (0.00)		2 (0.00)
SMOKING CESSATION THERAPY	4 (0.08)	53 (0.36)	36 (0.14)	1 (0.02)	94 (0.18)
SNEEZING	4 (0.08)	1 (0.01)			5 (0.01)
SNORING		1 (0.01)	1 (0.00)		2 (0.00)
SOCIAL PHOBIA	4 (0.08)	6 (0.04)			10 (0.02)
SOFT TISSUE DISORDER			1 (0.00)		1 (0.00)
SOFT TISSUE INFECTION	2 (0.04)	1 (0.01)			3 (0.01)
SOMATOFORM DISORDER		2 (0.01)			2 (0.00)
SOMNOLENCE	2 (0.04)	10 (0.07)	15 (0.06)		27 (0.05)
SPINA BIFIDA		1 (0.01)			1 (0.00)
SPINAL ANAESTHESIA	2 (0.04)	4 (0.03)	2 (0.01)		8 (0.02)
SPINAL COLUMN STENOSIS		9 (0.06)	17 (0.06)	7 (0.11)	33 (0.06)
SPINAL COMPRESSION FRACTURE		1 (0.01)		3 (0.05)	4 (0.01)
SPINAL CORD DISORDER			2 (0.01)		2 (0.00)
SPINAL CORD INFECTION		1 (0.01)			1 (0.00)
SPINAL CORD INJURY		1 (0.01)	1 (0.00)		2 (0.00)
SPINAL DISORDER		3 (0.02)	5 (0.02)	1 (0.02)	9 (0.02)
SPINAL FRACTURE			9 (0.03)		9 (0.02)
SPINAL FUSION SURGERY		3 (0.02)	3 (0.01)		6 (0.01)
SPINAL LAMINECTOMY		1 (0.01)			1 (0.00)
SPINAL MUSCULAR ATROPHY	4 (0.08)				4 (0.01)
SPINAL MYELOGRAM		1 (0.01)	1 (0.00)		2 (0.00)
SPINAL OPERATION			2 (0.01)		2 (0.00)
SPINAL OSTEOARTHRITIS		6 (0.04)	32 (0.12)	3 (0.05)	41 (0.08)
SPINE MALFORMATION				1 (0.02)	1 (0.00)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
SPLENECTOMY	1 (0.02)				1 (0.00)
SPONDYLITIS		26 (0.18)	50 (0.19)	5 (0.08)	81 (0.15)
SPONDYLOARTHROPATHY		1 (0.01)	2 (0.01)		3 (0.01)
SPONDYLOLISTHESIS			4 (0.02)	3 (0.05)	7 (0.01)
SPORTS INJURY			6 (0.02)		6 (0.01)
SPUTUM PURULENT			2 (0.01)		2 (0.00)
SPUTUM RETENTION		1 (0.01)		4 (0.06)	5 (0.01)
SQUAMOUS CELL CARCINOMA		15 (0.10)	51 (0.19)	2 (0.03)	68 (0.13)
SQUAMOUS CELL CARCINOMA OF SKIN				1 (0.02)	1 (0.00)
SQUAMOUS CELL CARCINOMA OF THE CERVIX		1 (0.01)			1 (0.00)
STAPHYLOCOCCAL ABSCESS			1 (0.00)		1 (0.00)
STAPHYLOCOCCAL BACTERAEMIA		3 (0.02)	10 (0.04)	3 (0.05)	16 (0.03)
STAPHYLOCOCCAL INFECTION	7 (0.14)	11 (0.08)	28 (0.11)	13 (0.20)	59 (0.11)
STAPHYLOCOCCAL OSTEOMYELITIS	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.01)
STAPHYLOCOCCAL SEPSIS		3 (0.02)		4 (0.06)	7 (0.01)
STASIS DERMATITIS			1 (0.00)		1 (0.00)
STATUS ASTHMATICUS	5 (0.10)	1 (0.01)	2 (0.01)		8 (0.02)
STATUS EPILEPTICUS		3 (0.02)	5 (0.02)		8 (0.02)
STEM CELL TRANSPLANT	10 (0.21)	15 (0.10)	15 (0.06)		40 (0.08)
STENT OCCLUSION			2 (0.01)		2 (0.00)
STENT PLACEMENT		9 (0.06)	54 (0.20)	19 (0.29)	82 (0.16)
STERILISATION			1 (0.00)		1 (0.00)
STEROID THERAPY			1 (0.00)	1 (0.02)	2 (0.00)
STEVENS-JOHNSON SYNDROME	1 (0.02)				1 (0.00)
STIFF-MAN SYNDROME				1 (0.02)	1 (0.00)
STOMACH DISCOMFORT	2 (0.04)	3 (0.02)	9 (0.03)	1 (0.02)	15 (0.03)
STOMATITIS		2 (0.01)	13 (0.05)	1 (0.02)	16 (0.03)
STRABISMUS		1 (0.01)			1 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
STREPTOCOCCAL INFECTION		2 (0.01)	4 (0.02)	1 (0.02)	7 (0.01)
STRESS		17 (0.12)	11 (0.04)	1 (0.02)	29 (0.06)
STRESS FRACTURE		2 (0.01)			2 (0.00)
STRESS INCONTINENCE		7 (0.05)	16 (0.06)	2 (0.03)	25 (0.05)
STRESS ULCER			2 (0.01)		2 (0.00)
STRIDOR	3 (0.06)				3 (0.01)
STRONGYLOIDIASIS				2 (0.03)	2 (0.00)
SUBACUTE ENDOCARDITIS	1 (0.02)		1 (0.00)		2 (0.00)
SUBARACHNOID HAEMORRHAGE			1 (0.00)		1 (0.00)
SUBCLAVIAN ARTERY THROMBOSIS				1 (0.02)	1 (0.00)
SUBCUTANEOUS ABSCESS		1 (0.01)	1 (0.00)		2 (0.00)
SUBDURAL HAEMATOMA		1 (0.01)	5 (0.02)		6 (0.01)
SUDDEN HEARING LOSS			2 (0.01)		2 (0.00)
SUICIDAL IDEATION		4 (0.03)			4 (0.01)
SUICIDE ATTEMPT	22 (0.46)	17 (0.12)	4 (0.02)		43 (0.08)
SUPERINFECTION		1 (0.01)		2 (0.03)	3 (0.01)
SUPERINFECTION LUNG	1 (0.02)	3 (0.02)	2 (0.01)	3 (0.05)	9 (0.02)
SUPRAVENTRICULAR EXTRASYSTOLES			1 (0.00)		1 (0.00)
SUPRAVENTRICULAR TACHYCARDIA	2 (0.04)	2 (0.01)	11 (0.04)	5 (0.08)	20 (0.04)
SURGERY		8 (0.05)	28 (0.11)	8 (0.12)	44 (0.08)
SUSPICIOUSNESS		2 (0.01)			2 (0.00)
SWELLING	1 (0.02)	11 (0.08)	28 (0.11)	2 (0.03)	42 (0.08)
SWELLING FACE	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.01)
SYNCOPE		1 (0.01)	1 (0.00)		2 (0.00)
SYNOVIAL CYST		1 (0.01)			1 (0.00)
SYNOVITIS		3 (0.02)	1 (0.00)		4 (0.01)
SYPHILIS		1 (0.01)	1 (0.00)		2 (0.00)
SYPHILITIC ENDOCARDITIS OF HEART VALVE	1 (0.02)				1 (0.00)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
SYRINGOMYELIA			1 (0.00)		1 (0.00)
SYSTEMIC ANTIBACTERIAL THERAPY		1 (0.01)	1 (0.00)	2 (0.03)	4 (0.01)
SYSTEMIC ANTIVIRAL TREATMENT		3 (0.02)	1 (0.00)		4 (0.01)
SYSTEMIC CANDIDA		1 (0.01)	4 (0.02)	1 (0.02)	6 (0.01)
SYSTEMIC LUPUS ERYTHEMATOSUS	18 (0.37)	23 (0.16)	11 (0.04)	1 (0.02)	53 (0.10)
SYSTEMIC LUPUS ERYTHEMATOSUS RASH			1 (0.00)		1 (0.00)
SYSTEMIC MYCOSIS	1 (0.02)			1 (0.02)	2 (0.00)
T-CELL LYMPHOMA	1 (0.02)	5 (0.03)	3 (0.01)	1 (0.02)	10 (0.02)
T-CELL LYMPHOMA REFRACTORY		1 (0.01)			1 (0.00)
T-CELL PROLYMPHOCYTIC LEUKAEMIA			1 (0.00)		1 (0.00)
TACHYARRHYTHMIA			4 (0.02)	2 (0.03)	6 (0.01)
TACHYCARDIA	3 (0.06)	5 (0.03)	13 (0.05)	4 (0.06)	25 (0.05)
TARSAL TUNNEL SYNDROME		1 (0.01)			1 (0.00)
TAY-SACHS DISEASE	1 (0.02)				1 (0.00)
TEETHING	3 (0.06)				3 (0.01)
TELANGIECTASIA			2 (0.01)		2 (0.00)
TEMPORAL ARTERITIS			2 (0.01)	4 (0.06)	6 (0.01)
TEMPORAL LOBE EPILEPSY	4 (0.08)	1 (0.01)	5 (0.02)	2 (0.03)	12 (0.02)
TEMPOROMANDIBULAR JOINT SYNDROME		6 (0.04)	7 (0.03)		13 (0.02)
TENDON DISORDER		1 (0.01)	3 (0.01)		4 (0.01)
TENDON INJURY			2 (0.01)		2 (0.00)
TENDON REPAIR			1 (0.00)		1 (0.00)
TENDON RUPTURE			1 (0.00)		1 (0.00)
TENDONITIS	1 (0.02)	22 (0.15)	29 (0.11)	2 (0.03)	54 (0.10)
TENOSYNOVITIS		3 (0.02)	1 (0.00)		4 (0.01)
TENSION		3 (0.02)	2 (0.01)	3 (0.05)	8 (0.02)
TENSION HEADACHE		4 (0.03)	1 (0.00)		5 (0.01)
TESTICULAR CANCER METASTATIC		1 (0.01)			1 (0.00)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
TESTICULAR GERM CELL CANCER		2 (0.01)			2 (0.00)
TESTICULAR MASS		2 (0.01)			2 (0.00)
TESTIS CANCER	2 (0.04)	11 (0.08)	3 (0.01)		16 (0.03)
THALASSAEMIA	2 (0.04)				2 (0.00)
THERAPEUTIC EMBOLISATION		1 (0.01)			1 (0.00)
THERAPEUTIC PROCEDURE			5 (0.02)	1 (0.02)	6 (0.01)
THERAPY NON-RESPONDER		1 (0.01)			1 (0.00)
THERMAL BURN			1 (0.00)		1 (0.00)
THINKING ABNORMAL		1 (0.01)			1 (0.00)
THIRST		1 (0.01)		2 (0.03)	3 (0.01)
THORACIC VERTEBRAL FRACTURE				1 (0.02)	1 (0.00)
THREATENED LABOUR	1 (0.02)				1 (0.00)
THROAT CANCER			1 (0.00)	1 (0.02)	2 (0.00)
THROAT IRRITATION			1 (0.00)		1 (0.00)
THROMBOCYTHAEMIA		2 (0.01)	1 (0.00)	1 (0.02)	4 (0.01)
THROMBOCYTOPENIA	2 (0.04)	1 (0.01)	4 (0.02)	1 (0.02)	8 (0.02)
THROMBOCYTOPENIC PURPURA	1 (0.02)	1 (0.01)	1 (0.00)	2 (0.03)	5 (0.01)
THROMBOEMBOLECTOMY				1 (0.02)	1 (0.00)
THROMBOEMBOLIC STROKE			1 (0.00)		1 (0.00)
THROMBOPHLEBITIS			1 (0.00)	1 (0.02)	2 (0.00)
THROMBOSIS		6 (0.04)	22 (0.08)	14 (0.21)	42 (0.08)
THROMBOSIS IN DEVICE			3 (0.01)		3 (0.01)
THROMBOSIS PROPHYLAXIS	3 (0.06)	14 (0.10)	62 (0.23)	23 (0.35)	102 (0.19)
THROMBOTIC STROKE				1 (0.02)	1 (0.00)
THROMBOTIC THROMBOCYTOPENIC PURPURA				3 (0.05)	3 (0.01)
THYMOMA		1 (0.01)	2 (0.01)		3 (0.01)
THYMUS DISORDER			3 (0.01)		3 (0.01)
THYROID CANCER METASTATIC			4 (0.02)		4 (0.01)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
THYROID DISORDER		14 (0.10)	40 (0.15)	7 (0.11)	61 (0.12)
THYROID FUNCTION TEST ABNORMAL			2 (0.01)		2 (0.00)
THYROID GLAND CANCER		1 (0.01)	4 (0.02)		5 (0.01)
THYROIDECTOMY		2 (0.01)	6 (0.02)	2 (0.03)	10 (0.02)
THYROIDITIS		2 (0.01)	3 (0.01)		5 (0.01)
THYROXINE DECREASED			2 (0.01)		2 (0.00)
TIBIA FRACTURE		2 (0.01)			2 (0.00)
TIC	1 (0.02)				1 (0.00)
TINEA BLANCA			1 (0.00)		1 (0.00)
TINEA CAPITIS			1 (0.00)		1 (0.00)
TINEA CRURIS		1 (0.01)			1 (0.00)
TINEA INFECTION	1 (0.02)	2 (0.01)			3 (0.01)
TINEA PEDIS	2 (0.04)		4 (0.02)	2 (0.03)	8 (0.02)
TINNITUS		2 (0.01)	1 (0.00)		3 (0.01)
TOBACCO USER			1 (0.00)		1 (0.00)
TOCOLYSIS		1 (0.01)			1 (0.00)
TOE AMPUTATION			1 (0.00)		1 (0.00)
TOE DEFORMITY		2 (0.01)	1 (0.00)		3 (0.01)
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED		4 (0.03)	11 (0.04)	2 (0.03)	17 (0.03)
TONIC CONVULSION	1 (0.02)				1 (0.00)
TONSIL CANCER		1 (0.01)	1 (0.00)		2 (0.00)
TONSILLITIS	9 (0.19)	6 (0.04)	3 (0.01)	2 (0.03)	20 (0.04)
TOOTH ABSCESS	2 (0.04)	5 (0.03)	3 (0.01)		10 (0.02)
TOOTH DISORDER	1 (0.02)	4 (0.03)	2 (0.01)		7 (0.01)
TOOTH EXTRACTION	2 (0.04)	2 (0.01)	2 (0.01)		6 (0.01)
TOOTH FRACTURE		1 (0.01)			1 (0.00)
TOOTH INFECTION		10 (0.07)	4 (0.02)		14 (0.03)
TOOTH REPAIR				1 (0.02)	1 (0.00)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
TOOTHACHE	6 (0.12)	5 (0.03)	9 (0.03)		20 (0.04)
TORSADE DE POINTES		1 (0.01)			1 (0.00)
TORTICOLLIS		2 (0.01)	5 (0.02)	1 (0.02)	8 (0.02)
TOURETTE'S DISORDER	2 (0.04)	2 (0.01)			4 (0.01)
TOXIC EPIDERMAL NECROLYSIS				4 (0.06)	4 (0.01)
TOXIC NODULAR GOITRE			1 (0.00)		1 (0.00)
TOXOPLASMOSIS	1 (0.02)				1 (0.00)
TRABECULECTOMY			1 (0.00)		1 (0.00)
TRACHEAL CANCER			1 (0.00)		1 (0.00)
TRACHEITIS	2 (0.04)	6 (0.04)			8 (0.02)
TRACHEOBRONCHITIS			1 (0.00)		1 (0.00)
TRANSDERMAL CONTRACEPTION		1 (0.01)			1 (0.00)
TRANSIENT ISCHAEMIC ATTACK		2 (0.01)	19 (0.07)	21 (0.32)	42 (0.08)
TRANSITIONAL CELL CARCINOMA			4 (0.02)	1 (0.02)	5 (0.01)
TRANSPLANT	2 (0.04)	7 (0.05)	2 (0.01)		11 (0.02)
TRANSPLANT REJECTION		3 (0.02)	1 (0.00)		4 (0.01)
TRAUMATIC ARTHRITIS			1 (0.00)		1 (0.00)
TRAUMATIC BRAIN INJURY	1 (0.02)				1 (0.00)
TRAUMATIC HAEMORRHAGE	1 (0.02)	5 (0.03)		1 (0.02)	7 (0.01)
TREMOR	1 (0.02)	3 (0.02)	11 (0.04)	3 (0.05)	18 (0.03)
TRICHIASIS				1 (0.02)	1 (0.00)
TRICHOMONIASIS		1 (0.01)			1 (0.00)
TRICHOPHYTON INFECTION				1 (0.02)	1 (0.00)
TRICHOTILLOMANIA		1 (0.01)			1 (0.00)
TRIGEMINAL NERVE DISORDER			1 (0.00)		1 (0.00)
TRIGEMINAL NEURALGIA		9 (0.06)	11 (0.04)	4 (0.06)	24 (0.05)
TRIPLE VESSEL BYPASS GRAFT			2 (0.01)		2 (0.00)
TRISOMY 21		1 (0.01)			1 (0.00)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
TROPONIN INCREASED	1 (0.02)	1 (0.01)			2 (0.00)
TUBAL LIGATION		1 (0.01)			1 (0.00)
TUBERCULIN TEST	4 (0.08)	9 (0.06)	4 (0.02)	1 (0.02)	18 (0.03)
TUBERCULIN TEST POSITIVE		3 (0.02)	4 (0.02)		7 (0.01)
TUBERCULOSIS	7 (0.14)	15 (0.10)	15 (0.06)	1 (0.02)	38 (0.07)
TUBERCULOUS PLEURISY			2 (0.01)	3 (0.05)	5 (0.01)
TURNER'S SYNDROME	11 (0.23)				11 (0.02)
TYPE IIA HYPERLIPIDAEMIA	3 (0.06)	1 (0.01)	5 (0.02)	3 (0.05)	12 (0.02)
TYPE IIB HYPERLIPIDAEMIA			1 (0.00)		1 (0.00)
ULCER	4 (0.08)	2 (0.01)	20 (0.08)	6 (0.09)	32 (0.06)
ULCER HAEMORRHAGE			2 (0.01)	1 (0.02)	3 (0.01)
ULTRASOUND SCAN		3 (0.02)			3 (0.01)
UNEVALUABLE EVENT	2 (0.04)	1 (0.01)	2 (0.01)		5 (0.01)
UPPER GASTROINTESTINAL HAEMORRHAGE			5 (0.02)		5 (0.01)
UPPER LIMB FRACTURE	1 (0.02)	4 (0.03)	3 (0.01)		8 (0.02)
UPPER RESPIRATORY TRACT CONGESTION			1 (0.00)		1 (0.00)
UPPER RESPIRATORY TRACT INFECTION	12 (0.25)	21 (0.14)	26 (0.10)	11 (0.17)	70 (0.13)
UPPER RESPIRATORY TRACT INFLAMMATION	3 (0.06)	4 (0.03)	5 (0.02)	1 (0.02)	13 (0.02)
URAEMIC NEUROPATHY			2 (0.01)		2 (0.00)
URETERIC CANCER METASTATIC			9 (0.03)	1 (0.02)	10 (0.02)
URETEROSCOPY				1 (0.02)	1 (0.00)
URETHRAL CANCER METASTATIC			2 (0.01)		2 (0.00)
URETHRITIS			1 (0.00)		1 (0.00)
URGE INCONTINENCE		5 (0.03)	5 (0.02)	5 (0.08)	15 (0.03)
URINARY INCONTINENCE		1 (0.01)	14 (0.05)	29 (0.44)	44 (0.08)
URINARY RETENTION			4 (0.02)	5 (0.08)	9 (0.02)
URINARY TRACT CARCINOMA IN SITU		2 (0.01)			2 (0.00)
URINARY TRACT DISORDER	1 (0.02)	4 (0.03)	2 (0.01)	2 (0.03)	9 (0.02)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=4591)	<i>Group2 (26-50)</i> (N=14283)	<i>Group3 (51-75)</i> (N=25653)	<i>Group4 (75+)</i> (N=6415)	<i>Total</i> (N=50942)
URINARY TRACT INFECTION	6 (0.12)	36 (0.25)	60 (0.23)	48 (0.73)	150 (0.28)
URINARY TRACT INFECTION ENTEROCOCCAL	1 (0.02)	1 (0.01)	1 (0.00)		3 (0.01)
URINARY TRACT INFECTION STAPHYLOCOCCAL			1 (0.00)		1 (0.00)
URINARY TRACT OBSTRUCTION			1 (0.00)		1 (0.00)
URINE ABNORMALITY		1 (0.01)	1 (0.00)		2 (0.00)
URINE ANALYSIS ABNORMAL			1 (0.00)		1 (0.00)
URINE FLOW DECREASED				2 (0.03)	2 (0.00)
URINE OUTPUT DECREASED				1 (0.02)	1 (0.00)
UROGENITAL DISORDER			2 (0.01)		2 (0.00)
UROGRAM	2 (0.04)				2 (0.00)
UROSEPSIS			4 (0.02)	1 (0.02)	5 (0.01)
URTICARIA	1 (0.02)	9 (0.06)	3 (0.01)		13 (0.02)
URTICARIA CHOLINERGIC		2 (0.01)			2 (0.00)
UTERINE CANCER		4 (0.03)	14 (0.05)	2 (0.03)	20 (0.04)
UTERINE CONTRACTIONS ABNORMAL	2 (0.04)				2 (0.00)
UTERINE DISORDER		1 (0.01)			1 (0.00)
UTERINE HAEMORRHAGE	2 (0.04)	3 (0.02)			5 (0.01)
UTERINE LEIOMYOMA		11 (0.08)	1 (0.00)		12 (0.02)
UTERINE LEIOMYOSARCOMA			1 (0.00)		1 (0.00)
UVEITIS	2 (0.04)	2 (0.01)	2 (0.01)	2 (0.03)	8 (0.02)
VAGINAL BURNING SENSATION	3 (0.06)	6 (0.04)			9 (0.02)
VAGINAL CANDIDIASIS		1 (0.01)			1 (0.00)
VAGINAL DISCHARGE		6 (0.04)			6 (0.01)
VAGINAL INFECTION			1 (0.00)		1 (0.00)
VAGINAL PAIN		1 (0.01)			1 (0.00)
VAGINITIS BACTERIAL	4 (0.08)			2 (0.03)	6 (0.01)
VALVULOPLASTY CARDIAC			1 (0.00)		1 (0.00)
VARICELLA	7 (0.14)		4 (0.02)		11 (0.02)

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
VARICOSE VEIN			1 (0.00)	5 (0.08)	6 (0.01)
VARICOSE VEIN OPERATION			1 (0.00)		1 (0.00)
VASCULAR ANOMALY		1 (0.01)			1 (0.00)
VASCULAR BYPASS GRAFT			3 (0.01)		3 (0.01)
VASCULAR DEMENTIA			9 (0.03)	5 (0.08)	14 (0.03)
VASCULITIC RASH		1 (0.01)			1 (0.00)
VASCULITIS		2 (0.01)	2 (0.01)	3 (0.05)	7 (0.01)
VASCULITIS CEREBRAL			2 (0.01)		2 (0.00)
VASOCONSTRICTION			1 (0.00)		1 (0.00)
VASODILATATION		2 (0.01)	2 (0.01)		4 (0.01)
VASOSPASM			2 (0.01)		2 (0.00)
VEIN DISORDER			2 (0.01)		2 (0.00)
VENOUS INSUFFICIENCY			4 (0.02)		4 (0.01)
VENOUS THROMBOSIS			6 (0.02)	1 (0.02)	7 (0.01)
VENTRICULAR ARRHYTHMIA			2 (0.01)	3 (0.05)	5 (0.01)
VENTRICULAR DYSFUNCTION	1 (0.02)	1 (0.01)	3 (0.01)	2 (0.03)	7 (0.01)
VENTRICULAR EXTRASYSTOLES			3 (0.01)		3 (0.01)
VENTRICULAR FAILURE			1 (0.00)		1 (0.00)
VENTRICULAR FIBRILLATION	3 (0.06)		5 (0.02)		8 (0.02)
VENTRICULAR SEPTAL DEFECT REPAIR	1 (0.02)				1 (0.00)
VENTRICULAR TACHYCARDIA	1 (0.02)	1 (0.01)	18 (0.07)	6 (0.09)	26 (0.05)
VENTRICULOGram			1 (0.00)		1 (0.00)
VERTEBRAL INJURY		2 (0.01)	2 (0.01)		4 (0.01)
VERTEBROBASILAR INSUFFICIENCY				2 (0.03)	2 (0.00)
VERTIGO	1 (0.02)	6 (0.04)	7 (0.03)	3 (0.05)	17 (0.03)
VESTIBULAR DISORDER		1 (0.01)			1 (0.00)
VIRAL INFECTION	3 (0.06)	2 (0.01)	8 (0.03)		13 (0.02)
VIRAL UPPER RESPIRATORY TRACT INFECTION	1 (0.02)				1 (0.00)

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=4591)	Group2 (26-50) (N=14283)	Group3 (51-75) (N=25653)	Group4 (75+) (N=6415)	Total (N=50942)
VISION BLURRED			1 (0.00)		1 (0.00)
VISUAL ACUITY REDUCED				1 (0.02)	1 (0.00)
VISUAL DISTURBANCE	1 (0.02)				1 (0.00)
VITAMIN B COMPLEX DEFICIENCY		1 (0.01)			1 (0.00)
VITAMIN B1 DEFICIENCY		1 (0.01)			1 (0.00)
VITAMIN B12 DEFICIENCY			2 (0.01)		2 (0.00)
VITAMIN D DEFICIENCY		3 (0.02)	1 (0.00)	1 (0.02)	5 (0.01)
VITAMIN SUPPLEMENTATION	1 (0.02)	2 (0.01)	18 (0.07)	3 (0.05)	24 (0.05)
VITILIGO			3 (0.01)		3 (0.01)
VOCAL CORD DISORDER			1 (0.00)		1 (0.00)
VOMITING	8 (0.17)	15 (0.10)	32 (0.12)	6 (0.09)	61 (0.12)
VON WILLEBRAND'S DISEASE	2 (0.04)	3 (0.02)			5 (0.01)
VULVAL CANCER		1 (0.01)	3 (0.01)		4 (0.01)
VULVAL DISORDER	1 (0.02)				1 (0.00)
VULVOVAGINAL DRYNESS	1 (0.02)	1 (0.01)	5 (0.02)		7 (0.01)
VULVOVAGINAL MYCOTIC INFECTION	298 (6.16)	503 (3.45)	50 (0.19)	15 (0.23)	866 (1.64)
WAGNER'S DISEASE			1 (0.00)		1 (0.00)
WALDENSTROM'S MACROGLOBULINAEMIA		1 (0.01)	9 (0.03)	1 (0.02)	11 (0.02)
WALDENSTROM'S MACROGLOBULINAEMIA REFRACTORY			1 (0.00)		1 (0.00)
WEGENER'S GRANULOMATOSIS		3 (0.02)			3 (0.01)
WEIGHT			2 (0.01)		2 (0.00)
WEIGHT CONTROL		5 (0.03)	10 (0.04)		15 (0.03)
WEIGHT DECREASED	1 (0.02)	11 (0.08)	11 (0.04)		23 (0.04)
WEIGHT GAIN POOR				1 (0.02)	1 (0.00)
WEIGHT INCREASED			1 (0.00)		1 (0.00)
WEIGHT LOSS DIET			1 (0.00)		1 (0.00)
WHEEZING	6 (0.12)		7 (0.03)	2 (0.03)	15 (0.03)
WHIPLASH INJURY	1 (0.02)		1 (0.00)		2 (0.00)

Indication Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=4591)</i>	<i>Group2 (26-50)</i> <i>(N=14283)</i>	<i>Group3 (51-75)</i> <i>(N=25653)</i>	<i>Group4 (75+)</i> <i>(N=6415)</i>	<i>Total</i> <i>(N=50942)</i>
WHITE BLOOD CELL COUNT DECREASED		1 (0.01)		1 (0.02)	2 (0.00)
WHITE BLOOD CELL COUNT INCREASED			1 (0.00)	1 (0.02)	2 (0.00)
WILLIAMS SYNDROME	1 (0.02)				1 (0.00)
WOLFF-PARKINSON-WHITE SYNDROME	1 (0.02)		1 (0.00)		2 (0.00)
WOUND			4 (0.02)		4 (0.01)
WOUND COMPLICATION				1 (0.02)	1 (0.00)
WOUND INFECTION	2 (0.04)	3 (0.02)	6 (0.02)	1 (0.02)	12 (0.02)
WOUND INFECTION STAPHYLOCOCCAL		2 (0.01)	3 (0.01)		5 (0.01)
WOUND TREATMENT	2 (0.04)		2 (0.01)		4 (0.01)
WRIST FRACTURE		2 (0.01)			2 (0.00)
WRIST SURGERY	1 (0.02)				1 (0.00)
WRONG DRUG ADMINISTERED			1 (0.00)		1 (0.00)
ZYGOMYCOSIS		1 (0.01)	1 (0.00)		2 (0.00)

4. Graphs and Visual Summaries

This section presents key graphical summaries derived from the FAERS (FDA Adverse Event Reporting System) database to enhance understanding of adverse event trends and patient characteristics. Visual displays help identify safety signals, monitor reporting patterns, and support data-driven decision-making.